UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549
 
 
FORM 10-K  
(Mark One)
  x
ANNUAL REPORT PURSU ANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 
2018 o
TRANSITION REPORT PURSUAN T TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transitio
n period from              to             Commission file number 1-3619
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
13-5315170 (State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)  
  235 East 42nd Street New York, New York10017 (Address of principal executive offices)
(Zip Code) (212) 733-2323
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered Common Stock, $.05 par value
New York Stock Exchange Floating Rate Notes due 2019
New York Stock Exchange 0.000% Notes due 2020
New York Stock Exchange 0.250% Notes due 2022
New York Stock Exchange 1.000% Notes due 2027
New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: 
None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
     Yes   x
     No   oIndicate by check mark if the registrant is not required to file reports pursuant to Section 13
 or Section 15(d) of the Act.   Yes  o
      No   xIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
 Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such 
filing requirements for the past 90 days.    Yes   x No  
oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)  
  Yes   x
    No   oIndicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 o
f this chapter) is not contained herein, and will not be contained, tothe best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III o
f this Form 10-K or any amendment to this Form 10-K. x Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer   
x Accelerated filer   o  Non-accelerated filer   o  Smaller reporting company   o  Emerging growth company   o If an emerging growth company, indicate by check mark if the registrant has elected not to use
 the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act
.  o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
    Yes   o
     No   xThe aggregate market value of the voting stock held by non-affiliates of the
 registrant, computed by reference to the closing price as of the last business day of the registrant’smost recently completed second fiscal quarter, 
July 1, 2018 , was approximately $212 billion . This excludes shares of common stock held by directors and executive officers at July 1, 2018 
. Exclusion of shares held by any person should not be construed to indicate tha t such person possesses the power, directly or indirectly, to direct or cause thedirection of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has
 no non-votingcommon stock.
The number of shares outstanding of the registrant’s common stock as of 
February 26, 2019 was 5,551,804,790 shares of common stock, all of one class. DOCUMENTS INCORPORATED
 BY REFERENCEPortions of the 2018 Annual Report to Shareholders
Parts I, II and IV Portions of the Proxy Statement for 
the 2019 Annual Meeting of ShareholdersPart III 
TABLE OF CONTENTS  
 Page PART I
1 ITEM 1. BUSINESS
1 About Pfizer
1 Available Information and
 Pfizer Website1 Commercial Operations
2 Innovative Health
3 Essential Health
3 Collaboration and Co-Promotion
 Agreements4 Research and Development
4 International Operations
4 Marketing
5 Patents and Oth
er Intellectual Property Rights6 Competition
6 Raw Materials
8 Government Regulation 
and Price Constraints8 Environmental Matters
8 Tax Matters
8 Employees
9 Disclosure Pursuant to 
Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 20129 ITEM 1A. RISK FACTORS
10 ITEM 1B. UNRESOLVED STAFF COMMENTS
25 ITEM 2. PROPERTIES
25 ITEM 3. LEGAL PROCEEDINGS
25 ITEM 4. MINE SAFETY DISCLOSURES
25 EXECUTIVE OFFICERS OF THE COMPANY
26  
  PART II27 ITEM  5. MARKET FOR THE COMPANY’S COMMON EQUITY
, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITYSECURITIES
27 ITEM 6. SELECTED FINANCIAL DATA
27 ITEM  7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT
ION AND RESULTS OF OPERATIONS27 ITEM 7A. QUANTITATIVE AND QUALITA
TIVE DISCLOSURES ABOUT MARKET RISK27 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
27 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
28 ITEM 9A. CONTROLS AND PROCEDURES
28 ITEM 9B. OTHER INFORMATION
28  
  PART III29 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE G
OVERNANCE29 ITEM 11. EXECUTIVE COMPENSATION
29 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MAT
TERS29 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
29 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
29  
  PART IV30 ITEM 15. EXHIBITS, FINANCIAL S
TATEMENT SCHEDULES30 15(a)(1) Financial Statements
30 15(a)(2) Financial Stateme
nt Schedules30 15(a)(3) Exhibits
30 ITEM 16. FORM 10-K SUMMARY
33 Pfizer Inc.
2018 Form 10-K i 
DEFINED TERMSUnless the context req
uires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2018 Form 10-K (defined below) refe r to Pfizer Inc. and itssubsidiaries. We also have use
d several other terms in this 2018 Form 10-K, most of which are exp lained or defined below.2018 Financial Report
Exhibit 13 to this 2018 Form 10-K 2018 Form 10-K
This Annual Report on Form 10-K fo r the fiscal year ended December 31, 20182019 Proxy Statement
Proxy Statement for the 2019 Annual Meeting of ShareholdersACA
U.S. Patient Protection and Affordab le Care Act, as amended by the Health Care and Education Reconciliation ActACIP
Advisory Committee on Immunizatio n PracticesAlliance revenues
Revenues from alliance ag reements under which we co-promote products discovered or developed by other companies or usAnacor
Anacor Pharmaceuticals, Inc. ANDA
Abbreviated New Drug Application Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.Bain Capital
Bain Capital Private Equity and  Bain Capital Life SciencesBLA
Biologics License Application BMS
Bristol-Myers Squibb Company Cerevel
Cerevel Therapeutics, LLC cGMPs
current Good Manu facturing PracticesDEA
U.S. Drug Enforcement Agency Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New ZealandEFPIA
European Federation of Pharmaceutica l Industries and AssociationsEH
Essential Health EMA
European Medicines Agency Emerging Markets
Includes, but is not lim ited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe,Africa, the Middle East, 
Central Europe and TurkeyEU
European Union Exchange Act
Securities Exchange Act of  1934, as amendedFCPA
U.S. Foreign Corrupt Practices  ActFDA
U.S. Food and Drug A dministrationFFDCA
U.S. Federal Food, Dru g and Cosmetic ActGPD
Global Product Development  organizationGSK
GlaxoSmithKline plc HIS
Hospira Infusion Systems Hospira
Hospira, Inc. ICU Medical
ICU Medical, Inc. IH
Innovative Health IPR&D
In-process Research and  DevelopmentLIBOR
London Interbank Offered Rate LOE
Loss of Exclusivity MCO
Managed Care Organization Medivation
Medivation, Inc. NDA
New Drug Application NMPA
National Medical Product Administratio n (formerly known as China Food and Drug Administration or CFDA)NYSE
New York Stock Exchange OTC
over-the-counter PBM
Pharmacy Benefit Manager PGS
Pfizer Global Supply PMDA
Pharmaceuticals and Medical Device A gency in JapanR&D
Research and Development SEC
U.S. Securities and Exchang e CommissionTax Cuts and Jobs Act
Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017U.K.
United Kingdom U.S.
United States VAI
Voluntary Action Indicated WRD
Worldwide Research and Development 
Pfizer Inc.2018 Form 10-K ii 
~$53.6 Billion   in Revenues in 2018 
  
10 
  Products with Direct Product and/or Alliance Revenues ofGreater than $1 Billion 
in 2018 
  
2 
 Distinct Business Segments in 2018 —   Pfizer Innovative Health 
( ~$33.4 Billion 2018 Revenues ) / Pfizer Essential Health ( ~$20.2Billion 2018 Revenues 
)  
  
6 
 Primary Therapeutic Areas in Pfizer Innovative Health in 2018—
Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare D
isease andConsumer Healthcare
 
  
4 
 Pfizer Essential Health Product Categories in 2018  — Global Brands 
(Legacy Established Products & Peri-LOE Products) , Sterile Injectable Pharmaceuticals, Biosimilars and Pfizer CentreOne
 
  
>125 
 Countries Where We Sell Our Products  
  
100 
  Projects in Clinical Research & Development* 
  
~$8 Billion 
 2018 R&D Expense  
  
58 
 Manufacturing Sites Worldwide Operated by PGS 
  
~92,400 
  Employees GloballyUnless indicated otherwise, the information contained in this summary is as of 
December 31, 2018 .
 This summary does not include information that will be incorporated by reference into Part III ofthis 
2018 Form 10-K from our 2019 Proxy Statement. * 
As of January 29, 2019 Pfizer Inc.
2018 Form 10-K iii 
TABLE OF CONTENTSPART I
ITEM 1.
BUSINESS 
 
ABOUT PFIZERPfizer Inc. is a research-b
ased, global biopharmaceutical company. We apply science and our globa l resources to bring therapies to people that extend andsignificantly i
mprove their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines andvaccines, as well a
s many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness,prevention, treatments and cures that chal
lenge the most feared diseases of our time. We collaborate with healthcare providers, governments and localcommunities to support and expand acce
ss to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to amuch lesser extent, from al
liance agreements, under which we co-promote products discovered or developed by other companies or us . The majority of our revenues come from the manufacture and sale of b
iopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June2, 1942.
We believe that our medic
ines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but alsofrom a reduction in o
ther healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. Wecontinue to actively engage in d
ialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treatdisease and improve ou
tcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements andcontracting methods with
 payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling ourcompany’s purpose: 
Breakthroughs that  change patients’ lives . By doing so, we expect to create va lue for the patients we serve and for our shareholders.We are committed to ca
pitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as throughvarious forms of business 
development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions,mergers and acquisitions. 
We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhanceshareholder value by pursuing a d
isciplined, strategic and financial approach to evaluating business development opportunities.Our significant recent b
usiness development activities include:•
On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine ourrespective consumer healthca
re businesses into a new consumer healthcare joint venture that will operate globally under the GSK ConsumerHealthcare name. The joint venture 
is expected to be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health,skin health and therapeutic oral hea
lth and will be the largest global OTC consumer healthcare business. In exchange for contributing our ConsumerHealthcare business, we will receive a 
32% equity stake in the company and GSK will own the remaining 68%. The transaction is expected to close inthe second half of 2019, subject to customary 
closing conditions including GSK shareholder approval and required regulatory approvals.•
On February 3, 2017, we completed the sale of Pfizer’s global infusion systems net assets, HIS, to ICU Medical for up to approximately $900 million , composed of cash a
nd contingent cash consideration, ICU Medical common stock and seller financing . HIS, which was acquired as part of the Hospiraacquisition in September 2015, 
includes intravenous pumps, solutions and devices.•
On December 22, 2016, for $1,040 million we acquired the develo pment and commercialization rights to AstraZeneca’s small molecule anti-infectivesbusiness, primarily outside the
 U.S. , which includes the market ed products Zavicefta™ (ceftazidime-avibactam), Merrem™/Meronem™ (meropenem)and Zinforo™ (ceftar
oline fosamil), and the clinical development assets aztreonam-avibactam and ceftaroline fosamil-avibactam.•
On September 28, 2016, we acquired Medivation for approximately $14.3 billion in cash ( $13.9 billion , net of cash ac quired). Medivation is abiopharmaceutical company 
focused on developing and commercializing small molecules for oncology.•
On June 24, 2016, we acquired Anacor for approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is a biopharmaceu
tical company focused on novel small-molecule therapeutics derived from its boron chemistry platform.For a further discussion of our st
rategy and our business development initiatives, see the Notes to Consolidated Financial Statements— Note 2 . Acquisitions,Divestitures, Assets and Liabilities Held 
for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-MethodInvestments and Privat
ely Held Investment and the Overview of Our Performance, Ope rating Environment, Strategy and Outlook — Our Strategy and — Our Business Development Initiatives 
sections in our 2018 Financial Report. Our businesses are heavil
y regulated in most of the countries in which we operate. In the U.S., the principal authority regulating our operations is the FDA. TheFDA regulates the safety and efficac
y of the products we offer and our research, quality, manufacturing processes, product promotion, advertising and productlabeling. Simi
lar regulations exist in most other countries, and in many countries the government also regulates our prices. In the EU, the EMA conducts thescientific evaluat
ion, supervision and safety monitoring of our products, and employs a centralized procedure for approval of medicines for the EU and theEuropean Economic Area c
ountries. In China, the NMPA (formerly CFDA) is the primary regulatory authority for approving and supervising medicines. In Japan,the PMDA is involved in a wide ran
ge of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. Healthauthorities in many midd
le and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of the FDA orEMA) before they begin to conduct their app
lication review process and/or issue their final approval. For additional information, see the Item 1. Business — Government Regulation 
and Price Constraints section below. Note: 
Some amounts in this 2018 Form 10-K may not add due to rounding. Al l percentages have been calculated using unrounded amounts.AVAILABLE INFORMATION AND PFIZER WEBSITE
Our website is located at 
www.pfizer.com . This 2018 Form 10-K, our Quarterly Report s on Form 10-Q and our Current Reports on Form 8-K, and amendmentsto those reports filed or furnished pu
rsuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text formatand, where applicable, in 
interactive data file format , as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.
Throughout this 2018 Form 10-K, we “incorporate by reference” certain information from other documents filed or to be filed with the SEC, including our 2019 Proxy Statement and the 
2018 Financial Report, portions of which are filed as Exhibit 13 to this 2018 Form 10-K, and which also  will be contained in Appendix Ato our 
2019 Proxy Statement. The SEC al lows us to disclose important information by referring to it in that manner. Please refer to this information. Our 2018 Annual Report to Shar
eholders consists of the 2018 Financial Report and the Corpo rate and Shareholder Information attached to the 2019 Proxy Statement. Our 2018 
Financial Report w ill be available on our website on or about February 28, 2019. Our 2019 Proxy Statement will be available on our website on or aboutMarch 14, 2019.
We may use our website as
 a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosurepromulgated by the
 SEC. These disclosures are included on our website in the “Investors” or “News” sections. Accordingly, investors should monitor theseportions of our website
, in addition to following Pfizer’s press releases, SEC filings, public conference calls and webcasts, as well as Pfizer’s social mediachannels (Pfizer’s Fa
cebook, YouTube and LinkedIn pages and Twitter accounts ( @Pfizer and @Pfizer_News )). Information relating t
o corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies onBusiness Conduct (for all of
 our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of BusinessConduct and Ethics for
 Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; BoardCommittees; Committee 
Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on ourwebsite. We wil
l provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, NewYork, NY 10017. We will disclose any 
future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our ChiefExecutive Officer, Chief Fina
ncial Officer and Controller on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules.Information relating to shareholde
r services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, isalso available on our website.
The information contained on our webs
ite, our Facebook, YouTube and LinkedIn pages or our Twitter accounts does not, and shall not be deemed to, constitutea part of this 
2018 Form 10-K. Pfizer’s refe rences to the URLs for websites are intended to be inactive textual references only.Pfizer Inc.
2018 Form 10-K 1 
TABLE OF CONTENTSCOMMERCIAL OPERATIONS
From the second quarter of our 2016 fiscal 
year until the end of 2018, we managed our commercial operations through two distinct business segments: PfizerInnovative Health (IH) and Pf
izer Essential Health (EH). The IH and EH operating segments were each led by a single manager. Each operating segment hadresponsibility for its commercial activities an
d for certain IPR&D projects for new investigational products and additional indications for in-line products thatgenerally have achieved proof-of
-concept. Each business had a geographic footprint across developed and emerging markets.At the beginning of our fiscal yea
r 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each ofwhich is led by a single manag
er—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Consumer Healthcare. We designed this new global structure totake advantage of new growth opportunities d
riven by the evolving and unique dynamics of relevant markets.Some additional informat
ion about each business follows:•
Pfizer Biopharmaceuticals Group - a science-based Innovative Med icines business that includes our Innovative Health business units (except ConsumerHealthcare) as well as a new Hospit
al business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We alsoincorporated our biosim
ilar portfolio into our Oncology and Inflammation & Immunology therapeutic areas;•
Upjohn - an off-patent branded and generic established medicines business headquartered in China that includes 20 of our off-patent solid oral dose legacybrands, including 
Lyrica , Lipitor , Norvasc, Viagra and Celebrex , as well as certain generic m edicines; and•
Consumer Healthcare - an over-the-counter medicine s business, which we announced on December 19, 2018 will be contributed to, and combined with,GSK’s consumer healthcare bu
siness to form a new consumer healthcare joint venture.Results for 2018 and prior per
iods in our 2018 Form 10-K are reported on the basis under which we managed our businesses in 2018 and do not reflect the2019 reorganization.
 Beginning with our first-quarter 2019 financial results, our financial reporting will reflect the new organizational structure.For additional information
 regarding our new global structure, as well as our Organizing for Growth initiative, see the Overview of Our Performanc e, OperatingEnvironment, Strategy and Outlook––Our 
Strategy––Organizing for Growth section in our 2018 Financial Report.Some additional informat
ion about our business segments as of December 31, 2018 (prior to our new 2019 commercial organizational re-alignment) follows:
 
IH focused on develo
ping and commercializing novel, value-creatingmedicines and vaccines tha
t significantly improve patients’ lives, as well asproducts for consumer healthcare. 
Key therapeutic areas
 included internal medicine, vaccines, oncology,inflammation & immunology, rare
 disease and consumer healthcare. EH included legacy brands that have lost or will soon lose marketexclusivity in both developed
 and emerging markets, branded generics,generic sterile injectable prod
ucts, biosimilars and select branded productsincluding anti-infectives. EH also includ
ed an R&D organization, as well asour contract manufacturing busines
s. Through February 2, 2017, EH alsoincluded HIS.
Leading brands included: 
- 
Prevnar 13/Prevenar 13- 
Xeljanz- 
Eliquis- Lyrica 
(U.S., Japan and cer tain other markets)- 
Enbrel (outside the U.S. and Canada) - 
Ibrance- 
Xtandi- 
Chantix/Champix- Several OTC consumer he
althcare products(e.g., 
Centrum  and Advil )   Leading brands included: - 
Lipitor- Norvasc
- Lyrica 
(Europe, Russia, Turkey, Israel and Central Asia countries)- Celebrex
- Viagra*
- 
Inflectra/Remsima- Sulperazon
- 
Several sterile injectable products* 
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.
Pfizer Inc.
2018 Form 10-K 2 
TABLE OF CONTENTSFor a further discussion of these operat
ing segments, see the Innovative Health and Essential Health sections below and the Notes to Consolidat ed FinancialStatements— 
Note 18. Segment, Geographic and Other Revenue Informat ion , including the tables therein captioned Selected Income Statement Information , Geographic Information 
and Significant Product Revenues , the table captioned Revenues by Segment and Geography in the Analysis of the Consolidated Statements of Income 
section, and the Analysis of Operating Segm ent Information section in our 2018 Financial Report, wh ich are incorporated by reference.INNOVATIVE HEALTH
The key therapeu
tic areas comprising our IH business segment included:Therapeutic Area
Description Key Products Internal Medicine
Included innovative brands from two therapeutic areas,Cardiovascular Metabolic and Pain
, as well as regional brands.Lyrica  (outside Europe, Russia, Tur key, Israel and CentralAsia countries), 
Chantix/Champix  and  Eliquis  (jointly developed and commercialized
 with BMS)Vaccines
Included innovative vaccines brands across all ages—infants,adolescents and ad
ults—in pneumococcal disease, meningitisand tick-borne encep
halitis, with a pipeline focus on healthcare-acquired infections and
 maternal health.Prevnar 13/Prevenar 13 (pediatric/adult), Trumenba and FSME-IMMUN
Oncology
Included innovative oncology brands of biologics, smallmolecules and immunothera
pies across a wide range ofcancers.
Ibrance, Sutent, Xalkori, Inlyta  and Xtandi (jointly developed and commercialized
 with Astellas)Inflammation and
Immunology
Included innovative brands for chronic immune andinflammatory diseases.
Enbrel  (outside the U.S. and Canada), Xeljanz  and Eucrisa
Rare Disease
Included innovative brands for a number of rare diseases,including hematology, neuros
cience, and inherited metabolicdisorders.
BeneFix , Genotropin  and Refacto AF/Xyntha Consumer Healthcare*
Included over-the-counter (OTC) brands with a focus on dietarysupplements, pain management, gastrointe
stinal andrespiratory and personal care. In 2018, a
ccording to NicholasHall’s retail sales data (based o
n moving annual total datathrough the third quarter of 2018), Pfizer
’s ConsumerHealthcare business wa
s the fifth-largest branded multi-national, OTC consumer healthca
re business in the world andproduced two of the ten largest sell
ing consumer healthcarebrands (Centrum and A
dvil) in the world.Dietary Supplements: Centrum  brands, Caltrate  and Emergen-C
Pain Management: 
Advil  brands and ThermaCare Gastrointestinal: 
Nexium 24HR/Nexium Control  and  Preparation H
Respiratory and Personal Care
: Robitussin , Advil Cold &Sinus 
and ChapStick*
On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumerhealthcare businesses into a new consumer healthcare joint venture, which will operate globally under the GSK Consumer Healthcare name. Assets and liabilities
associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. We expect to complete
the transaction during the second half of 2019, subject to cus
tomary closing conditions, including GSK shareholder approval and required regulatory approvals. For additional information, see the Notes to Consolidated Financial Statements— 
Note 2 C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, LicensingArrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
: Assets and Liabilities Held for Sale.
We recorded direct product and/or a
lliance revenues of more than $1 billion for each of eight IH products in 2018 , and seven IH products in 2017 and 2016 : Innovative Health $1B+ Products
2018
2017 2016 Prevnar 13/Prevenar 13
Prevnar 13/Prevenar 13 Prevnar 13/Prevenar 13 Lyrica IH
Lyrica IH Lyrica IH Ibrance
Ibrance Enbrel Eliquis*
Eliquis* Ibrance Enbrel
Enbrel Eliquis* Xeljanz
Xeljanz Viagra IH Chantix/Champix
  Sutent   Sutent Sutent
      * 
Eliquis  includes alliance revenues and direct sales in 2018, 2017 and 2016. For a discussion of certain I
H products and additional information regarding the revenues of our IH business, including revenues by geography and of significantIH products, see the Notes to Conso
lidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Informat ion and the Analysis of the Consolidated Statements of Income 
— Revenues — Overview, — Revenues by Segment and Geography and — Revenues—Selected Product  Discussionsections in our 
2018 Financial Report; and for addit ional information on the key operational revenue drivers of our IH business, see the Analysis of Operating Segment Information 
— Innovative Health Operating Segment section of our 2018 Financial Report. For a discussion of the risks associated with ourdependence on certain of our major products, 
see Item 1A. Risk Factors — Dependence on Key In-Line Products below. ESSENTIAL HEALTH

The product categories in our EH business segment included:Product Category
Description Key Products Global Brands 
— LegacyEstablished Products
Included products that have lost patent protection (excludingSterile Injectable Pharmaceu
ticals and Peri-LOE Products).Lipitor , Premarin  family and Norvasc Global Brands 
— Peri-LOE Products
Included products that have recently lost or are anticipated tosoon lose patent protection.
Lyrica (Europe, Russia, Turkey, Israel and Central Asia),Viagra* 
, Celebrex , Pristiq , Zyvox , Vfend , Revatio  and Inspra
Sterile Injectable
Pharmaceuticals
Included generic injectables and proprietary specialtyinjectables (excluding Peri-LOE Prod
ucts).Medrol , Sulperazon , Fragmin  and Tygacil Biosimilars
Included recombinant and monoclonal antibodies, primarily ininflammation, oncology an
d supportive care.Inflectra / Remsima  (biosimilar infliximab) (U.S., Canada, the EU, Australia and cer
tain international markets),Nivestim/Nivestym 
 (biosimilar filgrastim) (U.S. and certain European, Asian and
 Africa/Middle East markets), Retacrit  (biosimilar epoetin alfa-epbx/
epoetin zeta) (U.S. andcertain European and Africa/M
iddle East markets) and Ixifi Infliximab BS for I.V. In
fusion 100mg (Japan) Pfizer CentreOne
Included revenues from our contract manufa cturing and activepharmaceutical ingredient s
ales operation, including sterileinjectables contract manufactu
ring, and revenues related to ourmanufacturing and supply agreements, 
including with ZoetisInc.
--*
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.
We recorded direct product revenue
s of more than $1 billion for two EH products in 2018 , one EH product in 2017 , and two EH products in 2016 : Essential Health $1B+ Products
2018
  2017   2016 Lipitor
  Lipitor   Lipitor Norvasc
     Premarin family of products For a discussion of certain 
EH products and additional information regarding the revenues of our EH business, including revenues by geography and ofsignificant EH products, see
 the Notes to Consolidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Informat ion and the Analysis of the Consolidated Statements of Income 
— Revenues — Overview, — Revenues by Segment and Geography and — Revenues—Selected Product Discussion 
sections in our 2018 Financial Report; and for addit ional information on the key operational revenue drivers of our EH business, see the Analysis of Operating Segment Information 
— Essential Health Operating Segment section of our 2018 Financial Report. For a discussion of the risks associated with ourdependence on certain of our major products, 
see Item 1A. Risk Factors — Dependence on Key In-Line Products below. Pfizer Inc.
2018 Form 10-K 3 
TABLE OF CONTENTSCOLLABORATION AND CO-PROMOTION AGREEMENTS
We are party to collaboration and/o
r co-promotion agreements relating to certain biopharmaceutical products, including, among others, Eliquis , Xtandi and Bavencio 
. Revenues from Eliquis (except in certain markets  where we have direct sales) , Xtandi and Bavencio are included in alliance reven ues.Eliquis 
has been jointly developed and i s being commercialized in collaboration with BMS. Pfizer funds between 50% and 60% of all development costsdepending on the study. Profits and losse
s are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. 
We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plusa percentage of the net sales to end-customers 
in these markets. Eliquis is part of the Novel Oral Ant icoagulant market; the agents in this class were developedas alternative treatment options to 
warfarin in appropriate patients.Xtandi 
is being developed an d commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related toU.S. net sales of 
Xtandi . Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributa ble to the U.S. market.In addition, Pfizer and Astel
las share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of internationalXtandi 
net sales (recorded in Other (Income)/Deductions––Net ). Xtandi is an androgen receptor inhibito r that blocks multiple steps in the androgen receptorsignaling pathway within tumor c
ells.Bavencio 
(avelumab) is being develop ed and commercialized in collaboration with Merck KGaA. Both companies jointly fund the majority of development andcommercialization costs, and split 
equally any profits generated from selling any products containing avelumab from this collaboration. Bavencio is currently approved in metasta
tic Merkel cell carcinoma and for patients with locally advanced or metastatic urothelial carcinoma in certain countries and in developmentas a potential treatment for multip
le other types of cancer.RESEARCH AND DEVELOPMENT
Innovation is critica
l to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. Our goal is to discover, develop and bring to ma
rket innovative products that address major unmet medical needs.Our R&D Priorities and Strategy
Our R&D priorities include:
•
delivering a pipeline of differentiated therapies and vaccines with the greatest medical and commercial potential;•
advancing our capabilities that can position Pfizer for long-term leadership; and•
creating new models for biomedical collaboration that will expedite the pace of innovation and productivity.To that end, our research and development prima
rily focuses on:•
Inflammation and Immunology ; •
Internal Medicine ; •
Oncology ; •
Rare Diseases ; •
Vaccines ; and •
Biosimilars.In January 2018, we announced our decision to end 
internal neuroscience discovery and early development efforts and re-allocate funding to other areas wherewe have stronger scientif
ic leadership. The development of tanezumab and potential treatments for rare neuromuscular disorders is not impacted by thisdecision. In June 2018, we announced our plan to 
invest up to $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, ourventure investment vehicle. In 
September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, tocontinue development
 of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, includingParkinson’s disease, epilepsy, Alzheimer’s 
disease, schizophrenia and addiction. For additional information on the transaction with Bain Capital, see the Notesto Consolidated Financial St
atements–– Note 2B. Acquisitions, Divestitures,  Assets and Liabilities Held for Sale, Licensing Arrangements, Research andDevelopment and Collaborat
ive Arrangements, Equity-Method Investments and Privately Held Investment: Divestitures in our 2018 Financial Report. While a significant portion of
 R&D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologiesdeveloped by third parties to in
corporate into our discovery and development processes or projects, as well as our product lines, by entering into collaboration,alliance and license ag
reements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable usto co-develop, license or acqu
ire promising compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees tofund a portion of the development costs of one or more of ou
r pipeline products in exchange for rights to receive potential milestone payments, revenue sharingpayments, profit sharing payments and/o
r royalties. Collaboration, alliance, license and funding agreements and equity- or debt-based investments allow us toshare risk and cost and to access e
xternal scientific and technological expertise, and provide us the opportunity to advance our own products as well as the in-licensed or acquired prod
ucts.Our R&D Operations
We conduct R&D internally and 
also through contracts with third parties, through collaborations with universities and biotechnology companies and incooperation with other
 pharmaceutical firms. In 2018, we continued to strengthen our global R&D organization and pursue strategies intended to improveinnovation and overall product
ivity in R&D to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time.Our R&D spending in 2018 wa
s conducted through a number of matrix organizations:•
Research Units within our WRD organization were generally responsible for research and early-stage development assets for our IH business (assets thathave not yet achieved proof-of-concept).
•
Our R&D organization within the EH business supported the large base of EH products and helped develop potential new sterile injectable drugs andtherapeutic solutions, 
as well as biosimilars.•
Our Global Product Development organization, a unified center for late-stage deve lopment for our innovative products that was generally responsible for theoperational execution 
of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in the Innovative portfolio. For WRD
assets, GPD worked in close collaboration with the Early Clinical Development group, which has expertise in various disciplines such as Biostatistics,Clinical Pharmacology and Digital Medicine.
•
Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurred, provided technical expertise andother services to the various 
R&D projects, and were organized into science-based functions (which were part of our WRD organization), such asPharmaceutical Sciences, Medicine Desig
n, Regulatory and Drug Safety, and non-science-based functions, such as Facilities, Business Technology andFinance.
At the beginning of 2019, we reorganized our 
R&D operations as part of our Organizing for Growth reorganization:•
WRD is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical & Safety organization thatincorporates the form
er Chief Medical Office as well as the Worldwide Safety function;•
The R&D organization within the EH business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars intoWRDM and GPD and real
igning them with the relevant therapeutic areas (e.g., Oncology and Inflammation & Immunology);•
The Regulatory function has been moved from the WRDM organization into the GPD organization; and•
Late-stage portfolio spend has been moved from IH to GPD and from EH to GPD and Upjohn.For discussion regarding t
hese R&D matrix organizations and additional information on our R&D operations and expenses, see the Overview of Our Performance, Operating Environ
ment, Strategy and Outlook — Our Strategy — Description of Research and Development Operations and Costs and Expenses— 
Research and Development (R&D) Expenses sections in our 2018 Financial Report. Our R&D Pipeline and Competition
The discovery and development of safe, effect
ive new products, as well as the development of additional uses for existing products, are necessary for thecontinued strength of our businesses. 
Drug candidates can fail at any stage of the process, and candidates may not receive regulatory approval even after manyyears of research and development. The proce
ss from discovery to development to regulatory approval can take more than ten years.As of 
January 29, 2019 , we had the following number of projects in various stages of R&D:
Development of a single compound 
is often pursued as part of multiple programs. While these drug candidates may or may not eventually receive regulatoryapproval, new drug candidates enter
ing clinical development phases are the foundation for future products. In addition to discovering and developing newproducts, our R&D efforts seek to add 
value to our existing products by improving their effectiveness, enhancing ease of dosing and by discovering potential newindications for them.
Information concerning severa
l of our drug candidates in development, as well as supplemental filings for existing products, is set forth in the Analysis of the Consolidated Statements of Income 
— Product Developments––Biopharmaceutical section in our 2018 Financial Report, which is incorpora ted by reference.Our competitors also devote substant
ial funds and resources to R&D. We also compete against numerous small biotechnology companies in developingpotential drug candidates. The extent to wh
ich our competitors are successful in their research could result in erosion of the sales of our existing products andpotential sales of products in de
velopment, as well as unanticipated product obsolescence. In addition, several of our competitors operate without large R&Dexpenses and make a regular practi
ce of challenging our product patents before their expiration. For additional information, see the Competition and Item 1A.Risk Factors 
— Competitive Products sections below. INTERNATIONAL OPERATIONS
We have significant operat
ions outside the U.S. In 2018, operations in developed and emerging markets were managed through our two business segments: IHand EH. Emerging markets are an 
important component of our strategy for global leadership, and our commercial structure recognizes that the demographicsand rising economic powe
r of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets.Urbanization in emerging marke
ts, particularly in Asia, is creating additional access opportunities for our medicines.We sell our products in o
ver 125 countries. Revenues from operations outside the U.S. of $28.3 billion accounted for 53% of our total revenues in 2018 . By total revenues, China and Japan are our two 
largest national markets outside the U.S. For a geographic breakdown of revenues, see the table captioned Geographic Information 
in the Notes to Consolida ted Financial Statements— Note 18. Segment, Geographic and Other Revenue Informat ion in our 2018 Financial Report, and the 
Analysis of the Consol idated Statements of Income — Revenues — Overview and — Revenues by Segment and Geography sections in our 2018 Financial Report.

Pfizer Inc.2018 Form 10-K 4 
TABLE OF CONTENTSOur international operations are 
subject, in varying degrees, to a number of risks inherent in carrying on business in other countries, including, among otherthings, currency fluctuation
s, capital and exchange control regulations and expropriation and other restrictive government actions. See Item 1A. Risk Factors — International Operations 
below. Our international businesses are also subject to government-imposed constraints, including laws and regulations on pricing,reimbursement, and access to our produ
cts. See Item 1. Business — Government Regulation and Price Constraints — Outside the United States below for a discussion of these matters.
Depending on the direction of change re
lative to the U.S. dollar, foreign currency values can increase or decrease the reported dollar value of our net assets andresults of operations. Whi
le we cannot predict with certainty future changes in foreign exchange rates or the effect they will have on us, we attempt to mitigatetheir impact through operational 
means and by using various financial instruments, depending upon market conditions. For additional information, see the Notesto Consolidated Financial St
atements— Note 7 F . Financial Instruments : Derivative Financial Instruments and Hedging Activities in our 2018 Financial Report, as well as the 
Forward-Looking Information and Facto rs That May Affect Future Results — Financial Risk Management section in our 2018 Financial Report. Those sections of our 
2018 Financial Report are incorpor ated by reference.MARKETING
In our global biopharmaceutica
l businesses, we promote our products to healthcare providers and patients. Through our marketing organizations, we explain theapproved uses, benefits and risks of ou
r products to healthcare providers, such as doctors, nurse practitioners, physician assistants and pharmacists; MCOs thatprovide insurance coverage, su
ch as hospitals, Integrated Delivery Systems, Pharmacy Benefit Managers and health plans; and employers and governmentagencies who hire MCOs to p
rovide health benefits to their employees. We also market directly to consumers in the U.S. through direct-to-consumer advertisingthat seeks to communicate the approved uses, benef
its and risks of our products while motivating people to have meaningful conversations with their doctors. Inaddition, we sponsor general adve
rtising to educate the public on disease awareness, prevention and wellness, important public health issues, and our patientassistance programs.
Our prescription pharmace
utical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies andpharmacies, and, in t
he case of our vaccines products in the U.S., we primarily sell directly to the U.S. Centers for Disease Control and Prevention, wholesalers,individual provide
r offices, retail pharmacies, and integrated delivery networks. We seek to gain access for our products on healthcare authority and PBMformularies, which are lists of a
pproved medicines available to members of the PBMs. PBMs use various benefit designs, such as tiered co-pays for formularyproducts, to drive u
tilization of products in preferred formulary positions. We may also work with payers to assist them with disease management, patienteducation and other tools that help their med
ical treatment routines.In 
2018 , our top three biopharmaceutical wholesalers accounted for approximately 37% of our total reven ues (and approximately 76% of our total U.S. revenues).
% of 
2018 Total Revenues and U.S. Revenues from Major Biopharmaceutical Wholesale
rs and Other Customers
 
Our global Consumer Healthcar
e business uses its own sales and marketing organizations to promote its products, and occasionally uses distributors andagents, principally in smaller markets
. The advertising and promotions for our Consumer Healthcare business are generally disseminated to consumers throughtelevision, print, digital and
 other media advertising, as well as through in-store promotion. Consumer Healthcare products are sold through a wide variety ofchannels, including distributors
, pharmacies, retail chains and grocery and convenience stores. Our Consumer Healthcare business generates a significantportion of its sales from se
veral large customers, the loss of any one of which could have a material adverse effect on the Consumer Healthcare business.Pfizer Inc.
2018 Form 10-K 5 
TABLE OF CONTENTSPATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS
Our products are sold around the wor
ld under brand-name, logo and certain product design trademarks that we consider, in the aggregate, to be of materialimportance to Pfizer. Trademar
k protection continues in some countries for as long as the mark is used and, in other countries, for as long as it is registered.Registrations generally are f
or fixed, but renewable, terms.We own or license a number of 
U.S. and foreign patents. These patents cover pharmaceutical and other products and their uses, pharmaceutical formulations,product manufacturing processes and 
intermediate chemical compounds used in manufacturing.Patents for individual produ
cts extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countrieswhere patent protection is obtained. The actua
l protection afforded by a patent, which can vary from country to country, depends upon the type of patent, thescope of its coverage and the availab
ility of legal remedies in the country. Further, patent term extension may be available in many major countries tocompensate for a regulatory delay 
in approval of the product. For additional information, see Item 1. Business — Government Regulation and Price Constraints— 
Outside the United States — Intellectual Property below. In various markets, a period of regu
latory exclusivity may be provided to certain therapeutics upon approval. The scope and term of such exclusivity will vary but,in general, the perio
d of regulatory exclusivity will run concurrently with the term of any existing patent rights associated with the therapeutic.In the aggregate, our patent and related rights are of mater
ial importance to our businesses in the U.S. and most other countries. Based on current productsales, and considering the v
igorous competition with products sold by our competitors, the patent rights we consider most significant in relation to our businessas a whole, togeth
er with the year in which the basic product patent expires (including, where applicable, the additional six-month pediatric exclusivity periodand/or the granted patent term extension), are those for the med
icines set forth in the table below. Unless otherwise indicated, the years set forth in the tablebelow pertain to the basic product patent e
xpiration for the respective products. Patent term extensions, supplementary protection certificates and pediatricexclusivity per
iods are not reflected in the expiration dates listed in the table below, unless they have been granted by the issuing authority. In some instances,there are later-expiring patents 
relating to our products directed to particular forms or compositions, to methods of manufacturing, or to use of the drug in thetreatment of particular disease
s or conditions. However, in some cases, such patents may not protect our drug from generic or, as applicable, biosimilarcompetition after the expiration of the ba
sic patent.Drug
 U.S. Basic Product PatentExpiration Year 
  Major EU Basic Product PatentExpiration Year
  Japan Basic Product PatentExpiration Year
Lyrica
  2019 (1)  2014 (2)  2022 (3)Chantix/Champix
  2020   2021   2022 Sutent
  2021   2021   2024 Ibrance
  2023   2028   2028 Inlyta
  2025   2025   2025 Xeljanz
  2025   2028 (4)  2025 Prevnar 13/Prevenar 13
  2026   2026 (5)  2029 Eucrisa
  2026   N/A (6)  N/A (6)Eliquis 
(7)  2026   2026   2026 Xtandi 
(8)  2027   * (8)  * (8)Besponsa
  2027   2023   2028 (9)Xalkori
  2029   2027   2028 Bavencio 
(10)  2033   2032   2033 (1) 
 In November 2018, the FDA granted pediatric exclusivity for Lyrica in the U.S. for an additional six months to June 2019; pediatric exclusivity applies to both the basicproduct patent for Lyrica and a method of treatment patent
, both of which expired in the U.S. in December 2018.(2) 
 Lyrica regulatory exclusivity in the EU expired in July 2014. (3) 
 Lyrica is covered by a Japanese method-of-use patent which expires in 2022. The patent is currently subject to an invalidation action. (4) 
 Xeljanz EU expiry is provided by regulatory exclusivity. (5) 
 The EU patent that covers the combination of the 13 serotype conjugates of Prevenar 13 has been revoked following an opposition proceeding. This first instance decisionhas been appealed. There are other EU patents and pending applications covering the formulation and various aspects of the
 manufacturing process of Prevenar 13 thatremain in force.
(6) 
 Eucrisa is not approved in the EU or Japan. (7) 
 Eliquis was developed and is being commercialized in collaboration with BMS. (8) 
 Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. (9) 
 Besponsa Japan expiry is provided by regulatory exclusivity. (10) 
 Bavencio is being developed and commercialized in collaboration with Merck KGaA. A number of our current products have exper
ienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For additional information, 
including further discussion of our products experiencing, or expected to experience in 2019 , patent expirations  or loss of regulatoryexclusivity in the 
U.S., Europe or Japan, see the Overview of Our Performance, Ope rating Environment, Strategy and Outlook — Our Operating Environment — Industry-Specific Challenges 
— Intellectual Property Rights and Collaboration/Licensing Rights section in our 2018 Financial Report and Item 1A. Risk Factors — 
Dependence on Key In-Line Products below. Companies have filed appl
ications with the FDA seeking approval of product candidates that such companies claim do not infringe our patents; these includecandidates that would compete w
ith, among other products, Eliquis , Xeljanz and Xtandi . We also are often involved in other proceedings, such as inter partesreview, post-grant revie
w, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreigncounterparts relating to our inte
llectual property or the intellectual property rights of others. For additional information , see the Notes to Consolidated FinancialStatements— 
Note 17 A1 . Contingencies and Certain Commitments — Legal Proceedings––Patent Litigation in our 2018 Financial Report. 
The expiration of a basic product patent or loss of patent protection resulting from a legal challenge normally results in significant competition from genericproducts against the original
ly patented product and can result in a significant reduction in revenues for that product in a very short period of time. In somecases, however, we can continue to obta
in commercial benefits from product manufacturing trade secrets; patents on uses for products; patents on processesand intermediates for the economica
l manufacture of the active ingredients; patents for special formulations of the product or delivery mechanisms; orconversion of the active ingred
ient to OTC products.Biologic Products
Our biologic products, includin
g BeneFIX , ReFacto , Xyntha , Bavencio , Prevnar 13/Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada), may face in the fu
ture, or already face, competition from biosimilars (also referred to as follow-on biologics). In the U.S., such biosimilars would reference ouroriginator biologic products 
approved under the U.S. Public Health Service Act. Additionally, the FDA has approved a follow-on recombinant human growthhormone that referenced our biotechnology produ
ct, Genotropin , that was approved under the FFDCA. Biosimilars are versions of biologic medicines 
that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacyand that have 
no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives tobiologic medicine
s. Abbreviated legal pathways for the approval of biosimilars exist in certain international markets and, since the passage of the ACA in 2010, aframework for such approval e
xists in the U.S. In Europe, the European Commission grants marketing authorizations for biosimilars pursuant to a set of generaland product class-specific g
uidelines for biosimilar approvals.As part of our business strategy, 
we are capitalizing on our expertise in biologics manufacturing, as well as our regulatory and commercial strengths, to developand commercialize biosimilar medicines. See 
Item 1A. Risk Factors — Biologic Products below. We may face litigation 
with respect to the validity and/or scope of patents relating to our biologic products. Likewise, as we develop, manufacture and seek tolaunch biosimila
rs, patents may be asserted against us.International
One of the main limitations on ou
r operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products. Underinternational and U.S. free trade agree
ments in recent years, we have seen some improvement in global protection of intellectual property rights. For additionalinformation, see 
Item 1. Business — Government Regulation and Price Constraints — Outside the United States — Intellectual Property below. COMPETITION
Our businesses are conducted in 
intensely competitive and often highly regulated markets. Many of our prescription  pharmaceutical products face competition inthe form of bran
ded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of com petition include efficacy, safety, ease ofuse, and cost effectiveness. Though the means of compet
ition vary among product categories and business groups, demonstrating the value of our products is acritical factor for success in all o
f our principal businesses.Our competitors include o
ther worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus,generic and biosimi
lar drug manufacturers and consumer healthcare manufacturers. We compete with other companies that manufacture and sell products thattreat diseases or indicatio
ns similar to those treated by our major products.This competition affects our co
re product business, which is focused on applying innovative science to discover and market products that satisfy unmet medicalneeds and provide 
therapeutic improvements. Our emphasis on innovation is underscored by our multi-billion-dollar investment in R&D, as well as our businessdevelopment transactions, both designed to 
result in a strong product pipeline. Our investment in research does not stop with drug approval; we continue toinvest in further understanding the va
lue of our products for the conditions they treat, as well as potential new applications. We seek to protect the health andwell-being of patients by 
striving to ensure that medically sound knowledge of the benefits and risks of our medicines is understood and communicated topatients, physicians, payer
s and global health authorities. We also seek to continually enhance the organizational effectiveness of all of our biopharmaceuticalfunctions, including coord
inating support for our salespersons’ efforts to accurately and ethically launch and promote our products to our customers.Operating conditions have become mo
re challenging under mounting global pressures of competition, industry regulation and cost containment. We continue totake measures to evaluate, adapt and improve ou
r organization and business practices to better meet customer and public needs. We believe that we havetaken an industry-leading ro
le in evolving our approaches to U.S. direct-to-consumer advertising; interactions with, and payments to, healthcare professionals;and medical education grants. We a
lso continue to sponsor programs to address patient affordability and access barriers, as we strive to advance fundamentalhealth system change through support for better hea
lthcare solutions.Our vaccines business ma
y face competition from the introduction of alternative or next generation vaccines. For example, Prevnar 13 may face competition in the form of alternative 13-valent or add
itional valent next-generation pneumococcal conjugate vaccines prior to the expiration of its patents, which may adverselyaffect our future results.
Our generics and biosimilars busin
esses compete with branded products from competitors, as well as other generics and biosimilars manufacturers. Globally,Pfizer sells generic versions of Pfizer’s,
 as well as certain competitors’, solid oral dose and sterile injectable pharmaceutical products, as well as biosimilars. Weseek to maximize the opportunit
y to establish a “first-to-Pfizer Inc.
2018 Form 10-K 6 
TABLE OF CONTENTSmarket” or early market p
osition for our generic injectable drugs and biosimilars, as a “first-to-market” position provides customers a lower-cost alternativeimmediately when available and 
also may provide us with potentially higher levels of sales and profitability until other generic or biosimilar competitors enter themarket.
Our Consumer Healthcare bus
iness faces competition from OTC business units in other major pharmaceutical and consumer packaged goods companies, andretailers who carry the
ir own private label brands. Our competitive position is affected by several factors, including the amount and effectiveness of our and ourcompetitors’ promotiona
l resources; customer acceptance; product quality; our and our competitors’ introduction of new products, ingredients, claims, dosageforms, or other forms of innovation; and p
ricing, regulatory and legislative matters (such as product labeling, patient access and prescription to OTC switches).Managed Care Organizations
The evolution of managed care in the U.S. ha
s been a major factor in the competitive makeup of the healthcare marketplace. Approximately 298 million peoplein the U.S. now have some form of hea
lth insurance coverage. Due to the expansion of health insurance coverage (see Item 1. Business — GovernmentRegulation and Price Constrain
ts — In the United States below), the marketing of presc ription drugs to both consumers and the entities that manage thisexpanded coverage in the U.S. continues to g
row in importance.The influence of MCOs has inc
reased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, thoseorganizations have been consol
idating into fewer, even larger entities. This consolidation enhances both their ability to negotiate, as well as their importance toPfizer.
The growth of MCOs has increased p
ressure on drug prices as well as revenues. One objective of MCOs is to contain and, where possible, reduce healthcareexpenditures. MCOs typically ne
gotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to membersof the MCOs), clinica
l protocols (requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one ormore generic products before perm
itting access to a branded medicine), volume purchasing, long-term contracts and their ability to influence volume and marketshare of prescription drugs. In add
ition, by placing branded medicines on higher-tier status in their formularies (leading to higher patient co-pays) or non-preferred tier status, MCOs tran
sfer a portion of the cost of the medicine to the patient, resulting in significant out-of-pocket expenses for the patient, especiallyfor chronic treatments. This f
inancial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. MCOsalso use additional measur
es such as new-to-market blocks, exclusion lists, indication-based pricing, “copay accumulator” programs and value-basedpricing/contracting to i
mprove their cost containment efforts. We are closely monitoring these newer approaches and developing appropriate strategies torespond to them.
Due to their generally lower c
ost, generic medicines typically are placed in lowest cost tiers of MCO formularies. The breadth of the products covered byformularies can vary con
siderably from one MCO to another, and many formularies include alternative and competitive products for treatment of particularmedical problems. MCOs are curre
ntly evaluating the appropriate placement of biosimilars on their formularies.Exclusion of a product from a for
mulary or other MCO-implemented restrictions can significantly impact drug usage in the MCO patient population.Consequently, pharmaceutica
l companies compete to gain access to formularies for their products. Unique product features, such as greater efficacy, betterpatient ease of use, or fewer side effects, a
re generally beneficial to achieving access to formularies. However, lower overall cost of therapy is also an importantfactor. We have be
en generally, although not universally, successful in having our major products included on MCO formularies. However, increasingly ourbranded products are being placed on the higher t
iers or in a non-preferred status.MCOs also emphasize pr
imary and preventive care, out-patient treatment and procedures performed at doctors’ offices and clinics as another way to managecosts. Hospitalizat
ion and surgery, typically the most expensive forms of treatment, are carefully managed. Since the use of certain drugs can reduce the needfor hospitalization, profes
sional therapy, or even surgery, such drugs can become favored first-line treatments for certain diseases.The ACA has accelerated
 payment reform by distributing risk across MCOs and other stakeholders in care delivery with the intent of improving quality whilereducing costs, which c
reates pressure on MCOs to tie reimbursement to defined outcomes. We anticipate continued Congressional interest in modifyingprovisions of the ACA, par
ticularly given the recent ruling in Texas v. Azar to invalidate the law as unconstitutional, though we believe it is unlikely Congress willfind bipartisan consensus to advan
ce any significant changes to the ACA until the legal process unfolds. We are monitoring any such actions to see if anychanges to the ACA will be 
enacted that would impact our business.Generic Products
One of the biggest competitive chal
lenges that our branded products face is from generic pharmaceutical manufacturers. Upon the expiration or loss of patentprotection for a product, especial
ly a small molecule product, we can lose the major portion of revenues for that product in a very short period of time. Severalcompetitors make a regular pra
ctice of challenging our productPfizer Inc.
2018 Form 10-K 7 
TABLE OF CONTENTSpatents before their expiration. Gener
ic competitors often operate without large R&D expenses, as well as without costs of conveying medical information aboutproducts to the m
edical community. In addition, the FDA approval process exempts generics from costly and time-consuming clinical trials to demonstrate theirsafety and efficacy, allow
ing generic manufacturers to rely on the safety and efficacy data of the innovator product. Generic competitors can market a competingversion of our product after the expirat
ion or loss of our patent and often charge much less. In China, for example, we are expected to face strong competition bycertain generic manufacturers 
in 2019, which may result in price cuts and volume loss of some of our products. In addition, our patent-protected products can face 
competition in the form of generic versions of competitors’ branded products that lose their market exclusivity.As noted above, MCOs that focus prima
rily on the immediate cost of drugs often favor generics over brand-name drugs. Many governments also encourage theuse of generics as alt
ernatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S. Laws in the U.S. generally allow, and in somecases require, pharmacist
s to substitute, for brand-name drugs, generic drugs that have been rated under government procedures to be chemically andtherapeutically equiva
lent to brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. Favoringgenerics may reduce sales of ou
r branded products.RAW MATERIALS
Raw materials essential to our 
businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials areavailable from multiple sources. 
In 2018 , we experienced periodic shortages of select materials due to constrained capacity or operational challenges with theassociated suppliers. Supp
lier management activities are ongoing to work to ensure the necessary supply to meet our requirements for these materials. Nosignificant impact to our ope
rations is anticipated in 2019.GOVERNMENT REGULATION AND PRICE CONSTRAINTS
Pharmaceutical companie
s are subject to extensive regulation by government authorities in the countries in which they do business. Certain laws andregulations that gov
ern Pfizer’s business are discussed below.General 
. Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations, includingthose governing the manufacture and marketing of ou
r products, could subject us to administrative and legal proceedings and actions by various governmentalbodies. For additional infor
mation on these proceedings and actions, see the Notes to Consolidated Financial Statements— Note 17 A . Contingencies andCertain Commitments 
— Legal Proceedings in our 2018 Financial Report. Criminal charges, s ubstantial fines and/or civil penalties, warning letters and productrecalls or seizures, delays in pro
duct approvals, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from suchproceedings and actions.
In the United States
Drug Regulation 
. In the U.S., biopharmaceutical products are subject to extensive pre- and postmarket regulation by the FDA, including regulations that govern,among other things, the safety and efficacy of our 
medicines, clinical trials, advertising and promotion, manufacturing, labeling and record keeping. Our productsare also subject to p
ostmarket surveillance under the FFDCA and its implementing regulations with respect to drugs, as well as the Public Health Service Actand its implementing regula
tions with respect to biologics. Our Consumer Healthcare products are also subject to FDA regulation.Other U.S. federal agencies, in
cluding the DEA, also regulate certain of our products. The U.S. Federal Trade Commission has the authority to regulate theadvertising of consumer health
care products, including OTC drugs and dietary supplements. Many of our activities also are subject to the jurisdiction of the SEC.Biopharmaceutical compan
ies seeking to market a product in the U.S. must first test the product to demonstrate that it is safe and effective for its intended use.If, after evaluation, the FDA determine
s the product is safe (i.e., its benefits outweigh its known risks) and effective, then the FDA will approve the product formarketing, issuing a NDA or BLA 
as appropriate. Companies seeking to market a generic prescription drug must scientifically demonstrate that the generic drugis bioequivalent to the innovato
r drug. The ANDA, or generic drug application, must show, among other things, that the generic drug is pharmaceuticallyequivalent to the brand, the manufacturer is 
capable of making the drug correctly, and the proposed label is the same as that of the innovator/brand drug’s label.Even after a drug
 or biologic is approved for marketing, it may still be subject to postmarketing commitments or postmarketing requirements. Postmarketingcommitments are studies or 
clinical trials that the drug or biologic sponsor has agreed to conduct, but are not required by law and/or regulation. Postmarketingrequirements include stud
ies and clinical trials that sponsors are required to conduct, by law and/or regulation, as a condition of approval. Postmarketing studiesor clinical tr
ials can be required in order to assess a known risk or demonstrate clinical benefit for drugs or biologics approved pursuant to accelerated approval.If a company fails to meet its post
marketing requirements, the FDA may assess a civil monetary penalty, issue a warning letter or deem the drug or biologicmisbranded. Once a drug or biolog
ic is approved, any modifications to the product must be notified to the FDA and may also require a manufacturer to submitadditional studies or con
duct clinical trials. In addition, we are also required to report adverse events and comply with cGMPs, as well as advertising andpromotion regulations. 
Failure to comply with the FFDCA may subject us to administrative and/or judicial sanctions, including warning letters, product recalls,seizures, delays in product
 approvals, injunctions, fines, civil penalties and/or criminal prosecution.Biosimilar Regulation. 
The ACA created a fr amework for the approval of biosimilars (also known as follow-on biologics) following the expiration of 12 years ofexclusivity for the innovator
 biologic, with a potential six-month pediatric extension. Under the ACA, biosimilar applications may not be submitted until four yearsafter the approval of the reference innovator b
iologic.The FDA is responsible fo
r implementation of the legislation and approval of new biosimilars. Through FDA approvals and the issuance of draft and finalguidance, the FDA has addressed a number of 
issues related to the biosimilars approval pathway, such as the labeling expectations for biosimilars. Over thenext several years, the FDA 
is expected to issue additional draft and final guidance documents impacting biosimilars, including updated draft or final guidanceregarding the standards for demonstrating 
interchangeability with a U.S.-licensed reference product. In addition, in 2017, the Biosimilar User Fee Act wasreauthorized for a 
five-year period, which should lead to a significant increase in the FDA’s biosimilar user fee revenues, thereby providing the FDA withadditional resources to proce
ss biosimilar applications. For example, in the first year under the newly authorized fee structure, the FDA estimates its revenuesfrom biosimilar user fees will increase by m
ore than $10 million.Sales and Marketing Laws 
and Regulations . The marketing practices of U.S. biopharmaceutical companies are generally subject to various federal and statehealthcare laws that are intended, among othe
r things, to prevent fraud and abuse in the healthcare industry and to protect the integrity of governmenthealthcare programs. 
These laws include anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a biopharmaceutical company fromsoliciting, offering, receiving, 
or paying anything of value to generate business, including purchasing or prescribing of a particular product. False claims lawsgenerally prohibit anyone
 from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods (including drugs or biologics) orservices to third-party pa
yers (including Medicare and Medicaid) that are false or fraudulent and generally treat claims generated through kickbacks as false or
fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions and/or exclusion from federal healthcare programs (includingMedicare and Medicaid). The federa
l government and various states also have enacted laws to regulate the sales and marketing practices of pharmaceuticalcompanies. The laws and
 regulations generally limit financial interactions between manufacturers and healthcare providers, require disclosure to the federal orstate government and the public of such inte
ractions, and/or require the adoption of compliance standards or programs. Many of these laws and regulationscontain ambiguous requirements o
r require administrative guidance for implementation. Individual states, acting through their attorneys general, have becomeactive as well, seek
ing to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. Given the lack of clarity inlaws and their imple
mentation, our activities could be subject to the penalties under the pertinent laws and regulations.Pricing and Reimbursement 
. Pricing and reimbursement for our pharmaceutical products depends in part on government regulation. Pfizer must offerdiscounted pricing or rebates on pu
rchases of pharmaceutical products under various federal and state healthcare programs, such as the Medicaid Drug RebateProgram, the “feder
al ceiling price” drug pricing program, the 340B drug pricing program and the Medicare Part D Program. Pfizer must also report specificprices to government agencies under hea
lthcare programs, such as the Medicaid Drug Rebate Program and Medicare Part B. The calculations necessary todetermine the prices reported are co
mplex and the failure to report prices accurately may expose Pfizer to penalties. See the discussion regarding rebates in theAnalysis of the Consol
idated Statements of Income — Revenues — Overview section in our 2018 Financial Report and in the Notes to Consolidated FinancialStatements— 
Note 1 G . Basis of Presentation and Significant Accounting Policies : Revenues and Trade Accounts Receivable in our 2018 Financial Report, which are incorporated by
 reference.Government and private third-party pa
yers routinely seek to manage utilization and control the costs of our products. For example, the majority of states usepreferred drug lists to restr
ict access to certain pharmaceutical products under Medicaid. Restrictions exist for some Pfizer products under certain state Medicaidprograms. As another example, acce
ss to our products under the Medicaid managed care program is typically determined by the health plans with which stateMedicaid agencies contract
 to provide services to Medicaid beneficiaries. Given certain states’ current and potential ongoing fiscal crises, a growing number ofstates are considering a var
iety of cost-control strategies, including capitated managed care plans that typically contain cost by restricting access to certaintreatments. In addition, we expect that conso
lidation and integration of pharmacy chains and wholesalers, who are the primary purchasers of our pharmaceuticalproducts in the U.S.,
 will increase pricing pressures on pharmaceutical manufacturers, including us.Efforts by governmen
t officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drugimportation, could adverse
ly affect our business if implemented. Recently, there has been considerable public and government scrutiny of pharmaceutical pricingand proposals to address the perceived h
igh cost of pharmaceuticals. At the federal level, for example, in May 2018, President Trump released his Blueprint to Lower Drug Prices and Reduce
 Out-of-Pocket Costs (Blueprint). Certain proposals in  the Blueprint, and related drug pricing measures proposed since theBlueprint, could cause s
ignificant operational and reimbursement changes for the pharmaceutical industry. As another example, in October 2018, the Centers forMedicare and Medicaid Services s
olicited public comments on potential changes to payment for certain Medicare Part B drugs, including reducing the Medicarepayment amount for selected Medicare 
Part B drugs to more closely align with international drug prices. In addition, in January 2019, the White House Office ofManagement and Budget released the long awaited p
roposed rule submitted by the Office of Inspector General of the Department of Health and HumanServices to remove safe harbor p
rotections for drug rebates paid to insurance plans and PBMs for Medicare Part D and Managed Medicaid and to create newsafe harbors. Among other changes, the proposed ru
le would explicitly exclude the reductions in price offered by drug manufacturers to PBMs in Medicare PartD and Managed Medicaid plans fro
m protection under the “discount” safe harbor. It would also create a new safe harbor designed specifically for pricereductions in pharmaceutica
l products, but only those that are fully reflected in the price to the patient at the pharmacy counter. Additionally, a new safe harborwas proposed to protect administ
rative fees paid to PBMs, which must be at fair market value, a fixed fee and not based upon a percentage of volume or listprice. Manufacturers could cont
inue to negotiate price reductions with PBMs and Medicare Part D and Managed Medicaid plans if their reductions meet thatcriterion. The proposed rule rep
resents a large step toward significantly altering the current rebate model in place with MCOs. We are in the process ofevaluating the implicat
ions of the proposed rule on our operations and processes, as well as the infrastructure that will be required in order to implement the ruleonce it is finalized. The
re have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency arounddrug costs or limit
ing drug prices. Certain state legislation has been subject to legal challenges. Adoption of new legislation regulating drug pricing at the federalor state level could further affect de
mand for, or pricing of, our products.We believe medicine
s are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We willcontinue to work with la
wmakers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and ensureaccess to medicines within an 
efficient and affordable healthcare system.Healthcare Reform. 
There have been significant efforts at the federa l and state levels to reform the healthcare system by enhancing access to healthcare,improving the deliver
y of healthcare and further rationalizing payment for healthcare. For example, we face uncertainties due to federal legislative andadministrative efforts to repea
l, substantially modify or invalidate some or all of the provisions of the ACA. For example, tax reform legislation enacted at the endof 2017 eliminates the tax penalty for 
individuals who do not maintain sufficient health insurance coverage beginning in 2019 (the so-called “individualmandate”). We anticipat
e continued Congressional interest in modifying provisions of the ACA, particularly given the recent ruling in Texas v. Azar to invalidate the law as unconstitutional. 
At this time, the law remains in effect pending appeals of the decision. Given the outcomes of the 2018 U.S. midterm elections withDemocrats taking over th
e U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we believe it is unlikely Congress will findbipartisan consensus to advance any 
significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer by the health insuranceexchanges and Medicaid expansion unde
r the ACA are not material, so the impact of the change in law and similar recent administration actions is expected tobe limited. Any future r
eplacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislationreduces incentives for emp
loyer-sponsored insurance coverage. As another example, the Bipartisan Budget Act of 2018, which increased the discount we pay inthe Medicare Part D “coverage gap
” from 50% to 70%, will modestly increase our future Medicare Part D rebates. Any future healthcare reform efforts mayadversely affect our 
business and financial results.Anti-Corruption. 
The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreigngovernment official, government 
staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPAincludes interactions with certain
 healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.Outside the United States
We encounter similar regulatory
 and legislative issues in most other countries.New Drug Approvals. 
In the EU, the approval of new drugs may be a chieved using the Mutual Recognition Procedure, the Decentralized Procedure or the EUCentralized Procedure. These p
rocedures apply in the EU member states, plus the European Economic Area countries, Norway, Iceland and Liechtenstein. TheCentralized Procedure, managed b
y the EMA, results in one single authorization for the whole EU, which provides the most rapid and efficient means of gainingapproval across the EU and i
s the one most commonly used for new products.In China, the regulatory system h
istorically presented numerous challenges for the pharmaceutical industry, as its requirements for drug development andregistration were often incon
sistent with U.S. or other international standards. In recent years, however, China has introduced reforms and draft reforms, whichare discussed in more detai
l below, that attempt to address these challenges. 2018 was another active year in this respect, with a number of reforms coming intoeffect, and more proposals and drafts being 
issued for consultation. Also, in 2018, a significant government restructuring resulted in the creation of the National
Medical Product Administration (NMPA), replacing the former CFDA.In Japan, the PMDA is the point of entry fo
r businesses looking to sell drugs in the country. The PMDA, which is involved in a wide range of regulatory activities,including clin
ical studies, approvals, postmarketing reviews and pharmaceuticals safety, must approve an application before a new drug product may bemarketed in Japan. 
The PMDA also offers consultations on clinical trials of new drugs and provides advice on product classifications and approvals.Health authorities in man
y middle and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of theFDA or the EMA) before
 they begin to conduct their application review process and/or issue their final approval. Many authorities also require local clinical datain the country’s popula
tion in order to receive final marketing approval.Pharmacovigilance. 
In the EU, detailed legis lation and guidance on pharmacovigilance has increased and strengthened in recent years. The EMA’sPharmacovigilance Risk Assessment Committee
 has the responsibility for reviewing and making recommendations on product safety issues for the EUauthorities. EU regulator
s may require pharmaceutical companies to conduct post-authorization safety and efficacy studies at the time of approval, or at any timeafterwards in light of sc
ientific developments. There are also additional extensive requirements regarding adverse drug reaction reporting and additionalmonitoring of products. Outside deve
loped markets such as the EU and Japan, pharmacovigilance requirements vary and are generally not as extensive, butthere is a trend t
oward increasing regulation.Pricing and Reimbursement 
. In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low-to-zero direct cost to consumers at the po
int of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursementlevels to control costs for
 the government-sponsored healthcare system, particularly under recent global economic pressures. Governments may use a variety of cost-containment measures for our pha
rmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as acondition of market access and 
international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries).This international patchwork
 of price regulation and differing economic conditions and incomplete value assessments across countries has led to varying healthoutcomes and some third-party trade 
in our products between countries.In particular, internationa
l reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Pricevariations, exacerbated by inte
rnational reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resultingfrom this dynamic can be expected to 
continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in someEuropean countries.
In addition, several impor
tant multilateral organizations, such as the United Nations (UN), including the World Health Organization (WHO), and the Organizationfor Economic Cooperation 
and Development (OECD), are increasing scrutiny of international pharmaceutical pricing through issuing reports and policyrecommendations (e.g., 
2016 UN High Level Panel Repor t on Access to Medicines ). Late in 2018,  two new reports critical of the pharmaceutical industry’spricing practices were published:
 OECD’s Pharmaceutical Innovation  and Access to Medicines and WHO’s Pricing of Cancer Medicines and  its Impacts . These reports and upcoming public foru
ms focused on their recommendations will continue to exert additional pricing pressures.In China, pricing pressu
res have increased in recent years. Top Chinese government officials have consistently emphasized the importance of improved healthoutcomes, the need for healthcare reform and decrea
sed drug prices as a key indicator of progress towards reform. Even though the government provides basichealth insurance for the vast majo
rity of Chinese citizens, the insurance is not adequate to cover innovative medicines. Alternative funding sources for innovativemedicines remain suboptimal, as
 private health insurance growth is restrained by issues with access to healthcare data, potential corruption concerns andcontrol over providers.
In 2017 and 2018, Chinese authorities entered 
into special negotiations with China’s National Medical Security Bureau to add approximately 60 high-value drugs(mainly oncology medicines) to t
he National Reimbursement Drug List. Prices for drugs were reduced dramatically through these negotiations, some by as muchas 70 percent. While these negotiat
ions included a path to access for companies, market access is not strictly assured. In addition, significant questions aboutthe processes and 
negotiations for provincial tendering remain. In addition, multi-layered negotiations are required across provincial, municipal and hospitallevels, and the linkage of pr
ice negotiations to reimbursement is inconsistent. In the off-patent space, in 2013, China began to implement a quality consistency(QCE) process in order to impr
ove the quality of domestically-manufactured generic drugs, primarily by requiring such drugs to pass a test to assess theirbioequivalence to a qualif
ied reference drug (typically the originator drug). In 2018, numerous local generics were officially deemed bioequivalent under theQCE. A pilot project for 
centralized procurement of 31 categories of drugs covering 11 major Chinese cities now drives patients to generics that have passed theQCE, which has resulted in dr
amatic price cuts for off-patent drugs.In Japan, the access environment for inno
vative medicines continued to deteriorate in 2018 with tighter restrictions around the criteria to gain a pricemaintenance premium and a push by the Japanese go
vernment to adopt healthcare technology assessments based on rigid cost-effectiveness criteria for re-pricing of reimbursed medicines.
 Additionally, the Japanese government has officially requested the Ministry of Health, Labour and Welfare to look into usingcost-effectiveness analyse
s to make reimbursement decisions at the launch of a drug.EU Regulatory Changes 
. The EU adopted a new Clinical Trials Regulation in May 2014, which is expected to come into effect sometime in late 2019. Thisregulation is aimed at simplifying 
and harmonizing the governance of clinical trials in the EU and will require increased public posting of clinical trial results.Brexit 
. In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as “Brexit”. In March 2017, the U.K. governmentformally notified the European 
Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation processestablishing the terms of the ex
it and outlining the future relationship between the U.K. and the EU. Formal negotiations officially started in June 2017. Thisprocess continues to be highly 
complex and the end result of these negotiations may pose certain implications to our research, commercial and generalbusiness operations in the U.
K. and the EU, including the approval and supply of our products. The EMA will be relocating from London, U.K. to Amsterdam,Netherlands by the scheduled date of Bre
xit at the end of March 2019. At present, it is still unclear whether and to what extent the U.K. will remain within oraligned to the EU system of med
icines regulation, and/or what separate requirements will be imposed in the U.K. after it leaves the EU. However, both the U.K.and the EU have issue
d detailed guidance for the industry on how medicines, medical devices and clinical trials will be separately regulated in their respectiveterritories in the event of a ‘ha
rd Brexit’, meaning an outcome where no negotiated settlement is reached. For additional information  on Brexit, see the Overview of Our Performance, Operating Envi
ronment, Strategy and Outlook — Our Operating Environment — The Global Economic Environment in our 2018 Financial Report 
. China Regulatory Changes 
. In an effort to encourage drug innovation and reduce backlogs for existing applications for drug approval, the NMPA has unveilednumerous reform initiatives f
or China’s drug approval system, and engaged in significant efforts to build its capabilities. The NMPA now divides drugs into newdrugs and generics, with the defin
ition for new drugs changed from “China New” to “Global New.” This means that drugs previously approved in other markets(such as the U.S. or Europe) w
ill not be considered new drugs under China’s regulatory regime. This change in definition creates more opportunities for China’sdomestic drug manufac
turers than for multinational firms, because multinational firms have historically had significant competitive advantage in successfullyachieving regulatory approva
ls for drugs first approved outside of China. Revisions in 2017 made clear, however, that regulatory approval from the FDA or theEMA would no longer be requi
red for approval of imported drugs, though a notable exception persists for imported vaccines, which still require prior approvalfrom a relevant regula
tory agency. The “marketing authorization holder” system, which will allow for more flexibility in contract manufacturing arrangements and
asset transfers, is now being piloted in ten Chinese provinces, but not yet for imported drugs.While challenges re
main, a number of other policy changes are streamlining and accelerating approvals of domestic and imported drugs in China. Thesereforms, along with Ch
ina’s June 2018 entry into the Management Committee of the International Council for Harmonisation of Technical Requirements forPharmaceuticals for Hu
man Use, are expected to pave the way for integration of Chinese regulations with global practices. These changes include introducingan umbrella clinical trial authorization
 for all three phases of registration studies (instead of the original phase-by-phase approvals), a filing/recordation systemfor bioequivalence studies on gene
rics (instead of the original review and approval system), admitting more categories of drugs as innovative drugs eligible forthe fast track/“green channel” approva
l pathway and ongoing implementation of previously announced regulatory reforms. In 2018, the review timeline for clinicaltrial authorizations was short
ened to 60 working days due to the introduction of a clinical trial notification system, and China’s Fast Track Policy was finalized, fora specific group of products se
lected by the Center for Drug Evaluation, part of the NMPA.In addition, China’s Human 
Genetic Resources Administrative Office strictly scrutinizes clinical trials involving the collection, storage, export and use of humangenetic resources and relevant der
iving data from the Chinese population, adding an extra layer of review in addition to that of the NMPA.Healthcare Provider Transpar
ency and Disclosures. A number of countries  have implemented laws requiring (or their industry associations have recommended)disclosure of transfers o
f value made by pharmaceutical companies to healthcare providers. For example, the EFPIA’s disclosure code requires all members,including Pfizer, to d
isclose transfers of value to healthcare professionals and healthcare organizations.Intellectual Property 
. The World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) required participantcountries to amend their intel
lectual property laws to provide patent protection for pharmaceutical products by 2005, with an extension until 2033 for least-developed countries. Whi
le we still face patent grant, enforcement and other intellectual property challenges around the world, some countries have madeimprovements. We inc
lude stronger patent protection among the factors we consider for continued business expansion in other participant countries.While the global intellectual pro
perty environment has generally improved following WTO-TRIPS and bilateral/multilateral trade agreements, our future businessgrowth depends on further progress in 
intellectual property protection. In emerging market countries in particular, governments have used intellectual propertypolicies as a tool for red
ucing the price of imported medicines, as well as to protect their local pharmaceutical industries. Considerable political and economicpressure exists to weaken cu
rrent intellectual property protection and resist implementation of any further protection, which has led to policies such as morerestrictive standards for obta
ining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types ofinventions (e.g., new medica
l treatment methods), revocation of patents, issuance (and threat of issuance) of compulsory licenses, weak intellectual propertyenforcement and failure to imple
ment effective regulatory data protection. Our industry advocacy efforts focus on seeking a more balanced businessenvironment for foreign manufacturer
s, as well as on underscoring the importance of strong intellectual property systems for local innovative industries. Indeveloped countries as
 well, including the EU, we are facing an increasingly challenging intellectual property environment.Canada’s intellectual property
 regime for drugs provides some level of patent protection and data exclusivity (currently eight years plus six-month pediatricextension), but it lacks the pred
ictability and stability that otherwise comparable countries provide. Through intense negotiations as part of the Canada/EUComprehensive Economi
c & Trade Agreement (CETA), Canadian authorities have amended the Patent Medicines (Notice of Compliance) Regulations toprovide the innovator a right of appeal, and 
Canada now provides sui generis protection for patent term extensions of up to t wo years for basic patents.Furthermore, the US-Mexico
-Canada Agreement (USMCA), if ratified and implemented, would establish 10 years of data protection for biologics and patent termadjustment for unreasonable or unnecessa
ry delays in the grant of patents.In China, the intellectual p
roperty environment has improved, although effective enforcement and adequate legal remedies remain areas of concern. Thegovernment has tak
en steps to protect intellectual property rights in conformity with World Trade Organization provisions, and several companies, includingPfizer, have established R&D ce
nters in China due to increased confidence in China’s intellectual property environment. Despite this, China remained on theU.S. Trade Representative’
s Priority Watch List for 2018. Further, the standards for patentability in China remain more restrictive than in other major markets,including the U.S., Europe and Japan. 
Also, while a framework exists for protecting patents for 20 years, enforcement mechanisms are often lacking orinconsistent. For example, the absen
ce of effective patent linkage mechanisms and preliminary injunctions, impractical evidentiary burdens, and heightenedsufficiency standards have been used to 
invalidate patents at the enforcement stage.In Brazil and other L
atin American countries, the role of health regulatory authorities in reviewing patents (e.g., National Health Surveillance Agency in Brazil),restrictive patentabil
ity rules, ambiguity regarding the term of certain patents and backlogs at patent agencies may limit our ability to protect our products throughpatents. The lack of regulatory data protect
ion and difficulties in protecting certain types of inventions, such as new medical uses of drug products, may limit thecommercial lifespan of some p
harmaceutical products. Additionally, an increased threat of issuance of compulsory licenses for biopharmaceutical productsexists, which adds to busin
ess uncertainty.In India, we have seen some progress 
in terms of expediting patent approval processes to reduce pendency rates and implementing training programs toenhance enforcement. Despite these posit
ive steps, gaps remain in terms of addressing longstanding intellectual property concerns. For example, policiesfavoring compulsory l
icensing of patents, the tendency of the Indian Patent Office to revoke pharmaceutical patents in opposition proceedings (both pre- andpost-grant), and restrictive 
standards for patentability of pharmaceutical products have made it difficult to safeguard many of our inventions and our investmentsin innovation. These polic
ies heighten the risk of additional patent challenges targeting innovative pharmaceutical products, especially in areas perceived asbeing important to the public health of the popu
lation. Challenges against Pfizer patents in India are ongoing.ENVIRONMENTAL MATTERS
Most of our operations are affected by nationa
l, state and/or local environmental laws. We have made, and intend to continue to make, the expendituresnecessary for compliance with 
applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. See the Notesto Consolidated Financial St
atements— Note 17 A3 . Contingencies and Certain Commitments — Legal Proceedings––Commercial and Other Matters in our 2018 
Financial Report. As a re sult, we incurred capital and operational expenditures in 2018 for environmental compl iance purposes and for the clean-up ofcertain past industrial activity 
as follows:•
environment-related capital expenditures— $33 million ; and •
other environment-related expenses— $162 million . While capital expenditures or 
operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have amaterial effect on o
ur capital expenditures or competitive position.Climate change presents r
isks to our operations, including the potential for additional regulatory requirements and associated costs, and the potential for morefrequent and severe weather events and water ava
ilability challenges that may impact our facilities and those of our suppliers. For example, in 2017, ourmanufacturing and commercia
l operations in Puerto Rico were impacted by hurricanes. For additional information, see the Overview of Our Performance, Operating Environment, Strategy and Out
look — Our Business — Impact of Hurricanes in Puerto Rico section of the 2018 Financial Report. We canno t provide
assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future; however, we have a program for reviewing ourvulnerability to potentia
l weather-related risks and we update our assessments periodically. To date, we have concluded that, because of our facility locations,our existing distribut
ion networks and our controls, we do not anticipate that these risks will have a material impact on Pfizer in the near term.TAX MATTERS
The discussion of tax-related 
matters in the Notes to Consolidated Financial Statements— Note 5 . Tax Matters in our 2018 Financial Report is incorporate d byreference.
Pfizer Inc.
2018 Form 10-K 8 
TABLE OF CONTENTSEMPLOYEES
In our innovation-inte
nsive business, our employees are vital to our success. We generally believe we have good relationships with our employees. As ofDecember 31, 
2018 , we employed approximat ely 92,400 people in our operations throughout the wor ld.DISCLOSURE PURSUANT TO SECTION 219 OF THE IRAN THREAT REDUCTION AND SYRIA HUMAN RIGHTS ACT OF 2012
Section 219 of Ira
n Threat Reduction and Syria Human Rights Act of 2012 (ITRSHRA) requires disclosure by public companies of certain transactions involvingthe Government of Iran, as well as ent
ities and individuals designated under Executive Order 13382 and Executive Order 13224 (the Executive Orders). In someinstances, ITRSHRA requires compa
nies to disclose these types of transactions, even if they were permissible under U.S. law or were conducted by a non-U.S.affiliate in accordance with 
the local law under which such entity operates.As a global biopharmaceu
tical company, we conduct business in multiple jurisdictions throughout the world. During 2018 , our activities included sup plying life-saving medicines, med
ical products and consumer products (Pfizer products) for patient and consumer use in Iran. We ship Pfizer products to Iran, and conductrelated activities, 
in accordance with licenses issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control and other U.S. and non-U.S.governmental entities, 
and in line with our corporate policies. We will continue our global activities to improve the health and well-being of patients andconsumers in a manner c
onsistent with applicable laws and our corporate policies. To our knowledge, none of our activities during 2018 are required to be disclosed pursuant to 
ITRSHRA.Pfizer Inc.
2018 Form 10-K 9 
TABLE OF CONTENTSITEM 1A.
RISK FACTORS The statements in this Section des
cribe the major risks to our business and should be considered carefully. In addition, these statements constitute ourcautionary statements under the Pri
vate Securities Litigation Reform Act of 1995.Our disclosure and analysis in 
this 2018 Form 10-K and in our 2018 Annual Report to Shareholders conta in forward-looking statements. From time to time, wealso provide forward-looking st
atements in other materials we release to the public, as well as oral forward-looking statements. Such forward-looking statementsinvolve substantial risks and u
ncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,”“ongoing,” “anticipate,” “est
imate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” andother words and terms of sim
ilar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating andfinancial performance, bus
iness plans and prospects, in-line products and product candidates, including anticipated regulatory submissions, data read-outs,study starts, approvals, performan
ce, timing of exclusivity and potential benefits of Pfizer’s products and product candidates, strategic reviews, capital allocation,business-development plans, the benef
its expected from the reorganization of our commercial operations into three businesses effective at the beginning of our2019 fiscal year, our 
acquisitions and other business development activities, our ability to successfully capitalize on growth opportunities or prospects,manufacturing and product supply and plan
s relating to share repurchases and dividends. In particular, these include statements relating to future actions,business plans and prospects, our a
cquisitions and other business development activities, our proposed transaction with GSK to combine our respectiveconsumer healthcare businesse
s into a new consumer healthcare joint venture, prospective products or product approvals, our product pipeline, futureperformance or results of current and ant
icipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, suchas legal proceedings, pla
ns relating to share repurchases and dividends, government regulation and financial results, including, in particular, the availability ofraw materials for 2019 set forth 
in Item 1. Business–– Raw Materials in this 2018 Form 10-K; the anticipated progress in remediation efforts at certain of ourHospira manufacturing fac
ilities and the expectations related to our supply issues set forth in the Overview of Our Performance, Ope rating Environment,Strategy and Outlook 
–– Our Business –– Product Manufacturing section in our 2018 Financial Report; the benefits e xpected from the reorganization of ourcommercial operations 
into three businesses effective at the beginning of our 2019 fiscal year and our expectations regarding growth set forth in the Overview of Our Performance, Operating Envi
ronment, Strategy and Outlook –– Our Strategy –– Organizing for Growth section in our 2018 Financial Report; the expected timing of completion and benefit
s of our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumerhealthcare joint venture set forth 
in the Item 1. Business–– About Pfizer and –– Innovative Health , and Item 1A. Risk Factors sections in this 2018 Form 10-K and in the 
Overview of Our Performance, Ope rating Environment, Strategy and Outlook –– Our Business , –– Our Strategy and –– Our Business Development Initiatives 
sections in our 2018 Financial Report; the antic ipated costs related to our preparations for Brexit set forth in the Overview of Our Performance,Operating Environment, Strategy and Out
look––Our Operating Environment––The Global Economic Environment section in our 2018 Financial Report; our anticipated liquidity position se
t forth in the Overview of Our Performance, Ope rating Environment, Strategy and Outlook –– Our Operating Environment — TheGlobal Economic Environment 
and the Analysis of Financial Condition, Liq uidity and Capital Resources sections in our 2018 Financial Report; our plans  forincreasing investment 
in the U.S. set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––CapitalAllocation and Expense Management––In
creasing Investment in the U.S. section in our 2018 Financial Report; the financ ial guidance set forth in the Overview of Our Performance, Operating Envi
ronment, Strategy and Outlook — Our Financial Guidance for 2019 section in our 2018 Financial Report; the a nticipatedcosts and savings, including
 from our cost-reduction/productivity initiatives, as well as from our Organizing for Growth initiative, set forth in the Costs and Expenses 
— Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives section in our 2018 Financial Report and in the Notes to Consol
idated Financial Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives 
; the benefits expected from our business de velopment transactions; the planned capital spending set forth in the Analysis of Financial Condition, Liquidity an
d Capital Resources — Selected Measures of Liquidity and Capital Resources — Contractual Obligations section in our 2018 Financial Report; and the contr
ibutions that we expect to make from our general assets to the Company’s pension, postretirement and deferred compensationplans during 
2019 set forth in the Analysis of Financial Condition, Liq uidity and Capital Resources — Selected Measures of Liquidity and Capital Resources — Contractual Obligations 
section and in the Notes to Conso lidated Financial Statements— Note 11 . Pension and Postretirement Benefit Plans and DefinedContribution Plans 
in our 2018 Financial Report. We cannot guarantee that any forward-look
ing statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties andinaccurate assumptions. S
hould known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results couldvary materially fro
m past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, andyou are cautioned not to put undue reliance on for
ward-looking statements.We undertake no obligation to publ
icly update forward-looking statements, whether as a result of new information, future events or otherwise, except as requiredby law or by the rules and regu
lations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects. Also note that weprovide the following caut
ionary discussion of risks, uncertainties and possibly inaccurate assumptions relevant to our businesses. These are factors that,individually or 
in the aggregate, may cause our actual results to differ materially from expected, projected or historical results. We note these factorsPfizer Inc.
2018 Form 10-K 10 
TABLE OF CONTENTSfor investors as permitted by the 
Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all suchfactors. Consequently,
 you should not consider the following to be a complete discussion of all potential risks or uncertainties.RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS 
: MANAGED CARE TRENDS
Private third-party payer
s and other managed care entities, such as pharmacy benefit managers, continue to take action to manage the utilization of drugs andcontrol the cost of drugs. Consol
idation among MCOs has increased the negotiating power of MCOs and other private third-party payers. Private third-partypayers, as well as governme
nts, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formularyinclusion or favorable fo
rmulary placement. Failure to obtain or maintain timely adequate pricing or favorable formulary placement for our products, or failure toobtain such formulary plac
ement at favorable pricing, could adversely impact revenue. Private third-party payers, including self-insured employers, oftenimplement formularies with copayme
nt tiers to encourage utilization of certain drugs and have also been raising co-payments required from beneficiaries,particularly for branded 
pharmaceuticals and biotechnology products. Private third-party payers are also implementing new initiatives like so-called “copayaccumulators” (poli
cies that provide that the value of copay assistance does not count as out-of-pocket costs that are applied toward deductibles) that can shiftmore of the cost burden to manufacturers and patients. Th
is cost shifting has increased consumer interest and input in medication choices, as they pay for alarger portion of their presc
ription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals. Private third-partypayers also use addition
al measures such as new-to-market blocks, exclusion lists, indication-based pricing, and value-based pricing/contracting to improve theircost containment ef
forts. Private third-party payers also are increasingly imposing utilization management tools, such as clinical protocols, requiring priorauthorization for a branded product if a gener
ic product is available or requiring the patient to first fail on one or more generic products before permitting accessto a branded medicine. As the U.S. paye
r market consolidates further and as more drugs become available in generic form, biopharmaceutical companies mayface greater pricing pr
essure from private third-party payers, who will continue to drive more of their patients to use lower cost generic alternatives.GENERIC COMPETITION
Competition from manufacturer
s of generic drugs is a major challenge for our branded products around the world, and the loss or expiration of intellectualproperty rights can have a sign
ificant adverse effect on our revenues. The date at which generic competit ion commences may be different from the date that thepatent or regulat
ory exclusivity expires. However, upon the loss or exp iration of patent protection for one of our products, or upon the “at-risk” launch (despitepending patent infringement lit
igation against the generic product) by a generic manufacturer of a generic version of one of our patented products, we can losethe major portion of revenues for that product 
in a very short period of time, which can adversely affect our business. A number of our products are expected toface significantly 
increased generic competition over the next few years. In China, for example, we are expected to face strong competition by certain genericmanufacturers in 2019, which ma
y result in price cuts and volume loss of some of our products.Also, generic manufacturers ha
ve filed applications with the FDA seeking approval of product candidates that such companies claim do not infringe our patents;these include candidates that wou
ld compete with, among other products, Eliquis, Xeljanz and Xtandi . Our licensing and collabor ation partners also facechallenges by generic drug manufa
cturers to patents covering products for which we have licenses or co-promotion rights. In addition, our patent-protectedproducts may face competition 
in the form of generic versions of competitors’ branded products that lose their market exclusivity.COMPETITIVE PRODUCTS
We cannot predict with accu
racy the timing or impact of the introduction of competitive products, including new product entrants, in-line branded products,generic products, private labe
l products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs anddrug candidates. The introduction of compet
itive products can result in erosion of the sales of our existing products and potential sales of products indevelopment, as well as unant
icipated product obsolescence. Competitive product launches have occurred in recent years, and certain potentially competitiveproducts are in various stages of de
velopment. Some of these have been filed for approval with the FDA and with regulatory authorities in other countries.We also produce generic 
and biosimilar pharmaceutical products that compete with products from competitors, including other generic and biosimilarmanufacturers. The ability to 
launch a generic or biosimilar pharmaceutical product at or before the anticipated formation of the generic or biosimilar marketplaceis important to that
 product’s profitability. Prices for products typically decline, sometimes dramatically, following generic or biosimilar entry, and as additionalcompanies receive approva
ls to market that product, competition intensifies. If a company’s generic or biosimilar product can be “first-to-market” such that itsonly competition is the branded d
rug for a period of time, higher levels of sales and profitability can be achieved until other generic or biosimilar competitorsenter the market.
 With increasing competition in the generic or biosimilar product market, the timeliness with which we can market new generic or biosimilarproducts will increase in importance
. Our success will depend on our ability to bring new products to market quickly. The FDA, along with other regulatoryagencies around the world, has been
Pfizer Inc.
2018 Form 10-K 11 
TABLE OF CONTENTSexperiencing a backlog o
f generic drug applications, which may result in delayed approvals of new generic products. While the FDA is taking steps to addressthe backlog of pending application
s, continued approval delays may be experienced by generic drug applicants over the next few years. Also, we may faceaccess challenges for our
 biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative tothe innovator product. For example, 
Inflectra/Remsima has experienced access c hallenges among commercial payers. In September 2017, Pfizer filed suit in theU.S. District Court for the Eas
tern District of Pennsylvania against Johnson & Johnson (J&J) alleging that J&J’s exclusionary contracts and other anticompetitivepractices concerning Remicade® (in
fliximab) violate federal antitrust laws.DEPENDENCE ON KEY IN-LINE PRODUCTS
We recorded direct product and/or a
lliance revenues of more than $1 billion for each of ten biopharmaceutical products in 2018: Prevnar 13/Prevenar 13 , Lyrica, 
Ibrance , Eliquis , Enbrel , Lipitor , Xeljanz , Chantix/Champix, Sutent and Norvasc . Those products accounted for 51% of our total revenues in 2018 . If these products or any of our other major product
s were to become subject to problems such as loss of patent protection (if applicable), changes in prescription growthrates, material product l
iability litigation, unexpected side effects, regulatory proceedings, publicity affecting doctor or patient confidence, pressure from existingcompetitive products, changes 
in labeling, pricing and access pressures, supply shortages or, if a new, more effective treatment should be introduced, theadverse impact on our revenues cou
ld be significant. A number of our current products have experienced patent-based expirations or loss of regulatoryexclusivity in certain markets in th
e last few years (including some of our billion-dollar and previously billion-dollar products), and patents covering a number ofour best-selling medi
cines are, or have been, the subject of pending legal challenges. For example, as a result of a patent litigation settlement, TevaPharmaceuticals US
A, Inc. launched a generic version of Viagra in the U.S. in December 2017. In add ition, the basic product patent for Lyrica in the U.S. will expire in June 2019, which 
includes the FDA’s grant of pediatric exclusivity that extended the period of market exclusivity in the U.S. for Lyrica for an additional six months from December 2018. In add
ition, our revenues could be significantly impacted by the timing and rate of commercial acceptance of key newproducts. For additional infor
mation, see the Overview of Our Performance, Ope rating Environment, Strategy and Outlook –– Our Operating Environment — Industry-Specific Challenges 
— Intellectual Property Rights and Collaboration/Licensing Rights — Recent Losses and Expected Losses of Product Exclusivitysection in our 
2018 Financial Report. Further, our Alliance revenues will be adversely affected by the termination or expiration of collaboration and co-promotionagreements that we have entered into and that we may ente
r into from time to time.RESEARCH AND DEVELOPMENT INVESTMENT
The discovery and development of safe, effect
ive new products, as well as the development of additional uses for existing products, are necessary for thecontinued strength of our businesses. Our p
roduct lines must be replenished over time in order to offset revenue losses when products lose their marketexclusivity, as 
well as to provide for earnings growth. Our growth potential depends in large part on our ability to identify and develop new products or newindications for exist
ing products that address unmet medical needs and receive reimbursement from payers, either through internal R&D or throughcollaborations, acquis
itions, joint ventures or licensing or other arrangements with third parties. However, balancing current growth, investment for future growthand the delivery of shareholder retu
rn remains a major challenge. The average costs of product development continue to rise, as do the regulatory requirementsin many therapeutic areas, wh
ich may affect the number of candidates funded as well as the sustainability of the R&D portfolio. Our ongoing investments in newproduct introductions and in R
&D for new products and existing product extensions could exceed corresponding sales growth.Additionally, our R
&D investment plans and resources may not be correctly matched between science and markets, and failure to invest in the right technologyplatforms, therapeutic segments, produ
ct classes, geographic markets and/or in-licensing and out-licensing opportunities could adversely impact the productivityof our pipeline. Further, even if the area
s with the greatest market attractiveness are identified, the scientific approach may not succeed for any given programdespite the significant in
vestment required for R&D, and the commercial potential of the product may not be as competitive as expected because of the highlydynamic market environment and the hu
rdles in terms of access and reimbursement.We continue to strengthen our global 
R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve asustainable pipeline that 
is positioned to deliver value in the near-term and over time. These strategies may not deliver the desired result, which could affectgrowth and profitability in 
the future.BIOLOGIC PRODUCTS
Abbreviated legal pathways fo
r the approval of biosimilars exist in many international markets and, since the passage of the ACA, a framework for such approvalexists in the U.S. If compet
itors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subjectto competition from t
hese biosimilars, with attendant competitive pressure, and price reductions could follow. For example, Enbrel faces ongoing biosimilar competition in most developed 
Europe markets. The expiration or successful challenge of applicable patent rights could trigger this competition, assuming anyrelevant regulatory exclu
sivity period has expired. We may face litigation with respect to the validity and/or scope of patents relating to our biologic products.Pfizer Inc.
2018 Form 10-K 12 
TABLE OF CONTENTSWe are developing biosimilar medicines.
 Risks related to our development of biosimilars include the potential for steeper than anticipated price erosion due toincreased competitive 
intensity (or, as in the case of Inflectra/Remsima , exclusionary contract ing by the originator that leads to a lack of payer coverage andlower uptake), coupled with
 high costs associated with clinical development or intellectual property challenges that may preclude timely commercialization of ourpotential biosimilar products. 
There is also a risk of lower uptake for biosimilars due to various factors that may vary for different biosimilars (e.g., anti-competitive practices, physician r
eluctance to prescribe biosimilars for existing patients taking the originator product, or misaligned financial incentives). See alsothe 
Competitive Products risk factor above. RESEARCH STUDIES
Decisions about research 
studies made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketingstrategy and payer reimbursement pos
sibilities if it receives regulatory approval. For example, a wider range of studies can lead to approval for a broader set ofindications that may impa
ct the marketing and payer reimbursement process. However, each additional indication must be balanced against the time andresources required to demonstrate benef
it, the increased complexity of development and manufacturing and the potential delays to approval of the leadindication. We try to plan 
clinical trials prudently and to reasonably anticipate and address challenges, but there is no guarantee that an optimal balance betweentrial conduct, speed and desired outco
me will be achieved each time. The degree to which such potential challenges are foreseen and adequately addressedcould affect our future results.
INTERNATIONAL OPERATIONS
Our international operations cou
ld be affected by currency fluctuations, capital and exchange controls, economic conditions, expropriation and other restrictivegovernment actions, changes in inte
llectual property legal protections and remedies, trade regulations and procedures and actions affecting approval,production, pricing, and market
ing of, reimbursement for and access to our products, as well as by political unrest, unstable governments and legal systems andinter-governmental disputes. 
Any of these changes could adversely affect our business.Many emerging markets have exper
ienced growth rates in excess of developed markets, leading to an increased contribution to the industry’s globalperformance. As a result, we have been e
mploying strategies to grow in emerging markets. However, our strategies in emerging markets may not be successfuland these countries may not continue to susta
in these growth rates. For example, even though China is growing faster than most emerging markets, we facecertain challenges in China d
ue to government imposed pricing controls affecting certain Pfizer medicines. In addition, some emerging market countries may beparticularly vulnerable to perio
ds of financial or political instability or significant currency fluctuations or may have limited resources for healthcare spending.Even though we cons
tantly monitor the evolving emerging markets for any unanticipated risk to Pfizer, certain financial or political events in such markets, asdiscussed above, can adversel
y affect our results.SPECIALTY PHARMACEUTICALS
Specialty pharmaceuticals are m
edicines that treat rare or life-threatening conditions that typically have smaller patient populations. The growing availability anduse of innovative specialt
y pharmaceuticals, combined with their relative higher cost as compared to other types of pharmaceutical products, has generatedpayer interest in developing 
cost-containment strategies targeted to this sector. The impact of payers’ efforts to control access to and pricing of specialtypharmaceuticals is 
increasing. For Pfizer to date, a number of factors create a more challenging paradigm given our growing specialty business portfolio. Theseinclude formulary rest
rictions and increasing use of utilization management tools such as step edits, which can lead to higher negotiated rebates or discounts tohealth plans and PBMs in the U.
S., as well as the increasing use of health technology assessments in markets around the world.CONSUMER HEALTHCARE
The Consumer Healthcare bus
iness may be impacted by economic volatility, the timing and severity of the cough, cold and flu season, generic or store brandcompetition affecting consumer 
spending patterns and market share gains of competitors’ branded products or generic store brands. In addition, regulatory andlegislative outcomes regarding
 the safety, efficacy or unintended uses of specific ingredients in our Consumer Healthcare products may require withdrawal,reformulation and/or relabel
ing of certain products (e.g., cough/cold products). See Consumer Healthcare Joint Ve nture with GSK and The Global EconomicEnvironment 
risk factors below. PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
Difficulties or de
lays in product manufacturing, sales or marketing could affect future results through regulatory actions, shut-downs, work stoppages or strikes,approval delays, withdrawals, rec
alls, penalties, supply disruptions or shortages, reputational harm, product liability, unanticipated costs or otherwise. Examplesof such difficulties or de
lays include, but are not limited to, the inability to increase production capacity commensurate with demand; the failure to predict marketdemand for, or to gain market acceptance of, approved p
roducts; the possibility that the supply of incoming materials may be delayed or become unavailableand that the quality of incoming mater
ials may be substandard and not detected; the possibility that we may fail to maintain appropriate quality standardsthroughout the internal and external suppl
y network and/or comply with cGMPs andPfizer Inc.
2018 Form 10-K 13 
TABLE OF CONTENTSother applicable regulation
s such as serialization (which allows for track and trace of products in the supply chain to enhance patient safety); risks to supplychain continuity and comm
ercial operations as a result of natural (including hurricanes, earthquakes and floods) or man-made disasters (including arson orterrorist attacks) at our fac
ilities or at a supplier or vendor, including those that may be related to climate change; or failure to maintain the integrity of our supplychains against intentional and 
criminal acts such as economic adulteration, product diversion, product theft, counterfeit goods and cyberattacks.Regulatory agencies periodically insp
ect our drug manufacturing facilities to evaluate compliance with applicable cGMP requirements. Failure to comply withthese requirements may subject u
s to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions,debarment, voluntary recall of a p
roduct or failure to secure product approvals, any of which could have a material adverse effect on our business, financialcondition and results of operation
s. In February 2017, for example, we received a warning letter from the FDA communicating the FDA’s view that certainviolations of cGMP regulations
 exist at Hospira’s manufacturing facility in McPherson, Kansas. We are undertaking corrective actions to address the concernsraised by the FDA. In January 2018, the FD
A upgraded the status of Pfizer’s McPherson manufacturing facility to VAI based on an October 2017 inspection. Thechange to VAI status lifted the compl
iance hold that the FDA placed on approval of pending applications. In June 2018, the FDA informed us that it hadcompleted an evaluation of correct
ive actions and closed out the February 2017 warning letter issued to our McPherson manufacturing facility after determiningthat we had addressed the violations 
contained in the warning letter. In July-August 2018, the FDA conducted a follow-up inspection of our McPherson facilityand issued an inspection report not
ing several findings. Pfizer responded to the FDA’s findings, and is in the process of implementing a corrective andpreventive action plan to address the F
DA’s concerns. On the basis of the July-August 2018 FDA inspection, the FDA changed the inspection classificationstatus of the McPherson site to Offic
ial Action Indicated (OAI). Future FDA inspections and regulatory activities will further assess the adequacy andsustainability of these co
rrections. Communication with the FDA on the status of the McPherson site is ongoing. As a result of this status, the FDA has refused,and may continue to refuse, to grant premarket appro
val of applications and/or the FDA may refuse to grant export certificates related to products manufacturedat our McPherson site until the 
site status is upgraded, which will require a successful re-inspection by the FDA. The product shortages we have beenexperiencing within our port
folio are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints, technical issues andsupplier quality concerns. We c
ontinue to remediate issues at legacy Hospira facilities manufacturing sterile injectables. Any continuing product shortageinterruption at thes
e manufacturing facilities could negatively impact our financial results, specifically in our Sterile Injectable Pharmaceuticals portfolio.In addition, in September 2017, Merid
ian Medical Technologies, Inc., a subsidiary of Pfizer Inc., received a warning letter from the FDA asserting the FDA’s viewthat certain violations o
f cGMP and Quality System Regulations exist at Meridian’s manufacturing sites in St. Louis, Missouri. Meridian responded to the warningletter and committed to making 
improvements across the sites. We are undertaking corrective actions to address the concerns raised by the FDA, andcommunication with the FDA is o
ngoing. Until the corrective actions are implemented and confirmed by the FDA following a re-inspection, the FDA may refuse togrant premarket approval of appli
cations and/or the FDA may refuse to grant export certificates related to products manufactured at our St. Louis sites.OUTSOURCING
We outsource certain services
 to other parties, including transaction processing, accounting, information technology, manufacturing, clinical trial recruitment andexecution, clinical lab services, no
n-clinical research, safety services, integrated facilities management and other areas. Outsourcing of services to third partiescould expose us to s
uboptimal quality of service delivery or deliverables and potentially result in repercussions such as missed deadlines or other timelinessissues, erroneous dat
a, supply disruptions, non-compliance (including with applicable legal or regulatory requirements and industry standards) and/orreputational harm, with potentia
l negative effects on our results.COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES
We depend on third-party collabo
rators, service providers, and others in the research, development, manufacturing and commercialization of our products andproduct candidates and also enter into 
joint ventures and other business development transactions in connection with our business. To achieve expected longerterm benefits, we may make substant
ial upfront payments in such transactions, which may negatively impact our reported earnings. We rely heavily on theseparties for multiple aspe
cts of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities.Third parties may not complete a
ctivities on schedule or in accordance with our expectations. Failure by one or more of these third parties to meet theircontractual or other obligation
s to Pfizer; failure of one or more of these parties to comply with applicable laws or regulations; or any disruption in therelationships between Pf
izer and one or more of these third parties, could delay or prevent the development, approval, manufacturing or commercialization ofour products and product candidates and could a
lso result in non-compliance or reputational harm, all with potential negative implications for our product pipelineand business.
BIOPHARMACEUTICAL WHOLESALERS
In 
2018 , our largest biopharm aceutical wholesaler accounted for approximately 15% of our total reven ues (and approximately 31% of our total U.S. revenues), and our top three biopharmaceutical 
wholesalers accounted for approximately 37% of our total Pfizer Inc.
2018 Form 10-K 14 
TABLE OF CONTENTSrevenues (and approximately 
76% of our total U.S. revenues). If one of our s ignificant biopharmaceutical wholesalers should encounter financial or otherdifficulties, such 
wholesaler might decrease the amount of business that it does with us, and we might be unable to collect all the amounts that the wholesalerowes us on a timely basi
s or at all, which could negatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacychains and wholesalers will increase comp
etitive and pricing pressures on pharmaceutical manufacturers, including us.BUSINESS DEVELOPMENT ACTIVITIES
We expect to continue to enhance our in-
line products and product pipeline through various forms of business development, which can include alliances,licenses, joint ventures, collab
orations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. However, these enhancementplans are subject to the availab
ility and cost of appropriate opportunities, competition from other pharmaceutical companies that are seeking similar opportunitiesand our ability to successfu
lly identify, structure and execute transactions, including the ability to satisfy the conditions to closing of announced transactions inthe anticipated timeframes or at a
ll, and successfully integrate acquisitions. Pursuing these opportunities may require us to obtain additional equity or debtfinancing, and could result 
in increased leverage and/or a downgrade of our credit ratings. Where we acquire debt or equity securities as all or part of theconsideration for business de
velopment activities, such as in connection with our contribution agreement entered into with Allogene Therapeutics, Inc., the valueof those securities will fluctuat
e, and may depreciate in value. We may not control the company in which we acquire securities, such as in connection with adivestiture or collaborative arr
angement, and as a result, we will have limited ability to determine its management, operational decisions and policies. Further,while we seek to mitigate risks an
d liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such duediligence efforts fail to d
iscover, that are not disclosed to us, or that we inadequately assess. Legal proceedings or regulatory issues often arise as a result ofactivities that occurred at a
cquired companies, their partners and other third parties. In 2016, for example, we paid $784.6 million to resolve allegations related toWyeth’s reporting of pri
ces to the government with respect to Protonix for activities that occurred prior to our acquisition of Wyeth. For these and other reasons,we may not realize the antic
ipated benefits of such transactions, and expected synergies and accretion may not be realized within the expected timeframes, orat all.
COUNTERFEIT PRODUCTS
A counterfeit medicine i
s one that has been deliberately and fraudulently mislabeled as to its identity and source. A counterfeit Pfizer medicine, therefore, is onemanufactured by someone other than Pfizer, but 
which appears to be the same as an authentic Pfizer medicine. The prevalence of counterfeit medicines is asignificant and growing 
industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the Internet, which hasgreatly facilitated the ease by 
which counterfeit medicines can be advertised, purchased and delivered to individual patients; the availability of sophisticatedtechnology that makes it easier fo
r counterfeiters to make counterfeit medicines; the growing involvement in the medicine supply chain of under-regulatedwholesalers and repackagers
; the lack of adequate inspection at certain international postal facilities as counterfeit medicines are increasingly delivered direct tocustomers in small pa
rcel packages; the tendency to misuse and abuse medicines; and the relatively modest risk of penalties faced by counterfeiters comparedto the large profits that can be earned by them from the 
sale of counterfeit medicines. Further, laws against pharmaceutical counterfeiting vary greatly fromcountry to country,
 and the enforcement of existing law varies greatly from jurisdiction to jurisdiction. For example, in some countries, pharmaceuticalcounterfeiting is not a cri
me; in others, it may result in only minimal sanctions. In addition, those involved in the distribution of counterfeit medicines use complextransport routes in order to evade custom
s controls by disguising the true source of their products.Pfizer’s global reputat
ion makes its medicines prime targets for counterfeiting organizations. Counterfeit medicines pose a risk to patient health and safetybecause of the conditions under whi
ch they are manufactured—often in unregulated, unlicensed, uninspected and unsanitary sites—as well as the lack ofregulation of their contents. Fai
lure to mitigate the threat of counterfeit medicines, which is exacerbated by the complexity of the supply chain, could adverselyimpact our business, by, among other th
ings, causing the loss of patient confidence in the Pfizer name and in the integrity of our medicines, potentially resultingin lost sales, product rec
alls, and an increased threat of litigation.We undertake significant effort
s to counteract the threats associated with counterfeit medicines, including, among other things, working with the FDA and otherregulatory authorities and mu
ltinational coalitions to combat the counterfeiting of medicines and supporting efforts by law enforcement authorities to prosecutecounterfeiters; assessing ne
w and existing technologies to seek to make it more difficult for counterfeiters to copy our products and easier for patients andhealthcare providers to dist
inguish authentic from counterfeit medicines; implementing business practices designed to protect patient health; promoting publicpolicies intended to hind
er counterfeiting; working diligently to raise public awareness about the dangers of counterfeit medicines; working collaboratively withwholesalers, pharmac
ies, customs offices, and law enforcement agencies to increase inspection coverage, monitor distribution channels, and improvesurveillance of dist
ributors and repackagers, and using data analytics and risk assessment tools to better target the factors that give rise to the counterfeitingproblem in the first place. 
However, our efforts and the efforts of others may not be entirely successful, and the presence of counterfeit medicines may continueto increase.
Pfizer Inc.
2018 Form 10-K 15 
TABLE OF CONTENTSRISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS 
: PRICING AND REIMBURSEMENT
U.S. and international governmenta
l regulations that mandate price controls and limitations on patient access to our products or establish prices paid bygovernment entities or programs fo
r our products impact our business, and our future results could be adversely affected by changes in such regulations orpolicies.
In the U.S., many of our products are subje
ct to increasing pricing pressures. Pharmaceutical product pricing is subject to enhanced government and publicscrutiny and calls for 
reform. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints underthe Medicaid program, and some states a
re considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. There have also been 
recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costsor limiting drug prices. Efforts
 by government officials or legislators to implement measures to regulate prices or payments for pharmaceutical products, includinglegislation on drug impo
rtation, could adversely affect our business if implemented. See the discussion regarding pricing and reimbursement in the Item 1. Business 
— Government Regulation and Price Constraints — In the United States — Pricing and Reimbursement section of this 2018 Form 10-K. Private third- party payers, such as
 health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and areduction in demand for our products. P
ricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare providerpurchasers, directly or th
rough group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing reviewprocesses.
We encounter similar 
regulatory and legislative issues in most other countries. In certain international markets, such as the different EU Member States, Japan,China, Canada and South Korea, governments ha
ve significant power as large single payers to regulate prices, access criteria (e.g., through public or privatehealth technology assessments), o
r other means of cost control, particularly under recent global financing pressures. As a result, we expect that pressures onthe pricing component of operating resu
lts will continue.The adoption of
 restrictive price controls in new jurisdictions or more restrictive ones in existing jurisdictions, failure to obtain or maintain timely or adequatepricing or favorable formu
lary placement for our products, or failure to obtain such formulary placement at favorable pricing, could also adversely impactrevenue. In our v
accines business, we participate in a tender process in many countries for participation in national immunization programs. Failure to secureparticipation in nationa
l immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business.U.S. HEALTHCARE REFORM
The U.S. healthcare industry 
is highly regulated and subject to frequent and substantial changes. For example, the ACA was enacted by Congress in March2010 and established a major expans
ion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effecton our expenses and profitabilit
y. See the discussion under the Overview of Our Performance, Ope rating Environment, Strategy and Outlook — Our OperatingEnvironment 
— Industry-Specific Challenges — Regulatory Environment/Pricing and Access––U.S. Healthcare Legislation section in our 2018 Financial Report and in 
Item 1. Business — Government Regulation and Price Constraints — In the United States . We face uncertainties due to federal legislative andadministrative efforts to repea
l, substantially modify or invalidate some or all of the provisions of the ACA. For example, tax reform legislation enacted at the endof 2017 eliminates the tax penalty for 
individuals who do not maintain sufficient health insurance coverage beginning in 2019 (the so-called “individualmandate”). We anticipat
e continued Congressional interest in modifying provisions of the ACA, particularly given the recent ruling in Texas v. Azar to invalidate the law as unconstitutional. 
At this time, the law remains in effect pending appeals of the decision. Given the outcomes of the 2018 U.S. midterm elections withDemocrats taking over th
e U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we believe it is unlikely Congress will findbipartisan consensus to advance any 
significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer by the health insuranceexchanges and Medicaid expansion unde
r the ACA are not material, so the impact of the change in law and similar recent administration actions is expected tobe limited. Any future r
eplacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislationreduces incentives for emp
loyer-sponsored insurance coverage, and we cannot predict how other future federal or state legislative or administrative changesrelating to healthcare
 reform will affect our business.Other U.S. federal or state legi
slative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budgetcontrol actions, changes in patent 
laws, the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreigncountries (which is among th
e U.S. presidential administration’s policy proposals), revisions to reimbursement of biopharmaceuticals under governmentprograms (such as the imple
mentation of international reference pricing for Medicare Part B drugs, or changes to protected class criteria for Part D drugs),restrictions on U.S. direct-to-c
onsumer advertising, limitations on interactions with healthcare professionals, or the use of comparative effectivenessmethodologies that could be imp
lemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences amongpharmaceutical products 
and restricts access to innovative medicines.Pfizer Inc.
2018 Form 10-K 16 
TABLE OF CONTENTSU.S. ENTITLEMENT REFORM
In the U.S., government action to reduce federa
l spending on entitlement programs including Medicare and Medicaid may affect payment for our products orservices provided us
ing our products. The Congressional Budget Office routinely releases options for reducing federal spending, and the December 2018release includes proposa
ls to cap federal Medicaid payments to the states, and to require manufacturers to pay a minimum rebate on drugs covered underMedicare Part D for low-income b
eneficiaries. Significant Medicare reductions could also result if, for example, Congress proceeds with certain proposals toconvert the Medicare fee-for-ser
vice program into a premium support program, or Congress chooses to implement the recommendations made annually by theMedicare Payment Advisory Commission, which
 are primarily intended to extend the fiscal solvency of the Medicare program. These and any other significantspending reductions or cost contro
ls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could havean adverse impact on our results of ope
rations.SUBSTANTIAL REGULATION
We are subject to extensive, co
mplex, costly and evolving regulation by federal and state governmental authorities in the U.S., principally by the FDA and theDEA, and foreign regula
tory authorities. Failure to comply with all applicable regulatory requirements may subject us to operating restrictions and criminalprosecution, monetary
 penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension,revocation of approvals, corporate 
integrity or deferred prosecution agreements or exclusion from future participation in government healthcare programs, aswell as reputational harm.
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
Innovation is critica
l to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. The outcome of the lengthy and complex process of 
identifying new compounds and developing new products is inherently uncertain and involves a high degree of risk and cost.The process from early dis
covery to design and adequate implementation of clinical trials to regulatory approval can take many years. Drug candidates can anddo fail at any stage of the process, inc
luding as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new clinical data and furtheranalyses of existing c
linical data, including results that may not support further clinical development of the applicable product candidate or indication. We maynot be able to m
eet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatorysubmission dates, regulator
y approval dates and/or launch dates. Similarly, we may not be able to successfully address all of the comments received fromregulatory authorities such a
s the FDA and the EMA, or obtain approval from regulators. Regulatory approval of drug or biologic products depends on myriadfactors, including a regulato
r making a determination as to whether a product’s benefits outweigh its known risks and a determination of the product’s efficacy.Additionally, cl
inical trial data are subject to differing interpretations and assessments by regulatory authorities. Even after a drug or biologic is approved, it couldbe adversely affected by regulatory de
cisions impacting labeling, manufacturing processes, safety and/or other matters. We may not be able to receive ormaintain favorable recomme
ndations by technical or advisory committees, such as the Advisory Committee on Immunization Practices that may impact the useof our vaccines. For example, dur
ing the October 2018 ACIP meeting, the U.S. Centers for Disease Control and Prevention presented initial data and indicatedformal evaluation of evidence 
(grading) and a potential vote on the maintenance of the 65 years and older recommendation for Prevnar 13 would likely happenin 2019. A potential adverse change in the 
ACIP recommendation would negatively impact future Prevnar 13 revenues. For additional information, see theAnalysis of the Consol
idated Statements of Income — Revenues — Selected Product Discussion section of our 2018 Financial Report. Further, claims andconcerns that may arise regard
ing the safety and efficacy of in-line products and product candidates can result in a negative impact on product sales, productrecalls or withdrawals, and/or co
nsumer fraud, product liability and other litigation and claims. Increasing regulatory scrutiny of drug safety and efficacy, withregulatory authorities in
creasingly focused on product safety and the risk/benefit profile of products as they relate to already-approved products, has resulted in amore challenging, expensi
ve and lengthy regulatory approval process due to requests for, among other things, additional or more extensive clinical trials prior togranting approval or increased po
st-approval requirements. For these and other reasons discussed in Item 1A. Risk Factors , we may not obtain the approvals we expect within the timef
rame we anticipate, or at all.POST-APPROVAL DATA
As a condition to granting market
ing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in thesePhase 4 trials could resu
lt in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of aproduct. Regulatory agencies 
in countries outside the U.S. often have similar authority and may impose comparable requirements. Postmarketing studies,whether conducted by us or by others and whethe
r mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such asadverse event reports, may also adve
rsely affect the availability or commercial potential of our products. Further, the discovery of significant problems with aproduct similar to one of our produ
cts could implicate the entire class of products; and this, in turn, could have an adverse effect on the availability or commercialviability of our product(s) as
 well as other products in the class.Pfizer Inc.
2018 Form 10-K 17 
TABLE OF CONTENTSINTERACTIONS WITH HEALTHCARE PROFESSIONALS AND GOVERNMENT OFFICIALS
Risks and uncertaintie
s apply if we provide, offer, or promise something of value to a healthcare professional, other healthcare provider and/or governmentofficial. Requirement
s or industry standards in the U.S. and certain jurisdictions abroad that require pharmaceutical manufacturers to track and disclose financialinteractions with health
care professionals and healthcare providers increase government and public scrutiny of such financial interactions. If an interaction isfound to be improper, government enforcement act
ions and penalties could result. These risks may increase as both U.S. and foreign enforcement agenciesadopt or increase enforcement efforts in 
respect of existing and new laws and regulations governing product promotion, marketing, anti-bribery and kickbacks,industry regulations, an
d codes of conduct.CHANGES IN LAWS AND ACCOUNTING STANDARDS
Our future results could be adverse
ly affected by changes in interpretations of existing laws and regulations, or changes in laws and regulations, including,among others, changes in accounting standard
s, taxation requirements (including tax rate changes, new tax laws, changes to existing tax laws and revised taxlaw and regulatory clar
ifications and/or interpretations, including changes affecting the taxation by the U.S. of income earned outside the U.S. that may resultfrom pending and possible future proposa
ls, including further clarifications and/or interpretations of the Tax Cuts and Jobs Act), competition laws, privacy lawsand environmental laws 
in the U.S. and other countries. For additional information, see the Provision/(Benefit) for Taxes  on Income — Changes in Tax Laws and New Accounting Standards 
sections, and Notes to Consol idated Financial Statements— Note 1 B. Basis of Presentation and Significant Accounting Policies : Adoption of New Accountin
g Standards in 2018 in our 2018 Financial Report. LEGAL PROCEEDINGS
We and certain of our subsidia
ries are involved in various legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do notcover the product of the generic drug manufacture
r or where one or more third parties seeks damages and/or injunctive relief to compensate for allegedinfringement of its patents by our co
mmercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-labelpromotion, securities, ant
itrust and breach of contract claims, commercial, environmental, government investigations, employment, tax litigation and other legalproceedings, including va
rious means for resolving asbestos litigation, that arise from time to time in the ordinary course of our business. Litigation is inherentlyunpredictable, and excessive 
verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, wecould in the future incur judgment
s, enter into settlements of claims or revise our expectations regarding the outcomes of certain matters, and suchdevelopments could have a materia
l adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in theperiod in which the amou
nts are paid.Claims against our patents 
include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we havesubstantial defenses to these chal
lenges with respect to all of our material patents, there can be no assurance as to the outcome of these matters, and a loss inany of these cases could result 
in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and couldmaterially affect future
 results of operations.Like other pharmaceutical co
mpanies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multipleemerging markets in wh
ich we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, substantial finesand/or civil penalties, limitations o
n our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well asreputational harm and increased pub
lic interest in the matter could result from government investigations. In addition, in a qui tam lawsuit in which thegovernment declines to intervene, the 
relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.Our activities relat
ing to the sale and marketing and the pricing of our products are subject to extensive regulation under the FFDCA, the Medicaid Drug RebateProgram, the FCPA and other federal and state 
statutes, including those discussed elsewhere in this 2018 Form 10-K, as well as anti-kickback  and false claimslaws, and similar laws in international jurisdictions
. Like many companies in our industry, we have from time to time received inquiries and subpoenas and othertypes of information demands from gove
rnment authorities, and been subject to claims and other actions related to our business activities brought bygovernmental authorities, as 
well as by consumers and private payers. In some instances, we have incurred significant expense, civil payments, fines and otheradverse consequences
 as a result of these claims, actions and inquiries. For example, these claims, actions and inquiries may relate to alleged failures toaccurately interpret or ident
ify or prevent non-compliance with the laws and regulations associated with the dissemination of product information (approved andunapproved), potentially resu
lting in government enforcement and damage to our reputation. This risk may be heightened by digital marketing, including socialmedia, mobile applications an
d blogger outreach.In connection with the resolut
ion of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance toMedicare patients, in May 2018, 
we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Healthand Human Services, which is ef
fective for a period of fivePfizer Inc.
2018 Form 10-K 18 
TABLE OF CONTENTSyears. In the CIA, we agreed to imp
lement and/or maintain certain compliance program elements to promote compliance with federal healthcare programrequirements. Breaches of the CIA 
could result in severe sanctions against us.For additional information
, including information regarding certain legal proceedings in which we are involved in, see Notes to Consolidated Financial Statements— 
Note 17 A . Contingencies and Certain Commitments — Legal Proceedings in our 2018 Financial Report. ENVIRONMENTAL CLAIMS AND PROCEEDINGS
We and certain of o
ur subsidiaries are subject to numerous contingencies arising in the ordinary course of business relating to environmental claims andproceedings. 
Amounts recorded for legal and env ironmental contingencies can result from a complex series of judgments about future events and uncertaintiesand can rely heavily on est
imates and assumptions. While we have accrued for worldwide  environmental liabilities, there is no guarantee that additional costswill not be incurred be
yond the amounts accrued. If we fail to properly manage the safety of our facilities and the environmental risks associated therewith or ifwe are required to increase our a
ccruals for contingencies for environmental claims and proceedings in the future, it could potentially have an adverse effect onour results of operations.
RISKS RELATED TO INTELLECTUAL PROPERTY 
: PATENT PROTECTION
Our long-term success la
rgely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination ofintellectual property, 
including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and licenseagreements, to protect our intellectua
l property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not beable to prevent third parties from 
launching generic or biosimilar versions of our branded products, using our proprietary technologies or from marketing productsthat are very similar o
r identical to ours. Our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis.Similarly, any te
rm extensions that we seek may not be granted on a timely basis, if at all. In addition, our issued patents may not contain claims sufficientlybroad to protect
 us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particularproduct area. The scope of our patent claims a
lso may vary between countries, as individual countries have distinct patent laws. We may be subject tochallenges by third parties
 regarding our intellectual property, including, among others, claims regarding validity, enforceability, scope and effective term.Our ability to enforce our patents a
lso depends on the laws of individual countries and each country’s practice with respect to enforcement of intellectual propertyrights, and the extent to which certa
in sovereigns may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., a policyof routine compulsory licensing
 (or threat of compulsory licensing) of pharmaceutical intellectual property). In countries that provide some form of regulatoryexclusivity, mechanisms exist permitting s
ome form of challenge to our patents by competitors or generic drug marketers prior to or immediately following theexpiration of such reg
ulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as “at risk” launches that challenge ourpatent rights. Most of the suits invo
lve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or donot cover the product of the generic drug manufacture
r. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rightswith respect to certain product
s constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions webring to enforce our patents. We are also pa
rty to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers,governments or other parties are seek
ing damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as interpartes review, post-grant rev
iew, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or otherforeign counterparts relating to our 
intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by suchproceedings, generic or compet
itive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, severalof the patents in our pneumococcal vacc
ine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In June 2018, thePatent Trial and Appeal Board ru
led on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent hasappealed the decision. Chal
lenges to other patents remain pending before the U.S. Patent and Trademark Office. The invalidation of these patents couldpotentially allow a 
competitor pneumococcal vaccine into the marketplace. Further, if we are unable to maintain our existing license agreements or otheragreements pursuant to which third pa
rties grant us rights to intellectual property, including because such agreements expire or are terminated, our operatingresults and financial conditio
n could be materially adversely affected.Likewise, in the U.S. and othe
r countries, we currently hold issued trademark registrations and have trademark applications pending, any of which may be thesubject of a governmental or third
-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance onour trademarks and trade dress to different
iate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting,registering or using trad
emarks and trade dress that infringe, dilute or otherwise violate our trademark rights, our business could be materially adverselyaffected. We actively seek to prote
ct our proprietary information, including our trade secrets and proprietary know-how, byPfizer Inc.
2018 Form 10-K 19 
TABLE OF CONTENTSrequiring our employees, con
sultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon thecommencement of their employment, engage
ment or other relationship. Despite these efforts and precautions, we may be unable to prevent a third party fromcopying or otherwise obtain
ing and using our trade secrets or our other intellectual property without authorization, and legal remedies in some countries may notadequately compensate us for the damages caused by 
such unauthorized use. Further, others may independently and lawfully develop substantially similar oridentical products that
 circumvent our intellectual property by means of alternative designs or processes or otherwise.THIRD PARTY INTELLECTUAL PROPERTY CLAIMS
A properly functioning int
ellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights ofother companies, but the patent granting process 
is imperfect. Accordingly, the pursuit of valid busines s opportunities may require us to challenge intellectualproperty rights held by
 other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not alwaysbe successful.
Part of our business depends upon succes
sfully identifying generic pharmaceutical product and biosimilar opportunities and launching products to takeadvantage of those opportunities, which 
may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities mayarise in situations 
where patent protection of equivalent branded products has expired, where patents have been declared invalid, or where products do notinfringe the patents of others. To achieve a “f
irst-to-market” or early market position for generic pharmaceutical products and biosimilars, we may take action,such as litigation, asse
rting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable.Third parties may cla
im that our products infringe one or more patents owned or controlled by the third party. Claims of intellectual property infringement can becostly and time-consum
ing to resolve, may delay or prevent product launches, and may result in significant damages. We are involved in patent-related disputeswith third parties over ou
r attempts to market generic pharmaceutical products and biosimilars. Once we have final regulatory approval of the related genericpharmaceuticals products 
or biosimilars, we may decide to commercially market these products even though associated legal proceedings (including anyappeals) have not been resolved (i.e., 
“at-risk” launch). If one of our marketed products is found to infr inge valid patent rights of a third party, such third partymay be awarded significant da
mages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in theevent that we or 
one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Any of these adverse consequences could have a material adverse effe
ct on our profitability and financial condition.RISK RELATED TO TECHNOLOGY 
: INFORMATION TECHNOLOGY AND SECURITY
Significant disrupt
ions of information technology systems or breaches of information security could adversely affect our businesses. We rely to a large extentupon sophisticated information te
chnology systems to operate our businesses. In the ordinary course of business, we collect, store and transmit large amountsof confidential information 
(including, but not limited to, personal information and intellectual property), and we deploy and operate an array of technical andprocedural controls to mainta
in the confidentiality and integrity of such confidential information. We also have outsourced significant elements of our operationsto third parties, includ
ing significant elements of our information technology infrastructure and, as a result, we are managing many independent vendorrelationships with th
ird parties who may or could have access to our confidential information. The size and complexity of our information technology andinformation security s
ystems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present onthem), make such systems potentia
lly vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees orvendors, or from at
tacks by malicious third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with awide range of motives (includin
g, but not limited to, industrial espionage) and expertise, including organized criminal groups, “hacktivists,” nation states andothers. As a global pharmaceuti
cal company, our systems are subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that theymay remain undetected for a period of ti
me. While we have invested in the protection of data and information technology, our efforts may not prevent serviceinterruptions or securit
y breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss ofcritical or sensitive confidential inform
ation or intellectual property, and could result in financial, legal, business and reputational harm to us. We maintain cyberliability in
surance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruptionor breach of our systems.
Pfizer Inc.
2018 Form 10-K 20 
TABLE OF CONTENTSRISKS RELATED TO OUR STRATEGIC TRANSACTIONS 
: STRATEGIC ACQUISITIONS
The success of any of our strategic acqu
isitions will depend, in large part, on our ability to realize anticipated benefits from combining these businesses withPfizer. We, for example, m
ay fail to achieve cost savings anticipated with certain of these acquisitions, or such cost savings within the expected time frame.Similarly, the ac
cretive impact anticipated from certain of these acquisitions may not be realized or may be delayed. Integration of these businesses may resultin the loss of key employees, the d
isruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures andpolicies. We also 
may fail to generate the revenue growth for the acquired business that we expected at the time of entering into the transaction. Expectedrevenue from acquired products and product 
candidates also may be constrained by developments outside of our control. Unsuccessful clinical trials, regulatoryhurdles and commercial
ization challenges may adversely impact revenue and income contribution from products and product candidates, including thoseacquired in these acq
uisitions. Hospira, for example, has experienced manufacturing disruptions and substantial regulatory scrutiny due to quality issues.Manufacturing problems, as we
ll as any corrective actions and their operational implementation, could adversely impact the revenue we generate from productsacquired from Hospira and re
sult in substantial unanticipated costs. For additional information, see the Overview of Our Performance, Ope rating Environment,Strategy and Outlook 
–– Our Business — Product Manufacturing section in our 2018 Financial Report. CONSUMER HEALTHCARE JOINT VENTURE WITH GSK
The required shareholder and regulatory app
rovals may not be obtained or the regulatory approvals may contain materially burdensome conditionsthat could have an adverse effect on us or the joint ventu
re or the other conditions to the completion of the proposed transaction may not besatisfied in a timely manner or at all.
Completion of the proposed transact
ion is subject to a number of conditions, including, among others, the approval of GSK’s shareholders and the receipt ofcertain governmental and regulator
y approvals, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino AntitrustImprovements Act of 1976, as amended, and the receipt of a
ll required approvals under the antitrust laws of certain other jurisdictions, including the EU.Although Pfizer and GSK have agreed to do a
ll things necessary under applicable antitrust laws to complete the proposed transaction as promptly as reasonablypracticable, there can be no assurance that the
se approvals will be obtained in a timely manner or at all or that the other conditions to closing will be satisfied. Inaddition, in connection w
ith obtaining the required regulatory approvals, governmental authorities may impose conditions on the completion of the proposedtransaction or require changes to the ter
ms of the proposed transaction. If any such conditions or changes are imposed, they may jeopardize or delaycompletion of the proposed transaction, 
reduce or delay the anticipated benefits of the proposed transaction or allow the parties to terminate the stock and assetpurchase agreement, which could negat
ively impact our stock price and our or the joint venture’s, as applicable, future business and financial results.We may fail to realize all of the anticipated bene
fits of the proposed transaction.The success of the proposed transaction 
will depend, in part, on the joint venture’s ability to realize the anticipated benefits and cost synergies from theproposed transaction. These anticipated benef
its and cost savings may not be realized or may not be realized within the expected time period. The jointventure’s integration o
f Pfizer’s and GSK’s consumer healthcare businesses may result in material unanticipated problems, costs, expenses, liabilities,competitive responses, a
nd loss of customer and other business relationships. Any material unanticipated issues arising from the integration process couldnegatively impact our stoc
k price and our or the joint venture’s, as applicable, future business and financial results.Moreover, uncertainty about the effect of the proposed tran
saction on employees, customers, suppliers, distributors and other business partners may have anadverse effect on us and the joint venture. These unce
rtainties may impair our and/or the joint venture’s ability to attract, retain and motivate key personnel untilthe transaction is consummated and for a pe
riod of time thereafter, and could cause customers, suppliers, distributors and others who deal with us and/or thejoint venture to seek
 to change or cancel existing business relationships with us and/or the joint venture or fail to renew existing relationships. Employeeretention may be challenging dur
ing the pendency of the proposed transaction, as certain employees may experience uncertainty about their future roles. If keyemployees depart because of issues 
related to the uncertainty and difficulty of integration or a desire not to remain with the combined business, our businessand the business of the joint venture fol
lowing the completion of the transaction could be adversely affected.Following the integration of the 
combined business, GSK intends to separate the joint venture as an independent company via a demerger of its equity interestto its shareholders and a li
sting of the combined business on the U.K. equity market. GSK will have the sole right to decide whether and when to initiate aseparation and listing for a per
iod of five years from closing of the proposed transaction. GSK may also sell all or part of its stake in the joint venture in acontemporaneous initial pub
lic offering. Should a separation and listing occur during the first five years after closing, Pfizer has the option to participate throughthe distribution of some or al
l of its equity interest in the joint venture to its shareholders. Following a separation or listing, and subject to customary lock-up orsimilar restrictions, Pfizer will also have the 
ability to sell its equity interest in the joint venture through the capital markets. After the fifth anniversary of theclosing of the proposed transaction, both G
SK and Pfizer will have the right to decide whether and when to initiate a separation and public listing of the jointventure. The planned separation and
Pfizer Inc.
2018 Form 10-K 21 
TABLE OF CONTENTSpublic listing tran
sactions may not be initiated or completed within the expected time periods or at all, and both the timing and success of any separation andpublic listing transaction, as well as
 the value generated for Pfizer or its shareholders in any such transaction, will be subject to prevailing market conditions andother factors at the time of such transact
ion. Although Pfizer is entitled to participate in any separation and listing transaction initiated by GSK during the first fiveyears after closing, it is n
ot required to do so, and any future distribution or sale of Pfizer’s equity stake in the joint venture will similarly be subject to prevailingmarket conditions and other factors at the t
ime of such transaction. Pfizer’s ability to complete any such future distribution or sale may also be impacted by thesize of Pfizer’s reta
ined equity stake at the time. The uncertainty relating to the separation and public listing transactions, their implementation, their timing andtheir yet to be determined effects on the jo
int venture’s business may subject us and the joint venture to risks and uncertainties that may adversely affect ourbusiness and financial results.
The joint venture may be subject to additional risks beyond those associated wi
th Pfizer’s consumer healthcare business.After completion of the transaction, the 
joint venture will be subject to the risks associated with GSK’s consumer healthcare business in addition to the risksassociated with Pfize
r’s consumer healthcare business, and the business, financial condition and results of operations of the joint venture may be affected byfactors that are different from or in add
ition to those currently affecting the independent business, financial condition and results of operations of Pfizer’sconsumer healthcare business. 
Many of these factors are outside of our and the joint venture’s control, and could materially impact the business, financialcondition and results of operation
s of the joint venture. Moreover, although we will have certain consent, board representation and other governance rights withrespect to the joint venture, Pfize
r will be a minority owner of the joint venture following the completion of the proposed transaction. As a result, Pfizer will nothave control over the joint venture, 
its management or its policies and we may have business interests, strategies and goals that differ in certain respects fromthose of GSK or the joint venture.
The market value of our common stock 
may be adversely affected as a result of expected and unexpected costs associated with the proposedtransaction and integration of the businesses.
We have incurred, and expect to incu
r, transaction- and integration-related costs in connection with the proposed transaction. We expect that a substantialportion of these transaction- and integrat
ion-related costs will be comprised of non-recurring fees for professional services to complete the proposed transaction,facilities and syste
ms consolidation costs and employment-related costs, although certain unanticipated costs and expenses may be incurred as well. If the stockand asset purchase agreement is term
inated, we would have incurred many of these costs, fees and expenses without realizing the expected benefits of thetransaction. These costs, fees and expenses 
could adversely affect our financial results.OTHER RISKS:
THE GLOBAL ECONOMIC ENVIRONMENT
Like all businesses of our size
, we are exposed to both global and industry-specific economic conditions. Governments, corporations, and insu rance companies,which provide insuran
ce benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients toswitch to generic or bio
similar products, delay treatments, skip doses or use less effective treatments. Government financing pressures can lead to negativepricing pressure in va
rious markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technologyassessments), or other means of cost 
control. Examples include the different EU Member States, Japan, China, Canada, South Korea and a number of otherinternational markets. The U.
S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growinggovernment influence as government prog
rams continue to grow as a source of coverage.The global economic environ
ment has not had, nor do we anticipate that it will have, a material impact on our liquidity or capital resources. Due to our significantoperating cash flows, financ
ial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that wehave, and will mainta
in, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolvingeconomic conditions, but there can be no gua
rantee that changes in global financial markets and global economic conditions will not affect our liquidity or capitalresources or impact our abi
lity to obtain financing in the future.We continue to monitor
 credit, capital restrictions and economic situations in volatile regions and markets, especially where the ability to obtain U.S. dollars forlocal currency is unp
redictable and challenging. We cannot predict the likelihood of future changes in these economic conditions, or what impact they may haveon our results of operations, financ
ial condition or business.In addition, given that a signif
icant portion of our business is conducted in the EU, including the U.K., the formal change in the relationship between the U.K. andthe EU caused by Brexit m
ay pose certain implications for our research, commercial and general business operations in the U.K. and the EU, including theapproval and supply o
f our products. Details on how Brexit will be executed and the impact on the remaining EU countries will dictate how and whether thebroader EU will be impacted
Pfizer Inc.
2018 Form 10-K 22 
TABLE OF CONTENTSand what the resulting impact on our bu
siness may be. For additional information, see the see the Overview of Our Performance, Ope rating Environment,Strategy and Outlook 
–– Our Operating Environment — The Global Economic Environment section in our 2018 Financial Report. We also continue to monitor the g
lobal trade environment and potential trade conflicts and impediments. If trade restrictions or tariffs reduce global economicactivity, or if other fac
tors lead to a general economic downturn, potential impacts could include declining sales; increased costs; volatility in foreign exchangerates; a decline in the value of our f
inancial assets and pension plan investments; required increases of our pension funding obligations; increased governmentcost control efforts; delays or fa
ilures in the performance of customers, suppliers, and other third parties on whom we may depend for the performance of ourbusiness; and the risk that our al
lowance for doubtful accounts may not be adequate.FOREIGN EXCHANGE AND INTEREST RATE RISK
Significant portions of our 
revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates.53% 
of our total 2018 revenues were derived fr om international operations, including 21% from Europe and 22% from China, Japan and the rest of Asia. As weoperate in multiple foreign 
currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound, the Canadian dollar and approximately 100other currencies, chan
ges in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken againstanother currency, assuming al
l other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenseswould increase, having a negat
ive impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variablesremained constant, our revenues wou
ld decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact onearnings. Therefore, signifi
cant changes in foreign exchange rates can impact our results and our financial guidance.The impact of possible c
urrency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela andArgentina, can impact our resu
lts and financial guidance . For additional information about ou r exposure to foreign currency risk, see the Overview of Our Performance, Operating Environ
ment, Strategy and Outlook –– Our Financial Guidance for 2019 and Analysis of Financial Condition, Liquidity and CapitalResources 
sections in our 2018 Financial Report. In addition, our interest-bearing 
investments and borrowings, and our pension benefit obligations, net, and our postretirement benefit obligations, net, are subjectto risk from changes in inte
rest rates and foreign exchange rates. These risks related to interest-bearing investments and borrowings and the measures we havetaken to help contain them are discus
sed in the Forward-Looking Information and Facto rs That May Affect Future Results — Financial Risk Management section in our 
2018 Financial Report. For ad ditional details, see the Notes to Consolidated Financial Statements— Note 7 F . Financial Instruments : Derivative FinancialInstruments and Hed
ging Activities and — Note 11 . Pension and Postretirement Benefit Plans and Defined Contribution Plans in our 2018 Financial Report and the 
Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions ––Benefit Plans section in our 2018 Financial Report. Those sections of our 
2018 Financial Report are incorpor ated by reference.From time to time, we is
sue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. There iscurrently uncertainty around 
whether LIBOR will continue to exist after 2021. If LIBOR ceases to exist, we may need to amend certain agreements and wecannot predict what alternative 
index would be negotiated with our counterparties. As a result, our interest expense could increase and our available cash flowfor general corporate requirements 
may be adversely affected. Additionally, uncertainty as to the nature of a potential discontinuance, modification, alternativereference rates or other reforms may 
materially adversely affect the trading market for securities linked to such benchmarks. For additional information, seeAnalysis of Financial Condition, Liq
uidity and Capital Resources — Selected Measures of Liquidity and Capital Resources — LIBOR . Notwithstanding our efforts to fore
see and mitigate the effects of changes in external fiscal circumstances, we cannot predict with certainty changes in currencyand interest rates, inflation or othe
r related factors affecting our businesses.MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS
In the first quarter of 2018, we adopted a new account
ing standard whereby certain equity investments are measured at fair value with changes in fair value nowrecognized in net income. We e
xpect the adoption of this new accounting standard may increase the volatility of our income in future periods due to changes inthe fair value of equity invest
ments. For additional information, see Notes to Consolidated Financial Statements— Note 1 B. Basis of Presentation andSignificant Accounting Policies 
: Adoption of New Accounting Standards in 2018 and the Forward-Looking Information and Facto rs That May Affect FutureResults 
— Financial Risk Management sections in our 2018 Financial Report. Pfizer Inc.
2018 Form 10-K 23 
TABLE OF CONTENTSOur pension benefit obligations and po
stretirement benefit obligations, net of our plan assets, are subject to volatility from changes in fair value of equityinvestments and other investment r
isk. For additional information, see Notes to Consolidated Financial Statements— Note 11. Pension and Postretirement Benefit Plans and Define
d Contribution Plans and the Significant Accounting Policies and  Application of Critical Accounting Estimates and Assumptions — Benefit Plans 
section in our 2018 Financial Report.COST AND EXPENSE CONTROL/UNUSUAL EVENTS/FAILURE TO REALIZE THE ANTICIPATED BENEFITS OF STRATEG
IC INITIATIVES ANDACQUISITIONS
Growth in costs and expenses, changes 
in product, segment and geographic mix and the impact of acquisitions, divestitures, restructurings, internalreorganizations, product w
ithdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization andorganizational restructur
ing could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of(i) our cost-reduction and produ
ctivity initiatives; (ii) the reorganization of our commercial operations into three businesses effective at the beginning of thecompany’s 2019 fiscal year;
 (iii) any other corporate strategic initiatives; and (iv) any acquisitions, divestitures or other initiatives, such as our proposedtransaction with GSK to comb
ine our respective consumer healthcare businesses into a new consumer healthcare joint venture.INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
Our consolidated balanc
e sheet contains significant amounts of intangible assets, including goodwill. For IPR&D assets, the risk of failure is significant, andthere can be no certainty that these assets ult
imately will yield successful products. The nature of the biopharmaceutical business is high-risk and requires thatwe invest in a large number of p
rojects in an effort to achieve a successful portfolio of approved products. Our ability to realize value on these significantinvestments is often contingent upon, among othe
r things, regulatory approvals and market acceptance. As such, we expect that many of these IPR&D assetswill become impa
ired and be written off at some time in the future. If the associated R&D effort is abandoned, the related IPR&D assets will likely be written-off,and we will record an impairment c
harge. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge(such as, among other things, unantic
ipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in thebusiness climate and/or a fa
ilure to replace the contributions of products that lose exclusivity). Any such charge may be significant. Our other intangible assets,including developed tech
nology rights and brands, face similar risks for impairment and charges related to such assets may be significant as well. For additionaldetails, see the 
Significant Accounting Policies and  Application of Critical Accounting Estimates and Assumptions section in our 2018 Financial Report. We also regularly re
view our equity-method investments for impairment. An impairment charge may result from the occurrence of unexpected adverse events ormanagement decisions that impact ou
r estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as aresult of a weak economic env
ironment, events related to particular customers or asset types, challenging market conditions or decisions by management.INTERNAL CONTROL OVER FINANCIAL REPORTING
The accuracy of our financial 
reporting depends on the effectiveness of our internal control over financial reporting. Internal control over financial reporting canprovide only reasonable assu
rance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements.Failure to maintain eff
ective internal control over financial reporting, or lapses in disclosure controls and procedures, could undermine the ability to provideaccurate disclosure (including with r
espect to financial information) on a timely basis, which could cause investors to lose confidence in our disclosures(including with respect to fin
ancial information), require significant resources to remediate the lapse or deficiency, and expose us to legal or regulatoryproceedings.
TERRORIST ACTIVITY
Our future results could be adverse
ly affected by changes in business, political and economic conditions, including the cost and availability of insurance, due tothe threat of terrorist activit
y in the U.S. and other parts of the world and related U.S. military action overseas.Pfizer Inc.
2018 Form 10-K 24 
TABLE OF CONTENTSITEM 1B.
UNRESOLVED STAFF COMMENTS Not applicable.
ITEM 2.
PROPERTIES As of December 31, 
2018 , we had 498 owned and leased properties, amount ing to approximately 53 million square feet.Pfizer continues to own and lea
se space around the world for sales and marketing, customer service, regulatory compliance, R&D, manufacturing anddistribution, and admini
strative support functions. In many locations, business lines and operations are co-located to achieve synergy and operationalefficiencies.
Pfizer’s corporate headq
uarters are in New York City and Pfizer’s properties extend internationally to over 90 countries.In April 2018, we entered an agreement to lea
se space at the Spiral, an office building in the Hudson Yards neighborhood of New York City. We will relocate ourglobal headquarters to this property 
with occupancy expected beginning in 2022. In July 2018, we completed the sale of our current headquarters in New YorkCity. We are in a lease
-back arrangement with the buyer while we complete our relocation. We continue to advance our global workplace strategy to provideworkplaces that enable col
laboration and foster innovation.We have numerous facilities acr
oss the world to support our R&D organizations, with a heavy concentration in North America. In 2019 , we will operationalize the new R&D facilities in St. Louis,
 Missouri and Andover, Massachusetts.Our PGS division is headquar
tered in various locations, with leadership teams primarily in New York City, New York and in Peapack, New Jersey. As ofDecember 31, 
2018 , PGS had responsibility for  58 plants around the world, which manufacture products for our commercial divisions. Locations with majormanufacturing facilities include B
elgium, China, Germany, India, Ireland, Italy, Japan, Puerto Rico, Singapore and the U.S. Our PGS division’s plant networkstrategy is expected to result 
in the exit of four of these sites over the next several years. PGS also operates multiple distribution facilities around the world.In general, we believe that our propert
ies are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeablefuture. See the Notes to Consolidated F
inancial Statements— Note 9 . Property, Plant and Equipment in our 2018 Financial Report, which provides amountsinvested in land, build
ings and equipment and which is incorporated by reference. See also the discussion in the Notes to Consolidated Financial Statements—Note 15 
. Lease Commitments in our 2018 Financial Report, which is also incorp orated by reference.ITEM 3.
LEGAL PROCEEDINGS Certain legal proceedings in which
 we are involved are discussed in the Notes to Consolidated Financial Statements— Note 17 A . Contingencies and CertainCommitments 
— Legal Proceedings in our 2018 Financial Report, which is incorpora ted by reference.ITEM 4.
MINE SAFETY DISCLOSURES Not applicable.
Pfizer Inc.
2018 Form 10-K 25 
TABLE OF CONTENTSEXECUTIVE OFFICERS OF THE COMPANY
The executive officers of the Compan
y are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at theregular meeting of the Board of Di
rectors to be held on the date of the 2019 Annual Meeting of Shareholders, or unt il his or her earlier death, resignation orremoval. Each of the executive off
icers is a member of the Pfizer Executive Leadership Team.Name
  Age   Position  
      Albert Bourla
 
57 
Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018;Group President, Pfizer Innovat
ive Health from June 2016 until December 2017; Group President, GlobalInnovative Pharma Business
 (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) fromFebruary 2016 until June 2016. President and Gene
ral Manager of Established Products Business Unit fromDecember 2010 until Decemb
er 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Healthfrom 2009 until November 2010. Area 
President Europe, Africa and Middle East of Pfizer Animal Health from2005 until 2009. Our Director s
ince February 2018. Board member of Pharmaceutical Research andManufacturers of America (Ph
RMA). Board member of the Pfizer Foundation, which promotes access to qualityhealthcare. Member of the Board of Di
rectors of the Partnership for New York City and Catalyst, a global non-profit organization accele
rating progress for the advancement of women into leadership. 
      Frank A. D’Amelio
 
61 
Chief Financial Officer, Executive Vice President, Business Operations and Global Supply since November2018. Executive Vice Preside
nt, Business Operations and Chief Financial Officer from December 2010 untilOctober 2018. Senior Vice Pres
ident and Chief Financial Officer from September 2007 until December 2010.Prior to joining Pfizer, he was S
enior Executive Vice President of Integration and Chief Administrative Officer ofAlcatel-Lucent from Nove
mber 2006 until August 2007. Prior to the Alcatel-Lucent merger, he was ChiefOperating Officer of Lucent and before that Chief F
inancial Officer of Lucent. Director of Zoetis Inc. and ofHumana Inc. and Chair of the Humana Aud
it Committee. Director of the Independent College Fund of NewJersey.
 
      Mikael Dolsten
 
60 
Chief Scientific Officer, President, Worldwide Research, Development and Medical since January 2019.President of Worldwide Research 
and Development from December 2010 until December 2018. Senior VicePresident; President of
 Worldwide Research and Development from May 2010 until December 2010. SeniorVice President; Pres
ident of Pfizer BioTherapeutics Research & Development Group from October 2009 untilMay 2010. He was Senior V
ice President of Wyeth and President, Wyeth Research from June 2008 untilOctober 2009. He was a Private Equ
ity Partner at Orbimed Advisors, LLC from January 2008 until June 2008.Director of Karyopharm Therapeut
ics Inc. Chairman of the Translational Advisory Board of Apple Tree Partnersfrom 2016 to 2017.
 
      Lidia Fonseca
 
50 
Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officerand Senior Vice President of Que
st Diagnostics Incorporated from 2014 to 2018. Senior Vice President ofLaboratory Corporation of Amer
ica Holdings from 2008 until March 2013. Director of Tegna, Inc. 
      Michael Goettler
 
51 
Group President, Pfizer Upjohn since January 2019. Executive Vice President from July 2018 until December2018. Global President of Pfize
r Inflammation & Immunology from January 2018 until June 2018. GlobalPresident of Pfizer Rare Disease
 from January 2016 until December 2017. Global Commercial Officer, SeniorVice President for Pfizer’s Global 
Innovative Pharma Business from January 2014 until December 2015.Regional President, Europe fo
r Pfizer Specialty Care and the chair of the European Management Team fromJune 2012 until December 2013. Reg
ional President Asia - Pacific for Specialty Care from October 2009 untilJune 2012. Member of the board of directors of PSI 
(Population Services International). 
      Angela Hwang
 
53 
Group President, Pfizer Biopharmaceuticals Group since January 2019. Group President, Pfizer EssentialHealth from January 2018 until 
December 2018. Global President, Pfizer Inflammation and Immunology fromJanuary 2016 until December 2017. 
Regional Head, U.S. Vaccines from January 2014 until December 2015.Vice President, Emerging Marke
ts for the Primary Care business from September 2011 until December 2013.Vice President, U.S. Brands 
business within Essential Health from October 2009 until August 2011. 
      Rady A. Johnson
 
57 
Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive VicePresident, Chief Compliance an
d Risk Officer from December 2013 until December 2018. Senior VicePresident and Associate Genera
l Counsel from October 2006 until December 2013. 
      Douglas M. Lankler
 
53 
General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014until February 2014.
 Executive Vice President, Chief Compliance and Risk Officer from February 2011 untilDecember 2013. Executive
 Vice President, Chief Compliance Officer from December 2010 until February 2011.Senior Vice President and Chie
f Compliance Officer from January 2010 until December 2010. Senior VicePresident, Deputy General Coun
sel and Chief Compliance Officer from August 2009 until January 2010. SeniorVice President, Associate Ge
neral Counsel and Chief Compliance Officer from October 2006 until August2009.
 
      
Freda C. Lewis-Hall 
64 
Chief Patient Officer, Executive Vice President since January 2019. Executive Vice President, Chief MedicalOfficer from December 20
10 until December 2018. Senior Vice President, Chief Medical Officer from May 2009until December 2010. Previo
usly, she was Chief Medical Officer and Executive Vice President, MedicinesDevelopment at Vertex P
harmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was Senior VicePresident, U.S. Pharmaceu
ticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008.Director of Tenet Healthcare 
Corporation from December 2014 to May 2017. 
      A. Rod MacKenzie
 
59 
Chief Development Officer, Executive Vice President since June 2016. Senior Vice President, ChiefDevelopment Officer from Ma
rch 2016 until June 2016. Group Senior Vice President and Head, PharmaTherapeutics Research and Deve
lopment from 2010 until March 2016. Senior Vice President, Head ofWorldwide Research from 2007 
until 2010. Dr. MacKenzie represents Pfizer as a member of the Board ofDirectors of ViiV Healthcare Limited.
 
      Dawn Rogers
 
54 
Chief Human Resources Officer, Executive Vice President since January 2019. Executive Vice President,Worldwide Human Resources from Jun
e 2018 until December 2018. Senior Vice President, Human Resourcesfor the Chief Operating Officer fro
m November 2017 until May 2018. Senior Vice President of HumanResources for Pfizer Essential Healt
h, Global Product Development, and the Legal and Compliance Divisionsfrom 2016 until November 2017. Sen
ior Vice President of Human Resources for the Global Innovative PharmaBusiness from 2013 un
til 2016. Senior Vice President of Human Resources for the Primary Care Business Unitfrom 2011 until 201
3. Senior Vice President of Human Resources for Worldwide Research and Developmentfrom 2008 until 201
1. Vice President of Human Resources for Pfizer's European Commercial Operations from2006 to 2008.
 
      Sally Susman
 
57 
Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President,Corporate Affairs (formerly Policy, Ex
ternal Affairs and Communications) from December 2010 until December2018. Senior Vice Presiden
t, Policy, External Affairs and Communications from December 2009 until December2010. Senior Vice President and 
Chief Communications Officer from February 2008 until December 2009. Priorto joining Pfizer, Ms. Susman
 held senior level positions at The Est é e Lauder Companies, including ExecutiveVice President from 2004
 to January 2008. Director of WPP plc. 
      John D. Young
 
54 
Chief Business Officer, Group President since January 2019. Group President, Pfizer Innovative Health fromJanuary 2018 until December 2018. Group 
President, Pfizer Essential Health from June 2016 until December2017; Group President, Global Estab
lished Pharma Business from January 2014 until June 2016. Presidentand General Manag
er, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Unit’sRegional President for Eu
rope and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until2009. Director of Johnson Contro
ls International plc.Pfizer Inc.
2018 Form 10-K 26 
TABLE OF CONTENTSPART II
ITEM 5.
MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The principal market for our 
common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol “PFE”. As of February 26, 2019 , there were 
150,398 holders of record of our common stoc k. Additional information required by this item is incorporated by reference from the Selected Quarterly Financial Data 
(Unaudited) and Peer Group Performance Graph sections in our 2018 Financial Report. The following table prov
ides certain information with respect to our purchases of shares of the Company’s common stock during the fourth fiscal quarter of 2018 :
Issuer Purchases of Equity Securities 
(a)  Period
Total Numberof Shares
Purchased 
(b)       Average PricePaid per
    Share 
(b)       Total Number ofShares Purchased as
Part of Publicly
    Announced Plan 
(a) Approximate DollarValue of Shares
that May Yet Be
Purchased
    Under the Plan 
(a)      October 1, 2018 through October 28, 2018
38,477,427   $44.25  38,410,129   $7,487,879,989 October 29, 2018 through November 30, 2018
43,812,603   $43.50  43,795,856   $5,582,880,460 December 1, 2018 through December 31, 2018
32,598,112   $43.77  32,559,080   $14,157,881,147 Total
114,888,142  $43.83  114,765,065    (a) 
 For additional information, see the Notes to Consolidated Financial Statements –– Note 12 . Equity in our 2018 Financial Report, which is incorporated by reference. (b) 
 In addition to the amounts purchased under our share repurchase program, these columns represent (i) 118,667 shares, primarily representing common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by
the trustee of 
4,410 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance share awards and who deferred receipt of such awards.
On 
February 7, 2019 , we entered into an accelerated share repu rchase agreement with Goldman, Sachs & Co. LLC. This agreement was entered into pursuantto our previously announced share repu
rchase authorization. For additional information, see the Notes to Consolidated Fin ancial Statements — Note 19.Subsequent Event 
in our 2018 Financial Report, which is incorpora ted by reference . ITEM 6.
SELECTED FINANCIAL DATA Information required by this 
item is incorporated by reference from the discussion under the heading Financial Summary in our 2018 Financial Report. ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Information required by this 
item is incorporated by reference from the discussion under the heading Financial Review in our 2018 Financial Report. ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Information required by this 
item is incorporated by reference from the discussion under the Forward-Looking Information and Facto rs That May Affect FutureResults 
— Financial Risk Management section in our 2018 Financial Report. ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Information required by this 
item is incorporated by reference from the Report of Independent Registered Publ ic Accounting Firm on the Consolidated FinancialStatements 
in our 2018 Financial Report and from the con solidated financial statements, related notes and supplementary data in our 2018 Financial Report. Pfizer Inc.
2018 Form 10-K 27 
TABLE OF CONTENTSITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None.
ITEM 9A.
CONTROLS AND PROCEDURES Disclosure Controls
As of the end of the period covered by this 
2018 Form 10-K, we carried out an eva luation, under the supervision and with the participation of our principalexecutive officer and princ
ipal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term isdefined in Rules 13a-15(e) and 15d-15
(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officerconcluded that our disclosure 
controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in ourperiodic reports filed with th
e SEC.Internal Control over F
inancial ReportingManagement’s report on the Company’
s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the ExchangeAct), and the related report of our independent reg
istered public accounting firm, are included in our 2018 Financial Report under t he headings Management’s Report on Internal Co
ntrol Over Financial Reporting and Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting , respectively, and are inco
rporated by reference.Changes in Internal Controls
During our most recent fis
cal quarter, there has not been any change in the Company’s internal control over financial reporting (as such term is defined in Rules13a-15(f) and 15d-15(f) under the Exchange Act) that ha
s materially affected, or is reasonably likely to materially affect, the Company’s internal control overfinancial reporting.
ITEM 9B.
OTHER INFORMATION Not applicable.
Pfizer Inc.
2018 Form 10-K 28 
TABLE OF CONTENTSPART III
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Information about our Directors 
is incorporated by reference from the discussion under the heading Item 1 — Election of Directors in our 2019 Proxy Statement. Information about compliance w
ith Section 16(a) of the Exchange Act is incorporated by reference from the discussion under the heading Securities Ownership — 
Section 16(a) Beneficial Ownership Reporting Compliance in our 2019 Proxy Statement. Information about the Pfi zer Policies on Business Conduct governingour employees, including o
ur Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business Conduct and Ethics forMembers of the Board of Director
s, is incorporated by reference from the discussions under the headings Governance — Pfizer Policies on Business Conductand — 
Code of Conduct for  Directors in our 2019 Proxy Statement. Information regard ing the procedures by which our shareholders may recommend nomineesto our Board of Directors i
s incorporated by reference from the discussion under the headings Item 1 — Election of Directors — Criteria for Board Membershipand 
Submitting Proxy Proposals and Director Nominations for the 2020 Annual Meeting in our 2019 Proxy Statement. Information about our Aud it Committee,including the members of the Co
mmittee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the headingGovernance 
— Board Information—Board and Committee Information — Board Committees—The Audit Committee in our 2019 Proxy Statement. The balance of the information required by thi
s item is contained in the discussion entitled Executive Officers of th e Company in Part I of this 2018 Form 10-K. ITEM 11.
EXECUTIVE COMPENSATION Information about Director and execut
ive compensation is incorporated by reference from the discussion under the headings Non-Employee Director Compensation 
; Executive Compensation ; and Governance—Board Information—Board and Committee Information—Board Committees — The CompensationCommittee 
— Compensation Committee Interlocks and Insider Participation in our 2019 Proxy Statement. ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Information required by this 
item is incorporated by reference from the discussion under the headings Executive Compensation — Compensation Tables—Equity Compensation Plan I
nformation and Securities Ownership in our 2019 Proxy Statement. ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Information about certain relation
ships and transactions with related parties is incorporated by reference from the discussion under the headings Related Person Transactions and In
demnification — Transactions with Related Persons in our 2019 Proxy Statement. Information about dire ctor independence is incorporatedby reference from the discuss
ion under the heading Governance — Other Governance Practices and Policies — Director Independence in our 2019 Proxy Statement.
ITEM 14.
PRINCIPAL ACCOUNTING FEES AND SERVICES Information about the fees for professional 
services rendered by our independent registered public accounting firm in 2018 and 2017 is incorporated by reference from the discussion unde
r the heading Item 2 — Ratification of Selection of Independent Registered Public Accounting Firm — Audit and Non-AuditFees 
in our 2019 Proxy Statement. Our Audit Com mittee’s policy on pre-approval of audit and permissible non-audit services of our independent registeredpublic accounting firm 
is incorporated by reference from the discussion under the heading Item 2 — Ratification of Selection of Independent Registered PublicAccounting Firm 
— Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm in our 
2019 Proxy Statement. Pfizer Inc.
2018 Form 10-K 29 
TABLE OF CONTENTSPART IV
ITEM 15.
EXHIBITS, FINANCIAL STATEMENT SCHEDULES 15(a)(1) Financial Statements. 
The following consol idated financial statements, related notes, report of independent registered public accounting firm andsupplementary data from our 
2018 Financial Report are in corporated by reference into Item 8 of Part II of this 2018 Form 10-K: •
Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements•
Consolidated Statements of Income•
Consolidated Statements of Comprehensive Income•
Consolidated Balance Sheets•
Consolidated Statements of Equity•
Consolidated Statements of Cash Flows•
Notes to Consolidated Financial Statements•
Selected Quarterly Financial Data (Unaudited)15(a)(2) Financial Statement Schedules. 
Schedules are omitted because they are not required or because the information is provided elsewhere in thefinancial statements. The financ
ial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute asignificant subsidiary.
15(a)(3) Exhibits. 
These exhibits are availab le upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, NewYork, New York 10017. T
he exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this 2018 Form 10-K. All other exhibit  numbers indicateexhibits filed by in
corporation by reference. Exhibit numbers 10.1 through 10.33 are management contracts or compensatory plans or arrangements. 
   2.1 
Agreement and Plan of Merger, dated as of August 20, 2016, among Pfizer Inc., Montreal, Inc. and Medivation, Inc. is incorporated byreference from our Current Report on Fo
rm 8-K filed on August 22, 2016 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supple
mentally furnish to the Securities and Exchange Commission upon request any omitted schedule orexhibit to the Merger Agreement.)
 
   *2.2 
Stock and Asset Purchase Agreement, dated December 19, 2018, by and among Pfizer Inc., GlaxoSmithKline plc and GlaxoSmithKlineConsumer Healthcare Ho
ldings Limited. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementallyfurnish to the Securities and E
xchange Commission upon request any omitted schedule or exhibit to the Stock and Asset PurchaseAgreement.) 
1 
   3.1 
Our Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our Quarterly Report on Form 10-Q for theperiod ended March 28, 2004 (File No. 001
-03619). 
   3.2 
Amendment dated May 1, 2006 to Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our QuarterlyReport on Form 10-Q for the period ended Jul
y 2, 2006 (File No. 001-03619). 
   3.3 
Our By-laws, as amended December 18, 2017, are incorporated by reference from our Current Report on Form 8-K filed on December 21,2017 (File No. 001-03619).
 
   4.1 
Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Reporton Form 8-K filed on January 30, 2001 (F
ile No. 001-03619). 
   4.2 
First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan ChaseBank, N.A. (formerly J
PMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,is incorporated by reference fro
m our Quarterly Report on Form 10-Q for the period ended June 28, 2009 (File No. 001-03619). 
   4.3 
Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan ChaseBank, N.A. (formerly J
PMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,is incorporated by reference fro
m our Current Report on Form 8-K filed on June 3, 2009 (File No. 001-03619). 
   4.4 
Third Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan ChaseBank, N.A. (formerly J
PMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,is incorporated by reference fro
m our Current Report on Form 8-K filed on June 3, 2013 (File No. 001-03619). 
   1 Application has been made to the Securities and Exchange Commission for confidential treatment of certain portions of this exhibit. Omitted material for which confidentialtreatment has been requested has been separately filed with the Securities and Exchange Commission.
Pfizer Inc.
2018 Form 10-K 30 
TABLE OF CONTENTS4.5
 
Fourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan ChaseBank, N.A. (formerly J
PMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,is incorporated by reference fro
m our Current Report on Form 8-K report filed on May 15, 2014 (File No. 001-03619). 
   4.6 
Fifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan ChaseBank, N.A. (formerly J
PMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,is incorporated by reference fro
m our Current Report on Form 8-K report filed on October 6, 2015 (File No. 001-03619). 
   4.7 
Sixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York(successor to JPMorgan Chas
e Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),as trustee, to Indenture dated as of January 30, 2001, is in
corporated by reference from our Current Report on Form 8-K report filed on June3, 2016 (File No. 001-03619).
 
   4.8 
Seventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank ofNew York (successor to JPMorgan
 Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (NationalAssociation)))), as t
rustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-Kreport filed on November 21, 2016 (F
ile No. 001-03619). 
   4.9 
Eighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York(successor to JPMorgan Cha
se Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the ChaseManhattan Bank (National Asso
ciation)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenturedated as of January 30, 2001, is incorporated by 
reference from our Current Report on Form 8-K report filed on March 17, 2017 (File No.001-03619).
 
   4.10 
Ninth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York(successor to JPMorgan Chas
e Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),as trustee, and The Bank of New York Me
llon, London Branch, as paying agent and calculation agent, to Indenture dated as of January 30,2001, is incorporated by reference fro
m our Current Report on Form 8-K report filed on March 6, 2017 (File No. 001-03619). 
   4.11 
Tenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York(successor to JPMorgan Chas
e Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),as trustee, and The Bank of New York Me
llon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporatedby reference from our Current Repo
rt on Form 8-K report filed on December 19, 2017 (File No. 001-03619). 
   4.12 
Indenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon(as successor to JPMorgan 
Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3(File No. 33-57339), filed on 
January 18, 1995. 
   4.13 
Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorganChase Bank, N.A.), as trustee, 
is incorporated by reference from Wyeth’s Registration Statement on Form S-3 (File No. 33-57339), filed onJanuary 18, 1995.
 
   4.14 
Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor toJPMorgan Chase Bank, N.A.), a
s trustee, is incorporated by reference from Wyeth’s 2003 Annual Report on Form 10-K (File No. 001-01225).
4.15
 
Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor toJPMorgan Chase Bank, N.A.), a
s trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on November 15,2005 (File No. 001-01225).
 
   4.16 
Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor toJPMorgan Chase Bank, N.A.), a
s trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on March 28, 2007(File No. 001-01225).
 
   4.17 
Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor toJPMorgan Chase Bank, former
ly The Chase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October13, 1992), is incorporated by reference f
rom our Current Report on Form 8-K filed on November 3, 2009 (File No. 001-03619). 
   4.18 
Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from ourCurrent Report on Form 8-K fi
led on September 7, 2018 (File No. 001-03619). 
   4.19 
First Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated byreference from our Current Report on Fo
rm 8-K filed on September 7, 2018 (File No. 001-03619). 
   4.20 
Except as set forth in Exhibits 4.1-19 above, the instruments defining the rights of holders of long-term debt securities of the Company andits subsidiaries have been 
omitted. 2 
   2 We agree to furnish to the Securities and Exchange Commission, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company andits subsidiaries.
Pfizer Inc.
2018 Form 10-K 31 
TABLE OF CONTENTS10.1
 
2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders (File No.001-03619).
 
   10.2 
Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 Annual Report on Form 10-K (File No.001-03619).
 
   10.3 
Pfizer Inc. 2014 Stock Plan is incorporated by reference from our Proxy Statement for the 2014 Annual Meeting of Shareholders (File No.001-03619).
 
   10.4 
Form of Acknowledgment and Consent and Summary of Key Terms for Stock Option Grants, RSUs and TSRUs is incorporated by referencefrom our 2017 Annual Report on Form 10-K 
(File No. 001-03619). 
   10.5  Form of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K (File No. 001-03619). 
   10.6 
Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2017Annual Report on Form 10-K (Fi
le No. 001-03619). 
   *10.7  Amendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees. 
   10.8 
Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2016(File No. 001-03619).
 
   10.9 
Amendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by referencefrom our Quarterly Report on Form 10
-Q for the period ended October 1, 2017 (File No. 001-03619). 
   10.10 
Amendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K (FileNo. 001-03619).
 
   10.11 
Amendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for theperiod ended September 30, 2018 (File No. 001
-03619). 
   *10.12  Amendment No. 4 to the Pfizer Supplemental Savings Plan. 
   *10.13  Amendment No. 5 to the Pfizer Supplemental Savings Plan. 
   10.14 
Pfizer Inc. Global Performance Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1,2017 (File No. 001-03619).
 
   10.15  Executive Annual Incentive Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No. 001-03619). 
   10.16 
Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No.001-03619).
 
   10.17 
Amendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013Annual Report on Form 10-K (Fi
le No. 001-03619). 
10.18 
Amendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from ourQuarterly Report on Form 10-Q for the per
iod ended July 3, 2016 (File No. 001-03619). 
   10.19 
Wyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with all material Amendments, is incorporated byreference from our 2013 Annual Report on For
m 10-K (File No. 001-03619). 
   10.20 
Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012),together with all materia
l Amendments is incorporated by reference from our 2011 Annual Report on Form 10-K (File No. 001-03619). 
   10.21 
Amendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by referencefrom our 2013 Annual Report on Form 10-K 
(File No. 001-03619). 
   10.22 
The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Reporton Form 10-K (File No. 001-03619).
 
   10.23 
The form of Indemnification Agreement with each of the Named Executive Officers identified in our 2018 Proxy Statement is incorporated byreference from our 1997 Annual Report on For
m 10-K (File No. 001-03619). 
   10.24 
Letter to Frank A. D’Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our CurrentReport on Form 8-K filed on August 22, 2007 
(File No. 001-03619). 
   10.25 
Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009 (FileNo. 001-03619).
 
   *10.26  Amendment No. 1 to Pfizer Inc. Executive Severance Plan. 
   
Pfizer Inc.2018 Form 10-K 32 
TABLE OF CONTENTS10.27
 
Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference fromour 2008 Annual Report on Form 10-K (F
ile No. 001-03619). 
   10.28 
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from ourQuarterly Report on Form 10-Q for the per
iod ended September 28, 2014 (File No. 001-03619). 
   10.29 
Form of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009 (FileNo. 001-03619).
 
   10.30 
Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the periodended April 3, 2011
 (File No. 001-03619). 
   10.31 
Form of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (FileNo. 001-03619).
 
   10.32 
Form of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (FileNo. 001-03619).
 
   * 10.33  Time Sharing Agreement, dated December 17, 2018, by and between Pfizer Inc. and Ian C. Read. 
   * 13 
Portions of the 2018 Financial Report, which, except for those sections incorporated by reference, are furnished solely for the information ofthe SEC and are not to be deemed “filed.”
 
   * 21  Subsidiaries of the Company. 
   * 23  Consent of Independent Registered Public Accounting Firm. 
   * 24  Power of Attorney (included as part of signature page). 
   *31.1  Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 
   * 31.2  Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 
   * 32.1 
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-OxleyAct of 2002.
 
   * 32.2 
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-OxleyAct of 2002.
 
   *101.INS  XBRL Instance Document 
   *101.SCH  XBRL Taxonomy Extension Schema 
   *101.CAL  XBRL Taxonomy Extension Calculation Linkbase 
   *101.LAB  XBRL Taxonomy Extension Label Linkbase 
   *101.PRE  XBRL Taxonomy Extension Presentation Linkbase 
   *101.DEF  XBRL Taxonomy Extension Definition DocumentITEM 16.
FORM 10-K SUMMARY A Form 10-K summary is p
rovided at the beginning of this 2018 Form 10-K, with hyperlinked cr oss-references. This allows users to easily locate thecorresponding items in this 
2018 Form 10-K, where the disclo sure is fully presented. The summary does not include certain Part III information that isincorporated by reference from our 
2019 Proxy Statement. Pfizer Inc.
2018 Form 10-K 33 
TABLE OF CONTENTSSIGNATURES
Under the requirements of Section 13 or 15(d) of the Securities Exchang
e Act of 1934, this report was signed on behalf of the Registrant by theauthorized person named below.
 
Pfizer Inc.  
    Dated: February 28, 2019By:   /S/    MARGARET M. MADDEN 
    Margaret M. MaddenSenior Vice President and Corporate Secretary
Chief Governance Counsel
We, the undersigned directors and off
icers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, ourtrue and lawful attorneys w
ith full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to thisAnnual Report on Form
 10-K filed with the Securities and Exchange Commission.Under the requirements of the Secur
ities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacitiesand on the date indicated.
Signature
  Title  Date 
      /S/    ALBERT BOURLA
Albert Bourla
  Chief Executive Officer and Director(Principal Executive Officer)
  February 27, 2019  
      /S/    FRANK A. D’AMELIO
Frank A. D’Amelio
  Chief Financial Officer, Executive Vice President, Business Operations and GlobalSupply 
  (Principal Financial Officer)  February 26, 2019  
      /S/    LORETTA V. CANGIALOSI
Loretta V. Cangialosi
  Senior Vice President—Controller(Principal Accounting Officer)
  February 26, 2019  
      /S/    IAN C. READ
Ian C. Read
  Executive Chairman of the Board February 28, 2019 
      /S/    DENNIS A. AUSIELLO
Dennis A. Ausiello
  Director February 26, 2019  
      /S/    RONALD E. BLAYLOCK 
Ronald E. Blaylock
  Director February 27, 2019  
      /S/    W. DON CORNWELL 
W. Don Cornwell
DirectorFebruary 26, 2019  
      /S/    JOSEPH J. ECHEVARRIA
Joseph J. Echevarria
  Director February 26, 2019  
      /S/    HELEN H. HOBBS
Helen H. Hobbs
  Director February 28, 2019  
      
TABLE OF CONTENTSSignature
  Title  Date 
      /S/    JAMES M. KILTS
James M. Kilts
  Director February 26, 2019  
      /S/    DAN R. LITTMAN
Dan R. Littman
  Director February 26, 2019  
      /S/    SHANTANU NARAYEN
Shantanu Narayen
  Director February 26, 2019  
      /S/    SUZANNE NORA JOHNSON
Suzanne Nora Johnson
  Director February 26, 2019  
      /S/    JAMES C. SMITH
James C. Smith
  Director February 26, 2019  
      
EXHIBIT 2.2 
 
STOCK AND ASSET PURCHASE AGREEMENT
by and among
PFIZER INC.,
GLAXOSMITHKLINE PLC
and
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED
DATED AS OF DECEMBER 19, 2018
Confidential Treatment Requested by Pfizer Inc.

TABLE OF CONTENTS 
Page  
ARTICLE I 
   
DEFINITIONS AND TERMS
 
Section 1.1
Definitions       2Section 1.2
Interpretation     39 
ARTICLE II
 
PURCHASE AND SALE
 
Section 2.1
Purchase and Sale of Purchased Assets     40Section 2.2
Consents; Shared Contracts     43Section 2.3
Excluded Assets     47Section 2.4
Assumption of Assumed Liabilities     50Section 2.5
Retained Liabilities     51Section 2.6
Purchase Consideration     51Section 2.7
Delivery of the Purchase Consideration     52Section 2.8
Estimated Closing Statement; Estimated Adjustment Payments     52Section 2.9
Post-Closing Working Capital and Net Cash Adjustments     53Section 2.10
Withholding     57 
ARTICLE III
 
CLOSING
 
Section 3.1
Closing     57Section 3.2
Restated Purchaser Articles of Association     58 
    ARTICLE IV
 
    REPRESENTATIONS AND WARRANTIES OF SE
LLER PARENT 
Section 4.1
Organization     58Section 4.2
Authority; Binding Effect     58Section 4.3
Conveyed Subsidiaries; Capital Structure     59Section 4.4
No Conflicts; Consents     60Section 4.5
Governmental Authorization     61
Section 4.6Financial Information     61Section 4.7
Absence of Material Changes     62Section 4.8
No Litigation     62Section 4.9
Compliance with Laws     63Section 4.10
Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and Recalls
    63Section 4.11
Environmental Matters     64Section 4.12
Material Contracts     65Section 4.13
Intellectual Property     66Section 4.14
Real Property     67Section 4.15
Assets     68Section 4.16
Taxes     69Section 4.17
Employee Benefits; Employees     71Section 4.18
Global Trade Controls; Anti-Corruption Matters     73Section 4.19
Brokers     74Section 4.20
No Other Representations or Warranties     74i

ARTICLE V 
REPRESENTATIONS AND WARRANTIES OF PUR
CHASER PARENT 
Section 5.1
Organization     76Section 5.2
Authority; Binding Effect     76Section 5.3
Purchaser; Purchaser Subsidiaries; Capital Structure     78Section 5.4
No Conflicts; Consents     79Section 5.5
Governmental Authorization     80Section 5.6
Financial Information     80Section 5.7
Absence of Material Changes     81Section 5.8
Securities Act     81Section 5.9
No Litigation     81Section 5.10
Compliance with Laws     81Section 5.11
Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and Recalls
    82Section 5.12
Environmental Matters     83Section 5.13
Material Contracts     84Section 5.14
Intellectual Property     85Section 5.15
Real Property     86Section 5.16
Assets     87Section 5.17
Taxes     88Section 5.18
Employee Benefits; Employees     90Section 5.19
Global Trade Controls; Anti-Corruption Matters     92Section 5.20
Brokers     93Section 5.21
No Other Representations or Warranties     93 
ARTICLE VI
 
COVENANTS
 
    Section 6.1
Information and Documents     96Section 6.2
Conduct of Business     98Section 6.3
Regulatory Approvals 105 Section 6.4
Reasonable Best Efforts; Further Assurances 115 Section 6.5
Tax Matters 117 Section 6.6
Employees and Employee Benefits 136 Section 6.7
Intercompany Accounts and Arrangements 153 Section 6.8
Access to Records and Information 155 Section 6.9
Mail and Other Communications 156 Section 6.10
Transfer of Business IP and Registrations 157 Section 6.11
No Solicitation 157 Section 6.12
Confidentiality 157 Section 6.13
Guarantees; Letters of Credit 159 Section 6.14
Certain Ancillary Agreements 161 
Section 6.15Retained and Transferred Names 162 Section 6.16
Compliance with WARN 163 Section 6.17
Litigation Support; Non-Indemnified Claims 164 Section 6.18
Insurance 165 Section 6.19
Trade Notification 167 Section 6.20
Accounts; Products Received 167 Section 6.21
Directors’ and Officers’ Indemnification 167 Section 6.22
Return of Assets; Transfer of Purchased Assets 168 Section 6.23
Bulk Transfer Laws 169 ii

Section 6.24Purchaser Parent Shareholder Meeting; Purchaser Parent Board Recommendation 170 Section 6.25
Resignations 173 Section 6.26
Remedial Action Access 173 Section 6.27
Acknowledgements 173  
          ARTICLE VII
 
INDEMNIFICATION
 
Section 7.1
Indemnification by Seller Parent and Purchaser Parent 174 Section 7.2
Indemnification by Purchaser 175 Section 7.3
Indemnification Procedures 175 Section 7.4
Expiration 177 Section 7.5
Certain Limitations 178 Section 7.6
Losses Net of Insurance, Etc. 178 Section 7.7
No Right of Set-Off 178 Section 7.8
Materiality 178 Section 7.9
Mitigation; Other Limitations 179 Section 7.10
Sole Remedy/Waiver 180 Section 7.11
Indemnification Payments 181  
ARTICLE VIII
 
CONDITIONS TO CLOSING
 
Section 8.1
Conditions to the Obligations of the Parties 181 Section 8.2
Conditions to the Obligations of Purchaser and Purchaser Parent 181 Section 8.3
Conditions to the Obligations of Seller Parent 182 Section 8.4
Frustration of Closing Conditions 182  
ARTICLE IX
 
TERMINATION
 
Section 9.1
Termination 183 Section 9.2
Effect of Termination 184  
ARTICLE X
 
    MISCELLANEOUS
 
Section 10.1
Notices 186 Section 10.2
Amendment; Waiver 187 Section 10.3
Assignment 187 Section 10.4
Entire Agreement 188 Section 10.5
Parties in Interest 188 Section 10.6
Public Disclosure 188 Section 10.7
Expenses 188 Section 10.8
Disclosure Letters; Disclosures Modifying Other Sections of Agreement 188 
Section 10.9No Admission 189 Section 10.10
Governing Law; Jurisdiction 189 Section 10.11
Counterparts 190 Section 10.12
Headings 190 Section 10.13
Severability 190 Section 10.14
Rules of Construction 190 Section 10.15
Specific Performance 190 iii

Section 10.16Affiliate Status 191 Section 10.17
Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege 191 Section 10.18
Translation of Currencies 193 ANNEXES
 
  ANNEX A
Index of Defined Terms ANNEX B-1
Accounting Principles ANNEX B-2
Sample Closing Statement ANNEX B-3
Purchaser Accounting Principles ANNEX B-4
Sample Purchaser Closing Statement ANNEX C
List of Antitrust Approvals ANNEX D
PCH Split Products ANNEX E-1
Business Key Products ANNEX E-2
Purchaser Key Products ANNEX F
PCH Switch Products ANNEX G
Purchaser Parent Retained Assets  
EXHIBITS
 
  EXHIBIT A
List of instruments and documents to be delivered by Seller Parent EXHIBIT B
List of instruments and documents to be delivered by Purchaser and Purchaser Parent EXHIBIT C
Form of Purchaser Shareholders Agreement EXHIBIT D
Form of Structuring Considerations Agreement EXHIBIT E
Form of Restated Purchaser Articles of Association EXHIBIT F
Seller Parent Draft Ancillary Agreements EXHIBIT G
Purchaser Parent Draft Ancillary Agreements  
Seller Disclosure Letter
Purchaser Parent Disclosure Letter
iv

STOCK AND ASSET PURCHASE AGREEMENTThis
 STOCK AND ASSET PURCHASE AGREEMENT, dated as of December 19, 2018 (this “ Agreement  ”),  is byand
 among Pfizer Inc., a Delaware corporation (“ Seller  Parent ”),  GlaxoSmithKline Plc, a public limited company incorporatedunder
 the laws of England (“ Purchaser  Parent  ”, and together with Seller Parent, the “ Parents  ”), and GlaxoSmithKline ConsumerHealthcare Holdings Limited,
 a company incorporated under the laws of England (“ Purchaser  ,” and  together with the Parents, the “Parties 
”).W I T N E S S E T H 
: WHEREAS,
 in addition to its other businesses, Seller Parent is engaged through certain of its Subsidiaries in theBusiness (as defined below);
WHEREAS,
 in addition to its other businesses, Purchaser Parent is engaged through Purchaser in the PurchaserBusiness (as defined below);
WHEREAS,
 the Parties desire that (a) the Sellers (as defined below) sell and transfer to Purchaser or the PurchaserDesignated Affiliates (as
 defined below), and that Purchaser or such Purchaser Designated Affiliates purchase from the Sellers, all ofSeller
 Parent’s and the other Sellers’ right, title and interest in the Purchased Assets; (b) Purchaser and such Purchaser DesignatedAffiliates
 assume the Assumed Liabilities (as defined below); and (c) Purchaser allot and issue to Seller Parent or its applicabledesignee B
 Ordinary Shares in the capital of Purchaser, in the case of each of clauses (a)  ,   (b) , and (c) , in the manner and upon theterms and conditions set forth herein;
WHEREAS,
 certain Sellers, Purchaser, Purchaser Parent and the Purchaser Designated Affiliates, at or prior to theClosing, will execute each of the Ancillary Agreements; and
WHEREAS,
 the respective Boards of Directors of Seller Parent, Purchaser Parent and Purchaser have approved thisAgreement,
 the Structuring Considerations Agreement, the Purchaser Shareholders Agreement and the transactions contemplatedhereby and thereby.
NOW,
 THEREFORE, in consideration of the foregoing, the representations, warranties, covenants and agreementscontained
 herein, and other good and valuable consideration, the adequacy and receipt of which are hereby acknowledged, theParties hereby agree as follows:

ARTICLE IDEFINITIONS AND TERMS
Section
 1.1       Definitions .  As used in this Agreement, the following terms have the meanings set forth or asreferenced below:
“ 
A Ordinary Shares ” has the meaning set forth in  Section 2.7  . “ 
ABO ” has the meaning set forth in Section 6.6(e)(i)  . “ 
Accounting Principles ” has the meaning set forth in  Section 2.8  . “ 
Action ”  means  any  action,  cause  of  action,  claim,  charge,  suit,  countersuit,  hearing,  complaint,  arbitration,subpoena, audit, investigation, litigation or proceeding by or before any court, Governmental Authority or arbitration tribunal.
“ 
ADR ” means American Depositary Receipts of Purchaser Parent issued under the Deposit Agreement.“ 
Affiliate ” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, orunder
 common control with, such Person at any time during the period for which the determination of affiliation is being made. Forpurposes
 of this Agreement, (a) the Conveyed Subsidiaries (and their Subsidiaries) shall be deemed to be (i) Affiliates of SellerParent
 (and not Purchaser Parent or Purchaser) prior to the Closing, and (ii) Affiliates of Purchaser Parent and Purchaser (and notSeller
 Parent or any other Seller) as of and following the Closing and (b) Purchaser and its Subsidiaries shall be deemed to beAffiliates of Purchaser Parent (and not Seller Parent) prior to, as of and following the Closing.
“ 
Agreement ”  has the meaning set forth in the preamble of this Agreement, as the same may be amended orsupplemented from time to time in accordance with the terms hereof.
“ 
Amended Consignment Selling Agreement ”  means the amended consignment selling agreement, substantially inthe
 form provided to Seller Parent prior to the date hereof, to be entered into between Hindustan Unilever Limited and Leo AsiaPrivate
 Limited on or around the time of completion of the divestiture of Horlicks and other consumer healthcare nutrition brands toUnilever plc and the merger of Leo Consumer Healthcare Limited India with Hindustan Unilever Limited.
“ 
Ancillary Agreements ”  means, collectively, the Transition Services Agreement, Intellectual Property LicenseAgreement,
 Manufacturing and Supply Agreement (Seller Parent as Supplier), Manufacturing and Supply Agreement (Purchaser asSupplier),
 IP  Assignment  Agreements,  Transitional  Trademark  License  Agreement,  Safety  Data  Exchange  Agreement,  LeaseAgreement, Local Implementing Agreements, the Structuring Considerations Agreement and the Purchaser Shareholders Agreement.
2

“ Ancillary  Implementing  Agreements ”  means,  collectively,  the  IP  Assignment  Agreements  and  the  LocalImplementing Agreements.
“ 
Anti-Corruption Laws ”  means the U.S. Foreign Corrupt Practices Act of 1977, as amended; the U.K. Bribery Actof
 2010; and any applicable Law related to anti-bribery or anti-corruption in any other jurisdiction in which the Business or thePurchaser
 Business, as applicable, markets, commercializes, distributes and sells products as of the date of this Agreement or as ofthe Closing.
“ 
Antitrust Laws ”  means statutes, rules, regulations, orders, decrees, administrative and judicial doctrines, and otherLaws
 of any jurisdiction that are designed or intended to prohibit, restrict or regulate actions that may have the purpose or effect ofcreating a monopoly, lessening competition or restraining trade.
“ 
Approvals ”  means any consent, approval or authorization of, permit or license issued or granted by, GovernmentalOrder,
 waiver or exemption by, negative clearance from, or the expiration or early termination of any waiting period imposed by,any Person (including any third party or Governmental Authority (including any Governmental Antitrust Authority)).
“ 
Assumed Contracts ” has the meaning set forth in  Section 2.1(e)  . “ 
Assumed Liabilities ” has the meaning set forth in  Section 2.4  . “ 
B Ordinary Shares ” has the meaning set forth in  Section 2.7  . “ 
Balance Sheet Date ” has the meaning set forth in  Section 4.6(a)  . “ 
Business ”  means the worldwide business of researching, developing, manufacturing, marketing, commercializing,distributing and selling (a) the products sold under the brand names set forth on 
Annex E-1  or variations or derivatives of such names (including
 translations thereof) (the “ Business  Key Products ”,  and such brands, the “ Business  Key Brands ”),  as conducted bySeller
 Parent (directly and indirectly through its Subsidiaries) as of the date of this Agreement and as of immediately prior to theClosing
 and (b) any over-the-counter consumer healthcare or medicine products, wellness products and other personal care, oralcare, nutrition, skin health, cosmetic and related products (other than the PCH Split Products), as conducted by Seller Parent (directly
and
 indirectly through its Subsidiaries) through its Pfizer Consumer Healthcare business unit (directly or indirectly pursuant to acontractual
 arrangement with any other Pfizer business unit, to the extent of the Pfizer Consumer Healthcare business unit’s rightspursuant to such contractual arrangement) as of the date of this Agreement and as of immediately prior to the Closing.
“ 
Business Copyrights ” means  all Copyrights, Copyright registrations and applications for Copyright registration thatboth (a) are owned by Seller Parent or its Subsidiaries and (b) are Related to the Business.
“ 
Business Day ”  means any day other than a Saturday, a Sunday or a day on which banks in New York City orLondon are authorized or obligated by Law or executive order to close.
3

“ Business Employee ”  means each individual who, immediately prior to the Closing (a) is employed by Seller Parentor
 its Affiliates (other than the Conveyed Subsidiaries or their Subsidiaries) and devotes 70% or more of his or her services to theBusiness,
 or (b) is employed by any of the Conveyed Subsidiaries (or their Subsidiaries), including, to the extent required by Law,any
 individual described in clause  (a) or  (b)  who is not actively at work as a result of an approved leave of absence (includingdisability leave, military leave, or family medical leave).
“ 
Business Employee (non-U.S.) ” means a Business Employee based outside of the United States. “ 
Business Employee (U.S.) ” means a Business Employee based in the United States. “ 
Business IP ”  means (a) all Business Copyrights, Business Patent Rights ,  Business Trademark Rights, BusinessKnow-How
 and Business Software, (b) all other Intellectual Property that both (i) is owned, or purported to be owned, by SellerParent
 or its Subsidiaries and (ii) is Related  to the Business, and (c) all Intellectual Property listed in the IP Schedules; provided  that the Business IP does not include any Registered IP that is not listed, or required to be listed, on the IP Schedules 
. “ 
Business IT Systems ”  means all Information Systems that both (a) are owned by Seller Parent or its Subsidiariesand (b)(i) are solely related to, solely held for use with, or solely used in connection with the Business; or (ii) located at a Facility.
“ 
Business Key Brands ” has the meaning set forth in the definition of “Business.” “ 
Business Key Products ” has the meaning set forth in the definition of “Business.” “ 
Business Know-How ”  means all Know-How that both (a) is owned by Seller Parent or its Subsidiaries and (b) isRelated to the Business.
“ 
Business Licensed IP ” has the meaning set forth in  Section 4.13(c)  . “ 
Business Net Cash ”  means the amount (which may be a positive or negative number) equal to (a) all CashEquivalents 
minus
 (b) all outstanding Funded Indebtedness, in each case, of the Conveyed Subsidiaries and their Subsidiaries, as of12:01
 a.m. (New York time) on the Closing Date; provided  that  any Cash Equivalents or Funded Indebtedness of the ConveyedSubsidiaries
 or their Subsidiaries as of 12:01 a.m. (New York time) on the Closing Date that will not be Purchased Assets orAssumed Liabilities (subject to the last sentence of 
Section 2.2(b)  ) shall be excluded from the calculation of Business Net Cash. “ 
Business Patent Rights ”  means all Patent Rights that (a) both (i) are owned by Seller Parent or its Subsidiaries and(ii) are solely related to, solely held for use with,
 or solely used in connection with the Business; or (b) are listed on the IP Schedules.“ 
Business Software ”  means all Software that both (a) is owned or purported to be owned by Seller Parent or itsSubsidiaries and (b) is Related to the Business.
4

“ Business Trademark Rights ”  means all of the following that are owned by or registered to Seller Parent or itsSubsidiaries
 (a)(i) all Trademarks (including Trademark registrations and applications for Trademark registrations) that are (A)solely
 related to, solely held for use with, or solely used in connection with the Business; or (B) listed in the IP Schedules; (b) allTrademarks
 that contain, comprise, or include (but only to the extent they include) a Trademark described in the foregoing clause(a); (c)
 all Trademarks that are confusingly similar to the Trademarks described in clauses (a) or (b) such that they could not be usedin commerce without infringing such Trademarks
; (d) all Internet Identifiers and telephone numbers or other alphanumeric addressesor mnemonics containing any of the foregoing; and (e) the goodwill of the Business symbolized by any of the foregoing.
“ 
Business Working Capital ” means the amount (which may be a positive or negative number) equal to (a) the sum of the
 assets of the Business as of 12:01 a.m. (New York time) on the Closing Date represented in the line items shown on the SampleClosing
 Statement for the Business as of such time, minus
 (b) the sum of the liabilities of the Business as of 12:01 a.m. (New Yorktime)
 on the Closing Date represented in the liability line items shown on the Sample Closing Statement for the Business as of suchtime, in each
 case calculated in a manner consistent with the Accounting Principles and the Sample Closing Statement; provided  that there
 shall be excluded from such calculation the Excluded Assets, the Retained Liabilities, all assets or Liabilities in respect ofIncome
 Taxes (whether current, deferred, or contingent), any amounts included in the calculation of Business Net Cash, anyintercompany
 accounts or Liabilities to be repaid or extinguished pursuant to this Agreement in connection with the Closing,including pursuant to 
Section 6.7  , and any intercompany receivables and intercompany payables, and other intercompany Liabilities, solely between or among any Conveyed Subsidiaries and any of their Subsidiaries.
“ 
Cash Equivalents ”  means, with respect to any Person and as of any time, all cash and cash equivalents, checks,money
 orders, marketable  securities,  short-term  instruments,  bank and other depositary  accounts,  certificates  of deposit, timedeposits,
 negotiable instruments, securities and brokerage accounts, funds in time and demand deposits or similar accounts of suchPerson as of such time, calculated, in the
 case of Seller Parent, in a manner consistent with the Accounting Principles and the SampleClosing
 Statement, and in the case of Purchaser, in a manner consistent with the Purchaser Accounting Principles and  the PurchaserSample
 Closing Statement, (a) excluding the value of outstanding checks and wire transfers that have been issued or transmitted bysuch
 Person but have not yet cleared as of such time, unless a corresponding liability is included in the calculation of BusinessWorking
 Capital or Purchaser Working Capital, as applicable, (b) including the value of uncollected bank deposits of such Personand
 outstanding checks and wire transfers that have been issued or transmitted to such Person but have not yet cleared as of suchtime
 ( provided that  such outstanding checks and wire transfers ultimately clear), unless in each case a corresponding asset isincluded
 in the calculation of Business Working Capital or Purchaser Working Capital, as applicable, and (c) including (i) withrespect
 to Purchaser, the value of any out-of-pocket costs or expenses incurred by either Purchaser or Purchaser Parent prior to theClosing
 pursuant to Section  2.2 ,  Section 6.3(d) or  Section 6.3(i) (in  each case, other than any Purchaser Parent TransactionExpenses) and
 (ii) with respect to the Conveyed Subsidiaries and their Subsidiaries, the value of any out-of-pocket costs or expensesincurred by either Seller Parent or
5

its Affiliates prior to the Closing pursuant to Section 2.2  ,  Section 6.3(d) or  Section 6.3(i) (in  each case, other than any Seller ParentTransaction Expenses).
“ 
China Entities ” has the meaning set forth in  Section 6.5(g)(iii)(A)  . “ 
Clean Team Agreement ”  means the Clean Team Confidentiality Agreement between Seller Parent and PurchaserParent, dated as of December 17, 2018, as amended or supplemented from time to time.
“ 
Closing ” means the closing of the transactions contemplated by this Agreement pursuant and subject to the terms ofthis Agreement.
“ 
Closing Date ” has the meaning set forth in  Section 3.1(a)  . “ 
Closing Statement Finalization Date ” has the meaning set forth in  Section 2.9(f)  . “ 
Code ” means the Internal Revenue Code of 1986, as amended.“ 
Collateral Source ” has the meaning set forth in  Section 7.6  . “ 
Collective Bargaining Agreement ”  means any collective bargaining agreement, labor agreement, work rules orpractices,
 or  any  other  labor-related  agreements or  arrangements with  any  labor  union,  labor  organization,  works council  orconsultation body.
“ 
Comparable Position ” has the meaning set forth in  Section 6.6(b)(i)  . “ 
Compliance Requirements ” has the meaning set forth in  Section 6.15(a)  . “ 
Confidential Information ” has the meaning set forth in  Section 6.12(b)  . “ 
Confidentiality Agreement ”  means the Confidentiality Agreement between Seller Parent and Purchaser Parent,dated as of October 11, 2018, as amended or supplemented from time to time.
“ 
Continuation Period ” has the meaning set forth in  Section 6.6(c)(i)  . “ 
Contract ”  means any contract, agreement, lease or license (other than any Governmental Authorization) that isbinding
 on any Person or any part of its property under applicable Law, including any amendment thereto, other than any SellerGroup Plan, Purchaser Group Plan, Foreign Seller Group Plan and Foreign Purchaser Group Plan.
“ 
Controlling Party ” has the meaning set forth in  Section 6.5(e)(iii)  . “ 
Conveyed Subsidiaries ”  means those entities set forth in Section  1.1(A) of  the Seller Disclosure Letter, as suchSection
 may be amended by Seller Parent prior to the Closing Date solely to reflect any changes pursuant to the Seller InternalRestructurings (including any steps Seller

6
Parent shall undertake to effect the Seller Internal Restructurings) made in accordance with Section 6.5(f)(i)  . “ 
Conveyed Subsidiary Excluded Asset ” has the meaning set forth in  Section 2.1  . “ 
Conveyed Subsidiary Plan ”  means each Seller Group Plan and each Foreign Seller Group Plan sponsored andmaintained by any Conveyed Subsidiary or Subsidiary thereof.
“ 
Copyrights ” has the meaning set forth in the definition of “Intellectual Property.” “ 
Counterparty ” has the meaning set forth in  Section 6.3(d)(ii)(A)  . “ 
D&O Indemnitees ” has the meaning set forth in  Section 6.21(a)  . “ 
DC Employees (non-U.S.) ” has the meaning set forth in  Section 6.6(g)(i)  . “ 
DC Employees (U.S.) ” has the meaning set forth in  Section 6.6(f)(i)  . “ 
DC Transfer Amounts ” has the meaning set forth in  Section 6.6(g)(ii)  . “ 
Deductible ” has the meaning set forth in  Section 7.5(a)  . “ 
De Minimis Claim Threshold ” has the meaning set forth in  Section 7.5(a)  . “ 
Delayed Antitrust Approval ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Delayed Business ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Delayed Business Cut-Off Date ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Delayed Business Notice ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Delayed Business Purchaser ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Delayed Employment Period ” has the meaning set forth in  Section 6.6(b)(iii)  . “ 
Delayed Transfer Employee ” has the meaning set forth in  Section 6.6(b)(iii)  . “ 
Deposit Agreement ”  means the deposit agreement dated December 27, 2000, as amended and restated as ofDecember 21, 2007, between Purchaser Parent,
 the Bank of New York Mellon (as depositary thereunder) and the owners and holdersof ADRs issued thereunder.
“ 
Direct Transfer ” has the meaning set forth in  Section 6.5(g)(iii)(A)  . 
“ Disability Employee ” has the meaning set forth in  Section 6.6(b)(iv)  . “ 
Disputed Item ” has the meaning set forth in  Section 2.9(b)  . 7

“ Environmental Law ”  means the Resource Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq., theComprehensive
 Environmental Response, Compensation, and Liability Act, 42 U.S.C. Section 9601 et seq., and any applicable Lawof
 any jurisdiction, as in effect on or prior to the Closing Date, relating to pollution or the protection of the environment, naturalresources, wildlife or
 threatened or endangered species (including indoor and outdoor air, soil, sediment, surface water, groundwater,drinking
 water, and surface or subsurface land), public or worker health or safety with respect to Hazardous Materials, or theexposure
 to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, Release, disposal,recycling, treatment or other management of Hazardous Materials.
“ 
Environmental Liability ” means any Liability arising under Environmental Laws. “ 
Environmental Permit ”  means any Governmental Authorization held by either a Conveyed Subsidiary (or aSubsidiary
 thereof) for its then-current operations or a Seller for the then-current operation of any Real Property, each following theconsummation of any Seller Internal Restructurings and as of the Closing Date, and required pursuant to an Environmental Law.
“ 
Equipment ” has the meaning set forth in  Section 2.1(d)  . “ 
Equipment Leases ” has the meaning set forth in  Section 2.1(d)  . “ 
ERISA ” means the Employee Retirement Income Security Act of 1974, as amended.“ 
ERISA Affiliate ”  means any Person that would be treated at a relevant time as a single employer with any otherPerson under Section 4001(b) of ERISA or Section 414 of the Code.
“ 
Estimated Business Deficit Adjustment ” has the meaning set forth in  Section 2.8(c)  . “ 
Estimated Business Excess Adjustment ” has the meaning set forth in  Section 2.8(b)  . “ 
Estimated Business Net Cash ”  means Seller Parent’s good-faith estimate of the Business Net Cash as set forth onthe Estimated Closing Statement.
“ 
Estimated Business Working Capital ”  means Seller Parent’s good-faith estimate of the Business Working Capitalas set forth on the Estimated Closing Statement.
“ 
Estimated Closing Statement ”  means a written statement setting forth the Estimated Business Working Capital andthe Estimated Business Net Cash, prepared in a manner consistent with the Accounting Principles and the Sample Closing Statement.
“ 
Estimated Purchaser Closing Statement ”  means a written statement setting forth the Estimated Purchaser WorkingCapital
 and the Estimated Purchaser Net Cash, prepared in a manner consistent with the Purchaser Accounting Principles and theSample Purchaser Closing Statement.
“ 
Estimated Purchaser Deficit Adjustment ” has the meaning set forth in  Section 2.8(e)  . 8

“ Estimated Purchaser Excess Adjustment ” has the meaning set forth in  Section 2.8(d)  . “ 
Estimated Purchaser Net Cash ” means Purchaser Parent’s good-faith estimate of the Purchaser Net Cash as set forth on the Estimated Purchaser Closing Statement.
“ 
Estimated Purchaser Working Capital ”  means Purchaser Parent’s good-faith estimate of the Purchaser WorkingCapital as set forth on the Estimated Purchaser Closing Statement.
“ 
Excluded Assets ” has the meaning set forth in  Section 2.3(a)  . “ 
Facilities ”  means the manufacturing and research and development facilities listed in Section  1.1(B) of  the SellerDisclosure Letter.
“ 
FCA ” means the United Kingdom Financial Conduct Authority.“ 
FICA ” has the meaning set forth in Section 6.6(p)  . “ 
Filings ” means any registrations, applications, declarations, reports, submissions or other filings with, or anynotices to, any Person (including any third party or Governmental Authority (including any Governmental Antitrust Authority)).
“ 
Final Business Deficit Adjustment ” has the meaning set forth in  Section 2.9(h)  . “ 
Final Business Excess Adjustment ” has the meaning set forth in  Section 2.9(g)  . “ 
Final Business Net Cash ” has the meaning set forth in  Section 2.9(e)  . “ 
Final Business Working Capital ” has the meaning set forth in  Section 2.9(e)  . “ 
Final Closing Statement ”  means (a) if no notice of Disputed Items with respect to the Proposed Closing Statementis delivered
 by either Parent within the period provided in Section 2.9(b)  , the Proposed Closing Statement as prepared by Purchaser, or (b) if such a notice of Disputed Items
 with respect to the Proposed Closing Statement is timely delivered by a Parent, the ProposedClosing
 Statement with modifications as agreed to in writing by the Parties and/or as directed by the Independent Accountantpursuant to 
Section 2.9(d)  , as applicable. “ 
Final Determination ”  means (a) with respect to U.S. federal Income Taxes, a “determination” as defined inSection 1313(a) of the Code, and (b) with respect to Taxes other than U.S. federal Income Taxe
s, any final determination of Liabilityin
 respect of a Tax that, under applicable Law, is not subject to further appeal, review or modification through proceedings orotherwise, including the
 expiration of a statute of limitations or a period for the filing of claims for refunds, amended Tax Returns orappeals from adverse determinations.
“ 
Final Pre-Closing Income Tax Amount ” has the meaning set forth in  Section 6.5(d)(vi)(A)  . 9

“ Final Purchaser Net Cash ” has the meaning set forth in  Section 2.9(e)  . “ 
Final Purchaser Parent Deficit Adjustment ” has the meaning set forth in  Section 2.9(j)  . “ 
Final Purchaser Parent Excess Adjustment ” has the meaning set forth in  Section 2.9(i)  . “ 
Final Purchaser Working Capital ” has the meaning set forth in  Section 2.9(e)  . “ 
Financial Statements ” has the meaning set forth in  Section 4.6(a)  . “ 
Foreign Purchaser Group Plan ”  means each pension, profit sharing, savings, retirement, health, life, disability,deferred
 compensation, incentive, bonus, employment, retention, change in control, termination, severance and fringe benefit plan,program,
 or arrangement maintained, or contributed to, by Purchaser Parent or any of its Affiliates in which any Purchaser BusinessEmployee
 (non-U.S.) or Former Purchaser Business Employee (non-U.S.) participates or is a party, other than plans, programs, orarrangement
s required to be maintained or contributed to by the Laws of the relevant jurisdiction and other than the Purchaser GroupPlans.
“ 
Foreign Seller Group Plan ”  means each pension, profit sharing, savings, retirement, health, life, disability, deferredcompensation,
 incentive, bonus, employment, retention, change in control, termination, severance and fringe benefit plan, program,or arrangement
 maintained, or contributed to, by Seller Parent or any of its Affiliates in which any Business Employee (non-U.S.) orFormer
 Business Employee (non-U.S.) participates or is a party, other than plans, programs, or arrangements required to bemaintained or contributed to by the Laws of the relevant jurisdiction and other than the Seller Group Plans.
“ 
Form Ancillary Agreement ” has the meaning set forth in  Section 6.14(a)  . “ 
Former Business Employee ”  means an employee of Seller Parent or its Affiliates who both (A) performed serviceson behalf of or to the Business as of immediately prior to his or her termina
tion of employment, and (B) would have been considereda
 Business Employee if his or her employment had not terminated prior to the Closing.  The term “Former Business Employee”when
 followed by “(U.S.)” means a Former Business Employee who was employed in the United States and when followed by“(non-U.S.)” means a Former Business Employee who was employed outside the United States.
“ 
Former  Purchaser  Business  Employee ”  means  an  employee  of  Purchaser  Parent  or  its  Affiliates  who  both(A)
 performed services on behalf of or to the Purchaser Business as of immediately prior to his or her termination of employment,and
 (B) would have been considered a Purchaser Business Employee if his or her employment had not terminated prior to theClosing.
  The term “Former Purchaser Business Employee” when followed by “(U.S.)” means a Former Purchaser BusinessEmployee
 who was employed in the United States and when followed by “(non-U.S.)” means a Former Purchaser BusinessEmployee who was employed outside the United States.
10

“ FSMA ” means the UK Financial Services and Markets Act 2000.“ 
Fundamental Purchaser Parent Representations ”  means the representations and warranties of Purchaser Parentcontained in 
Section 5.1  ,  Section 5.2 ,  Section 5.3(a) ,  Section 5.3(b) ,  Section 5.16 and  Section 5.20 . “ 
Fundamental Seller Parent Representations ”  means the representations and warranties of Seller Parent contained inSection 4.1 
,  Section 4.2 ,  Section 4.3(a) ,  Section 4.3(b) ,  Section 4.15 and  Section 4.19 . “ 
Funded Indebtedness ”  means, with respect to any Person and as of any time, without duplication, the followingobligations of such Person as of such time
 (including in respect of principal, accrued and unpaid interest, premiums (including make-whole
 premiums), prepayment penalties, breakage costs and other fees, expenses and charges that would arise as a result of thedischarge of such amount owed and directly attributable to the consummation of the Closing), calculated, in the case of Seller Parent,
in
 a manner consistent with the Accounting Principles and the Sample Closing Statement, and in the case of Purchaser, in a mannerconsistent
 with the Purchaser Accounting Principles and the Purchaser Sample Closing Statement: (a) the outstanding principalamount
 of any indebtedness for borrowed money; (b) all capitalized lease obligations that are classified by such Person as a balancesheet
 liability  in accordance  with  the  Accounting  Principles  or Purchaser  Accounting  Principles,  as applicable;  (c)  all  directreimbursement
 obligations in respect of letters of credit, solely to the extent such letters of credit have actually been drawn; (d) allobligations
 evidenced by bonds, notes, debentures or debt securities; (e) any net payment obligations under any interest rate orcurrency
 hedging Contract to the extent classified by such Person as a balance sheet liability in accordance with the AccountingPrinciples
 or Purchaser Accounting Principles, as applicable, calculated as of such time as the net amount of payment that would berequired
 to be paid by such Person to the counterparty bank(s) upon the unwind or early termination of such Contract at such time;(f)
 any amounts owing as deferred purchase price of, or a contingent payment for, any business, assets, property, goods or services(other
 than ordinary course trade payables and those listed on Section  1.1(C) of  the Seller Disclosure Letter); (g) all guarantees andkeepwell
 arrangements issued by such Person to a creditor against a loss with respect to the obligations described in clauses  (a)through 
(f) of another Person; and (h) in the case of the Conveyed Subsidiaries and their Subsidiaries, Seller Accrued Income Taxesand,
 in the case of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries and their Subsidiaries), Purchaser AccruedIncome Taxes; 
provided  that Funded Indebtedness shall not include (i) any intercompany payables, or other intercompany Liabilities, solely between or
 among (A) any Conveyed Subsidiaries (or any of their Subsidiaries) and any of their Subsidiaries or (B) Purchaser(or
 any  of  its  Subsidiaries)  and  any  of  its  Subsidiaries,  (ii)  any  intercompany  accounts  or  other  Liabilities  to  be  repaid  orextinguished
 pursuant to this Agreement in connection with the Closing, including pursuant to Section  6.7 ,  (iii) any Liabilities inrespect
 of Taxes (other than Purchaser Accrued Income Taxes or Seller Accrued Income Taxes), including any reserves forcontingent Taxes, or (iv) any amounts included in the calculation of the Business Working Capital or Purchaser Working Capital.
“ 
FUTA ” has the meaning set forth in Section 6.6(p)  . “ 
GAAP ” means generally accepted accounting principles in the United States.11

“ Global Trade Control Laws ” means U.S. Export Administrat ion Regulations; the U.S. International Traffic in ArmsRegulations;
 the  U.S.  economic  sanctions  rules  and  regulations  implemented  under  statutory  authority  and/or  the  President’sExecutive
 Orders and administered by the U.S. Department of the Treasury Office of Foreign Assets Control; European Union(E.U.)
 Council Regulations on export controls, including Nos. 428/2009, 267/2012; other E.U. Council sanctions regulations, asimplemented
 in E.U. Member States; United Nations sanctions policies; and other relevant economic sanctions, export and importcontrol
 Laws in any other jurisdiction in which the Business or the Purchaser Business, as applicable, markets, commercializes,distributes and sells products as of the date of this Agreement or as of Closing.
“ 
Goods in Transit ” means Products that have left  a facility of Seller Parent (or any Subsidiary of Seller Parent), wererecorded by Seller Parent (or the Subsidiary of Seller Parent) as sales in their accounting systems at or prior to 12:01 a.m. (New York
time) on the Closing Date, but have not been received by customers or Purchaser.
“ 
Governmental Antitrust Authority ”  means any of the U.S. Federal Trade Commission, the Antitrust Division of theU.S.
 Department of Justice, the attorneys general of the several states of the United States and any other Governmental Authorityhaving jurisdiction with respect to the transactions contemplated hereby pursuant to applicable Antitrust Laws.
“ 
Governmental Authority ”  means any supra-national, transnational, national, state, municipal or local government,any
 federal,  state,  city,  municipality  or other  political  subdivision  thereof  and  any  entity,  department,  bureau,  body,  agency,commission,
 authority  or  court  of  competent  jurisdiction,  whether  domestic,  foreign  or  multinational,  exercising  executive,legislative,
 judicial, regulatory, taxing or administrative functions of or pertaining to government and any executive official thereofor any arbitral body 
. “ 
Governmental Authorizations ” means  all licenses, permits, certificates, clearances, registrations, consents and otherauthorizations
 and approvals from any Governmental Authority required to carry on the Business or the Purchaser Business, asapplicable, under the applicable Laws of any Governmental Authority.
“ 
Governmental Order ”  means any order, writ, judgment, injunction, decree, ruling, stipulation, determination oraward entered by or with any Governmental Authority.
“ 
Hazardous Materials ”  means all pollutants, contaminants, wastes or chemicals or other materials or substancesdefined,
 classified,  listed  or  regulated  as  “hazardous,”  “extremely  hazardous,”  “restricted  hazardous  wastes,”  “dangerous,”“pollutants,”
 “contaminants,” “toxic,” or words of similar import under any Environmental Law, including asbestos, asbestoscontaining
 materials, lead-based paint, toxic mold, petroleum, and petroleum products, or for which Liability may be imposed underEnvironmental Law.
“ 
Hold-Back Termination Date ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
HSR Act ”  means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules andregulations promulgated thereunder.
12

“ IFRS ” means the body of pronouncements issued by the International Accounting Standards Board (IASB),including Internation
al Financial Reporting Standards and interpretations approved by the IASB, International Accounting Standardsand
 Standing Interpretations Committee interpretations approved by the predecessor International Accounting Standards Committeeas
 endorsed under the EU accounting regulations and included in the periodic report showing the status of endorsement by theEuropean Financial Reporting Advisory Group.
“ 
Income Tax ”  means any U.S. federal, state, local or non-U.S. Taxes imposed on or calculated by reference to netincome or profits (however denominated), franchise Taxes and other similar Taxes.
“ 
Income Tax Return ” means any Tax Return in respect of Income Taxes. “ 
Indebtedness ”  means, with respect to any Person and as of any time, without duplication, the following obligationsas
 of such time: (a) all Funded Indebtedness of such Person and (b) all letters of credit or performance bonds issued for the accountof such Person (and reimbursement obligations in respect thereof).
“ 
Indemnified Party ” has the meaning set forth in  Section 7.3(a)  . “ 
Indemnifying Party ” has the meaning set forth in  Section 7.3(a)  . “ 
Independent Accountant ”  means any registered independent public accounting firm of international standing asSeller Parent and Purchaser shall mutually agree upon.
“ 
Indirect Transfers ” has the meaning set forth in  Section 6.5(g)(iii)(B)  . “ 
Information  Systems ”  means  (a)  computer  systems,  servers,  workstations,  routers,  hubs,  switches,  datacommunications
 networks (other than the Internet) and other information technology equipment used to create, store, transmit,exchange
 or receive information, voice or data and (b) documentation, user manuals, and training manuals documenting thefunctionality or use of any of the foregoing.
“ 
Insurance Matter ” has the meaning set forth in  Section 6.18(b)  . “ 
Insurance Policy ” has the meaning set forth in  Section 6.18(b)  . “ 
Intellectual Property ”  means all intellectual property rights throughout the world, including: (a) Patent Rights,(b)
 trademarks, service marks, corporate names, trade names, Internet Identifiers, logos, slogans, trade dress, and other similardesignations of
 source or origin, together with the goodwill symbolized by any of the foregoing (“ Trademarks  ”), (c) copyrights and intellectual property
 rights in copyrightable and other works, moral rights, design rights and other sui generis rights (“ Copyrights  ”), (d)
  trade secrets or other proprietary rights in clinical, technical, scientific, manufacturing, regulatory and other information,inventions
 (whether or not patentable), discoveries, designs, results, techniques, database rights, data, databases, data collections andother
 know-how,  including  plans,  processes,  practices,  methods,  trade  secrets,  instructions,  formulae,  formulations,  recipes,compositions, specifications, protocols, analytical and quality control
13

information and procedures, test data and results, reports, studies, and marketing, pricing, distribution, cost and sales information (“Know-How 
”),  (e) intellectual property rights in Software and (f) applications and registrations and renewals for, and all associatedrights
 with respect to, any of the foregoing in any jurisdiction, including all rights to collect royalties, products and proceeds withrespect to any of the foregoing.
“ 
Intellectual Property License Agreement ” has the meaning set forth in  Section 6.14(a)  . “ 
Intentional Breach ”  means, with respect to any representation, warranty, covenant or agreement in this Agreement,an
 action or omission taken or omitted to be taken on or after the date hereof that the breaching Person intentionally takes (or fails totake)
 and knows would, or would reasonably be expected to, cause a material breach of such representation, warranty, covenant oragreement.
“ 
Internet Identifier ”  means any Internet domain name or electronic address, Internet domain name registration,uniform
 resource locator, social media accounts, or social media account addresses or other identifiers, alpha-numeric designationsassociated
 with any of the foregoing, and account names or identifiers, passwords or other credentials to access or modify the accessrights to any of the foregoing.
“ 
Inventory ” means (a) all  raw material inventory, work-in-process inventory, Goods in Transit and finished Productsinventory,
 in each case, solely owned by Sellers or the Conveyed Subsidiaries (or any of their Subsidiaries) and solely used or heldfor
 use in the Business (other than any raw material inventory, work-in-process inventory and finished products inventory subject toa
 Manufacturing and Supply Agreement (Seller Parent as Supplier)) and (b) raw material inventory, work-in-process inventory andfinished
 products inventory, in each case, solely owned by Sellers or the Conveyed Subsidiaries (or any of their Subsidiaries) andsolely
 used or held for use in a Manufacturing and Supply Agreement (Purchaser as Supplier), but excluding any raw materialinventory
 or work-in-process inventory (including any active pharmaceutical ingredients) that Seller Parent or any of its Affiliatessupplies
 through a tolling or similar arrangement (including, following the Closing, any Manufacturing and Supply Agreement(Purchaser
 as Supplier), and including all Customer-Supplied Materials (as defined therein)) to a Facility prior to, on or followingthe
 Closing for the manufacture of products subject to a Manufacturing and Supply Agreement (Purchaser as Supplier) (which rawmaterial
 inventory and work-in-process inventory (including such Customer-Supplied Materials), for clarity, shall not be Inventoryor any other Purchased Asset and Purchaser shall acquire no right, title or interest therein).
“ 
IP Assignment Agreements ” has the meaning set forth in  Section 6.14(a)  . “ 
IP Schedules ” has the meaning set forth in  Section 4.13(a)  . “ 
IRS ” means the U.S. Internal Revenue Service.“ 
Know-How ” has the meaning set forth in the definition of “Intellectual Property.” 14

“ Knowledge of Purchaser Parent ”  means the actual knowledge of any of the individuals listed in Section  1.1(B) of the Purchaser Parent Disclosure Letter.
“ 
Knowledge of Seller Parent ”  means the actual knowledge of any of the individuals listed in Section  1.1(D) of the Seller Disclosure Letter.
“ 
Laws ” means any law, act, statute, ordinance, rule, directive, regulation, code, treaty (including any Tax treaty) ofany Governmental Authority or any Governmental Order.
“ 
Lease Agreement ” has the meaning set forth in  Section 6.14(d)  . “ 
Leased Purchaser Real Property ”  means all real property primarily related to, held for use with, or used inconnection with the Purchaser Business, other than the Owned Purchaser Real Property.
“ 
Leased Real Property ” has the meaning set forth in  Section 2.1(c)  . “ 
Liabilities ”  means any and all Losses, debts, liabilities and obligations, whether accrued or unaccrued, fixed orvariable, known or unknown, absolute or contingent, matured or unmatured or determined or determinable.
“ 
Liens ” means any lien, security interest, mortgage, charge, pledge, license, easement or other similar encumbrance,title
 defect or material use or transfer restriction, it being understood and agreed that “Lien” does not include any non-exclusivelicense or other non-exclusive grant of rights to Intellectual Property.
“ 
Listing Rules ”  means the rules and regulations made by the FCA pursuant to Part 6, section 73A of the FSMA andcontained in the FCA’s publication of the same name.
“ 
Local  Implementing  Agreements ”  means  the  various  Share  transfer  agreements,  Purchased  Asset  transferagreements
 and  other  agreements  and  the  schedules  and  exhibits  thereto  to  be  entered  into  by  Purchaser  and  the  PurchaserDesignated
 Affiliates and the applicable Sellers for purposes of implementing the sale, transfer, conveyance, and assignment, asapplicable,
 of the applicable Sellers’ right, title and interest in the Shares and the other Purchased Assets to, and the employment ofthe
 Business Employees consistent with Section  6.6 by,  Purchaser and such Purchaser Designated Affiliates, and the assumption ofthe Assumed Liabilitie
s, as the case may be, in the appropriate jurisdictions, prepared and executed in accordance with Section 6.14  . The
 Parties agree that the Local Implementing Agreements shall not expand or limit the rights and obligations of the Parties or theirAffiliates
 beyond those provided for in this Agreement, and that the Local Implementing Agreements shall not provide for anyadditional
 rights, obligations or indemnities of the Parties or their Affiliates, that are not provided for in this Agreement. For clarity,the Indirect Transfers shall be effected pursuant to a Local Implementing Agreement.
“ 
Loss ” means any and all damages, losses, Taxes, penalties, judgments, settlements, payments, fines, interest, costsand
 expenses (including the reasonable out-of-pocket costs and expenses of attorneys and other professional advisors incurred in theinvestigation, defense and/or
15

settlement thereof), but excluding any damages to the extent not reasonably foreseeable, loss of business reputation, or punitive orexemplary
 damages (in each case, other than to the extent such damages are awarded to any third party by Governmental Orderagainst, and paid by, an Indemnified Party).
“ 
Make-Whole Award ” has the meaning set forth in  Section 6.6(c)(vi)  . “ 
Manufacturing and Supply Agreement (Purchaser as Supplier) ” has the meaning set forth in  Section 6.14(a)  . “ 
Manufacturing and Supply Agreement (Seller Parent as Supplier) ” has the meaning set forth in  Section 6.14(a)  . “ 
Manufacturing Registrations ”  means all Governmental Authorizations granted to Seller Parent or any of itsAffiliates by, or pending with, any Governmental Authority for manufacturing facilities that are Facilities.
“ 
Material Adverse Effect ”  means any change, event, development, occurrence or effect that, individually or in theaggregate,
 has had, or would reasonably be expected to have, a material adverse effect on the business, results of operations orfinancial condition of the Busines
s, taken as a whole; provided  ,  however , that any change, event, development, occurrence or effectto
 the extent resulting from or arising out of any of the following, either alone or in combination, shall not be considered indetermining
 whether there has been or may be a Material Adverse Effect: (i) general economic conditions (including changes in(A)
 financial or market conditions, (B) currency exchange rates, (C) prevailing interest rates or credit markets or (D) the price ofcommodities
 or raw materials) applicable in countries, jurisdictions or markets in which there are Purchased Assets or sales ofProducts
 (or the securities, syndicated loan, credit or financial markets globally or in any such economies, countries, jurisdictions ormarkets);
 (ii) changes (or proposed changes) in the legal, Tax, regulatory or political conditions (including changes in Law or in theinterpretation
 or application of Law) applicable in countries, jurisdictions or markets in which there are Purchased Assets or sales ofProducts;
 (iii) changes (or proposed changes) in GAAP or other applicable accounting standards or the interpretations thereof;(iv)
 conditions  in  or  affecting  the  industries  in  which  the  Business  operates;  (v)  conditions  resulting  from  natural  disasters,earthquakes,
 hurricanes, tsunamis, floods, fires, storms, typhoons, lightning, hail storms, blizzards, tornadoes, droughts, cyclones,arctic
 frosts, mudslides, wildfires, manmade disasters, acts of God, pandemics or other weather-related or natural conditions, or thecommencement,
 occurrence, continuation or intensification of any war (whether or not declared), sabotage, armed hostilities, civilunrest,
 military attacks or acts of terrorism or declaration of national emergency; (vi)  any failure by the Business to meet budgets,plans,
 projections or forecasts (whether internal or otherwise) for any period (it being understood that the underlying causes of thefailure
 to meet such budgets, plans, projections or forecasts may be taken into account in determining whether a Material AdverseEffect
 has occurred unless such causes are otherwise excepted under this paragraph; provided  that  this clause  (vi) shall  not beconstrued
 as implying that Seller Parent is making any representation or warranty herein with respect to any budgets, plans,projections
 or forecasts, and no such representations or warranties are being made); (vii) any change in Seller Parent’s stock price ortrading volume (it being understood that the underlying causes of such change may be taken
16

into account in determining whether a Material Adverse Effect has occurred unless such causes are otherwise excepted under thisparagraph);
 (viii) Seller Parent’s pursuit of strategic alternatives for the Business or the negotiation, execution, announcement,performance,
 pendency or consummation of this Agreement, the transactions contemplated hereby or by any of the AncillaryAgreements
 (it being understood and agreed that the foregoing shall not apply to the representations and warranties set forth inSection
 4.4 ),  the identity of Purchaser or any of its Affiliates or any acts or omissions of Purchaser or its Affiliates or anycommunication
 by Purchaser or any of its Affiliates, including in respect of its plans or intentions (including in respect of theBusiness
 Employees) with respect to the Business, including the impact thereof on relationships, contractual or otherwise, withcustomers,
 suppliers, distributors, partners or employees; (ix) without limiting clause  (viii) above,  any action taken by Seller Parentor
 its Affiliates (including any Conveyed Subsidiary and their Subsidiaries) as expressly required by this Agreement, including anychanges,
 events or effects arising out of the application of Antitrust Laws (including any action or judgment arising under AntitrustLaws)
 to this Agreement or the transactions contemplated hereby or the effect of any action taken (or agreed to be taken) by SellerParent, Purchaser,
 or any of their respective Affiliates pursuant to Section 6.3  ;  (x) any action taken, or failure to take action, or suchother
 changes or events, in each case, to which Purchaser has consented in writing; (xi) any labor strike, slow down, lockout orstoppage,
 pending or threatened, against the Business; or (xii) any Excluded Assets or Retained Liabilities; provided  ,  further , thatany
 change, event, development, occurrence or effect referred to in clauses  (i) ,  (ii) , (iii) , (iv) and (v) may be considered indetermining
 whether there has been or may be a Material Adverse Effect to the extent such change, event, development, occurrenceor effect has a disproportionate adverse impact on the business, results of operations or financial condition of the Business, taken as a
whole,
 relative to the other businesses in the industries in which the Business operates (in which case only such incrementaldisproportionate impact may be considered in determining whether there has been or may be a Material Adverse Effect).
“ 
Material Contract ” has the meaning set forth in  Section 4.12(a)  . “ 
Most Cost-Effective Manner ”  means a Remedial Action based upon (a) the least stringent clean-up standards that,based on
 the use classification (industrial, commercial or residential) as of the Closing Date of the applicable real property subject tothe
 Remedial Action, are established under Environmental Law and (b) the least-costly methods that are in accordance withEnvironmental
 Law, in each case of (a) and (b) that are approved by or otherwise acceptable to the applicable GovernmentalAuthorities,
 including the use of engineering and institutional controls to eliminate or minimize exposure pathways, and may alsoinclude,
 in the reasonable discretion of the Party responsible for such Remedial Action, any other Remedial Action that is allowedunder applicable Environmental Law and approved by or otherwise acceptable to the applicable Governmental Authorities.
“ 
Name Change Date ” has the meaning set forth in  Section 6.15(a)  . “ 
New Subsidiaries ” has the meaning set forth in  Section 6.27  . “ 
Non-Controlling Party ” has the meaning set forth in  Section 6.5(e)(iii)  . “ 
Non-Indemnified Claims ” has the meaning set forth in  Section 6.17(b)  . 17

“ Notice 7 ” has the meaning set forth in Section 6.5(g)(iii)(B)  . “ 
Off-the-Shelf Software ”  means software licensed from a third party on general commercial terms that continues tobe commonly available for license on such general commercial terms.
“ 
Ordinary Shares ” means the A Ordinary Shares and the B Ordinary Shares. “ 
Outside Date ” has the meaning set forth in  Section 9.1(b)  . “ 
Outstanding Antitrust Jurisdiction ” has the meaning set forth in  Section 6.3(e)(i)  . “ 
Owned Purchaser Real Property ”  means the real property that both (a) is owned by Purchaser Parent or itsSubsidiaries and (b) is primarily related to, held for use with, or used in connection with the Purchaser Business.
“ 
Owned Real Property ” has the meaning set forth in  Section 2.1(b)  . “ 
Parent Indemnified Parties ” has the meaning set forth in  Section 7.2  . “ 
Parents ” has the meaning set forth in the preamble of this Agreement.“ 
Parties ” has the meaning set forth in the preamble of this Agreement.“ 
Patent Rights ”  means (a) issued patents, (b)  invention disclosures, and pending  patent applications, including allprovisional
 applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon,(c)
 patents-of-addition,  reissues,  reexaminations  and  extensions  or  restorations  by  existing  or  future  extension  or  restorationmechanisms,
 including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalentthereof, (d) inventor’s certificates, (e)  
registered or other  utility model rights, registered or other design rights and registered or other industrial property rights and (f) United States and foreign counterparts of any of the foregoing.
“ 
PCH Split Products ” has the meaning set forth in the definition of “Retained Businesses.” “ 
Pension Transfer Amounts ” has the meaning set forth in  Section 6.6(e)(ii)  . “ 
Permitted Liens ”  means (a) Liens approved in writing by Purchaser; (b) statutory Liens arising out of operation ofLaw
 with respect to a Liability incurred in the ordinary course of business for amounts which are not yet due and payable or forwhich
 an adequate reserve has been established in the Financial Statements; (c) Liens and other imperfections of title that do notmaterially
 detract from the value or materially impair the use of the property subject thereto or make such property unmarketable oruninsurable;
 (d) with respect to real property, (i) easements, declarations, covenants, rights-of-way, restrictions and other charges,instruments or encumbrances that are recorded against title to real estate which do not materially impair the use or occupancy of such
real property in the operation of the Business conducted thereon; (ii) zoning ordinances,
18

variances, conditional use permits and similar regulations, permits, approvals and conditions which are not violated by the currentuse
 of the real property subject thereto in the operation of the Business conducted thereon; (iii) Liens not created by the Sellers thataffect
 the underlying fee interest of any leased real property, including master leases or ground leases, which do not materiallyimpair
 the use or occupancy of such real property in the operation of the Business conducted thereon; and (iv) all matters of recordand
 any state of facts that an accurate survey or inspection of the property would disclose to the extent such matters or states of factdo
 not materially detract from the value or materially impair the use or occupancy of such real property in the operation of theBusiness
 conducted thereon; (e) Liens for Taxes, assessments or other governmental charges or levies (i) that are not yet due orpayable
 or (ii) that are being contested in good faith by appropriate proceedings and for which an adequate reserve has beenestablished
 in  the  Financial  Statements;  (f)  mechanics’,  materialmen’s,  carriers’,  workmen’s,  warehousemen’s,  repairmen’s,landlords’ or other similar Liens and security obligations arising in the ordinary course of business for amounts which are not yet due
and
 payable or for which an adequate reserve has been established in the Financial Statements; (g) Liens arising under originalpurchase
 price conditional sales contracts and equipment leases with third parties entered into in the ordinary course of business;(h) Liens
 that will be released and, as appropriate, removed of record, at or prior to the Closing Date in accordance with the terms ofthis
 Agreement; (i) Liens arising on assets and products sold in the ordinary course of business; (j) Liens arising in connection withany
 consignment arrangement entered into in the ordinary course of business; (k) Liens identified in the Financial Statements(including
 in the notes thereto); (l) with respect to any equity of a Conveyed Subsidiary (or any of its Subsidiaries), any restrictionsunder
 applicable securities Laws and any Lien set forth in the governing documents of such Conveyed Subsidiary (or any of itsSubsidiaries);
 (m) other Liens that do not materially detract from the value of, or materially impair the current use of, the assetssubject thereto; and (n) Liens disclosed or set forth in the Seller Disclosure Letter.
“ 
Person ” means an individual, a limited liability company, joint venture, a corporation, a partnership, an association,a trust, a division or operating group of any of the foregoing or other entity or organization, including a Governmental Authority.
“ 
Plan Regulatory or Funding Documents ”  means (to the extent applicable) (i) the most recent summary plandescription
 with respect to each such plan, (ii) any related trust or other funding vehicle and any current administrative or servicecontract
 or insurance policy, (iii) the most recent annual report on IRS Form 5500 and the most recent actuarial report, financialstatements or
 similar reports or statements, (iv) the most recent determination or opinion letter received from the IRS with respect toeach
 such plan intended to qualify under Section 401 of the Code and (v) any documents applicable to a Foreign Seller Group Planor Foreign Purchaser Group Plan (as applicable) that are analogous to those contemplated by 
clauses (i)  through  (iv) .“ 
Post-Closing Representation ” has the meaning set forth in  Section 10.17(a)  . “ 
Post-Closing Tax Period ” means any taxable period (or portion thereof) beginning after the Closing Date and, in the case of any Straddle Period, the portion of such period beginning after the Closing Date.
19

“ PRC Taxing Authority ” means any Taxing Authority in the People’s Republic of China. “ 
Pre-Closing Income Tax Amount ” has the meaning set forth in  Section 6.5(d)(vi)(A)  . “ 
Pre-Closing Separate Tax Returns ” has the meaning set forth in  Section 6.5(a)(i)  . “ 
Pre-Closing Tax Period ” means any taxable period  (or portion thereof) ending on or before the Closing Date and, inthe case of any Straddle Period, the portion of such period ending on and including the Closing Date.
“ 
Preference Shares ”  means non-voting, irredeemable preference shares with a nominal value of £1.00 each in thecapital
 of Purchaser, having the rights and restrictions set out in the Restated Purchaser Articles of Association and the PurchaserShareholders Agreement.
“ 
Product Registrations ”  means all Governmental Authorizations granted to a Conveyed Subsidiary or a Seller by, orpending
 with, any Governmental Authority and Related to the Business, to market any Product, including FDA drug listings, FDAProduct
 Marketing Authorizations, other national or regional marketing authorizations or permits and CE marks anywhere in theworld. “Product Registrations” shall not include any Manufacturing Registrations.
“ 
Products ”  means (a) the products researched, developed, manufactured, marketed, commercialized, distributedand/or
 sold under the brand names set forth on Annex E-1  or  variations or derivatives of such names (including translations thereof)that
 are researched, developed, manufactured, marketed, commercialized, distributed and/or sold by or on behalf of Seller Parent(directly
 and indirectly through its Subsidiaries) as of the date hereof and as of immediately prior to the Closing, (b) any over-the-counter
 consumer healthcare or medicine products, wellness products and other personal care, oral care, nutrition, skin health,cosmetic
 and  related  products  (other  than  the  PCH  Split  Products)  that  are  researched,  developed,  manufactured,  marketed,commercialized,
 distributed and/or sold by or on behalf of Seller Parent (directly and indirectly through its Subsidiaries) through thePfizer Consumer Healthcare bus
iness unit (directly or indirectly pursuant to a contractual arrangement with any other Pfizer businessunit,
 to the extent of the Pfizer Consumer Healthcare business unit’s rights pursuant to such contractual arrangement) as of the datehereof and as of immediately prior to the Closing and (c) with respect to each of the foregoing products (clauses (a) and (b)), any line
extensions
 or other developments with respect to such product that are in progress as of the date hereof or immediately prior to theClosing Date.
“ 
Property Taxes ” means real, personal and intangible  ad
valorem
 property Taxes. “ 
Proposed Closing Statement ” has the meaning set forth in  Section 2.9(a)  . “ 
Proposed Divestiture ” has the meaning set forth in  Section 6.3(d)(ii)  . “ 
Purchase Consideration ” has the meaning set forth in  Section 2.7  . “ 
Purchased Assets ” has the meaning set forth in  Section 2.1  . 20

“ Purchaser ” has the meaning set forth in the preamble of this Agreement. “ 
Purchaser Account ”  means the bank account or accounts controlled solely by Purchaser specified by Purchaser inwriting to the other Parties at least two (2) Business Days before the Closing Date.
“ 
Purchaser Accrued Income Taxes ” means an  amount (not less than zero) equal to the aggregate current Income Taxliabilities
 of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries and their Subsidiaries) (which shall not be lessthan
 zero in any jurisdiction) for all taxable periods (or portions thereof) ending on or before the Closing Date for which final TaxReturns
 have not been filed. The calculation of Purchaser Accrued Income Taxes shall (i) exclude any deferred Tax liabilities ordeferred
 Tax assets and any amounts in respect of speculative or contingent liabilities for Tax, (ii) include estimated (or otherprepaid)
 Income Tax payments only to the extent that such payments have the effect of reducing (not below zero) the particularcurrent
 Income Tax liability in respect of which such payments were made, (iii) include Income Tax deductions or Tax refunds(including
 for overpayments of estimated Taxes), in each case, only to the extent such deductions or Tax refunds have the effect ofreducing
 (not below zero) a particular current Income Tax liability to which they are relevant, (iv) be prepared in accordance withthe
 past practice (including reporting positions and accounting methods) of Purchaser or its applicable Subsidiary in preparing TaxReturns for Income Taxes and (v) in the case of a Straddle Period, be determined in accordance with 
Section 6.5(d)(iii)  . “ 
Purchaser Accounting Principles ” has the meaning set forth in  Section 2.8(a)  . “ 
Purchaser Adverse Action ” has the meaning set forth in  Section 6.3(f)  . “ 
Purchaser Ancillary Agreement ” has the meaning set forth in  Section 6.7(b)  . “ 
Purchaser Assumed Employee Liabilities ” has the meaning set forth in  Section 6.6(a)(i)  . “ 
Purchaser Assumed Severance Liabilities ” has the meaning set forth in  Section 6.6(c)(ii)  . “ 
Purchaser Business ”  means (a) the worldwide business of researching, developing, manufacturing, marketing,commercializing, distributing and selling the
 products sold under the brand names set forth on Annex E-2  or variations or derivatives of
 such names (including translations thereof) (the “ Purchaser  Key Products ”,  and such brands, the “ Purchaser  Key Brands ”), as conducted
 by Purchaser Parent (directly and indirectly through its Subsidiaries, including Purchaser and its Subsidiaries) as of thedate
 of this Agreement and as of immediately prior to the Closing, (b) the business reflected in the Purchaser Financial Statements,including the assets, rights, properties, activities, operations and
 liabilities that comprise such business, (c) the business of marketing,commercializing,
 distributing and selling any over-the-counter consumer healthcare or medicine products, wellness products andother
 personal care, oral care, nutrition, skin health, cosmetic and related products (the “ Consumer  Healthcare Products ”)  asconducted
 by Leo Asia Private Limited (including, for clarity, pursuant to the Amended Consignment Selling Agreement) as of thedate of
21

this Agreement and as of immediately prior to the Closing and (d) to the extent not otherwise reflected in the Purchaser FinancialStatements,
 the research and development of any Consumer Healthcare Products, as conducted by Purchaser Parent (directly andindirectly
 through its Subsidiaries) through its GlaxoSmithKline Consumer Healthcare business (directly or indirectly pursuant to acontractual
 arrangement with any other GlaxoSmithKline business, to the extent of the GlaxoSmithKline Consumer Healthcarebusiness’
 rights pursuant to such contractual arrangement) as of the date of this Agreement and as of immediately prior to theClosing.
 Notwithstanding the foregoing, the following shall not be included in Purchaser Business: (x) the worldwide business ofresearching,
 developing, manufacturing, marketing, commercializing, distributing and selling pharmaceutical products to the extentsuch
 business and the economic benefit attendant to such business is not reflected in the Purchaser Financial Statements and (y)those assets listed in 
Annex G  . “ 
Purchaser Business Employee ”  means each individual who, immediately prior to the Closing: (a) is employed byPurchaser
 Parent or its Affiliates (other than Purchaser or its Subsidiaries) and devotes 70% or more of his or her services to thePurchaser Busine
ss but excluding any individual who is based in France or employed by  any French Affiliate of Purchaser Parent, or(b) is employed by Purchaser (or its Subsidiaries).
“ 
Purchaser Business Employee (non-U.S.) ”  means a Purchaser Business Employee based outside of the UnitedStates.
“ 
Purchaser Business Employee (U.S.) ” means a Purchaser Business Employee based in the United States. “ 
Purchaser Business Plan ” means each Purchaser  Group Plan and each Foreign Purchaser Group Plan sponsored andmaintained by Purchaser or a Subsidiary of Purchaser.
“ 
Purchaser Copyrights ”  means all Copyrights, Copyright registrations and applications for Copyright registrationthat are owned by Purchaser or its Subsidiaries.
“ 
Purchaser Current Representation ” has the meaning set forth in  Section 10.17(b)  . “ 
Purchaser DC Plans (non-U.S.) ” has the meaning set forth in  Section 6.6(g)(i)  . “ 
Purchaser DC Plans (U.S.) ” has the meaning set forth in  Section 6.6(f)(i)  . “ 
Purchaser Designated Affiliate ” has the meaning set forth in  Section 10.3  (b). “ 
Purchaser Designated Person ” has the meaning set forth in  Section 10.17(b)  . “ 
Purchaser Environmental Permit ”  means any Governmental Authorization held by Purchaser Parent or any of itsSubsidiaries
 for the then-current operations of the Purchaser Business or for the then-current operation of any Purchaser RealProperty, as of the Closing Date, and required pursuant to an Environmental Law.
“ 
Purchaser Facilities ” has the meaning set forth in  Section 5.15(d)  . 22

“ Purchaser Financial Statements ” has the meaning set forth in  Section 5.6(a)  . “ 
Purchaser FSA Plan ” has the meaning set forth in  Section 6.6(i)  . “ 
Purchaser Group Plan ”  means any employee benefit plan as defined in Section 3(3) of ERISA and any othermaterial
 written fringe benefit, incentive, bonus, employment, retention, change in control, termination or severance plan, program,fund,
 agreement or arrangement, whether or not subject to ERISA, maintained (or contributed to or required to be contributed to) byPurchaser Parent or
 any of its Affiliates, in which any Purchaser Business Employee (U.S.) or Former Purchaser Business Employee(U.S.) participates or is a party.
“ 
Purchaser Indemnified Parties ” has the meaning set forth in  Section 7.1(a)  . “ 
Purchaser Internal Restructurings ” has the meaning set forth in  Section 6.5(f)(ii)  . “ 
Purchaser  IP ”  means  (a)  all  Purchaser  Copyrights,  Purchaser  Patent  Rights ,  Purchaser  Trademark  Rights,Purchaser
 Know-How and Purchaser Software, and (b) all other Intellectual Property that is owned, or purported to be owned, byPurchaser or its Subsidiaries.
“ 
Purchaser IT Systems ” means all Information Systems that are owned by Purchaser or its Subsidiaries. “ 
Purchaser Key Products ” has the meaning set forth in the definition of “Purchaser Business.” “ 
Purchaser Key Brands ” has the meaning set forth in the definition of “Purchaser Business.” “ 
Purchaser Know-How ” means all Know-How that is owned by Purchaser or its Subsidiaries. “ 
Purchaser Liabilities ” means  any and all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaserand
 its Subsidiaries), other than Liabilities identified as Purchaser Parent Retained Liabilities in clauses  (a) through  (f) of thedefinition
 of “Purchaser Parent Retained Liabilities”, whether arising prior to, on or after the Closing, to the extent resulting from orarising out of the past, present or future ownership, operation, use or conduct of the Purchaser Business.
“ 
Purchaser Licensed IP ”  means all Intellectual Property owned by Purchaser Parent or any of its Affiliates that hasbeen
 licensed to Purchaser or its Subsidiaries pursuant to a Purchaser  Ancillary Agreement, including the Purchaser LicensedTrademark Rights 
. “ 
Purchaser Licensed Trademark Rights ” has the meaning set forth in  Section 5.14(h)  . “ 
Purchaser Manufacturing Registrations ” means all Governmental Authorizations granted to Purchaser Parent or any of its Affiliates by, or pending with, any Governmental Authority for manufacturing facilities that are Purchaser Facilities.
23

“ Purchaser Material Adverse Effect ”  means any change, event, development, occurrence or effect that, individuallyor in
 the aggregate, has had, or would reasonably be expected to have, a material adverse effect on the business, results of operationsor
 financial condition of the Purchaser Business, taken as a whole, or Purchaser and its Subsidiaries, taken as a whole; provided  , however 
,  that any change, event, development, occurrence or effect to the extent resulting from or arising out of any of thefollowing,
 either alone or in combination, shall not be considered in determining whether there has been or may be a PurchaserMaterial
 Adverse Effect: (i) general economic conditions (including changes in (A) financial or market conditions, (B) currencyexchange
 rates, (C) prevailing interest rates or credit markets or (D) the price of commodities or raw materials) applicable incountries,
 jurisdictions or markets in which there are assets of the Purchaser Business or sales of Purchaser Products (or thesecurities,
 syndicated loan, credit or financial markets globally or in any such economies, countries, jurisdictions or markets);(ii)
 changes  (or  proposed  changes)  in the  legal,  Tax,  regulatory  or political  conditions  (including  changes  in Law  or  in theinterpretation
 or application of Law) applicable in countries, jurisdictions or markets in which there are assets of the PurchaserBusiness
 or sales of Purchaser Products; (iii) changes (or proposed changes) in IFRS or other applicable accounting standards or theinterpretations
 thereof; (iv) conditions in or affecting the industries in which the Purchaser Business operates; (v) conditionsresulting
 from natural disasters, earthquakes, hurricanes, tsunamis, floods, fires, storms, typhoons, lightning, hail storms, blizzards,tornadoes,
 droughts, cyclones, arctic frosts, mudslides, wildfires, manmade disasters, acts of God, pandemics or other weather-related or
 natural conditions, or the commencement, occurrence, continuation or intensification of any war (whether or not declared),sabotage,
 armed hostilities, civil unrest, military attacks or acts of terrorism or declaration of national emergency; (vi) any failure bythe
 Purchaser Business to meet budgets, plans, projections or forecasts (whether internal or otherwise) for any period (it beingunderstood
 that the underlying causes of the failure to meet such budgets, plans, projections or forecasts may be taken into accountin
 determining whether a Purchaser Material Adverse Effect has occurred unless such causes are otherwise excepted under thisparagraph; 
provided  that  this clause (vi) shall  not be construed as implying that Purchaser Parent is making any representation orwarranty
 herein with respect to any budgets, plans, projections or forecasts, and no such representations or warranties are beingmade);
 (vii) any change in Purchaser Parent’s stock price or trading volume (it being understood that the underlying causes of suchchange
 may be taken into account in determining whether a Purchaser Material Adverse Effect has occurred unless such causes areotherwise
 excepted under this paragraph); (viii) the negotiation, execution, announcement, performance, pendency or consummationof
 this Agreement, the transactions contemplated hereby or by any of the Ancillary Agreements (it being understood and agreed thatthe
 foregoing shall not apply to the representations and warranties set forth in Section 5.4  );  (ix) without limiting clause (viii)  above, any
 action taken by Purchaser Parent, Purchaser or any of their Affiliates as expressly required by this Agreement, including anychanges,
 events or effects arising out of the application of Antitrust Laws (including any action or judgment arising under AntitrustLaws)
 to this Agreement or the transactions contemplated hereby or the effect of any action taken (or agreed to be taken) by SellerParent,
 Purchaser or any of their respective Affiliates pursuant to Section 6.3  ;  (x) any action taken, or failure to take action, or suchother
 changes or events, in each case, to which Seller Parent has consented in writing; (xi) any labor strike, slow down, lockout orstoppage, pending or threatened,
 against the Purchaser Business; or (xii) any Purchaser Parent Retained Liabilities; provided  ,  further, that any change, event, development, occurrence or effect referred to in 
clauses (i)  ,  (ii) , (iii) , (iv) and (v)24

may be considered in determining whether there has been or may be a Purchaser Material Adverse Effect to the extent such change,event,
 development, occurrence or effect has a disproportionate adverse impact on the business, results of operations or financialcondition
 of the Purchaser Business, taken as a whole, relative to the other businesses in the industries in which the PurchaserBusiness operates (in which case
 only such incremental disproportionate impact may be considered in determining whether there hasbeen or may be a Purchaser Material Adverse Effect).
“ 
Purchaser Material Contract ” has the meaning set forth in  Section 5.13(a)  . “ 
Purchaser Net Cash ”  means the amount (which may be a positive or negative number) equal to (a) all CashEquivalents 
minus
 (b) all outstanding Funded Indebtedness, in each case, of Purchaser and its Subsidiaries (other than the ConveyedSubsidiaries
 and their Subsidiaries), as of 12:01 a.m. (New York time) on the Closing Date; provided  that  all proceeds, payments orconsideration
 received by Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) as a result of any actiontaken
 (or agreed to be taken) by Seller Parent, Purchaser Parent, Purchaser or any of their respective  Affiliates  pursuant toSection 6.3 
shall be excluded from the calculation of Purchaser Net Cash. “ 
Purchaser Parent ” has the meaning set forth in the preamble of this Agreement. “ 
Purchaser Parent Account ”  means the bank account or accounts specified by Purchaser Parent in writing to theother Parties hereto at least two (2) Business Days before the Closing Date.
“ 
Purchaser Parent Adverse Recommendation Change ” has the meaning set forth in  Section 6.24(e)  . “ 
Purchaser Parent Board Recommendation ” has the meaning set forth in  Section 5.2(a)  . “ 
Purchaser Parent Combined Tax Returns ” has the meaning set forth in  Section 6.5(e)(v)  . “ 
Purchaser Parent Disclosure Letter ”  means the disclosure letter that Purchaser Parent has delivered to Seller Parentas of the date of this Agreement.
“ 
Purchaser Parent Estimated Closing Statement ”  means a written statement setting forth the Estimated PurchaserWorking
 Capital and the Estimated Purchaser Net Cash, prepared in a manner consistent with the Purchaser Accounting Principlesand the Purchaser Sample Closing Statement.
“ 
Purchaser Parent Final Plan ” has the meaning set forth in  Section 6.5(f)(iv)  . “ 
Purchaser Parent Indemnified Parties ” has the meaning set forth in  Section 7.1(a)  . “ 
Purchaser Parent Indemnified Taxes ” has the meaning set forth in  Section 6.5(d)(ii)  . 25

“ Purchaser Parent Retained Businesses ” mean all businesses of  Purchaser Parent or any of its Subsidiaries other thanthe
 Purchaser Business, including the worldwide business of researching, developing, manufacturing, marketing, commercializing,distributin
g and selling (i) any products not included in the definition of “Purchaser Business” and (ii) without limiting the foregoingclause
 (i) ,  any pharmaceutical products or pharmaceutical products that have become or may in the future become, in whole or inpart, over-the-counter products (other than the products included in the definition of “Purchaser Business”).
“ 
Purchaser Parent Retained Liabilities ”  means any Liabilities of Purchaser Parent or its Affiliates (includingPurchaser and its Subsidiaries) other than the Purchaser Liabilities. The Purchaser Parent Retained Liabilities shall include:
(a) 
     all Liabilities for which Purchaser Parent or any of its Affiliates (other than Purchaser and its Subsidiaries)expressly has responsibility pursuant to the terms of this Agreement or any Purchaser Ancillary Agreement;
(b) 
     all Purchaser Parent Transaction Expenses;(c) 
     all Liabilities, including Liabilities for Taxes, of Purchaser Parent or its Subsidiaries to the extent related to orarising
 out of the assets, properties and rights of Purchaser Parent or its Affiliates (other than Purchaser and its Subsidiaries) or thePurchaser
 Parent Retained Businesses (including the assets listed in Annex  G )  (other than any Liabilities for which Purchaser orSeller
 Parent expressly has responsibility pursuant to the terms of this Agreement or any Ancillary Agreement, and other than anyLiabilities
 that are separately allocated pursuant to any other agreement or transaction related to such assets, properties or rightsbetween
 Seller Parent or any of its Affiliates, on the one hand, and Purchaser Parent or any of its Affiliates, on the other hand,including
 any commercial or other agreements unrelated to this Agreement), including Environmental Liabilities, whether arisingprior
 to, on or after the Closing, to the extent arising out of or related to the ownership or occupancy of any manufacturing, office,research
 and development, or warehouse facilities owned, leased or operated by Purchaser Parent or its Affiliates other than thePurchaser Facilities;
(d) 
     all Indebtedness of Purchaser Parent and its Affiliates other than (i) Funded Indebtedness of Purchaser and itsSubsidiaries included in the calculation of Final Purchaser Net Cash and (ii) Indebtedness of Purchaser and its Subsidiaries that is not
Funded Indebtedness;
(e) 
     all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) (i) pursuantto
 the Put Option Implementation Agreement, dated as of March 27, 2018, by and among Purchaser Parent, Purchaser and NovartisAG
 (among others), or (ii) related to or arising out of the divestiture of Horlicks and other consumer healthcare nutrition brands toUnilever
 plc or its Affiliates and the merger of GSK Consumer Healthcare Limited India with Hindustan Unilever Limited, and thetransactions
 contemplated  thereby  and  any  related  Contracts  entered  into  in  connection  therewith  other  than  the  AmendedConsignment Selling Agreement; and
(f) 
     all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) set forth inSection 1.1(C) 
of the Purchaser Parent Disclosure Letter. 26

“ Purchaser Parent Shareholder Approval ” has the meaning set forth in  Section 5.2(a)  . “ 
Purchaser  Parent  Shareholder  Approval  Resolution ”  means  the  ordinary  resolution  of  Purchaser  Parent’sshareholders required to approve the arrangements as contemplated herein or by any of the Ancillary Agreements.
“ 
Purchaser Parent Shareholder Circular ”  means the related party (as defined in Chapter 11 of the Listing Rules)circular to be prepared and published by Purchaser Parent in connection with the Purchaser Parent Shareholder Meeting.
“ 
Purchaser Parent Shareholder Meeting ” has the meaning set forth in  Section 6.24(a)  . “ 
Purchaser Parent Termination Fee ” has the meaning set forth in  Section 9.2(b)  . “ 
Purchaser Parent Transaction Expenses ”  means any outside counsel, investment banking, accounting, financialadvisory
 and other advisory costs, fees and expenses incurred by Purchaser Parent or any of its Affiliates (including Purchaser andits
 Subsidiaries) at or prior to the Closing specifically in connection with the evaluation and negotiation of a transaction involvingSeller
 Parent and the Business, and the negotiation, execution and performance of this Agreement and the consummation of thetransaction
s contemplated by this Agreement, including the Purchaser Internal Restructurings, in each case other than costs, fees andexpenses
 for which Seller Parent or its Affiliates expressly has responsibility (including pursuant to payment, reimbursement,indemnification or other similar obligations set forth herein) pursuant to the terms of this Agreement.
“ 
Purchaser Patent Rights ” means all Patent Rights that are owned by Purchaser or its Subsidiaries. “ 
Purchaser Pension Plans ” has the meaning set forth in  Section 6.6(e)(i)  . “ 
Purchaser Permitted Liens ”  means (a) Liens approved in writing by Seller Parent; (b) statutory Liens arising out ofoperation
 of Law with respect to a Liability incurred in the ordinary course of business for amounts which are not yet due andpayable
 or  for  which  an  adequate  reserve  has  been  established  in  the  Purchaser  Financial  Statements;  (c)  Liens  and  otherimperfections of title that do not materially detract from the value or materially impair the use of the property subject thereto or make
such
 property unmarketable or uninsurable; (d) with respect to real property, (i) easements, declarations, covenants, rights-of-way,restrictions
 and other charges, instruments or encumbrances that are recorded against title to real estate which do not materiallyimpair
 the use or occupancy of such real property in the operation of the Purchaser Business conducted thereon; (ii) zoningordinances,
 variances, conditional use permits and similar regulations, permits, approvals and conditions which are not violated bythe
 current use of the real property subject thereto in the operation of the Purchaser Business conducted thereon; (iii) Liens notcreated by
 Purchaser Parent or its Affiliates that affect the underlying fee interest of any leased real property, including master leasesor
 ground leases, which do not materially impair the use or occupancy of such real property in the operation of the PurchaserBusiness conducte
d thereon; and (iv)  all matters of record and any state of facts that an accurate survey or inspection of the propertywould disclose to the extent such matters or states of fact do not materially detract from the value or materially impair the use
27

or occupancy of such real property in the operation of the Purchaser Business conducted thereon; (e) Liens for Taxes, assessments orother
 governmental charges or levies (i) that are not yet due or payable or (ii) that are being contested in good faith by appropriateproceedings
 and  for  which  an  adequate  reserve  has  been  established  in  the  Purchaser  Financial  Statements;  (f)  mechanics’,materialmen’s, carriers’, workmen’s, warehousemen’s, repairmen’s,
 landlords’ or other similar Liens and security obligations arisingin
 the ordinary course of business for amounts which are not yet due and payable or for which an adequate reserve has beenestablished
 in the Purchaser Financial Statements; (g) Liens arising under original purchase price conditional sales contracts andequipment leases with third parties entered into in the
 ordinary course of business; (h) Liens that will be released and, as appropriate,removed
 of record, at or prior to the Closing Date in accordance with the terms of this Agreement; (i) Liens arising on assets andproducts
 sold in the ordinary course of business; (j) Liens arising in connection with any consignment arrangement entered into inthe
 ordinary course of business; (k) Liens identified in the Purchaser Financial Statements (including in the notes thereto); (l) withrespect
 to any equity of Purchaser or any of its Subsidiaries, any restrictions under applicable securities Laws and any Lien set forthin the governing documents of Purcha
ser (or any of its Subsidiaries); (m) other Liens that do not materially detract from the value of,or
 materially impair the current use of, the assets subject thereto; and (n) Liens disclosed or set forth in the Purchaser ParentDisclosure Letter.
“ 
Purchaser Privileged Communications ” has the meaning set forth in  Section 10.17(d)  . “ 
Purchaser  Product  Registrations ”  means  all  Governmental  Authorizations  granted  to  Purchaser  Parent  or  aSubsidiary
 of Purchaser Parent by, or pending with, any Governmental Authority and Related to the Purchaser Business to marketany
 Purchaser Products, including FDA drug listings, FDA Product Marketing Authorizations, other national or regional marketingauthorizations
 or permits and CE marks anywhere in the world. “Purchaser Product Registrations” shall not include any PurchaserManufacturing Registrations.
“ 
Purchaser  Products ”  means  the  products  researched,  developed,  manufactured,  marketed,  commercialized,distributed
 and/or sold by the Purchaser Business, and any line extensions or other developments with respect to such products thatare in progress as of the date hereof or immediately prior to the Closing Date.
“ 
Purchaser Real Property ”  means, collectively, the Leased Purchaser Real Property and the Owned Purchaser RealProperty.
“ 
Purchaser Real Property Leases ”  means real property leases, subleases, licenses and occupancy arrangements withrespect to the Leased Purchaser Real Property.
“ 
Purchaser Related Party Contract ”  means any Contract between Purchaser Parent and any of its Affiliates (otherthan Purchaser and its Subsidiaries), on the one hand, and Purchaser or its Subsidiaries, on the other hand.
“ 
Purchaser Retiree Medical Plan ” has the meaning set forth in  Section 6.6(h)  . 28

“ Purchaser Shared Contract ”  means any Contract, sales order, purchase order, instrument or other commitment,obligation
 or arrangement entered into prior to the date hereof (or entered into prior to the Closing in accordance with thisAgreement)
 that is between Purchaser Parent or any of its Subsidiaries (including Purchaser and its Subsidiaries), on the one hand,and
 one or more third parties, on the other hand, that inures to the benefit or burden of both the Purchaser Business and anyPurchaser
 Parent Retained Business, other than any enterprise-wide Contracts, Contracts with respect to Off-the-Shelf Software,Purchaser
 Group Plans, Foreign Purchaser Group Plans, Collective Bargaining Agreements and any agreement or grant with anyTaxing
 Authority; provided  that  any such Contract that provides only de 
minimis
assets  or services to the Purchaser Business or thePurchaser Parent Retained Business, as the case may be, shall not be deemed to be a Purchaser Shared Contract for purposes hereof.
“ 
Purchaser Shareholders Agreement ” has the meaning set forth in  Section 6.14(b)  . “ 
Purchaser Software ”  means  all  Software  (a)  that  is owned  by Purchaser  or its Subsidiaries  and  (b)  that  isexclusively used by Purchaser or its Subsidiaries in the operation of the Purchaser Business.
“ 
Purchaser Tax Act ” has the meaning set forth in  Section 6.5(d)(i)  . “ 
Purchaser Tax Indemnified Parties ” has the meaning set forth in  Section 6.5(d)(i)  . “ 
Purchaser Trademark Rights ”  means all Trademarks,  including  Trademark  registrations  and applications  forTrademark
 registrations, (a) that are owned by or registered to Purchaser or its Subsidiaries (including any Purchaser Key Brands);or
 (b) containing, comprising, or including (but only to the extent they include) any of the foregoing clause (a), including, in eachcase
 of clauses (a) and (b), (x) all Trademarks that are confusingly similar to the Trademarks described in clauses (a) and (b) (suchthat
 they could not be used in commerce without infringing such Trademarks), (y) all Internet Identifiers and telephone numbers orother
 alphanumeric addresses or mnemonics containing any of the foregoing and (z) the goodwill symbolized by any of theforegoing.
“ 
Purchaser Working Capital ”  means the amount (which may be a positive or negative number) equal to (a) the sumof
 the assets of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries and their Subsidiaries), on a consolidated basis,as
 of 12:01 a.m. (New York time) on the Closing Date represented in the asset line items shown on the Purchaser Sample ClosingStatement as of such time, 
minus
 (b) the sum of the liabilities of Purchaser and its Subsidiaries (other than the Conveyed Subsidiariesand
 their Subsidiaries), on a consolidated basis, as of 12:01 a.m. (New York time) on the Closing Date represented in the liabilityline
 items shown on the Purchaser Sample Closing Statement for Purchaser as of such time, in each case calculated in a mannerconsistent
 with the Purchaser Accounting Principles and the Purchaser Sample Closing Statement; provided  that  there shall beexcluded
 from such calculation any Purchased Assets (regardless of the time of day at which the Closing occurs), the PurchaserParent
 Retained Liabilities, all assets or Liabilities in respect of Income Taxes (whether current, deferred, or contingent), anyamounts
 included in the calculation of Purchaser Net Cash, the proceeds, payments or consideration paid or payable to PurchaserParent or any of its Affiliates (including Purchaser and its Subsidiaries)
29

as a result of any action taken (or agreed to be taken) by Seller Parent, Purchaser Parent, Purchaser or any of their respectiveAffiliates
 pursuant to Section  6.3 ,  any intercompany accounts or other Liabilities to be repaid or extinguished pursuant to thisAgreement
 in connection with the Closing, including pursuant to Section  6.7 ,  and any intercompany receivables and intercompanypayables,
 and other intercompany  Liabilities,  solely between or among Purchaser (or any of its Subsidiaries)  and any of itsSubsidiaries.
“ 
Real Property ” means, collectively, the Leased Real Property and the Owned Real Property. “ 
Real Property Leases ” has the meaning set forth in  Section 2.1(c)  . “ 
Records ” means (a) all current and historical books, records, reports and other documents and information thatpertain
 to business plans, budgets, financial and accounting data, brand insights and research, Business IP, vendors, manufacturing,customers,
 research  and  development  of  the  Products,  invoices,  marketing  and  advertising  operations,  policies,  procedures,techniques,
 systems, employee handbooks or manuals, training materials, operating manuals and documentation, and productionmanuals
 and documentation, in each case, in any form or medium, but in each case excluding personnel files and Seller CombinedTax
 Returns  and  (b)  Registration  Information  (including  in  relation  to  pending  applications  for  Product  Registrations  andManufacturing Registrations).
“ 
Registered IP ” has the meaning set forth in  Section 4.13(a). “ 
Registered Business IP ” has the meaning set forth in  Section 4.13(a)  . “ 
Registered Purchaser IP ” has the meaning set forth in  Section 5.14(a)  . “ 
Registration Information ”  means copies of the Product Registrations and Manufacturing Registrations and anyexisting files Related to the Product Registrations and Manufacturing Registrations in the possession of the relevant Seller.
“ 
Regulatory Action ” has the meaning set forth in  Section 6.3(c)(iv)  . “ 
Related to the Business ”  or “ Relating to the Business ”  means primarily relating to, primarily held for use with, orprimarily used in connection with the Business.
“ 
Related to the Purchaser Business ”  or “ Relating to the Purchaser Business ”  means primarily relating to, primarilyheld for use with, or primarily used in connection with the Purchaser Business.
“ 
Release ” means any releasing, spilling, leaking, pumping, pouring, emitting, emptying, injecting, depositing,disposing,
 discharging, dispersal, escaping, dumping, migrating or leaching into the environment, including ambient air, indoor air,sediments,
 drinking water, water, surface or subsurface strata or groundwater, including the movement of Hazardous Materialsthrough or in the indoor or outdoor air, soil, surface water, groundwater or property.
30

“ Remedial Action ”  means any action required by a Governmental Authority or Governmental Order or pursuant toEnvironmental
 Law to clean up or remediate soil, sediments, air, building materials, drinking water, surface water, groundwater orother
 environmental media in response to a Release or presence of Hazardous Materials, including any associated action taken toinvestigate,
 monitor, assess and evaluate the extent and severity of any such Release, action taken to remediate any such Release,post-remediation
 monitoring of any such Release, and preparation of all reports, studies, analyses or other documents relating to theforegoing.
 “Remedial Action” also refers to any Action relating to any of the above, including the negotiation and execution ofjudicial or
 administrative consent decrees, or defending claims brought by any Governmental Authority or any other Person, whethersuch
 claims are equitable or legal in nature, relating to the relevant cleanup or remediation in response to the relevant Release orpresence of Hazardous Materials and associated actions.
“ 
Remediation Completion Date ”  means the date that (a) the Governmental Authority with jurisdiction over aRemedial
 Action issues a written notice indicating that no further action, other than operation and maintenance of institutional orengineering
 controls is required, or (b) if, after requesting in writing such a notice from such a Governmental Authority, despite theParty
 responsible for such a Remedial Action having reasonably completed the requirements to obtain such a written notice, no suchwritten notice is
 issued within 90 days after such Governmental Authority’s receipt of such request or any longer time period grantedto
 such Governmental Authority under the relevant Environmental Law, then the Remediation Completion Date shall mean the datethat
 an engineering firm mutually selected by the Parties and consistently ranked on the list of the Top 200 Environmental Firmspublished
 by the Engineering News-Record, and employing an Environmental Professional as defined in 40 CFR Part 312.10 andASTM
 E1527-13, concurs that no further action, other than operation and maintenance of institutional or engineering controls, isrequired.
“ 
Replacement Shared Contract ” has the meaning set forth in  Section 2.2(d)  . “ 
Representatives ”  means, with respect to any Person, such Person’s Affiliates and any of such Person’s or any of itsAffiliates’
 directors,  officers,  managers,  partners,  employees,  counsel,  financial  advisors,  accountants,  consultants  and  otheradvisors, representatives and agents.
“ 
Resolution Period ” has the meaning set forth in  Section 2.9(c)  . “ 
Restated Purchaser Articles of Association ” has the meaning set forth in  Section 3.2  . “ 
Restricted Market ”  means, as applicable under Global Trade Control Laws, the Crimean Peninsula, Cuba, theDonbass Region, Iran, North Korea, Sudan, and Syria.
“ 
Restricted Party ”  means any individual(s) or entity(ies) on any of the following lists (such lists, the “ Restricted Party
 Lists ”):  the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and theSectoral Sanctions Iden
tifications List, as administered by the U.S. Department of the Treasury Office of Foreign Assets Control; theU.S.
 Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce;the entities subject to restrictive measures and the Consolidated List of
31

Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign & Security Policy;the
 List of Excluded Individuals / Entities, as published by the U.S. Health and Human Services – Office of Inspector General; anylists of prohibited or debarre
d parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of persons and entitiessuspended
 or  debarred  from  contracting  with  the  U.S.  government;  and  similar  lists  of  restricted  parties  maintained  by  aGovernmental
 Authority  of  any  other  jurisdiction  in  which  the  Business  or  the  Purchaser  Business,  as  applicable,  markets,commercializes, distributes and sells products as of the date of this Agreement or as of the Closing Date.
“ 
Restricted Party Lists ” has the meaning set forth in the definition of “Restricted Party.” “ 
Retained Brands ” has the meaning set forth in  Section 6.15(a)  . “ 
Retained Businesses ”  mean all businesses of Seller Parent or any of its Subsidiaries (including the ConveyedSubsidiaries
 and any of their Subsidiaries) other than the Business, including the worldwide business of researching, developing,manufacturing,
 marketing, commercializing, distributing and selling (a) any products not included in the definition of “Business”,(b)
 each of the products set forth on Annex  D (the  “ PCH Split Products ”),  (c) without limiting the foregoing clauses  (a) and  (b) ,any
 pharmaceutical products or pharmaceutical products that have become or may in the future become, in whole or in part, over-the-counter products (other than the products included in the definition of “Business”) and (d) any products set forth on 
Annex F  .“ 
Retained Environmental Liabilities ” has the meaning set forth in  Section 2.5(b)  . “ 
Retained Facilities ”  means the manufacturing, office, research and development, and warehouse facilities owned,leased or operated by Seller Parent or any of its Affiliates, other than the Facilities.
“ 
Retained Facilities Environmental Liabilities ” has the meaning set forth in  Section 2.5(b)  . “ 
Retained Liabilities ” has the meaning set forth in  Section 2.5  . “ 
Retained Names ”  means (a) the Pfizer trademark, name and brand, (b) the Wyeth trademark, name and brand,(c)
 all Trademarks owned or used by Seller Parent or any of its Affiliates other than the Business Trademark Rights, and (d) allTrademarks
 containing, comprising, or related to any of the foregoing, including (i) all Trademarks that are variations or derivativesthereof
 or confusingly similar thereto, and (ii) all Internet Identifiers and telephone numbers or other alphanumeric addresses ormnemonics containing
 any of the foregoing. Notwithstanding anything in this Agreement to the contrary, Retained Names expresslyincludes those Trademarks set forth in 
Section 1.1(E)  of the Seller Disclosure Letter. “ 
Retained Real Property ”  shall mean all real property owned, leased or used by Seller Parent or any of its Affiliates,other than the Owned Real Property and the Leased Real Property.
32

“ Retained Subsidiaries ”  means any Subsidiary of Seller Parent, other than the Conveyed Subsidiaries and theirSubsidiaries.
“ 
Review Period ” has the meaning set forth in  Section 2.9(b)  . “ 
Safety Data Exchange Agreement ” has the meaning set forth in  Section 6.14(a)  . “ 
Sale ” has the meaning set forth in Section 2.6  . “ 
Sample Closing Statement ”  means the calculation set forth on Annex  B-2 ,  in a manner consistent with theAccounting Principle
s, for illustrative purposes only, of the Business Working Capital and the Business Net Cash, in each case, as ofDecember
 31, 2017, including the line items to be included as assets and liabilities in the calculation of the Business WorkingCapital.
“ 
Sample Purchaser Closing Statement ”  means the calculation set forth on Annex  B-4 ,  in a manner consistent withthe Purchaser Accounting
 Principles, for illustrative purposes only, of the Purchaser Working Capital and the Purchaser Net Cash, ineach case, as of December 31, 2017, including the line items to be included as assets and liabilities in the calculation of the Purchaser
Working Capital.
“ 
Securities Act ”  means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgatedthereunder.
“ 
Seller Account ”  means the bank account or accounts specified by Seller Parent in writing to the other Parties atleast two (2) Business Days before the Closing Date.
“ 
Seller Accrued Income Taxes ”  means an amount (not less than zero) equal to the aggregate current Income Taxliabilities
 of the Conveyed Subsidiaries and their Subsidiaries (which shall not be less than zero in any jurisdiction) for all taxableperiods
 (or portions thereof) ending on or before the Closing Date for which final Tax Returns have not been filed. The calculationof
 Seller Accrued Income Taxes shall (i) exclude any deferred Tax liabilities or deferred Tax assets and any amounts in respect ofspeculative
 or contingent liabilities for Tax, (ii) include estimated (or other prepaid) Income Tax payments only to the extent thatsuch
 payments have the effect of reducing (not below zero) the particular current Income Tax liability in respect of which suchpayments
 were made, (iii) include Income Tax deductions or Tax refunds (including for overpayments of estimated Taxes), in eachcase,
 only to the extent such deductions or Tax refunds have the effect of reducing (not below zero) a particular current Income Taxliability
 to which they are relevant,  (iv) be prepared  in accordance  with the past practice  (including  reporting  positions  andaccounting
 methods) of the applicable Conveyed Subsidiary or its applicable Subsidiary in preparing Tax Returns for Income Taxesand (v) in the case of a Straddle Period, be determined in accordance with 
Section 6.5(d)(iii)  . “ 
Seller Cash Incentive Plan ” has the meaning set forth in  Section 6.6(c)(v)  . “ 
Seller Closing Bonus ” has the meaning set forth in  Section 6.6(c)(v)  . “ 
Seller Combined Tax Returns ” has the meaning set forth in  Section 6.5(a)(i)  . 33

“ Seller Current Representation ” has the meaning set forth in  Section 10.17(a)  . “ 
Seller DC Plans (non-U.S.) ” has the meaning set forth in  Section 6.6(g)(i)  . “ 
Seller DC Plans (U.S.) ” has the meaning set forth in  Section 6.6(f)(i)  . “ 
Seller Designated Person ” has the meaning set forth in  Section 10.17(a)  . “ 
Seller Disclosure Letter ”  means the disclosure letter that Seller Parent has delivered to Purchaser as of the date ofthis Agreement.
“ 
Seller Facilities ” has the meaning set forth in  Section 4.14(d)  . “ 
Seller FSA Plan ” has the meaning set forth in  Section 6.6(i)  . “ 
Seller Group Plan ”  means any employee benefit plan as defined in Section 3(3) of ERISA and any other materialwritten
 fringe benefit, incentive, bonus, employment, retention, change in control, termination or severance plan, program, fund,agreement
 or arrangement, whether or not subject to ERISA, maintained (or contributed to or required to be contributed to) by anySeller
 or any Conveyed Subsidiary (or Subsidiary thereof), or any of their respective Affiliates, in which any Business Employee(U.S.) or Former Business Employee (U.S.) participates or is a party.
“ 
Seller Indemnifiable Tax Return ” has the meaning set forth in  Section 6.5(a)(ii)  . “ 
Seller Indemnified Taxes ” has the meaning set forth in  Section 6.5(d)(i)  . “ 
Seller Internal Restructurings ” has the meaning set forth in  Section 6.5(f)(i)  . “ 
Seller LTD Plan ” has the meaning set forth in  Section 6.6(b)(iv)  . “ 
Seller Parent ” has the meaning set forth in the preamble of this Agreement. “ 
Seller Parent Equity Awards ” has the meaning set forth in  Section 6.6(c)(vi)  . “ 
Seller Parent Final Plan ” has the meaning set forth in  Section 6.5(f)(iii)  . “ 
Seller Parent Guarantees ”  means all obligations of Seller Parent or any of the Retained Subsidiaries under anyContract,
 instrument or other commitment, obligation or arrangement (other than Seller Parent LCs) or other obligation in existenceas
 of the Closing Date to the extent related to the Business for which Seller Parent or any of the Retained Subsidiaries is or may beliable,
 as guarantor, indemnitor, original tenant, primary obligor, Person required to provide financial support or collateral in anyform whatsoever, or otherwise (including by reason of performance guarantees).
“ 
Seller Parent Indemnified Parties ” has the meaning set forth in  Section 7.1(b)  . “ 
Seller Parent LCs ”  means all letters of credit issued by or for the account of Seller Parent or the Retained
Subsidiaries on behalf of or in favor of any Conveyed Subsidiary, any of34

their Subsidiaries or the Business, and all obligations (including reimbursement obligations) of Seller Parent or the RetainedSubsidiaries in respect of the foregoing.
“ 
Seller  Parent  Related  Party  Contract ”  means  any  Contract  between  a  Conveyed  Subsidiary  or  any  of  theirSubsidiaries,
 on  the  one  hand,  and  Seller  Parent  or  its  Subsidiaries  (other  than  the  Conveyed  Subsidiaries  or  any  of  theirSubsidiaries), on the other hand.
“ 
Seller Pension Plans ” has the meaning set forth in  Section 6.6(e)(i)  . “ 
Seller Privileged Communications ” has the meaning set forth in  Section 10.17(c)  . “ 
Seller Retained Plan ”  means each Seller Group Plan and Foreign Seller Group Plan that is not a ConveyedSubsidiary Plan.
“ 
Seller Retained Severance Liabilities ” has the meaning set forth in  Section 6.6(c)(ii)  . “ 
Seller Retention Awards ” has the meaning set forth in  Section 6.6(j)  . “ 
Seller Retiree Medical Plans ” has the meaning set forth in  Section 6.6(h)  . “ 
Seller Tax Act ” has the meaning set forth in  Section 6.5(d)(ii)  . “ 
Seller Transaction Expenses ”  means any outside counsel, investment banking, accounting, financial advisory andother advisory
 costs, fees and expenses incurred by Seller Parent or any of its Subsidiaries (including the Conveyed Subsidiaries andany
 of their Subsidiaries) at or prior to the Closing specifically in connection with the Strategic Process conducted by Seller Parentor
 the negotiation, execution and performance of this Agreement and the consummation of the transactions contemplated by thisAgreement,
 including the Seller Internal Restructurings, other than costs, fees and expenses for which Purchaser or its Affiliatesexpressly
 has responsibility (including pursuant to payment, reimbursement, indemnification or other similar obligations set forthherein) pursuant to the terms of this Agreement.
“ 
Sellers ” means (i) Seller Parent and (ii) all of the Subsidiaries of Seller Parent that, as of immediately prior to theClosing, own any Purchased Assets.
“ 
Shared Contract ”  means any Contract, sales order, purchase order, instrument or other commitment, obligation orarrangement
 entered into prior to the date hereof (or entered into prior to the Closing in accordance with this Agreement) that isbetween
 Seller Parent or any of its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries), on the one hand, andone
 or more third parties, on the other hand, that inures to the benefit or burden of both the Business and any Retained Business,other than any enterprise-wide Contracts,
 Contracts with respect to Off-the-Shelf Software, Seller Group Plans, Foreign Seller GroupPlans,
 Collective Bargaining Agreements and any agreement or grant with any Taxing Authority; provided  that  any such Contractthat
 provides only de
minimis
 assets  or services to the Business or the Retained Businesses, as the case may be, shall not be deemedto be a Shared Contract for purposes hereof.
35

“ Shared Contractual Liabilities ” means Liabilities in respect of Shared Contracts. “ 
Shares ” has the meaning set forth in Section 2.1(a)  . “ 
Software ”  means  (a)  computer  programs,  including  software  implementation  of  algorithms,  models  andmethodologies,
 whether in source code, object code, human readable form or other form, (b) user interfaces, report formats,firmware,
 development tools, templates, menus, buttons and icons and (c) documentation, user manuals, and training manualsdocumenting the functionality or use of any of the foregoing.
“ 
Specified Records ” has the meaning set forth in  Section 2.1(j)  . “ 
Straddle Period ” has the meaning set forth in  Section 6.5(a)(ii)  . “ 
Straddle Period Tax Returns ” has the meaning set forth in  Section 6.5(a)(ii)  . “ 
Strategic Process ”  means all matters, whether occurring before or after the date of this Agreement, relating to thereview
 of strategic alternatives with respect to the Business, including the potential sale or other separation of the Business, and allactivities
 in connection therewith, including matters relating to (a) the solicitation of proposals from and negotiations with thirdparties
 in connection with the potential sale of the Business or (b) the drafting, negotiation or interpretation of any of the provisionsof
 this Agreement or the Ancillary Agreements, or the determination of the allocation of any assets or Liabilities pursuant to theforegoing agreements or the transactions contemplated thereby.
“ 
Subsequent Loss ” has the meaning set forth in  Section 6.5(b)  . “ 
Subsidiary ” means an entity as to which Seller Parent, Purchaser Parent or Purchaser or any other relevant entity, as the
 case may be, owns as of the date of determination, directly or indirectly, more than fifty percent (50%) of the voting power orother
 similar interests. Any Person which comes within this definition as of the date of this Agreement but thereafter fails to meetsuch
 definition shall from and after such time not be deemed to be a Subsidiary of Seller Parent, Purchaser Parent or Purchaser orany
 other relevant entity, as the case may be. Similarly, any Person which does not come within such definition as of the date of thisAgreement
 but which thereafter meets such definition shall from and after such time be deemed to be a Subsidiary of Seller Parent,Purchaser Parent or Purchaser or any other relevant entity, as the case may be.
“ 
Target Business Net Cash ” means [***]. “ 
Target Business Working Capital ” means [***]. “ 
Target Purchaser Net Cash ” means [***]. “ 
Target Purchaser Working Capital ” means [***]. Note:
 Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portionshave been omitted from this filing and have been filed separately with the SEC.
36

“ Tax Asset ”  means any Tax Item that could reduce a Tax otherwise payable, including a net operating loss, netcapital loss,
 general business credit, foreign Tax credit, investment credit, research or experimentation credit, charitable deduction orcredit related to alternative minimum Tax or other Tax credit.
“ 
Tax Benefit ”  means the Tax effect of any Tax Item that decreases Taxes paid or payable, including any interestwith
 respect thereto or interest that would have been payable but for such item. For purposes of determining the amount and timingof
 any Tax Benefit, the recipient of the Tax Benefit shall be deemed to realize or utilize any Tax Benefit as and when such recipientactually receives
 such Tax Benefit in the form of a reduction in the amount of Taxes that would otherwise be payable, including as acredit
 against estimated Taxes, or actually receives such Tax Benefit in the form of a cash refund, with the amount of such TaxBenefit
 being determined on a “with and without” basis taking the Tax Item into account by treating it as the last item available incomputing
 taxable income and as having been used after any other Tax attribute, and such Tax Benefit shall be determined net ofany
 Tax detriments (including reduction of Tax basis of any asset) attributable to any Loss generating the Tax Item giving rise tosuch Tax Benefit.
“ 
Tax Claim ” has the meaning set forth in  Section 6.5(e)(i)  . “ 
Tax Item ”  means any item of income, gain, loss, deduction, credit, recapture of credit or any other item thatincreases
 or decreases Taxes paid or payable, including an adjustment under Section 481 of the Code (or any similar provision ofstate, local or foreign Law) resulting from a change in accounting method.
“ 
Tax Proceeding ”  means any audit, inquiry, examination, contest, litigation or other Action by, with, or against anyTaxing Authority.
“ 
Tax Return ”  means any return, report, declaration, information return, statement or other document filed orrequired
 to be filed with any Taxing Authority (including any schedule or attachment thereto and any amendment thereof), inconnection with the determination, assessment or collection of any Tax or the administration of any Laws relating to any Tax.
“ 
Taxes ” means all taxes, charges, duties, imposts, fees, levies and other assessments of any kind whatsoever,whether
 or not disputed, including income, alternative or add-on minimum, gross receipts, estimated, capital stock, excise, real orpersonal
 property, sales or use, value added, goods and services, registration, windfall, profits, excess profits, documentary, ad valorem
,  intangibles,  license,  withholding  (with  respect  to  compensation  or  otherwise),  payroll,  employment,  workers’compensation,
 unemployment  compensation,  premium,  occupancy,  disability,  net  worth,  capital  gains,  transfer,  stamp,  socialsecurity,
 environmental, occupation and franchise taxes, imposed by any Governmental Authority, and including any interest,penalties and additions attributable thereto.
“ 
Taxing Authority ”  means any Governmental Authority responsible for the imposition, regulation, collection oradministration of any Taxes.
“ 
Termination Expenses ” has the meaning set forth in  Section 6.6(c)(ii)  . 37

“ Third Party Claim ” has the meaning set forth in  Section 7.3(a)  . “ 
Trademarks ” has the meaning set forth in the definition of “Intellectual Property.” “ 
Transfer of Undertakings Laws ”  means (a) the Council of the European Union Directive 2001/23/EC of March 21,2001
 on the approximation of the Laws of the member states of the European Union relating to the safeguarding of employees’rights
 in the event of transfers of undertakings,  businesses or parts of undertakings  or businesses and/or local implementinglegislation
 both as amended from time to time or (b) any similar or equivalent Laws applicable in jurisdictions outside of theEuropean Union providing for an automatic transfer of employment or employer substation.
“ 
Transfer Taxes ”  means any federal, state, county, local, foreign and other sales, bulk sales, use, transfer, realproperty
 transfer, excise, license, privilege, gross receipts, conveyance, documentary transfer, stamp, land, customs, recording,registration
 or other similar Tax (including any notarial fee), but excluding any VAT, imposed in connection with, or otherwiserelating
 to, the transactions contemplated by this Agreement or the recording of any sale, transfer, conveyance or assignment ofproperty (or any interest therein) effected pursuant to or contemplated by this Agreement.
“ 
Transferred Employee (non-U.S.) ” has the meaning set forth in  Section 6.6(b)(v)  . “ 
Transferred Employee (U.S.) ” has the meaning set forth in  Section 6.6(b)(v)  . “ 
Transferred Employees ” has the meaning set forth in  Section 6.6(b)(v)  . “ 
Transferred FSA Balances ” has the meaning set forth in  Section 6.6(i)  . “ 
Transferred Pension Plan Employees ” has the meaning set forth in  Section 6.6(e)(i)  . “ 
Transition Plan ” has the meaning set forth in  Section 6.4(c)  . “ 
Transition Services Agreement ” has the meaning set forth in  Section 6.14(a)  . “ 
Transition Team ” has the meaning set forth in  Section 6.4(b)  . “ 
Transitional Trademark License Agreement ” has the meaning set forth in  Section 6.14(a)  . “ 
Treasury Regulations ” means the United States Treasury regulations promulgated under the Code. “ 
TUL Employee ” has the meaning set forth in  Section 6.6(b)(ii)  . “ 
UKLA ” means the United Kingdom Listing Authority.38

“ United States ” means the United States of America, including its territories and possessions. “ 
VAT ” means goods and services Tax, value added Tax and other similar transactional indirect Taxes (but excludingtransfer Tax, stamp duty and other similar Taxes).
“ 
WARN ” means the Worker Adjustment and Retraining Notification Act of 1988, as amended or any similar Law.Section
 1.2       Interpretation .  The words “hereof,” “herein,” “hereto” and “hereunder” and words of similar importrefer
 to this Agreement as a whole, including all Annexes, Exhibits and Schedules, and not to any particular provision of thisAgreement
 and the words “date hereof” refer to the date of this Agreement. The terms defined in the singular have a comparablemeaning
 when used in the plural, and vice versa. The terms “dollars” and “$” mean U.S. dollars. Wherever the words “include,”“includes” or
 “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” Unlessotherwise
 specifically provided for herein, the term “or” shall not be deemed to be exclusive. When a reference is made in thisAgreement
 to an Article, a Section, an Annex, an Exhibit or a Schedule, such reference shall be to an Article or a Section of, or anAnnex, an
 Exhibit or a Schedule to, this Agreement unless otherwise indicated. Any Law defined or referred to in this Agreement orin
 any agreement or instrument that is referred to herein means such Law as from time to time amended, modified or supplemented,including
 (in the case of statutes) by succession of comparable successor Laws and the related regulations thereunder and publishedinterpretations
 thereof; provided  that,  for purposes of any representations and warranties contained in this Agreement that are madeas
 of a specific date or dates, references to any Law shall be deemed to refer to such Law, as amended, and the related regulationsthereunder
 and published interpretations thereof, in each case, as of such date. Any reference to “writing” or comparable expressionsincludes
 a  reference  to  facsimile  transmission,  e-mail  or  comparable  means  of  communication.  Where  used  with  respect  toinformation,
 the phrases “delivered” or “made available” means that the information referred to has been physically or electronicallydelivered
 to the relevant parties or their respective Representatives, including material that has been posted in the “data room”(virtual or
 otherwise) established by a Party two (2) Business Days prior  to the date hereof (or the Closing Date, but only in the caseof
 information required to be delivered or made available under this Agreement prior to the Closing Date) .  The term “disclosed,”when
 used in reference to information disclosed to Purchaser Parent or Purchaser, shall be understood to include (but not be limitedto) all disclosures contained in the Seller
 Disclosure Letter and all written information as shared over e-mail or otherwise included inSeller Parent’s virtual data room made available to Purchaser Parent or its Affiliates or Representatives (including in any confidential
information
 memorandum) two (2) Business Days prior  to the date hereof (or the Closing Date, but only in the case of informationrequired
 to be disclosed under this Agreement prior to the Closing Date), and when used in reference to information disclosed toSeller
 Parent, shall  be understood to include (but not be limited to) all disclosures contained in the Purchaser Parent DisclosureLetter and all written information as shared over e-mail or otherwis
e included in Purchaser Parent’s virtual data room made availableto
 Seller Parent or its Affiliates or Representatives (including in any confidential information memorandum) two (2) Business Daysprior to the date hereof (or the Closing Date, but only in the case of information required to be
39

disclosed under this Agreement prior to the Closing Date) .  Reference to “day” or “days” are to calendar days. When calculating theperiod
 of time before which, within which or following which any act is to be done or step taken (or not taken) pursuant to thisAgreement, the date
 that is the reference date in calculating such period shall be excluded, except that if the last day of such period isa
 non-Business Day, the period in question shall end on the next succeeding Business Day. Amounts used in any calculations forpurposes
 of this Agreement, the Ancillary Agreements or any other document delivered in connection herewith may be eitherpositive
 or negative, it being understood that the addition of a negative number shall mean the subtraction of the absolute value ofsuch
 negative number and the subtraction of a negative number shall mean the addition of the absolute value of such negativenumber.
ARTICLE II
PURCHASE AND SALE
Section
 2.1       Purchase and Sale of Purchased Assets .  Upon the terms and subject to the conditions set forth in thisAgreement,
 at the Closing, Seller Parent shall, and shall cause the other Sellers to, sell, convey, assign and transfer to Purchaser orthe
 applicable Purchaser Designated Affiliates, and Purchaser shall or shall cause the applicable Purchaser Designated Affiliates topurchase,
 acquire and accept, all of Seller Parent’s and its Subsidiaries’ right, title and interest, free and clear of all Liens other thanPermitted Liens, as at the Closing in the following (collectively, the “ 
Purchased Assets  ”): (a) 
     the equity interests in the Conveyed Subsidiaries (collectively, the “ Shares  ”);(b) 
     the real property that is set forth in Section  2.1(b) of  the Seller Disclosure Letter (collectively, the “ Owned Real Property 
”)  and the Facilities (including the related improvements and fixtures), and all easements and other rights and interestsappurtenant thereto;
(c) 
     the real property leases, subleases, licenses and occupancy arrangements that are set forth in Section  2.1(c) of the Seller Disclosure Letter (collectively, the “ 
Real Property Leases  ” and the real property related to such Real Property Lease s, the“ 
Leased Real Property ”), including the  right to all security deposits and other amounts and instruments deposited by or on behalf ofthe Sellers thereunder;
(d) 
     (i) other than Information Systems (which are the subject of clauses (ii) and (iii)), the owned and leasedfurniture,
 equipment, fixtures, machinery, supplies, spare parts, tools, tangible personal property and other tangible property (A) thatis Related to the Business and
 located at a Facility, except as set forth on Section 2.3(a)(xx)  of the Seller Disclosure Letter, or (B) set forth
 on Section 2.1(d)(i)(B) of  the Seller Disclosure Letter, (ii) personal computers and vehicles primarily used by the TransferredEmployees in
 respect of the Business (the assets described in the foregoing clauses (i)  and  (ii) , collectively, the “ Equipment  ”), (iii) Business IT Systems, and (iv) any leases relating to such Equipment or Business IT Systems (the “ 
Equipment Leases  ”); (e) 
     Contracts, sales orders, purchase orders, instruments and other commitments, obligations and arrangements (i)to which Seller Parent or any of its Subsidiaries is a party and that
40

are related solely to the Business, a Purchased Asset or an Assumed Liability, or (ii) that constitute a Shared Contract, but only theportion of such Shared Contract related to the Business (collectively, the “ 
Assumed Contracts  ”); (f) 
     all Inventory and samples of any Product;(g) 
     all Business IP, including the right to sue and recover and retain damages for past, present and futureinfringement or
 misappropriation of or other violation of any Business IP and all corresponding rights that, now or hereafter, may besecured throughout the world with respect to any Business IP, but for clarity excluding all Retained Names;
(h) 
     all Registration Information (including in relation to pending applications for Product Registrations andManufacturing Registrations) Related to the Business;
(i) 
     all  Governmental  Authorizations,  including  Product  Registrations,  Manufacturing  Registrations  andEnvironmental Permits, that are owned, used or licensed (subject to the terms of such licenses) and Related to the Business;
(j) 
     without duplication, (A) all Records Relating to the Business (including any applicable attorney-client privilege,attorney
 work product protection and expectation of client privilege attaching to any such Record), other than the Records set forthon 
Section 2.1(j) of  the Seller Disclosure Letter (the “ Specified  Records ”);  provided that  the Sellers and their Affiliates may retainone (1) copy of each of the foregoing pursuant to 
Section 6.8  and remove or  redact the names of any customers or vendors from suchlists
 to the extent such customers or vendors relate solely to the Retained Businesses, (B) copies of (x) the portions of all Recordsthat
 relate to, but do not primarily relate to, the Business and (y) the Specified Records, and (C) the corporate books and records(including
 Tax Returns other than any Seller Combined Tax Returns) of the Conveyed Subsidiaries and their Subsidiaries to theextent
 related to the Business; provided  ,  further , that in each case of clauses (A)-(C), Seller Parent may redact or remove anyinformation not related to the Business;
(k) 
     all accounts receivable and all other assets, in each case included in the calculation of Final Business WorkingCapital, and all Cash Equivalents included in the calculation of Final Business Net Cash;
(l) 
     the goodwill Relating to the Business, together with the right to represent to third parties that Purchaser is thesuccessor to the Business;
(m) 
     all claims, defenses, causes of action, counterclaims and rights of set-off against third parties (at any time or inany
 manner arising or existing, whether choate or inchoate, known or unknown, contingent or non-contingent) relating primarily tothe Business, a Purchased Asset or an Assumed Liability;
(n) 
     all credits, prepaid expenses, rebates, deferred charges, advance payments, security deposits and other depositsor amounts held as surety by third Persons and prepaid items,
41

in each case Related to the Business or primarily related to a Purchased Asset or an Assumed Liability and included in thecalculation of Final Business Working Capital or Final Business Net Cash;
(o) 
     the amount of any insurance proceeds, recoveries or refunds (net of any reasonable costs of investigating andpursuing
 the underlying claim and of collection and any Taxes imposed in respect thereof) received by Seller Parent or any of itsAffiliates
 under the Insurance Policies after the date hereof in respect of any Loss prior to the Closing in respect of any PurchasedAsset
 or Assumed Liability to the extent Purchaser does not otherwise receive the benefit thereof (including through application ofsuch
 proceeds) and except to the extent the related Liabilities are included in the calculation of Final Business Working Capital orFinal Business Net Cash;
(p) 
     the assets of all Conveyed Subsidiary Plans and the assets transferred to Purchaser and the PurchaserDesignated Affiliates pursuant to 
Section 6.6  ; (q) 
     the assets set forth in Section 2.1(q)  of the Seller Disclosure Letter; (r) 
     to the extent legally transferable, all third-party warranties, indemnities, further assurance and other similarcovenants, and guarantees to the extent
 relating to any of the Equipment, Inventory, other Purchased Assets and Assumed Liabilities;and
(s) 
     any other assets,  properties or rights in each case Relating to the Business, other than those assets specificallyidentified as Excluded Assets in 
clauses (i)  through  (xx) of Section 2.3(a) . Notwithstanding
 anything else herein to the contrary, (i) any assets, properties or rights of any Conveyed Subsidiary (or Subsidiarythereof)
 that constitute Purchased Assets hereunder shall be deemed Purchased Assets for all purposes of this Agreement (includingArticle
 VII ),  except to the extent any such asset, property or right otherwise would be an Excluded Asset had it not been an asset,property
 or right of such Conveyed Subsidiary or Subsidiary (and instead an asset, right, or property of Seller Parent or any of itsAffiliates
 (other than a Conveyed Subsidiary (or a Subsidiary thereof))) (a “ Conveyed  Subsidiary Excluded Asset ”),  (ii) anyConveyed Subsidiary
 Excluded Asset shall be deemed an Excluded Asset for all purposes of this Agreement (including Article VII  ) and
 Seller Parent shall use commercially reasonable efforts to transfer such Conveyed Subsidiary Excluded Asset, subject toobtaining
 required consents and Approvals, out of the relevant Conveyed Subsidiary (or Subsidiary thereof) on or prior to theClosing,
 or thereafter in accordance with Section  6.22 ,  and (iii) any Liability of any Conveyed Subsidiary (or Subsidiary thereof)that
 otherwise would be a Retained Liability had it not been a Liability of such Conveyed Subsidiary or Subsidiary (and instead aLiability
 of Seller Parent or any of its Affiliates (other than a Conveyed Subsidiary (or a Subsidiary thereof))) shall be deemed aRetained
 Liability for all purposes of this Agreement (including Article  VII )  and Seller Parent shall use commercially reasonableefforts
 to transfer such Retained Liability, subject to obtaining required consents and Approvals, out of such Conveyed Subsidiary(or
 Subsidiary thereof) on or prior to the Closing, or thereafter in compliance with Section  6.22 .  The transfer of assets, propertiesand
 rights of any Conveyed Subsidiaries (or any Subsidiary thereof) deemed a Purchased Asset shall be effected solely by virtue ofthe
 transfer of the Sellers’ right, title and interest in the Shares and not through the direct transfer of such assets, properties or rights,and Seller Parent and its Subsidiaries shall not be required to transfer any such
42

assets, properties or rights of the Conveyed Subsidiaries and their Subsidiaries other than through the transfer of the Sellers’ right,title and interest in the Shares.
Section 2.2 
      Consents; Shared Contracts . (a) 
     Notwithstanding any other provision of this Agreement, neither this Agreement nor any Ancillary Agreementshall
 constitute an agreement to, directly or indirectly, sell, convey, assign, transfer or deliver any interest in any Purchased Asset(other than
 the Shares) or any right or benefit arising thereunder or resulting therefrom if such sale, conveyance, assignment, transferor
 delivery, or the purchase or assumption thereof by Purchaser or the applicable Purchaser Designated Affiliates, without theconsent
 or Approval of any Person(s) (including consents or Approvals of any Governmental Authorities), or otherwise, (i) wouldconstitute
 a breach or other contravention of the rights of such Person(s), (ii) would be ineffective under, or contravene, applicableLaw
 or (iii) would result in the termination, cancellation or acceleration of any material right or obligation of, or result in the loss ofany
 material benefit of, or otherwise adversely affect in any material respect the contractual rights of, the Sellers or any of theirAffiliates,
 or upon transfer, Purchaser or the applicable Purchaser Designated Affiliates; provided  ,  however ,  that the Parties shalltreat
 Purchaser or the applicable Purchaser Designated Affiliate, as the case may be, as the owner of any such Purchased Asset (andof (x)
 any portion of any Shared Contract that relates to and is allocated to the Business and the benefits and burdens of which are tobe
 transferred to Purchaser or a Purchaser Designated Affiliate, as the case may be, pursuant to Section  2.2(d) and  (y) any DelayedBusiness) to
 the fullest extent permitted by applicable Law for all purposes as of the Closing Date. Without limiting the foregoing, ifany
 direct or indirect sale, conveyance, assignment, transfer or delivery, or any agreement to do the same, by the Sellers of, or anydirect
 or indirect purchase or assumption by Purchaser or any Purchaser Designated Affiliate of, any interest in any Purchased Assetor
 any right or benefit arising thereunder or resulting therefrom, requires the consent or Approval of any Person(s) (includingconsents
 or Approvals of any Governmental Authorities), then such sale, conveyance, assignment, transfer, delivery, agreement,purchase
 or assumption shall be made subject to (and shall only be effective upon) such consent or Approval being obtained and theremainder of this Section.
(b) 
     Each of Seller Parent, Purchaser Parent and Purchaser shall, and shall cause its Affiliates to, use theirreasonable
 best efforts to obtain all consents or Approvals referred to in Section  2.2(a) (other  than from Governmental Authoritiesunder
 applicable Law, which are the subject of Section  6.3 and  Section 6.4 ,  and with respect to the Purchaser Parent ShareholderApproval,
 which is the subject of Section  6.24 ),  including by executing, acknowledging and delivering such assignments, transfers,consents,
 assumptions, and other agreements, documents and instruments and taking such other actions as may reasonably berequested
 by the other Party in order to carry out the intent of this Agreement and any Ancillary Agreements and in order to conveyand
 transfer to, and vest in, Purchaser and the applicable Purchaser Designated Affiliates, the Sellers’ right, title and interest in thePurchased
 Assets and to effectuate the assumption by Purchaser of the Assumed Liabilities, as contemplated by this Agreement, theLocal
 Implementing Agreements and the transactions contemplated hereby and thereby; provided  that  except as otherwise expresslyprovided
 by this Agreement or any Ancillary Agreement, none of Seller Parent, Purchaser Parent or Purchaser or any of theirrespective Affiliates shall be required to expend any money or
43

commence any litigation, or offer or grant any accommodation (financial or otherwise) to obtain any such consent or Approval.Purchaser
 Parent and Purchaser agree to provide such reasonable security and assurances as to financial capability, resources andcreditworthiness
 as may be reasonably requested by any Person(s) whose consent or Approval is sought in connection with thetransactions
 contemplated hereby. If any consent or Approval referred to in Section  2.2(a) is  not obtained prior to the Closing,subject
 to Article  VIII ,  the Closing shall nonetheless take place, and (i) for a period of up to twenty-four (24) months following theClosing Date or until such earlier time as
 such consent or Approval is obtained, in the case of consents or Approvals other than thoserequired
 from Governmental Authorities under applicable Law, and (ii) until (A) the earliest to occur of (x) thirty-six (36) monthsfollowing
 the Closing Date, (y) the completion of a Listing Transaction (as defined in the Purchaser Shareholders Agreement) or (z)such
 time as such consent or Approval is obtained, in the case of consents or Approvals from Governmental Authorities underapplicable
 Law other than Antitrust Laws or (B) the Delayed Business Cut-Off Date, in the case of any Delayed Business subject toa
 Delayed Antitrust Approval, Seller Parent shall use reasonable best efforts to continue to perform its obligations under and complywith
 the terms of any Purchased Asset, as applicable, upon the direction of Purchaser, in all material respects in the ordinary courseof
 business, and the Parties shall (and shall cause their Affiliates to) use reasonable best efforts to, at no cost to the Sellers or theirAffiliates,
 (x) in the case of consents or Approvals other than those required from Governmental Authorities under applicable Law(which are the subject of 
Section 6.3  and  Section 6.4) , obtain  such consents or Approvals, subject to and in accordance with the firstsentence
 of this Section  2.2(b) and  (y) obtain or structure an arrangement for Purchaser or such Purchaser Designated Affiliates toreceive
 (or for the Sellers and their Affiliates to enforce for the benefit of Purchaser or such Purchaser Designated Affiliates),whether
 by license, sub-license, sub-assignment, or by other means, the economic and operational claims, rights and benefits ofownership
 of such Purchased Assets (including any Delayed Business), including the net profits from the operation or subsequentsale
 of such Purchased Assets (including any Delayed Business), and including the right to manage and control such PurchasedAssets
 and direct the exercise of voting rights associated with any Purchased Assets that are Shares or, if such arrangement is notmade, to agree
 to such other good faith equitable result; provided  that the  Sellers and their Affiliates shall not be required to take anyaction that
 would, in the good-faith reasonable judgment of the Sellers, constitute a breach or other contravention of the rights of anyPerson(s),
 be ineffective under, or contravene, applicable Law (but only to the extent enforceable against Seller Parent or any of itsAffiliates)
 or result in the termination, cancellation or acceleration of any material right or obligation of, or result in the loss of anymaterial
 benefit of, or otherwise adversely affect in any material respect the contractual rights of, the Sellers or any of theirAffiliates.
 To the extent Seller Parent is not permitted under applicable Law to obtain or structure an arrangement for Purchaser orsuch
 Purchaser Designated Affiliates to receive (or for the Sellers and their Affiliates to enforce for the benefit of Purchaser or suchPurchaser
 Designated Affiliates) the economic and operational claims, rights and benefits of ownership of such Purchased Assets(including
 any Delayed Business), Seller Parent shall use reasonable best efforts to segregate any net profits associated with theownership
 of such Purchased Assets (including any Delayed Business) in an account for Purchaser’s benefit, such funds to bereleased
 as promptly as practicable once permitted under applicable Law. Purchaser shall indemnify and hold harmless the Sellersand
 the Seller Parent Indemnified Parties for and against all burdens (including losses from the operation or subsequent sale of suchPurchased Assets (including any Delayed Business)) and Liabilities arising out of or relating to each such arrangement
44

or the ownership of the underlying Purchased Asset (including any Delayed Business), and any risk of loss or damage to suchPurchased Asset (including any Delayed Business), and
 shall be responsible for all Assumed Liabilities related thereto in accordancewith
 this Agreement (without limiting any express indemnification obligations of Seller Parent set forth in Section  7.1 ).  Withoutlimiting 
Section 6.3(f) ,  upon obtaining the requisite consents and Approvals following the Closing, any such Purchased Asset shallbe
 transferred  and  assigned  to,  and  accepted  and  assumed  by,  Purchaser  and  the  applicable  Purchaser  Designated  Affiliateshereunder.
 The obligations of the Parties pursuant to Section  6.3 shall  be in addition to this Section  2.2(b) ,  and in the event of anyconflict
 between this Section  2.2(b) and  Section 6.3 ,  Section 6.3 shall  control. Without limiting Section  2.2(a) or  Section 6.3(f)(i) , notwithstanding
 the fact that any applicable consent or Approval referred to in Section  2.2(a) is  not obtained prior to the Closing(including any consent or Approval required to
 transfer an interest in a Purchased Asset to which an Assumed Liability relates), eachof the assets, properties and rights described in 
Section 2.1  shall be deemed to be Purchased Assets under this Agreement and each of the Liabilities described in 
Section 2.4  shall be deemed to be Assumed Liabilities under this Agreement. (c) 
     Purchaser Parent and Purchaser acknowledge that certain consents or Approvals of or related to the transactionscontemplated
 by this Agreement may be required from certain Persons (including Governmental Authorities) with respect to thePurchased
 Assets, and the sale, conveyance, assignment, transfer, delivery, purchase or assumption of any interest therein, and thatsuch
 consents and Approvals may not be obtained. Notwithstanding anything to the contrary set forth in this Agreement, PurchaserParent and Purchaser agree that the Sellers and
 their Affiliates shall not have any Liability whatsoever arising out of or relating to thefailure
 to obtain any consents or Approvals that may have been or may be required in connection with or related to the transactionscontemplated
 by this Agreement or because of any default under, or acceleration or termination of or loss of any benefit under, anyReal
 Property Lease, Equipment Lease, Contract, sales order, purchase order, instrument or other commitment, obligation orarrangement,
 Product Registration, Manufacturing Registration, Environmental Permit, Governmental Authorization or any claim,right
 or benefit arising under or from any Purchased Asset, as a result thereof, except in the case of a breach by Seller Parent of itsexpress
 covenants,  agreements,  obligations,  representations  or  warranties  set  forth  in  this  Agreement  related  thereto.Notwithstanding
 anything to the contrary set forth in this Agreement, Purchaser Parent and Purchaser expressly acknowledge andagree
 that (other than the conditions expressly set forth in Sections  8.1(a) and  8.1(b) ) in no event shall the receipt of any suchconsents
 and Approvals be a condition to the obligations of Purchaser Parent or Purchaser to consummate the Sale and the othertransactions
 contemplated  by  this  Agreement,  and  Purchaser  Parent  and  Purchaser  reaffirm  their  respective  obligations  toconsummate
 the Sale and the other transactions contemplated by this Agreement subject only to the express conditions set forth inSections 8.1 
and  8.2 , irrespective and independent of whether any such consents or Approvals are obtained.(d) 
     Except as otherwise agreed by Seller Parent and Purchaser Parent or as otherwise provided in this Agreement oran
 Ancillary Agreement, and except with respect to any Shared Contracts that relate to services to be provided under the TransitionServices
 Agreement, and without limiting the other provisions of this Section  2.2 ,  to the extent reasonably requested by Purchaser(i) Seller Parent, Purchaser Parent and Purchaser shall, and shall cause their respective
45

Affiliates to, reasonably cooperate and use their reasonable best efforts (at Purchaser’s cost) to obtain the consent and agreement ofthe
 third party that is a counterparty to any Shared Contract to enter into a new Contract with Purchaser or the applicable PurchaserDesignated
 Affiliate (or a Conveyed Subsidiary or its Subsidiary) or to assign or transfer, to the extent assignable or transferableunder the
 terms of such Shared Contract, to Purchaser or the applicable Purchaser Designated Affiliate (or a Conveyed Subsidiary orits
 Subsidiary) the portion of such Shared Contract (and the rights, benefits, obligations and burdens thereunder) that relates to theBusiness, pursuant
 to which Purchaser or the applicable Purchaser Designated Affiliate (or a Conveyed Subsidiary or its Subsidiary)receives
 the rights and benefits, and bears the obligations and burdens, of such portion of any such Shared Contract that relates toand
 is allocated to the Business, as reasonably agreed by Seller Parent and Purchaser, in each case effective as of the Closing Date(each,
 a “ Replacement  Shared  Contract ”),  unless such Shared Contract relates to a Delayed Business, in which case effective as ofthe
 date of transfer of such Delayed Business to Purchaser or the applicable Purchaser Designated Affiliate; provided  that the failure to
 obtain such consent or agreement or such Replacement Shared Contract shall in no event be deemed a breach of this Agreementby
 Seller Parent or any of its Affiliates, except in the case of a breach by Seller Parent of its express covenants, agreements,obligations, representations or warranties set forth in this Agreement related thereto, and (ii) to the extent such a Replacement Shared
Contract
 is not obtained, until the earlier of twenty-four (24) months following the Closing Date and the expiration or terminationdate
 of the applicable Shared Contract (assuming, for these purposes, that the then-current term in effect as of immediately prior tothe
 Closing is not renewed or extended), the Parties shall (and shall cause their Affiliates to) use reasonable best efforts to, atPurchaser’s
 cost, obtain or structure an arrangement for Purchaser or the applicable Purchaser Designated Affiliates to receive therights
 and benefits, and bear the obligations and burdens, of such portion of any such Shared Contract that relates to and is allocatedto
 the Business, as reasonably agreed by Seller Parent and Purchaser; provided  that  in the case of each of clauses  (i) and  (ii) , theSellers,
 Purchaser Parent and Purchaser and their respective Affiliates shall not be required to take any action that would, in thegood-faith
 reasonable judgment of the Sellers or Purchaser, constitute a breach or other contravention of the rights of any Person(s),be
 ineffective under, or contravene, applicable Law or any such Shared Contract or result in the termination, cancellation oracceleration
 of any material right or obligation of, or result in the loss of any material benefit of, or otherwise adversely affect in anymaterial
 respect the contractual rights of, the Sellers, Purchaser or any of their respective Affiliates. Purchaser shall indemnify andhold
 harmless the Sellers and the Seller Parent Indemnified Parties for and against all burdens and Liabilities arising out of anyReplacement Shared Contr
act, each such arrangement referred to in this Section 2.2(d)  and the portion of any Shared Contract that  issubject
 to any such arrangement  (other than Shared Contractual  Liabilities  allocated to Seller Parent in accordance  with thefollowing
 sentence). With respect to Shared Contractual Liabilities pursuant to, under or relating to any Shared Contract, suchShared Contractual Liabi
lities shall be allocated between Seller Parent and Purchaser as follows: (i) if a Liability is incurred solely inrespect
 of the Business or the Retained Businesses, such Liability shall be allocated to Purchaser (in respect of the Business) orSeller
 Parent (in respect of the Retained Businesses); and (ii) if a Liability cannot be so allocated under clause  (i) ,  such Liabilityshall
 be allocated to Seller Parent or Purchaser, as the case may be, based on the relative proportion of total benefit received by theBusiness
 and the Retained Businesses under the relevant Shared Contract, as reasonably agreed by Seller Parent and Purchaser.Notwithstanding the foregoing, (A) each of Seller Parent and Purchaser shall be responsible for any or all Liabilities
46

arising from its (or its Affiliates’) direct or indirect breach of any Shared Contract and (B) Purchaser shall be solely responsible forany or all Liabilities arising out of or relating to any Replacement Shared Contract.
(e) 
     To the extent an asset or liability that comprises the business as reflected in the Financial Statements is not aPurchased
 Asset or an Assumed Liability, the Parties shall work together in good faith to determine whether, consistent with theterms of this Agreement, and if so how best to, transfer the benefit or detriment of such asset or liability to Purchaser.
Section 2.3 
      Excluded Assets . (a) 
     Notwithstanding any provision in this Agreement, Purchaser and the Purchaser Designated Affiliates are notpurchasing
 or acquiring any of Seller Parent’s or its Affiliates’ (including the Conveyed Subsidiaries’ or their Subsidiaries’) right,title or interest in any assets, properties or rights other than the Purchased Assets (the “ 
Excluded Assets  ”), including: (i) 
     all assets constituting ownership interests in, or that are used or held for use in, the Retained Businesses,other than those assets identified as Purchased Assets in 
clauses (a)  through  (s) of Section 2.1 ; (ii) 
     all Retained Real Property;(iii) 
     (A) the Retained Facilities, (A) any owned and leased furniture, equipment, fixtures, machinery,supplies, spare
 parts, tools, tangible personal property and other tangible property located at the Retained Facilities ornot
 Related to the Business, except as set forth on Section  2.1(d)(i)(B) of  the Seller Disclosure Letter, and anypersonal
 computers and vehicles that are not primarily used by the Transferred Employees in respect of the Business,(A)
 the Information Systems of Seller Parent and its Subsidiaries, other than the Business IT Systems and (A) anyleases relating to the assets described in the foregoing 
clauses (B)  through  (D) ;(iv) 
     all legal and beneficial interest in the share capital or equity interest of any Person other than theConveyed
 Subsidiaries (and their Subsidiaries), other than those equity interests set forth on Section  2.1(q) of  theSeller Disclosure Letter;
(v) 
     all Shared Contracts and all other Contracts, sales orders, purchase orders, instruments and othercommitments,
 obligations and arrangements to which Seller Parent or any of its Affiliates is a party or by which anyof its or their properties, assets or rights is subject, in each case other than Assumed Contracts;
(vi) 
     all inventory (including all raw material inventory, work-in-process inventory, spare parts inventoryand finished products inventory) other than the Inventory and any samples of Products;
(vii) 
     the Retained Names and all other Intellectual Property that is not Business IP, including suchIntellectual Property licensed to Purchaser under an
47

Ancillary Agreement or otherwise, and including as set forth on Section  2.3(a)(vii)  of  the Seller Disclosure Letter,and
 including  the  right  to  sue  and  recover  and  retain  damages  for  past,  present  and  future  infringement  ormisappropriation or any other violation of any such Intellectual Property;
(viii) 
     all Governmental Authorizations, including product registrations, manufacturing registrations andenvironmental
 permits, owned, used or licensed by Seller Parent or any of its Affiliates and not Related to theBusiness;
(ix) 
     all customer and vendor lists, all advertising, marketing, sales and promotional materials, and businessand
 financial records, books, and documents and other Records, in each case not Related to the Business, and theSpecified Records;
(x) 
     all accounts receivable and other current assets and all cash and cash equivalents, checks, money orders,marketable
 securities,  short-term  instruments,  bank  and  other  depositary  accounts,  certificates  of  deposit,  timedeposits,
 negotiable instruments, securities and brokerage accounts, funds in time and demand deposits or similaraccounts
 of Seller Parent or any of its Affiliates (including the Conveyed Subsidiaries or any of their Subsidiaries)(other
 than the accounts receivable and other assets, in each case included in the calculation of the Final BusinessWorking Capital, and the Cash Equivalents included in the calculation of Final Business Net Cash);
(xi) 
     all Tax refunds, Tax credits or other Tax Assets of the Sellers and any refund or credit against SellerIndemnified
 Taxes to which Seller Parent is entitled pursuant to Section  6.5(c) ,  whether or not derived from theBusiness
 and whether or not existing prior to the Closing, but excluding any refunds or credits or other Tax Assets tothe
 extent reflected as an asset on the Final Closing Statement and taken into account in the calculation of (a) theFinal
 Business Working Capital or (b) Seller Accrued Income Taxes (to the extent, with respect to clause (b)  ,offsetting a Tax Liability in such calculation);
(xii) 
     all Seller Combined Tax Returns and all Tax Returns of the Sellers or any of their Affiliates (other thanthe
 Conveyed  Subsidiaries  and  their  Subsidiaries)  that  do  not  relate  solely  to  Purchased  Assets  or  AssumedLiabilities, and in each case any books and records relating thereto;
(xiii) 
     all claims, defenses, causes of action, counterclaims and rights of set-off against third parties (at anytime
 or in any manner arising or existing, whether choate or inchoate, known or unknown, contingent or non-contingent) other than those identified as Purchased Assets in 
Section 2.1  ; (xiv) 
     all rights of Seller Parent or any of its Affiliates (for clarity, other than, from and after the Closing, theConveyed Subsidiaries and their Subsidiaries) under
48

this Agreement or the Ancillary Agreements and any documents delivered or received in connection herewith ortherewith;
(xv) 
     except as set forth in Section 2.1(o)  and subject to  Section 6.18  , all current and prior insurance policies and
 all rights of any nature with respect thereto, including all insurance recoveries thereunder and rights to assertclaims with respect to any such insurance recoveries;
(xvi) 
     except as expressly set forth in this Agreement (including Section 2.1(p)  and  Section 6.6 ), all assets of any Seller Group Plan or Foreign Seller Group Plan that is not a Conveyed Subsidiary Plan;
(xvii) 
     all corporate-level services (but not the assets related to such services to the extent such assets arePurchased
 Assets) of the type currently provided to the Business by Seller Parent or any of its Affiliates, and withoutlimiting Seller Parent’s obligations under the Transition Services Agreement;
(xviii) 
     all third-party warranties, indemnities, further assurances and similar covenants and guarantees otherthan those identified as Purchased Assets in 
Section 2.1  ; (xix) 
     all assets, properties and rights of any Person that are not Related to the Business, including all assets,properties
 and rights constituting ownership interests in, or that are used or held for use in, or related to, the RetainedBusinesses,
 in each case other than those assets, properties or rights identified as Purchased Assets in clauses  (a)through 
(s) of Section 2.1 ; and (xx) 
     the assets set forth in Section 2.3(a)(xx)  of the Seller Disclosure Letter. (b) 
     Notwithstanding anything in this Agreement to the contrary but subject to Section  6.5(f) ,  prior to the Closing,Seller
 Parent shall use commercially reasonable efforts to take (or cause one or more of its Affiliates to take) such action as isnecessary,
 advisable or desirable to transfer the Excluded Assets from the Conveyed Subsidiaries and their Subsidiaries (and, ifneeded,
 from the Sellers) to Seller Parent or one or more of its Retained Subsidiaries for such consideration or for no consideration,as
 may be determined by Seller Parent in its sole discretion, but in compliance with all applicable Laws and as would not result inany
 material adverse impact to the Purchased Assets or the Business. After the Closing Date, the Parties shall continue to usecommercially
 reasonable efforts to take all actions (and shall cause their Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries)
 to continue to use commercially reasonable efforts to take all actions) reasonably requested by the other Party to effectthe
 provisions of this Section  2.3 ,  including the return of any Excluded Assets for no additional consideration. Any action takenpursuant
 to this Section  2.3(b) after  the Closing Date shall be deemed for purposes of calculating the Business Working Capital andthe Business Net Cash pursuant to 
Section 2.9  to have occurred as of 12:01 a.m. (New York time) on the Closing Date. 49

Section 2.4       Assumption of Assumed Liabilities . Upon the  terms and subject to the conditions of this Agreement, atthe
 Closing, Purchaser shall (i) assume and, subject to Section  2.5 ,  Section 6.5 ,  Section 6.6 and  Article VII ,  pay, perform, satisfyand
 discharge any and all Liabilities of the Sellers or any of their Affiliates (including the Conveyed Subsidiaries and theirSubsidiarie
s), whether arising prior to, on or after the Closing, to the extent resulting from or arising out of the past, present or futureownership,
 operation, use or conduct of the Business or the Purchased Assets (including the Shares) and (ii) cause the ConveyedSubsidiaries
 and their Subsidiaries to pay, perform, satisfy and discharge any and all of their respective Liabilities, in each case ofthe
 foregoing clauses (i)  and (ii), other than Liabilities identified as Retained Liabilities in clauses  (a) through  (g) of Section 2.5 (all of
 the foregoing Liabilities being collectively referred to herein as the “ Assumed  Liabilities ”).  The Assumed Liabilities shall alsoinclude the following:
(a) 
     all Liabilities to the extent expressly assumed by, retained by or agreed to be performed by Purchaser or itsSubsidiaries
 (including the Conveyed Subsidiaries and their Subsidiaries) pursuant to the terms of this Agreement, including allLiabilities
 to  the  extent  transferred  to  or  assumed  or  retained  by  Purchaser  or  its  Subsidiaries  pursuant  to Section  6.6 and Section 6.13 
; (b) 
     all Liabilities in respect of any Action, whether class, individual or otherwise in nature, in law or in equity,whether
 or not presently threatened, asserted or pending, to the extent arising out of, or to the extent relating to, the Business or theoperation or conduct of the Business prior to, on or after the Closing;
(c) 
     all Liabilities for Taxes of the Conveyed Subsidiaries and their Subsidiaries and, without duplication, all otherLiabilities
 for Taxes imposed with respect to, arising out of or relating to the Purchased Assets or the Business, in each case, otherthan Seller Indemnified Taxes for which Seller Parent is liable pursuant to this Agreement;
(d) 
     all Liabilities to the extent arising out of, or to the extent relating to, the design, manufacture, testing,marketing, distribution, use or sale of Products prior to, on or after the Closing, including warranty obligations and irrespective of the
legal theory asserted;
(e) 
     all Liabilities to suppliers and customers, in each case to the extent arising out of, or to the extent relating to, theBusiness, including in respect of any Products returned prior to, on or after the Closing;
(f) 
     all accounts payable and all other Liabilities, in each case included in the calculation of Final Business WorkingCapital,
 all Funded Indebtedness included in the calculation of Final Business Net Cash and all other Indebtedness of the ConveyedSubsidiaries (or their Subsidiaries) that is not Funded Indebtedness;
(g) 
     all Environmental Liabilities of any nature whatsoever to the extent arising out of, or relating to, or in respect ofthe Conveyed
 Subsidiaries (or their Subsidiaries), the Purchased Assets, the Business or the Facilities, whether arising prior to, on orafter the Closing, other than the Retained Facilities Environmental Liabilities or the Retained Environmental Liabilities;
50

(h)      all Liabilities to the extent relating to, resulting from or arising out of the Assumed Contracts, includingPurchaser’s
 or its Affiliates’ (including any Conveyed Subsidiary’s or its Subsidiaries’) portion of Shared Contractual Liabilitiespursuant to 
Section 2.2(d)  ; and (i) 
     the Liabilities set forth in Section 2.4(i)  of the Seller Disclosure Letter. Section
 2.5       Retained Liabilities .  Except as otherwise set forth in this Agreement, and subject to Article  VII , the Sellers
 shall retain, and none of Purchaser or any of its Affiliates shall assume or be responsible for pursuant to this Agreement, anyLiabilities of Sellers
 or any of their Affiliates other than the Assumed Liabilities (such Liabilities other than the Assumed Liabilities,the “ 
Retained Liabilities ”). The Retained Liabilities shall include: (a) 
     all Liabilities for which any Seller expressly has responsibility pursuant to the terms of this Agreement or anyAncillary Implementing Agreement, including all Liabilities for which the Sellers have responsibility pursuant to 
Section 6.6  ; (b) 
     all Liabilities of any Seller or Conveyed Subsidiary (or Subsidiaries thereof) to the extent related to or arisingout of (i)
 the Excluded Assets (other than any Liabilities for which Purchaser or its Affiliates expressly has responsibility pursuant tothe
 terms of this Agreement or any Ancillary Agreement, and other than any Liabilities that are separately allocated pursuant to anyother
 agreement or transaction related to such Excluded Assets between Seller Parent or any of its Affiliates, on the one hand, andPurchaser
 or any of its Affiliates, on the other hand, including any commercial or other agreements unrelated to this Agreement),including
 Environmental Liabilities, whether arising prior to, on or after the Closing, to the extent arising out of or related to theownership
 or occupancy of the Retained Facilities (the “ Retained  Facilities Environmental Liabilities  ”)  or (ii) the matters set forthon 
Section 2.5(b)(ii) of the Seller Disclosure Letter (the “  Retained Environmental Liabilities  ”); (c) 
     all Seller Indemnified Taxes;(d) 
     all Seller Transaction Expenses;(e) 
     Seller Parent’s portion of Shared Contractual Liabilities pursuant to Section 2.2(d)  ; (f) 
     all Indebtedness of Seller Parent and its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries)that are not Assumed Liabilities under 
Section 2.4  ; and (g) 
     all Liabilities of Seller Parent or any of its Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries) set forth in 
Section 2.5(g)  of the Seller Disclosure Letter. Section
 2.6       Purchase Consideration .  In consideration of the sale and transfer to Purchaser or the applicablePurchaser
 Designated Affiliates of the applicable Sellers’ right, title and interest in the Purchased Assets, including the Shares, inaccordance
 with and subject to the terms of this Agreement (the “ Sale  ”), and the other obligations of Seller Parent pursuant to thisAgreement, at the Closing, Purchaser shall, and Purchaser Parent shall cause Purchaser to, (a) allot, issue and
51

deliver the Purchase Consideration in accordance with Section 2.7  , and (b) assume the Assumed Liabilities. Section
 2.7       Delivery of the Purchase Consideration .  At the Closing, Purchaser shall, and Purchaser Parent shallcause Purchaser to, allot and issue to Seller Parent
 (and/or Seller Parent’s designee(s) (which shall be one or more Affiliates of SellerParent),
 in such allocations as may be directed by Seller Parent), free and clear of all Liens except for Liens arising under applicablesecurities
 Laws, and credited as fully paid, a number of B ordinary shares in the capital of Purchaser, having the rights andrestrictions
 set  out  in  the  Restated  Purchaser  Articles  of  Association  (the  “ B  Ordinary  Shares ”),  in  such  number  so  that,immediately
 following Closing, (a) the B Ordinary Shares owned by Seller Parent (and/or Seller Parent’s designee(s)) will represent32%
 of the Ordinary Shares (such B Ordinary Shares, the “ Purchase Consideration  ”)  and (b) the A ordinary shares in the capital ofPurchaser,
 having the rights and restrictions set out in the Restated Purchaser Articles of Association, owned by a wholly ownedSubsidiary of
 Purchaser Parent (the “ A Ordinary  Shares  ”) will represent the remaining 68% of the Ordinary Shares, in each case ofthe
 foregoing clauses (a) and (b), after giving effect to (and including) the issuance of the B Ordinary Shares, and, together with thePreference Shares, such shares will represent all of the issued share capital of Purchaser.
Section 2.8 
      Estimated Closing Statement; Estimated Adjustment Payments . (a) 
     No fewer than seven (7) Business Days before the Closing Date, (a) Seller Parent shall prepare in good faith anddeliver
 to Purchaser Parent the Estimated Closing Statement, which shall include Seller Parent’s good faith calculation of theEstimated
 Business Working Capital, Estimated Business Net Cash and any Estimated Business Excess Adjustment or EstimatedBusiness
 Deficit Adjustment to be paid at Closing, prepared in a manner consistent with the accounting principles, procedures,policies
 and methods set forth in Annex  B-1 (the  “ Accounting Principles ”)  and the Sample Closing Statement and (b) PurchaserParent
 shall prepare in good faith and deliver to Seller Parent the Purchaser Estimated Closing Statement, which shall includePurchaser
 Parent’s good faith calculation of the Estimated Purchaser Working Capital, Estimated Purchaser Net Cash and anyEstimated
 Purchaser Parent Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment to be paid at Closing, prepared ina
 manner consistent with the accounting principles, procedures, policies and methods set forth in Annex  B-3 (the  “ PurchaserAccounting
 Principles ”)  and the Sample Purchaser Closing Statement. The Parties shall have the right to review the EstimatedClosing
 Statement and the Purchaser Parent Estimated Closing Statement and the Parties shall cooperate in good faith in an effort toagree to any required modification based on such review.
(b) 
     If (i) the amount equal to (A) the Estimated Business Working Capital plus
 (B) the Estimated Business NetCash
 exceeds (ii) the amount equal to (A) the Target Business Working Capital plus
 (B) the Target Business Net Cash (the amountof
 such excess, the “ Estimated  Business  Excess Adjustment ”),  at the Closing, Purchaser shall, and Purchaser Parent shall causePurchaser to, pay to Seller Parent (and/or
 Seller Parent’s designee(s), in such allocations as may be directed by Seller Parent) by wiretransfer of immediately available funds to the Seller Account, an amount in cash equal to the Estimated Business Excess Adjustment.
52

(c)      If (i) the amount equal to (A) the Target Business Working Capital plus
 (B) the Target Business Net Cashexceeds (ii)
 the amount equal to (A) the Estimated Business Working Capital plus
 (B) the Estimated Business Net Cash (the amountof
 such excess, the “ Estimated  Business Deficit  Adjustment ”),  at the Closing, Seller Parent shall pay to Purchaser by wire transferof immediately available funds to the Purchaser Account, an amount in cash equal to the Estimated Business Deficit Adjustment.
(d) 
     If (i) the amount equal to (A) the Estimated Purchaser Working Capital plus
 (B) the Estimated Purchaser NetCash exceeds (ii) the
 amount equal to (A) the Target Purchaser Working Capital plus
 (B) the Target Purchaser Net Cash (the amountof
 such excess, the “ Estimated  Purchaser  Parent Excess Adjustment ”),  at the Closing, Purchaser shall, and Purchaser Parent shallcause
 Purchaser to, pay to Purchaser Parent (and/or Purchaser Parent’s designee(s), in such allocations as may be directed byPurchaser
 Parent) by wire transfer of immediately available funds to the Purchaser Parent Account, an amount in cash equal to theEstimated Purchaser Parent Excess Adjustment.
(e) 
     If (i) the amount equal to (A) the Target Purchaser Working Capital plus
 (B) the Target Purchaser Net Cashexceeds
 (ii) the amount equal to (A) the Estimated Purchaser Working Capital plus
 (B) the Estimated Purchaser Net Cash (theamount
 of such excess, the “ Estimated  Purchaser Parent Deficit Adjustment ”),  at the Closing, Purchaser Parent shall pay toPurchaser
 by wire transfer of immediately available funds to the Purchaser Account, an amount in cash equal to the EstimatedPurchaser Parent Deficit Adjustment.
(f) 
     Any Estimated Business Excess Adjustment, Estimated Business Deficit Adjustment, Estimated PurchaserParent
 Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment paid at the Closing shall be subject to the post-Closingadjustment provisions of 
Section 2.9  . Section 2.9 
      Post-Closing Working Capital and Net Cash Adjustments . (a) 
     Within one hundred and twenty (120) days after the Closing Date, Purchaser shall deliver to Seller Parent andPurchaser
 Parent  a  statement  setting  forth  Purchaser’s  calculation  of  the  Business  Working  Capital,  the  Business  Net  Cash,Purchaser Working Capital and Purchaser Net Cash (together with reasonabl
e documentation, back-up and supporting detail for eachof
 the items and calculations in such statement, the “ Proposed  Closing Statement ”).  The Proposed Closing Statement shall beunaudited
 but shall be prepared in a manner consistent with (i) with respect to the calculation of Business Working Capital andBusiness Net Cash,
 the Accounting Principles and the Sample Closing Statement and (ii) with respect to the calculation of PurchaserWorking
 Capital and Purchaser Net Cash, the Purchaser Accounting Principles and the Sample Purchaser Closing Statement,including
 as to line items and the classification of asset and liability line items set forth thereon, and take into account any transfersmade
 pursuant to Section 2.3(b)  ,  and to the extent the Proposed Closing Statement reflects amounts that are different from amountspresented
 on the balance sheet included in the Financial Statements or the Purchaser Financial Statements, as applicable, as of theBalance
 Sheet Date, such differences shall be based on facts or occurrences arising solely between the Balance Sheet Date and theClosing.
53

(b)      Following the delivery of the Proposed Closing Statement until the date that is ninety (90) days thereafter (the “Review Period 
”),  either or both Parents may, by delivering a written notice to the other Parties, dispute the amounts reflected on theline items of the
 Proposed Closing Statement (any such disputed amount, a “ Disputed Item  ”). A  Parent’s written notice of DisputedItems shall
 identify each Disputed Item and specify the nature of such Parent’s disagreement, the amount of each item in dispute andthe
 basis therefor, and the amount that such Parent believes is the correct amount of the Business Working Capital, the Business NetCash, Purchaser Working Capital or Purchaser Net Cash, as
 applicable, based on the disagreements set forth in its notice of DisputedItems,
 including the adjustments applied by such Parent to the Proposed Closing Statement in calculating any such amounts. AParent shall be deemed to
 have agreed with all other items and amounts contained in the Proposed Closing Statement not so objectedto
 by it in a notice of Disputed Items within the Review Period in accordance with this Section 2.9(b)  ,  and the failure by a Parent toprovide
 a notice of Disputed Items to the other Parties within the Review Period will constitute such Parent’s agreement with all ofthe
 items in the Proposed Closing Statement, and the Proposed Closing Statement shall be conclusive, final and binding upon theParties as the Final Closing Statement with respect to the items thereon so agreed by both Parents.
(c) 
     If a notice of Disputed Items shall be timely delivered in accordance with Section  2.9(b) ,  the Parties shall,during
 the forty-five (45) days following the date of such delivery (the “ Resolution  Period ”),  negotiate in good faith to resolve theDisputed
 Items. During the Review Period and the Resolution Period, each Party and its Representatives (including its accountants)shall be permitted
 to review the working papers of the other Parties and their accountants relating to the notice of Disputed Items andthe
 Proposed Closing Statement (subject to execution of customary working paper access letters). To the extent any Disputed Itemsare
 so resolved in writing by mutual agreement of all Parties within the Resolution Period, then the Proposed Closing Statement, asrevised
 to incorporate such changes as have been agreed between all Parties, shall be conclusive, final and binding upon the Partiesas the Final Closing Statement with respect to the items thereon so agreed.
(d) 
     If during such Resolution Period the Parties are unable to reach agreement on all Disputed Items, the Partiesshall
 refer all unresolved Disputed Items to the Independent Accountant. The Independent Accountant shall make a determinationwith
 respect to each unresolved Disputed Item within forty-five (45) days after its engagement by the Parties to resolve suchDisputed
 Items, which determination shall be made in accordance with the rules set forth in this Section  2.9 .  Except as the Partiesmay otherwise
 agree, all communications between any of the Parties or any of their respective Representatives, on the one hand, andthe
 Independent Accountant, on the other hand, will be in writing with copies simultaneously delivered to the non-communicatingParties.
 The Parties shall cooperate with the Independent Accountant in its proceedings, including by providing such accountingbooks
 and records and working papers of each Party and its accountants, as the Independent Accountant may reasonably request(subject to
 execution of customary working paper access letters). The Independent Accountant shall make its determination (i) basedsolely
 on the documentation submitted by, and presentations made by, any of the Parties (any such documentation or presentationmust
 be provided to the other Parties at the same time as its submission or presentation to the Independent Accountant) and (ii) in amanner consistent with (A) the Accounting Principles and the Sample Closing Statement and the definitions
54

of Business Working Capital and Business Net Cash, in the case of the calculation of Business Working Capital and Business NetCash,
 and (B) the Purchaser Accounting Principles and the Sample Purchaser Closing Statement, and the definitions of PurchaserWorking
 Capital and Purchaser Net Cash, in the case of the calculation of Purchaser Working Capital and Purchaser Net Cash (andin
 each case each of the defined terms used in each of those terms or in which those terms are used and the related provisions of thisAgreement).
 The Independent Accountant shall deliver to the Parties, within such forty-five (45)-day period, a written report settingforth
 its adjustments, if any, to the Proposed Closing Statement and the calculations supporting such adjustments, and any suchadjustments
 must be within the range of values established for such Disputed Item by Purchaser in the Proposed Closing Statementand
 by the applicable Parent(s) in the notice of Disputed Items delivered pursuant to Section  2.9(b) .  Absent manifest errors, suchreport
 shall be conclusive, final and binding on the Parties and enforceable in a court of law, effective as of the date the IndependentAccountant’s
 written determination is received by the Parties, and the Proposed Closing Statement, as revised to incorporate theIndependent
 Accountant’s resolution of the Disputed Items, shall be conclusive, final and binding upon the Parties as the FinalClosing
 Statement. Purchaser shall pay the fees and expenses of the Independent Accountant, and the Independent Accountant shallbill
 Purchaser accordingly. The Parties acknowledge that they have discussed their past contacts, if any, with the IndependentAccountant,
 and that no Party shall have the right to object to the Independent Accountant’s service in such role by reason of non-disclosure
 of past contacts, conflicts of interest or any other reason. If, before the Independent Accountant renders its determinationwith
 respect to the Disputed Items in accordance with this Section  2.9(d) ,  any Disputed Items are resolved in writing by mutualagreement
 of all Parties, then in each case such items as so agreed will be conclusive, final and binding on the Parties immediatelyupon such notice as the Final Closing Statement with respect to the items thereon so agreed.
(e) 
     As used herein, “ Final  Business Working Capital ”,  “ Final Business Net Cash  ”, “ Final Purchaser WorkingCapital 
” and “ Final Purchaser Net Cash ”  mean (i) if no notice of Disputed Items with respect to the Business Working Capital,Business
 Net Cash, Purchaser Working Capital or Purchaser Net Cash, respectively, is delivered by either Parent within the periodprovided
 in Section  2.9(b) ,  the Business Working Capital, Business Net Cash, Purchaser Working Capital or Purchaser Net Cash,respectively,
 as shown in the Proposed Closing Statement as prepared by Purchaser, or (ii) if such a notice of Disputed Items withrespect
 to the Business Working Capital, Business Net Cash, Purchaser Working Capital or Purchaser Net Cash, respectively, istimely
 delivered by either Parent, either (A) the Business Working Capital, Business Net Cash, Purchaser Working Capital orPurchaser
 Net Cash, respectively, as mutually agreed to in writing by the Parties or (B) the Business Working Capital, Business NetCash,
 Purchaser Working Capital or Purchaser Net Cash, respectively, as shown in the Independent Accountant’s calculationdelivered pursuant to 
Section 2.9(d)  . (f) 
     Until the date on which the Proposed Closing Statement shall become conclusive, final and binding on theParties
 pursuant to this Section  2.9 (the  “ Closing Statement Finalization  Date ”),  each Party agrees that following the Closing itshall,
 and shall cause its Representatives to, preserve the accounting books and records of the Business and of Purchaser and itsAffiliates
 on which the Proposed Closing Statement is to be based and shall not take any actions with respect to such books andrecords that would obstruct or prevent the procedures set
55

forth in this Section 2.9  (including books  and records related to the Business Working Capital, the Business Net Cash, the PurchaserWorking
 Capital and the Purchaser Net Cash or the Proposed Closing Statement or the preparation of the Proposed ClosingStatement).
(g) 
     If (i) the amount equal to (A) the Final Business Working Capital plus
 (B) the Final Business Net Cash exceeds(ii)
 the amount equal to (A) the Estimated Business Working Capital plus
 (B) the Estimated Business Net Cash (the amount of suchexcess,
 the “ Final  Business Excess  Adjustment ”),  Purchaser shall, and Purchaser Parent shall cause Purchaser to, pay within five(5)
 Business Days of the Closing Statement Finalization Date to Seller Parent (and/or Seller Parent’s designee(s), in such allocationsas
 may be directed by Seller Parent) by wire transfer of immediately available funds to the Seller Account, an amount in cash equalto the amount of the Final Business Excess Adjustment.
(h) 
     If (i) the amount equal to (A) the Estimated Business Working Capital plus
 (B) the Estimated Business NetCash
 exceeds (ii) the amount equal to (A) the Final Business Working Capital plus
 (B) the Final Business Net Cash (the amount ofsuch
 excess, the “ Final  Business Deficit Adjustment  ”),  Seller Parent shall pay within five (5) Business Days of the ClosingStatement
 Finalization Date to Purchaser by wire transfer of immediately available funds to the Purchaser Account, an amount incash equal to the amount of the Final Business Deficit Adjustment.
(i) 
     If (i) the amount equal to (A) the Final Purchaser Working Capital plus
 (B) the Final Purchaser Net Cashexceeds
 (ii) the amount equal to (A) the Estimated Purchaser Working Capital plus
 (B) the Estimated Purchaser Net Cash (theamount
 of such excess, the “ Final  Purchaser Parent  Excess Adjustment ”),  Purchaser shall, and Purchaser Parent shall causePurchaser
 to, pay within five (5) Business Days of the Closing Statement Finalization Date to Purchaser Parent (and/or PurchaserParent’s
 designee(s), in such allocations as may be directed by Purchaser Parent) by wire transfer of immediately available funds tothe Purchaser Parent Account, an amount in cash equal to the amount of the Final Purchaser Parent Excess Adjustment.
(j) 
     If (i) the amount equal to (A) the Estimated Purchaser Working Capital plus
 (B) the Estimated Purchaser NetCash exceeds (ii) the
 amount equal to (A) the Final Purchaser Working Capital plus
 (B) the Final Purchaser Net Cash (the amount ofsuch
 excess, the “ Final  Purchaser Parent Deficit Adjustment ”),  Purchaser Parent shall pay within five (5) Business Days of theClosing
 Statement Finalization Date to Purchaser by wire transfer of immediately available funds to the Purchaser Account, anamount in cash equal to the amount of the Final Purchaser Parent Deficit Adjustment.
(k) 
     Until the date on which the Proposed Closing Statement shall become conclusive, final and binding on theParties
 pursuant to this Section 2.9  ,  each Party agrees that following the Closing it shall afford and cause to be afforded to the otherParties
 and their Affiliates and the Representatives retained by the other Parties in connection with the preparation of the ProposedClosing
 Statement and any adjustment to the Estimated Business Excess Adjustment, Estimated Business Deficit Adjustment,Estimated Purchaser
 Parent Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment contemplated by this Section 2.9  , reasonable
 access upon reasonable notice during normal business hours to the properties, books, contracts, personnel and records ofthe Business and Purchaser and Purchaser Parent and such Party’s, its Affiliates’ and
56

their respective accountants’ working papers (subject to execution of customary working paper access letters) relevant to thepreparation
 of the Proposed Closing Statement and any adjustment contemplated by this Section  2.9 ,  including any notice ofDisputed
 Items, and shall provide the other Parties and their Affiliates and Representatives, upon the other Party’s reasonablerequest, with copies of any such books, contracts, records and work papers.
(l) 
     Except in cases of fraud with respect to the representations, warranties, covenants and agreements contained inthis
 Agreement, the process set forth in this Section  2.9 shall  be the sole and exclusive remedy of any of the Parties and theirrespective
 Affiliates for any disputes related to the Final Business Excess Adjustment, the Final Business Deficit Adjustment, theFinal Purchaser Parent Excess Adjustment and the Final Purchaser Parent Deficit Adjustment.
Section
 2.10       Withholding .  Absent any change in Law after the date hereof, Purchaser acknowledges and agreesthat
 no withholding is required in respect of the payment of the Purchase Consideration or any amounts payable to Seller Parentpursuant
 to Section  2.8 or  Section 2.9 as  a result of Purchaser’s tax residence to the extent Seller Parent satisfies its obligationspursuant
 to Section  3.1(b) .  In the event that any deduction or withholding for Taxes in respect of the payment of the PurchaseConsideration
 or any amounts payable to Seller Parent pursuant to Section  2.8 or  Section 2.9 is  required by Law, Purchaser and thePurchaser
 Designated Affiliates shall be entitled to deduct and withhold such amounts from such payments to the extent requiredunder applicable Law; provided that Purchaser shall give Seller Parent written notice of any such requirement to deduct and withhold
any
 Taxes from such amounts promptly after becoming aware of such requirement. Purchaser and Seller Parent shall reasonablycooperate
 with each other to minimize the amounts, if any, required to be deducted and withheld. If any amount is withheld inaccordance
 with the foregoing provisions of this Section  2.10 ,  such withheld amount shall be treated for all purposes of thisAgreement as having been paid to the applicable recipient of such amount otherwise payable.
ARTICLE III
CLOSING
Section 3.1 
      Closing .(a) 
     Subject to Section 3.1(d)  ,  the Closing shall take place at the offices of Wachtell, Lipton, Rosen & Katz locatedat
 51 West 52nd Street, New York, New York 10019, at 10:00 a.m. (New York time) on the third (3rd) Business Day following thesatisfaction or waiver of all the conditions set forth in 
Article VIII  (other than the  conditions that by their nature are to be satisfied onthe
 Closing Date, but subject to the satisfaction or waiver of such conditions), or at such other time and place as the Parties maymutually
 agree. The date on which the Closing occurs is referred to as the “ Closing  Date .”  Unless the Parties agree otherwise, andnotwithstanding the actual occurrence of the Closing at any particular time on the Closing Date, the Closing shall be deemed to occur
and
 be effective as of 12:01 a.m. (New York time) on the Closing Date. In addition to payment of the amounts set forth inSection 2.8 
: 57

(b)      At the Closing, Seller Parent shall deliver, or cause to be delivered, to Purchaser the instruments and documentsset forth in 
Exhibit A  . (c) 
     At the Closing, Purchaser shall, and Purchaser Parent shall cause Purchaser to, deliver to Seller Parent, as agentfor the
 Sellers, or its designee(s) the following: (i) customary and satisfactory evidence of the allotment and issuance of the PurchaseConsideration to Seller Parent or its designee(s), credited as fully paid and (ii) the instruments and documents set forth in 
Exhibit B  . (d) 
     Seller Parent and Purchaser Parent hereby agree that if the Closing Date does not fall on the last day of acalendar
 month, the Parties shall cooperate in good faith and discuss designing a lock box construct to facilitate a month end closingfor
 accounting purposes pursuant to which each of Seller Parent and Purchaser Parent is put in the same economic position as if theClosing
 had  occurred  on  the  originally  contemplated  Closing  Date  and  so  that  neither  Party  bears  any  additional  closingconditionality risk or value leakage risk during the interim period.
Section 3.2 
      Restated Purchaser Articles of Association .  Purchaser Parent shall, in accordance with applicable Lawand
 the articles of association of Purchaser, cause the articles of association of Purchaser to be amended and restated, effective as ofimmediately prior to the Closing, to be in the form set forth in 
Exhibit E  (the “  Restated Purchaser Articles of Association ”). ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF SELLER PAR
ENTExcept
 as set forth in the Seller Disclosure Letter and in accordance with Section  10.8 ,  Seller Parent herebyrepresents and warrants to Purchaser Parent and Purchaser as follows:
Section
 4.1       Organization .  Seller Parent is a corporation duly organized, validly existing and in good standingunder
 the Laws of the State of Delaware. Each Seller is, or will be as of the Closing, a corporation, partnership or other legal entityduly organized, validly exis
ting and, where applicable, in good standing under the Laws of the jurisdiction of its organization, exceptwhere
 the failure to be so organized, existing or in good standing would not, individually or in the aggregate, be materially adverseto the Business or prevent or reasonably be expected to prevent the Sellers from consummating the Closing prior to the Outside Date.
Section 4.2 
      Authority; Binding Effect . (a) 
     Seller Parent has all requisite corporate power and authority to execute and deliver this Agreement and eachAncillary Agreement
 to which it will be a party and to perform its obligations hereunder and thereunder. The execution and deliveryby
 Seller Parent of this Agreement and each such Ancillary Agreement, and the performance by Seller Parent of its obligationshereunder
 and thereunder, have been, or will have been as of the Closing, duly authorized by all requisite corporate action. EachSeller
 has, or will have as of the Closing, all requisite corporate or other similar applicable power and authority to execute anddeliver each Ancillary Agreement
58

to which it will be a party and to perform its obligations thereunder. The execution and delivery by each Seller of each AncillaryAgreement
 to which it will be a party, if applicable, and the performance by it of its obligations thereunder, have been, or will havebeen as of the Closing, duly authorized by all requisite corporate or other similar applicable action.
(b) 
     Seller Parent has, and each other Seller has, or will have as of the Closing, all requisite corporate or othersimilar
 applicable power and authority to carry on its respective business as it pertains to the Business as currently conducted and toown,
 lease and operate its properties and assets related to the Business, except where the failure to have such power and authoritywould not, individually or in the
 aggregate, be materially adverse to the Business or prevent or reasonably be expected to prevent theSellers from consummating the Closing prior to the Outside Date.
(c) 
     This Agreement has been duly executed and delivered by Seller Parent and, assuming this Agreement has beenduly executed and
 delivered by Purchaser Parent and Purchaser, constitutes a legal, valid and binding obligation of Seller Parent, andeach
 Ancillary Agreement will be as of the Closing duly executed and delivered by each Seller that will be a party thereto and will,assuming
 such  Ancillary  Agreement  has been  duly  executed  and  delivered  by Purchaser  Parent,  Purchaser  or the  applicablePurchaser
 Designated Affiliate, constitute a legal, valid and binding obligation of such Seller, in each case enforceable against SellerParent
 or  such  other  Seller  in  accordance  with  its  terms,  except  as  enforcement  may  be  limited  by  bankruptcy,  insolvency,reorganization,
 fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles ofequity (regardless of whether enforcement is sought in a proceeding in equity or law).
Section 4.3 
      Conveyed Subsidiaries; Capital Structure . (a) 
     Each of the Conveyed Subsidiaries is, or will be as of the Closing, a corporation, partnership or other legalentity
 duly organized and validly existing, with all requisite corporate or other similar applicable power and authority to own, leaseand
 operate its properties and assets related to the Business and to carry on its respective business as it pertains to the Business, ascurrently
 conducted, except where the failure to be so organized or existing or to have such power and authority would not,individually
 or in the aggregate, be materially adverse to the Business. Each of the Conveyed Subsidiaries is, or will be as of theClosing, duly qualified to
 do business and, where applicable, in good standing in each jurisdiction where the nature of its business orproperties makes such
 qualification necessary, except where the failure to be so qualified or in good standing would not, individuallyor in the aggregate, be materially adverse to the Business.
(b) 
     Section 4.3(b) of the  Seller Disclosure Letter sets forth, as of immediately prior to the Closing, (i) the name andthe
 jurisdiction of organization of each of the Conveyed Subsidiaries and (ii) the record owners of such outstanding equity interests.All
 of the outstanding equity interests of each of the Conveyed Subsidiaries are, or will be as of the Closing, validly issued, fullypaid
 and, in the case of any Conveyed Subsidiary which is a corporation, non-assessable, and the Shares are not subject to, and werenot
 issued in violation of, any preemptive right. As of the Closing, there will be no outstanding warrants, options, agreements,subscriptions, convertible or exchangeable securities or other commitments pursuant to which any of the Conveyed Subsidiaries
59

is or may become obligated to issue, sell, purchase, return, redeem or otherwise acquire any equity interests of the ConveyedSubsidiarie
s, or any securities convertible into or exchangeable for the capital stock or voting securities of any Conveyed Subsidiary.As
 of the Closing, there will be no rights of first refusal, rights of first offer, voting trusts, stockholder agreements, proxies or otherContracts
 in effect with respect to the sale or voting of the equity interests of the Conveyed Subsidiaries. The Sellers own of recordand beneficially as of the date of
 this Agreement, or will own of record and beneficially as of immediately prior to the Closing, all ofthe
 issued and outstanding Shares, free and clear of all material Liens except for Liens arising under applicable securities Laws.Except
 for the Shares and the equity interests of any Subsidiary of a Conveyed Subsidiary, the Purchased Assets do not include, andthe Conveyed Subsidiaries do not own, any other equity interests of any Person.
(c) 
     Section 4.3(c) of the  Seller Disclosure Letter sets forth, as of immediately prior to the Closing, (i) the name andthe
 jurisdiction of organization of each Subsidiary of the Conveyed Subsidiaries and (ii) the record owners of the outstanding equityinterests
 of such Subsidiaries. Each such Subsidiary is, or will be as of the Closing, a corporation, partnership or other legal entityduly
 organized and validly existing, with all requisite corporate or other similar applicable power and authority to own, lease andoperate
 its properties and assets related to the Business and to carry on its respective business as it pertains to the Business, ascurrently
 conducted, except where the failure to be so organized or existing or to have such power and authority would not,individually
 or in the aggregate, be materially adverse to the Business. Except as set forth in Section  4.3(c) of  the Seller DisclosureLetter,
 all of the outstanding equity interests of each Subsidiary of a Conveyed Subsidiary are owned of record and beneficially bysuch
 Conveyed Subsidiary (or a Subsidiary thereof) as of the date of this Agreement, or will be owned of record and beneficially bysuch
 Conveyed Subsidiary (or a Subsidiary thereof) as of immediately prior to the Closing, free and clear of all Liens except forLiens
 arising under applicable securities Laws. All of the outstanding equity interests of each Subsidiary of a Conveyed Subsidiaryare,
 or will be as of the Closing, validly issued, fully paid and, in the case of any such Subsidiary which is a corporation, non-assessab
le. As of the Closing, there will be no outstanding warrants, options, agreements, subscriptions, convertible or exchangeablesecurities
 or other commitments pursuant to which any Subsidiary of a Conveyed Subsidiary is or may become obligated to issue,sell,
 purchase, return, redeem or otherwise acquire any equity interests of such Subsidiary, or any securities convertible into orexchangeable
 for the capital stock or voting securities of such Subsidiary. As of the Closing, there will be no rights of first refusal,rights of first offer, voting trusts, stockholder agreements, proxie
s or other Contracts in effect with respect to the sale or voting of theequity interests of any Subsidiary of a Conveyed Subsidiary.
Section
 4.4       No Conflicts; Consents .  The execution, delivery and performance of this Agreement by Seller Parentand each
 Ancillary Implementing Agreement by a Seller party to such Ancillary Implementing Agreement, and the consummation ofthe
 transactions contemplated hereby and thereby, by Seller Parent and such Seller do not and will not (a) violate any provision ofthe
 certificate of incorporation or bylaws of Seller Parent or the comparable organizational documents of any of the other Sellers orany
 of the Conveyed Subsidiaries (or any Subsidiary thereof), (b) subject to obtaining the consents set forth in Section  4.4 of  theSeller Disclosure Letter, result in a violation of, or require the consent of any Person pursuant to, or conflict with, constitute
60

a default under, or result in the breach or termination, cancellation or acceleration (whether with or without the giving of notice orthe
 lapse of time or both) of any right or obligation of the Sellers or the Conveyed Subsidiaries (or any Subsidiary thereof) under, orto a loss of any benefit of the Business to which the Sellers or the Conveyed Sub
sidiaries (or their Subsidiaries) is entitled, under anyMaterial
 Contract or Real Property Lease, or result in the imposition of a Lien on any Purchased Assets, other than Permitted Liens,and (c)
 assuming compliance with the matters set forth in Sections 4.5  and  5.5 , violate or result in a breach of or constitute a defaultunder
 any Law, Governmental Authorization or other restriction of any Governmental Authority to which any Seller or ConveyedSubsidiary
 (or Subsidiary thereof) is subject, except, with respect to clauses  (b) and  (c) , as would not, individually or in theaggregate,
 be materially adverse to the Business or prevent or reasonably be expected to prevent the Sellers from consummating theClosing prior to the Outside Date.
Section
 4.5       Governmental Authorization .  The execution, delivery and performance of this Agreement by SellerParent
 and each Ancillary Implementing Agreement by a Seller party to such Ancillary Implementing Agreement does not requireany
 Approval of, or Filing with, any Governmental Authority, except for (a) the expiration or early termination of the applicablewaiting
 period under the HSR Act, (b) the Approvals and Filings set forth in Section  4.5 of  the Seller Disclosure Letter, (c) theApprovals
 and Filings which if not obtained or made would not, individually or in the aggregate, be materially adverse to theBusiness
 or prevent or reasonably be expected to prevent the Sellers from consummating the Closing prior to the Outside Date, and(d) the Approvals and Filings required due to the regulatory obligations of Purchaser, Purchaser Parent or any of their Affiliates.
Section 4.6 
      Financial Information . (a) 
     Section 4.6(a) of  the Seller Disclosure Letter contains copies of the audited balance sheet of the Business as ofDecember
 31, 2017 (the “ Balance  Sheet Date ”),  December 31, 2016 and December 31, 2015 and the related audited incomestatement for the years ended December 31, 2017, December 31, 2016 and December 31, 2015 (together with any notes thereto, the “
Financial 
Statements  ”).  Section 4.6(a) of  the Seller Disclosure Letter also sets forth the accounts of the Business as of March 31,2018,
 June 30, 2018, and September 30, 2018 corresponding to the accounts included in the Sample Closing Statement (the “Business
 Working Capital Accounts ”).  The Business Working Capital Accounts were prepared using principles, procedures,policies
 and methods consistent in all material respects with those used in the preparation of the balance sheet of the Business as ofthe Balance Sheet Date included in the Financial Statements.
(b) 
     Except as set forth in Section  4.6(b) of  the Seller Disclosure Letter or as noted in the Financial Statements, theFinancial
 Statements were prepared in accordance with GAAP, on a consistent basis for each period presented, and present fairly inall
 material respects, (i) the financial condition, assets and liabilities of the Business as of the dates therein specified and (ii) theresults
 of  operations  of  the  Business  for  the  periods  indicated; provided  that  the  Financial  Statements  and  the  foregoingrepresentations
 and warranties concerning the Financial Statements are qualified by the fact that the Business has not operated as aseparate standalone entity and has received certain
61

allocated charges and credits as stated therein which do not necessarily reflect amounts that would have resulted from arm’s-lengthtransactions or that the Business would incur on a standalone basis.
(c) 
     Except as set forth in Section  4.6(c) of  the Seller Disclosure Letter, the Business does not have anyIndebtedness
 or other Liabilities of any nature or kind whatsoever (whether accrued, known or unknown, absolute, contingent orotherwise) that would be required to be reflected on a balance sheet of the Business prepared in accordance with GAAP except for (i)
Liabilities
 accrued  for,  reflected  on,  disclosed  and/or  reserved  against  on  the  Financial  Statements,  (ii)  Liabilities  incurredsubsequent
 to the Balance Sheet Date in the ordinary course of business, (iii) Liabilities taken into account in the Final ClosingStatement,
 Final Business Working Capital or Final Business Net Cash, (iv) the Retained Liabilities, (v) Liabilities incurred inconnection
 with or arising out of the transactions contemplated hereby, (vi) Liabilities disclosed or set forth in the Seller DisclosureLetter and (vii) Liabilities which would not, individually or in the aggregate, be materially adverse to the Business.
(d) 
     All of the information supplied by Seller Parent or its Affiliates to Purchaser Parent expressly for inclusion, orto
 support statements made, in the announcement of the Sale and the other transactions contemplated by this Agreement to bereleased immediately
 following execution of this Agreement in compliance with the Listing Rules, the Purchaser Parent ShareholderCircular,
 or any amendment or supplement thereto, or any announcement to any regulatory information service approved by theUKLA
 in connection with the Purchaser Parent Shareholder Circular, and any other related documents required to be filed orpublished in connection
 with the Sale and/or the other transactions contemplated by this Agreement, will have been prepared in goodfaith
 and will not to the Knowledge of Seller Parent, in the case of the Purchaser Parent Shareholder Circular, at the time thePurchaser Parent Sharehol
der Circular and any amendments or supplements thereto are first published in accordance with the ListingRules
 and at the time of the Purchaser Parent Shareholder Meeting, and in the case of any other such document, at the time it is firstpublished,
 contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessaryin order to make the statements therein, in light of the circumstances under which they were made, not misleading.
Section
 4.7       Absence of Material Changes .  Except as otherwise contemplated by this Agreement and thetransactions
 contemplated hereby (including the Strategic Process and the Seller Internal Restructurings), since December 31, 2017(a) 
 there has not been any Material Adverse Effect and (a)   until the date of this Agreement, the Business has been operated, in allmaterial respects, in the ordinary course of business.
Section 4.8 
      No Litigation . (a) 
     Except as set forth in Section  4.8(a) of  the Seller Disclosure Letter, there is no Action pending or, to theKnowledge
 of Seller Parent, threatened against a Conveyed Subsidiary or any Subsidiaries thereof or the Sellers or their Affiliatesrelating
 to the Business or any properties or rights of a Conveyed Subsidiary or its Subsidiaries or any Purchased Asset, before anyGovernmental
 Authority or arbitration tribunal other than Actions which would not, individually or in the aggregate, be materiallyadverse to the Business.
62

(b)      Except as set forth in Section  4.8(b) of  the Seller Disclosure Letter, none of the Conveyed Subsidiaries or anySubsidiaries
 thereof or the Sellers is subject to any Governmental Order relating to the Business or any Purchased Asset other thanthose which would not, individually or in the aggregate, be materially adverse to the Business.
Section 4.9 
      Compliance with Laws . Except as set forth in  Section 4.9  of the Seller Disclosure Letter: (a) 
     Each Seller and each Conveyed Subsidiary (and Subsidiary thereof) is, and for the last three (3) years has been,in
 compliance with all Laws applicable to the ownership, lease or operation of the Purchased Assets and the Business, including (i)the
 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq. and applicable binding implementing regulations issued by theU.S.
 Food  and  Drug  Administration,  (ii)  the  applicable  Laws  of  the  European  Union  and  applicable  binding  implementingregulations
 issued by applicable Governmental Authorities in those jurisdictions in the European Union in which the Businessmarkets,
 commercializes, distributes and sells Products, or otherwise operates, or has marketed, commercialized, distributed or soldProducts,
 or otherwise operated, in the last three (3) years (including European Union’s Directive 95/46/EC, as amended, andRegulation
 EU 2016/679 (the General Data Protection Regulation), and any national implementing legislation of the foregoing) andas
 of the Closing and (iii) the applicable Laws of any other jurisdiction in which the Business markets, commercializes, distributesand
 sells Products, or otherwise operates, or has marketed, commercialized, distributed or sold Products, or otherwise operated, inthe last three (3) years and as of the Closing, except in the case of
 each of the foregoing clauses (i)  ,  (ii) and (iii) to the extent that thefailure to comply therewith would not, individually or in the aggregate, be materially adverse to the Business.
(b) 
     The Sellers and the Conveyed Subsidiaries (and Subsidiaries thereof) collectively possess, or will possess as ofthe
 Closing, all Governmental Authorizations necessary for the conduct of the Business, as currently conducted, and each suchGovernmental
 Authorization is in full force and effect, except where the failure to possess any such Governmental Authorization orthe
 failure of such Governmental Authorization to be in full force and effect would not, individually or in the aggregate, materiallyimpair the operations of the Business, taken as a whole.
Section
 4.10       Product Registrations; Manufacturing Registrations; Regulatory Compliance;  Product Liability andRecalls 
.(a) 
     Except with respect to Environmental Permits (which are the subject of Section 4.11  ): (i) 
     Seller Parent and its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) own, possessor
 validly have the right to use all Governmental Authorizations required to research, develop, manufacture, market,commercialize,
 distribute, test, use, store and sell the Products, except where the failure to so own, possess or validlyhave
 such right would not, individually or in the aggregate, materially impair the operations of the Business, taken asa whole;
63

(ii)      All Products sold under the Product Registrations are manufactured and marketed in accordance withthe
 specifications  and  standards  contained  in  such  Product  Registrations,  and  the  applicable  ManufacturingRegistrations,
 except where the failure to comply therewith would not, individually or in the aggregate, be materiallyadverse to the Business; and
(iii) 
     Except as set forth in Section  4.10(a)(iii) of  the Seller Disclosure Letter, a Seller or ConveyedSubsidiary
 (or Subsidiary thereof) is, or will be as of the Closing, the sole and exclusive owner of each ProductRegistration and Manufacturing Registration.
(b) 
     Except as set forth in Section  4.10(b) of  the Seller Disclosure Letter, there is no Action pending, or, to theKnowledge
 of Seller Parent, threatened, relating to the Business or Purchased Assets (i) arising from complaints, allegations orActions
 relating to any injury to person or property or as a result of ownership, possession, provision or use of any of the Productsthat
 were manufactured, processed, distributed, shipped or sold prior to the date of this Agreement or (ii) relating to any allegedhazard
 or alleged defect in design, manufacture, materials or workmanship, including any failure to warn or alleged breach ofexpress
 or implied warranty or representation, relating to the Products, except in the case of each of the foregoing clauses (i)  and  (ii), for Actions which would not, individually or in the aggregate, be materially adverse to the Business.
(c) 
     Except as set forth in Section 4.10(c)  of  the Seller Disclosure Letter, since January 1, 2016, there have been norecalls
 or market withdrawals of Products and, to the Knowledge of Seller Parent, no facts or circumstances exist that wouldreasonably
 be expected to result in recalls or market withdrawals of Products that would, individually or in the aggregate, bematerially adverse to the Business.
(d) 
     Notwithstanding any other provision of this Agreement, this Section  4.10 sets  forth the sole and exclusiverepresentations
 and warranties of Seller Parent with respect to Product Registrations and Manufacturing Registrations, productsliability and product recalls, and the other regulatory matters described in this 
Section 4.10  . Section 4.11 
      Environmental Matters . Except as set forth in  Section 4.11  of the Seller Disclosure Letter: (a) 
     (i) the Sellers (with respect to the Business), the  Conveyed Subsidiaries and their Subsidiaries, the Business (ascurrently
 or formerly conducted), the Purchased Assets and the  Facilities are and  have been since January 1, 2016 in  compliancewith
 all  applicable  Environmental  Laws  and Governmental  Authorizations  required  under  Environmental  Law  (includingEnvironmental
 Permits); (ii) none of the Sellers nor  their Affiliates (in each case, with respect to the Business or the PurchasedAssets) 
are undertaking or required to undertake any Remedial Action at the Real Property or  any property formerly owned, leasedor
 operated by a Conveyed Subsidiary or their Subsidiaries (or any of their respective predecessors) or by the Business (as currentlyor
 formerly conducted) ;  and (iii) since January 1, 2016, none of the Sellers or their Affiliates has received written notice from aGovernmental
 Authority or other Person that it is subject to any unresolved enforcement action or Liability with respect to theConveyed Subsidiaries or their
64

Subsidiaries,  the  Business  (as  currently  or  formerly  conducted),  the  Purchased  Assets  or the  Facilities  under  any  applicableEnvironmental
 Laws or Environmental Permits, except for such noncompliance, Remedial Actions, Liabilities or enforcementactions that would not, individually or in the aggregate, be materially adverse to the Business;
(b) 
     all Governmental Authorizations (including Environmental Permits) required of the Sellers and  their Affiliates(in each case, with respect to the Business or the Purchased Assets) 
under all applicable Environmental Laws have been obtained and are
 held by a Seller or Conveyed Subsidiary (or Subsidiary thereof), except for such failures to obtain as would not, individually orin the aggregate, materially impair the operations of the Business, taken as a whole; and
(c) 
     no Actions or written claims are pending or,  to the Knowledge of Seller Parent, threatened against any Seller  or their Affiliates (in each case, with respect to
 the Business or the Purchased Assets) arising from or  as a result of, and there have beenno
 (i)  exposures  to  Hazardous  Materials ,  including  on,  in,  under,  about  or  from  the  Purchased  Assets  or at  the  Facilities,(ii)
 Releases of Hazardous Materials, including at ,  on, in, under, or from any Purchased Assets or from  any Facilities, (iii) off-sitetreatment,
 storage or disposal of Hazardous Materials generated by t he  Business (as currently or formerly conducted), the Sellers(with
 respect to the Business )  or any Conveyed Subsidiary or their Subsidiaries or (iv) any violations of any Environmental Lawsarising, directly or
 indirectly, in connection with the Business (as currently or formerly conducted) or any of the Purchased Assets orFacilities,
 in each case that  has resulted or would result in Environmental Liability ,  except for such claims, Actions, EnvironmentalLiabilities or investigations that would not, individually or in the aggregate, be materially adverse to the Business.
(d) 
     Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection
 4.11 are  the sole and exclusive representations and warranties of Seller Parent with respect to Environmental Laws,Environmental Permits, Environmental Liabilities, Hazardous Materials and other environmental matters.
Section 4.12 
      Material Contracts . (a) 
     Except (x) for Contracts entered into after the date of this Agreement, (y) for intercompany agreements solelybetween
 or among Conveyed Subsidiaries (or any of their Subsidiaries) or that shall be terminated as of or prior to the Closing Datein
 accordance with Section  6.7 or  (z) as set forth in Section  4.12(a) of  the Seller Disclosure Letter, none of the ConveyedSubsidiaries (or any Subsidiary thereof), Seller Parent or any of
 its Affiliates is a party to or bound by any Contract in effect as of thedate hereof that is material to the Business, taken as a whole (a “ 
Material Contract  ”). (b) 
     Except as set forth in Section 4.12(b)  of  the Seller Disclosure Letter, (i) except as would not, individually or inthe
 aggregate, be materially adverse to the Business, each Material Contract is legal, valid and binding on the Seller or ConveyedSubsidiary
 (or Subsidiary thereof) that is a party thereto and, to the Knowledge of Seller Parent, each other party thereto, and is infull
 force and effect, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance,moratorium or similar Laws affecting creditors’ rights
65

generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), and(ii)
 no Seller or Conveyed Subsidiary (or Subsidiary thereof) or, to the Knowledge of Seller Parent, any other party thereto, is inbreach
 of, or default under, any such Material Contract, except for such breaches or defaults as would not, individually or in theaggregate, be materially adverse to the Business.
(c) 
     Section 4.12(c) of the Seller Disclosure Letter lists all material Seller Parent Related Party Contracts. Section 4.13 
      Intellectual Property . (a) 
     Seller Parent has made available to Purchaser (at least two (2) Business Days prior  to the date hereof ),  acomplete
 and accurate listing (the “ IP  Schedules ”)  of all issued Patent Rights, pending applications for Patent Rights, registeredTrademarks,
 pending Trademark registration applications and registered Copyrights (collectively, the “ Registered  IP ”)  that areBusiness 
IP  (collectively, the “ Registered Business  IP ”)  which listing shall be incorporated by reference into Section 4.13(a)  of the Seller
 Disclosure Letter. To the Knowledge of Seller Parent (but only as to validity and enforceability), as of the date of thisAgreement,
 except as would not, individually or in the aggregate, be materially adverse to the Business, the Registered Business IPis
 in effect and subsisting and, if registered, is not invalid or unenforceable. The Business Trademarks Rights, together withTrademarks that are licensed to the Sellers or the Conveyed Subsidiaries by a third party, include all of the Business Key Brands.
(b) 
     All material Business IP and Business Licensed IP shall be, following the Closing, transferable and licensable(or
 sublicensable, as the case may be) by Purchaser and its Subsidiaries, without payment of any kind to Seller Parent or anyAffiliate
 of Seller Parent, as may be needed in the ordinary course of the operation of the Business, and shall be fully transferable,assignable
 and assumable, as the case may be, without payment of any kind to Seller Parent or any Affiliate of Seller Parent, inconnection
 with a change of control (that constitutes an assignment) of Purchaser or any Listing Transaction (as defined in thePurchaser
 Shareholders Agreement) or the sale of substantially all of the assets of a business unit of Purchaser to the extent suchBusiness IP or Business Licensed IP is related to such business unit.
(c) 
     Except as would not, individually or in the aggregate, be materially adverse to the Business, and taking intoaccount 
Section 6.22 ,  the Business IP, together with the Intellectual Property (i) licensed to Purchaser or its Subsidiaries by SellerParent
 or any of its Affiliates under the Ancillary Agreements (the “ Business Licensed IP  ”), (ii) covered by  the Assumed Contractsor
 Shared Contracts, or (iii) to which Purchaser or its Affiliates are provided access under any Ancillary Agreement, including inconnection
 with the services provided under the Transition Services Agreement, constitutes all of the Intellectual Property owned orcontrolled
 by Seller Parent or any of its Subsidiaries that is used or held for use in, or that is necessary for, the conduct of theBusiness,
 as conducted as of the date of this Agreement. The operation of the Business immediately following the Closing will notinfringe any of Seller Parent’s or any of its Affiliates’ Intellectual Property.
(d) 
     Except as would not, individually or in the aggregate, be materially adverse to the Business, (x) the conduct ofthe Business does not, to the Knowledge of Seller Parent, infringe,
66

misappropriate or otherwise violate the Intellectual Property of any Person and (y) as of the date of this Agreement, there is noAction
 pending or, to the Knowledge of Seller Parent, threatened in writing against any Conveyed Subsidiary or any Subsidiarythereof
 or any Seller or any of its Affiliates (i) alleging any such infringement, misappropriation, or other violation, or (ii)challenging
 the validity, enforceability, ownership, use, registrability, or patentability of the Business IP, other than ordinary courseprosecution proceedings associated with the application for or registration of Registered IP.
(e) 
     Except as would not, individually or in the aggregate, be materially adverse to the Business, as of the date ofthis
 Agreement, to the Knowledge of Seller Parent, no Person is infringing, misappropriating or otherwise violating any Business IPand
 as of the date of this Agreement, no such Actions are pending or, to the Knowledge of Seller Parent, threatened against anyPerson by Seller Parent, or any of its Affiliates (including any Conveyed Subsidiary or any Subsidiary thereof) or any other Seller.
(f) 
     Seller Parent or its Subsidiaries (including the Conveyed Subsidiaries), as applicable, are the sole legal ownersof
 all Registered Business IP that is owned or purported to be owned by Seller Parent or its Affiliates. None of the RegisteredBusiness IP or any other material Business IP is subject to any Lien, other than Permitted Liens.
(g) 
     Since January 1, 2016, to the Knowledge of Seller Parent, there (i) have been no failures of the Business ITSystems
 that have materially and adversely impacted the conduct of the Business and (ii) has been no unauthorized access, loss, useor
 breach of security with respect to the Business IT Systems or any material sensitive, confidential or proprietary information(including personally identifiable information) relating to the Business that have materially and adversely impacted the Business.
(h) 
     Notwithstanding any provision of this Agreement to the contrary, except with respect to Section  4.7 , Section
 4.12 ,  and this Section  4.13 sets  forth the sole and exclusive representations and warranties of Seller Parent with respect toIntellectual Property.
Section 4.14 
      Real Property . (a) 
     The Sellers or the Conveyed Subsidiaries (or their Subsidiaries) have, or will have as of the Closing, insurabletitle
 in fee simple to the Owned Real Property, free and clear of any Liens, other than Permitted Liens. Except as set forth inSection
 4.14(a) of  the Seller Disclosure Letter or as would not, individually or in the aggregate, materially impair the operations ofthe
 Business, taken as a whole, neither Sellers nor the Conveyed Subsidiaries (or their Subsidiaries) is leasing or otherwise grantingto any third party the right to use or occupy any Owned Real Property or any portion thereof.
(b) 
     Except as set forth in Section 4.14(b)(i)  of the Seller Disclosure Letter, Selle rs or the Conveyed Subsidiaries (ortheir
 Subsidiaries) has a valid leasehold interest and valid and continuing right to use and occupy each Leased Real Propertypursuant
 to a Real Property Lease. Except (x) as set forth in Section  4.14(b)(ii) of  the Seller Disclosure Letter, or (y) as would not,individually or in the aggregate, materially impair the operations of the Business, taken as a whole,
67

(i) each Real Property Lease is legal, valid and binding on the Seller or Conveyed Subsidiary (or Subsidiary thereof) that is a partythereto
 and, to the Knowledge of Seller Parent, each other party thereto and is in full force and effect, except as enforcement may belimited
 by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rightsgenerally
 or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), (ii) noSeller
 or Conveyed Subsidiary (or Subsidiary thereof) or, to the Knowledge of Seller Parent, any other party thereto, is in breach of,or
 default under, any such Real Property Lease and (iii) neither the Sellers nor the Conveyed Subsidiaries (or their Subsidiaries) isleasing or otherwise granting to any third party the right to use or occupy any Leased Real Property or any portion thereof.
(c) 
     Except as set forth in Section  4.14(c) of  the Seller Disclosure Letter, (i) no certificate, permit or license fromany
 Governmental Authority having jurisdiction over any of the Real Property, or any Contract, easement or other right which isnecessary
 to permit the lawful occupancy of the buildings and improvements on any of the Real Property or which is necessary topermit
 the lawful use of all driveways, roads and other means of egress and ingress to and from any of the Real Property, in eachcase,
 with respect to the Business, has not been obtained or, to the Knowledge of Seller Parent, is not in full force and effect, whichwould,
 individually or in the aggregate, materially impair the operations of the Business, taken as a whole, and (ii) none of theSellers
 (in respect of the Business) or the Conveyed Subsidiaries or their Subsidiaries has received any written notice from anyGovernmental
 Authority that the Real Property is currently in violation of any applicable Law that would, individually or in theaggregate, materially impair the operations of the Business, taken as a whole.
(d) 
     Section 4.14(d)(i) of  the Seller Disclosure Letter sets forth each manufacturing and research and developmentfacility at
 which Products are manufactured or developed that is owned or operated by Sellers or the Conveyed Subsidiaries (or theirSubsidiaries)
 (the “ Seller  Facilities ”).  Except as set forth in Section  4.14(d)(ii) of  the Seller Disclosure Letter, Sellers or theConveyed
 Subsidiaries (or their Subsidiaries) has insurable title in fee simple to, or a valid leasehold interest and valid andcontinuing right to use and occupy, each Seller Facility.
Section 4.15 
      Assets .(a) 
     Except as otherwise provided in this Agreement or as would not, individually or in the aggregate, materiallyimpair
 the operations of the Business, taken as a whole, the Sellers or the Conveyed Subsidiaries (or their Subsidiaries) have, or willhave
 as of the Closing, good and valid title to, or other legal rights to possess and use, all of the assets comprising the businessreflected
 in the Financial Statements (for clarity, excluding any assets sold or disposed of in the ordinary course of business after thedate thereof), free and clear of any Liens other than Permitted Liens.
(b) 
     Except (i) as set forth in Section 4.15(b)  of the  Seller Disclosure Letter (ii) for Excluded Services (as defined inthe
 Transition Services Agreement) and (iii) as would not, individually or in the aggregate, materially impair the operations of theBusiness,
 taken as a whole, the Purchased Assets (assuming all consents and Approvals as may be required in connection with theconsummation of the transactions contemplated by this Agreement and the Ancillary Agreements
68

have been obtained; provided  ,  that no such assumption shall be made to the extent Seller Parent is not in compliance with itsobligations
 under Section  2.2 and  Section 6.3 of  this Agreement), together with the benefits, services, assets, licenses, sublicensesand other
 rights and benefits to be provided to Purchaser and its Affiliates pursuant to this Agreement and the Ancillary Agreements,will,
 in the aggregate, constitute all of the assets either used in or necessary for Purchaser and its Subsidiaries (including theConveyed
 Subsidiaries and their Subsidiaries) to conduct the Business as conducted as of the date of this Agreement and as of theClosing.
(c) 
     After giving effect to the Seller Internal Restructurings and the other transactions contemplated by thisAgreement
 and  the  Ancillary  Agreements  (assuming  all  consents  and  Approvals  as  may  be  required  in  connection  with  theconsummation of the transactions contemplated
 by this Agreement and the Ancillary Agreements have been obtained; provided  , that no
 such assumption shall be made to the extent Seller Parent is not in compliance with its obligations under Section  2.2 and Section
 6.3 of  this Agreement) and except as provided for in the Ancillary Agreements, the Conveyed Subsidiaries (and theSubsidiaries
 thereof) will not, directly or indirectly, be engaged in any Retained Business, or hold or be subject to any RetainedLiability or Excluded Asset (other than non-material 
or ministerial liabilities, assets, rights or properties). Section 4.16 
      Taxes .(a) 
     All income and other material Tax Returns that are required to be filed in respect of the Purchased Assets or theBusiness
 or by or on behalf of any Conveyed Subsidiary or Subsidiary thereof have been timely filed (taking into account anyapplicable extensions), and all such Tax Returns are true, correct and complete in all material respects.
(b) 
     All income and other material Taxes required to be paid in respect of the Purchased Assets or the Business orby
 or in respect of any Conveyed Subsidiary or any Subsidiary thereof have been timely paid (taking into account any applicableextensions).
(c) 
     The Conveyed Subsidiaries (and the Subsidiaries thereof), and the Sellers solely with respect to the Business,have
 deducted or withheld and paid over to the applicable Taxing Authority all material Taxes required to have been deducted orwithheld and paid over in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder
or
 other third party and each such Conveyed Subsidiary or Subsidiary thereof has (if required by any applicable Laws to do so)provided appropriate certificates of deduction.
(d) 
     There are no Liens for material Taxes upon any of the Purchased Assets or the assets of the ConveyedSubsidiaries or any of their Subsidiaries, except for Permitted Liens.
(e) 
     Within the past three (3) years, none of the Conveyed Subsidiaries and none of their Subsidiaries has been a“distributing corporation” or a “controlled corporation” in a distribution intended to qualify under Section 355(a) of the Code.
(f) 
     There are no current or pending audits, examinations, contests or other Actions with respect to material Taxes ofany Conveyed Subsidiary or any Subsidiary thereof or of
69

any Seller with respect to any Purchased Assets or the Business, and no such audits, examinations, contests or other Actions havebeen threatened in writing.
(g) 
     There are no outstanding powers of attorney granted by any of the Conveyed Subsidiaries or any Subsidiarythereof with
 respect to material Taxes for any taxable period beginning after the Closing Date, other than powers of attorney grantedto other Conveyed Subsidiaries or Subsidiaries thereof.
(h) 
     None of the Conveyed Subsidiaries or any Subsidiary thereof is party to any Tax sharing, allocation, indemnityor
 similar agreement or arrangement (other than (x) any such agreement or arrangement solely between or among two or moreConveyed
 Subsidiaries and/or Subsidiaries thereof and (y) provisions contained in commercial agreements or arrangements theprimary
 purpose of which is not Taxes (including employment agreements, credit agreements, leases and supply or manufacturingagreements)).
(i) 
     None of the Conveyed Subsidiaries or Subsidiaries thereof is or has been party to any “listed transaction” asdefined
 in Section 6707A of the Code and Treasury Regulations Section 1.6011-4. No Conveyed Subsidiary or Subsidiary thereofhas
 at any time entered into or been engaged in or been a party to or promoter of any scheme, transaction or arrangement which wasrequired
 by Law to be specifically disclosed to a Taxing Authority or a main or dominant purpose or object of which was theavoidance or deferral of or the obtaining of a reduction in or other advantage in respect of any Taxes.
(j) 
     In the last three (3) years, no claim has been made in writing by any Taxing Authority in any jurisdiction inwhich
 any of the Conveyed Subsidiaries or Subsidiaries thereof, or any Seller with respect to the Business or any Purchased Assets,does
 not file income or franchise Tax Returns to the effect that such entity is or may be subject to income or franchise taxation bysuch jurisdiction.
(k) 
     None of the Conveyed Subsidiaries or Subsidiaries thereof will be required to include any material item ofincome
 in, or exclude any material item of deduction from, taxable income for any taxable period beginning after the Closing Dateas
 a result of: (i) change in method of accounting for a taxable period ending on or prior to the Closing Date made prior to theClosing,
 (ii) “closing agreement” executed prior to the Closing, (iii) intercompany transaction or excess loss account described inTreasury
 Regulations under Section 1502 of the Code entered into or existing prior to the Closing, (iv) prepaid amount received onor
 prior to the Closing, (v) election under Section 108(i) of the Code made prior to the Closing or (vi) installment sale or opentransaction disposition occurring on or before the Closing Date.
(l) 
     Neither entering into this Agreement nor consummating the transactions contemplated hereby, nor, so far asSeller
 Parent is aware, any other event, transaction, action or circumstance will give rise to any Liability for Tax or result in thewithdrawal
 or clawback of any Tax Benefit for any Conveyed Subsidiary or any Subsidiary of any Conveyed Subsidiary as a resultof any Conveyed Subsidiary or any Subsidiary of any Conveyed Subsidiary ceasing to be a member of a group with any other Person
for Tax purposes.
70

(m)      Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection
 4.16 and  Section 4.17 (to  the extent related to Taxes) are the sole and exclusive representations and warranties of SellerParent with respect to Taxes.
Section 4.17 
      Employee Benefits; Employees . (a) 
     Set forth in Section  4.17(a) of  the Seller Disclosure Letter is a true and complete list of each material SellerGroup
 Plan and Foreign Seller Group Plan categorized by (i) whether the Seller Group Plan or Foreign Seller Group Plan is aConveyed
 Subsidiary Plan and (ii) the country or countries for which such Seller Group Plan or Foreign Seller Group Plan providesbenefits.
 No Conveyed Subsidiary Plan provides benefits to, or otherwise covers, any individual who is not a Business Employee,Former Business Employee, or the dependents or beneficiaries thereof.
(b) 
     With respect to each material Conveyed Subsidiary Plan (other than Foreign Seller Group Plans that are notdefined
 benefit pension plans), Seller Parent has made available to Purchaser Parent, prior to the date of this Agreement, true andcomplete copies of (i) each such plan’s governing
 document and any amendments thereto (or a written summary of all material termsif
 the plan has not been reduced to writing) and (ii) any applicable Plan Regulatory or Funding Documents. In addition, within thirty(30)
 days following the date hereof, with respect to each (x) material Conveyed Subsidiary Plan that is a Foreign Seller Group Plan,Seller
 Parent shall make available to Purchaser true and complete copies of the documents contemplated by the immediatelypreceding
 sentence, and (y) each other material Seller Group Plan or Foreign Seller Group Plan for which Purchaser, the ConveyedSubsidiaries
 or their respective Affiliates have or will assume Liability following the Closing, Seller Parent shall make available toPurchaser
 Parent summaries of the material terms of such plans, the most recent summary plan description (if any) and excerpts orsummaries
 of the actuarial reports for such plans to the extent relevant to the Liabilities being assumed. Seller Parent has madeavailable
 to Purchaser Parent, on or prior to the date of this Agreement, a summary that is accurate in all material respects of thevalue
 of the assets and Liabilities of the Seller Pension Plans that relate to Business Employees and Former Business Employees asof the end of the 2017 fiscal year of Seller Parent.
(c) 
     The IRS has issued a favorable determination letter, or for a prototype plan, opinion letter, with respect to eachConveyed Subsidiary Plan intended to be qualified
 within the meaning of Section 401(a) of the Code or, if no such determination hasbeen made, either
 an application for such determination is pending with the IRS or the time within which such determination may besought
 from the IRS has not yet expired, and, to the Knowledge of Seller Parent, nothing has occurred since the date of suchdetermination
 or opinion that would reasonably be expected to result in disqualification of such Conveyed Subsidiary Plan. EachConveyed Subsidiary Plan
 that is intended to qualify for any particular tax or regulatory treatment under the Laws of a country otherthan
 the United States (i) has received documentation of such qualification from a Governmental Authority (if available), and, to theKnowledge
 of Seller Parent, nothing has occurred since the date of such documentation that would reasonably be expected to resultin
 disqualification of such Conveyed Subsidiary Plan or (ii) if such documentation is not available, to the Knowledge of SellerParent, so qualifies.
71

(d)      No Seller Group Plan is a “multiemployer plan,” as such term is defined in Section 3(37) of ERISA, nor is anyConveyed
 Subsidiary Plan subject to Section 302 or Title IV of ERISA or Section 412 of the Code. None of the Purchased Assets issubject
 to a lien under Section 430(k) of the Code or Section 4068 of ERISA, and neither Seller Parent nor any of its ERISAAffiliates
 has incurred any liability under Title IV of ERISA (other than premium payments to the Pension Benefit GuarantyCorporation
 in the ordinary course) or Section 4971 of the Code which has not been and will not be fully paid as of the Closing.None
 of the Conveyed Subsidiaries (or the Subsidiaries thereof) or the Business has as of the date of this Agreement, or will have asof
 the Closing, any Liability in respect of post-employment or post-retirement medical, health or life insurance benefits for anycurrent
 or former employees, except as required by applicable Law or to avoid excise tax under Section 4980B of the Code. Exceptas
 set forth on Section 4.17(d)  of the  Seller Disclosure Letter, no Seller Group Plan or Foreign Seller Group Plan is a defined benefitpension plan.
(e) 
     Each Seller Group Plan and Foreign Seller Group Plan (other than a Conveyed Subsidiary Plan) has beenmaintained,
 operated, funded and administered in compliance in all respects with its terms and applicable Law, except for suchinstances
 of noncompliance that would not, individually or in the aggregate, be materially adverse to the Business. Each ConveyedSubsidiary
 Plan has been established, maintained, funded and administered in compliance in all material respects its terms andapplicable
 Law. All material contributions or premiums with respect to each Conveyed Subsidiary Plan have been paid or deductedin a timely
 fashion and there are no material outstanding defaults or violations thereunder that have not been properly recorded in theFinancial
 Statements. Other than routine claims for benefits, there are no suits, claims, proceedings, actions, governmental audits orinvestigations
 that are pending or threatened against or involving any Seller Group Plan or Foreign Seller Group Plan or assertingany
 rights to or claims for benefits under any Seller Group Plan or Foreign Seller Group Plan, except for such actions that have nothad and would not, individually or in the aggregate, a be materially adverse to the Business.
(f) 
     Except as set forth in Section  4.17(f) of  the Seller Disclosure Letter: (i) none of the Conveyed Subsidiaries (oremployers
 of Business Employees who are not as of Closing employed in a Conveyed Subsidiary) recognize a labor union (in thecase
 of employers that are not Conveyed Subsidiaries or Subsidiaries thereof, excluding any labor union that does not represent theBusiness
 Employees) and none of the Business Employees are represented by any labor organization, works council or consultationbody
 (other than industry-wide or national labor organizations) or subject to, or covered by, the terms of any material CollectiveBargaining
 Agreement in connection with their services to the Business, (ii) no labor union, labor organization, works council orconsultation
 body has made a demand for recognition or certification, and there are no representation or certification proceedings,union
 elections or, to the Knowledge of Seller Parent, union organizing activities, pending or threatened in writing with respect tothe Business
 Employees, the Business or the Conveyed Subsidiaries or their Affiliates with respect to the Business, (iii)  there are nopending
 or threatened in writing strikes, lockouts, work stoppages or slowdowns involving the Business Employees or against theBusiness
 or the Conveyed Subsidiaries or their Affiliates with respect to the Business and (iv) there is no unfair labor practicecharge,
 labor arbitration or labor grievance proceeding pending or threatened in writing against the Business or the ConveyedSubsidiaries or their Affiliates with respect to the Business that would, in the case of
72

the foregoing clauses  (iii)  and  (iv) , individually or in the aggregate, be materially adverse to the Business. As of the date hereof,Seller
 Parent has provided copies to Purchaser of all material Collective Bargaining Agreements applicable to Business Employees,the
 Business or the Conveyed Subsidiaries or their Subsidiaries. Seller Parent, the Conveyed Subsidiaries and their respectiveSubsidiaries
 have satisfied any material pre-signing requirement to provide notice to, or enter into any information and consultationprocedure
 with, any labor union, labor organization, works council or consultation body in connection with the execution of thisAgreement or the transactions contemplated by this Agreement as required by any Contract or Laws.
(g) 
     As of the Closing, Seller Parent represents that each Business Employee devotes, and has devoted seventypercent (70%)
 or more of his or her working time in the last twelve (12) months (or such shorter period he or she has been employedby Seller Parent and its Affiliates) to performing services on behalf of the Business.
(h) 
     As at the date hereof, the Seller Internal Restructurings in France and Netherlands have been completed inaccordance
 with  applicable  Laws  (including  obtaining  requisite  opinions  from  applicable  works  councils  and  employeerepresentative
 bodies) such that there are no Business Employees employed in the Business in France or Netherlands other thanthose employed by a Conveyed Subsidiary.
(i) 
     Except as required by plans, programs, or arrangements required to be maintained or contributed to by the Lawsof
 a  non-U.S.  jurisdiction,  neither  the  execution  and  delivery  of  this  Agreement,  nor  the  consummation  of  the  transactionscontemplated
 hereby (either alone or in conjunction with any other event), will cause any (i) payments to become due or payable toany Business
 Employee, Former Business Employee, current or former consultant or director, (ii) acceleration, vesting or increase inany
 compensation or benefits to any Business Employee, Former Business Employee, current or former consultant or director, or(iii)
 Conveyed Subsidiary (or a Subsidiary thereof) to transfer or set aside any assets to fund any benefits under any ConveyedSubsidiary
 Plan, or limit or restrict in any material respect the right of Purchaser or any of its Affiliates or any Conveyed Subsidiary(or
 a Subsidiary thereof) to amend, terminate or transfer the assets of any Conveyed Subsidiary Plan. Neither the execution anddelivery
 of this Agreement, nor the consummation of the transactions contemplated herein, will constitute a “change in ownership orcontrol” or
 “change in effective control” of Seller Parent within the meaning of Section 280G of the Code. No Conveyed Subsidiary(or
 any Subsidiary thereof) is party to any plan, program, policy or arrangement providing for the “gross-up” or other compensationto
 any individual because of the imposition of any Tax on any payment to the individual related to Section 4999 or Section 409A ofthe Code.
Section 4.18 
      Global Trade Controls; Anti-Corruption Matters . (a) 
     The Sellers (with respect to the Business), the Conveyed Subsidiaries (and their Subsidiaries), as well as theirrespective
 directors, officers, and employees, are in compliance with all Global Trade Control Laws, including possession of andcompliance
 with Governmental Authorizations required by Global Trade Control Laws, except for such noncompliance as wouldnot, individually or in the aggregate, be materially adverse to the Business.
73

(b)      The Sellers (with respect to the Business) and the Conveyed Subsidiaries (and their Subsidiaries) do not engagein
 any business with, or use, directly or indirectly, any corporate funds to contribute to or finance the activities of, any RestrictedParty
 or in any Restricted Market except as permitted by Governmental Authorization, except as would not, individually or in theaggregate, be materially adverse to the Business.
(c) 
     None of the Sellers (with respect to the Business), the Conveyed Subsidiaries (and their Subsidiaries), nor anyof their respective directors, officers, and employees, is a Restricted Party or owned or controlled by a Restricted Party.
(d) 
     To Seller Parent’s Knowledge, the Sellers (with respect to the Business), the Conveyed Subsidiaries (and theirSubsidiaries),
 as well as their respective directors, officers, and employees are in compliance with all Anti-Corruption Laws, exceptfor
 such noncompliance as would not, individually or in the aggregate, be materially adverse to the Business. For purposes of thisSection
 4.18(d) only,  “Seller Parent’s Knowledge” means that the conduct giving rise to the noncompliance with or violation ofAnti-Corruption
 Law was reported to the Compliance Division of Seller Parent and such conduct is or was the subject of aCompliance Division investigation on or prior to the Closing Date.
(e) 
     Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection
 4.18 are  the sole and exclusive representations and warranties of Seller Parent with respect to Global Trade Control Lawsand Anti-Corruption Laws.
Section
 4.19       Brokers . No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee orcommission
 in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf ofSeller
 Parent  for  which  Purchaser  or  any  of  its  Affiliates  (including,  after  the  Closing,  the  Conveyed  Subsidiaries  or  theirSubsidiaries)
 would  be  liable.  Seller  Parent  is  solely  responsible  for  the  fees  and  expenses  of  Centerview  Partners,  LLC,Guggenheim Securities, LLC and Morgan Stanley & Co. LLC.
Section 4.20 
      No Other Representations or Warranties . (a) 
     Except for the representations and warranties contained in this Article  IV or  in any Ancillary ImplementingAgreement,
 neither Seller Parent, the other Sellers nor any of their respective Affiliates, Representatives or any other Person makesany
 express or implied representation or warranty with respect to Seller Parent, the other Sellers, the Conveyed Subsidiaries or anyof their respective Subsidiaries or Affiliates, the
 Purchased Assets, the Business or with respect to any other information provided, ormade
 available, to Purchaser Parent, Purchaser or any of their Affiliates or Representatives in connection with the transactionscontemplated
 hereby. Except as expressly set forth in the representations and warranties contained in this Article  IV or  in anyAncillary Implementin
g Agreement, neither Seller Parent nor any of its Affiliates, Representatives or any other Person has made anyrepresentat
ion or warranty, express or implied, as to the prospects of the Business or its profitability, or with respect to any forecasts,projections or
 business plans or other information (including any Evaluation Material (as defined in the Confidentiality Agreement))delivered
 to Purchaser Parent, Purchaser or any of their Affiliates or Representatives in connection with Purchaser Parent’s andPurchaser’s review of the Business and
74

the negotiation and execution of this Agreement, including as to the accuracy or completeness thereof or the reasonableness of anyassumptions
 underlying any such forecasts, projections or business plans or other information. Except to the extent expresslyprovided
 in this Agreement with respect to the representations and warranties contained in this Article  IV or  in any AncillaryImplementing
 Agreement, neither Seller Parent, the other Sellers nor any of their respective Affiliates, Representatives or any otherPerson will have,
 or be subject to, any Liability or other obligation to Purchaser Parent, Purchaser, their Affiliates or Representativesor
 any other Person resulting from the sale and purchase of the Purchased Assets, or the Business to Purchaser Parent, Purchaser ortheir
 Affiliates or Purchaser Parent’s or Purchaser’s use of, or the use by any of their Affiliates or Representatives of, anyinformation,
 including information, documents, projections, forecasts, business plans or other material (including any EvaluationMaterial
 (as  defined  in  the  Confidentiality  Agreement))  made  available  to  Purchaser  Parent,  Purchaser,  their  Affiliates  orRepresentatives
 by  any  means,  including  in  any  virtual  data  room,  confidential  information  memorandum,  managementpresentations, offering materials, site tours or visits, diligence calls or
 meetings or any documents prepared by, or on behalf of, SellerParent,
 the other Sellers or any of their respective Affiliates or Representatives, or Purchaser Parent, Purchaser or their Affiliates orRepresentatives.
 Each of Seller Parent and the other Sellers and their respective Affiliates disclaims any and all representations andwarranties,
 whether express or implied, except for the representations and warranties contained in this Article IV  or  in any AncillaryImplementing
 Agreement. Notwithstanding anything to the contrary contained in this Agreement, neither Seller Parent, the otherSellers
 nor any of their respective Affiliates makes any express or implied representation or warranty with respect to ExcludedAssets, Retained Businesses or Retained Liabilities.
(b) 
     Seller Parent acknowledges and agrees that, except for the representations and warranties contained in Article V or
 in  any  Ancillary  Implementing  Agreement,  neither  Purchaser  Parent,  Purchaser  nor  any  of  their  respective  Affiliates,Representatives
 or any other Person makes any express or implied representation or warranty with respect to Purchaser Parent,Purchaser
 or any of their respective Subsidiaries or Affiliates, the Purchaser Business or with respect to any other informationprovided,
 or  made  available,  to  Seller  Parent  or  any  of  its  Affiliates  or  Representatives  in  connection  with  the  transactionscontemplated
 hereby. Seller Parent acknowledges and agrees that, except to the extent expressly provided in this Agreement withrespect
 to the representations and warranties contained in Article  V or  in any Ancillary Implementing Agreement, neither PurchaserParent,
 Purchaser nor any of their respective Affiliates, Representatives or any other Person will have, or be subject to, any Liabilityor
 other obligation to Seller Parent or any of its Affiliates or Representatives or any other Person resulting from Seller Parent’s useof, or the use by any
 of its Affiliates or Representatives of any information, including information, documents, projections, forecasts,business plans
 or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) made available toSeller
 Parent or any of its Affiliates or Representatives by any means, including in any virtual data room, confidential informationmemorandum,
 management presentations, offering materials, site tours or visits, diligence calls or meetings or any documentsprepared
 by, or on behalf of, Purchaser Parent, Purchaser or any of their respective Affiliates or Representatives. Seller Parentacknowledges
 and agrees that it is not relying on any representation or warranty of Purchaser Parent, Purchaser, or any of theirAffiliates or Representatives or any other
 Person, other than those representations and warranties specifically set forth in Article V  or in any Ancillary Implementing Agreement. Seller
75

Parent acknowledges and agrees that each of Purchaser Parent and Purchaser and their respective Affiliates disclaims any and allrepresentations and
 warranties, whether express or implied, except for the representations and warranties contained in Article V  or in any
 Ancillary Implementing Agreement. Seller Parent acknowledges and agrees that neither Purchaser Parent, Purchaser nor any oftheir
 respective Affiliates makes any express or implied representation or warranty with respect to the Purchaser Parent RetainedBusinesses or Purchaser Parent Retained Liabilities.
(c) 
     Seller Parent acknowledges that it has conducted to its satisfaction an independent investigation of the financialcondition,
 results of operations and projected operations of Purchaser and the Purchaser Business and the nature and condition of itsproperties,
 assets, liabilities and businesses and, in making the determination to proceed with the transactions contemplated hereby,has
 relied solely on the results of its own independent investigation and the representations and warranties set forth in Article  V or any
 Ancillary Implementing Agreement. In light of these inspections and investigations and the representations and warranties madeto
 Seller Parent by Purchaser Parent in Article  V or  in any Ancillary Implementing Agreement, Seller Parent is relinquishing anyright
 to any claim based on any representations and warranties other than those specifically included in Article V  or in any Ancillary Implementing
 Agreement. Any claims Seller Parent may have for breach of representation or warranty shall be based solely on therepresentations and warranties of Purchaser Parent set forth in 
Article V  or in any Ancillary Implementing Agreement. (d) 
     Seller Parent acknowledges that, except as explicitly set forth herein, neither Purchaser Parent, Purchaser norany
 of their Affiliates has made any warranty, express or implied, as to the prospects of Purchaser or the Purchaser Business or theirprofitability,
 or with respect to any forecasts, projections or business plans or other information (including any Evaluation Material(as
 defined in the Confidentiality Agreement)) delivered to Seller Parent or any of its Affiliates or Representatives in connectionwith
 Seller Parent’s review of the Purchaser Business and the negotiation and execution of this Agreement, including as to theaccuracy
 or completeness thereof or the reasonableness of any assumptions underlying any such forecasts, projections or businessplans or other information.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF PURCHASER PARENT
Except
 as set forth in the Purchaser Parent Disclosure Letter and in accordance with Section  10.8 ,  Purchaser Parenthereby represents and warrants to Seller Parent and Purchaser as follows:
Section
 5.1       Organization .  Each of Purchaser Parent and Purchaser is validly existing and is a company dulyincorporated and registered under the laws of England.
Section 5.2 
      Authority; Binding Effect . (a) 
     Purchaser Parent, Purchaser and each applicable Purchaser Designated Affiliate have all requisite corporate orother similar applicable power and authority to execute and
76

deliver this Agreement and each Ancillary Agreement to which it will be a party, and, subject to receipt of the Purchaser ParentShareholder
 Approval, to perform their obligations hereunder and thereunder. The execution and delivery by Purchaser Parent andPurchaser
 of this Agreement and, subject to receipt of the Purchaser Parent Shareholder Approval, the performance by PurchaserParent
 and Purchaser of their obligations hereunder have been, and the execution and delivery by Purchaser Parent, Purchaser andeach
 Purchaser Designated Affiliate of each Ancillary Agreement to which it will be a party and the performance by PurchaserParent,
 Purchaser and such Purchaser Designated Affiliates of their obligations thereunder have been or will have been as of theClosing, duly
 authorized by all requisite corporate or other similar applicable action. At a meeting duly called and held, the Board ofDirectors
 of Purchaser Parent has unanimously (i) approved this Agreement and the Sale and the other transactions contemplatedhereby
 in accordance with applicable Law, (ii) directed that the Purchaser Parent Shareholder Circular be prepared and, subject tothe
 approval of that circular by the UKLA, published in accordance with the terms of this Agreement, (iii) subject to the publicationof
 the Purchaser Parent Shareholder Circular and Section  6.24(f) ,  resolved that the Purchaser Parent Shareholder Meeting beconvened
 for the purpose of obtaining the Purchaser Parent Shareholder Approval and (iv) resolved, subject to Section  6.24(f) ,  to(1)
 unanimously recommend approval by Purchaser Parent’s shareholders of the Purchaser Parent Shareholder Approval Resolutionto
 Purchaser Parent’s shareholders, including in the Purchaser Parent Shareholder Circular, without qualification, and (2) state in thePurchaser
 Parent Shareholder Circular that the Sale and the other transactions contemplated by this Agreement are, in the Board ofDirectors
 of the Purchaser Parent’s opinion, fair and reasonable so far as the Purchaser Parent shareholders are concerned and thatthe
 Board  of  Directors  have  been  so  advised  by  Citigroup  Global  Markets  Limited  and  J.P.  Morgan  Securities  plc  (suchrecommendation
 and statement being together, the “ Purchaser  Parent Board Recommendation ”).  As of the date of this Agreement,the
 Board of Directors of Purchaser Parent has not subsequently rescinded, modified or withdrawn any of the foregoing resolutions.The
 approval of the Sale and the other transactions contemplated by this Agreement by the holders of ordinary shares of PurchaserParent,
 by way of approval of the Purchaser Parent Shareholder Approval Resolution at the Purchaser Parent Shareholder Meeting(the
 “ Purchaser Parent Shareholder Approval ”)  is the only Approval required from the holders of Purchaser Parent’s ordinaryshares
 or other securities of Purchaser Parent or its Affiliates in connection with the consummation of the Sale and the othertransactions contemplated by this Agreement.
(b) 
     Purchaser Parent, Purchaser and each Subsidiary of Purchaser has, or will have as of the Closing, all requisitecorporate
 or other similar applicable power and authority to carry on its respective business as it pertains to the Purchaser Businessas
 currently conducted and to own, lease and operate its properties and assets related to the Purchaser Business, except where thefailure
 to have such power and authority would not, individually or in the aggregate, be materially adverse to Purchaser or thePurchaser
 Business or prevent or reasonably be expected to prevent Purchaser Parent, Purchaser or any Purchaser DesignatedAffiliate from consummating the
 Closing prior to the Outside Date. Purchaser is duly qualified to do business and, where applicable,in
 good standing in each jurisdiction where the nature of its business or properties makes such qualification necessary, except wherethe
 failure to be so qualified or in good standing would not, individually or in the aggregate, be materially adverse to Purchaser orthe Purchaser Business.
77

(c)      This Agreement has been duly executed and delivered by Purchaser Parent and Purchaser and, assuming thisAgreement
 has been duly executed and delivered by Seller Parent, constitutes a legal, valid and binding obligation of PurchaserParent
 and Purchaser, and each Ancillary Agreement will be as of the Closing duly executed and delivered by Purchaser Parent,Purchaser
 and each Purchaser Designated Affiliate which will be a party thereto and will, assuming such Ancillary Agreement hasbeen
 duly executed and delivered by each Seller that will be a party thereto, constitute a legal, valid and binding obligation ofPurchaser
 Parent, Purchaser and such Purchaser Designated Affiliate, in each case enforceable against Purchaser Parent, Purchaserand
 such Purchaser Designated Affiliate (as applicable) in accordance with its terms, except as enforcement may be limited bybankruptcy,
 insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally orby general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).
Section 5.3 
      Purchaser; Purchaser Subsidiaries; Capital Structure . (a) 
     As of the date hereof, the issued share capital of Purchaser is 63,500 ordinary shares. All of the issued ordinaryshares
 of Purchaser have been validly issued, fully paid and non-assessable, and are not subject to, and were not issued in violationof,
 any preemptive right. The B Ordinary Shares, when issued in accordance with this Agreement at Closing, will be validly issued,fully
 paid and non-assessable, and will not be issued in violation of any preemptive right. As of the Closing, there will be nooutstanding
 warrants, options, agreements, subscriptions, convertible or exchangeable securities or other commitments pursuant towhich
 Purchaser is or may become obliged to issue, sell, purchase, return, redeem or otherwise acquire any of its shares, or anysecurities convertible into or exchangeable for its shares. As of the Closing, there will be no rights of first refusal, rights of first offer,
voting
 trusts, shareholder agreements, proxies or other Contracts in effect with respect to the sale or voting of any of the shares ofPurchaser.
 A wholly owned Subsidiary of Purchaser Parent owns legally and beneficially as of the date of this Agreement, and willown legally
 and beneficially as of immediately prior to the Closing, all of the issued shares in the capital of Purchaser, free and clearof
 all Liens except for Liens arising under applicable securities Laws. As of and immediately following the Closing, after givingeffect
 to the Sale and the issuance of the Purchase Consideration, a wholly owned Subsidiary of Purchaser Parent will own legallyand
 beneficially 680,000 A Ordinary Shares and 300,000 Preference Shares, and Seller Parent (or its applicable designee(s)) willown
 legally and beneficially 320,000 B Ordinary Shares, in each case on the terms and subject to the rights and restrictions set forthin
 the Restated Purchaser Articles of Association and the Purchaser Shareholders Agreement, which such shares shall togetherconstitute
 the entire issued share capital of Purchaser, and there will be no other ordinary shares, preference shares or other equityinterests,
 or warrants, options, agreements, subscriptions, convertible or exchangeable securities or other commitments pursuant towhich
 Purchaser is or may become obliged to issue, sell, purchase, return, redeem or otherwise acquire any shares, or any otherequity interests, or any securities convertible into or exchangeable for shares, or any other equity interests, of Purchaser.
(b) 
     Each Subsidiary of Purchaser is, or will be as of the Closing, a corporation, partnership or other legal entityduly
 organized and validly existing under the laws of its jurisdiction of organization, with all requisite corporate or other similarapplicable power and authority to own,
78

lease and operate its properties and assets and to carry on its respective business, as currently conducted, except where the failure tobe
 so organized or existing or to have such power and authority would not, individually or in the aggregate, be materially adverse toPurchaser
 or the Purchaser Business. Each Subsidiary of Purchaser is duly qualified to do business and, where applicable, in goodstanding
 in each jurisdiction where the nature of its business or properties makes such qualification necessary, except where thefailure
 to be so qualified or in good standing would not, individually or in the aggregate, be materially adverse to Purchaser or thePurchaser
 Business. Section  5.3(b) of  the  Purchaser  Parent  Disclosure  Letter  sets  forth  (i)  the  name  and  the  jurisdiction  oforganization
 of each Subsidiary of Purchaser and (ii) the record owners of such outstanding equity interests. All of the issued andoutstanding
 equity interests of each Subsidiary of Purchaser are validly issued, fully paid and, in the case of any Subsidiary ofPurchaser which is a corporation, non-assessable, and are not subject to, and were not issued in violation of, any preemptive right. As
of
 the Closing, there will be no outstanding warrants, options, agreements, subscriptions, convertible or exchangeable securities orother
 commitments pursuant to which any Subsidiary of Purchaser is or may become obliged to issue, sell, purchase, return, redeemor
 otherwise acquire any equity interests of any Subsidiary of Purchaser, or any securities convertible into or exchangeable for anyequity
 interests of any Subsidiary of Purchaser. As of the Closing, there will be no rights of first refusal, rights of first offer, votingtrusts,
 stockholder agreements, proxies or other Contracts in effect with respect to the sale or voting of the equity interests of anySubsidiary
 of Purchaser. Purchaser or another wholly owned Subsidiary of Purchaser owns legally and beneficially, or will ownlegally
 and beneficially as of the Closing, all of the issued and outstanding equity interests of each Subsidiary of Purchaser, free andclear
 of all Liens except for Liens arising under applicable securities Laws. Except for the equity interests of the Subsidiaries ofPurchaser, Purchaser and its Subsidiaries do not own any other equity interests of any Person.
Section
 5.4       No Conflicts; Consents .  Subject to the receipt of the Purchaser Parent Shareholder Approval, theexecution,
 delivery and performance by Purchaser Parent and Purchaser of this Agreement and each Ancillary ImplementingAgreement
 by Purchaser Parent, Purchaser or a Purchaser Designated Affiliate party to such Ancillary Implementing Agreement,and
 the consummation of the transactions contemplated hereby and thereby by Purchaser Parent, Purchaser and such PurchaserDesignated
 Affiliate, do not and will not (a) violate any provision of the articles of association or equivalent organizationaldocuments
 of Purchaser Parent, Purchaser or any of their Affiliates, (b) subject to obtaining the consents set forth in Section  5.4 of the
 Purchaser Parent Disclosure Letter, result in a violation of, or require the consent of any Person pursuant to, or conflict with,constitute
 a default under, or result in the breach or termination, cancellation or acceleration (whether with or without the giving ofnotice
 or the lapse of time or both) of any right or obligation of (or to the loss of any benefit of) Purchaser Parent, Purchaser or anyof
 their Affiliates under any Purchaser Material Contract or Purchaser Real Property Lease, or result in the imposition of a Lien onany
 assets, properties or rights, other than Purchaser Permitted Liens, relating to the Purchaser Business or owned, used or held byPurchaser or any of its Subsidiaries, or (c) assuming compliance with the matters set forth in 
Sections 4.5  and  5.5 , violate or result ina breach of or constitute a
 default under any Law, Governmental Authorization or other restriction of any Governmental Authority towhich
 Purchaser Parent, Purchaser or any of their Affiliates is subject, except, with respect to clauses  (b) and  (c) , as would not,individually
 or in the aggregate, be materially adverse to Purchaser or the Purchaser Business or prevent or reasonably be expectedto prevent Purchaser
79

Parent, Purchaser or any Purchaser Designated Affiliate from consummating the Closing prior to the Outside Date.Section
 5.5       Governmental Authorization .  The execution, delivery and performance of this Agreement byPurchaser
 Parent  and  Purchaser  and  each  Ancillary  Implementing  Agreement  by  any  of  Purchaser  Parent,  Purchaser  or  anyPurchaser
 Designated Affiliate party thereto does not require any Approval of, or Filing with, any Governmental Authority, exceptfor (a) the expiration or
 early termination of the applicable waiting period under the HSR Act, (b) the Approvals and Filings set forthin 
Section 5.5 of  the Purchaser Parent Disclosure Letter, (c) Approvals and Filings which if not obtained or made would not,individually
 or in the aggregate, be materially adverse to Purchaser or the Purchaser Business or prevent or reasonably be expectedto
 prevent Purchaser Parent, Purchaser or any Purchaser Designated Affiliate from consummating the Closing prior to the OutsideDate, and (d) the Approvals and Filings required due to the regulatory obligations of Seller Parent or any of its Subsidiaries.
Section 5.6 
      Financial Information . (a) 
     Section 5.6(a) of  the Purchaser Parent Disclosure Letter contains copies of (i) the unaudited balance sheet ofPurchaser
 Business as of September 30, 2018, June 30, 2018 and March 31, 2018 (the “ Purchaser  Working Capital Statements ”) and
 (ii) the audited balance sheet of the Purchaser Business as of December 31, 2017, December 31, 2016, and December 31, 2015,and
 the related audited income statement for the years ended December 31, 2017, December 31, 2016 and December 31, 2015 (the “Audited
 Purchaser Financial Statements ”)  (the foregoing clauses (i) and (ii) collectively, and together with any notes thereto, the “Purchaser Financial Statements 
”). (b) 
     Except as set forth in Section  5.6(b) of  the Purchaser Parent Disclosure Letter or as noted in the AuditedPurchaser Financial Statements, the
 Audited Purchaser Financial Statements were prepared in accordance with IFRS, on a consistentbasis
 for each period presented and present a true and fair view of (x) the state of affairs of the Purchaser Business as of the datestherein specified and (y) the results of
 operations of the Purchaser Business for the periods indicated. The Purchaser Working CapitalStatements were prepared
 using principles, procedures, policies and methods consistent in all material respects with those used in thepreparation
 of the balance sheet of the Purchaser Business as of the Balance Sheet Date included in the Audited Purchaser FinancialStatements.
(c) 
     Except as set forth in Section 5.6(c)  of  the Purchaser Parent Disclosure Letter, the Purchaser Business does nothave
 any Indebtedness or other Liabilities of any nature or kind whatsoever (whether accrued, known or unknown, absolute,contingent
 or otherwise) that would be required to be reflected on a balance sheet of the Purchaser Business prepared in accordancewith
 IFRS,  except  for  (i)  Liabilities  accrued  for,  reflected  on,  disclosed  and/or  reserved  against  on  the  Purchaser  FinancialStatements,
 (ii) Liabilities incurred subsequent to the Balance Sheet Date in the ordinary course of business, (iii) Liabilities takeninto
 account in the Final Closing Statement, Final Purchaser Working Capital or Final Purchaser Net Cash, (iv) Liabilities incurredin
 connection with or arising out of the transactions contemplated hereby, (v) Liabilities disclosed or set forth in the PurchaserDisclosure
 Letter and (vi) Liabilities which would not, individually or in the aggregate, be materially adverse to Purchaser or thePurchaser Business.
80

Section 5.7       Absence of Material Changes .  Except as otherwise contemplated by this Agreement and thetransactions
 contemplated hereby (including in connection with the review of strategic alternatives with respect to the PurchaserBusiness),
 since December 31, 2017 (a)   there has not been any Purchaser Material Adverse Effect and (a)   until the date of thisAgreement, the Purchaser Business has been operated, in all material respects, in the ordinary course of business.
Section
 5.8       Securities Act .  Purchaser is acquiring the Shares solely for the purpose of investment and not with aview
 to, or for sale in connection with, any distribution thereof in violation of the Securities Act. Purchaser acknowledges that theShares are not registered under the Securiti
es Act, any applicable state securities Laws or any applicable foreign securities Laws, andthat
 such Shares may not be transferred or sold except pursuant to the registration provisions of the Securities Act and applicablestate
 and foreign  securities  Laws or pursuant  to an applicable  exemption  therefrom.  Purchaser  has sufficient  knowledge  andexperience
 in financial and business matters so as to be capable of evaluating the merits and risks of its investment in the Shares andis capable of bearing the economic risks of such investment.
Section
 5.9       No Litigation .  Except as set forth in Section  5.9 of  the Purchaser Parent Disclosure Letter, there is noAction
 pending or, to the Knowledge of Purchaser Parent, threatened against Purchaser or any of its Subsidiaries, or againstPurchaser Parent or any
 of its Affiliates relating to the Purchaser Business or any assets, properties or rights relating to the PurchaserBusiness
 or owned, used or held by Purchaser or any of its Subsidiaries, before any Governmental Authority or arbitration tribunalother
 than Actions which would not, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.Neither
 Purchaser nor any of its Affiliates is subject to any outstanding Governmental Order which would, individually or in theaggregate, be materially adverse to Purchaser or the Purchaser Business.
Section 5.10 
      Compliance with Laws . Except as set forth in  Section 5.10  of the Purchaser Parent Disclosure Letter: (a) 
     Purchaser Parent and its Subsidiaries (including Purchaser and its Subsidiaries) are, and for the last three (3)years
 have been, in compliance with all Laws applicable to the ownership, lease or operation of the assets, properties or rightsrelating
 to the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries and the Purchaser Business,including
 (i) the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq. and applicable binding implementing regulationsissued
 by  the  U.S.  Food  and  Drug  Administration,  (ii)  the  applicable  Laws  of  the  European  Union  and  applicable  bindingimplementing
 regulations issued by applicable Governmental Authorities in those jurisdictions in the European Union in which thePurchaser
 Business markets, commercializes, distributes and sells Purchaser Products, or otherwise operates, or has marketed,commercialized,
 distributed or sold Purchaser Products, or otherwise operated, in the last three (3) years (including EuropeanUnion’s
 Directive 95/46/EC, as amended, and Regulation EU 2016/679 (the General Data Protection Regulation), and any nationalimplementing
 legislation of the foregoing) and (iii) the applicable Laws of any other jurisdiction in which the Purchaser Businessmarkets,
 commercializes,  distributes  and  sells  Purchaser  Products,  or  otherwise  operates,  or  has  marketed,  commercialized,distributed
 or sold Purchaser Products, or otherwise operated, in the last three (3) years, except in the case of each of the foregoingclauses
81

(i) , (ii) and (iii) to the extent that the failure to comply therewith would not, individually or in the aggregate, be materially adverse tothe Purchaser Business.
(b) 
     Purchaser and its Subsidiaries collectively possess all Governmental Authorizations necessary for the conductof
 the Purchaser Business, as currently conducted, and each such Governmental Authorization is in full force and effect, exceptwhere
 the failure to possess any such Governmental Authorization or the failure of such Governmental Authorization to be in fullforce
 and effect would not, individually or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business,taken as a whole.
Section
 5.11       Product Registrations; Manufacturing Registrations; Regulatory Compliance;  Product Liability andRecalls 
.(a) 
     Except with respect to Purchaser Environmental Permits (which are the subject of Section 5.12  ): (i) 
     Purchaser  and  its  Subsidiaries  own,  possess  or  validly  have  the  right  to  use  all  GovernmentalAuthorizations
 required to research, develop, manufacture, market, commercialize, distribute, test, use, store and sellthe
 Purchaser Products, except where the failure to so own, possess or validly have such right would not, individuallyor in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole;
(ii) 
     All Purchaser Products sold under the Purchaser Product Registrations are manufactured and marketedin
 accordance with the specifications and standards contained in such Purchaser Product Registrations, and theapplicable
 Purchaser  Manufacturing  Registrations,  except  where  the  failure  to  comply  therewith  would  not,individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business; and
(iii) 
     Except as set forth in Section  5.11(a)(iii) of  the Purchaser Parent Disclosure Letter, Purchaser or aSubsidiary
 of Purchaser is, or will be as of the Closing, the sole and exclusive owner of each Purchaser ProductRegistration and Purchaser Manufacturing Registration.
(b) 
     Except as set forth in Section 5.11(b)  of  the Purchaser Parent Disclosure Letter, there is no Action pending, or,to
 the Knowledge of Purchaser Parent, threatened, against Purchaser or any of its Subsidiaries or relating to the Purchaser Businessor any assets, propert
ies or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries (i)arising
 from complaints, allegations or Actions relating to any injury to person or property or as a result of ownership, possession,provision
 or use of any of the Purchaser Products that were manufactured, processed, distributed, shipped or sold prior to the date ofthis
 Agreement or (ii) relating to any alleged hazard or alleged defect in design, manufacture, materials or workmanship, includingany
 failure to warn or alleged breach of express or implied warranty or representation, relating to the Purchaser Products, except inthe case of each of the foregoing 
clauses 82

(i) and (ii) , for Actions which would not, individually or in the aggregate, be materially adverse to Purchaser or the PurchaserBusiness.
(c) 
     Except as set forth in Section  5.11(c) of  the Purchaser Parent Disclosure Letter, since January 1, 2016, therehave
 been  no  recalls  or  market  withdrawals  of  Purchaser  Products  and,  to  the  Knowledge  of  Purchaser  Parent,  no  facts  orcircumstances
 exist that would reasonably be expected to result in recalls or market withdrawals of Purchaser Products that would,individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.
(d) 
     Notwithstanding any other provision of this Agreement, this Section  5.11 sets  forth the sole and exclusiverepresentations
 and warranties of Purchaser Parent with respect to Purchaser Product Registrations and Purchaser ManufacturingRegistrations, products liability and product recalls, and the other regulatory matters described in this 
Section 5.11  . Section 5.12 
      Environmental Matters . Except as set forth in  Section 5.12  of the Purchaser Parent Disclosure Letter: (a) 
     (i) Purchaser Parent and its Subsidiaries (in each case, with respect to the Purchaser Business), Purchaser and its Subsidiaries,
 the Purchaser Business (as currently or formerly conducted), the assets,  properties or rights relating to the PurchaserBusiness
 or owned, used or held by Purchaser or any of its Subsidiaries, and  the Purchaser Real Property are and  have been sinceJanuary
 1,  2016 in  compliance  with  all  applicable  Environmental  Laws  and Governmental  Authorizations  required  underEnvironmental
 Law (including Purchaser Environmental  Permits); (ii) neither Purchaser Parent n or  its Subsidiaries (in each case,with respect to the Purchaser Business or the 
assets, properties or  rights relating to the Purchaser Business or owned, used or held byPurchaser or any of its Subsidiaries 
)  are undertaking or required to undertake any Remedial Action at the Purchaser Facilities or any property
 formerly owned, leased or operated by Purchaser or its Subsidiaries (or any of their respective predecessors) or by thePurchaser
 Business (as currently  or formerly  conducted) ;  and (iii)  since January  1, 2016,  neither  Purchaser  Parent  n or  itsSubsidiaries 
has  received written notice from a Governmental Authority or other Person that it is subject to any unresolvedenforcement
 action or Liability with respect to Purchaser or its Subsidiaries,  the Purchaser Business (as currently or formerlyconducted),
 the assets,  properties or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of itsSubsidiaries, 
or  the Purchaser Facilities under any applicable Environmental Laws or Purchaser Environmental Permits, except forsuch
 noncompliance, Remedial Actions, Liabilities or enforcement actions that would not, individually or in the aggregate, bematerially adverse to the Purchaser Business;
(b) 
     all Governmental Authorizations (including Purchaser Environmental Permits) required of Purchaser Parent and its
 Subsidiaries (in each case, with respect to the Purchaser Business or the assets,  properties or rights relating to the PurchaserBusiness
 or owned, used or held by Purchaser or any of its Subsidiaries )  under all applicable Environmental Laws have beenobtained
 and are held by Purchaser or a Subsidiary of Purchaser, except for such failures to obtain as would not, individually or inthe aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole; and
83

(c)      no Actions or written claims are pending or,  to the Knowledge of Purchaser Parent, threatened against Purchaser Parent 
or  its Subsidiaries (in each case, with respect to the Purchaser Business or the assets, properties  or rights relating tothe
 Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries )  arising from or as a result of, and there havebeen
 no (i) exposures to Hazardous Materials ,  including on, in, under, about or from the assets,  properties or rights relating to thePurchaser
 Business or owned, used or held by Purchaser or any of its Subsidiaries or  at the Purchaser Facilities, (ii) Releases ofHazardous Materials, including at 
, on, in, under, or from any  assets, properties or rights relating to the Purchaser Business or owned, used
 or held by Purchaser or any of its Subsidiaries or  from any Purchaser Facilities, (iii) off-site treatment, storage or disposal ofHazardous
 Materials generated by t he  Purchaser Business (as currently or formerly conducted), Purchaser Parent or its Subsidiaries(with
 respect to the Purchaser Business )  or Purchaser or its Subsidiaries or (iv) any violations of any Environmental Laws arising,directly
 or indirectly, in connection with the Purchaser Business (as currently or formerly conducted) or any of the assets, properties or
 rights relating to the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries or  Purchaser Facilities, ineach case 
that  has resulted or would result in Environmental Liability , except  for such claims, Actions, Environmental Liabilities orinvestigations that would not, individually or in the aggregate, be materially adverse to the Purchaser Business.
(d) 
     Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection
 5.12 are  the sole and exclusive representations and warranties of Purchaser Parent with respect to Environmental Laws,Purchaser Environmental Permits, Environmental Liabilities, Hazardous Materials and other environmental matters.
Section 5.13 
      Material Contracts . (a) 
     Except (x) for Contracts entered into after the date of this Agreement, (y) for intercompany agreements solelybetween
 or among Purchaser (or any of its Subsidiaries) and any of its Subsidiaries or that shall be terminated as of or prior to theClosing
 Date in accordance with Section  6.7 or  (z) as set forth in Section  5.13(a) of  the Purchaser Parent Disclosure Letter, neitherPurchaser
 Parent nor any of its Affiliates is a party to or bound by any Contract in effect as of the date hereof that is material toPurchaser or the Purchaser Business, taken as a whole (a “ 
Purchaser  Material Contract  ”). (b) 
     Except as set forth in Section  5.13(b) of  the Purchaser Parent Disclosure Letter, (i) except as would not,individually
 or in the aggregate, be materially adverse to Purchaser or the Purchaser Business, each Purchaser Material Contract islegal,
 valid and binding on Purchaser or its Subsidiary that is a party thereto and, to the Knowledge of Purchaser Parent, each otherparty
 thereto, and is in full force and effect, except as enforcement may be limited by bankruptcy, insolvency, reorganization,fraudulent
 conveyance,  moratorium  or  similar  Laws  affecting  creditors’  rights  generally  or  by  general  principles  of  equity(regardless
 of whether enforcement is sought in a proceeding in equity or law), and (ii) neither Purchaser Parent nor any of itsAffiliates
 or, to the Knowledge of Purchaser Parent, any other party thereto, is in breach of, or default under, any such PurchaserMaterial
 Contract, except for such breaches or defaults as would not, individually or in the aggregate, be materially adverse toPurchaser or the Purchaser Business. Neither Purchaser nor
84

any of its Subsidiaries is a party to or bound by any Contract that contains any non-compete or similar provision that wouldmaterially
 limit or impair Seller Parent or any of the Retained Subsidiaries’ ability to operate the Retained Businesses after theClosing.
(c) 
     Section 5.13(c) of the Purchaser Parent Disclosure Letter lists all material Purchaser Related Party Contracts. Section 5.14 
      Intellectual Property . (a) 
     To the Knowledge of Purchaser Parent (but only as to validity and enforceability), as of the date of thisAgreement,
 except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, all issued PatentRights,
 pending applications for Patent Rights, registered Trademarks, pending Trademark registration applications and registeredCopyrights
 that are included in the Purchaser IP (collectively, the “ Registered  Purchaser IP ”)  are in effect and subsisting, and, ifregistered, not invalid or unenforceable. The Purchaser Trademark Rights, together with Trademarks that are licensed to Purchaser or
its Subsidiaries by Purchaser Parent or its Subsidiaries or by a third party, include all of the Purchaser Key Brands.
(b) 
     All material Purchaser IP and Purchaser Licensed IP shall be, following the Closing, transferable and licensable(or
 sublicensable as the case may be) by Purchaser and its Subsidiaries, without payment of any kind to Purchaser Parent or anyAffiliate
 of Purchaser Parent, as may be needed in the ordinary course of the operation of the Purchaser Business, and shall be fullytransferable,
 assignable and assumable, as the case may be, without payment of any kind to Purchaser Parent or any Affiliate ofPurchaser Parent,
 in connection with a change of control (that constitutes an assignment) of Purchaser or any Listing Transaction (asdefined
 in the Purchaser Shareholders Agreement) or the sale of substantially all of the assets of a business unit of Purchaser to theextent such Purchaser IP or Purchaser Licensed IP is related to such business unit.
(c) 
     Except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, andtaking
 into account Section  6.22 ,  the Purchaser IP and the Purchaser Licensed IP constitutes all of the Intellectual Property ownedby
 either Purchaser Parent or any of its Subsidiaries or Purchaser or any of its Subsidiaries that is used or held for use in, or that isnecessary
 for, the conduct of the Purchaser Business as conducted as of the date of this Agreement. The operation of the PurchaserBusiness immediately following the Closing will not infringe any of Purchaser Parent’s or any of its Affiliates’ Intellectual Property.
(d) 
     Except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, (x) theconduct
 of the Purchaser Business does not, to the Knowledge of Purchaser Parent, infringe, misappropriate or otherwise violate theIntellectual
 Property of any Person and (y) as of the date of this Agreement, there is no Action pending or, to the Knowledge ofPurchaser
 Parent,  threatened  in  writing  against  Purchaser  Parent  or  any  of  its  Affiliates  (i)  alleging  any  such  infringement,misappropriation,
 or other violation, or (ii) challenging the validity, enforceability, ownership, use, registrability, or patentability ofthe
 Purchaser IP, other than ordinary course prosecution proceedings associated with the application for or registration of RegisteredPurchaser IP.
85

(e)      Except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, as of thedate
 of this Agreement, to the Knowledge of Purchaser Parent, no Person is infringing, misappropriating or otherwise violating anyPurchaser IP
 and as of the date of this Agreement, no such Actions are pending or, to the Knowledge of Purchaser Parent, threatenedagainst any Person by Purchaser Parent or any of its Affiliates.
(f) 
     Purchaser or its Subsidiaries, as applicable, are the sole legal owners of all Registered Purchaser IP that isowned
 or purported to be owned by Purchaser or its Subsidiaries. None of the Registered Purchaser IP or any other materialPurchaser IP is subject to any Lien, other than Purchaser Permitted Liens.
(g) 
     Since January 1, 2016, to the Knowledge of Purchaser Parent, there (i) have been no failures of the Purchaser ITSystems that have materially and adversely impacted
 the conduct of the Purchaser Business and (ii) has been no unauthorized access,loss,
 use or breach of security with respect to the Purchaser IT Systems or any material sensitive, confidential or proprietaryinformation
 (including personally identifiable information) relating to the Purchaser Business that have materially and adverselyimpacted the Purchaser Business.
(h) 
     Except for the Trademarks licensed by Purchaser Parent or any of its Subsidiaries (other than Purchaser and itsSubsidiaries)
 to Purchaser or any of its Subsidiaries under a Purchaser Ancillary Agreement (the “ Purchaser  Licensed TrademarkRights 
”), and taking into account Section  6.22 ,  as of the Closing Date, the Purchaser Trademark Rights will include all materialTrademarks under which
 the Purchaser Business operates that are owned by Purchaser Parent or any Subsidiary of Purchaser Parent.The
 Purchaser Licensed Trademark Rights are licensed to Purchaser or one or more of its Subsidiaries by Purchaser Parent or itsSubsidiaries (other
 than Purchaser and its Subsidiaries) on a perpetual, royalty free basis, and such license is (i) exclusive in the fieldin
 which the Purchaser Business operates (subject to limited exceptions to exclusivity for brands managed by Purchaser Parent’sAffiliates’
 pharmaceutical division, rights granted to third parties prior to the date licensed to Purchaser Parent, brands used for bothprescription
 and  non-prescription  products,  and  products  switched  from  prescription  to  non-prescription  sales)  and  (ii)  non-terminable
 solely due to a change of control of Purchaser or the occurrence of any Listing Transaction (as defined in the PurchaserShareholders
 Agreement) and assignable, without restriction, on the sale of substantially all of the assets of a business unit ofPurchaser to the extent such Purchaser Licensed Trademarks is related to such business unit.
(i) 
     Notwithstanding any provision of this Agreement to the contrary, except with respect to Section  5.7 , Section
 5.13 ,  and this Section  5.14 sets  forth the sole and exclusive representations and warranties of Purchaser Parent with respectto Intellectual Property.
Section 5.15 
      Real Property . (a) 
     Except as set forth in Section 5.15(a)(i)  of  the Purchaser Parent Disclosure Letter, Purchaser or a Subsidiary ofPurchaser
 has insurable title in fee simple to the Owned Purchaser Real Property, free and clear of any Liens, other than PurchaserPermitted
 Liens. Except as set forth in Section  5.15(a)(ii) of  the Purchaser Parent Disclosure Letter or as would not, individually orin the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken
86

as a whole, neither Purchaser Parent nor any of its Subsidiaries is leasing or otherwise granting to any third party the right to use oroccupy any Owned Purchaser Real Property or any portion thereof.
(b) 
     Except as set forth in Section 5.15(b)(i)  of  the Purchaser Parent Disclosure Letter, Purchaser or a Subsidiary ofPurchaser
 has a valid leasehold interest and valid and continuing right to use and occupy each Leased Purchaser Real Propertypursuant
 to a Purchaser Real Property Lease. Except (x) as set forth in Section  5.15(b)(ii) of  the Purchaser Parent Disclosure Letteror
 (y) as would not, individually or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, takenas
 a whole, (i) each Purchaser Real Property Lease is legal, valid and binding on Purchaser or its Subsidiary party thereto and, to theKnowledge
 of Purchaser Parent, each other party thereto and is in full force and effect, except as enforcement may be limited bybankruptcy,
 insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally orby
 general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), (ii) neither PurchaserParent
 nor any of its Subsidiaries or, to the Knowledge of Purchaser Parent, any other party thereto, is in breach of, or default under,any such
 Purchaser Real Property Lease and (iii) neither Purchaser Parent nor any of its Subsidiaries is leasing or otherwise grantingto any third party the right to use or occupy any Purchaser Leased Real Property or any portion thereof.
(c) 
     Except as set forth in Section  5.15(c) of  the Purchaser Parent Disclosure Letter, (i) no certificate, permit orlicense
 from any Governmental Authority having jurisdiction over any of the Purchaser Real Property, or any Contract, easement orother
 right which is necessary to permit the lawful occupancy of the buildings and improvements on any of the Purchaser RealProperty
 or which is necessary to permit the lawful use of all driveways, roads and other means of egress and ingress to and fromany of
 the Purchaser Real Property, in each case, with respect to the Purchaser Business, has not been obtained or, to the Knowledgeof
 Purchaser Parent, is not in full force and effect, which would, individually or in the aggregate, materially impair the operations ofPurchaser
 or the Purchaser Business, taken as a whole, and (ii) neither Purchaser Parent or any of its Subsidiaries (in respect of thePurchaser
 Business) or Purchaser or its Subsidiaries has received any written notice from any Governmental Authority that thePurchaser
 Real Property is currently in violation of any applicable Law that would, individually or in the aggregate, materiallyimpair the operations of Purchaser or the Purchaser Business, taken as a whole.
(d) 
     Section 5.15(d)(i) of  the Purchaser Parent Disclosure Letter sets forth each manufacturing and research anddevelopment
 facility at which Purchaser Products are manufactured or developed that is owned or operated by Purchaser Parent orits
 Subsidiaries (the “ Purchaser  Facilities  ”).  Except as set forth in Section  5.15(d)(ii) of  the Purchaser Parent Disclosure Letter,Purchaser or
 a Subsidiary of Purchaser has insurable title in fee simple to, or a valid leasehold interest and valid and continuing rightto use and occupy, each Purchaser Facility.
Section 5.16 
      Assets .(a) 
     Except as otherwise provided in this Agreement or as would not, individually or in the aggregate, materiallyimpair the
 operations of Purchaser or the Purchaser Business, taken as a whole, Purchaser or its Subsidiaries have, or will have as ofthe Closing, good and valid title to, or other legal rights to possess and use, all of the assets, properties and rights Relating to the
87

Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries, free and clear of any Liens other than PurchaserPermitted Liens.
(b) 
     Except as set forth in Section  5.16(b) of  the Purchaser Parent Disclosure Letter and as would not, individuallyor in
 the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole (assuming all consentsand
 Approvals as may be required in connection with the consummation of the transactions contemplated by this Agreement and theAncillary
 Agreements have been obtained; provided  ,  that no such assumption shall be made to the extent Purchaser Parent is not incompliance
 with its obligations under Section  2.2 or  Section 6.3 of  this Agreement), together with the benefits, services, assets,licenses,
 sublicenses and other rights and benefits to be provided to Purchaser and its Subsidiaries pursuant to this Agreement, theAncillary
 Agreements and the Purchaser Ancillary Agreements, the assets, properties and rights owned, or leased and licensed fromthird
 parties, by Purchaser or its Subsidiaries do and will following the Closing, in the aggregate, constitute all of the assets eitherused
 in or necessary for Purchaser and its Subsidiaries to conduct the Purchaser Business as conducted as of the date of thisAgreement and as of the Closing.
(c) 
     Except as set forth in Section  5.16(c) of  the Purchaser Parent Disclosure Letter, there are no material assets,properties
 or rights that are used or held for use by Purchaser or any Subsidiary of Purchaser or necessary for the conduct of thePurchaser
 Business and owned or controlled by Purchaser Parent or any Affiliate of Purchaser Parent (other than Purchaser or aSubsidiary of Purchaser).
(d) 
     Purchaser and its Subsidiaries are not, or will not at Closing be, directly or indirectly, engaged in any PurchaserParent
 Retained Businesses, and do not, or will not at Closing, hold and are not, or will not at Closing be, subject to any PurchaserParent Retained Liability or assets, properties and rights not relating to the Purchaser Business (other than non-material or ministerial
liabilities, assets, rights or properties).
Section 5.17 
      Taxes .(a) 
     All income and other material Tax Returns that are required to be filed by (i) Purchaser or any Subsidiary ofPurchaser
 or (ii) in respect of the Purchaser Business have, in each case, been timely filed (taking into account any applicableextensions), and all such Tax Returns are true, correct and complete in all material respects.
(b) 
     All income and other material Taxes required to be paid by (i) Purchaser or any Subsidiary of Purchaser or (ii)in respect of the Purchaser Business have, in each case, been timely paid (taking into account any applicable extensions).
(c) 
     Purchaser and its Subsidiaries, and Purchaser Parent and its Subsidiaries with respect to the Purchaser Business,have
 deducted or withheld and paid over to the applicable Taxing Authority all material Taxes required to have been deducted orwithheld and paid over in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder
or other third party, and Purchaser and each of its Subsidiaries, and Purchaser Parent and each of its
88

Subsidiaries with respect to the Purchaser Business, has (if required by any applicable Laws to do so) provided appropriatecertificates of deduction.
(d) 
     There are no Liens for material Taxes upon any of the assets relating to the Purchaser Business or owned, usedor held by Purchaser or any of its Subsidiaries, except for Purchaser Permitted Liens.
(e) 
     Within the past three (3) years, neither Purchaser nor any of its Subsidiaries has been a “distributingcorporation” or a “controlled corporation” in a distribution intended to qualify under Section 355(a) of the Code.
(f) 
     There are no current or pending audits, examinations, contests or other Actions with respect to material Taxes ofPurchaser
 or any Subsidiary of Purchaser or of Purchaser Parent or any of its Subsidiaries with respect to the Purchaser Business,and no such audits, examinations, contests or other Actions have been threatened in writing.
(g) 
     There are no outstanding powers of attorney granted by Purchaser or any Subsidiary of Purchaser with respectto
 material Taxes for any taxable period beginning after the Closing Date, other than powers of attorney granted to Purchaser oranother Subsidiary of Purchaser.
(h) 
     Neither Purchaser nor any Subsidiary of Purchaser is party to any Tax sharing, allocation, indemnity or similaragreement
 or arrangement (other than (x) any such agreement or arrangement solely between or among Purchaser and/or any of theSubsidiaries
 of Purchaser and (y) provisions contained in commercial agreements or arrangements the primary purpose of which isnot Taxes (including employment agreements, credit agreements, leases and supply or manufacturing agreements)).
(i) 
     Neither Purchaser nor any Subsidiary of Purchaser is or has been party to any “listed transaction” as defined inSection
 6707A of the Code and Treasury Regulations Section 1.6011-4. Neither Purchaser nor any Subsidiary of Purchaser has atany
 time entered into or been engaged in or been a party to or promoter of any scheme, transaction or arrangement which wasrequired
 by Law to be specifically disclosed to a Taxing Authority or a main or dominant purpose or object of which was theavoidance or deferral of or the obtaining of a reduction in or other advantage in respect of any Taxes.
(j) 
     In the last three (3) years, no claim has been made in writing by any Taxing Authority in any jurisdiction inwhich
 Purchaser or any Subsidiary of Purchaser, or Purchaser Parent or any of its Subsidiaries with respect to the PurchaserBusiness,
 does not file income or franchise Tax Returns to the effect that such entity is or may be subject to income or franchisetaxation by such jurisdiction.
(k) 
     Neither Purchaser nor any Subsidiary of Purchaser will be required to include any material item of income in,or
 exclude any material item of deduction from, taxable income for any taxable period beginning after the Closing Date as a resultof:
 (i) change in method of accounting for a taxable period ending on or prior to the Closing Date made prior to the Closing, (ii)“closing agreement” executed prior to the Closing, (iii) intercompany transaction or excess loss account
89

described in Treasury Regulations under Section 1502 of the Code entered into or existing prior to the Closing, (iv) prepaid amountreceived on or
 prior to the Closing, (v) election under Section 108(i) of the Code made prior to the Closing or (vi) installment sale oropen transaction disposition occurring on or before the Closing Date.
(l) 
     Neither entering into this Agreement nor consummating the transactions contemplated hereby, nor, so far as thePurchaser
 or Purchaser Parent is aware, will give rise to any other event, transaction, action, or circumstance Liability for Tax orresult
 in the withdrawal or clawback of any Tax Benefit for Purchaser or any Subsidiary of Purchaser as a result of Purchaser or anySubsidiary of Purchaser ceasing to be a member of a group with any other Person for Tax purposes.
(m) 
     Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection 5.17 
and  Section 5.18 (to  the extent relating to Taxes) are the sole and exclusive representations and warranties of PurchaserParent with respect to Taxes.
Section 5.18 
      Employee Benefits; Employees . (a) 
     Set forth in Section 5.18(a)  of the Purchaser Parent Disclosure Letter is a  true and complete list of each materialPurchaser
 Group Plan and Foreign Purchaser Group Plan categorized by (i) whether the Purchaser Group Plan or Foreign PurchaserGroup Plan
 is a Purchaser Business Plan and (ii) the country or countries for which such Purchaser Group Plan or Foreign PurchaserGroup
 Plan provides benefits. No Purchaser Business Plan provides benefits to, or otherwise covers, any individual who is not aPurchaser Business Employee, Former Purchaser Business Employee, or the dependents or beneficiaries thereof.
(b) 
     With respect to each material Purchaser Business Plan (other than Foreign Purchaser Group Plans that are notdefined
 benefit pension plans), Purchaser Parent has made available to Seller Parent, prior to the date of this Agreement, true andcomplete copies of (i) each such plan’s governing
 document and any amendments thereto (or a written summary of all material termsif
 the plan has not been reduced to writing) and (ii) any applicable Plan Regulatory or Funding Documents. In addition, within thirty(30)
 days following the date hereof, with respect to each (x) material Purchaser Business Plan that is a Foreign Purchaser GroupPlan,
 Purchaser Parent shall make available to Seller Parent true and complete copies of the documents contemplated by theimmediately
 preceding sentence, and (y) each other material Purchaser Group Plan or Foreign Purchaser Group Plan for whichPurchaser
 or its Subsidiaries has any Liability, Purchaser Parent shall make available to Seller Parent summaries of the materialterms
 of such plans, the most recent summary plan description (if any) and excerpts or summaries of the actuarial reports for suchplans to the extent relevant to the
 Liabilities of Purchaser or its Subsidiaries. Purchaser Parent has made available to Seller Parent, onor
 prior to the date of this Agreement, a summary that is accurate in all material respects of the value of the assets and Liabilities ofall Purchaser Business Plans that are defined benefit pension plans as of the end of the 2017 fiscal year of Purchaser Parent.
(c) 
     The IRS has issued a favorable determination letter, or for a prototype plan, opinion letter, with respect to eachPurchaser
 Business Plan intended to be qualified within the meaning of Section 401(a) of the Code or, if no such determination hasbeen made, either an
90

application for such determination is pending with the IRS or the time within which such determination may be sought from the IRShas not
 yet expired, and, to the Knowledge of Purchaser Parent, nothing has occurred since the date of such determination or opinionthat would reasonably be expected to result in disquali
fication of such Purchaser Business Plan. Each Purchaser Business Plan that isintended
 to qualify for any particular tax or regulatory treatment under the Laws of a country other than the United States (i) hasreceived
 documentation of such qualification from a Governmental Authority (if available), and, to the Knowledge of PurchaserParent,
 nothing has occurred since the date of such documentation that would reasonably be expected to result in disqualification ofsuch Purchaser Business Plan or (ii) if such documentation is not available, to the Knowledge of Purchaser Parent, so qualifies.
(d) 
     No Purchaser Group Plan is a “multiemployer plan,” as such term is defined in Section 3(37) of ERISA, nor isany
 Purchaser Business Plan subject to Section 302 or Title IV of ERISA or Section 412 of the Code. Neither Purchaser nor itsSubsidiaries
 (or any assets of Purchaser or its Subsidiaries) is subject to a lien under Section 430(k) of the Code or Section 4068 ofERISA,
 and neither Purchaser Parent nor any of its ERISA Affiliates has incurred any liability under Title IV of ERISA (other thanpremium
 payments to the Pension Benefit Guaranty Corporation in the ordinary course) or Section 4971 of the Code which has notbeen
 and will not be fully paid as of the Closing. None of Purchaser, its Subsidiaries or the Purchaser Business has as of the date ofthis
 Agreement, or will have as of the Closing, any Liability in respect of post-employment or post-retirement medical, health or lifeinsurance
 benefits for any current or former employees, except as required by applicable Law or to avoid excise tax under Section4980B
 of the Code. Except as set forth on Section  5.18(d) of  the Purchaser Parent Disclosure Letter, no Purchaser Group Plan orForeign Purchaser Group Plan is a defined benefit pension plan.
(e) 
     Each Purchaser Group Plan and Foreign Purchaser Group Plan (other than a Purchaser Business Plan) has beenmaintained,
 operated, funded and administered in compliance in all respects with its terms and applicable Law, except for suchinstances
 of noncompliance that would not, individually or in the aggregate, be materially adverse to Purchaser or the PurchaserBusiness.
 Each Purchaser Business Plan has been established, maintained, funded and administered in compliance in all materialrespects
 its terms and applicable Law. All material contributions or premiums with respect to each Purchaser Business Plan havebeen
 paid or deducted in a timely fashion and there are no material outstanding defaults or violations thereunder that have not beenproperly
 recorded  in  the  Purchaser  Financial  Statements.  Other  than  routine  claims  for  benefits,  there  are  no  suits,  claims,proceedings,
 actions, governmental audits or investigations that are pending or threatened against or involving any Purchaser GroupPlan
 or Foreign Purchaser Group Plan or asserting any rights to or claims for benefits under any Purchaser Group Plan or ForeignPurchaser
 Group Plan, except for such actions that have not had and would not, individually or in the aggregate, be materiallyadverse to Purchaser or the Purchaser Business.
(f) 
     Except as set forth in Section  5.18(f) of  the Purchaser Parent Disclosure Letter: (i) none of Purchaser or itsSubsidiarie
s (or employers of Purchaser Business Employees other than Purchaser or its Subsidiaries) recognize a labor union (in thecase of employers that are not Purchaser or
 its Subsidiaries, excluding any labor union that does not represent the Purchaser BusinessEmployees) and none of the Purchaser Business Employees are represented by any labor
91

organization, works council or consultation body (other than industry-wide or national labor organizations) or subject to, or coveredby,
 the terms of any material Collective Bargaining Agreement in connection with their services to the Purchaser Business, (ii) nolabor union,
 labor organization, works council or consultation body has made a demand for recognition or certification, and there areno
 representation or certification proceedings, union elections or, to the Knowledge of Purchaser Parent, union organizing activitiespending
 or threatened in writing with respect to the Purchaser Business or Purchaser or its Affiliates with respect to the PurchaserBusiness, (iii)
  there are no pending or threatened in writing strikes, lockouts, work stoppages or slowdowns involving the PurchaserBusiness
 Employees or against the Purchaser Business or Purchaser or its Affiliates with respect to the Purchaser Business and(iv)
 there is no unfair labor practice charge, labor arbitration or labor grievance proceeding pending or threatened in writing againstthe
 Purchaser Business or Purchaser or its Affiliates with respect to the Purchaser Business that would, in the case of the foregoingclauses
 (iii)  and  (iv) , individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business. As of the datehereof,
 Purchaser Parent has provided copies to Seller Parent of all material Collective Bargaining Agreements applicable toPurchaser
 Business Employees, the Purchaser Business or Purchaser or its Subsidiaries. Purchaser Parent, Purchaser and theirrespective
 Subsidiaries have satisfied any material pre-signing requirement to provide notice to, or enter into any information andconsultation
 procedure with, any labor union, labor organization, works council or consultation body in connection with theexecution of this Agreement or the transactions contemplated by this Agreement as required by any Contract or Laws.
(g) 
     As of the Closing, Purchaser Parent represents that each Purchaser Business Employee devotes, and hasdevoted
 seventy percent (70%) or more of his or her working time in the last twelve (12) months (or such shorter period he or shehas been employed by Purchaser Parent and its Affiliates) to performing services on behalf of the Purchaser Business.
(h) 
     Except as required by plans, programs, or arrangements required to be maintained or contributed to by the Lawsof
 a  non-U.S.  jurisdiction,  neither  the  execution  and  delivery  of  this  Agreement,  nor  the  consummation  of  the  transactionscontemplated
 hereby (either alone or in conjunction with any other event), will cause any (i) payments to become due or payable toany
 Purchaser Business Employee, Former Purchaser Business Employee, current or former consultant or director, (ii) acceleration,vesting
 or increase in any compensation or benefits to any Purchaser Business Employee, Former Purchaser Business Employee,current
 or former consultant or director, or (iii) Purchaser or any of its Subsidiaries to transfer or set aside any assets to fund anybenefits under any Purchaser Business Plan, or limit or
 restrict in any material respect the right of Purchaser or any of its Affiliates toamend, terminate or transfer the assets of any
 Purchaser Business Plan. Neither the execution and delivery of this Agreement, nor theconsummation
 of the transactions contemplated herein, will constitute a “change in ownership or control” or “change in effectivecontrol”
 of Purchaser Parent within the meaning of Section 280G of the Code. Neither Purchaser nor any of its Subsidiaries is partyto
 any plan, program, policy or arrangement providing for the “gross-up” or other compensation to any individual because of theimposition of any Tax on any payment to the individual related to Section 4999 or Section 409A of the Code.
Section 5.19 
      Global Trade Controls; Anti-Corruption Matters . 92

(a)      Purchaser  Parent  and  its  Subsidiaries  (with  respect  to  the  Purchaser  Business)  and  Purchaser  and  itsSubsidiaries,
 as well as their respective directors, officers, and employees, are in compliance with all Global Trade Control Laws,including
 possession of and compliance with Governmental Authorizations required by Global Trade Control Laws, except for suchnoncompliance as would not, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.
(b) 
     Purchaser and its Subsidiaries and, with respect to the Purchaser Business, Purchaser Parent and its otherSubsidiaries,
 do not engage in any business with, or use, directly or indirectly, any corporate funds to contribute to or finance theactivities
 of, any Restricted Party or in any Restricted Market except as permitted by Governmental Authorization, except as wouldnot, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.
(c) 
     None of Purchaser or its Subsidiaries or, with respect to the Purchaser Business, Purchaser Parent or its otherSubsidiaries,
 nor any of their respective directors, officers, and employees, is a Restricted Party or owned or controlled by aRestricted Party.
(d) 
     To Purchaser Parent’s Knowledge,  Purchaser and its Subsidiaries,  and Purchaser Parent and its otherSubsidiarie
s (with respect to the Purchaser Business), as well as their respective directors, officers, and employees are in compliancewith
 all Anti-Corruption Laws, except for such noncompliance as would not, individually or in the aggregate, be materially adverseto
 Purchaser or the Purchaser Business. For purposes of this Section  5.19 only,  “Purchaser Parent’s Knowledge” means that theconduct
 giving rise to the noncompliance with or violation of Anti-Corruption Law was reported to the Compliance Division (orsimilar
 responsible group or body) of Purchaser Parent and such conduct is or was the subject of an investigation by it on or prior tothe Closing Date.
(e) 
     Notwithstanding any other provision of this Agreement, the representations and warranties set forth in thisSection
 5.19 are  the sole and exclusive representations and warranties of Purchaser Parent with respect to Global Trade ControlLaws and Anti-Corruption Laws.
Section
 5.20       Brokers . No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee orcommission
 in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf ofPurchaser
 Parent or its Affiliates  for which Purchaser or any of its Subsidiaries  would be liable. Purchaser Parent is solelyresponsible
 for the fees and expenses of Citigroup Global Markets Limited, J.P. Morgan Securities plc and Greenhill & Co., whichshall be a Purchaser Parent Transaction Expense hereunder.
Section 5.21 
      No Other Representations or Warranties . (a) 
     Except for the representations and warranties contained in this Article  V or  in any Ancillary ImplementingAgreement, neither
 Purchaser Parent nor Purchaser nor any of their respective Affiliates, Representatives or any other Person makesany
 express  or  implied  representation  or  warranty  with  respect  to  Purchaser  Parent  or  Purchaser  or  any  of  their  respectiveSubsidiaries or Affiliates, the Purchaser Business or with respect to any other information provided,
93

or made available, to Seller Parent or any of its Affiliates or Representatives in connection with the transactions contemplatedhereby.
 Except  as  expressly  set  forth  in  the  representations  and  warranties  contained  in  this Article  V or  in  any  AncillaryImplementing Agreement,
 neither Purchaser Parent nor Purchaser nor any of their respective Affiliates, Representatives or any otherPerson
 has made any representation or warranty, express or implied, as to the prospects of Purchaser or the Purchaser Business ortheir
 profitability, or with respect to any forecasts, projections or business plans or other information (including any EvaluationMaterial
 (as defined in the Confidentiality Agreement)) delivered to Seller Parent or any of its Affiliates or Representatives inconnection
 with Seller Parent’s review of Purchaser or the Purchaser Business and the negotiation and execution of this Agreement,including
 as to the accuracy or completeness thereof or the reasonableness of any assumptions underlying any such forecasts,projections
 or business plans or other information. Except to the extent expressly provided in this Agreement with respect to therepresentations and warranties contained in this 
Article V  or in any  Ancillary Implementing Agreement, neither Purchaser Parent norPurchaser nor any of their respecti
ve Affiliates, Representatives or any other Person will have, or be subject to, any Liability or otherobligation
 to Seller Parent, its Affiliates or Representatives or any other Person resulting from Seller Parent’s use of, or the use byany
 of its Affiliates or Representatives of, any information, including information, documents, projections, forecasts, business plansor
 other material made available to Seller Parent, its Affiliates or Representatives by any means, including in any virtual data room,confidential
 information memorandum, management presentations, offering materials, site tours or visits, diligence calls or meetingsor
 any documents prepared by, or on behalf of, Purchaser Parent, Purchaser or any of their respective Affiliates or Representatives.Each
 of Purchaser Parent, Purchaser and their respective Affiliates disclaims any and all representations and warranties, whetherexpress
 or implied, except for the representations and warranties contained in this Article  V or  in any Ancillary ImplementingAgreement.
 Notwithstanding anything to the contrary contained in this Agreement, neither Purchaser Parent, Purchaser nor any oftheir
 respective Affiliates makes any express or implied representation or warranty with respect to the Purchaser Parent RetainedBusinesses or Purchaser Parent Retained Liabilities.
(b) 
     Purchaser Parent and Purchaser acknowledge and agree that, except for the representations and warrantiescontained
 in Article  IV or  in any Ancillary Implementing Agreement, neither Seller Parent, the other Sellers nor any of theirrespective
 Affiliates, Representatives or any other Person makes any express or implied representation or warranty with respect toSeller
 Parent, the other Sellers, the Conveyed Subsidiaries or any of their respective Subsidiaries or Affiliates, the Purchased Assets,the
 Business or with respect to any other information provided, or made available, to Purchaser Parent, Purchaser or any of theirrespective
 Affiliates or Representatives in connection with the transactions contemplated hereby. Purchaser Parent and Purchaseracknowledge
 and agree that, except to the extent expressly provided in this Agreement with respect to the representations andwarranties
 contained in Article  IV or  in any Ancillary Implementing Agreement, neither Seller Parent, the other Sellers nor any oftheir
 respective Affiliates, Representatives or any other Person will have, or be subject to, any Liability or other obligation toPurchaser
 Parent, Purchaser, any of their respective Affiliates or Representatives or any other Person resulting from the sale andpurchase
 of the Purchased Assets or the Business to Purchaser Parent, Purchaser or their Affiliates or Purchaser Parent’s orPurchaser’s
 use of, or the use by any of their respective Affiliates or Representatives of any information, including information,documents, projections,
94

forecasts, business plans or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) madeavailable
 to Purchaser Parent, Purchaser, any of their respective Affiliates or Representatives by any means, including in any virtualdata
 room, confidential information memorandum, management presentations, offering materials, site tours or visits, diligence callsor
 meetings or any documents prepared by, or on behalf of, Seller Parent, the other Sellers or any of their respective Affiliates orRepresentatives.
 Purchaser Parent and Purchaser acknowledge and agree that they are not relying on any representation or warrantyof
 Seller Parent, the other Sellers, or any of their Affiliates or Representatives or any other Person, other than those representationsand
 warranties specifically set forth in Article  IV or  in any Ancillary Implementing Agreement. Purchaser Parent and Purchaseracknowledge
 and agree that each of Seller Parent and the other Sellers and their respective Affiliates disclaims any and allrepresentations
 and warranties, whether express or implied, except for the representations and warranties contained in Article  IV or in
 any Ancillary Implementing Agreement. Purchaser Parent and Purchaser acknowledge and agree that neither Seller Parent, theother
 Sellers nor any of their respective Affiliates makes any express or implied representation or warranty with respect to ExcludedAssets, Retained Businesses or Retained Liabilities.
(c) 
     Purchaser Parent and Purchaser acknowledge that they have conducted to their satisfaction an independentinvestigati
on of the financial condition, results of operations and projected operations of the Business and the nature and condition ofits
 properties, assets, liabilities and businesses and, in making the determination to proceed with the transactions contemplatedhereby,
 have relied solely on the results of their own independent investigation and the representations and warranties set forth inArticle
 IV or  any Ancillary Implementing Agreement. In light of these inspections and investigations and the representations andwarranties
 made to Purchaser Parent and Purchaser by Seller Parent in Article  IV or  in any Ancillary Implementing Agreement,Purchaser Parent
 and Purchaser are relinquishing any right to any claim based on any representations and warranties other than thosespecifically
 included in Article  IV or  in any Ancillary Implementing Agreement. Any claims Purchaser Parent or Purchaser mayhave
 for breach of representation or warranty shall be based solely on the representations and warranties of Seller Parent set forth inArticle IV 
or in any Ancillary Implementing Agreement. (d) 
     Purchaser Parent and Purchaser acknowledge that, except as explicitly set forth herein, neither Seller Parent norany
 of its Affiliates has made any warranty, express or implied, as to the prospects of the Business or its profitability for Purchaser,or
 with respect to any forecasts, projections or business plans or other information (including any Evaluation Material (as defined inthe Confidentiality Agreement)) delivered
 to Purchaser Parent or Purchaser or any of their respective Affiliates or Representatives inconnection
 with Purchaser Parent’s and Purchaser’s review of the Business and the negotiation and execution of this Agreement,including
 as to the accuracy or completeness thereof or the reasonableness of any assumptions underlying any such forecasts,projections or business plans or other information.
ARTICLE VI
COVENANTS
95

Section 6.1       Information and Documents . (a) 
     From and after the date of this Agreement and to the earlier of the Closing Date and the date on which thisAgreement
 is terminated pursuant to Section  9.1 ,  to the extent permitted by applicable Law and upon reasonable advance notice,and
 solely for purposes of integration planning or in furtherance of the transactions contemplated by this Agreement and theAncillary
 Agreements, (1) Seller Parent shall, and shall cause its Subsidiaries to, permit Purchaser Parent and its Representatives tohave
 reasonable access, during normal business hours, to the books and records that constitute Purchased Assets, and to suchpersonnel,
 offices and other facilities and properties that constitute Purchased Assets, and to provide such other information inrespect
 of the Business as may be reasonably requested by Purchaser Parent for such purposes and (2) Purchaser Parent shall, andshall
 cause its Subsidiaries to, permit Seller Parent and its Representatives to have reasonable access, during normal business hours,to
 the books and records of Purchaser and its Subsidiaries or that are related to the Purchaser Business ( provided  that  PurchaserParent may redact any informatio
n in any such record not related to the Purchaser Business), and to such personnel, offices and otherfacilities
 and properties of Purchaser and its Subsidiaries or that are related to the Purchaser Business, and to provide such otherinformation in respect of the Purchaser Business as may be reasonably requested by Seller Parent for such purposes; 
provided  that all requests
 for access pursuant to this Section  6.1 shall  be directed to and coordinated with a person or persons designated by SellerParent
 or Purchaser Parent, as applicable, in writing; provided  ,  further , that each Parent and its Subsidiaries may restrict theforegoing
 access or the provision of such information to the extent that, in the reasonable judgment of such Parent, (i) applicableLaw
 requires such Parent or any of its Subsidiaries to restrict or prohibit such access or the provision of such information, (ii)providing
 such access would unreasonably interfere with the operation of such Parent’s and its Subsidiaries’ respective businesses,including
 the Business and the Purchaser Business, as applicable, (iii) providing such access or information would breach aconfidentiality obligation to a third party, (iv) providing such access or information would result in disclosure of any information that
is
 competitively or commercially sensitive, (v) in the case of access or information provided by Seller Parent, the information relatesto
 the Strategic Process, or in the case of access or information provided by Purchaser Parent, the information relates to review ofstrategic
 alternatives with respect to the Purchaser Business, or (vi) providing such access or disclosure of any such informationwould
 reasonably be expected to result in the loss or waiver of the attorney-client or other applicable privilege or protection. In theevent
 that a Parent or its Subsidiaries restricts access or withholds information on the basis of the foregoing clauses (i)  through  (vi) ,such
 Parent shall, if permitted, inform the other Parent as to the general nature of what is being restricted or withheld and the reasontherefor,
 and such Parent shall, and shall cause its Subsidiaries to, use its commercially reasonable efforts to make appropriatesubstitute
 arrangements to permit disclosure of the relevant information in a manner that does not suffer from such impediments.Notwithstanding
 the foregoing, (A) prior to the Closing, neither Parent, nor any of its Affiliates and Representatives, shall conductany
 phase II environmental site assessment or conduct any invasive testing or any sampling of soil, sediment, surface water,groundwater or
 building material at, on, under or within any property of the other Parent or its Subsidiaries and (B) prior to Closing,none
 of Seller Parent or any of its Affiliates, including the Conveyed Subsidiaries (and their Subsidiaries), shall provide BusinessEmployee
 personnel files to Purchaser Parent or its Affiliates or Representatives and none of Purchaser Parent or any of itsAffiliates, including Purchaser (and its Subsidiaries), shall provide
96

Purchaser Business Employee personnel files to Seller Parent or its Affiliates or Representatives. Notwithstanding the foregoing,following
 Closing (x) to the extent permitted by Law, Seller Parent shall, and shall cause its Affiliates to, provide Purchaser and itsSubsidiaries
 access to personnel records and other personnel information related to the Business Employees and Former BusinessEmployees
 reasonably requested by Purchaser and its Subsidiaries and (y) Seller Parent shall, and shall cause its Affiliates to, retainall
 material records related to the Business Employees and Former Business Employees in accordance with Seller Parent’s recordsretention
 policies and, in no event, for less than such period of time required by applicable Law. It is further agreed that, prior to theClosing,
 each Parent and its Affiliates and Representatives shall not contact any of the directors, officers, employees, agents,customers, suppliers, licensors,
 licensees, distributors or other business partners of the other Parent or any of its Affiliates (including,with
 respect to Seller Parent, the Conveyed Subsidiaries (or their Subsidiaries) and, with respect to Purchaser Parent, Purchaser andits
 Subsidiaries) in connection with the transactions contemplated by this Agreement, whether in person or by telephone, mail orother
 means of communication, without the specific prior authorization by the other Parent (not to be unreasonably withheld,conditioned
 or delayed); provided  that  the foregoing shall not prevent any Parent or its Affiliates from operating in the ordinarycourse
 of business and communicating with such parties on matters unrelated to the Business or the Purchaser Business, asapplicable,
 and the transactions contemplated by this Agreement. Notwithstanding anything to the contrary contained herein, in noevent
 shall Seller Parent or any of its Affiliates, including the Conveyed Subsidiaries (and their Subsidiaries), be required to provideany
 information as and to the extent it relates to any Retained Businesses, any Excluded Assets or any Retained Liabilities, or berequired
 to provide a copy of, or otherwise disclose the contents of, any Seller Combined Tax Return, and in no event shallPurchaser
 Parent or any of its Affiliates, including Purchaser and its Subsidiaries, be required to provide any information as and tothe extent
 it relates to any Purchaser Parent Retained Businesses or any Purchaser Parent Retained Liabilities. The Parties agree that,with respect to any matters that are the subject of both this 
Section 6.1(a)  and  Section 6.5(i) , the provisions of  Section 6.5(i)  (and not this 
Section 6.1(a) ) shall control. (b) 
     Subject to Section  6.12 ,  all information received or otherwise obtained by either Parent or its Affiliates orRepresentatives
 from, by or on behalf of the other Parent or any of its Affiliates or Representatives, in connection with thenegotiation,
 execution, performance or consummation of this Agreement and the transactions contemplated hereby, whether prior to,on or following the date of this Agreement, will be held by such Parent and its Affiliates and Representatives pursuant to the terms of
the
 Confidentiality Agreement and Section  6.12 .  Subject to Section  6.12(d) ,  the Confidentiality Agreement and the Clean TeamAgreement
 shall remain in full force and effect in accordance with their terms (subject to Section  9.2(d) )  notwithstanding anytermination of this Agreement.
(c) 
     From and after the date of this Agreement until the earlier of the Closing Date and the date on which thisAgreement
 is terminated pursuant to Section  9.1 ,  Seller Parent and its Subsidiaries shall consult with and provide material updatesto Purchaser Parent regarding the matters disclosed on 
Section 6.1(c)  of the Purchaser Disclosure Letter. 97

Section 6.2       Conduct of Business . (a) 
     From and after the date of this Agreement until the earlier of the Closing Date and the date on which thisAgreement
 is terminated pursuant to Section  9.1 ,  except (i) as set forth in Section  6.2(a) of  the Seller Disclosure Letter or asotherwise
 expressly contemplated by this Agreement (including Section  6.3 ),  (ii) as Purchaser Parent shall otherwise consent inwriting,
 which consent shall not be unreasonably withheld, conditioned or delayed, (iii) in connection with the Seller InternalRestructurings,
 the settlement of any intercompany accounts or arrangements pursuant to Section  6.7 or  the transfer of the ExcludedAssets
 pursuant to Section  2.3(b) ,  (iv) as required by Law or the terms of any Contract currently in effect and made available toPurchaser Parent, Purchase
r or any of their Representatives prior to the date hereof or (v) to the extent solely related to any ExcludedAssets,
 Retained  Businesses  or  Retained  Liabilities,  Seller  Parent  covenants  and  agrees  that  (x)  it  shall,  and  shall  cause  itsSubsidiaries
 to, use commercially reasonable efforts to conduct the Business in the ordinary course of business in all materialrespects
 and to maintain and preserve intact the Business in all material respects, and (y) it shall not, and shall cause its Subsidiariesnot to, in each case, to the extent with respect to the Purchased Assets and the Business:
(A) 
     change or amend the charter, bylaws or similar organizational documents of any of the ConveyedSubsidiaries (or any of their Subsidiaries);
(B) 
     incur, create or assume any Lien, other than Permitted Liens, with respect to any Purchased Asset that ismaterial
 to the Business other than (1) those that will be discharged at or prior to the Closing or (2) in the ordinarycourse of business;
(C) 
     acquire any assets outside of the ordinary course of business, except for transactions where the amountof
 upfront consideration paid or transferred in connection with such transactions would not exceed the amounts setforth on 
Section 6.2(a)(C) of the Seller Disclosure Letter; (D) 
     (1) amend any material term of, or waive any material right under, or terminate (other than uponexpiration
 in accordance with its terms), any Material Contract or Real Property Lease, or (2) enter into any Contractthat,
 if in effect on the date hereof, would be a Material Contract or Real Property Lease, other than, in the case ofeach
 of clauses (1) and  (2) , in the ordinary course of business or Contracts entered into in order to effect anacquisition,
 divestiture or other transaction or action expressly permitted under this clause  (y) of  this Section 6.2(a) , or (3) enter into any Contract that, if in effect on the date hereof, would be a Shared Contract;
(E) 
     issue, sell, pledge or transfer to any third party or propose to issue, sell, pledge or transfer to any thirdparty
 any shares or equity interests of any of the Conveyed Subsidiaries (or any of their Subsidiaries), or securitiesconvertible
 into, or exchangeable or exercisable for, or options with respect to, or warrants to purchase, or rights tosubscribe for, shares or equity interests of any of the Conveyed Subsidiaries (or any of their Subsidiaries);
98

(F)      change in any material respect any financial accounting method used with respect to the Business,unless required by GAAP or Law or interpretation thereof;
(G) 
     (1) enter into, adopt, amend in any material respect or terminate any Conveyed Subsidiary Plan (or anyother
 Seller Group Plan or Foreign Seller Group Plan to the extent applicable to any Business Employee, FormerBusiness
 Employee,  current  or  former  consultant  or  director),  (2)  grant  any  new,  or  increase  any  existing,  oraccelerate
 the vesting, funding or payment of any compensation or benefits of, or pay or otherwise grant any benefitnot
 required by any Seller Group Plan or Foreign Seller Group Plan to, any Business Employee, Former BusinessEmployee,
 current or former consultant or director, except, in the case of either clause  (1) or  (2) , (I) to the extentrequired
 by applicable Law or as required under any Seller Group Plan or Foreign Seller Group Plan as in effect onthe
 date of this Agreement (or as amended in accordance with the terms of this Agreement), (II) other than withrespect
 to any transaction or retention bonus or similar award or severance or termination enhancements, in theordinary
 course of business consistent with past practice, (III) as would not reasonably be expected, individually or inthe
 aggregate, to result in any non- de
minimis
 Liabilities to  Purchaser or any of its Affiliates or (IV) for amendmentssimilarly
 affecting all participating employees in any Seller Group Plan or Foreign Seller Group Plan, (3) grant anytransaction
 or retention bonus or similar award to any Business Employee, Former Business Employee, current orformer
 consultant or director or (4) transfer any Seller Retained Plan to a Conveyed Subsidiary (or Subsidiarythereof);
(H) 
     solely with respect to the Conveyed Subsidiaries or their Subsidiaries or the other Purchased Assets,and
 except with respect to any Seller Combined Tax Return, (1) make, change or revoke any material Tax election,(2)
 adopt or change any material method of Tax accounting on which Tax reporting is based, (3) amend any materialTax
 Return, (4) settle any Tax Proceeding, or (5) enter into any “closing agreement” within the meaning of 7121 ofthe
 Code (or any similar provision of state, local or foreign Law) that would be binding on Purchaser or any of itsAffiliates
 (including the Conveyed Subsidiaries and their Subsidiaries) in respect of a Post-Closing Tax Period, ineach
 case, if such action would reasonably be expected to materially increase the Tax liability of Purchaser and itsAffiliates
 (including the Conveyed Subsidiaries and their Subsidiaries after the Closing) for any Post-Closing TaxPeriod;
(I) 
     except in the ordinary course of business or as contemplated by Section  6.6 ,  (1) enter into, materiallyamend,
 extend or terminate any material Collective Bargaining Agreement covering any Business Employee orotherwise
 binding upon the Business or the Conveyed Subsidiaries or their Subsidiaries, (2) hire any individual whowill
 be a Business Employee at Closing, (3) terminate the employment of (other than for cause) any individual whowould have been a Business Employee at Closing, but for such termination of employment, or (4) reassign the
99

duties of (x) any individual who would have been a Business Employee at Closing, but for such reassigned duties, or(y)
 any employee of Seller Parent or its Affiliates who would not have been a Business Employee at Closing, but forsuch reassigned duties;
(J) 
     incur, assume or guarantee any material Indebtedness, other than (1) as would not exceed the amountsset forth on 
Section 6.2(a)(J)  of the Seller Disclosure Letter or (2)  intercompany Indebtedness that will be settled at orprior to the Closing;
(K) 
     defer payment of any accounts payable or accelerate payment of any accounts receivable, in anymaterial respect, outside of the ordinary course of business;
(L) 
     make capital expenditures in connection with the operation of the Business that are materiallyinconsistent
 with, or fail to make capital expenditures materially consistent with, the capital expenditure budget setforth in 
Section 6.2(a)(L) of the Seller Disclosure Letter; (M) 
     sell, assign, transfer, license, sublicense, abandon or otherwise dispose of any material PurchasedAssets,
 other than sales of Inventory and other assets, and non-exclusive licenses or sublicenses, in each case, in theordinary course of business;
(N) 
     (1) settle or compromise any Action made or pending against the Business or any of the ConveyedSubsidiaries
 (or any of their Subsidiaries) to the extent such settlement or compromise imposes material ongoingobligations or restric
tions on the operations of the Business, or (2) settle, compromise or file any Action that relates tothe
 Business IP that could materially impact such Business IP without consulting with and considering in good faiththe opinion of Purchaser;
(O) 
     materially accelerate or increase the quantity of the Products distributed to the relevant distributors orwholesalers
 outside of the ordinary course of business, except with respect to a bona 
fide
increase  in demand for anyProduct
 by the relevant distributor or wholesaler which has not been stimulated in any way following the date hereofby
 discounts, rebates, claw-backs or the like outside the ordinary course of business or the grant of preferred termsoffered by Seller Parent or any of its Affiliates outside the ordinary course of business; or
(P) 
     agree to take any of the foregoing actions described in this clause (y)  of this  Section 6.2(a) . (b) 
     From and after the date of this Agreement until the earlier of the Closing Date and the date on which thisAgreement is terminated pursuant to 
Section 9.1  , except (i) as set forth in  Section 6.2(b)  of the Purchaser Parent Disclosure Letter or as
 otherwise expressly contemplated by this Agreement (including Section  6.3 ),  (ii) as Seller Parent shall otherwise consent inwriting, which consent shall not be unreasonably withheld, conditioned or delayed, (iii) in
100

connection with the Purchaser Internal Restructurings or the settlement of any intercompany accounts or arrangements pursuant toSection 6.7 
, (iv)  as required by Law or the terms of any Contract currently in effect and made available to Seller Parent or any of itsRepresentatives
 prior to the date hereof or (v) to the extent solely related to any Purchaser Parent Retained Businesses or PurchaserParent
 Retained Liabilities, each of Purchaser Parent and Purchaser covenants and agrees that (x) it shall, and shall cause itsSubsidiaries
 to, use commercially reasonable efforts to conduct the Purchaser Business in the ordinary course of business in allmaterial
 respects and to maintain and preserve intact the Purchaser Business in all material respects, and (y) it shall not, and shallcause
 its Subsidiaries not to, in each case, to the extent with respect to the Purchaser Business or the assets, properties or rightscomprising the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries:
(A) 
     change or amend the charter, bylaws or similar organizational documents of Purchaser or any of itsSubsidiaries;
(B) 
     incur, create or assume any Lien, other than Purchaser Permitted Liens, with respect to any asset,property
 or right that is material to the Purchaser Business other than (1) those that will be discharged at or prior tothe Closing or (2) in the ordinary course of business;
(C) 
     acquire any assets outside of the ordinary course of business, except for transactions where the amountof
 upfront consideration paid or transferred in connection with such transactions would not exceed the amounts setforth on 
Section 6.2(b)(C) of the Purchaser Parent Disclosure Letter; (D) 
     (1) amend any material term of, or waive any material right under, or terminate (other than uponexpiration
 in accordance with its terms), any Purchaser Material Contract or Purchaser Real Property Lease, (2) enterinto
 any Contract that, if in effect on the date hereof, would be a Purchaser Material Contract or Purchaser RealProperty
 Lease, other than, in the case of each of clauses  (1) and  (2) , in the ordinary course of business or Contractsentered
 into in order to effect an acquisition, divestiture or other transaction or action expressly permitted under thisclause
 (y) of  this Section 6.2(b) ,  or (3) enter into any Contract that, if in effect on the date hereof, would be aPurchaser Shared Contract;
(E) 
     issue, sell, pledge or transfer to any third party or propose to issue, sell, pledge or transfer to any thirdparty
 any  shares  or  equity  interests  of  Purchaser  or  any  of  its  Subsidiaries,  or  securities  convertible  into,  orexchangeable
 or exercisable for, or options with respect to, or warrants to purchase, or rights to subscribe for, sharesor
 equity interests of Purchaser or any of its Subsidiaries, including in each case any ordinary shares or preferenceshares of Purchaser (other than the Preference Shares issued in accordance with this Agreement);
(F) 
     change in any material respect any financial accounting method used with respect to Purchaser, itsSubsidiaries or the Purchaser Business, unless required by IFRS or Law or interpretation thereof;
101

(G)      (1) enter into, adopt, amend in any material respect or terminate any Purchaser Business Plan (or anyother
 Purchaser Group Plan or Foreign Purchaser Group Plan to the extent applicable to any Purchaser BusinessEmployee,
 Former Purchaser Business Employee, current or former consultant or director), (2) grant any new, orincrease
 any existing, or accelerate the vesting, funding or payment of any compensation or benefits of, or pay orotherwise
 grant any benefit not required by any Purchaser Group Plan or Foreign Purchaser Group Plan to, anyPurchaser Business Employee, Former Purchaser Business Employee, current or former consultant or director, except,
in the
 case of either clause (1)  or  (2) , (I) to the extent required by applicable Law or as required under any PurchaserGroup
 Plan or Foreign Purchaser Group Plan as in effect on the date of this Agreement (or as amended in accordancewith
 the terms of this Agreement), (II)  other than with respect to any transaction or retention bonus or similar awardor
 severance or termination enhancements, in  the ordinary course of business consistent with past practice, (III) aswould
 not reasonably be expected, individually or in the aggregate, to result in any non- de 
minimis
Liabilities  toPurchaser
 or any of its Affiliates or (IV) for amendments similarly affecting all participating employees in anyPurchaser
 Group Plan or Foreign Purchaser Group Plan, (3) grant any transaction or retention bonus or similar awardto
 any Purchaser Business E mployee,  Former Purchaser Business Employee, current or former consultant or directoror
 (4) transfer any Purchaser Group Plan or Foreign Purchaser Group Plan that is not a Purchaser Business Plan toPurchaser or any of its Subsidiaries;
(H) 
     solely with respect to Purchaser and its Subsidiaries, and except with respect to any Purchaser ParentCombined
 Tax Return, (x) (1) make, change or revoke any material Tax election, (2) adopt or change any materialmethod
 of Tax accounting on which Tax reporting is based, (3) amend any material Tax Return, (4) settle any TaxProceeding,
 or (5) enter into any “closing agreement” within the meaning of 7121 of the Code (or any similarprovision
 of state, local or foreign Law) that would be binding on Purchaser or any of its Affiliates in respect of aPost-Closing
 Tax Period, in each case, if such action would reasonably be expected to materially increase the Taxliability
 of Purchaser and its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries following theClosing)
 for any Post-Closing Tax Period, or (y) take any action other than in the ordinary course of business thatwould
 reasonably be expected to violate Clauses 11.4(a) and 11.4(b) of the Structuring Considerations Agreement ifsuch Clauses were in effect from and after the date of this Agreeme
nt until the earlier of the Closing Date and the dateon which this Agreement is terminated pursuant to 
Section 9.1  ; (I) 
     except in the ordinary course of business, (1) enter into, materially amend, extend or terminate anymaterial
 Collective Bargaining Agreement covering any Purchaser Business Employee or otherwise binding upon thePurchaser
 Business or Purchaser or its Subsidiaries, (2) hire any individual who will be a Purchaser BusinessEmployee
 at Closing, (3) terminate the employment of (other than for cause) any individual who would have been aPurchaser Business Employee at
102

Closing, but for such termination of employment, or (4) reassign the duties of (x) any individual who would havebeen
 a Purchaser Business Employee at Closing, but for such reassigned duties, or (y) any employee of PurchaserParent
 or its Affiliates who would not have been a Purchaser Business Employee at Closing, but for such reassignedduties;
(J) 
     incur, assume or guarantee any material Indebtedness, other than (1) as would not exceed the amountsset
 forth on Section  6.2(b)(J) of  the Purchaser Parent Disclosure Letter or (2) intercompany Indebtedness that will besettled at or prior to the Closing;
(K) 
     defer payment of any accounts payable or accelerate payment of any accounts receivable, in anymaterial respect, outside of the ordinary course of business;
(L) 
     make capital expenditures in connection with the operation of the Purchaser Business or for whichPurchaser
 or any Subsidiary of Purchaser is responsible that are materially inconsistent with, or fail to make capitalexpenditures
 materially consistent with, the capital expenditure budget set forth in Section  6.2(b)(L) of  the PurchaserParent Disclosure Letter;
(M) 
     sell, assign, transfer, license, sublicense, abandon or otherwise dispose of any material assets,properties or
 rights (x) Related to the Purchaser Business and owned by Purchaser Parent or any of its Subsidiaries or(y)
 owned or held by Purchaser or any of its Subsidiaries, other than sales of inventory and other assets, and non-exclusive licenses or sublicenses, in each case, in the ordinary course of business;
(N) 
     (1) settle or compromise any Action made or pending against the Purchaser Business or Purchaser orany
 of  its  Subsidiaries  to  the  extent  such  settlement  or  compromise  imposes  material  ongoing  obligations  orrestriction
s on the operations of Purchaser or the Purchaser Business, or (2) settle, compromise or file any Action thatrelates
 to the Purchaser IP that could materially impact such Purchaser IP without consulting with and considering ingood faith the opinion of Seller Parent;
(O) 
     enter into or modify the terms of any material transaction, arrangement or Contract between Purchaseror
 its Subsidiaries,  on the one hand, and Purchaser Parent or any of its Affiliates  other than Purchaser or itsSubsidiaries, on the other hand;
(P) 
     materially accelerate or increase the quantity of the Purchaser Products distributed to the relevantdistributors
 or wholesalers outside of the ordinary course of business, except with respect to a bona 
fide
increase  indemand
 for any Purchaser Product by the relevant distributor or wholesaler which has not been stimulated in any wayfollowing the date hereof by discounts, rebates, claw-backs
103

or the like outside the ordinary course of business or the grant of preferred terms offered by Purchaser Parent or anyof its Affiliates outside the ordinary course of business; or
(Q) 
     agree to take any of the foregoing actions described in this clause (y)  of this  Section 6.2(b) . (c) 
     Notwithstanding any provision in this Agreement to the contrary, subject to Section 6.5(f)  ,  prior to the Closingand
 without  the  consent  of  Purchaser  Parent  or  Purchaser,  each  of  Seller  Parent  and  its  Affiliates,  including  the  ConveyedSubsidiaries and their Subsidiaries, will be permitted in their sole discretion in compliance with applicable Law to (i) declare and pay
dividends
 and distributions of, or otherwise transfer to Seller Parent or any Subsidiary thereof, (A) any Cash Equivalents or, subjectto 
Section 2.3(b) ,  Excluded Assets, and (B) any of the books and records of Seller Parent or any of its Affiliates that are notPurchased
 Assets,  (ii)  conduct  their  activities  regarding  cash  management  matters  (including,  to  the  extent  consistent  withSection
 6.2(a)(K) ,  the collection and transfer of accounts receivable and disbursement of funds, or in connection with any “cashsweep”
 practices), including to settle intercompany payables and receivables and to effect intercompany funding, (iii) make anypayments
 under, or repay (in part or in full), any indebtedness and (iv) execute, deliver and perform obligations under the LocalImplementing Agreements.
(d) 
     Notwithstanding any provision in this Agreement to the contrary, subject to Section 6.5(f)  ,  prior to the Closingand
 without the consent of Seller Parent, each of Purchaser Parent and its Affiliates, including Purchaser and its Subsidiaries, will bepermitted
 in their sole discretion in compliance with applicable Law to (i) declare and pay dividends and distributions of, orotherwise
 transfer to Purchaser Parent or any Subsidiary thereof, (A) any Cash Equivalents or assets that are not Related to thePurchaser
 Business, and (B) any of the books and records of Purchaser Parent or any of its Affiliates that are not Related to thePurchaser
 Business,  (ii)  conduct  their  activities  regarding  cash  management  matters  (including,  to  the  extent  consistent  withSection
 6.2(b)(K) ,  the collection and transfer of accounts receivable and disbursement of funds, or in connection with any “cashsweep”
 practices), including to settle intercompany payables and receivables and to effect intercompany funding, (iii) make anypayments
 under, or repay (in part or in full), any indebtedness and (iv) execute, deliver and perform obligations under the LocalImplementing
 Agreements. Until the earlier of the Closing Date and the date on which this Agreement is terminated pursuant toSection
 9.1 ,  neither Purchaser nor any of its Subsidiaries shall, and Purchaser Parent shall cause Purchaser and its Subsidiaries notto,
 without the written consent of Seller Parent, make any distributions of, or otherwise transfer, any assets, properties or rights(other
 than Cash Equivalents) Related to the Purchaser Business to Purchaser Parent or any of its Affiliates (other than to Purchaseror a Subsidiary of Purchaser).
(e) 
     Nothing contained in this Agreement shall be construed to give to Purchaser Parent or Purchaser, directly orindirectly,
 rights to control or direct the Business’s operations prior to the Closing, or give to Seller Parent, directly or indirectly,rights
 to control or direct the Purchaser Business’s operations prior to the Closing. Prior to the Closing, Seller Parent (and itsAffiliates) shall exercise, consistent with the terms and conditions of this Agreement, complete control and
104

supervision of the operations of the Business and Purchaser Parent (and its Affiliates) shall exercise, consistent with the terms andconditions of this Agreement, complete control and supervision of the operations of the Purchaser Business.
(f) 
     Purchaser agrees that it shall, and shall cause its applicable Affiliates to, on and immediately following theClosing,
 use the Purchased Assets to carry on the same kind of business as that carried on by the Sellers with respect to thePurchased Assets prior to the Closing.
Section 6.3 
      Regulatory Approvals . (a) 
     Upon the terms and subject to the conditions herein provided, Purchaser Parent, Purchaser and Seller Parenteach
 agree to take, and to cause their Affiliates to take, all actions and to do, and cause their Affiliates to do, all things necessaryunder
 applicable Antitrust Laws to consummate and make effective the transactions contemplated by this Agreement or anyAncillary
 Agreement as promptly as reasonably practicable (and in any event as required to effect the Closing prior to the OutsideDate),
 including all actions and all things necessary (i) to obtain, as promptly as reasonably practicable (and in any event as requiredto
 effect the Closing prior to the Outside Date), any consent, authorization, order or approval of, or any exemption by, or negativeclearance from, or the expiration or early termination of any waiting period imposed by, or any other Approval of, any Governmental
Antitrust
 Authority required to be obtained or made by Seller Parent, Purchaser Parent, Purchaser or their Affiliates in connectionwith
 the acquisition of the Purchased Assets or the consummation of the transactions contemplated hereby or by the AncillaryAgreements,
 (ii) to satisfy, as promptly as reasonably practicable and in any event prior to the date that is the third (3rd) BusinessDay prior to the Outside Date, the conditions precedent set forth in 
Sections 8.1(a)  and  8.1(b) to the extent relating to Antitrust Laws,(iii)
 to defend any Actions, whether judicial or administrative, brought by any Governmental Antitrust Authority or brought under,pursuant
 to or relating to any Antitrust Law challenging this Agreement, the Ancillary Agreements or the consummation of thetransactions
 contemplated hereby or thereby, and (iv) to comply as promptly as reasonably practicable with all legal requirementsunder
 Antitrust  Laws  which  may  be  imposed  with  respect  to  this  Agreement,  the  Ancillary  Agreements  or  the  transactionscontemplated
 hereby or thereby. Without limiting the foregoing, Purchaser Parent, Purchaser, Seller Parent and their Affiliates shallbe
 obligated to take such actions as are necessary to obtain, as promptly as reasonably practicable and in any event prior to the datethat is the third (3rd) Business Day prior to the Outside Date, the expiration or termination of any applicable waiting period under the
HSR
 Act and any consent, authorization, order or approval of, or any exemption by, or negative clearance from, or the expiration orearly
 termination of any waiting period imposed by, or any other Approval under, Antitrust Laws of the jurisdictions set forth onAnnex C 
. (b) 
     Subject to appropriate confidentiality protections, each of the Parties will furnish to the other Parties suchnecessary
 information and reasonable assistance as such other Parties may reasonably request in connection with the foregoing andwill
 provide the other Parties with any information supplied by such Party or its Affiliates to a Governmental Antitrust Authority inconnection with this Agreement and the transactions contemplated hereby.
105

(c)      Without limiting the generality of the undertakings pursuant to this Section 6.3  : (i) 
     Purchaser Parent, Purchaser, Seller Parent, and their respective Affiliates shall, with respect to theexecution
 of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplatedhereby
 and thereby, (A) as promptly as reasonably practicable, and in any event no later than fifteen (15) BusinessDays
 after the date hereof unless otherwise agreed to in writing by the Parties, file any notification and report formand
 related material required under the HSR Act, and (A) as promptly as reasonably practicable submit all necessaryFilings with the Governmental Antitrust Authorities set forth in 
Section 6.3(c)(i)  of the Seller Disclosure Letter; (ii) 
     In addition to the foregoing, in the event that a Party reasonably determines following the date hereofthat
 Filings other than the Filings described in Section 6.3(c)(i)  are  required to be made by one or more of the Partieswith,
 or additional Approvals are required to be obtained by the Parties from, any Governmental Antitrust Authoritiesunder any applicable Antitrust Law in connection with the execution and delivery of this Agreement and the Ancillary
Agreements
 and the consummation of the transactions contemplated hereby and thereby, the applicable Parties shalltimely
 make all such Filings and timely seek all such Approvals in accordance with the terms of this Section  6.3 . If, following
 good faith discussion and consideration, the Parties mutually agree that any such additional Approvalwould
 be required under applicable Antitrust Law to effect the Closing, and that effecting the Closing without havingobtained
 such additional Approval would reasonably be expected to violate applicable Antitrust Law (and that suchviolation
 could not be avoided or cured if the Business in the relevant jurisdiction were a Delayed Business), thejurisdiction
 to which such additional Approval relates shall be added to Annex  C, Part 1 ,  subject to each Party’sconsent
 (which shall not be unreasonably withheld, conditioned or delayed). If, following good faith discussion andconsideration,
 the Parties mutually agree that effecting the Closing without having obtained the Approval of anyGovernmental Antitrust Authority under
 applicable Antitrust Laws of any jurisdiction set forth on Annex C, Part 2  (as it
 may be supplemented pursuant to the immediately preceding sentence) would not violate applicable Antitrust Law(or that such violation could be avoided or cured if the Business in the relevant jurisdiction were a Delayed Busine
ss),such
 jurisdiction shall be removed from Annex  C ,  subject to each Party’s consent (which shall not be unreasonablywithheld, conditioned or delayed).
(iii) 
     Purchaser Parent, Purchaser, Seller Parent and their respective Affiliates shall each promptly respond toany
 formal  or  informal  requests  for  additional  information  or  documentary  material  that  may  be  made  by  aGovernmental
 Antitrust Authority and, in the case of a formal request for additional information and documentarymaterial
 under the HSR Act or any other Antitrust Law (to the extent applicable), certify substantial compliancetherewith as promptly as
106

reasonably practicable, unless the Parties otherwise agree in order to allow the Closing to occur more promptly;(iv) 
     In addition to the foregoing, Purchaser Parent, Purchaser and their Affiliates shall, as promptly asreasonably
 practicable take, or cause to be taken, any and all actions and do, or cause to be done, any and all thingsnecessary,
 required or advisable to avoid, eliminate and resolve each and every impediment and obtain all Approvalsunder
 Antitrust  Laws  that  may  be  required  by  any  Governmental  Antitrust  Authority  with  respect  to  theconsummation
 of the transactions contemplated hereby or by the Ancillary Agreements, in order to allow the Closingto
 occur as promptly as reasonably practicable after the date of this Agreement but in any event prior to the OutsideDate, including proposing, negotiating, offering to commit and effect (and if such offer is accepted, committing to and
effecting) through order, consent decree, settlement or otherwise, to (d) license, sell, divest, hold separate or otherwise
dispose
 of, directly or indirectly, any of the Purchased Assets (including any of the Shares), or any operations,divisions,
 Subsidiaries, specific assets or categories of assets, specific products (including any of the Products orPurchaser Products) or categories of products, product
 lines or businesses of Purchaser (or any of its Subsidiaries), theConveyed
 Subsidiaries (or any Subsidiary thereof), the Purchaser Business or the Business (whether now owned orhereafter
 acquired by Purchaser Parent, Purchaser or their Affiliates), (e) terminate any existing relationships andcontractual
 rights  and  obligations  of  Purchaser  and  its  Subsidiaries,  the  Conveyed  Subsidiaries  (and  theirSubsidiaries)
 and any such relationships, rights or obligations that form part of the Purchased Assets, (f) amend orterminate
 any licenses or other Intellectual Property agreements of Purchaser and its Subsidiaries, the ConveyedSubsidiaries
 (and their Subsidiaries) and any such licenses or other Intellectual Property agreements that form a partof
 the Purchased Assets and enter into such new licenses or other Intellectual Property agreements and (g) take anyactions
 or make any behavioral commitments that may limit or modify Purchaser’s (or any of its Subsidiaries’) or theConveyed Subsidiaries’ (or any of their Subsidiaries’) rights of ownership in, or ability to conduct the business of, one
or
 more of its operations, divisions, businesses, product lines, specific products (including any of the Products orPurchaser
 Products), categories of products, customers, specific assets or categories of assets, including, after theClosing,
 those of the Business or any of the Purchased Assets; provided  that,  without limiting any of PurchaserParent’s
 and its Subsidiaries’ obligations hereunder, Seller Parent and its Affiliates shall not take or agree to take anyof the
 actions listed in this Section 6.3(c)(iv)  without  the prior written consent of Purchaser Parent and Purchaser (notto
 be unreasonably withheld, delayed or conditioned); provided  further  that neither Parent shall be required to takeany
 action listed in Section  6.3(c)(iv)(A)-(D) (“  Regulatory Action ”)  with respect to the Retained Businesses,Excluded
 Assets or Purchaser Parent Retained Businesses, as applicable; and provided  further  that the proceeds,payments
 or consideration received or receivable in respect of any action contemplated by clauses (A)  through  (D) ofthis 
Section 6.3(c)(iv) shall  be paid directly to Purchaser and held by Purchaser through the Closing Date, it beingagreed that such proceeds, payments and
107

consideration shall not be included in the calculation of Purchaser Net Cash or Purchaser Working Capital.(v) 
     In furtherance of the foregoing: (x) (I) Purchaser Parent and Purchaser shall keep Seller Parentreasonably
 informed  of  all  matters,  discussions  and  activities  relating  to  any  of  the  matters  described  in  orcontemplated
 by clauses  (A) through  (D) of Section 6.3(c)(iv) ,  including satisfying each of its obligations underSection
 6.3(d) with  respect to any such matters, and (II) Purchaser Parent and Purchaser shall consider in good faithany
 of Seller Parent’s reasonable suggestions with respect to potential purchasers, licensees or other counterparties inrespect
 of any of the agreements, arrangements, transactions or other relationships described in or contemplated byclauses
 (A) through  (D) of Section 6.3(c)(iv) ,  (y) (I) Purchaser Parent and Purchaser shall permit Seller Parent toreview
 on a reasonably current basis, and shall discuss with Seller Parent, drafts of any agreements that PurchaserParent
 or Purchaser contemplates entering into, or contemplates causing any of their Affiliates (including, after theClosing,
 the Conveyed Subsidiaries and their Subsidiaries) to enter into, with respect to any of the matters describedin
 or contemplated by clauses  (A) through  (D) of Section 6.3(c)(iv) ,  (II) Purchaser Parent and Purchaser shallconsider
 in good faith Seller Parent’s views and comments with respect to such agreements, and (III) the Parties andtheir
 respective  Affiliates,  as  applicable,  shall  not  be  required  to  enter  into  any  such  agreements  unless  theeffectiveness of the transactions contemplated by such agreements is subject to the Closing and (IV) in the case of any
license,
 sale, divestiture, disposition or similar transaction, neither Purchaser Parent nor Seller Parent nor any of theirrespective
 Affiliates (other than Purchaser and its Subsidiaries) shall be the licensing, selling, divesting or disposingparty
 under any such agreements unless and except to the extent required by the relevant Governmental AntitrustAuthority
 or applicable Law and, even if so required, shall have no direct or indirect obligation thereunder for whichthey
 are not fully indemnified by Purchaser and (z) notwithstanding anything in any such agreement to the contrary,Seller
 Parent, Purchaser Parent and Purchaser agree (I) that neither Purchaser Parent nor Seller Parent nor any of theirrespective
 Affiliates (other than Purchaser and its Subsidiaries) shall have any Liability, including with respect toindemnification
 obligations, in respect of any agreements, arrangements, transactions or other relationships describedin
 or contemplated by clauses  (A) through  (D) of Section 6.3(c)(iv) ,  including the cooperation contemplated bySection
 6.3(d)(ii) ,  (II) that Purchaser shall indemnify Purchaser Parent, Seller Parent and their respective Affiliates(other
 than Purchaser and its Subsidiaries) for any Liabilities arising from, or attributable or related to, any suchagreements,
 arrangements, transactions or other relationships, including with respect to any agreements to whichPurchaser
 Parent, Seller Parent or any of their respective Affiliates (other than Purchaser and its Subsidiaries) areparty
 (except, in the case of (I) and (II), to the extent Seller Parent or Purchaser Parent, as applicable, is expresslyliable
 for such Liabilities or indemnification pursuant to this Agreement or any Ancillary Agreement) and (IV) thatneither
 Purchaser Parent nor Seller Parent nor their respective Affiliates (other than Purchaser and its Subsidiaries)shall be
108

required to take any of the actions contemplated by clauses  (A) through  (D) of Section 6.3(c)(iv) ,  or otherwise inconnection
 with the matters contemplated by this Section  6.3 ,  with respect to any of the Retained Businesses,Excluded Assets or Purchaser Parent Retained Businesses.
(vi) 
     In the event that any Action is threatened or commenced under Antitrust Laws, or a permanent orpreliminary
 injunction or other Governmental Order is threatened or entered under Antitrust Laws, that would makeconsummation
 of the transactions contemplated hereby or by the Ancillary Agreements in accordance with the termsof
 this Agreement and the Ancillary Agreements unlawful or that would prevent or delay consummation of thetransactions
 contemplated hereby or by the Ancillary Agreements (in each case, under Antitrust Laws), each ofPurchaser
 Parent, Purchaser and Seller Parent shall reasonably promptly take any and all actions and steps (includingthe
 defense against or appeal thereof, the posting of a bond and the taking of the steps contemplated  by thisSection 6.3(c) 
) necessary to resist and contest  such Action and to have vacated, modified, reversed or suspended suchinjunction
 or Governmental Order so as to permit such consummation as promptly as reasonably practicable, but inany event as required to allow the Closing to occur prior to the Outside Date.
(d) 
     Cooperation . (i) 
     Each Parent shall, and shall cause its Affiliates to, to the extent permitted by applicable Antitrust Law,(i)
 promptly notify the other Parent of, and, if in writing, provide to the other Parent copies of (or in the case of oralcommunications,
 advise the other orally of) all material or substantive communications between it (or its Affiliates orRepresentatives)
 and  any  Governmental  Antitrust  Authority  relating  to  the  consummation  of  the  transactionscontemplated
 hereby and by the Ancillary Agreements or any of the matters described in this Section 6.3  , (ii) consult with
 the other in good faith as regards strategy, permit the other to review and discuss in advance, and consider ingood
 faith  the  views  of  the  other  in  connection  with,  any  Filings,  notifications  or  material  or  substantivecommunications
 (whether written or oral) with any Governmental Antitrust Authority, including any presentations,memoranda,
 briefs, arguments, opinions or proposals and (iii) not participate in any material or substantive telephonecalls
 or any meetings with a Governmental Antitrust Authority regarding the consummation of the transactionscontemplated
 hereby and by the Ancillary Agreements or any of the matters described in this Section  6.3 without consulting
 with the other Parent in advance and, to the extent permitted by such Governmental Antitrust Authority,giving the other Parent a reasonable opportunity to attend and participate thereat.
(ii) 
     Subject to and without limiting Section  6.3(c)(iv) ,  Seller Parent shall, and shall cause its Affiliates to,reasonably
 cooperate, at Purchaser’s sole cost and expense (it being agreed that any expenses incurred by SellerParent or any of its Affiliates shall be reasonable, documented and out-of-pocket), with Purchaser Parent
109

and Purchaser on any proposed license, sale, divestiture, hold separate, disposal or other action undertaken byPurchaser
 Parent or Purchaser which Purchaser Parent or Purchaser reasonably concludes, in good faith, may benecessary
 to comply with its obligations under Section  6.3(c)(iv)(A) (a  “ Proposed Divestiture ”),  including usingreasonable best efforts in connection with:
(A) 
     providing, or causing to be provided, to Purchaser Parent and Purchaser, as well as any potentialcounterparty
 in any Proposed Divestiture (each, a “ Counterparty  ”),  any information, in an electronic data room orother
 customary format, solely with respect to the business, operations, financial condition and projections of theassets
 or business which are the subject of the Proposed Divestiture as may be reasonably requested by PurchaserParent,
 Purchaser or the Counterparty, in each case, solely to the extent such information is in Seller Parent’spossession at such time;
(B) 
     reasonably cooperating with Purchaser Parent and Purchaser in the preparation for Counterparties of acustomary
 confidential information memorandum and other customary marketing materials related to the ProposedDivestiture
 (and Seller Parent and its Affiliates hereby consent to the use of the logos of Seller Parent and itsAffiliates
 that solely relate to the Business in such confidential information memorandum and marketing materialsand
 solely in connection with the Proposed Divestiture during the period prior to the Closing (so long as such logosare
 used solely in a manner that is not intended to and is not reasonably likely to suggest or imply any affiliation,association
 or similar relationship with Seller Parent or its Affiliates, cause confusion arising out of their use of suchlogos
 simultaneously with the use of such logos by Seller Parent and its Affiliates, or harm or disparage Seller Parentor
 its Affiliates or the goodwill of Seller Parent or its Affiliates, including the Business, and are used solely inconnection
 with a truthful, non-misleading description of the Business and the Products subject to the ProposedDivestiture, and subject to Seller Parent’s review thereof);
(C) 
     causing the reasonable participation by relevant employees of the Business in marketing efforts relatedto
 the Proposed Divestiture and its potential transfer, during normal business hours, including participation in areasonable
 number  of  customary  due  diligence  sessions,  management  presentations  and  other  meetings  withCounterparties;
(D) 
     taking such actions within its reasonable control as are reasonably requested by Purchaser Parent tofacilitate
 the timely satisfaction of all conditions to the completion of the Proposed Divestiture, subject in all respectsto 
Section 2.2 and the other applicable provisions of this Agreement; (E) 
     seeking any consents and Approvals required to consummate the Proposed Divestiture from thirdparties
 (other than Governmental Authorities) reasonably requested by Purchaser Parent, subject in all respects toSection 2.2 
; and 110

(F)      requesting Seller Parent’s independent auditors to cooperate with Counterparties as may be reasonablyrequested by Seller Parent;
provided 
,  however , that notwithstanding the foregoing or anything to the contrary in this Agreement, nothing hereinshall
 (i) require Seller Parent and its Affiliates to provide any information to any Counterparties prior to receipt ofexecuted
 confidentiality and clean team agreements with respect to such information and on terms no less favorable(to
 the extent relevant) to Seller Parent than the Confidentiality Agreement and Clean Team Agreement, (ii) requirethe
 Sellers or any of their Affiliates to agree to pay any amounts for which they are not promptly reimbursed byPurchaser,
 or deliver or execute any opinions, authorization letters, certificates or other instruments, (iii) require theSellers
 or any of their Affiliates to take any action that would reasonably be expected to conflict with, or result in anyviolation
 or breach of, or default (with or without notice or lapse of time or both) under, any of their respectiveorganizational
 documents, any applicable Laws or Governmental Authorization or any material Contract or othermaterial
 obligation to a third party, (iv) cause any representation or warranty in this Agreement to be breached bySeller
 Parent (unless such breach is waived by Purchaser Parent and Purchaser), (v) cause any Representative of theSellers
 or any of their Affiliates to incur any personal liability, (vi) provide access to or disclose information that anyof
 the Sellers or any of their Affiliates reasonably determines would jeopardize any attorney-client or other privilegeor
 protection  of  any  of  the  Sellers  or  any  of  their  Affiliates  or  (vii)  prevent,  impair  or  materially  delay  theconsummation of the
 transactions contemplated hereby or by the Ancillary Agreements; provided  ,  further , that in thecase
 of the foregoing clause  (iii) and  (vi) Sellers shall, and shall cause their Affiliates to, inform Purchaser as to thegeneral
 nature of what is being restricted  or withheld  and the reason therefor,  and shall use its commerciallyreasonable
 efforts to make appropriate substitute arrangements to permit disclosure of the relevant information in amanner that does not suffer from such impediments.
(e) 
     Delayed Antitrust Approvals . (i) 
     Subject to Section 6.3(c)(ii)  , in the  event an Approval of a Governmental Antitrust Authority (other thana
 Governmental Antitrust Authority of the United States or Approvals under Antitrust Laws of the jurisdictions setforth on 
Annex C ) having  jurisdiction that is necessary to lawfully consummate the transactions contemplated herebyis
 not obtained on or prior to the date on which the conditions set forth in Sections  8.1 and  8.2 (other than theconditions
 that, by their nature, are to be satisfied on the Closing Date) shall have been satisfied or waived (each, a “Delayed
 Antitrust Approval ”  and, each such jurisdiction, an “Outstanding Antitrust Jurisdiction”), the Parties agree(subject to the satisfaction of the conditions set forth in 
Article VIII  ) that,  provided that the Laws of such Outstanding Antitrust
 Jurisdiction permit consummation of the transactions contemplated hereby in all territories other than theOutstanding Antitrust Jurisdiction, they will effect the Closing (which the Parties shall determine in
111

accordance  with  Section  6.3(c)(ii))  (including  the  issuance,  allotment  and  delivery  of  the  full  PurchaseConsideration),
 subject to the terms of this Agreement, including by selling, conveying, assigning, transferring ordelivering
 to Purchaser or the applicable Purchaser Designated Affiliates all of Seller Parent’s and its Subsidiaries’right,
 title and interest in the Purchased Assets pursuant to the terms and conditions hereof to the extent permissibleunder any applicable Law and
 subject to Section 2.2  , it  being agreed that the Closing shall refer to the consummationof
 such sale, conveyance, assignment, transfer or delivery of such Purchased Assets at such time and shall onlyexclude,
 subject to Section  2.2 ,  the Purchased Assets in that Outstanding Antitrust Jurisdiction to which suchDelayed
 Antitrust  Approval  relates  (a  “ Delayed  Business ”).  The  obligations  of  the  Parties  set  forth  in  thisSection
 6.3 shall  continue with respect to each such Delayed Antitrust Approval until the earliest to occur of (A) thedate
 such Delayed Antitrust Approval is obtained, (B) the date on which such Delayed Business is sold to a thirdparty
 designated by Purchaser (a “ Delayed  Business Purchaser ”)  (it being agreed that Purchaser shall consider ingood
 faith Seller Parent’s reasonable suggestions with respect to potential purchasers), as set forth in a written notice(a
 “ Delayed Business Notice ”)  delivered by Purchaser to Seller Parent in accordance with Section  10.1 and Section 6.3(e)(iii) 
and  (C) the date that is thirty-six (36) months after the Closing Date (the “ Hold-Back Termination Date 
”), and until the earliest to occur of the foregoing (the date of such earliest occurrence, the “ Delayed Business Cut-Off Date 
”), Seller  Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to operatethe Delayed Business in the ordinary course of business in all material respects.
(ii) 
     Upon obtaining a Delayed Antitrust Approval pursuant to Section  6.3(e)(i)(A) ,  the Parties shall effectthe
 transfer of such Delayed Business pursuant to a Local Implementing Agreement for the jurisdiction relatingthereto,
 and, to the extent permissible under applicable Antitrust Laws, such transfer shall be retroactive to, and bedeemed
 to have occurred on, the Closing Date; provided  that,  in accordance with Section  2.2(a) ,  to the fullest extentpermitted
 by applicable Law, the Parties shall treat Purchaser or the applicable Purchaser Designated Affiliate, as thecase may be, as the owner of the Delayed Business as of the Closing Date.
(iii) 
     In the event that Purchaser delivers a Delayed Business Notice to Seller Parent with respect to aDelayed
 Business, Seller Parent shall, and shall cause its Affiliates  to, use commercially  reasonable  efforts tofacilitate
 the sale of such Delayed Business to the Delayed Business Purchaser by Purchaser and on its behalf and atits
 direction as promptly as reasonably practicable, including the efforts described in Section 6.3(d)(ii)  ;  provided that (A)
 Purchaser acknowledges and agrees nothing in this Section  6.3(e) shall  require Seller Parent to transfer to theDelayed
 Business Purchaser such Delayed Business if Purchaser Parent or Purchaser is in material breach of itsobligations under this 
Section 6.3  , (B) such  Delayed Business Purchaser has obtained or will obtain prior to such saleall necessary Approvals under applicable Antitrust Laws with respect to such Delayed Business
112

and the sale of such Delayed Business would reasonably be expected to be consummated within ninety (90) daysfollowing
 the delivery of such Delayed Business Notice, (C) the sale of such Delayed Business to such DelayedBusiness
 Purchaser is not prohibited by, illegal under, or in contravention of, any applicable Law or GovernmentalOrder
 and (D) neither Purchaser Parent nor Seller Parent nor any of their respective Affiliates (other than Purchaserand its Subsidiaries)
 shall be the selling party under any agreements required to implement the transfer of the DelayedBusiness unless and except to the extent required by the relevant Governmental Antitrust Authority or applicable Law
and, even if
 so required, shall have no direct or indirect obligation thereunder for which they are not fully indemnifiedby
 Purchaser. The Parties agree (I) that neither Purchaser Parent nor Seller Parent nor any of their respectiveAffiliates
 (other  than  Purchaser  and  its  Subsidiaries)  shall  have  any  Liability,  including  with  respect  toindemnification
 obligations,  in  respect  of  any  agreements,  arrangements  or  transactions  contemplated  by  thisSection
 6.3(e)(iii) and  (II) that Purchaser shall indemnify Purchaser Parent and Seller Parent and their respectiveAffiliates
 (other than Purchaser and its Subsidiaries) for any Liabilities arising from, or attributable or related to, anysuch
 agreements, arrangements or transactions, including with respect to any agreements to which Seller Parent orPurchaser
 Parent or any of their respective Affiliates are party (except in the case of (I) and (II) to the extent SellerParent
 or Purchaser Parent, as applicable, is expressly liable for such Liabilities or indemnification pursuant to thisAgreement
 or any Ancillary Agreement). Purchaser shall promptly reimburse Seller Parent and Purchaser Parent, asapplicable,
 for any and all reasonable and documented out-of-pocket costs and expenses (including reasonableattorneys’
 and other Representatives’ fees) incurred in connection with the foregoing, including any such costs(including
 payments) or expenses incurred or made following the consummation of such transaction. Subject toapplicable Law,
 the proceeds of any sale of a Delayed Business shall be paid directly to Purchaser (or a Subsidiary ofPurchaser)
 by the Delayed Business Purchaser; provided  that  Seller Parent or Purchaser Parent, as applicable, mayrequire
 payment of its reasonable and documented out-of-pocket fees and expenses (or an estimate thereof) and anyTaxes
 payable as a result of such transaction from such proceeds as a direct wire transfer of immediately availablefunds at such applicable closing.
(iv) 
     In the event that a Delayed Antitrust Approval is not obtained with respect to a Delayed Business andPurchaser
 does not deliver a Delayed Business Notice in accordance with Section  6.3(e)(iii) with  respect to suchDelayed
 Business, in each case, prior to the Hold-Back Termination Date, the Parties shall withdraw any pendingFiling
 or notification for Approval for the transfer of such Delayed Business under applicable Antitrust Laws andSeller Parent
 may, as mutually agreed by the Parties, dispose of such Delayed Business, including by way of a sale toa
 third party. Purchaser Parent and Purchaser agree (1) that Seller Parent and its Affiliates shall not have anyobligation
 or  Liability,  including  with  respect  to  indemnification  obligations,  in  respect  of  any  agreements,arrangements or transactions contemplated by this 
Section 6.3(e)(iv)  for which it is not fully 113

indemnified by Purchaser and (2) that Purchaser shall indemnify Seller Parent and its Affiliates for any Liabilitiesarising from, or attributable or related to, any such agreements, arrangements or transactions, including with respect to
any
 agreements to which Seller Parent or any of its Affiliates are party (except in the case of (1) and (2) to the extentSeller
 Parent is expressly liable for such Liabilities or indemnification pursuant to this Agreement or any AncillaryAgreement).
 Purchaser shall promptly reimburse Seller Parent for any and all reasonable and documented out-of-pocket
 costs and expenses (including reasonable attorneys’ and other Representatives’ fees) incurred in connectionwith
 the foregoing, including any such costs (including payments) or expenses incurred or made following theconsummation
 of such transaction. Subject to applicable Law, the proceeds of any sale of a Delayed Business inaccordance
 with this Section  6.3(e)(iv) shall  be paid directly to Purchaser (or a Subsidiary of Purchaser) by thepurchaser
 of  such  Delayed  Business; provided  that  Seller  Parent  may  require  payment  of  its  reasonable  anddocumented
 out-of-pocket fees and expenses (or an estimate thereof) and any Taxes payable as a result of suchtransaction from such proceeds as a direct wire transfer of immediately available funds at such applicable closing.
(f) 
     None of Purchaser Parent, Purchaser or any of their Affiliates shall, or shall agree to, acquire, whether bymerging
 with or into, consolidating with, purchasing all or a portion of the assets of or all or a portion of the equity in, or otherwise,any
 business or corporation, partnership, or other business organization or division thereof or other Person, or dissolve, merge orconsolidate
 with any other Person, or engage in any business combination transaction or sale, whether by merging with or into,consolidating
 with, or selling all or a portion of its or its Affiliates’ assets or equity to, any other Person, or enter into, or agree toenter
 into, any license, joint venture or other similar agreement or transaction, which would reasonably be expected to, in each caseor
 in the aggregate, (i) impose any material delay in the obtaining of, or increase in any material respect the risk of not obtaining, theexpiration,
 termination or waiver of any applicable waiting period or any consent, approval, permit, ruling, authorization, clearanceor
 other Approval pursuant to the Antitrust Laws necessary to consummate the transactions contemplated hereby or by the AncillaryAgreements,
 (ii) increase in any material respect the risk of any Governmental Antitrust Authority entering an injunction or otherGovernmental
 Order prohibiting  the consummation  of the transactions  contemplated  hereby or by the Ancillary  Agreements,(iii)
 increase in any material respect the risk of not being able to remove any such injunction or other Governmental Order on appealor
 otherwise, (iv) impair, impede, hinder, or prevent or materially delay or adversely affect the consummation of the transactionscontemplated
 hereby or by the Ancillary Agreements or (v) cause any of the conditions set forth in Article VIII  to  fail to be satisfiedor
 impair, impede, hinder, or prevent or materially delay or adversely affect the ability of Purchaser Parent, Purchaser and theirAffiliates
 to perform their obligations under this Agreement and the Ancillary Agreements (any foregoing action or transaction, a “Purchaser Adverse Action 
”). (g) 
     Neither Seller Parent nor any of its Affiliates shall, or shall agree to, acquire, whether by merging with or into,consolidating
 with, purchasing all or a portion of the assets of or all or a portion of the equity in, or otherwise, any business orcorporation, partnership, or other business organization or division thereof or other Person, or dissolve, merge or consolidate with
114

any other Person, or engage in any business combination transaction or sale, whether by merging with or into, consolidating with, orselling
 all or a portion of its or its Affiliates’ assets or equity to, any other Person, or enter into, or agree to enter into, any license,joint
 venture or other similar agreement or transaction, which would reasonably be expected to, in each case or in the aggregate,(i)
 impose any material delay in the obtaining of, or increase in any material respect the risk of not obtaining, the expiration,termination
 or waiver of any applicable waiting period or any consent, approval, permit, ruling, authorization, clearance or otherApproval
 pursuant to the Antitrust Laws necessary to consummate the transactions contemplated hereby or by the AncillaryAgreements,
 (ii) increase in any material respect the risk of any Governmental Antitrust Authority entering an injunction or otherGovernmental
 Order prohibiting  the consummation  of the transactions  contemplated  hereby or by the Ancillary  Agreements,(iii)
 increase in any material respect the risk of not being able to remove any such injunction or other Governmental Order on appealor
 otherwise, (iv) impair, impede, hinder, or prevent or materially delay or adversely affect the consummation of the transactionscontemplated
 hereby or by the Ancillary Agreements or (v) cause any of the conditions set forth in Article VIII  to  fail to be satisfiedor
 impair, impede, hinder, or prevent or materially delay or adversely affect the ability of Seller Parent and its Affiliates to performtheir obligations under this Agreement and the Ancillary Agreements.
(h) 
     Each Party may, as each deems advisable or necessary, reasonably designate any competitively sensitivematerial
 provided to the other under this Section  6.3 or  otherwise as “Antitrust Counsel Only Material” or some similar notationagreed
 by the Parties. Such materials and the information contained therein shall be given only to the internal and outside antitrustcounsel
 of the recipient and will not be disclosed by such counsel to employees, officers or directors of the recipient and anyeconomic
 consultants retained in connection with the Parties’ obligations under this Section  6.3 unless  express permission isobtained
 in advance from the source of the materials (Seller Parent, Purchaser Parent or Purchaser, as the case may be) or its legalcounsel.
 Notwithstanding anything to the contrary in this Section  6.3 ,  and without limiting the restrictions on access and disclosureset
 forth in Section  6.1(a) ,  materials provided to the other Party or its counsel pursuant to this Agreement may be redacted (i) asnecessary
 to comply with contractual requirements, (ii) as necessary to address attorney-client or other privilege or protection orconfidentiality
 concerns and (iii) to remove references concerning the valuation of the Purchased Assets, the Business, or thePurchaser Business (or the Retained Businesses or Purchaser Parent Retained Businesses).
(i) 
     Purchaser shall be responsible for the payment of all filing and other fees owed to any Governmental Authorityin connection with the Filings to be made, and Approvals to be obtained, pursuant to this 
Section 6.3  . Section 6.4 
      Reasonable Best Efforts; Further Assurances . (a) 
     Under the terms and subject to the conditions set forth herein, except as otherwise provided in this Agreementor
 any Ancillary Agreement (and subject to Section  6.3 ),  each of the Parties agrees to use and to cause its Affiliates to use itsreasonable best efforts
 before and, as may be applicable, after the Closing Date, until the earlier to occur of (i) thirty-six (36) monthsfollowing the Closing Date and (ii) the completion of a Listing Transaction (as defined in the
115

Purchaser Shareholders Agreement), to take or cause to be taken all action, to do or cause to be done, and to assist and cooperatewith
 the other Parties in doing, all things necessary, proper or advisable under applicable Laws (other than with respect to AntitrustLaws,
 which are the subject of Section  6.3, and  with respect to the Purchaser Parent Shareholder Approval, which is the subject ofSection
 6.24 )  to consummate and make effective, as promptly as practicable, the transactions contemplated by this Agreement andthe
 Ancillary Agreements, including: (a) the satisfaction of the conditions precedent to the obligations of any of the Parties, (b) theobtaining
 of  all  necessary  actions,  consents,  approvals,  waivers  and  other  Approvals  of  all  Governmental  Authorities  underapplicable
 Law (other than with respect to Antitrust Laws, which are the subject of Section  6.3, and  with respect to the PurchaserParent
 Shareholder Approval, which is the subject of Section  6.24 ),  (c) without limiting the obligations of the Parties set forth inSection
 6.3 ,  the defending of any Action, whether judicial or administrative, challenging this Agreement or the performance of theobligations
 hereunder,  (d)  the  effecting  of  all  registrations,  filings  and  transfers  of  Governmental  Authorizations  (includingEnvironmental
 Permits) that constitute Purchased Assets, and the effecting of all registrations, filings and transfers of any licenses,permits,
 certificates or other authorizations or approvals which constitute Excluded Assets to be transferred to Seller Parent or anyRetained
 Subsidiary and (e) the executing, acknowledging and delivering of such documents and instruments and the taking of suchother
 actions as may reasonably be requested by the other Party in furtherance of the matters described in the foregoing clauses (a) through 
(d) ; provided that  except as otherwise expressly provided by this Agreement or any Ancillary Implementing Agreement,including 
Section  6.3 ,  none of Seller Parent, Purchaser Parent or any of their respective Affiliates shall be required to expend anymoney,
 commence any litigation or offer or grant any accommodation (financial or otherwise) in connection with the foregoing(other
 than filing and other fees owed to any Governmental Authority in connection with any Filings to be made with or Approvalsto
 be obtained from Governmental Authorities, for which Purchaser shall be responsible and shall reimburse Seller Parent and itsAffiliates).
 Purchaser  agrees  to  provide  such  reasonable  security  and  assurances  as  to  financial  capability,  resources  andcreditworthiness
 as may be reasonably requested by any Governmental Authority whose Approval is sought in connection with thetransactions contemplated hereby.
(b) 
     Without limiting and in furtherance of the provisions of Section  6.4(a) ,  and in order to facilitate theconsummation
 of the transactions contemplated by this Agreement and the Ancillary Agreements on a timely basis, promptlyfollowing the date hereof Seller
 Parent and Purchaser Parent shall organize a transition team (the “ Transition Team  ”), co-chaired by a
 representative of Seller Parent and by a representative of Purchaser Parent and including equal representation of Seller Parent andPurchaser
 Parent, which Transition Team shall, following the Closing, have responsibility for (A) coordinating and directing theefforts
 of the Parties with respect to (1) the administration and coordination of the Ancillary Agreements following the Closing, (2)subject
 to the terms of this Agreement, including Section  2.2 ,  Section 6.3 and  Section 6.4(a) ,  the process for seeking applicablethird
 party consents, Approvals, and Governmental Authorizations and making required filings or notices in connection with theconsummation
 of the transactions contemplated hereby, and (3) coordinating and directing the efforts of the Parties with respect toShared
 Contracts in accordance with Section  2.2 as  well as the efforts of the Parties with respect to the assets and liabilitiescontemplated
 by Section  2.2 ,  (B) coordinating communications, public relations and investor relations strategy and approach of theParties regarding this Agreement and
116

the transactions contemplated hereby in accordance with this Agreement, and (C) overseeing other business and operational mattersrelating
 to this Agreement and the transactions contemplated hereby in accordance with this Agreement, in the case of each ofclauses
 (A) ,  (B) and (C) , subject to applicable Laws, including Laws regarding the exchange of information and Antitrust Laws,and
 the  other  provisions  of  this  Agreement,  including  those  regarding  access  and  cooperation  (it  being  understood  that  thisSection
 6.4(b) is  intended to facilitate the administration of the matters referred to herein and is not intended to expand the scope ofor alter the substantive rights and obligations of the Parties under any other provisions of this Agreement).
(c) 
     Purchaser Parent shall develop, in consultation with Seller Parent, a detailed written transition plan (the “Transition
 Plan ”)  which shall set forth integration planning goals, activities and processes with respect to the period from the datehereof through the
 Closing Date and the transition activities to be implemented after the Closing Date. The Transition Plan shall alsoinclude
 reasonably detailed plans in respect of the matters set forth in Section  6.4(c) of  the Purchaser Parent Disclosure Letter. TheParties
 acknowledge and agree that the Transition Plan shall be prepared for convenience and informational purposes only, shall notbe
 binding on any Party or its respective Affiliates, and the taking of, or failure to take, any action set forth in the Transition Planshall
 in no event be a condition to the obligations of either Party to consummate the Sale and the other transactions contemplated bythis Agreement.
(d) 
     Purchaser Parent shall consult in good faith with Seller Parent prior to the Closing regarding (i) the identity ofthe
 initial direct reports to the Chief Executive Officer and to the Chief Financial Officer of Purchaser and (ii) the initial BusinessPlan (as defined in
 the Purchaser Shareholders Agreement), including any updates to any draft Business Plan previously provided, tobe
 adopted by Purchaser as of the Closing. If, as part of such consultation, Seller Parent wishes to escalate any matter regarding theforegoing
 matters, it shall be entitled to convene, on reasonable notice, a meeting between the Chief Executive Officers of SellerParent
 and Purchaser Parent to discuss such matters. In the event any disagreements regarding the foregoing matters cannot beresolved
 by such Chief Executive Officers prior to the Closing, the Chief Executive Officer of Purchaser Parent shall make the finaldetermination with respect thereto.
Section 6.5 
      Tax Matters . (a) 
     Preparation and Filing of Tax Returns . (i) 
     Seller Parent shall prepare or cause to be prepared all (A) Tax Returns that include Seller Parent or anyof
 its Affiliates (other than any Conveyed Subsidiary or any Subsidiary thereof), on the one hand, and any ConveyedSubsidiary
 or Subsidiary thereof, on the other hand (“ Seller  Combined Tax Returns ”)  and (B) Tax Returns of theConveyed
 Subsidiaries (and their Subsidiaries) for any Pre-Closing Tax Period other than any Straddle Period (“ Pre- Closing
 Separate Tax Returns ”).  All Pre-Closing Separate Tax Returns shall, where applicable, be prepared in amanner consistent with
 the past practices of the applicable Conveyed Subsidiary (or Subsidiary thereof), other than asrequired as a result of the Seller Internal Restructurings and except to the extent that there is not at least a “more likely
than not” basis for a position under applicable Law. In the case of any Pre-Closing
117

Separate Tax Return that is required to be filed after the Closing (taking into account any applicable extensions),Seller Parent shall deliver to Purchaser for its review and comment, at least thirty (30) days, in the case of Income Tax
Returns, and
 fifteen (15) days, in the case of non-Income Tax Returns, prior to the due date for the filing of such Pre-Closing
 Separate Tax Return (taking into account any applicable extensions), a draft copy of such Pre-ClosingSeparate Tax
 Return, together with any additional information that Purchaser may reasonably request. Purchaser shallhave
 the right to review such Pre-Closing Separate Tax Return and any such additional information prior to the filingof
 such Pre-Closing Separate Tax Return, and Seller Parent shall consider in good faith any reasonable commentssubmitted
 by Purchaser at least fifteen (15) days, in the case of Income Tax Returns, and five (5) days, in the case ofnon-Income
 Tax Returns, prior to the due date of such Pre-Closing Separate Tax Return (taking into account anyapplicable
 extensions). Purchaser shall timely file (taking into account any applicable extensions), or cause to betimely
 filed, such Pre-Closing Separate Tax Returns as prepared by Seller Parent (and as may be revised by SellerParent
 to reflect any comments received from Purchaser pursuant to the immediately preceding sentence), provided that
 such Tax Return was delivered to Purchaser at least five (5) days, in the case of Income Tax Returns, and three(3)
 days, in the case of non-Income Tax Returns, prior to the due date for filing such Tax Return (taking into accountany
 applicable extensions). Seller Parent shall timely file, or cause to be timely filed (taking into account anyapplicable
 extensions), any Seller Combined Tax Returns and any Pre-Closing Separate Tax Returns that are dueprior
 to the Closing (taking into account any applicable extensions) and pay any Taxes due on any such Tax Returnand,
 at least three (3) days before any Pre-Closing Separate Tax Return that is required to be filed after the Closing isdue
 (taking into account any applicable extensions), shall pay Purchaser (or a Subsidiary of Purchaser designated byPurchaser)
 the amount of Taxes shown as due thereon to the extent any such Taxes are Seller Indemnified Taxes forwhich Seller Parent is liable pursuant to this Agreement.
(ii) 
     Other than Tax Returns for which Seller Parent is responsible pursuant to Section 6.5(a)(i)  and any Tax Returns
 described in Section  6.5(g)(iii) ,  Purchaser shall prepare and timely file, or cause to be prepared and timelyfiled,
 all Tax Returns  of the Conveyed  Subsidiaries  and their Subsidiaries  (taking  into account any applicableextensions).
 Any such Tax Return required to be filed by Purchaser for a Tax period that includes (but does not endon)
 the Closing Date (any such Tax period, a “ Straddle  Period, ”  and any such Tax Return, a “ Straddle  Period TaxReturn 
,”) and any Tax Return (or relevant portion thereof) of Purchaser or any of its Affiliates (including theConveyed
 Subsidiaries and their Subsidiaries after the Closing) that includes or reflects (or is required to include orreflect)
 Seller Indemnified Taxes for which Seller Parent would reasonably be expected to be liable pursuant to thisAgreement
 (any  such  Tax  Return,  or  relevant  portion  thereof,  or  any  Straddle  Period  Tax  Return,  a  “ Seller Indemnifiable
 Tax Return ”)  shall, where applicable, be prepared (1) in a manner consistent with the past practices ofthe applicable Conveyed Subsidiary (or Subsidiary thereof), other than as required as a
118

result of the Seller Internal Restructurings and except to the extent that there is not at least a “more likely than not”basis
 for a position under applicable Law or such position would reasonably be expected to result in Purchaser or itsSubsidiarie
s being liable for any material Taxes that are not Seller Indemnified Taxes for which Seller Parent is liablepursuant
 to this Agreement and (2) in accordance with the terms of this Agreement. With respect to any SellerIndemnifiable Tax Return, Purchaser shall deliver to Seller Parent for its review, comment and approval, at least thirty
(30)
 days, in the case of Income Tax Returns, and fifteen (15) days, in the case of non-Income Tax Returns, prior tothe
 due date for the filing of such Seller Indemnifiable Tax Return (taking into account any applicable extensions), astatement
 setting forth the amount of Tax for which Seller Parent is responsible pursuant to Section  6.5(d)(i) and  acopy
 of such Seller Indemnifiable Tax Return, together with any additional information that Seller Parent mayreasonably
 request. Seller Parent shall have the right to review such Seller Indemnifiable Tax Return, statement andany
 additional information prior to the filing of such Seller Indemnifiable Tax Return, and Purchaser shall reflect onsuch
 Seller Indemnifiable Tax Return, as filed, any reasonable comments submitted by Seller Parent at least fifteen(15)
 days, in the case of Income Tax Returns, and five (5) days, in the case of non-Income Tax Returns, prior to thedue
 date of such Seller Indemnifiable Tax Return (taking into account any applicable extensions) to the extent anysuch
 comments would not be reasonably expected to result in Purchaser or its Subsidiaries being liable for anymaterial
 Taxes that are not Seller Indemnified Taxes for which Seller Parent is liable pursuant to this Agreement.Seller
 Parent  shall,  at  least  three  (3)  days  before  any  Tax  Return  that  Purchaser  is  obligated  to  file  underSection
 6.5(a)(ii) is  due, pay Purchaser (or a Subsidiary of Purchaser designated by Purchaser) the amount of Taxesshown as due thereon to the extent any such Taxes are Seller Indemnified Taxes.
(iii) 
     Neither Purchaser nor any of its Affiliates (including the Conveyed Subsidiaries and their Subsidiariesafter the Closing) shall amend or revoke any Pre-Closing Separate Tax Return or Straddle Period Tax Return, or agree
to
 any waiver or extension of the statute of limitations, relating to Taxes with respect to any Conveyed Subsidiary (orany
 Subsidiary thereof) for a Pre-Closing Tax Period, without the prior written consent of Seller Parent (whichconsent
 shall not be unreasonably withheld, conditioned or delayed). Upon Seller Parent’s reasonable request, at thesole
 cost and expense of Seller Parent, Purchaser shall file, or cause to be filed, any amended Pre-Closing SeparateTax
 Return in the form and substance reasonably requested by Seller Parent and in a manner consistent with the pastpractices
 of the applicable Conveyed Subsidiary or its Subsidiary (other than as required as a result of the SellerInternal
 Restructurings), except to the extent that there is not at least a “more likely than not” basis for a positionunder applicable Law, 
provided  that Purchaser shall not be required to file any such amended Tax Return to the extent it
 would reasonably be expected to result in Purchaser or its Subsidiaries being liable for any material Taxes that arenot Seller Indemnified Taxes
119

for which Seller Parent is liable pursuant to this Agreement or otherwise result in commercial consequences thatmaterially and adversely affect Purchaser.
(iv) 
     Notwithstanding anything herein to the contrary, this Section 6.5(a)  shall  not apply to any Tax Returnsin respect of Transfer Taxes described in 
Section 6.5(j)  or any VAT described in  Section 6.5(k)  . (b) 
     Carryforwards and Carrybacks .  Purchaser shall cause the Conveyed Subsidiaries and their Subsidiaries, to theextent
 permitted by applicable Law, not to carry back into any Pre-Closing Tax Period, and to carry forward into any taxable periodbeginning
 after the Closing Date any Tax Asset arising after the Closing Date (a “ Subsequent  Loss ”)  that could, whether in theabsence
 of an election or otherwise, be carried back to a Pre-Closing Tax Period. Purchaser shall take, and shall cause its Affiliates(including
 the Conveyed Subsidiaries and their Subsidiaries) to take, all steps reasonably necessary to avoid such carry back (andachieve such
 carryforward), including by making all necessary elections. If a Subsequent Loss is not permitted by applicable Law tobe
 carried forward into any taxable period beginning after the Closing Date and is required to be carried back into any Pre-ClosingTax
 Period, then after providing notice to Seller Parent of such required carryback, Purchaser and its Subsidiaries shall be entitled toany
 refund of Taxes resulting from any carryback of such Subsequent Loss into any such Pre-Closing Tax Period; provided  that Purchaser
 shall indemnify and hold Seller Parent and its Affiliates harmless from and against any Tax Liability resulting from thecarryback
 of a Subsequent Loss and any other costs and expenses associated with or incurred in connection with obtaining,collecting
 or paying over a refund resulting from such carryback to the extent such carryback of a Subsequent Loss is reflected on aSeller
 Combined Tax Return. To the extent any such Subsequent Loss or related refund is subsequently disallowed or required to bereturned
 by Seller Parent or its Affiliates to a Governmental Authority, Purchaser agrees to promptly repay any amounts previouslypaid
 over by Seller Parent to Purchaser (or its Subsidiaries) in respect of such Subsequent Loss or related refund, together with anyinterest, penalties or other additional amounts imposed by such Governmental Authority, to Seller Parent.
(c) 
     Refunds and Other Tax Benefits . (i) 
     Any Loss or Tax that Seller Parent or any of its Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries
 prior to the Closing), on the one hand, or Purchaser Parent or any of its Affiliates on the other hand, isresponsible
 for under this Agreement (including pursuant to this Section  6.5 ,  Section 6.6 or  Article VII ,  andincluding
 any amounts that are economically borne by Seller Parent or Purchaser Parent, as the case may be, throughan
 adjustment under Section  2.8 or  Section 2.9 ),  shall be determined net of any Tax Benefit arising from any TaxItem in respect of any
 such Loss or Tax realized in the taxable year of such Loss or Tax or the subsequent two taxableyears. If any such Tax Benefit was not included in the initial computation of such Loss or Tax, the Purchaser shall pay
to Seller Parent or Purchaser Parent, as
 the case may be, the amount of the applicable Tax Benefit. The amount of anypayment for a Tax Benefit that is
 due under the prior sentence shall be paid within fifteen (15) days of the filing of theTax Return with respect to
120

which the Tax Benefit is actually realized (or, if the Tax Benefit is in the form of an increased cash Tax refund, withinfifteen
 (15) days of the receipt of such cash Tax refund from the applicable Governmental Authority). To the extentpermitted to be claimed or deducted
 on a “more likely than not” basis on an applicable relevant Tax Return, Purchasershall,
 and shall cause its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries after the Closing) toclaim
 any Tax Item in respect of any Loss or Tax described in the first sentence of this Section  6.5(c) resulting  in aTax Benefit described in this 
Section 6.5(c)  on such Tax Return. (ii) 
     Without duplication of amounts covered by Section  6.5(c)(i) ,  Seller Parent shall be entitled to anyrefund
 or credit against any Seller Indemnified Taxes for which Seller Parent is liable pursuant to this Agreementexcept
 to the extent any such refund or credit was (A) reflected as an asset on the Final Closing Statement and takeninto
 account in the calculation of the Final Business Working Capital or Final Business Net Cash (with respect to thedetermination
 of Seller Accrued Income Taxes to the extent offsetting a Tax Liability in such calculation), (B) isdescribed
 in Section  6.5(b) ,  or (C) is required to be paid to any other Person pursuant to any Contract entered intoprior to
 the Closing by a Conveyed Subsidiary or any Subsidiary thereof. Purchaser shall be entitled to any refunds orcredits
 of or against any Taxes of the Conveyed Subsidiaries (and their Subsidiaries) other than refunds or credits towhich
 Seller Parent  is entitled  pursuant  to the foregoing  sentence.  If Seller Parent determines  that any of theConveyed
 Subsidiaries (or Subsidiaries thereof) is entitled to file or make a formal or informal claim for a refund ofTaxes
 (including by filing an amended Tax Return) to which Seller Parent would be entitled under this Section 6.5(c) (ii) 
, Seller Parent shall be entitled to file or make, or to request that Purchaser or its relevant Affiliate (including theapplicable
 Conveyed Subsidiary or Subsidiary thereof) file or make, such formal or informal claim for refund, andSeller
 Parent shall be entitled to control the prosecution of such claim for refund as if such claim was a TaxProceeding
 described in Section  6.5(e)(iii) and  Seller Parent were the Controlling Party provided  ,  that Seller Parentshall
 not be entitled to file or make, or to request that Purchaser or its relevant Affiliate (including the applicableConveyed
 Subsidiary or Subsidiary thereof) file or make, such formal or informal claim for refund to the extent itwould reasonably be expected to result
 in Purchaser or its Subsidiaries being liable for any material Taxes that are notSeller
 Indemnified  Taxes  for  which  Seller  Parent  is  responsible  under  this  Agreement  or  otherwise  result  inconsequences
 that materially and adversely affect Purchaser. Purchaser shall reasonably cooperate, and cause itsAffiliates (includin
g the Conveyed Subsidiaries and their Subsidiaries after the Closing) to reasonably cooperate, withrespect to
 any such request by Seller Parent or in any such claim for refund, and shall pay or cause to be paid to SellerParent
 the amount (including interest) of any related refund or credit received by Purchaser or any Affiliate thereof(including
 any  Conveyed  Subsidiary  or  Subsidiary  thereof),  net  of  any  costs,  expenses  and  Taxes  occurred  inobtaining,
 collecting or paying over such refund, credit, offset or other similar benefit within fifteen (15) days ofreceipt
 (or realization) thereof. Any refund of, or credit against, Taxes that is received or realized with respect toTaxes attributable to any
121

Conveyed Subsidiary (or Subsidiary thereof), the Purchased Assets or the Business for a Straddle Period shall beequitably
 apportioned between Seller Parent and Purchaser in a manner consistent with the principles set forth inSection 6.5(d)(iii) 
and the first sentence of this  Section 6.5(c)(ii)  . (iii) 
     Without duplication of amounts covered by Section 6.5(c)(i)  ,  Purchaser Parent shall be entitled to anyrefund
 or credit against any Purchaser Parent Indemnified Taxes for which Purchaser Parent is responsible under thisAgreement except
 to the extent any such refund or credit was (A) reflected as an asset on the Final Closing Statementand
 taken into account in the calculation of the Final Purchaser Working Capital or Final Purchaser Net Cash (withrespect
 to the determination of Purchaser Accrued Income Taxes to the extent offsetting a Tax Liability in suchcalculation)
 or (B) required to be paid to any other Person pursuant to any Contract entered into prior to the Closingby Purchaser or any Subsidiary thereo
f. Purchaser shall be entitled to any refunds or credits of or against any Taxes ofPurchaser
 or the Subsidiaries of Purchaser (other than the Conveyed Subsidiaries (and their Subsidiaries)) other thanrefunds
 or credits to which Purchaser Parent is entitled pursuant to the foregoing sentence. If Purchaser Parentdetermines
 that Purchaser or any of the Subsidiaries of Purchaser (other than the Conveyed Subsidiaries (and theirSubsidiaries))
 is entitled to file or make a formal or informal claim for a refund of Taxes (including by filing anamended
 Tax Return) to which Purchaser Parent would be entitled under this Section  6.5(c)(iii) ,  Purchaser Parentshall
 be entitled to file or make, or to request that Purchaser or its relevant Affiliate (including the applicableSubsidiary of
 Purchaser thereof) file or make, such formal or informal claim for refund, and Purchaser Parent shall beentitled
 to control the prosecution of such claim for refund as if such claim was a Tax Proceeding described inSection
 6.5(e)(iii) and  Purchaser Parent were the Controlling Party; provided  that  Purchaser Parent shall not beentitled
 to file or make, or to request that Purchaser or its relevant Affiliate file or make, such formal or informalclaim for refund to the extent
 it would reasonably be expected to result in Purchaser or its Subsidiaries being liable forany
 material Taxes that are not Purchaser Parent Indemnified Taxes for which Purchaser Parent is responsible underthis
 Agreement or otherwise result in consequences that materially and adversely affect Purchaser. Purchaser shallreasonably
 cooperate, and cause its Affiliates to reasonably cooperate, with respect to any such request by PurchaserParent
 or in any such claim for refund, and shall pay or cause to be paid to Purchaser Parent the amount (includinginterest)
 of any related refund or credit received or realized by Purchaser or any Affiliate thereof (including anyConveyed Subsidiary or
 Subsidiary thereof), net of any costs, expenses and Taxes occurred in obtaining, collecting orpaying
 over such refund or credit within fifteen (15) days of receipt (or realization) thereof. Any refund of, or creditagainst, Taxes that is received or realized with respect to Taxes attributable to Purchaser or its Subsidiaries (other than
the
 Conveyed Subsidiaries (and their Subsidiaries)) for a Straddle Period shall be equitably apportioned betweenPurchaser
 Parent and Purchaser in a manner consistent with the principles set forth in Section  6.5(d)(iii) and  the firstsentence of this 
Section 6.5(c)(iii)  . 122

(d)      Tax Indemnification . (i) 
     Subject to Section  6.5(d)(v) ,  from and after the Closing, Seller Parent agrees to indemnify and holdharmless
 Purchaser and its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries after the ClosingDate)
 (collectively, the “ Purchaser  Tax Indemnified Parties ”)  from and against all liability, without duplication, for(1)
 Taxes of the Conveyed Subsidiaries and their Subsidiaries for any Pre-Closing Tax Period (including any Taxespayable
 in respect of an election under Section 965(h) of the Code), (2) Taxes of any Seller (other than any TransferTaxes
 and VAT for which Purchaser is responsible hereunder) including, Taxes (other than Taxes of the ConveyedSubsidiaries
 and their Subsidiaries) imposed with respect to, arising out of or relating to the Purchased Assets or theBusiness
 for a Pre-Closing Tax Period, (3) Taxes of any Person (other than the Conveyed Subsidiaries and theirSubsidiaries)
 for a Pre-Closing Tax Period for which any Conveyed Subsidiary (or any Subsidiary thereof) is liableunder
 Treasury Regulation Section 1.1502-6 (or a similar provision of state, local or foreign Law), or as a transfereeor
 successor or by Contract (other than Contracts that do not relate primarily to Taxes), (4) Taxes arising out of orresulting
 from any breach of any covenant or agreement of Seller Parent or any of its Affiliates contained in thisAgreement, (5) Taxes for a
 Pre-Closing Tax Period imposed on (x) any transaction effected pursuant to Section 2.3(b) ,
 (y) any settlement of any intercompany accounts of Seller Parent or its Subsidiaries pursuant to Section  6.7 ,  or (z)any transaction or step forming part of the Seller Internal Restructurin
gs, (6) Transfer Taxes for which Seller Parent isresponsible
 under Section  6.5(j) ,  (7) Taxes required to be deducted or withheld with respect to the payment of thePurchase Conside
ration or any amounts payable to Seller Parent pursuant to Section 2.8  or  Section 2.9 , including any penalties
 imposed on Purchaser as a result of Purchaser’s failure to deduct or withhold any such amounts thatPurchaser (or a
 Purchaser Designated Affiliate) was permitted to withhold under Section 2.10  (in each case, subject to Purchaser’s
 compliance with the notice and cooperation requirements of Section  2.10 and  except for any such Taxes(and any related
 penalties) required to be deducted or withheld solely as a result of any assignment by Purchaser or itsAffiliates
 for which Purchaser is responsible pursuant to Section  10.3 ),  (8) Taxes arising from any breach of anyrepresentation
 or warranty contained in Section  4.16(k) ,  (9) Taxes arising as a result of any Conveyed Subsidiary orany
 Subsidiary of any Conveyed Subsidiary at any time ceasing to be a member of a group for the purposes of anyTax,
 of which group Seller Parent or any Subsidiary of Seller Parent is or was also a member and (10) any costs andexpenses,
 including  reasonable  legal  and  accounting  fees  and  expenses,  attributable  to  any  item  described  inclauses
 (1) through (9) (any such Taxes for which Seller Parent is responsible pursuant to this Section  6.5(d)(i) , subject
 to the following proviso, “ Seller  Indemnified Taxes ”);  provided that  Seller Parent shall not be required toindemnify
 or hold harmless any Purchaser Tax Indemnified Party from and against any liability pursuant to thisSection
 6.5(d)(i) for  (A) Taxes attributable to any action taken after the Closing by Purchaser, any of its Affiliates(including the Conveyed Subsidiaries and their Subsidiaries), or any transferee of Purchaser or any of its Affiliates
123

(including the Conveyed Subsidiaries and their Subsidiaries), other than any such action that (1) is in the ordinarycourse
 of business, (2) is expressly permitted or contemplated by this Agreement, or (3) is required to be taken inorder to comply with applicable Law or as a result of a change in applicable Law (a “ 
Purchaser Tax  Act  ”), (B) Taxesthat
 were reflected, accrued or reserved for in the Final Closing Statement, Final Business Working Capital, or FinalBusiness Net Cash, (C) Income Taxes
 to the extent that a Conveyed Subsidiary or any Subsidiary thereof had any TaxAssets
 as of the close of business on the Closing Date that were available, or would have been available but for theirprior
 utilization by Purchaser or any of its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries afterthe
 Closing) to offset or otherwise reduce the applicable Tax Liability in respect of such Income Taxes (except anyTax
 Asset reflected as an asset in the Final Closing Statement and taken into account in the calculation of the FinalBusiness
 Working Capital or the Final Business Net Cash), or (D) Taxes for which Purchaser Parent is responsibleunder 
Section 6.5(d)(ii) . (ii) 
     Subject to Section  6.5(d)(v) ,  from and after the Closing, Purchaser Parent shall indemnify and holdharmless the
 Purchaser Tax Indemnified Parties from and against all liability, without duplication, for (1) all Taxes ofPurchaser
 Parent and its Affiliates (other than Purchaser and its Subsidiaries) for any Tax period (other than TransferTaxes
 and VAT for which Seller Parent is responsible hereunder), (2) Taxes of Purchaser and its Subsidiaries (otherthan
 the Conveyed Subsidiaries and their Subsidiaries) for any Pre-Closing Tax Period, (3) Taxes of any Person for aPre-Closing
 Tax Period for which Purchaser (or any Subsidiary thereof other than any Conveyed Subsidiaries andtheir
 Subsidiaries) is liable under Treasury Regulation Section 1.1502-6 (or a similar provision of state, local orforeign
 Law), or as a transferee or successor or by Contract (other than Contracts that do not relate primarily toTaxes),
 (4) Taxes arising out of or resulting from any breach of any covenant or agreement of Purchaser Parent,Purchaser or
 their respective Affiliates contained in this Agreement, (5) Transfer Taxes for which Purchaser Parent isresponsible
 under Section  6.5(j) ,  (6)  Taxes  arising  from  any  breach  of  any  representation  or  warranty  inSection 5.17(k 
), (7)  Taxes for a Pre-Closing Tax Period imposed on (x) any settlement of any intercompany accountsof
 Purchaser or any Subsidiary of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of PurchaserParent
 (other than Purchaser and its Subsidiaries), on the other hand, pursuant to Section 6.7  or  (y) any transaction orstep
 forming part of the Purchaser Internal Restructurings, (8) Taxes required to be deducted or withheld with respectto
 any amounts payable to Purchaser Parent pursuant to Section  2.8 or  Section 2.9 ,  including any penalties imposedon Purchaser as a result
 of Purchaser’s failure to deduct or withhold any such amounts, (9) Taxes arising as a result ofPurchaser
 or any Subsidiary of Purchaser (other than any Conveyed Subsidiary or a Subsidiary thereof) at any timeceasing to be
 a member of a group for the purposes of any Tax, of which group Purchaser Parent or any Subsidiary ofPurchaser
 Parent (other than Purchaser or any Subsidiary of Purchaser) is or was also a member and (10) any costsand expenses, including reasonable legal and accounting fees and expenses,
124

attributable  to  any  item  described  in clauses  (1) through  (9 )  (any  such  Taxes  for  which  Purchaser  Parent  isresponsible pursuant to this 
Section 6.5(d)(ii)  , subject to the following proviso, “  Purchaser Parent Indemnified Taxes ”); 
provided that Purchaser Parent shall not be required to indemnify or  hold harmless any Purchaser Tax IndemnifiedParty from
 and against any liability for (A) Taxes attributable to any action taken after the Closing by Seller Parent orany of its
 Affiliates, other than any such action that (1) is in the ordinary course of business, (2) is expressly permittedor
 contemplated by this Agreement, or (3) is required to be taken in order to comply with applicable Law or as aresult
 of a change in applicable Law (a “ Seller  Tax Act ”),  (B) Taxes that were reflected, accrued or reserved for inthe
 Final Closing Statement, Final Purchaser Working Capital or the Final Purchaser Net Cash, (C) Income Taxes tothe extent that Purchaser or any
 Subsidiary thereof had any Tax Assets as of the close of business on the Closing Datethat
 were available, or would have been available but for their prior utilization by Purchaser or any of its Affiliates(including
 the Conveyed Subsidiaries and their Subsidiaries after the Closing), to offset or otherwise reduce theapplicable
 Tax Liability in respect of such Income Taxes (except any Tax Asset reflected as an asset in the FinalClosing
 Statement and taken into account in the calculation of the Final Purchaser Working Capital or the FinalPurchaser Net Cash), or (D) Taxes for which Seller Parent is responsible under 
Section 6.5(d)(i)  . (iii) 
     To the extent permitted or required by applicable Law, the taxable year of each of the ConveyedSubsidiaries
 and their Subsidiaries and any Subsidiary of Purchaser that includes the Closing Date shall be treated asclosing
 on (and including) the Closing Date. Otherwise, for purposes of this Agreement, in the case of any StraddlePeriod:
(A) 
     Property Taxes allocable to the Pre-Closing Tax Period shall be computed based upon the ratio of thenumber of days in the Pre-Closing Tax Period to the number of days in the entire Straddle Period; and
(B) 
     Taxes (other than Property Taxes) allocable to the Pre-Closing Tax Period shall be computed as if suchTax
 period ended as of the close of business on the Closing Date and, in the case of any Taxes of ConveyedSubsidiaries
 (and their Subsidiaries) and Seller Parent, or in the case of any Taxes of Purchaser Parent and Purchaser(and
 their Subsidiaries prior to the Closing), in each case attributable to the ownership of any equity interest in anypartnership
 or other “flow through” entity for tax purposes (including of any “controlled foreign corporation,” asdefined
 under the Code) as if the Tax period of such partnership or other “flow through” entity ended as of the closeof
 business on the Closing Date with the Taxes of such entity for the Pre-Closing Tax Period deemed to include anyTaxes
 on the allocable income of such entity in respect of such Tax period; provided  that  exemptions, allowances ordeductions
 that are calculated on an annual basis (including depreciation and amortization deductions) shall beallocated between the period ending on the Closing
125

Date and the period beginning after the Closing Date in proportion to the number of days in each period.(iv) 
     Any claim for indemnification under this Section  6.5(d) shall  be made in writing upon the party fromwhom
 indemnification is sought, and shall specify in reasonable detail the basis for such claim. Any indemnitypayment
 required  to  be  made  pursuant  to  this Section  6.5(d) shall  be  made  within  thirty  (30)  days  after  theindemnified
 party makes written demand upon the indemnifying party, but in no case earlier than five (5) BusinessDays prior to the date on which the relevant Taxes are required to be paid to the applicable Taxing Authority.
(v) 
     With respect to any Taxes suffered or incurred by any Conveyed Subsidiary (or any Subsidiary thereof)that
 was not wholly owned by Seller Parent (directly or indirectly) as of immediately prior to the Closing, theindemnification obligations of Seller Parent pursuant to 
Section 6.5(d)(i)  in respect of such Taxes (or related costs and expenses)
 shall in no event exceed an amount equal to (A) the amount of such Taxes (or related costs and expenses)for
 which  the  Purchaser  Tax  Indemnified  Parties  would  otherwise  be  entitled  to  indemnification  pursuant  toSection
 6.5(d) ,  as if such Conveyed Subsidiary (or any Subsidiary thereof) were wholly owned by Seller Parent,multiplied

by
(B)  the direct and indirect percentage ownership of Seller Parent of such Conveyed Subsidiary (orSubsidiary
 thereof) as of immediately prior to the Closing. With respect to any Taxes suffered or incurred by anySubsidiary
 of Purchaser Parent (including Purchaser and its Subsidiaries) that was not wholly owned by PurchaserParent
 (directly or indirectly) as of immediately prior to the Closing, the indemnification obligations of PurchaserParent
 pursuant to Section  6.5(d)(ii) in  respect of such Taxes (or related costs and expenses) shall in no event exceedan
 amount equal to (A) the amount of such Taxes (or related costs and expenses) for which the Purchaser TaxIndemnified
 Parties would otherwise be entitled to indemnification pursuant to Section  6.5(d) ,  as if such Subsidiarywere
 wholly owned by Purchaser Parent, multiplied 
by
(B)  the direct and indirect percentage ownership of PurchaserParent of such Subsidiary as of immediately prior to the Closing.
(vi) 
     Without duplication to any other amounts paid pursuant to this Section 6.5:(A) 
     Within thirty (30) days following the filing of any Income Tax Return for any Conveyed Subsidiary (orany
 Subsidiary  thereof),  on  the  one  hand,  or  Purchaser  (or  any  Subsidiary  thereof,  other  than  the  ConveyedSubsidiaries
 and their Subsidiaries), on the other hand, for any Pre-Closing Tax Period or for any Straddle Period,Seller
 Parent or Purchaser Parent shall (or Purchaser Parent shall cause Purchaser to) prepare a statement showing (i)the
 amount of Income Taxes shown as due on such filed Income Tax Return with respect to the relevant Pre-ClosingTax
 Period or the portion of any Straddle Period ending on and including the Closing Date (the “ Final  Pre-ClosingIncome Tax Amount 
”) and (ii) the amount of the Seller 126

Accrued Income Taxes or Purchaser Accrued Income Taxes, as applicable, attributable to such Income Tax Return asreflected
 on the Final Closing Statement (the “ Pre-Closing  Income Tax Amount ”)  and deliver such statement toSeller
 Parent and Purchaser Parent, as applicable. Purchaser Parent or Seller Parent, as applicable, shall have a periodof
 fifteen (15) Business Days to provide comments to a schedule prepared (or caused to be prepared) by Seller Parentor
 Purchaser Parent, respectively. If Purchaser Parent or Seller Parent, as applicable, do not provide any comments toSeller
 Parent or Purchaser Parent, respectively, during such period, the statement as so prepared shall be final andbinding.
(B) 
     In the event the Final Pre-Closing Income Tax Amount with respect to any Income Tax Return is lessthan the
 amount of the Pre-Closing Income Tax Amount attributable to such Income Tax Return that was included onthe
 Final Closing Statement, the Purchaser shall within five (5) Business Days following the finalization of the FinalPre-Closing
 Income Tax Amount hereunder (i) pay to Seller Parent the amount of such difference with respect to aConveyed
 Subsidiary and their Subsidiaries and (ii) pay to Purchaser Parent the amount of such difference withrespect to Purchaser and its Subsidiaries.
(vii) 
     The Parties shall use reasonable best efforts to structure any indemnity payment, true-up payment, orpayment
 in respect of Tax Benefits made by any Party pursuant to this Agreement (including pursuant to this Section 6.5 
, Section 6.6 and  Article VII )  and any payment made by Purchaser Parent to Purchaser pursuant to Section 2.8  or Section
 2.9 in  the manner set forth in Clause 10 of the Structuring Considerations Agreement. The Parties shall usereasonable best efforts to structure as a
 special dividend any payment made by Purchaser to Purchaser Parent pursuantto 
Section 2.8 ,  Section 2.9 or this  Section 6.5 . (e) 
     Tax Contests . (i) 
     If a claim shall be made by any Taxing Authority (a “ Tax  Claim ”)  which, if successful, wouldreasonably
 be expected to result in an indemnity payment pursuant to Section  6.5(d) ,  the indemnified party shallpromptly
 notify the indemnifying party in writing of such claim (and provide copies of any documents received fromthe
 Taxing Authority in respect of such claim); provided  that  the failure to provide such notice shall not relieve theindemnifying
 party  of  its indemnification  obligations hereunder  except  to  the  extent  the  indemnifying  party  isprejudiced
 thereby and expenses are incurred during the period in which notice was not provided. Such notice shallspecify
 in reasonable detail the basis for such Tax Claim and shall include a copy of the relevant portion of anycorrespondence received from the Taxing Authority.
(ii) 
     With respect to any Tax Claim relating to a Conveyed Subsidiary (or any Subsidiary thereof) for anyTax
 period ending on or before the Closing Date, to Seller Parent (or any Subsidiary thereof) for any taxable period,or with respect to, a Seller Combined Tax Return, Seller Parent shall control all Tax Proceedings and
127

shall make all decisions taken in connection with such Tax Proceeding (including selection of counsel), and, withoutlimiting
 the  foregoing,  may  pursue  or  forego  any  and  all  administrative  appeals,  proceedings,  hearings  andconferences
 with any Taxing Authority with respect thereto, and may either pay the applicable Tax Liability and suefor a
 refund or contest the Tax Claim; provided  , that  in the case of such Tax Proceeding with respect to a Tax Returnof
 a Conveyed Subsidiary (or any Subsidiary thereof) other than a Seller Combined Tax Return, Seller Parent shallnot
 settle such Tax Proceeding if doing so would reasonably be expected to materially increase the Tax Liability ofPurchaser
 or its Subsidiaries (including the Conveyed Subsidiaries and any Subsidiary thereof after the Closing),taking into
 account any indemnification for Tax Liabilities under this Agreement, without the prior written consent ofPurchaser,
 which consent shall not be unreasonably withheld, delayed or conditioned. In the case of any such TaxProceeding with respect to a Conveyed Subsidiary (or a Subsidiary thereof), Seller Parent shall (x) notify Purchaser of
any material development with respect to
 any such Tax Proceeding, (y) provide Purchaser with copies of any materialdocuments
 submitted in connection with such Tax Proceeding and (z) notify Purchaser regarding any material actionto
 be taken by Seller Parent with respect to such Tax Proceeding (and take Purchaser’s comments into considerationin
 good faith), in each case, solely to the extent relating to matters or aspects of such Tax Proceeding that wouldreasonably
 be expected to materially increase the Tax Liability of a Conveyed Subsidiary (or a Subsidiary thereof) ina Post-Closing Tax Period.
(iii) 
     In the case of any Tax Proceeding relating to Taxes of the Conveyed Subsidiaries (and theirSubsidiaries)
 for any Straddle Period, the Controlling Party shall have the right and obligation to conduct such TaxProceeding; 
provided  that  the  Controlling  Party  shall  (u)  notify  the  Non-Controlling  Party  of  any  materialdevelopment
 with respect to such Tax Proceeding, (v) provide the Non-Controlling Party with copies of any materialdocuments
 submitted in connection with such Tax Proceeding, (w) consult with the Non-Controlling Party beforesubmitting
 any  written  materials  or  taking  any  significant  action  in  connection  with  the  conduct  of  such  TaxProceeding, (x)
 provide, to the extent possible, for the Non-Controlling Party to participate in such Tax Proceeding atits
 own expense, (y) defend such Tax Proceeding diligently and in good faith, and (z) not settle any such TaxProceeding
 if doing so would reasonably be expected to materially increase the Tax Liability of the Non-ControllingParty
 or its Affiliates (taking into account any indemnification for Tax Liabilities under this Agreement), without theprior
 written consent of the Non-Controlling Party, which consent shall not be unreasonably withheld, delayed orconditioned.
 For purposes of this Agreement, “ Controlling  Party ”  shall mean Seller Parent if Seller Parent and itsAffiliates
 are reasonably expected to bear the greater Tax Liability in connection with such Tax Proceeding, orPurchaser
 if Purchaser and its Affiliates are reasonably expected to bear the greater Tax Liability in connection withsuch
 Tax Proceeding; and “ Non-Controlling  Party ”  means whichever of Seller Parent or Purchaser is not theControlling Party with respect to such Tax Proceeding.
128

(iv)      Except as otherwise provided herein, Purchaser shall control all Tax Proceedings with respect to theConveyed
 Subsidiaries (and their Subsidiaries) for any taxable period beginning after the Closing Date and any TaxProceeding with respect to Purchaser or any of its Affiliates relating to any Seller Indemnifiable Tax Return; 
provided that Seller Parent shall be deemed to be
 a Non-Controlling Party (with the rights described in Section 6.5(e)(iii)  ) with respect
 to any such Tax Proceeding if the resolution of any such Tax Proceeding would reasonably be expected tomaterially
 increase the Tax Liability of a Conveyed Subsidiary (or a Subsidiary thereof) in a Pre-Closing Tax Periodor the amount of indemnification for which Seller Parent is responsible pursuant to 
Section 6.5(d)(i)  . (v) 
     Purchaser, the Conveyed Subsidiaries and each of their respective Affiliates, on the one hand, and SellerParent
 and its Affiliates, on the other hand, shall cooperate in contesting any Tax Claim, which cooperation shallinclude
 the retention and, upon request, the provision to the requesting Party of records and information which arereasonably
 relevant to such Tax Claim, and making employees available on a mutually convenient basis to provideadditional
 information or explanation of any material provided hereunder or to testify at related Tax Proceedings.Purchaser
 Parent and Seller Parent and their applicable Affiliates shall execute and deliver such powers of attorneyand
 other documents as are necessary to carry out the intent of this Section  6.5(e)(v) .  Notwithstanding anythingherein
 to the contrary, (A) Seller Parent shall not be required to provide Purchaser or its Affiliates with a copy, orotherwise
 disclose the contents, of any Seller Combined Tax Return (except to the extent such information relatessolely
 to a Conveyed Subsidiary or its Subsidiaries), (B) Seller Parent shall have the exclusive right to control in allrespects,
 and neither Purchaser nor any of its Affiliates shall be entitled to participate in, any Tax Proceeding withrespect
 to  any  Tax  Return  of  Seller  Parent  or  any  of  its  Affiliates  or  any  Seller  Combined  Tax  Return,  and(C)
 Purchaser Parent shall not be required to provide Seller Parent, Purchaser or its Affiliates with a copy, orotherwise
 disclose the contents, of any Tax Return that includes Purchaser Parent or any of its Affiliates (other thanPurchaser
 and any Subsidiary thereof), on the one hand, and Purchaser and any Subsidiary thereof (other than anyConveyed
 Subsidiary or Subsidiary thereof), on the other hand (“ Purchaser  Parent Combined Tax Returns ”)  andPurchaser
 Parent shall have the exclusive right to control in all respects, and neither Seller Parent nor any of itsAffiliates
 shall be entitled to participate in, any Tax Proceeding with respect to any Purchaser Parent Combined TaxReturn.
(f) 
     Internal Restructurings . (i) 
     Notwithstanding anything herein to the contrary, but subject to Section  2.2 , Section 6.3 and  Section 6.4 , Seller
 Parent shall, at its sole cost and expense, effective from a date on or prior to the Closing Date, implement thetransactions
 necessary to deliver on the Closing Date the Business and the Purchased Assets in a manner consistentwith 
Section 6.5(f) of  the Seller Disclosure Letter (such transactions, as finally described in the Seller Parent FinalPlan (as defined below),
129

the “ Seller Internal Restructurings ”);  provided that  within seventy-five (75) days of the date hereof, Seller Parentshall
 deliver to Purchaser Parent for Purchaser Parent’s review and reasonable comment an initial draft of a step plan(the “ 
Seller Parent Preliminary Plan  ”) setting  forth the steps Seller Parent shall undertake to effect the Seller InternalRestructurings; 
provided  ,  further , that Seller Parent shall (x) consider in good faith any reasonable amendments,modifications
 or supplements to the Seller Parent Preliminary Plan proposed by Purchaser Parent and Purchaser and(y)
 shall, to the extent consistent with the principles set forth in Section  6.5(f) of  the Seller Disclosure Letter,incorporate
 the input of Purchaser Parent and Purchaser on the Seller Parent Preliminary Plan (including the timing,structure
 and other details of such transactions). Subject to the finalization of the Seller Parent Final Plan pursuant toSection
 6.5(f)(iii), at least twenty (20) Business Days prior to the Closing, Seller Parent shall provide to PurchaserParent
 a list of the U.S. federal tax classification elections for each of the Conveyed Subsidiaries and Subsidiariesthereof as
 of the Closing, which list shall be true, correct and complete in all material respects and consistent with theSeller Parent Final Plan.
(ii) 
     Notwithstanding anything herein to the contrary, but subject to Section  2.2 , Section 6.3 and  Section 6.4,Purchaser
 Parent shall, at its sole cost and expense, effective from a date on or prior to the Closing Date and Section 6.3(e) 
), implement the transactions necessary to deliver on the Closing Date any assets of Purchaser Parent or itsAffiliates
 (other than Purchaser and its Subsidiaries and except for any assets and/or employees based in France or employed by
 any French Affiliate of Purchaser Parent  )  transferred to Purchaser or its Subsidiaries in connection withthe
 transactions described herein in a manner consistent with Section  6.5(f) of  the Purchaser Parent Disclosure Letter(such
 transactions, as finally described in the Purchaser Parent Final Plan (as defined below), the “ Purchaser Internal Restructurings 
”);  provided that  within seventy-five (75) days of the date hereof, Purchaser Parent shall deliver toSeller
 Parent an initial draft of a step plan (the “ Purchaser  Parent Preliminary Plan ”,  and together with the SellerParent
 Preliminary Plan, the “ Preliminary  Plans ”)  setting forth steps Purchaser Parent shall undertake to effect thePurchaser
 Internal  Restructurings for  Seller  Parent’s review  and  reasonable comment; provided  ,  further ,  thatPurchaser
 Parent shall (x) consider in good faith any reasonable amendments, modifications or supplements to thePurchaser
 Parent Preliminary Plan proposed by Seller Parent and (y) Purchaser Parent shall, to the extent consistentwith
 the principles set forth in Section 6.5(f)  of  the Purchaser Parent Disclosure Letter, incorporate the input of SellerParent
 on  the  Purchaser  Parent  Preliminary  Plan  (including  the  timing,  structure  and  other  details  of  suchtransactions).
 Subject to the finalization of the Purchaser Parent Final Plan pursuant to Section 6.5(f)(iv), at leasttwenty
 (20) Business Days prior to the Closing, Purchaser Parent shall provide to Seller Parent a list of the U.S.federal tax classification elections for each of Purchaser and
 its Subsidiaries as of the Closing, which list shall be true,correct and complete in all material respects and consistent with the Purchaser Parent Final Plan.
130

(iii)      Following the delivery of the Seller Parent Preliminary Plan, any amendments, modifications orsupplements
 to the Seller Parent Preliminary Plan reasonably proposed by Seller Parent shall be considered in goodfaith
 by Purchaser Parent, and the Parties shall negotiate in good faith regarding any such proposed amendments,modifications
 or supplements to which Purchaser Parent objects. Purchaser Parent’s approval shall be required beforethe
 Seller Parent Preliminary Plan becomes final (such approval not to be unreasonably, withheld, conditioned ordelayed) (such
 plan, once finalized pursuant to this Section 6.5(f)  , the “  Seller Parent Final Plan  ”). For the avoidance of doubt,
 if no amendments, modifications or supplements are reasonably proposed by Purchaser Parent following thedelivery of the Seller Parent Preliminary Plan, the Seller Parent Preliminary Plan shall be the Seller Parent Final Plan.
(iv) 
     Following the delivery of the Purchaser Parent Preliminary Plan, any amendments, modifications orsupplements to
 the Purchaser Parent Preliminary Plan reasonably proposed by Purchaser Parent shall be considered ingood
 faith by Seller Parent, and the Parties shall negotiate in good faith regarding any such proposed amendments,modifications
 or supplements to which Seller Parent objects. Seller Parent’s approval shall be required before thePurchaser
 Parent Preliminary Plan becomes final (such approval not to be unreasonably, withheld, conditioned ordelayed)
 (such plan, once finalized pursuant to this Section  6.5(f) ,  the “ Purchaser Parent  Final Plan ”).  For theavoidance
 of doubt, if no amendments, modifications or supplements are reasonably proposed by Seller Parentfollowing
 the delivery of the Purchaser Parent Preliminary Plan, the Purchaser Parent Preliminary Plan shall be thePurchaser Parent Final Plan.
(v) 
     Seller Parent and Purchaser Parent each shall, when proposing amendments, modifications andsupplements to
 the Preliminary Plans and when reviewing and considering such proposed amendments, modificationsand
 supplements for their respective approval, act reasonably and in good faith consistent with the principles set forthin Section 6.5(f) of the Seller Disclosure Letter.
(g) 
     Certain Tax Elections and Post-Closing Actions .   (i) 
     Purchaser shall not, and shall cause its Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries)
 not to, take any action on the Closing Date (after the Closing) other than in the ordinary course ofbusiness with
 respect to the Purchased Assets, the Assumed Liabilities, the Business or any Conveyed Subsidiaries orSubsidiaries thereof, except as expressly contemplated herein.
(ii) 
     With respect to any Conveyed Subsidiary (or Subsidiary thereof), Purchaser shall not (A) make or causeor permit to be made an election under Section 338(g) of the Code (or any similar election permitted under state, local
or
 foreign Law), (B) make or cause or permit to be made any election (including any election pursuant to TreasuryRegulation Section 301.7701-3) that would be effective
131

on or prior to the Closing Date or otherwise have retroactive effect with respect to a Pre-Closing Tax Period.(iii) 
    (A) 
     Prior to the Closing, an Affiliate(s) of Seller Parent shall transfer the equity interests in WyethPharmaceutical
 Co. Ltd and Treerly Health Co. Ltd (the “ China  Entities ”)  to an Affiliate (or Affiliates) of SellerParent
 in a direct equity transfer (the “ Direct  Transfers ”)  that is intended to be fully taxable for Chinese Taxpurposes.
 Seller Parent or an applicable Affiliate shall timely pay any Chinese Taxes attributable to any such DirectTransfer,
 based on a third-party valuation by an independent PRC licensed appraiser of Seller Parent's choosing, tothe
 appropriate  PRC  Taxing  Authority  and  file  any  applicable  Tax  Returns  with  the  appropriate  PRC  TaxingAuthority.
 The applicable Seller(s) shall, within five (5) business days in China after (i) the filing of any such TaxReturns,
 deliver to Purchaser complete copies of such Tax Returns and (ii) the tax receipts(s) are issued by the taxbureau(s),
 provide  Purchaser  with  complete  copies  of  such  tax  receipt(s).  Any  such  Taxes  shall  be  the  soleresponsibility of Seller Parent or the applicable Affiliate and subject to 
Section 6.5(d)(i)  . (B) 
     Following the Direct Transfers, Seller Parent shall effect, through Local Implementing Agreements, theindirect
 transfer of the China Entities to the Purchaser (the “ Indirect  Transfers ”).  Within thirty (30) days followingthe
 Indirect Transfers, Seller Parent or the applicable Affiliate shall voluntarily file (whether in one or more filings),on
 behalf  of  the  applicable  Seller(s)  and  Purchaser  (or  the  applicable  Purchaser  Designated  Affiliate),  thedocumentation required by Circular – SAT Notice [2015] 7 (“ 
Notice 7  ”) as a result of the Indirect Transfers, and anyrelated transfers,
 with the applicable PRC Taxing Authority. Seller Parent or the applicable Affiliate shall, within five(5)
 Business Days after the submission of such Notice 7 filing(s), deliver to Purchaser complete copies of anyapplicable
 Notice 7 filing(s) and, if provided, an acknowledgement of receipt of such Notice 7 filing(s) issued by theapplicable
 PRC Taxing Authority. Seller Parent or the applicable Affiliate shall, in its sole discretion, control allcommunicatio
ns relating to the Indirect Transfers and such Notice 7 filing(s) with the relevant PRC Taxing Authorityand
 shall keep Purchaser reasonably informed of the progress of such communications (including by providing toPurchaser
 copies of all material reporting and filings relating to the Indirect Transfers and the Notice 7 filing(s)). IfSeller
 Parent or the applicable Affiliate has fully complied with its obligations pursuant to this Section  6.5(g)(iii) , then
 Purchaser (and its Affiliates) shall not communicate with or make any reporting to a PRC Taxing Authorityregarding
 the Indirect Transfers or the Notice 7 filing(s), except in agreement with Seller Parent or the applicableAffiliate.
 Purchaser shall notify the applicable Seller(s) promptly, but in any event not later than five (5) BusinessDays
 after receipt, of any queries or requests by any PRC Taxing Authority related to the transfer of the ChinaEntities to the Purchaser.
132

(C)      If the Indirect Transfers are determined to be taxable transactions in China, Seller Parent or theapplicable
 Affiliate  shall  timely  pay  any  additional  China  Taxes  attributable  to  the  Indirect  Transfers  to  theappropriate
 PRC Taxing Authority and file any applicable Tax Returns with the appropriate PRC Taxing Authority.Any
 such Taxes shall be the sole responsibility of Seller Parent or the applicable Affiliate and subject to Section 6.5(d)(i) 
.(D) 
     Absent a change in Law after the date hereof and subject to compliance with Clauses (A) through (C) ofthis 
Section 6.5(g)(iii) ,  Purchaser Parent acknowledges and agrees that, notwithstanding anything herein to thecontrary,
 it shall not, and it shall cause its Affiliates not to, withhold any amount with respect to Chinese Taxes inrespect of
 the payment of the Purchase Consideration or any amounts payable to Seller Parent pursuant to Section 2.8 or 
Section 2.9 herein  (nor reflect any such amount in the Final Closing Statement or take any such amount intoaccount in the calculation of the Final Business Working Capital or the Final Business Net Cash).
(h) 
     Tax Sharing Agreements .  All Tax sharing agreements and arrangements between (i) any Conveyed Subsidiaryor
 Subsidiary thereof, on the one hand, and Seller Parent or any of its Affiliates (other than any Conveyed Subsidiary or Subsidiarythereof),
 on the other hand, and (ii) Purchaser or any Subsidiary of Purchaser, on the one hand, and Purchaser Parent or anySubsidiary
 of Purchaser Parent (other than Purchaser and its Subsidiaries), on the other hand, shall be terminated effective at orbefore
 the Closing and shall have no further effect for any Tax period (whether past, present or future) and, after the Closing Date,neither
 Seller Parent nor any of its Affiliates, nor Purchaser nor any of its Affiliates, shall have any rights or obligations thereunder,and
 no additional payments shall be made thereunder with respect to any Tax period, whether in respect of a redetermination ofLiabilities for Taxes or otherwise.
(i) 
     Cooperation .  Each of Purchaser and Seller Parent shall (and shall cause their respective Affiliates to) providethe other
 with such cooperation, information and records, and make such of its officers, directors, employees and agents available, asmay reasonably be requested by the other Party in connection with the preparation or filing of any Tax Return, determining a liability
for Taxes or payment under this 
Section 6.5  , conducting any Tax Proceeding and the matters described in  Section 6.5(f)  of the Seller Disclosure Letter
 and Section  6.5(f) of  the Purchaser Parent Disclosure Letter. Each of Purchaser and Seller Parent shall, within theearlier
 to occur of one hundred twenty (120) days after the Closing Date and forty-five (45) days prior to the due date for a TaxReturn requiring such
 information (or as promptly as practicable to the extent any Tax Return is due within forty-five (45) days afterthe
 Closing  Date),  provide  the  other  with  Tax  information  materials,  including  schedules  and  work  papers  (including  anyinformation
 reasonably necessary to compile applicable transfer pricing documentation), prepared in a manner consistent with theConveyed
 Subsidiaries’ (and their Subsidiaries’) past practices, as requested by one another to enable one another to prepare, orcause
 to be prepared, all Tax Returns that each Party is obligated to prepare, or cause to be prepared, pursuant to Section 6.5(a)(i)  or Section
 6.5(a)(ii) ,  as applicable. Notwithstanding anything in this Agreement to the contrary, (i) Seller Parent shall not be requiredto provide Purchaser Parent or Purchaser, or any of their respective Affiliates, with a copy of, or
133

otherwise disclose the contents of, any Seller Combined Tax Return ( provided  that  Seller Parent shall extract information thereinand
 provide such information to Purchaser hereunder to the extent such information relates solely to a Conveyed Subsidiary or itsSubsidiaries),
 and (ii) Purchaser Parent shall not be required to provide Seller Parent or any of its Affiliates with a copy of, orotherwise disclose
 the contents of, any Purchaser Parent Combined Tax Return. Each Party shall retain (and cause to be retained) allTax
 Returns, schedules and work papers, and all material records and other documents relating to Tax matters, of the ConveyedSubsidiarie
s and their Subsidiaries for the Pre-Closing Tax Period until the expiration of the statute of limitations for the Tax periodsto which the Tax Returns and other documents relate.
(j) 
     Transfer Taxes .  Notwithstanding anything to the contrary in this Agreement, Seller Parent shall be responsiblefor half
 of, and Purchaser Parent shall be responsible for half of, any Transfer Taxes imposed on the transfer of the Purchased Assetsand
 Assumed Liabilities to Purchaser (or a Purchaser Designated Affiliate) and the costs of preparing and filing Tax Returns inrespect
 of any such Transfer Taxes. The Party responsible under applicable Law for filing Tax Returns with respect to TransferTaxes
 shall prepare and timely file such Tax Returns. Seller Parent and Purchaser Parent shall, and shall cause their respectiveAffiliates
 to, reasonably cooperate to timely prepare and file any Tax Returns or other filings relating to such Transfer Taxes and tominimize
 any such Transfer Taxes. For clarity, this Section  6.5(j) does  not apply to any Transfer Taxes imposed on any transactionor
 step forming part of the Seller Internal Restructurings or the Purchaser Internal Restructurings. Seller Parent shall be solelyresponsible for any Transfer Taxes imposed on any transaction or step forming part of the Seller Internal Restructurings and the costs
of
 preparing and filing any Tax Returns in respect of any such Transfer Taxes and Purchaser Parent shall be solely responsible forany
 Transfer Taxes imposed on any transaction or step forming part of the Purchaser Internal Restructurings and the costs ofpreparing and filing any Tax Returns in respect of any such Transfer Taxes.
(k) 
     VAT .(i) 
     Subject to Section 6.5(k)(ii)  ,  all payments made pursuant to this Agreement are exclusive of VAT. AnyVAT
 imposed on the transfers of the Purchased Assets and Assumed Liabilities to Purchaser (or any of the PurchaserDesignated Affiliates)
 shall be charged to Purchaser (or the relevant Purchaser Designated Affiliate) in addition to thePurchase
 Consideration. Purchaser (or the relevant Purchaser Designated Affiliate) shall pay any such VAT uponreceipt
 of the relevant VAT invoices, if such invoice is required under applicable Law. Purchaser and Seller Parentshall,
 and shall cause their respective Affiliates to, exercise commercially reasonable efforts to satisfy all complianceobligations
 necessary in order to treat any such transfer as a transfer of a going concern for VAT purposes wherepermissible under applicable Law. Where Seller
 Parent has treated, or caused its Affiliates to treat, a transaction underthis Agreement as a transfer of
 a going concern or otherwise exempt from or outside the scope of VAT and it receivesnotice
 that a Taxing Authority disagrees with that treatment, it shall promptly notify Purchaser and reasonablycooperate
 with Purchaser to contest such disagreement upon Purchaser’s request, provided  that  Purchaser shallindemnify Seller Parent in respect of any costs,
134

expenses, fees or Taxes incurred in connection with such contest. Seller Parent shall issue (or shall cause to be issued)any
 invoice  necessary  and  reasonably  cooperate  with  Purchaser  and  its  Affiliates  to  provide  information  anddocumentation
 necessary for Purchaser and its Affiliates to comply with its VAT obligations under applicable Law.For
 clarity, this Section  6.5(k)(i) does  not apply to any VAT imposed on any transaction or step forming part of theSeller
 Internal Restructurings or the Purchaser Internal Restructurings. Seller Parent shall be solely responsible forany
 VAT imposed on any transaction or step forming part of the Seller Internal Restructurings and the costs ofpreparing and
 filing any Tax Returns in respect of any such VAT and Purchaser Parent shall be solely responsible forany
 VAT imposed on any transaction or step forming part of the Purchaser Internal Restructurings and the costs ofpreparing and filing any Tax Returns in respect of any such VAT.
(ii) 
     The Purchaser Parent Termination Fee is inclusive of any amounts in respect of VAT thereon butsubject
 to the calculations set out in this Section  6.5(k)(ii) .  The Parties intend, and shall use reasonable efforts tosecure,
 that the Purchaser Parent Termination Fee, being compensatory in nature, is not and will not be treated forVAT
 purposes as consideration for a taxable supply. If a Taxing Authority determines that the Purchaser ParentTermination Fee is, in whole or in part, consideration for a Tax supply for VAT purposes, then:
(A) 
     if Purchaser Parent (or any other member of the VAT group to which it belongs) is liable to account forany
 VAT on the Purchaser Parent Termination Fee under a VAT reverse charge mechanism, the amount of thePurchaser Parent
 Termination Fee shall be reduced so that the sum of (x) the Purchaser Parent Termination Fee (as soreduced), and (y) any VAT reverse
 charge thereon which Purchaser Parent (or any other member of the VAT group towhich
 it belongs) is not entitled to recover (by way of credit or repayment) as input tax, is equal to the unreducedamount
 of  the  Purchaser  Parent  Termination  Fee.  In  that  scenario,  Purchaser  Parent  shall  be  responsible  forcomplying
 with all obligations relating to that reverse charge imposed by the Laws of the jurisdiction in which theVAT is accountable under the reverse charge mechanism; and
(B) 
     if Seller Parent is liable to account for any VAT on the Purchaser Parent Termination Fee, then to theextent
 that such VAT is recoverable (by way of credit or repayment) as input tax by Purchaser Parent (or any othermember
 of the VAT group to which it belongs), the amount of the Purchaser Parent Termination Fee shall beincreased
 such that, less any such recoverable VAT in respect thereof, it equals the amount of the Purchaser ParentTermination Fee before taking into account any adjustment under this 
Section 6.5(k)(ii)(B)  . (l) 
     Coordination .  Notwithstanding anything herein to the contrary, (i) the indemnification obligations set forth inSection
 6.5(d) shall  survive until thirty (30) days following the expiration of the applicable statutes of limitations in respect of therelevant Taxes, (ii) the representations and warranties contained in 
Section 4.16(k)  and  Section 5.17(k) shall survive until 135

thirty (30) days following the expiration of the applicable statute of limitations in respect of the relevant Taxes, and (iii) any and allindemnification
 in respect of Tax matters and the procedures relating thereto shall be governed exclusively by this Section  6.5 and, to
 the extent specified therein, Section 7.4  ,  Section 7.6 ,  Section 7.7 ,  Section 7.8 ,  Section 7.9 ,  Section 7.10 and  Section 7.11 , and shall
 not be governed by the provisions of Article  VII (other  than, to the extent specified in Section  7.4 ,  Section 7.6 ,  Section 7.7 , Section 7.8 
,  Section 7.9 ,  Section 7.10 and  Section 7.11 ). Section 6.6 
      Employees and Employee Benefits . (a) 
     Division of Liabilities Generally . (i) 
     Purchaser Assumed Employee Liabilities .  Purchaser and its Subsidiaries (including, after the Closing,the
 Conveyed Subsidiaries and the Subsidiaries thereof) shall, effective as of the Closing, assume or retain allLiabilities in respect of (A) the Conveyed Subsidiary Plans (including Liabilities thereunder that relate to an employee
or
 former employee who is not a Business Employee or Former Business Employee), (A) except as otherwiseexpressly
 provided in this Section 6.6  ,  the service of the Business Employees and Former Business Employees to theBusiness
 or Purchaser Business prior to, on or following the Closing Date, including all Liabilities for compensation(including
 commissions,  bonuses,  incentive  pay,  overtime,  premium  pay,  shift  differentials  and  severance  ortermination
 pay) that become payable on or after the Closing, (A) except as otherwise expressly provided in thisSection
 6.6 ,  compensation  and  benefits  required  to  be  provided  by,  or  transferring  to  Purchaser  pursuant  to,applicable Law with respect to
 a Business Employee or Former Business Employee, (A) the other Liabilities specifiedin
 this Section 6.6 as  being assumed, retained or reimbursable by Purchaser or its Subsidiaries, (A) except asotherwise
 expressly provided in this Section  6.6 ,  all costs and expenses arising from the obligations of Purchaser orits Subsidiaries under this 
Section 6.6  , and the  implementation by Purchaser of the compensation and benefit plans ascontemplated
 hereunder, and (A) any Liabilities arising out of the failure of Purchaser or its Subsidiaries to complywith
 its obligations under this Section  6.6 ,  including the failure to extend offers pursuant to Section  6.6(b)(i) or engage in any consultations required or contemplated by 
Section 6.6(b)(i)  or  Section 6.6(j) (the Liabilities assumed by Purchaser
 and  its  Subsidiaries  pursuant  to  this Section  6.6 ,  collectively,  the  “ Purchaser  Assumed  EmployeeLiabilities 
”).  For the avoidance of doubt, except as contemplated by clause  (A)  of  this Section 6.6(a)(i) ,  the termPurchaser
 Assumed Employee Liabilities shall not include Liabilities with respect to current or former employees ofSeller
 Parent or its Affiliates who are not Business Employees or Former Business Employees. For purposes of thisSection
 6.6 ,  Liabilities in respect of all compensation and benefits items shall include the employer side Taxes orother payments related thereto.
(ii) 
     Seller Parent Retained Employee Liabilities .  Seller Parent, or its applicable Affiliate (other than aConveyed
 Subsidiary or Subsidiary thereof), shall, effective as of the Closing, retain or assume (A) all assets andLiabilities under or
136

relating to each Seller Group Plan and each Foreign Seller Group Plan, and each other benefit or compensation plan,program,
 policy, agreement or arrangement at any time sponsored or maintained by Seller or any of its ERISAAffiliates
 (including non-U.S. Affiliates) that is not a Conveyed Subsidiary Plan, other than those Liabilities underany
 Seller Group Plan or Foreign Seller Group Plan expressly assumed by Purchaser and its Affiliates under thisSection
 6.6 ;  (B) all Liabilities with respect to current or former employees of Seller Parent or its Affiliates who arenot
 Business Employees or Former Business Employees; (C) all Liabilities with respect to the service prior to theClosing Date
 of the Business Employees and Former Business Employees to Seller Parent or its Affiliates (other thanthe
 Conveyed Subsidiaries and their Subsidiaries) to the extent such service was not related to the Business, and(D)
 all other Liabilities specified in this Section  6.6 as  being retained or assumed by Seller Parent or its applicableAffiliates
 pursuant to this Section  6.6 ,  which Liabilities shall be Retained Liabilities. Notwithstanding clause  (A) of the
 immediately preceding sentence, this Section  6.6(a)(ii) shall  not prevent Seller Parent or its Affiliates fromallocating
 chargebacks to Purchaser or its Subsidiaries with respect to compensation and benefits costs that constitutecurrent
 Liabilities for purposes of GAAP or IFRS (and excluding all other costs or Liabilities, such as pensionunderfunding
 or prior years’ accruals under qualified or non-qualified retirement or deferred compensation plans) inthe
 ordinary course of business consistent with past practice related to Business Employees’ service for periods priorto
 the Closing; provided  ,  however , that any such chargebacks shall be reflected as a Liability in Business WorkingCapital.
 Subject to the immediately preceding sentence, no Retained Liability shall be reflected as a Liability inBusiness Working Capital. Other than as expressly contemplated by this 
Section 6.6  , in no event may Seller Parent or its
 Affiliates transfer a Seller Group Plan or Foreign Seller Group Plan (or any related Liabilities) that is notmaintained
 by a Conveyed Subsidiary or a Subsidiary thereof as of the date of this Agreement to a ConveyedSubsidiary or a Subsidiary thereof.
(iii) 
     Purchaser Parent Retained Employee Liabilities .  Purchaser Parent and its Affiliates (other thanPurchaser
 and its Subsidiaries), shall, effective as of the Closing, retain or assume (A) all assets and Liabilities underor
 relating  to  each  Purchaser  Group  Plan  and  each  Foreign  Purchaser  Group  Plan,  and  each  other  benefit  orcompensation
 plan, program, policy, agreement or arrangement at any time sponsored or maintained by PurchaserParent
 or any of its ERISA Affiliates (including non-U.S. Affiliates) that is not a Purchaser Business Plan; (B) allLiabilities
 with respect to current or former employees of Purchaser Parent or its Affiliates who are not PurchaserBusiness
 Employees or Former Purchaser Business Employees; (C) all Liabilities with respect to the service prior tothe
 Closing Date of the Purchaser Business Employees and Former Purchaser Business Employees to PurchaserParent
 or its Affiliates (other than Purchaser and its Subsidiaries) to the extent such service was not related to thePurchaser
 Business; and (D) all other Liabilities specified in this Section  6.6 as  being retained or assumed byPurchaser Parent or its applicable Affiliates pursuant to this 
Section 6.6  , which Liabilities shall 137

be Purchaser Parent Retained Liabilities. Notwithstanding clause  (A) of  the immediately preceding sentence, thisSection
 6.6(a)(iii) shall  not prevent Purchaser Parent or its Affiliates from allocating chargebacks to Purchaser or itsSubsidiaries
 with respect to compensation and benefits costs that constitute current Liabilities for purposes of GAAPor
 IFRS (and excluding all other costs or Liabilities, such as pension underfunding or prior years’ accruals underqualified
 or non-qualified retirement or deferred compensation plans) in the ordinary course of business consistentwith
 past practice related to Purchaser Business Employees and, with respect to periods following the Closing,Transferred
 Employees; provided  ,  however ,  that any chargebacks in respect of the service of Purchaser BusinessEmployees
 for periods prior to the Closing shall be reflected as a Liability in Purchaser Working Capital. Subject tothe
 immediately preceding sentence, no Purchaser Parent Retained Liability shall be reflected as a Liability inPurchaser
 Working Capital. In no event may Purchaser Parent or its Affiliates transfer a Purchaser Group Plan orForeign
 Purchaser Group Plan (or any related Liabilities) that is not maintained by Purchaser or a Subsidiary thereofas of the date of this Agreement to Purchaser or a Subsidiary thereof.
(b) 
     Transfer of Employees . (i) 
     Business Employees Generally .  At least ninety (90) days prior to the Closing Date, Seller Parent shallprovide
 Purchaser with a list of all Business Employees as of such time, including each such Business Employee’sname,
 job title, date of hire, annual salary or hourly rate (as applicable) and incentive opportunity to which each suchBusiness
 Employee is entitled, provided that such information may be redacted to the extent Seller Parent is requiredto
 comply with data privacy and other applicable Laws (the “ Transferring  Employee List ”).  At least fifteen (15)Business Days
 prior to the Closing Date (or earlier, if required by applicable Law), Purchaser agrees to offer or causeto
 be offered continued employment as of the Closing Date to each Business Employee detailed on the TransferringEmployee List who is not employed
 at a Conveyed Subsidiary or a Subsidiary thereof or who is not a TUL Employee,in
 the same or a Comparable Position (as defined herein) and with compensation and benefits on terms that areconsistent
 with this Section  6.6 and  Seller Parent and its Affiliates will facilitate in finalizing and distributing suchoffers.
 In addition, effective as of the Closing, Purchaser agrees to cause the Conveyed Subsidiaries and theirSubsidiaries
 to continue the employment of each Business Employee employed by such entities as of the ClosingDate
 in the same or a Comparable Position and with compensation and benefits on terms that are consistent with thisSection 6.6 
. A “  Comparable Position  ” is a position with Purchaser or its Subsidiaries (including, after the Closing, aConveyed
 Subsidiary or Subsidiary thereof) in which (A) the Business Employee’s level of responsibilities is notsignificantly
 reduced, and (B) the Business Employee is not required to relocate more than fifty (50) miles from theBusiness Employee’s principal business location immediately prior to the Closing.
138

(ii)      TUL Employees . Except as  agreed between the Parties, with respect to each Business Employee who isnot employed
 by a Conveyed Subsidiary or Subsidiary thereof and is employed in a jurisdiction in which the Transferof
 Undertakings  Laws  have  been  implemented  or  apply  (a  “ TUL  Employee ”),  Seller  Parent  and  Purchaseracknowledge
 that the transactions contemplated by this Agreement are likely to give rise to a relevant transfer (orotherwise
 sustain the automatic transfer of employees) for purposes of the Transfer of Undertakings Laws and toapply
 the Transfer of Undertakings Laws insofar as they apply by Law, and accept and agree that in such event theterms
 and conditions of employment of each such TUL Employee shall transfer effective as of the Closing and in amanner
 contemplated by the Transfer of Undertakings Laws or other applicable Law. Seller Parent and Purchasershall
 inform and consult with the TUL Employees or any appropriate representatives of the TUL Employees to theextent
 required by the Transfer of Undertakings Laws or other applicable Law. In the event that a TUL Employeeobjects
 to the transfer of employment and cannot be transferred to Purchaser or its Subsidiaries, all Liabilitiesassociated
 with the continued employment of such TUL Employee by Seller Parent or its Affiliates for up to amaximum of two (2) calendar months (or any longer period required by applicable Law or the notice period under any
Foreign
 Seller Group Plan) following Closing, and the termination of employment of such TUL Employee by SellerParent
 or its Affiliates shall be considered Purchaser Assumed Employee Liabilities. For the avoidance of doubt, ifthe
 Transfer of Undertakings Laws are determined not to apply to a TUL Employee, Purchaser agrees to offer orcause
 to be offered continued employment as of the Closing Date to such TUL Employee in accordance with Section 6.6(b)(i) 
.(iii) 
     Delayed Transfer Employees .  Notwithstanding the foregoing, in the case of any Business Employeewhose
 employment does not and cannot commence or be transferred at the Closing by applicable Laws or Purchaserand
 Seller Parent mutually determine cannot commence or be transferred at the Closing or whose commencement ortransfer
 of employment is otherwise delayed (a “ Delayed  Transfer Employee  ”),  Seller Parent and Purchaser shallcooperate
 in good faith to cause the employment of such Delayed Transfer Employee to remain with Seller Parent ora
 Retained Subsidiary to allow such Delayed Transfer Employee to continue to participate on the compensation andbenefit
 platforms, plans and programs of Seller Parent or such Retained Subsidiary. The Parties agree that eachDelayed
 Transfer  Employee  shall  commence  employment  with  Purchaser,  a  Conveyed  Subsidiary  or  anotherSubsidiary
 of Purchaser, as appropriate, as soon as reasonably practicable following the Closing as permitted byapplicable
 Laws in such a manner that to the maximum extent possible does not trigger the right of such BusinessEmployee
 to separation pay and is otherwise consistent with the terms and conditions of this Section  6.6 and applicable Law. Notwithsta
nding the foregoing, Seller Parent shall have no obligation to transfer the employment of aDelayed
 Transfer Employee out of a Conveyed Subsidiary if the delayed transfer of employment is due to a delay inthe transfer of the Conveyed Subsidiary to Purchaser. In respect of the Delayed
139

Transfer Employees, each reference in Section 6.6(a)(iii)  (other than in this  Section 6.6(b)(iii)  and  Section 6.6(b)(iv) ) through 
Section 6.6(j) to  “Closing” and “Closing Date” shall be treated as a reference to the first date on which theapplicable Delayed Transfer Employee’s employment commences with or transfers to Purchaser. Notwithstanding the
delayed
 transfer of such Delayed Transfer Employees, from and for a period of two (2) years after the Closing or, ifearlier,
 the date of the applicable Delayed Transfer Employee’s termination of employment (“ Delayed Employment Period 
”), the (A) compensation paid to such Delayed Transfer Employees in respect of the Delayed EmploymentPeriod
 and (B) the fringe benefit rate for such Delayed Transferred Employees’ benefits under a Seller Group Plan orForeign Seller Group Plan that
 Seller Parent charges in the ordinary course of business consistent with past practice inrespect
 of the Delayed Employment Period shall, in the case of (A) and (B), be considered Purchaser AssumedEmployee
 Liabilities; provided that, during such period, Purchaser and its Subsidiaries receive the economic benefitof such Delayed Transferred Employee’s services.
(iv) 
     Disability Employees .  Without limiting the generality of Section  6.6(b)(iii) ,  and except as prohibitedby
 applicable Law or provided in the immediately following sentence, each Business Employee who is on a leave ofabsence
 as of the Closing due to short- or long-term disability (a “ Disability Employee  ”)  and is eligible for, or in anelimination
 period to be eligible for, long-term disability insurance coverage under a Seller Group Plan or ForeignSeller
 Group Plan (a “ Seller  LTD Plan  ”) that is not a Conveyed Subsidiary Plan shall be a Delayed TransferEmployee
 until he or she returns to active employment; provided  ,  that such return to active employment occurswithin six (6) months following the Closing (or such longer period as may be required by applicable Law or the notice
period
 under any Seller Group Plan or Foreign Seller Group Plan). If it is administratively impractical to delay thetransfer
 of a Disability Employee because Seller Parent and its Affiliates (other than the Conveyed Subsidiaries andtheir
 Subsidiaries) do not have an employing entity in the applicable jurisdiction following the Closing or becausesuch
 Disability Employee is, prior to the Closing and prior his or her disability, already an employee of a ConveyedSubsidiary, such
 Disability Employee shall be treated in the same manner as all other Business Employees, except heor
 she shall remain eligible for coverage under the Seller LTD Plan until the elimination period in effect as of theClosing
 elapses, and neither Purchaser nor its Affiliates shall have any Liability to provide long-term disabilitybenefits
 or otherwise with respect to the Seller LTD Plan. If such Disability Employee who is not a DelayedTransferred
 Employee in accordance with the first sentence hereof satisfies the requirements for coverage under theSeller
 LTD Plan at the end of such elimination period, the employment of such Disability Employee with Purchaserand
 its Affiliates shall terminate, and such Disability Employee shall be entitled to benefits under the Seller LTDPlan,
 and neither Purchaser nor its Affiliates shall have any Liability to provide long-term disability benefits orotherwise
 with respect to the Seller LTD Plan. Any Disability Employee who is a Delayed Transferred Employee inaccordance with the first sentence hereof and who does not return to active employment within six
140

(6) months following the Closing (or such longer period as may be required by applicable Law or the notice periodunder any Seller Group Plan
 or Foreign Seller Group Plan) shall not be a Transferred Employee under this Agreementand, upon the conclusion of such six (6)-month period (or such longer period as may be required by applicable Law or
the notice period under any Seller
 Group Plan or Foreign Seller Group Plan), shall no longer be considered a BusinessEmployee under this Agreement.
(v) 
     Definitions .  For purposes of this Agreement, (A) any Business Employee (U.S.) whose employmenttransfers
 pursuant to this Section  6.6(a)(iii) shall  be referred to as a “ Transferred  Employee (U.S.) ”  and (B) anyBusiness
 Employee (non-U.S.) whose employment transfers pursuant to this Section  6.6(a)(iii) shall  be referred to asa “ 
Transferred Employee (non-U.S.) ” (collectively, the “  Transferred Employees  ”). (c) 
     Compensation and Employee Benefits . (i) 
     Continued Employee Benefits .  For a period from the Closing Date until December 31, 2020 (or suchlonger
 period as required by applicable Law) (the “ Continuation  Period ”),  Purchaser shall, or shall cause itsAffiliates
 to, provide to each Transferred Employee whose terms and conditions of employment are not subject to anapplicable
 Collective Bargaining Agreement (A) a Comparable Position, (B) base salary or wage rates that, in eachcase,
 are no less favorable than those in effect for each such Transferred Employee immediately prior to the Closing,(C)
 cash-based incentive opportunities (which shall include, collectively, commission, cash bonus and cash incentivepay
 opportunities), equity incentive opportunities and nonqualified deferred compensation benefits that, in each case,are
 no less favorable than those provided to similarly situated Purchaser Business Employees, (D) employee benefits(excluding
 equity  incentive  opportunities  and  non-qualified  deferred  compensation)  that,  in  the  aggregate,  aresubstantially
 comparable to those in effect for each such Transferred Employee immediately prior to the Closing and(E)
 severance benefits that are no less favorable than the severance benefits that would have been payable to eachsuch
 Transferred Employee under the Seller Group Plans or Foreign Seller Group Plans set forth in Section  6.6(c) of the Seller
 Disclosure Letter in which such Transferred Employee participated or was eligible for benefits immediatelyprior
 to the Closing, taking into account such Transferred Employee’s additional period of service and increases (butnot
 decreases) in compensation following the Closing. In addition, notwithstanding anything to the contrary in thisAgreement,
 Purchaser or its Subsidiaries shall, and shall cause the Conveyed Subsidiaries and their Subsidiaries to,maintain
 terms and conditions of employment for Transferred Employees to the extent necessary to (x) effect theautomatic
 transfer  of  such  employees  under  applicable  Laws  (including  the  Transfer  of  Undertakings  Laws),Collective
 Bargaining Agreements or employment agreements, (y) comply with applicable Laws and (z) preventseverance from
141

becoming payable to any such employee under applicable Law as a result of the transactions contemplated by thisAgreement.
(ii) 
     Severance or Other Termination Liabilities .  Purchaser and its Subsidiaries shall be solely responsiblefor any severance, redundancy, long service, notice or garden leave pay, or similar payments, contributions or benefits
(collectively,
 “ Termination  Expenses ”)  that may become payable to any Business Employee arising out of or inconnection with the transactions contemp
lated by this Agreement (whether or not such Business Employee becomes aTransferred Employee), including
 any Termination Expenses that are required to be paid by applicable Law, that maybecome
 payable to any Business Employee who does not become an employee of Purchaser or its Subsidiariesbecause
 Purchaser or its Subsidiaries fail to take all actions required by applicable Law to effectuate such BusinessEmployee’s
 transfer, because such Business Employee rejects an offer of employment made in compliance with thisSection
 6.6 ,  refuses to transfer employment, or otherwise challenges such transfer of employment; provided  , however 
,  that Seller Parent and its Affiliates shall retain any Termination Expenses that may become payable inconnection
 with the Seller Internal Restructurings (collectively, the “ Seller  Retained Severance Liabilities ”), which shall be Retained Liabilities for all purposes hereunder. If Purchaser or any of its Subsidiaries becomes liable for, or is
legally
 required to make, severance, redundancy, long service, notice or garden leave pay, or similar payments,contribution
s or benefits to or on behalf of any Business Employee as a result of the transactions contemplated by thisAgreement
 (whether or not such Business Employee becomes a Transferred Employee), all such payments and anyrelated
 costs and expenses paid or incurred by Purchaser or its applicable Subsidiary, other than any Seller RetainedSeverance
 Liabilities, shall be Purchaser Assumed Employee Liabilities. Seller Parent and its Affiliates shall consultwith
 Purchaser prior to paying or committing to pay severance to a Business Employee who rejects an offer ofemployment
 made in compliance with this Section 6.6  ,  refuses to transfer employment, or otherwise challenges suchtransfer of employment.
(iii) 
     Service Credit .  For purposes of vesting, eligibility to participate and level of benefits (and for all otherpurposes
 to the extent required by applicable Law) under the employee benefit plans of Purchaser and its Affiliatesproviding
 benefits to any Transferred Employees after the Closing, each Transferred Employee shall be credited withhis
 or her years of service with Seller Parent and its Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries)
 and their respective predecessors to the same extent and for the same purpose as such TransferredEmployee
 was credited, before the Closing, under any similar Seller Group Plan or Foreign Seller Group Plan inwhich
 such Transferred  Employee  participated  or was eligible  to participate  immediately  prior  to the  Closing,provided 
that  the foregoing shall not apply (A) to the extent that its application would result in a duplication ofbenefits
 (including accrual of severance or termination related entitlements where these have been paid out as a resultof the transactions contemplated by this
142

Agreement) or (B) for purposes of level of benefits under any defined benefit pension plan (other than underPurchaser
 Pension  Plans  with  respect  to  the  transfer  of  Liabilities  from  Seller  Pension  Plans  as  described  inSection 6.6(e) 
, or as required by applicable Law). (iv) 
     Welfare Benefit Plan Obligations .  Commencing as of 12:01 a.m. (local time wherever applicable) onthe
 Closing Date, Purchaser shall, or shall cause its applicable Affiliates to, provide the Transferred Employees withwelfare benefits
 under plans and arrangements maintained or sponsored by Purchaser and its Affiliates that satisfy thestandards
 set forth in Section  6.6(c)(i) .  Purchaser shall, or shall cause its applicable Affiliates to, waive any waitingperiods
 under their welfare benefit plans (including medical, dental, life insurance and short-term and long-termdisability
 plans) and, with respect to any group health plans, shall waive any limitations for preexisting conditions,and,
 if applicable, shall ensure that such employees are given credit for any amounts paid toward deductibles, out-of-pocket
 limits or other fees on or prior to the Closing Date. Other than with respect to claims incurred under aConveyed
 Subsidiary Plan, claims by a Transferred Employee for welfare benefit plan benefits or services rendered(A)
 as of or following 12:01 a.m. (local time wherever applicable) on the Closing Date shall be the responsibility ofPurchaser
 and its Subsidiaries, and (B) prior to the Closing Date shall be the responsibility of Seller Parent and itsAffiliates
 (other than a Conveyed Subsidiary or any Subsidiary thereof). Seller Parent and its Affiliates (other than aConveyed
 Subsidiary or any Subsidiary thereof) will retain any obligations under Section 4980B of the Code orsimilar
 state Law (“ COBRA  ”)  with respect to Business Employees, Former Business Employees and any otherqualified
 beneficiaries who are enrolled in COBRA continuation coverage under a Seller Group Plan that is not aConveyed Subsidiary Plan as of
 the Closing or with respect to whom a COBRA qualifying event occurred prior to theClosing.
 This Section  6.6(c)(ii) does  not apply to any Liabilities under a Conveyed Subsidiary Plan, regardless ofwhether
 the event giving rise to the cost occurred before, on or after the Closing Date, which Liabilities shall beretained or assumed by Purchaser in accordance with 
Section 6.6(a)(i)(A)  . (v) 
     Cash Incentive Compensation .  Following the Closing, Purchaser shall, or shall cause its applicableSubsidiaries
 to pay awards under Seller Parent cash-based annual incentive plan (the “ Seller  Cash Incentive Plan ”) in
 which Transferred Employees participate for the performance period in which the Closing occurs, prorated for theperiod
 elapsed as of immediately prior to the Closing Date, or with respect to any Delayed Transfer Employee, thedate
 on  which  such  Delayed  Transferred  Employee  transfers  employment  (based  upon  actual  performance  asdetermined
 in good faith in the ordinary course of business consistent with past practice by Seller Parent or itsapplicable
 Affiliate), to each Transferred Employee who is eligible to receive such an award pursuant to the terms ofthe
 Seller Cash Incentive Plan, which awards shall be paid at such time and to the extent that the TransferredEmployees
 would have otherwise become entitled to such bonuses under the Seller Cash Incentive Plan (suchprorated bonus, the “ 
Seller Closing Bonus  ”); 143

provided ,  however ,  if Purchaser’s or its applicable Subsidiary’s payment of the Seller Closing Bonus is prohibitedunder
 applicable Law, Purchaser and Seller Parent will agree to an alternative arrangement with respect to any suchSeller
 Closing Bonus acting in good faith (which alternative arrangement shall preserve the division of Liabilitiesbetween Seller Parent
 and its Affiliates, on the one hand, and Purchaser and its Affiliates, on the other hand, generallycontemplated
 by this Section  6.6(c)(v) ).  The aggregate amount of the Seller Closing Bonuses and any relatedemployer-si
de Taxes (but less the amount of the Tax deduction that Seller Parent or its Affiliates would have realizedhad
 they paid the Seller Closing Bonuses) shall be reflected as a Liability in Business Working Capital. Withoutlimiting
 the generality of Section  6.6(c)(i) ,  effective  as of the Closing,  Purchaser  shall cause the TransferredEmployees
 to participate in the cash-based incentive plans of Purchaser and its Affiliates for the remainder of theperformance
 period in which the Closing occurs, which plans shall provide (A) incentive compensation opportunitiesthat
 are no less favorable than those provided to such Transferred Employees immediately prior to the Closing (provided 
that  such opportunities may be prorated for the period from and including the Closing Date until the end ofthe
 applicable performance period and may be based on reasonable performance criteria established by Purchaser inthe
 ordinary course of business) and (B) for payment of awards for the performance period in which the Closingoccurs
 at the time prescribed by the Seller Cash Incentive Plan as in effect immediately prior to the Closing and inaccordance
 with the historical past practices of Seller and its Affiliates, it being understood that this clause  (B) shall not require Purchaser to pay such awards automatically upon the Closing.
(vi) 
     Equity Incentive Compensation .  Upon the Closing, each incentive award in respect of the commonstock
 of Seller Parent (a “ Seller  Parent Equity Award  ”) held by a Transferred Employee shall become vested oreligible
 to vest (subject to the satisfaction of any applicable performance goals) in a prorated amount, determinedbased
 on the number of days in the applicable vesting period elapsed as of the Closing Date. Effective as of theClosing, Purchaser or its Affiliates shall grant to each Transferred Employee an equity- or cash-based incentive award
(a
 “ Make-Whole Award ”)  with a grant date fair value that is no less favorable than the value of the portion of theSeller
 Parent Equity Awards forfeited by the Transferred Employee in connection with the Closing (which forfeitedamount shall be
 disclosed to Purchaser Parent no later than five (5) Business Days prior to the Closing), which Make-Whole
 Award shall have terms and conditions that are no less favorable than the terms and conditions (includingvesting schedule and accelerated vesting
 terms) that were applicable to the corresponding Seller Parent Equity Award.In
 the event that the post-Closing transfer of a Delayed Transfer Employee results in a larger portion of the SellerParent
 Equity Awards held by such Delayed Transfer Employee becoming vested upon such Delayed TransferEmployee’s transfer of employment
 than if the employment of such Delayed Transfer Employee had transferred uponthe
 Closing, then the incremental cost of such additional vesting (which cost shall be measured based on the taxableincome
 the Delayed Transfer Employee either realized or would have realized had such awards been settled orexercised upon such
144

Delayed Transfer Employee’s transfer of employment to Purchaser or its Subsidiaries) shall be considered PurchaserAssumed Employee Liabilities.
(vii) 
     Accrued Time Off Entitlements .  Subject to applicable Law and any required consents, from and afterthe
 Closing, with respect to each Business Employee, either (A) Purchaser shall, or shall cause its Affiliates to,assume
 and honor all accrued but unused vacation and other paid time off of Business Employees or (B) if SellerParent
 or any of its Affiliates is required under applicable Law to make a payment in settlement of accrued vacationor
 paid time off of any Business Employee, such payments shall be considered Purchaser Assumed EmployeeLiabilities
 and such accruals under (A) shall not be assumed and/or honored by Purchaser or its Affiliates.  Under nocircumstance
 shall Purchaser or its Affiliates be responsible for satisfying both (A) and (B) with respect to the sameBusiness Employee.
(d) 
     Seller Benefit Plans .  Except as otherwise provided in this Section  6.6 ,  from and after the Closing, theTransferred
 Employees shall cease to be active participants in the Seller Group Plans and Foreign Seller Group Plans that are notConveyed Subsidiary Plans.
(e) 
     Foreign Defined Benefit Pension or Termination Benefit Plans .   (i) 
     Effective as of the Closing, Purchaser shall establish or designate non-U.S. defined benefit pension orpension-like
 termination benefit plans or arrangements, as applicable (collectively, the “ Purchaser  Pension Plans ”), for
 the benefit of the Transferred Employees (non-U.S.) who participate in the Foreign Seller Group Plans and othernon-U.S.
 arrangements that provide for similar benefits, whether under a plan or pursuant to applicable Law or localpractice
 set forth on Section  6.6(e) of  the Seller Disclosure Letter (collectively, the “ Seller  Pension Plans  ,” and theTransferred
 Employees (non-U.S.) who participate in or accrue benefits pursuant to the Seller Pension Plans, the “Transferred
 Pension Plan Employees  ”).  Each Purchaser Pension Plan shall provide, upon the transfer of assetsreferred to below (or, if there is no transfer of assets with respect to a particular plan because the plan is not funded, as
of
 the Closing), that the accrued benefits for the Transferred Pension Plan Employees under such Purchaser PensionPlan
 shall in no event be less than their accrued benefits under the corresponding Seller Pension Plan as of theClosing.
 With respect to any Seller Pension Plan that is funded, Seller Parent shall cause to be transferred from thetrusts
 or other funding vehicles under such Seller Pension Plan to the trusts or other funding vehicles under thecorresponding
 Purchaser Pension Plan assets in the form of cash, cash equivalents, marketable securities or insurancecontracts
 (to the extent allowable under the terms of such contracts and exclusively intended to cover plan benefits),the
 value of which shall be equal to: (x) the actuarial present value of accumulated benefits (that is, the “accumulatedbenefit
 obligation” as defined in Topic 715 in the FASB’s Accounting Standards Codification, the “ ABO  ”) undersuch Seller Pension Plan as
 of the Closing that are attributable to the Transferred Pension Plan Employees, divided bythe ABO
145

of all participants in such Seller Pension Plan as of the Closing, multiplied 
by
the  market value of the assets of suchSeller
 Pension Plan at the Closing, provided  that  such transferred amount shall not, in any event, exceed the ABOunder
 such Seller Pension Plan of all Transferred Pension Plan Employees as of the Closing Date or (y) such greateramount as is required by applicable Law.
(ii) 
     The amounts determined in accordance with Section  6.6(e)(i) are  collectively referred to as the “Pension Transfer
 Amounts .”  The transfer of the Pension Transfer Amounts, and the assumption by Purchaser and itsSubsidiaries
 of Liabilities with respect to or relating to the Transferred Pension Plan Employees under the applicableSeller
 Pension Plans, shall be subject to such consents, Approvals and other requirements as may apply underapplicable
 Law. Purchaser shall use commercially reasonable efforts to cause the corresponding Purchaser PensionPlans
 to  accept  the  Pension  Transfer  Amounts.  Actuarial  determinations  shall  be  made  in  accordance  withSection
 6.6(e)(vi) .  If a Seller Pension Plan is not required to be funded by applicable Law, and is not funded, thereshall be no transfer of assets by the Seller Pension Plan or by Seller Parent or its Affiliates.
(iii) 
     As of the Closing, Seller Parent shall cause the Transferred Employees to cease further accrual ofbenefits under the Seller Pension Plans.
(iv) 
     The Pension Transfer Amount, if any, from each Seller Pension Plan shall be equitably adjusted to takeinto account benefit payments made from the Seller Pension Plan to the Transferred Pension Plan Employees after the
Closing
 but prior to the date of transfer and for any earnings and losses on such amount during such period. ThePension Transfer Amount, if any, shall be determined pursuant to 
Section 6.6(e)(vi)  . (v) 
     At the times of the transfers of the Pension Transfer Amounts (or if there is no transfer of assets withrespect to a particular plan becaus
e the plan is not required to be funded under applicable Law and is not funded, fromand
 after the Closing), Purchaser and the Purchaser Pension Plans shall assume all Liabilities for all accrued benefits,including
 all  disability,  part-time,  early  retirement  and  other  ancillary  benefits,  under  the  corresponding  SellerPension
 Plans in respect of the Transferred Pension Plan Employees whose benefits are so transferred, and SellerParent
 and its Affiliates and the corresponding Seller Pension Plans shall be relieved of all Liabilities to providebenefits
 under the Seller Pension Plans to the Transferred Pension Plan Employees whose benefits are so transferred.From and after the date of such applicable transfer of the Pension Transfer Amounts (or if there is no transfer of assets
with respect to
 a particular plan because the plan is not required to be funded under applicable Law and is not funded,from
 and after the Closing), Purchaser agrees to indemnify and hold harmless Seller Parent and its Affiliates and itsofficers,
 directors, employees, and agents from and against any and all costs, damages, losses, expenses, or otherLiabilities arising out of or related to the Transferred Pension Plan
146

Employees’ benefits under the Seller Pension Plans that are transferred to Purchaser or Purchaser Pension Planspursuant to this 
Section 6.6(e)  . (vi) 
     For purposes of this Section  6.6(e) ,  actuarial determinations shall be based upon the actuarialassumptions
 and methodologies used in preparing the most recent audited financial statements of Seller Parent as ofthe
 date of the determination. The applicable plan sponsor of the Seller Pension Plans shall cause the plan actuary oradministrator
 to provide a report of its determination of such amount within ninety (90) days following the ClosingDate and
 any back-up information reasonably required by Purchaser to confirm the accuracy of such determination. IfPurchaser disputes the
 accuracy of the calculation, Purchaser and Seller Parent shall cooperate to identify the basis forsuch
 disagreement and act in good faith to resolve such dispute. To the extent that a dispute is unresolved after aforty-five (45)-day period following identification of such dispute, the calculations shall be verified by an independent
third-party
 benefits consulting firm selected by the mutual agreement of Seller Parent and Purchaser. The decision ofsuch
 consulting  firm  shall  be  final,  binding  and  conclusive  on  Seller  Parent  and  Purchaser.  NotwithstandingSection 6.6(a)(i)(E) 
, Seller Parent and Purchaser Parent shall share equally the costs of such consulting firm. (vii) 
     This Section 6.6(e) does  not apply to any Liabilities under a Conveyed Subsidiary Plan, whichLiabilities
 shall be retained or assumed by Purchaser in accordance with Section  6.6(a)(i)(A) .  For clarity, SellerParent
 and its Affiliates shall retain all assets and Liabilities, including those related to Business Employees andFormer
 Business Employees (and their service prior to Closing), in respect of Seller Group Plans and Foreign SellerGroup
 Plans that are defined benefit pension plans or pension-like termination benefit plans or arrangements but notConveyed Subsidiary Plans, or with respect to Transferred Employees (non-U.S.), Seller Pension Plans.
(f) 
     Defined Contribution Plans (U.S.) . (i) 
     Effective as of the Closing, Purchaser shall create or designate defined contribution pension plans(collectively,
 the “ Purchaser  DC Plans (U.S.) ”)  for the benefit of the Transferred Employees (U.S.) who participatein
 one or more of the defined contribution pension plans maintained by Seller Parent or its Affiliates (other than aConveyed Subsidiary Plan) that are intended to be qualified under Section 401(a) of the Code immediately prior to the
Closing or
 the corresponding provisions of the Puerto Rico Internal Revenue Code (collectively, the “Seller DC Plans(U.S.),” and the Transferred Employee
s who participate in the Seller DC Plans  (U.S.)  , the “ DC Employees (U.S. )”). The
 applicable Purchaser DC Plans (U.S.) shall be tax-qualified in the same manner as the corresponding Seller DCPlans
 (U.S.), and, prior to the Closing, Purchaser shall provide Seller Parent any determination letters or similardocumentation evidencing such qualification.
147

(ii)      Each Purchaser DC Plan (U.S.) shall allow for the receipt in cash from the DC Employees (U.S.) of“eligible
 rollover distributions” (as such term is defined under Section 402 of the Code or any equivalent term underthe
 Puerto Rico Internal Revenue Code), but also including notes corresponding to loans. Purchaser and Seller Parentshall
 work together in order to facilitate any such distribution or rollover and to effect an eligible rollover distributionfor those
 DC Employees (U.S.) who elect to rollover their account balances, including notes, directly into a PurchaserDC Plan (U.S.).
(iii) 
     Any DC Employee (U.S.) who has an unvested account balance under a Seller DC Plan (U.S.) as of theClosing
 Date shall become vested on the Closing Date in a prorated portion thereof, determined based on the numberof
 days in the applicable vesting period elapsed as of the Closing Date. Any DC Employee (U.S.) who would beeligible
 for an employer contribution had he or she remained an active participant in the applicable Seller DC Plan(U.S.)
 until the next date on which such employer contribution would be made, shall receive a prorated employercontribution under
 the applicable Seller DC Plan (U.S.) on or as soon as reasonably practicable following the ClosingDate,
 determined based on the number of days in the applicable service period elapsed as of the Closing Date. Thecontributions and vesting of benefits described in this Section 6.6(f)(iii) shall be Retained Liabilities.
(g) 
     Defined Contribution Plans (non-U.S.) . (i) 
     Effective as of the Closing, Purchaser shall establish or designate defined contribution plans orarrangements (collectively, the “ 
Purchaser DC Plans  (non-U.S.)  ”) for the benefit of the Transferred Employees (non- U.S.)
 who participate in one or more of the defined contribution plans maintained by Seller Parent or its Affiliates(other
 than a Conveyed Subsidiary Plan) or any other arrangement that provides for similar benefits pursuant toapplicable Law or local practice (collectively, the “ 
Seller DC Plans (non-U.S.),  ” and the Transferred Employees who participate
 in the Seller DC Plans (non-U.S.), the “ DC  Employees (non-U.S.) ”).  The applicable Purchaser DC Plans(non-U.S.)
 shall be tax-qualified in the same manner as the corresponding Seller DC Plans (non-U.S.), and, prior tothe
 Closing, Purchaser shall provide Seller Parent any determination letters or similar documentation evidencing suchqualification.
 To the extent permitted by applicable Law, each Purchaser DC Plan (non-U.S.) shall allow for thereceipt in
 cash from the DC Employees (non-U.S.) of rollover distributions, but also including notes corresponding toloans.
 Purchaser and Seller Parent shall work together in order to facilitate any such distribution or rollover and toeffect
 a rollover distribution for those DC Employees (non-U.S.) who elect to rollover their account balances,including notes, directly into a Purchaser DC Plan (non-U.S.).
(ii) 
     Notwithstanding Section 6.6(g)(i)  ,  if applicable Law requires Purchaser to assume the Liabilities of theDC
 Employees (non-U.S.) under a Seller DC Plan (non-U.S.), Seller Parent shall cause the transfer under each suchSeller
148

DC Plan (non-U.S.) to the corresponding Purchaser DC Plan (non-U.S.) of (A) the account balances of such DCEmployees
 (non-U.S.) as of the Closing or cash, cash equivalents or other property equal to the actual accountbalances
 of the DC Employees (non-U.S.) under each such Seller DC Plan (non-U.S.) as of the Closing or suchgreater
 amount as is required by any applicable Governmental Authority having jurisdiction over the Seller DC Plan(non-U.S.)
 in  order  to  obtain  approval  of  such  transfer,  and  (B)  any  notes  corresponding  to  loans  of  the  DCEmployees (non-U.S.) (collectively, the “ 
DC Transfer Amounts  ”). The transfer of the DC Transfer Amounts shall be subject
 to such consents, Approvals and other legal requirements as may apply under applicable Law. Purchaser shalluse
 commercially reasonable efforts to cause the DC Transfer Amounts to be accepted by such plans. The DCTransfer Amounts to be
 transferred, if any, from the respective Seller DC Plans (non-U.S.) shall be equitably adjustedto
 take into account benefit payments made from the respective Seller DC Plans (non-U.S.) to the DC Employees(non-U.S.)
 after the Closing but prior to the date of transfer and for any earnings and losses on such amount duringsuch
 period. The transfer of the DC Transfer Amounts, if any, shall take place within one hundred eighty (180) daysafter
 the Closing Date. At the times of the transfers of the DC Transfer Amounts, Purchaser and the Purchaser DCPlans
 (non-U.S.)  shall  assume  all  Liabilities  with  respect  to  the  DC  Transfer  Amounts  relating  to  TransferredEmployees
 (non-U.S.) that were transferred from the applicable Seller DC Plan (non-U.S.), and Seller Parent and itsAffiliates and
 the Seller DC Plans (non-U.S.) shall be relieved of all such Liabilities under such Seller DC Plan (non-U.S.)
 with respect to such Transferred Employees (non-U.S.). From and after the date of the transfer of the DCTransfer
 Amounts,  Purchaser  agrees  to  indemnify  and  hold  harmless  Seller  Parent  and  its  Affiliates  and  theirrespective
 officers, directors, employees and agents from and against any and all costs, damages, losses, expenses, orother Liabilities arising out of or related to the DC Transfer Amounts for Transferred Employees (non-U.S.) under the
applicable Seller DC Plans (non-U.S.).
(iii) 
     Any DC Employee (non-U.S.) who has an unvested account balance under a Seller DC Plan (non-U.S.)as of the
 Closing Date shall become vested on the Closing Date in a prorated portion thereof, determined based on thenumber
 of days in the applicable vesting period elapsed as of the Closing Date. Any DC Employee (non-U.S.) whowould
 be eligible for an employer contribution had he or she remained an active participant in the applicable SellerDC
 Plan (non-U.S.) until the next date on which such employer contribution would be made, shall receive a proratedemployer
 contribution under the applicable Seller DC Plan (non-U.S.) on or as soon as reasonably practicablefollowing the Closing Date, determ
ined based on the number of days in the applicable service period elapsed as of theClosing
 Date.  The  contributions  and  vesting  of  benefits  described  in  this Section  6.6(g)(iii) shall  be  RetainedLiabilities.
149

(iv)      This Section 6.6 does  not apply to any Liabilities under a Conveyed Subsidiary Plan, which Liabilitiesshall be retained or assumed by Purchaser in accordance with 
Section 6.6(a)(i)(A)  . (h) 
     Retiree Medical Plans .  Effective as of the Closing, each Transferred Employee who is eligible to become aparticipant upon termination of service in the Seller Retained Plans that provide retiree medical benefits set forth on 
Section 6.6(h)  of the
 Seller Disclosure Letter (the “ Seller  Retiree Medical Plans ”)  as of the Closing (i) shall cease being eligible to become aparticipant, or accrue service towards eligibility, in
 the Seller Retiree Medical Plans, and Seller Parent and its Affiliates shall have noLiabilities
 in respect of the provision of post-retirement medical benefits to such Transferred Employee, and (ii) shall commenceaccruing
 service towards eligibility and level of benefits (taking into account the recognition of all prior service credit in accordancewith 
Section 6.6(c)(iii) )  in a retiree medical plan maintained by Purchaser or its Affiliates that provides benefits that are either(A)
 no less favorable than those provided under the applicable Seller Retiree Medical Plans, including with respect to an employersubsidy, or
 (B) the same as those provided to similarly situated Purchaser Business Employees (“ Purchaser Retiree Medical  Plan  ”),which
 Purchaser Retiree Medical Plan shall not be modified in a manner adverse to the Transferred Employees relative to otherparticipants; 
provided  ,  however , such plans shall have requirements for retirement-eligibility that are the same as those provided toother
 Purchaser Retiree Medical Plan participants or, if more favorable, during the Continuation Period, the same as the applicableSeller
 Retiree  Medical  Plan  with  respect  to  the  Transferred  Employees.  Subject  to  continued  employment,  the  TransferredEmployees
 shall continue accruing service towards eligibility and levels of benefits thereunder, for at least the Continuation Period(or
 such longer period as required by applicable Law). This Section  6.6(h) shall  not limit Purchaser’s obligations with respect to aConveyed
 Subsidiary Plan or any other arrangement that provides for similar benefits as required by applicable Law, which shall beconsidered Purchaser Assumed Employee Liabilities, in accordance with 
Section 6.6(a)(i)  . (i) 
     Flexible Spending Accounts .  Seller Parent and Purchaser shall take all actions necessary or appropriate so that,effective as
 of the Closing Date (i) the account balances (whether positive or negative) (the “ Transferred FSA Balances  ”) under the applicable
 flexible spending plan of Seller Parent or its Affiliates (collectively, the “ Seller  FSA Plan ”)  of the TransferredEmployees
 who are participants in the Seller FSA Plan shall be transferred to one or more comparable plans of Purchaser or itsAffiliates
 (collectively, the “ Purchaser  FSA Plan ”);  (ii) the elections, contribution levels and coverage levels of such TransferredEmployees
 shall apply under the Purchaser FSA Plan in the same manner as under the Seller FSA Plan; and (iii) such TransferredEmployees
 shall be reimbursed from the Purchaser FSA Plan for claims incurred at any time during the plan year of the Seller FSAPlan in
 which the Closing Date occurs that are submitted to the Purchaser FSA Plan from and after the Closing Date on substantiallythe same basis and substantially the same terms and conditions as under
 the Seller FSA Plan. As soon as practicable after the ClosingDate,
 and in any event within thirty (30) Business Days after the amount of the Transferred FSA Balances is determined, SellerParent
 or its Affiliates shall pay to Purchaser or its Affiliates the net aggregate amount of the Transferred FSA Balances, if suchamount
 is positive, and Purchaser or its Subsidiaries shall pay to Seller Parent or its Affiliates the net aggregate amount of theTransferred FSA Balances, if such amount is negative.
150

(j)      Employment Agreements .  Except for any Liabilities related to transaction bonuses or retention awards grantedprior
 to  Closing  to  any  Transferred  Employee  that  are  or  were  adopted  without  Purchaser  Parent’s  prior  written  approval(collectively,
 the “ Seller  Retention Awards  ”), any employment, severance, retention or other individual agreement between SellerParent
 or its Affiliates and a Transferred Employee and the related Liabilities shall, effective as of the Closing, be assumed byPurchaser or
 its Subsidiaries, and shall be considered Purchaser Assumed Employee Liabilities in accordance with Section 6.6(a)(i)  . Seller
 Parent shall reimburse Purchaser or its applicable Affiliate, as soon as practicable but in any event within thirty (30) days ofreceipt
 of appropriate verification, for all costs and expenses paid or incurred by Purchaser or its applicable Affiliate after theClosing Date with respect to the Seller Retention Awards, including the employer side Taxes or other payments related thereto.
(k) 
     Deferred Compensation .  Seller Parent and its Affiliates shall retain all assets and Liabilities in respect of theSeller Group Plans
 and Foreign Seller Group Plans set forth on Section 6.6(k)  of the Seller Disclosure Letter, which are  nonqualifiedor
 non-approved retirement plans that are not Conveyed Subsidiary Plans. For purposes of any Seller Group Plan or Foreign SellerGroup
 Plan that provides for “nonqualified deferred compensation” within the meaning of Section 409A of the Code, in accordancewith
 Treasury Regulation § 1.409A-1(h)(4), Seller Parent and Purchaser agree that the transfer of a Transferred Employee’semployment
 in accordance with this Agreement shall not constitute a “separation from service” within the meaning of Section 409Aof
 the Code, and, further, for any such Seller Group Plan or Foreign Seller Group Plan in respect of which Seller Parent or itsAffiliates
 are retaining Liabilities related to a Transferred Employee, that Purchaser shall notify Seller Parent in writing of aTransferred Employee’s separation from service with Purchaser or its Affiliates within thirty (30) days thereafter.
(l) 
     Labor and Employment Law Matters .  Purchaser and Seller Parent shall, and shall cause their respectiveAffiliates
 to, cooperate to take all steps, on a timely basis, as are required under applicable Law (including the Transfer ofUndertakings
 Laws) or any Collective Bargaining Agreement to notify, consult with, or negotiate the effect, impact, terms or timingof
 the transactions contemplated by this Agreement with each works council, union, labor board, employee group (or employeesdirectly)
 or Governmental Authority related to the foregoing. Seller Parent shall regularly review with Purchaser the progress of thenotifications,
 consultations and negotiations with each such works council, union, labor board, employee group (or employeesdirectly)
 and Governmental Authority regarding the effect, impact or timing of the transactions contemplated by this Agreement.Purchaser
 and Seller Parent shall, and shall cause their respective Affiliates to, comply with all applicable Laws, directives andregulations
 relating to the Business Employees in connection with this Section  6.6(l) .  To the extent required by Law or CollectiveBargaining
 Agreement (and within the time periods required by Law or Collective Bargaining Agreement), Purchaser shall or shallcause
 its applicable Affiliate to (i) become a party to any Collective Bargaining Agreement with respect to applicable TransferredEmployees
 and shall be responsible for all Liabilities under any Collective Bargaining Agreement with respect to any BusinessEmployee
 or Former Business Employee, regardless of whether arising prior to, on or after the Closing Date, and (ii) join anyindustrial,
 employer or similar association or federation. Purchaser shall indemnify Seller Parent and its Affiliates for any Liabilitiesincurred
 by Seller Parent and its Affiliates with respect to Purchaser or its Affiliates’ failure to comply with the obligations underthis 
Section 6.6(l) , which 151

shall be considered Purchaser Assumed Employee Liabilities in accordance with Section  6.6(a)(i) .  Seller Parent shall indemnifyPurchaser and its
 Affiliates for any Liabilities incurred by Purchaser and its Affiliates with respect to Seller Parent’s or its Affiliates’failure to comply with the obligations under this 
Section 6.6(l)  . (m) 
     Immigration .  Purchaser and Seller Parent shall, or shall cause their respective Affiliates to, use commerciallyreasonable
 efforts to ensure that any foreign national, who requires a visa in order to work for Seller Parent or its Affiliate in his orher current
 position, may continue to work in such position as a Transferred Employee following the Closing Date, or, as applicable,such later date that such Business Employee’s employment transfers to Purchaser or its applicable Affiliate.
(n) 
     Access to Independent Contractors and Service Providers .  During the period prior to the Closing Date, SellerParent
 shall use commercially reasonable efforts to make individual natural person independent contractors related to the Businessand
 directly engaged by Seller Parent or its Affiliates available to Purchaser for the purpose of allowing Purchaser to interview eachsuch
 contractor and determine the nature and extent of each such person’s continuation with Purchaser, if any. Seller Parent shallprovide
 to Purchaser contact information for third-party service providers providing contingent personnel to the Business andreasonably cooperate
 in identifying and facilitating Purchaser’s engagement of such contingent work force to the extent requested byPurchaser.
(o) 
     Communications .  Prior to the Closing, any employee notices or communication materials (including websitepostings)
 from  Purchaser  or  its  Affiliates  to  the  Business  Employees  (including  their  representatives),  including  notices  orcommunication
 materials with respect to employment, compensation or benefits matters addressed in this Agreement or related,directly
 or indirectly, to the transactions contemplated by this Agreement or employment thereafter, shall be subject to the priorreview,
 comment and approval of Seller Parent (such approval not to be unreasonably withheld, conditioned or delayed). Prior to theClosing,
 any employee notices or communication materials (including website postings) from Seller Parent or its Affiliates to theBusiness
 Employees (or their representatives) with respect to employment with, or compensation or benefits to be provided by,Purchaser
 or its Affiliates following the Closing, shall be subject to the prior review, comment and approval of Purchaser (suchapproval not to be unreasonably withheld, conditioned or delayed). Further, prior to the Closing, Purchaser and its Affiliates shall not
make broad-based unwritten communications to
 the Business Employees without Seller Parent’s prior approval (such approval not tobe
 unreasonably withheld, conditioned or delayed). Seller Parent and Purchaser shall coordinate to establish a protocol for reviewingand approving
 forms of employee notices and communication materials, and employee notices and communication materials that areconsistent with the agreed form shall not be subject to further review and approval.
(p) 
     Taxes and Filings .  With respect to each Transferred Employee (U.S.), the Parties shall, or shall cause theirrespective
 Affiliates to, (i) treat Purchaser or its applicable Affiliate as a “successor employer” and Seller Parent or its applicableAffiliate
 as a “predecessor,” within the meaning of Sections 3121(a)(1) and 3306(b)(1) of the Code, for purposes of Taxes imposedunder the U.S. Federal Insurance Contributions Act, as amended (“ 
FICA  ”), or the U.S. Federal152

Unemployment Tax Act, as amended (“ FUTA  ”), (ii) cooperate with each other to avoid the restart of FICA and FUTA upon orfollowing
 the  Closing  with  respect  to  each  such  Transferred  Employee  for  the  year  during  which  the  Closing  occurs,  and(iii)
 implement the alternate procedure described in Section 5 of Revenue Procedure 2004-53, including with respect to the filing ofall
 applicable forms (including Form 941). In addition, with respect to each Transferred Employee (U.S.), Purchaser shall beresponsible
 for the filing of Form 1095-C in respect of the year in which the Closing occurs. In accordance with Section  6.5(c) , Seller
 Parent and its Affiliates shall be entitled to any Tax deduction available in respect of all compensation and benefit-relatedLiabilities that it retains pursuant to this 
Section 6.6  . (q) 
     Cooperation . Subject to  applicable Law and Section 2.2  and  Section 6.4 , from  the date of this Agreement untilthe
 Closing, Seller Parent, Purchaser, and their respective Affiliates will reasonably cooperate in all matters reasonably necessary toeffect
 the transactions contemplated by this Section  6.6 ,  including (i) exchanging information and data reasonably necessary forSeller
 Parent and Purchaser to comply with their respective obligations under this Section  6.6 ,  (ii) making any and all requiredfilings
 and notices, (iii) making any and all required communications with Business Employees, and (iv) obtaining any requiredapprovals of a Governmental Authority.
(r) 
     No Third Party Beneficiaries . This  Section 6.6 is included for  the sole benefit of the Parties and their respectivepermitted transferees and
 permitted assigns and does not and shall not create any right in any Person, including any current or formeremployee of
 Seller Parent or any of its Affiliates, any Business Employee, any Transferred Employee or beneficiary or dependent ofthe
 foregoing, who is not a Party. Nothing contained in this Agreement (express or implied) is intended to (a) create or amend anyemployee
 benefit plan or arrangement or (b) confer upon any individual any right to employment for any period of time, or any rightto a particular term or condition of employment. No current or former employee of Seller Parent or any of its Affiliates, any Business
Employee,
 Former Business Employee or any Transferred Employee, including any beneficiary or dependent thereof, or any otherPerson
 not a Party or permitted transferee or permitted assign thereof, shall be entitled to assert any claim against Purchaser, SellerParent or any of their respective Affiliates under this 
Section 6.6  . Section 6.7 
      Intercompany Accounts and Arrangements . (a) 
     Seller Parent may take (or cause one or more of its Affiliates to take) such action as is necessary or advisable tosettle, effective
 as of, or prior to, the Closing Date, all intercompany accounts that are in the nature of Funded Indebtedness betweena
 Conveyed Subsidiary or any Subsidiary thereof, on the one hand, and Seller Parent or any of the Retained Subsidiaries, on theother hand, in such a
 manner as Seller Parent shall determine in its sole discretion without any further Liability or obligation thereforof
 any Person. Any intercompany accounts that are in the nature of Funded Indebtedness between a Conveyed Subsidiary or anySubsidiary
 thereof, on the one hand, and Seller Parent or any of the Retained Subsidiaries, on the other hand, that are settled after12:01 a.m.
 (New York time) on the Closing Date but in connection with the Closing shall be deemed for purposes of this Agreementto
 have been settled as of 12:01 a.m. (New York time) on the Closing Date, and any intercompany accounts that are in the nature ofFunded
153

Indebtedness between a Conveyed Subsidiary (or any of its Subsidiaries), on the one hand, and Seller Parent or any of the RetainedSubsidiaries,
 on the other hand, that remain outstanding following the Closing shall not be deemed Purchased Assets or AssumedLiabilities
 for purposes of this Agreement. Except for the Ancillary Agreements or the agreements set forth in Section  6.7 of  theSeller
 Disclosure Letter or as otherwise expressly contemplated by this Agreement, all intercompany arrangements and agreements,that
 are in the nature of Funded Indebtedness whether written or oral, between Seller Parent or any of the Retained Subsidiaries, onthe
 one hand, and any of the Conveyed Subsidiaries or their Subsidiaries, on the other hand, shall be terminated as of or prior to theClosing Date
 without any further Liability or obligation thereunder of any Person and shall be of no further force and effect after theClosing.
(b) 
     Purchaser Parent may take (or cause one or more of its Affiliates to take) such action as is necessary oradvisable
 to settle, effective as of, or prior to, the Closing Date, all intercompany accounts that are in the nature of FundedIndebtedness
 (other than intercompany accounts arising pursuant to a Purchaser Ancillary Agreement) between Purchaser or anySubsidiary
 of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser Parent (other than Purchaser and itsSubsidiaries),
 on the other hand, in such a manner as Purchaser Parent shall determine in its sole discretion without any furtherLiability
 or obligation therefor of any Person. Any such intercompany accounts that are in the nature of Funded Indebtednessbetween
 Purchaser or any Subsidiary of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser Parent(other
 than Purchaser and its Subsidiaries), on the other hand, that are settled after 12:01 a.m. (New York time) on the Closing Datebut
 in connection with the Closing shall be deemed for purposes of this Agreement to have been settled as of 12:01 a.m. (New Yorktime)
 on the Closing Date, and any intercompany accounts that are in the nature of Funded Indebtedness between Purchaser or anySubsidiary
 of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser Parent (other than Purchaser and itsSubsidiaries),
 on the other hand (other than intercompany accounts arising pursuant to a Purchaser Ancillary Agreement), thatremain
 outstanding following the Closing shall not be deemed an asset of Purchaser or a Purchaser Liability for purposes of thisAgreement
 (including for purposes of calculating the Purchaser Working Capital), and Purchaser Parent shall cancel or otherwisetransfer
 such intercompany account from Purchaser and its Subsidiaries for no consideration. All Liabilities related to or arising outof
 the intercompany loan between Setfirst Limited and Purchaser in respect of the acquisition by Purchaser or its applicableAffiliates
 of Novartis AG’s interest in Purchaser and its applicable Affiliates shall  be fully extinguished and cancelled, effectiveprior
 to the Closing Date, or shall otherwise be transferred to Purchaser Parent or its Affiliates (other than Purchaser and itsSubsidiaries)
 prior to the Closing Date and shall constitute a Purchaser Parent Retained Liability for all purposes hereunder, in anycase without any further Liability or
 obligation therefor for Purchaser or any of its Subsidiaries. Except for the Ancillary Agreementsor
 the Purchaser Related Party Contracts set forth in Section  6.7 of  the Purchaser Parent Disclosure Letter (the Purchaser RelatedParty
 Contracts  set  forth  thereon,  the  “ Purchaser  Ancillary  Agreements ”)  or  as  otherwise  expressly  contemplated  by  thisAgreement,
 all Purchaser Related Party Contracts shall be terminated as of or prior to the Closing Date without any further Liabilityor obligation thereunder of any Person and shall be of no further force and effect after the Closing.
154

(c)      Except to the extent provided to the contrary in this Section 6.7  and for any rights or obligations pursuant to this Agreement
 or any Ancillary Agreement or any commercial or other matter unrelated to this Agreement, effective as of the Closing,each
 of Purchaser Parent and Purchaser, on behalf of itself and its respective Affiliates, including the Conveyed Subsidiaries andtheir Subsidiaries, hereby releases Seller Parent and
 each of its Subsidiaries and Affiliates (and their respective officers, directors andemployees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any and all past actions
or
 failures to take action prior to the Closing directly or indirectly relating to or arising out of the Business, the Retained Businesses,the
 Purchaser Business or the operations of the Conveyed Subsidiaries (or their Subsidiaries) prior to the Closing, or relating to orarising out of Seller Parent’s or its Affiliate’s ownership of the Purchased Assets.
(d) 
     Except to the extent provided to the contrary in this Section 6.7  and for any rights or obligations pursuant to this Agreement or
 any Ancillary Agreement, effective as of the Closing, Purchaser Parent, on behalf of itself and its respective Affiliates(other
 than Purchaser and its Subsidiaries) hereby releases Purchaser and each of its Subsidiaries (and their respective officers,directors
 and employees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any andall past actions or failures to take action prior
 to the Closing directly or indirectly relating to or arising out of the Purchaser Business,the
 Purchaser Parent Retained Businesses or the operations of Purchaser and its Subsidiaries prior to the Closing, or relating to orarising
 out of the assets, properties or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of itsSubsidiaries.
(e) 
     Except to the extent provided to the contrary in this Section 6.7  and for any rights or obligations pursuant to this Agreement
 or any Ancillary Agreement or, in the case of Purchaser Parent, Purchaser and each of its Subsidiaries and Affiliates(other
 than the Conveyed Subsidiaries and their Subsidiaries), any commercial or other matter unrelated to this Agreement, effectiveas
 of the Closing, Seller Parent, on behalf of itself and its Affiliates, hereby releases each of Purchaser Parent, Purchaser and each ofits
 Subsidiaries and Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) (and their respective officers, directorsand
 employees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any and all pastactions
 or failures to take action prior to the Closing directly or indirectly relating to or arising out of the Business, PurchaserBusiness, the Retained Businesses or the operations of the Conveyed Subsidiaries (or their Subsidiaries) prior to the Closing.
Section 6.8 
      Access to Records and Information . (a) 
     Each of Seller Parent and its Affiliates and each of Purchaser Parent, Purchaser and their Affiliates shall retainthe
 books, records, documents, instruments, accounts, correspondence, writings, evidences of title and other papers relating to theBusiness or
 the Purchaser Business in its possession for at least seven (7) years following the Closing Date or for such longer periodas
 may be required by Law or any applicable Governmental Order. Each Party shall give reasonable written notice to the otherParties
 before ceasing to maintain any such materials, and shall deliver to the other Parties at the other Parties’ expense upon requestany such materials that it has proposed no longer to maintain.
155

(b)      Following the Closing and subject to applicable Law, each Party shall, and shall cause its Affiliates (including,in the case of Purchaser Parent and
 Purchaser, the Conveyed Subsidiaries and their Subsidiaries) to, permit the other Parties and theirAffiliates
 and Representatives reasonable access during normal business hours to such books, records, documents, instruments,accounts, correspondence, writings, evidences of title and other papers and to personnel having knowledge of the whereabouts and/or
contents
 of such books, records, documents, instruments, accounts, correspondence, writings, evidences of title and other papers, forlegitimate
 business reasons, including in connection with financial statements, reporting obligations and compliance with applicableLaws,
 and to provide such other information relating to the Business or the Purchaser Business as may be reasonably requested byany
 such other Party for such purposes; provided  that  each Party may restrict the foregoing access or the provision of suchinformation
 to the extent that, in the reasonable judgment of such Party, (i) applicable Law requires it or any of its Affiliates torestrict or
 prohibit such access or the provision of such information, (ii) providing such access would unreasonably interfere with theoperation
 of its and its Subsidiaries’ respective businesses, (iii) providing such access or information would breach a confidentialityobligation
 to  a  third  party,  (iv)  providing  such  access  or  information  would  result  in  disclosure  of  any  information  that  iscompetitively
 or commercially sensitive, (v) in the case of Seller Parent, the information relates to the Strategic Process, or in thecase of Purchaser Parent, the information relates to the review of strategic alternatives with respect to the Purchaser Business, and for
clarity
 in each case (with respect to both Seller Parent and Purchaser Parent) pertaining to such review prior to the Closing, or(vi)
 providing such access or disclosure of any such information would reasonably be expected to result in the loss or waiver of theattorney-client
 or other applicable privilege or protection. In the event that a Party restricts access or withholds information on thebasis
 of the foregoing clauses (i) through (vi), such Party shall, if permitted, inform the Party requesting such access or informationas
 to the general nature of what is being restricted or withheld and the reason therefor, and such Parties shall each use theircommercially
 reasonable efforts to make appropriate substitute arrangements to permit disclosure of the relevant information in amanner
 that does not suffer from such impediments. Each Party will hold in confidence all Confidential Information obtained fromthe
 other Parties or any of their Affiliates in accordance with Section  6.12 .  The Parties agree that, with respect to any matters thatare the subject of this 
Section 6.8(b)  and  Section 6.5(i) , the provisions of  Section 6.5(i)  (and not this  Section 6.8(b)  ) shall control. (c) 
     Without limiting the foregoing in this Section 6.8  ,  Purchaser Parent and Purchaser acknowledge and agree thatSeller
 Parent and its Affiliates shall retain, after the Closing, access and use rights with respect to, and may retain copies of, theRegistration
 Information (including in relation to pending applications for Product Registrations and Manufacturing Registrations)for Seller Parent’s and its Affiliates’ use for legal and regulatory compliance purposes.
Section
 6.9       Mail and Other Communications .  After the Closing Date, each Party and their respective Affiliatesmay
 receive mail and other communications properly belonging to the other Parties (or the other Parties’ Affiliates). Accordingly, atall
 times after the Closing Date, each Party authorizes each of the other Parties and their respective Affiliates to receive and open allmail
 and other communications received by it and not unambiguously intended for any other Party (or its Affiliates) or any otherParty’s
 (or its Affiliates’) officers or directors, and to retain the same to the extent that they relate to the business of the receivingParty or, to the extent that they
156

do not relate to the business of the receiving Party, the receiving Party shall promptly deliver such mail or other communications (or,in
 case the same relate to both businesses, copies thereof) to the Party for which such mail and communications are intended. Theprovisions
 of this Section  6.9 are  not intended to, and shall not be deemed to, constitute an authorization by any Party to permit theother
 to accept service of process on its behalf and no Party is or shall be deemed to be the agent of any other for service of processpurposes.
Section
 6.10       Transfer of Business IP and Registrations .  Notwithstanding anything to the contrary in thisAgreement or any Ancillary Agreement, Purchaser Parent shall be responsible for preparing and filing all instruments and documents
necessary
 to effect the assignment of the Business IP that is owned by Seller Parent or its Subsidiaries, Product Registrations andManufacturing
 Registrations to Purchaser and its Affiliates, including all costs and expenses of preparing and recording country-specific
 assignments and legalization of signatures (where required). Subject to Section 2.2  and  Section 6.4 ,  Seller Parent shall, andshall
 cause its Affiliates to, cooperate with the foregoing as set forth herein and in Section  6.4 ;  provided that,  notwithstandinganything
 to the contrary herein, such obligation of Seller Parent to cooperate shall expire twenty-four (24) months following theClosing
 Date (except with respect to Registered Business IP that is owned or purported to be owned by Seller Parent or itsSubsidiaries
 or their predecessors with respect to which there are gaps in the chain of title and the record or beneficial title is, as ofthe
 Closing Date, not in the name of a Seller, which obligation shall continue until forty-eight (48) months following the ClosingDate.
Section
 6.11       No Solicitation .  For a period of two (2) years after the Closing Date, (a) Seller Parent shall not, andshall
 cause its Affiliates not to, directly or indirectly, solicit for employment or hire any employee of Purchaser or its Subsidiarieswith
 the title of vice-president or senior director or more senior and (b) Purchaser Parent shall not, and shall cause its Affiliates(other
 than Purchaser and its Subsidiaries) not to, solicit for employment or hire any employee of Purchaser or its Subsidiaries withthe
 title of vice-president or senior director or more senior; provided  ,  however , that the foregoing will not restrict Seller Parent’s,Purchaser
 Parent’s or their respective Affiliates’ ability to conduct generalized searches for officers or employees, including throughsearch
 firms, bona fide public advertisements on websites or in periodicals of general circulation, so long as such searches are nottargeted
 at any such employees (or hire any person as a result of such searches), or to solicit (or hire) any person whose employmenthas been terminated by Purchaser or any of its Affiliates at least six (6) months prior to any such solicitation.
Section 6.12 
      Confidentiality . (a) 
     For a period of five (5) years after the Closing Date (and for trade secrets, for so long as they remain tradesecrets),
 each Party shall hold, and shall cause their respective Affiliates to hold, and shall cause their respective Representatives tohold,
 in confidence and not to disclose or release or use in any manner without the prior written consent of the other Parties any andall
 of the other Parties’ Confidential Information; provided  that  the Parties may disclose, or may permit disclosure of, ConfidentialInformation
 (i) to their respective Affiliates or Representatives who have a need to know such information and are informed of theirobligation to treat such information in the same manner as is applicable to the Parties and in respect of whose
157

failure to comply with such obligations Seller Parent, Purchaser Parent or Purchaser, as the case may be, will be responsible, (ii) ifthe
 Parties or their respective Affiliates or Representatives are compelled to disclose, on the advice of legal counsel, any suchConfidential Informa
tion by judicial or administrative process or by other requirements of Law or any securities exchange, market orautomated
 quotation system to which such Person is subject or (iii) in connection with any Action to enforce such Party’s rightsunder
 this Agreement or any Ancillary Agreement, or otherwise in the performance by such Party of this Agreement or anyAncillary
 Agreement in accordance with its terms. Notwithstanding the foregoing, in the event that any demand or request fordisclosure
 of Confidential Information is made by a Party pursuant to clause  (ii) above,  such Party shall (x) to the extent legallypermissible,
 promptly notify the other Parties of the existence of such request or demand and the disclosure that is expected to bemade
 in respect thereto, in each case with sufficient specificity so that the other Parties may, at their expense, seek a protective orderor other appropriate remedy or waive compliance with the provisions of this 
Section 6.12  and (y) if requested by another Party, assist such
 other Party, at such other Party’s expense, in seeking a protective order or other appropriate remedy in respect of such requestor
 demand; provided  that  a Party and its Affiliates and Representatives shall be permitted to disclose such Confidential Informationwithout
 notice  in  response  to  a  demand  or  request  for  disclosure  of  Confidential  Information  in  connection  with  a  routineexamination
 or  audit  by  a  Governmental  Authority  that  is  not  specifically  directed  at  the  transactions  contemplated  by  thisAgreement or such
 Confidential Information, provided  that such  disclosing Party and, if applicable, such Affiliate or Representative,exercise
 its and their reasonable best efforts to preserve the confidentiality of such Confidential Information, including by obtainingreasonable
 assurances that confidential treatment shall be accorded any Confidential Information so disclosed. If such a protectiveorder
 or other remedy or the receipt of a waiver by another Party is not obtained and such disclosing Party or any of its Affiliates orRepresentatives
 is, nonetheless, following consultation with its legal counsel, required by such judicial or administrative process,Law
 or securities exchange, market or automated quotation system to disclose any Confidential Information, such disclosing Party(or
 such Affiliate or Representative) may, after compliance with the immediately preceding sentence of this Section  6.12(a) , disclose
 only that portion of the Confidential Information which it has been advised by its legal counsel is required to be disclosed,provided 
that  such disclosing Party and, if applicable, such Affiliate or Representative, exercise its and their reasonable best effortsto
 preserve the confidentiality of such Confidential Information, including by obtaining reasonable assurances that confidentialtreatment shall be accorded any Confidential Information so disclosed.
(b) 
     As used in this Agreement, “ Confidential Information  ” means  all non-public proprietary, technical, economic,environmental,
 operational, financial or other business information or material, data, reports, interpretations, forecasts and businessplans,
 in written, oral (including by recording), electronic or visual form, in the possession of, or which has been disclosed to,whether
 prior to or following the Closing Date, a Party or its Affiliates or Representatives by any other Party or its Affiliates orRepresentatives,
 including pursuant to the access provisions of this Agreement or any Ancillary Agreement, (i) related to thetransactions
 contemplated by this Agreement or the Strategic Process, (ii) in the case of Seller Parent and its Affiliates andRepresentatives,
 to the extent relating to the Purchaser Parent Retained Businesses or the Purchaser Parent Retained Liabilities, and(iii)
 in the case of Purchaser Parent, Purchaser and their respective Affiliates and Representatives, to the extent relating to theExcluded Assets, the Retained Businesses
158

or the Retained Liabilities (except, in each case, to the extent that such information can be shown to have been (A) in the publicdomain (other
 than as a result of a disclosure by such Party or its Affiliates or Representatives), (B) available after the date hereof tosuch
 Party or its Affiliates or Representatives on a non-confidential basis from a source other than the other Parties or theirrespective Affiliates or
 Representatives without, to such Party’s knowledge after reasonable inquiry, being subject to any contractualor
 other obligation of confidentiality to the other Parties or their respective Affiliates or Representatives or (C) independentlydeveloped
 by or on behalf of such Party or its Affiliates or Representatives without use of, reference to or reliance upon anyConfidential
 Information of the other Parties (as can be demonstrated by such Party by appropriate documentary evidence) and not,to
 such Party’s knowledge after reasonable inquiry, subject to any contractual or other obligation of confidentiality to the otherParties or their respective Affiliates or Representatives).
(c) 
     Notwithstanding anything to the contrary set forth herein, (i) Seller Parent and its Affiliates, on the one hand,and
 Purchaser Parent, Purchaser and their respective Affiliates, on the other hand, shall be deemed to have satisfied their obligationshereunder
 with respect to Confidential Information if they exercise the same degree of care (but no less than a reasonable degree ofcare)
 as they take to preserve confidentiality for their own similar information, materials or other documents and (ii) confidentialityobligations
 contained in any agreement between Seller Parent or any of its Affiliates, or Purchaser Parent, Purchaser or any of theirrespective
 Affiliates, on the one hand, and any employee of Seller Parent or any of its Affiliates, or Purchaser Parent, Purchaser orany of their respective Affiliates, on the other hand, shall remain in full force and effect.
(d) 
     Notwithstanding the foregoing in this Section  6.12 ,  to the extent that an Ancillary Agreement or anotherContract pursuant to which a Party or any of its Affiliates is bound provides that certain Confidential Information shall be maintained
confidential
 on a basis that is more protective of such Confidential Information or for a longer period of time than provided for inthis 
Section 6.12 ,  then the applicable provisions contained in such Ancillary Agreement or other Contract shall control with respectthereto.
 After the Closing Date, the Confidentiality Agreement shall be deemed to have been terminated by the parties thereto andshall
 no longer be in effect. Seller Parent shall enforce, or otherwise assign to Purchaser, its rights under any confidentialityagreements
 entered into by Seller Parent with other potential purchasers of the Business in connection with the Strategic Processwith respect to the confidentiality, non-disclosure
 or use of Evaluation Material (as defined in such confidentiality agreements) to theextent
 related to the Business. Seller Parent shall, promptly after the date hereof, request the return or destruction of any suchEvaluation Material provided
 to such other potential purchasers to the extent required to be returned or destroyed in accordance withand subject to the terms of such confidentiality agreements.
Section 6.13 
      Guarantees; Letters of Credit . (a) 
     Without limiting Section  6.13(b) in  any respect, Purchaser shall use its reasonable best efforts to cause itself,one of
 its Affiliates or the Conveyed Subsidiaries to be substituted in all respects for the Sellers and any of their respective Affiliatesand for the Sellers
159

and their respective Affiliates to be released, effective as of the Closing, in respect of all Liabilities and obligations of the Sellers andany
 of their respective Affiliates under or related to each of the Seller Parent Guarantees and Seller Parent LCs (other than to theextent
 related to the Retained Business, Excluded Assets or Retained Liabilities), and Purchaser Parent and the Sellers shallreasonably cooperate in
 Purchaser’s efforts. Subject to the parenthetical in the preceding sentence, for any Seller Parent Guarantee orSeller
 Parent LC for which Purchaser or any Conveyed Subsidiary, as applicable, is not substituted in all respects for the Sellers andtheir
 respective Affiliates (or for which the Sellers and their respective Affiliates (other than the Conveyed Subsidiaries) are notreleased),
 effective as of the Closing, Purchaser shall continue to use its reasonable best efforts, and shall cause the ConveyedSubsidiaries to use their reasonable best efforts, to effect such substitution and release after the Closing, and Purchaser Parent and the
Sellers
 shall continue to reasonably cooperate in Purchaser’s efforts; provided  that  none of the Sellers, Purchaser Parent or any oftheir
 respective Affiliates (other than Purchaser and its Subsidiaries) shall have any obligation to make payments or incur any costsor
 expenses, grant any concession or incur any other Liability in connection with such cooperation pursuant to this Section  6.13except
 to the extent Purchaser agrees to promptly reimburse Sellers, Purchaser Parent and their Affiliates (other than Purchaser andits
 Subsidiaries), as applicable, or agrees to fully indemnify the Sellers, Purchaser Parent and their Affiliates (other than Purchaserand
 its Subsidiaries), as applicable, for any such Liabilities to Seller Parent’s or Purchaser Parent’s reasonable satisfaction, asapplicable.
 Without limiting the foregoing, neither Purchaser nor any of its Affiliates shall extend, renew, increase its obligationsunder or transfer to a third party any
 Contract containing or underlying a Seller Parent Guarantee or Seller Parent LC or any Contractto
 which any Seller Parent Guarantee or Seller Parent LC relates or pursuant to which any Seller Parent Guarantee or Seller ParentLC
 was issued or required to be issued unless, prior to or concurrently with such extension, renewal, increase or transfer, Purchaseror
 a Subsidiary of Purchaser is substituted in all respects for the Sellers and each of their respective Affiliates, and the Sellers andtheir respective Affiliates are released, in respect of all Liabilities and obligations of the Sellers and each of their respective Affiliates
under
 or in respect of such Seller Parent Guarantee or Seller Parent LC. In no event shall Seller Parent or any of its Affiliates beobligated
 to pay any money to any Person to effect the substitutions described in this Section 6.13(a)  .  The Parties agree that neitherSeller Parent nor any of the Retained Subsidi
aries will have any obligation to renew any Seller Parent LCs after the expiration of anysuch letter of credit. Neither the Seller Parent Guarantees nor the Seller Parent LCs shall be deemed Purchased Assets hereunder.
(b) 
     Without limiting Section  6.13(a) in  any respect, from and after the Closing, Purchaser and its Subsidiaries,including
 the Conveyed Subsidiaries (and their Subsidiaries), jointly and severally, shall indemnify and hold harmless the SellerParent
 Indemnified Parties against any Liabilities that the Sellers or any of their respective Affiliates suffer, incur or are liable forfollowing
 the Closing by reason of or arising out of or in consequence of (i) the Sellers or any of their respective Affiliates issuing,making
 payment under, being required to pay or reimburse the issuer of or any other Person in connection with, or being a party to,any Seller
 Parent Guarantee or Seller Parent LC, (ii) any claim or demand for payment made on the Sellers or any of their respectiveAffiliates
 with respect to any Seller Parent Guarantee or Seller Parent LC or (iii) any Action by any Person who is or claims to beentitled to
 the benefit of or claims to be entitled to payment, reimbursement or indemnity with respect to any Seller Parent Guaranteeor Seller Parent LC.
160

Section 6.14       Certain Ancillary Agreements . (a) 
     Prior to the date hereof, Purchaser Parent has delivered to Seller Parent true and complete copies of allPurchaser
 Ancillary Agreements currently in effect (and within forty-five (45) days following the date hereof shall provide SellerParent
 with true and complete copies of any other material Purchaser Related Party Contracts to the extent not previously provided).Following
 the date hereof, the Parties will discuss, cooperate and negotiate reasonably and in good faith to cause to be preparedreasonably
 in advance of the Closing, and in any event to be finalized within one hundred and twenty (120) days following the datehereof,
 forms of each of the following: (i) a transition services agreement with respect to the provision of certain services on atransitional
 basis following the Closing by Seller Parent, or certain of its Affiliates, to Purchaser and its Subsidiaries (and, to theextent
 reasonably requested by Seller Parent, a reciprocal reverse transition services agreement with respect to the provision ofservices
 by Purchaser and its Subsidiaries to Seller Parent and its Affiliates relating to any Excluded Assets that are not transferredout
 of the Conveyed Subsidiaries or their Subsidiaries prior to the Closing, if any) (the “ Transition  Services Agreement  ”),  (ii) across-license
 agreement with respect to the license of certain Intellectual Property related to and used in the Business to Purchaserand
 its Subsidiaries and certain Business IP related to and used in the Retained Businesses to Seller Parent and its Affiliates (the “Intellectual
 Property License  Agreement ”),  (iii) a manufacturing and supply agreement with respect to the supply of certainProducts
 manufactured at Retained Facilities by Seller Parent, or certain of its Affiliates, to Purchaser, or certain of its Subsidiaries(the
 “ Manufacturing and Supply Agreement (Seller Parent as  Supplier) ”),  (iv) a manufacturing and supply agreement with respectto
 the supply of certain products commercialized by the Retained Businesses that are manufactured at the Facilities by Purchaser, orcertain
 of its Subsidiaries, to Seller Parent, or certain of its Affiliates (the “ Manufacturing  and Supply Agreement (Purchaser asSupplier) 
”),  (v) Intellectual Property assignment agreements with respect to the assignment of Seller Parent’s and its Subsidiaries’right,
 title and interest in the Business IP in accordance with this Agreement to Purchaser and its Subsidiaries (the “ IP Assignment Agreements 
”),  (vi) a transitional trademark license agreement with respect to the license of certain Trademarks on a transitionalbasis
 following the Closing by Seller Parent, or certain of its Affiliates, to Purchaser and its Subsidiaries (the “ Transitional Trademark
 License Agreement ”),  (vii) a safety data exchange agreement to govern the provision and safeguarding of certaininformation
 provided  pursuant  to  this  Agreement  in  a  manner  compliant  with  applicable  Law  (the  “ Safety  Data  ExchangeAgreement 
”), and (viii) the Local Implementing Agreements (the forms of each of the agreements described in the foregoing clauses (i)
 through (viii), collectively the “ Form  Ancillary Agreements ”).  The Parties agree that the Form Ancillary Agreements shall beprepared
 substantially based on the Form Ancillary Agreements previously provided by Seller Parent to Purchaser Parent appendedhereto as 
Exhibit F  and  the Parties shall negotiate in good faith those terms that were not agreed to as reflected in Purchaser Parent’sresponses
 to such, which are appended hereto as Exhibit  G .  The Manufacturing and Supply Agreement (Purchaser as Supplier) andthe
 Manufacturing and Supply Agreement (Seller Parent as Supplier) shall be negotiated in accordance with the specific terms andprinciples
 set forth on Section 6.14  of  the Seller Disclosure Letter. The terms of such Form Ancillary Agreements shall in each casebe consistent with the terms of this Agreement.
161

(b)      At the Closing, Purchaser Parent, Purchaser and Seller Parent, as applicable, shall enter into, execute anddeliver,
 or cause their applicable Affiliates to enter into, execute and deliver, each Form Ancillary Agreement, a shareholdersagreement
 substantially  in  the  form  set  forth  in Exhibit  C (the  “ Purchaser  Shareholders  Agreement ”),  and  a  StructuringConsiderations Agreement substantially in the form set forth in 
Exhibit D  (the “  Structuring Considerations Agreement  ”). (c) 
     Promptly after the date hereof, Seller Parent and Purchaser Parent shall reasonably cooperate to discuss theservice charges in the Support Services Agreement, dated as of March 2, 2015, by and between GlaxoSmithKline Services Unlimited
and Purchaser, as amended, and to provide details on such charges to ensure a reasonable methodology is being applied.
(d) 
     Promptly after the date here, the Seller Parent and Purchaser Parent shall negotiate a lease agreement andrelated
 documentation in accordance with the terms set forth on Section  6.14(d) of  the Seller Disclosure Letter (the “ Lease Agreement 
”). Section 6.15 
      Retained and Transferred Names . (a) 
     Retained Names .  (i) As soon as reasonably practicable, but in no event later than forty-five (45) days after theClosing, unless a longer period of time is necessary to
 comply with applicable Law (including to the extent a longer period of time isnecessary
 to assign or update any Product Registrations, Manufacturing Registrations, or Governmental Authorizations or for legalor
 regulatory compliance purposes) (“ Compliance  Requirements ”),  and, in such event, as reasonably promptly as possible asallowed
 under applicable Law, Purchaser shall cause each Conveyed Subsidiary (and each Subsidiary thereof) to file to change itsname
 and cause its certificate of incorporation (or equivalent organizational document), as applicable, to be amended to remove anyand
 all references to (A) “Pfizer”, “Wyeth” or “Pfizer Consumer Health”, and (B) all other Retained Names set forth in Section1.1(E)
 of the Seller Disclosure Letter or otherwise designated by Seller Parent in writing prior to the Closing (clauses (A) and (B),collectively,
 the “ Retained  Brands  ”); and (ii) notwithstanding anything to the contrary in this Agreement, in the event any namechange of any Conveyed Subsidiary (or
 Subsidiary thereof) in accordance with this Section 6.15(a) would take effect during the termof
 the Transition Services Agreement, including any extensions thereof, Purchaser shall (a) at least thirty (30) days prior to suchname
 change, consult with Seller Parent regarding the contemplated change and (b) upon Seller Parent’s request, refrain frommaking
 any such change if Seller Parent determines in good faith that such change would reasonably be expected to result inadditional
 cost or operation burden to Seller Parent or any of its Affiliates in connection with one or more Services (as defined in theTransition
 Services Agreement) provided by Seller Parent or any of its Affiliates under the Transition Services Agreement, untilsuch
 time as is as soon as reasonably practicable after the term of the applicable Service (or Services) is terminated or expirespursuant to the terms of the Transition Service
s Agreement (the date that Purchaser is required to cause each Conveyed Subsidiary tomake
 such name change filing in accordance with clauses (i) and (ii), the “ Name  Change Date ”).  Except as authorized pursuant toan
 Ancillary Agreement, as soon as reasonably practicable after the later of (a) the Closing, but in no event later than forty-five (45)days
 after the Closing (or, if later, by the later of the Name Change Date or such other date as agreed between Purchaser and SellerParent) and (b) any longer period of time necessary
162

with respect to any Compliance Requirement, Purchaser shall, and shall cause its Affiliates to, remove, strike over or otherwiseobliterate
 all Retained Brands from all assets and other materials owned by the Conveyed Subsidiaries (and Subsidiaries thereof),including
 any sales and product literature, vehicles, business cards, schedules, stationery, packaging materials, displays, signage,advertising,
 marketing, promotional and related materials, training materials, audio and visual materials, manuals, forms, websites,social
 media pages and accounts, e-mail and e-mail addresses, computer software and other materials and systems, and shall ceaseand
 discontinue any other use of the Retained Brands as of the Closing in the operation of their businesses. Notwithstanding theforegoing,
 nothing in this Agreement is intended to prohibit any use (or require any removal, striking over, or other obliteration) byPurchaser
 or any of its Affiliates of any Retained Brand (x) for historical references, including in regulatory filings and to describethe
 past ownership and affiliation of the Business, and (y) in any manner as is or would have been permitted by applicable Law withrespect to Trademarks, including fair use, or nominal use, and other uses not prohibited by Law.
(b) 
     Purchaser Names . As  soon as reasonably practicable after the Closing, but in no event later than forty-five (45)days
 unless a longer period of time is necessary to comply with applicable Law, and, in such event, as reasonably promptly aspossible
 as allowed under applicable Law, Seller Parent shall, and shall cause its Affiliates to, remove, strike over or otherwiseobliterate
 all Business Trademark Rights, as applicable, from all assets and other materials owned by Seller Parent and its Affiliatesand,
 to  the  extent  applicable  file  to  change  its  name  and  cause  its  certificate  of  incorporation  (or  equivalent  organizationaldocument),
 as applicable, to be amended to remove any and all references to any Business Trademark Rights, as applicable,including
 any sales and product literature, vehicles, business cards, schedules, stationery, packaging materials, displays, signage,advertising,
 marketing, promotional and related materials, training materials, audio and visual materials, manuals, forms, websites,social
 media pages and accounts, e-mail and e-mail addresses, computer software and other materials and systems, and shall ceaseand discontinue any other use of such Business Trademark Rights in the operation of their business.
Section
 6.16       Compliance with WARN .  Purchaser agrees to provide or cause to be provided any required noticeunder
 WARN, and otherwise to comply with WARN with respect to any “plant closing” or “mass layoff” or similar event affectingTransferred
 Employees and occurring on or after the Closing Date. Purchaser agrees to, and shall cause its Affiliates to, indemnifyand
 hold harmless Seller Parent and the Retained Subsidiaries from and against any and all Losses which Seller Parent and theRetained
 Subsidiaries may incur in connection with any Action or claim of violation brought against Seller Parent and any of theRetained
 Subsidiaries under WARN (including with respect to any “plant closing” or “mass layoff”), which relate, in whole or inpart,
 to actions taken by Purchaser or any of its Affiliates following the Closing with regard to any site of employment of theConveyed Subsidia
ries (or their Subsidiaries) or the Purchased Assets or any of their respective operating units within any site wherea
 Transferred Employee is located. On or as soon as reasonably practicable following the Closing Date, Seller Parent shall provide,by
 termination date and work location, the name or employee identification number of each employee or former employee of SellerParent
 or its Affiliates and the Conveyed Subsidiaries who has suffered an “employment loss” under WARN at any site ofemployment where a Business Employee is located within the ninety (90) days immediately preceding the Closing Date.
163

Section 6.17       Litigation Support; Non-Indemnified Claims . (a) 
     Following the Closing, each Party and its respective Affiliates, shall cooperate with each other Party and itsrespective
 Affiliates in the mitigation, defense or settlement of any Liabilities or Actions involving the Business or RetainedBusinesses
 or the Purchaser Business or Purchaser Parent Retained Businesses for which such other Party has responsibility underthis
 Agreement, including with respect to any Retained Liabilities, Purchaser Parent Retained Liabilities, Assumed Liabilities orPurchaser
 Liabilities, by providing such other Party and such other Party’s legal counsel, upon reasonable advance notice in writingand
 during normal business hours, access to current and former employees, contractors, records, documents, data, equipment,facilities,
 products, parts, prototypes and other information as such other Party may reasonably request, to the extent maintained orunder
 the possession or control of such Party and its Affiliates; provided  that  any Party may restrict the foregoing access or theprovision
 of such information to the extent that, in the reasonable judgment of such Party, (i) applicable Law requires such Party orany
 of its Affiliates, as applicable, to restrict or prohibit such access or the provision of such information, (ii) providing such accesswould
 unreasonably interfere with the operation of its and its Subsidiaries’ respective businesses, (iii) providing such access orinformation
 would breach a confidentiality obligation to a third party, (iv) providing such access or information would result indisclosure
 of any information that is competitively or commercially sensitive, (v) in the case of Seller Parent, the information relatesto
 the Strategic Process or, in the case of Purchaser Parent, the information relates to review of strategic alternatives with respect tothe
 Purchaser Business, and for clarity in each case (with respect to both Seller Parent and Purchaser Parent) pertaining to suchreview
 prior to the Closing, or (vi) providing such access or disclosure of any such information would reasonably be expected toresult
 in the loss or waiver of the attorney-client or other applicable privilege or protection. In the event that a Party restricts accessor
 withholds information on the basis of the foregoing clauses  (i) through  (vi) , such Party shall, if permitted, inform the requestingParty
 as to the general nature of what is being restricted or withheld and the reason therefor, and such Parties shall each use theircommercially
 reasonable efforts to make appropriate substitute arrangements to permit disclosure of the relevant information in amanner
 that does not suffer from such impediments. The requesting Party shall reimburse the other Party for its reasonable out-of-pocket expenses paid to
 third parties in performing its obligations under this Section 6.17  . The Parties agree that, with respect to any matters
 that are the subject of this Section  6.17 and  Section 6.5(i) ,  the provisions of Section  6.5(i) (and  not this Section  6.17 ) shall control.
(b) 
     From and after the Closing, (i) Purchaser shall promptly notify Seller Parent of any Action brought by oragainst a
 third party with respect to the Business that would reasonably be expected to affect any Retained Business, Excluded Assetor
 Retained Liability, (ii) Purchaser shall promptly notify Purchaser Parent of any Action brought by or against a third party withrespect
 to the Purchaser Business that would reasonably be expected to affect any Purchaser Parent Retained Business or PurchaserParent
 Retained Liability, (iii) Seller Parent shall promptly notify Purchaser and Purchaser Parent of any Action brought by oragainst
 a third party with respect to the Retained Businesses that would reasonably be expected to affect the Business or anyPurchased
 Asset or Assumed Liability and (iv) Purchaser Parent shall promptly notify Purchaser and Seller Parent of any Actionbrought
 by or against a third party with respect to the Purchaser Parent Retained Businesses that would reasonably be expected toaffect the Purchaser Business or any Purchaser
164

Liability or any assets, properties or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of itsSubsidiaries.
 The provisions of Article  VII shall  apply to any Third Party Claim with respect to which any Indemnified Party isentitled
 to indemnification under Article  VII .  With respect to any other third party Action (“ Non-Indemnified  Claims ”),  if suchNon-Indemnified
 Claim could reasonably be expected to (i) affect any Purchaser Parent Retained Businesses or Purchaser ParentRetained Liability,
 Purchaser Parent shall have the right but not the obligation, at its option and its own expense, to participate in thedefense
 or settlement of such Non-Indemnified Claim and to employ counsel of its own choosing for such purpose, (ii) affect anyRetained Business, Excluded Asset or Retained Liability, Seller Parent shall have the right but
 not the obligation, at its option and itsown
 expense, to participate in the defense or settlement of such Non-Indemnified Claim and to employ counsel of its own choosingfor
 such purpose or (iii) affect the Business, the Purchaser Business or any Purchased Asset or Assumed Liability or PurchaserLiability, or any other assets, properties or rights relating to the Purchaser Business or owned, used or held
 by Purchaser or any of itsSubsidiaries,
 Purchaser shall have the right but not the obligation, at its option and its own expense, to participate in the defense orsettlement
 of such Non-Indemnified Claim; provided  ,  in each case, that such participation would not materially adversely affect thedefense
 of such Non-Indemnified Claim and there is no material conflict of interest between the applicable Parties with respect tosuch Action.
(c) 
     In furtherance of the foregoing, from and after the Closing Date, each Party shall, and shall cause its respectiveAffiliates to, (i) cooperate with each
 other Party and its respective Affiliates in the mitigation, defense or settlement of any Liabilitiesor
 Actions described in Section  6.17(b) and  (ii) provide to each other, upon written request, reasonable access during normalbusiness
 hours  to  their  current  and  former  officers,  directors,  employees,  contractors,  personnel  and  agents  for  fact  finding,consultation
 and interviews and as witnesses in connection with any Action in which the requesting Party may from time to time beinvolved
 relating to the matters described in Section 6.17(b)  ,  in each case subject to Section 6.17(a)  . The  requesting party agrees toreimburse
 the other for reasonable out-of-pocket expenses (other than officers’ or employees’ salaries) incurred in connection withproviding individuals and witnesses pursuant to this 
Section 6.17(c)  . Section 6.18 
      Insurance . (a) 
     From and after the Closing Date, the Conveyed Subsidiaries and their Subsidiaries shall cease to be insured bySeller
 Parent’s or its Affiliates’ insurance policies or by any of their self-insured programs. Seller Parent or any of its Affiliates mayamend,
 effective at or prior to the Closing, any insurance policies in the manner it deems appropriate to give effect to thisSection
 6.18 .  From and after the Closing, Purchaser shall be responsible for securing all insurance it considers appropriate for itsoperation
 of the Conveyed Subsidiaries and their Subsidiaries and the Business. Seller Parent shall use reasonable best efforts tokeep
 or cause its Affiliates to keep all insurance policies currently maintained with respect to the Business, or suitable replacementsor renewals, in full force and effect through 12:01 a.m. (New York time) on the Closing Date.
(b) 
     With respect to any Assumed Liability arising out of events or circumstances pertaining to the Business orPurchased
 Assets that occurred or existed prior to the Closing and are covered under any occurrence-based unaffiliated third partyautomobile or general liability
165

insurance  policy  of  Seller  Parent  or  its  Subsidiaries  (an  “ Insurance  Policy ”)  in  effect  as  of  the  Closing  (such  events  orcircumstances,
 an “ Insurance  Matter ”),  Purchaser may tender such Insurance Matter for submission by Seller Parent or one of itsSubsidiaries
 to the applicable insurer under such Insurance Policy under which the Sellers or the Conveyed Subsidiaries (or any oftheir
 Subsidiaries) were insured as of the date of the applicable events or circumstances, in which case Seller Parent will usecommercially
 reasonable efforts to submit a claim with respect to such Insurance Matter to the applicable insurer; provided  that Purchaser
 and the Conveyed Subsidiaries (and their Subsidiaries) shall indemnify Seller Parent and its Affiliates for any reasonabledirect
 costs and expenses (including reasonable costs of investigation of the underlying claim and of collection and any Taxesimposed
 in respect of such insurance proceeds) in connection with the foregoing and shall be solely responsible for (i) any per claimdeductible
 or per claim self-insured retentions with respect to such Insurance Matter, (ii) any claims, costs and expenses (includingattorneys’
 fees) with respect to such Insurance Matter that are not covered under the relevant Insurance Policy, and (iii) anycollateral
 requirements with respect to such Insurance Matter; provided  ,  further that (A) Purchaser shall not, and shall cause itsAffiliates
 not to, in connection with any Insurance Matter under any Insurance Policy, take any action that would be reasonablylikely to
 result in the applicable insurer terminating or materially reducing coverage under such Insurance Policy, (B) if an InsurancePolicy
 aggregate is exhausted, or believed likely to be exhausted, due to noticed claims, Purchaser, on the one hand, and SellerParent,
 on the other hand, shall be responsible for their pro rata portion of the reinstatement premium, if any, based upon the amountof
 the claims submitted by each of them (or their respective Affiliates) thereunder and (C) Purchaser shall not be entitled to makeany
 claims or receive any proceeds to the extent the related Liabilities are included in the calculation of Final Business WorkingCapital
 or Final Business Net Cash or such proceeds were otherwise credited to Purchaser at or prior to the Closing. Except as setforth
 in Section 2.1(o) and  the immediately preceding sentence, from and after the Closing, none of Purchaser Parent, Purchaser orany
 of their respective Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) shall have any access, right, title orinterest
 to or in any of Seller Parent’s or its Affiliates’ past or current insurance policies or any of their self-insured programs(including to all claims and rights to make claims and all rights to proceeds) to cover any assets of the Conveyed Subsidiaries or their
Subsidiaries
 or any Assumed Liability or any other Liability arising from the operation of the Business or the ownership or use ofany
 Purchased Asset before, on or after the Closing, and Purchaser shall not and shall cause its Affiliates (including the ConveyedSubsidiaries
 and their Subsidiaries) not to seek to assert or to exercise any rights or claims of any Conveyed Subsidiaries or theirSubsidiaries
 or the Business under or in respect of any such past or current insurance policy, including under which any ConveyedSubsidiary
 or Affiliate thereof or the Business is a named insured, and without limiting the foregoing shall not seek to assert orexercise
 (w) any rights with respect to any self-insurance programs of Seller Parent or any of its Affiliates, (x) any rights under anyfronting
 insurance programs or arrangements of Seller Parent or its Affiliates, (y) any rights under any claims-made insuranceprograms of
 Seller Parent or its Affiliates or (z) any rights to cause Seller Parent or any of its Affiliates to pay any deductible or self-insured
 retention amount with respect to any claim. Purchaser shall notify Seller Parent promptly of any such Insurance Matter forwhich
 it seeks coverage and Purchaser and Seller Parent shall keep each reasonably informed regarding the status of the InsuranceMatter.
166

Section 6.19       Trade Notification .  Seller Parent and Purchaser Parent shall agree on the method and content of thenotifications
 to partners, customers, suppliers, wholesalers and distributors of the Business and the Purchaser Business of thetransactions
 contemplated by this Agreement prior to the Closing. Seller Parent and Purchaser agree that such notifications are toprovide
 sufficient advance notice of the transactions contemplated hereby and the plans associated therewith, with the objective ofminimizing any disruption of the Business and the Purchaser Business.
Section 6.20 
      Accounts; Products Received . (a) 
     All payments and reimbursements received by Seller Parent, Purchaser Parent or their Affiliates after theClosing
 that, consistent with the terms and conditions of this Agreement or any Ancillary Agreement, are the property of Purchaseror its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries) shall be held by such Person in trust for the benefit of
Purchaser
 and, promptly following receipt by such Person of any such payment or reimbursement, such Person shall pay over toPurchaser
 the amount of such payment or reimbursement without right of set-off. All payments and reimbursements received afterthe
 Closing by Purchaser Parent, Purchaser or their Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) that,consistent
 with the terms and conditions of this Agreement or any Ancillary Agreement, are the property of Seller Parent or any ofits
 Affiliates, shall be held by such Person in trust for the benefit of Seller Parent and, promptly following receipt by such Person ofany
 such payment or reimbursement, such Person shall pay over to Seller Parent the amount of such payment or reimbursementwithout
 right of set-off. All payments and reimbursements received after the Closing by (x) Seller Parent or its Affiliates or (y)Purchaser
 or its Subsidiaries that, consistent with the terms and conditions of this Agreement or any Ancillary Agreement, are theproperty
 of Purchaser Parent or any of its Affiliates (other than Purchaser and its Subsidiaries), shall be held by such Person in trustfor
 the benefit of Purchaser Parent and, promptly following receipt by such Person of any such payment or reimbursement, suchPerson shall pay over to Purchaser Parent the amount of such payment or reimbursement without right of set-off.
(b) 
     If Products or Purchaser Products are received by Seller Parent or its Affiliates or Purchaser Parent or itsAffiliates
 (other than Purchaser and its Subsidiaries) after the Closing, Seller Parent or Purchaser Parent, as applicable, shall or shallcause
 such Affiliate to ship those Products or Purchaser Products to Purchaser, or Purchaser’s stated representative, at Purchaser’ssole
 cost and expense. Purchaser shall have sole responsibility for accepting and processing all returns following the Closing ofProducts
 and disbursing refunds and credits in respect thereof (whether such Products were sold prior to, on or after the ClosingDate).
Section 6.21 
      Directors’ and Officers’ Indemnification . (a) 
     If the Closing occurs, Purchaser shall, and shall cause the Conveyed Subsidiaries and their Subsidiaries to, takeany
 necessary actions to provide that all rights to indemnification and all limitations on liability existing in favor of any current orformer
 officers, directors, partners, members, or managers of the Conveyed Subsidiaries or their Subsidiaries (or their respectivepredecessors) (collectively,
 the “ D&O Indemnitees  ”), as  provided in (i) the organizational documents of the Conveyed Subsidiariesand their Subsidiaries or (ii) any agreement
167

providing for indemnification by the Conveyed Subsidiaries or their Subsidiaries of any of the D&O Indemnitees, which agreementsare
 set forth in Section  6.21 of  the Seller Disclosure Letter, shall survive the consummation of the transactions contemplated herebyand continue in full force and effect and be honored by the Conveyed Subsidiaries or their Subsidiaries after the Closing.
(b) 
     In the event that any of the Conveyed Subsidiaries or their Subsidiaries or Purchaser or any of their respectivesuccessors
 or assigns (i) consolidates with or merges into any other Person and is not the continuing or surviving corporation orentity
 of such consolidation or merger or (ii) transfers or conveys all or a majority of its properties and assets to any Person, then,and
 in each such case, proper provision shall be made so that the successors and assigns of the Conveyed Subsidiaries or theirSubsidiaries or Purchaser, as the case may be, shall succeed to the obligations set forth in this 
Section 6.21  . (c) 
     The obligations of Purchaser under this Section 6.21  shall  not be terminated or modified in such a manner as toadversely
 affect any D&O Indemnitee without the express written consent of such affected D&O Indemnitee (it being expresslyagreed that the D&O Indemnitees shall be third party beneficiaries of this 
Section 6.21  ). Section 6.22 
      Return of Assets; Transfer of Purchased Assets . (a) 
     If, at any time after the Closing, any asset held by Purchaser or any of its Subsidiaries (including the ConveyedSubsidiaries
 and their Subsidiaries) is ultimately determined to be an Excluded Asset or an asset of the Purchaser Parent RetainedBusiness,
 or Purchaser or any of its Subsidiaries is found subject to a Retained Liability, or Purchaser or any of its Subsidiaries isfound
 subject to a Purchaser Parent Retained Liability, within thirty (30) days of such determination (i) Purchaser shall return ortransfer
 and convey (without further consideration) to Seller Parent or the appropriate Affiliate of Seller Parent such Excluded Assetor
 Retained  Liability,  or  to  Purchaser  Parent  or  the  appropriate  Affiliate  of  Purchaser  Parent  (other  than  Purchaser  and  itsSubsidiaries)
 such asset of the Purchaser Parent Retained Business or such Purchaser Parent Retained Liability, as applicable;(ii)
 Seller Parent shall, or shall cause its appropriate Affiliate to, assume (without further consideration) such Retained Liability, orPurchaser
 Parent shall assume (without further consideration) such Purchaser Parent Retained Liability; and (iii) Seller Parent orPurchaser
 Parent, as applicable, and Purchaser shall, and shall cause their appropriate Affiliates to, execute such documents orinstruments of conveyance
 or assumption and take such further acts, in each case consistent with the terms of this Agreement and theAncillary
 Agreements, as are reasonably necessary or desirable to effect the transfer of such Excluded Asset or Retained Liabilityback
 to Seller Parent or its appropriate Affiliate or such asset of the Purchaser Parent Retained Business or Purchaser ParentRetained
 Liability back to Purchaser Parent, as applicable, in each case such that each Party is put into the same economic positionas
 if such action had been taken on or prior to the Closing Date. In furtherance of the foregoing, Purchaser and its Affiliates shall,and shall cause
 the Conveyed Subsidiaries and their Subsidiaries to, promptly pay or deliver (1) to Seller Parent (or its designee) anymonies
 or checks which have been sent to Purchaser or any of its Affiliates (including the Conveyed Subsidiaries and theirSubsidiaries)
 to the extent they are not due to the Business and which should have been sent to Seller Parent or one of its Affiliates(including promptly forwarding invoices or similar documentation to Seller Parent) or (2) to Purchaser Parent
168

(or its designee other than Purchaser and its Subsidiaries) any monies or checks which have been sent to Purchaser or any of itsSubsidiaries
 to the extent they are not due to the Purchaser Business and which should have been sent to Purchaser Parent or one ofits
 Affiliates (other than Purchaser and its Subsidiaries) (including promptly forwarding invoices or similar documentation toPurchaser Parent).
(b) 
     Subject to Sections 2.1  and  2.2 , if, at any time after the Closing, any asset held by Seller Parent or its Affiliatesis
 ultimately determined to be a Purchased Asset or Seller Parent or any of its Affiliates is found to be subject to an AssumedLiability,
 within thirty (30) days of such determination, (i) Seller Parent shall return or transfer and convey (without furtherconsideration)
 to Purchaser such Purchased Asset or Assumed Liability; (ii) Purchaser shall, or shall cause its appropriate Affiliateto,
 assume (without further consideration) such Assumed Liability; and (iii) Seller Parent and Purchaser shall, and shall cause theirappropriate
 Affiliates to, execute such documents or instruments of conveyance or assumption and take such further acts, in eachcase consistent
 with the terms of this Agreement and the Ancillary Agreements, as are reasonably necessary or desirable to effect thetransfer
 of such Purchased Asset or Assumed Liability back to Purchaser, in each case such that each Party is put into the sameeconomic
 position as if such action had been taken on or prior to the Closing Date. In furtherance of the foregoing, Seller Parentshall
 promptly pay or deliver to Purchaser (or its designee) any monies or checks which have been sent to Seller Parent or any of itsAffiliates
 to the extent they are due to the Business and which should have been sent to Purchaser or one of its Affiliates (includingpromptly forwarding invoices or similar documentation to Purchaser).
(c) 
     If any asset, property or right held by Purchaser Parent or any of its Affiliates (other than Purchaser or itsSubsidiarie
s) is determined to be an asset of the Purchaser Business or Purchaser Parent or any of its Affiliates (other than Purchaserand its
 Subsidiaries) is found subject to a Purchaser Liability, within thirty (30) days of such determination (i) Purchaser Parent shall(or
 shall cause its Affiliate to) transfer and convey (without consideration) to Purchaser or its appropriate Subsidiary such asset,property
 or  right  or  Purchaser  Liability;  (ii)  Purchaser  shall,  or  shall  cause  its  appropriate  Subsidiary  to,  assume  (withoutconsiderati
on) such Purchaser Liability; and (iii) Purchaser Parent and Purchaser shall, and shall cause their appropriate Subsidiariesto, in each case consistent with the terms of this Agreement and the Ancillary Agreements, execute such documents or instruments of
conveyance
 or assumption and take such further acts as are reasonably necessary or desirable to effect such transfer of such asset,property
 or right or Purchaser Liability back to Purchaser or its appropriate Subsidiary, in each case such that each Party is put intothe
 same economic position as if such action had been taken on or prior to the Closing Date. In furtherance of the foregoing,Purchaser
 Parent and its Affiliates (other than Purchaser or its Subsidiaries) shall promptly pay or deliver to Purchaser (or itsdesignee)
 any monies or checks which have been sent to Purchaser Parent or any of its Affiliates to the extent they are due to theBusiness
 or the Purchaser Business and which should have been sent to Purchaser or one of its Subsidiaries (including promptlyforwarding invoices or similar documentation to Purchaser).
Section
 6.23       Bulk Transfer Laws .  Purchaser Parent and Purchaser acknowledge that Seller Parent has not taken,and
 does not intend to take, any action required to comply with any applicable so-called “bulk sale” or “bulk transfer” Laws orsimilar Laws, and Purchaser Parent
169

and Purchaser hereby waive, to the fullest extent permitted by applicable Law, compliance by Seller Parent and its Affiliates with theprovisions of any such Laws of any jurisdiction in connection with the sale of the Purchased Assets.
Section 6.24 
      Purchaser Parent Shareholder Meeting; Purchaser Parent Board Recommendation  . (a) 
     Subject to Section  6.24(f) and  Section 6.24(g) ,  Purchaser Parent shall, and shall cause its Representatives to,(i) as soon
 as reasonably practicable, prepare and file with the UKLA the Purchaser Parent Shareholder Circular, which shall complywith the content requirement
s of the Listing Rules, including Chapter 11 thereof, and applicable Law, and include a notice of generalmeeting
 for the purpose of placing the Purchaser Parent Shareholder Approval Resolution before Purchaser Parent’s shareholders,and
 (ii) use reasonable best efforts to finalize the Purchaser Parent Shareholder Circular and have it approved by the UKLA as soonas
 reasonably  practicable  after  such  filing,  including  by taking  all  such  actions  (including  supplying  undertakings,  executingdocuments
 and paying fees and expenses) as may be required by the UKLA. As promptly as practicable (and in any event withinthree
 (3) Business Days) after UKLA approval of the Purchaser Parent Shareholder Circular, Purchaser Parent shall publish thePurchaser Parent
 Shareholder Circular and send it to its shareholders and shall, subject to Section 6.24(f)  and  Section 6.24(g) , cause a
 general meeting of the shareholders of Purchaser Parent for the purpose of obtaining the Purchaser Parent Shareholder Approval(together
 with any adjournment or postponement thereof, the “ Purchaser  Parent Shareholder Meeting ”)  to be convened and held ontwenty-one
 (21) clear days’ notice (subject to the notice being deemed served in accordance with the Deposit Agreement to enableADR
 voting),  in  each  case  in  compliance  with  the  Listing  Rules  and  applicable  Law  and  Purchaser  Parent’s  constitutionaldocuments, and, subject to 
Section 6.24(f)  and  Section 6.24(g) , shall propose the Purchaser Parent Shareholder Approval Resolut ion(without amendment) at the Purchaser Parent Shareholder Meeting.
(b) 
     Seller Parent and its Representatives shall cooperate reasonably and in good faith with Purchaser Parent, andprovide,
 at  Purchaser’s sole cost and  expense, all  such information  and  documentation  requested by  Purchaser Parent  or  itsRepresentatives,
 in each case to the extent reasonably necessary for the purposes of Purchaser Parent’s preparation of the PurchaserParent
 Shareholder Circular and any supplementary circular thereto, including for the purposes of the preparation of pro formafinancial
 information (and related reporting requirements), if applicable. Seller Parent and its Representatives shall be given areasonable
 opportunity to review and comment upon the Purchaser Parent Shareholder Circular (and any supplementary circularthereto)
 before  each  such  document  is  filed  with  the  UKLA  and  is  published,  and  Purchaser  Parent  shall  give  reasonableconsideration to any additions, deletions or changes reasonably and timely suggested thereto by Seller Parent and its Representatives.
In
 addition, Purchaser Parent shall provide Seller Parent and its Representatives with copies of any written comments, and shallinform
 them of any material or substantive oral comments, Purchaser Parent or its Representatives may receive from time to timefrom
 the UKLA or its staff with respect to the Purchaser Parent Shareholder Circular (and any supplementary circular thereto)promptly
 after receipt of such comments, and any written or oral responses thereto. Seller Parent and its Representatives shall begiven a reasonable opportunity to review and comment upon any such written responses and Purchaser Parent shall
170

give  reasonable  consideration  to  any  additions,  deletions  or  changes  reasonably  suggested  thereto  by  Seller  Parent  and  itsRepresentatives.
 In the event that Purchaser Parent or its Representatives receives any comments from the UKLA or their staff withrespect
 to  the  Purchaser  Parent  Shareholder  Circular  (or  any  amendment  or  supplement  thereto),  Purchaser  Parent  and  itsRepresentatives
 shall use reasonable best efforts to respond as promptly as practicable to such comments and shall take such otheractions
 as may be reasonably necessary to resolve the issues raised therein as promptly as practicable, and Seller Parent and itsRepresentatives
 shall cooperate reasonably and in good faith with Purchaser Parent and its Representatives to the extent reasonablynecessary for the purposes of resolving such comments.
(c) 
     Subject to Section 6.24(f)  and  Section 6.24(g) , Purchaser Parent and the Board of Directors of Purchaser Parent shall
 (i) include the Purchaser Parent Board Recommendation in the Purchaser Parent Shareholder Circular, (ii) use its reasonablebest
 efforts to obtain the Purchaser Parent Shareholder Approval as promptly as practicable, and to the extent any further PurchaserParent’s
 shareholders’ resolution is required to approve the transactions contemplated hereby or by any of the Ancillary Agreementsprior
 to Closing, use its reasonable best efforts to procure that such further shareholder resolution is passed by the requisite vote ofPurchaser
 Parent’s shareholders, and (iii) ensure that the Purchaser Parent Shareholder Circular includes a statement that eachDirector
 of Purchaser Parent who holds shares in Purchaser Parent intends to vote his or her shares in favor of the Purchaser ParentShareholder
 Approval Resolution. Subject to Section  6.24(f) and  Section 6.24(g) ,  Purchaser Parent shall not, without the priorwritten
 consent of Seller Parent, adjourn, postpone or otherwise delay the Purchaser Parent Shareholder Meeting; provided  that Purchaser
 Parent may adjourn, postpone or otherwise delay the Purchaser Parent Shareholder Meeting (including an adjournment toallow
 reasonable additional time for the preparation and publication of any supplement or amendment to the Purchaser ParentShareholder
 Circular) if required to comply with Purchaser Parent’s obligations under the Listing Rules or otherwise by applicableLaw,
 and/or where, and to the extent that, the Board of Directors of Purchaser Parent shall have determined in good faith (afterconsultation
 with its legal counsel) that the failure to so adjourn, delay or postpone the Purchaser Parent Shareholder Meeting wouldbe
 inconsistent with its fiduciary duties under applicable Law. After Purchaser Parent has established a record date for the PurchaserParent
 Shareholder Meeting, Purchaser Parent shall not change such record date or establish a different record date for the PurchaserParent
 Shareholder Meeting without the prior written consent of Seller Parent, unless (x) required to do so by applicable Law orPurchaser
 Parent’s constitutional documents or (y) as required in connection with any adjournment, postponement or delay of thePurchaser
 Parent Shareholder Meeting permitted by the immediately preceding sentence (it being understood that Purchaser Parentshall
 consult with and consider in good faith the reasonable views of Seller Parent in connection with setting such new record date).Without the prior written consent of
 Seller Parent, the Purchaser Parent Shareholder Approval Resolution shall be the only resolution(other
 than matters of procedure and matters required by applicable Law or Purchaser Parent’s constitutional documents to be votedon
 by Purchaser Parent’s shareholders in connection with the approval of the Sale and the transactions contemplated hereby) thatPurchaser Parent shall propose to be acted on by Purchaser Parent’s shareholders at the Purchaser Parent Shareholder Meeting.
171

(d)      Purchaser Parent shall notify Seller Parent: (i) on a regular basis after publication of the Purchaser ParentShareholder
 Circular and prior to the Purchaser Parent Shareholder Meeting of the proxy votes received in respect of the PurchaserParent
 Shareholder Meeting; and (ii) promptly following the Purchaser Parent Shareholder Meeting, of the result of the vote on theresolutions proposed to the Purchaser Parent’s shareholders at the Purchaser Parent Shareholder Meeting.
(e) 
     Except as expressly permitted by Section  6.24(f) ,  Purchaser Parent and the Board of Directors of PurchaserParent
 (and any committee or other subdivision thereof) shall not, and shall not permit its Representatives to, directly or indirectly,(i)
 fail to make, withdraw, withhold, change, amend, qualify or modify in a manner adverse to Seller Parent, or publicly propose tofail
 to make in the Purchaser Parent Shareholder Circular, withdraw, withhold, change, amend, qualify or modify in a manneradverse to
 Seller Parent, the Purchaser Parent Board Recommendation, (ii) make any public announcement or statement inconsistentwith the Purchaser Parent Board Recommendation
, (iii) fail to include the Purchaser Parent Board Recommendation in the PurchaserParent
 Shareholder Circular (or any supplement or amendment thereto), (iv) recommend in favor of, or fail to recommend against,any
 matter that could reasonably be expected to result in a Purchaser Adverse Action or a Purchaser Material Adverse Effect or(v)
 publicly  propose  to  do  any  of  the  foregoing  (any  of  the  foregoing  in  this  sentence,  a  “ Purchaser  Parent  AdverseRecommendation 
Change  ”).(f) 
     Notwithstanding any other provision of this Section  6.24 ,  at any time prior to obtaining the Purchaser ParentShareholder
 Approval, the Board of Directors of Purchaser Parent may effect a Purchaser Parent Adverse Recommendation Changeif
 the Board of Directors of Purchaser Parent shall have determined in good faith (after consultation with its legal counsel) that thefailure
 to  effect  a  Purchaser  Parent  Adverse  Recommendation  Change  would  be  inconsistent  with  its  fiduciary  duties  underapplicable
 Law. Subject always to applicable Law and the fiduciary duties of the Board of Directors of Purchaser Parent underapplicable Law,
 Purchaser Parent shall promptly notify Seller Parent in the event that it intends to effect a Purchaser Parent AdverseRecommendation
 Change, describing in reasonable detail the underlying facts giving rise to, and the reasons for making, suchPurchaser
 Parent Adverse Recommendation Change and shall provide Seller Parent with a reasonable opportunity to consult withPurchaser Parent in respect of the same.
(g) 
     Notwithstanding  anything  to  the  contrary  contained  in  this  Agreement,  a  Purchaser  Parent  AdverseRecommendation
 Change pursuant to Section  6.24(f) shall  relieve Purchaser Parent of its obligations to convene the PurchaserParent
 Shareholder  Meeting,  to  prepare  and  file  the  Purchaser  Parent  Shareholder  Circular  and  have  the  Purchaser  ParentShareholder
 Circular approved by the UKLA and publish the Purchaser Parent Shareholder Circular and send it to its shareholders,and
 to submit the Purchaser Parent Shareholder Approval Resolution to a vote of the holders of ordinary shares of Purchaser Parentat
 the Purchaser Parent Shareholder Meeting and seek to obtain the Purchaser Parent Shareholder Approval for all purposes of thisAgreement.
(h) 
     As required by Listing Rule 11.1.7R(4), Seller Parent shall not, and shall use reasonable efforts to ensure that itsassociates
 (as defined in the Listing Rules) do not, vote on any resolution(s) proposed at the Purchaser Parent Shareholder Meetingrelating to the Sale and/or other
172

transactions contemplated by this Agreement, in each case to the extent that Seller Parent or any such associate either holds oracquires any shares or other securities in Purchaser Parent.
Section 6.25 
      Resignations .  Seller Parent shall use reasonable best efforts to deliver to Purchaser Parent, at or priorto
 the Closing, the resignations, effective as of the Closing, of all officers and directors of each Conveyed Subsidiary (and eachSubsidiary
 thereof) who will be officers, directors or employees of Seller Parent or any of its Affiliates after the Closing Date fromtheir positions with such Conveyed Subsidiary (or such Subsidiary thereof).
Section 6.26 
      Remedial Action Access .  In respect of its indemnity obligations under Article VII  of this Agreement, each
 Parent shall have the right, but not the obligation, to conduct and control any relevant Remedial Action. If a Parent opts toconduct a Remedial Action at any
 Real Property or Purchaser Real Property, the applicable Parent shall use reasonable best efforts tonot
 unreasonably interfere with Purchaser’s operations, and the Purchaser Indemnified Parties shall, and shall cause their respectiveRepresentatives
 to, reasonably cooperate with the applicable Parent, including by timely filing any required documents with theappropriate
 Governmental Authorities, providing reasonable access to and reasonable use of the subject site, employees, documentsand
 on-site structures, infrastructure and utility services (including electricity, underground piping or wastewater or sewer systems)and/or
 utilities as necessary to perform any required Remedial Action, including reasonable access to install, maintain, replace andoperate
 wells and remove impacted soil and/or groundwater. To the extent required under any Environmental Law, the applicablePurchaser
 Indemnified Parties shall execute, record, obtain and maintain in good standing any authorization, permit or “generatornumber”
 as may be necessary for the proper storage, transportation and/or off-site disposal of any Hazardous Material generated inthe course of the Remedial Action.
 The applicable Purchaser Indemnified Parties shall sign (with respect to the Owned Real Propertyor the Owned Purchaser Real Property) or use commer
cially reasonable efforts to cause to be signed (with respect to the Leased RealProperty
 or the Leased Purchaser Real Property) and record (with respect to the Owned Real Property or the Owned Purchaser RealProperty)
 or use commercially reasonable efforts to cause to be recorded (with respect to the Leased Real Property or the LeasedPurchaser
 Real Property) any deed or other recordable real property instrument reasonably requested by the Parent conducting theRemedial
 Action which is necessary to permit the use of site specific corrective action remedies or remedies based on exposurecontrols as part of such
 Remedial Action; provided  ,  however , that the instrument does not unreasonably interfere with the operationof the Facilities or the Purchaser Fac
ilities or materially impact the value of the Real Property or Purchaser Real Property that are thesubject
 of such Remedial Action. The applicable Purchaser Indemnified Parties agree not to use groundwater under any RealProperty
 or Purchaser Real Property, as applicable, to the extent such restriction is necessary to permit the use of site specificcorrective
 action remedies or remedies based on exposure controls as part of such Remedial Action. All reasonable and documentedout-of-pocket
 costs incurred by the applicable Purchaser Indemnified Parties or their respective Representatives cooperating with orotherwise
 assisting the Parent conducting the Remedial Action pursuant to this Section  6.26 shall  be promptly reimbursed by theParent conducting the Remedial Action.
Section 6.27 
      Acknowledgements .  The Parties acknowledge and agree that certain of the Sellers and the ConveyedSubsidiaries (the “ 
New Subsidiaries  ”) will be established, formed 173

or incorporated, as applicable, following the date of this Agreement and prior to the Closing in connection with the Seller InternalRestructurings,
 and such New Subsidiaries are therefore not in existence as of the date of this Agreement. Accordingly, the Partiesacknowledge
 and agree that, notwithstanding anything in this Agreement to the contrary, Seller Parent makes no representations andwarranties
 with respect to the organization, good standing, authority, capital structure, operations and Liabilities of any such NewSubsidiary
 as of or prior to the date of each respective New Subsidiary’s establishment, formation or incorporation. Seller Parentmay
 at any time prior to the Closing supplement or amend the lists set forth in Section  4.3(b) or  Section 4.3(c) of  the SellerDisclosure
 Letter, solely to reflect any changes pursuant to the Seller Internal Restructurings (including any steps Seller Parent shallundertake to effect the Seller Internal Restructurings) made in accordance with 
(f)(i)  .ARTICLE VII
INDEMNIFICATION
Section 7.1 
      Indemnification by Seller Parent and Purchaser Parent . (a) 
     Subject to the provisions of this Article  VII ,  from and after the Closing, Seller Parent agrees to indemnify andhold
 harmless (x) Purchaser and its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries) (collectively, the “Purchaser
 Indemnified Parties ”)  and (y) Purchaser Parent and its Subsidiaries (other than Purchaser and its Subsidiaries) (the “Purchaser
 Parent Indemnified Parties ”)  from and against any and all Losses (other than Taxes arising out of a Tax Claim, which arethe
 subject of Section  6.5(d) )  that any such Purchaser Indemnified Party or Purchaser Parent Indemnified Party suffers or incurs tothe
 extent resulting from (b)  any Retained Liability, (c)  any breach by any Seller of any of its covenants or agreements contained inthis
 Agreement or in any Ancillary Implementing Agreement or (d)  any breach of any representation or warranty of Seller Parentcontained
 in Article  IV (other  than Section  4.16 )  or in any Ancillary Implementing Agreement, in each case as of the Closing Dateas
 though made on the Closing Date (or, in the case of representations and warranties that address matters only as of a particulardate, as of such date).
(e) 
     Subject to the provisions of this Article  VII ,  from and after the Closing, Purchaser Parent agrees to indemnifyand
 hold harmless (x) the Purchaser Indemnified Parties and (y) Seller Parent and its Subsidiaries (collectively, the “ Seller  ParentIndemnified
 Parties ”)  from and against any and all Losses (other than Taxes arising out of a Tax Claim, which are the subject ofSection 6.5(d) 
) that  any such Purchaser Indemnified Party or Seller Parent Indemnified Party suffers or incurs to the extent resultingfrom 
(f) any Purchaser Parent Retained Liability, (g)  any breach by Purchaser Parent or any of its Affiliates (which shall not includePurchaser
 or  its  Subsidiaries  with  respect  to  post-Closing  covenants  or  agreements)  of  any  of  their  respective  covenants  oragreements
 contained in this Agreement or in any Ancillary Implementing Agreement or (h)  any breach of any representation orwarranty of
 Purchaser Parent contained in Article V  (other than  Section 5.17  )  or in any Ancillary Implementing Agreement, in eachcase
 as of the Closing Date as though made on the Closing Date (or, in the case of representations and warranties that addressmatters only as of a particular date, as of such date).
174

(i)      The Parties acknowledge and agree that indemnification shall not be available with respect to any Loss resultingfrom
 a breach of any representation or warranty contained in this Agreement or in any Ancillary Implementing Agreement to theextent (and only to the extent) the Loss (or related Liabili
ty) was accrued or reserved for in the Financial Statements or the PurchaserFinancial
 Statements, as applicable, or actually taken into account in the Final Closing Statement or the calculation of the FinalBusiness
 Working Capital, the Final Business Net Cash, the Final Purchaser Working Capital or the Final Purchaser Net Cash, asapplicable.
Section 7.2 
      Indemnification by Purchaser . Subject to the provisions of this  Article VII  , from and after the Closing, Purchaser
 agrees to indemnify and hold harmless the Seller Parent Indemnified Parties and the Purchaser Parent Indemnified Parties(collectively,
 the “ Parent  Indemnified Parties ”)  (a) from and against any and all Losses (other than Taxes arising out of a TaxClaim,
 which are the subject of Section 6.5(d)  )  that any such Parent Indemnified Party suffers or incurs to the extent resulting from(i) any
 Assumed Liability or (ii) any Purchaser Liability and (b) from and against any and all Losses (other than Taxes arising out ofa
 Tax Claim, which are the subject of Section  6.5(d) )  any such Parent Indemnified Party suffers or incurs to the extent resultingfrom
 any breach following the Closing by Purchaser of any covenant or agreement expressly made by Purchaser in this Agreementor
 in any Ancillary Implementing Agreement, in its capacity as a Party hereto (and not in its capacity as an Affiliate or Subsidiary ofPurchaser Parent), which covenant or agreement by its terms contemplates actions or imposes obligations following the Closing.
Section 7.3 
      Indemnification Procedures . (a) 
     Any Person entitled to be indemnified under this Article  VII (the  “ Indemnified Party ”)  shall promptly givewritten
 notice to the Party from whom indemnification may be sought (the “ Indemnifying  Party ”)  and each other Party hereto ofany
 pending or threatened Action against the Indemnified Party that has given or would reasonably be expected to give rise to suchright
 of indemnification with respect to such Action (a “ Third  Party Claim ”),  indicating, with reasonable specificity, and based onthe
 facts then known to the Indemnified Party, the nature of such Third Party Claim, the basis therefor, a copy of any documentationreceived from the third party, the
 amount and calculation of the Losses for which the Indemnified Party is entitled to indemnificationunder this 
Article VII  (and  a good faith estimate of any such future Losses relating thereto), and the provisions of this Agreement orany
 Ancillary Implementing Agreement in respect of which such Losses shall have occurred, and the Indemnified Party shallpromptly
 deliver to the Indemnifying Party any information or documentation related to the foregoing reasonably requested by theIndemnifying
 Party. A failure by the Indemnified Party to give notice in a timely manner pursuant to this Section  7.3(a) shall  notlimit
 the obligations of the Indemnifying Party under this Article  VII ,  except (i) to the extent such Indemnifying Party is actuallyprejudiced
 thereby and (ii) as provided by Section  7.4 (unless,  with respect to indemnification pursuant to Section  7.1(b) or  Section7.2 
,  in  the  case  of  the  foregoing  clauses  (i)  and  (ii),  Purchaser  Parent  has  Intentionally  Breached  (or  caused  Purchaser  toIntentionally Breach) its obligations pursuant to the immediately foregoing sentence).
(b) 
     With respect to any Third Party Claim, the Indemnifying Party under this Article  VII shall  have the right, butnot the obligation, to assume the defense, at its own expense
175

and by counsel of its own choosing, of such Third Party Claim and any Third Party Claims related to the same or a substantiallysimilar
 set of facts; provided  that  the Indemnifying Party shall not be entitled to assume the defense of such Third Party Claim, andshall
 pay the reasonable fees and expenses of counsel retained by the Indemnified Party, if such Third Party Claim seeks aninjunction or
 equitable relief against the Indemnified Party or is a criminal Action. If the Indemnifying Party so undertakes to defendany
 such Third Party Claim, it shall notify the Indemnified Party of its intention to do so, and the Indemnified Party shall cooperatefully
 with the Indemnifying Party and its counsel in the defense against, and settlement of, any such Third Party Claim; provided  , however 
,  that the Indemnifying Party shall not settle any such Third Party Claim without the written consent of the IndemnifiedParty
 (not to be unreasonably withheld, conditioned or delayed) unless such settlement does not involve any injunctive relief againstor
 any finding or admission of any violation of Law or wrongdoing by the Indemnified Party, and any money damages are bornesolely
 by the Indemnifying Party (other than solely with respect to the Deductible, to the extent such damages would constituteLosses
 to which such Deductible would be applicable); provided  ,  further , that if the Indemnifying Party is Purchaser, Purchasershall not settle any such
 Third Party Claim without the written consent of both Parents (not to be unreasonably withheld, conditionedor delayed). Subject to the foregoing, the
 Indemnified Party shall have the right to employ separate legal counsel and to participate inbut
 not control the defense of such Action at its own cost and expense; provided  that,  subject to the provisions of this Article  VII , the
 Indemnifying Party shall bear the reasonable fees of one firm of legal counsel (and one additional firm of legal counsel in eachjurisdiction
 implicated in such Action) representing all Indemnified Parties in such Action and all related Actions, if, but only if, thedefendants
 in such Action include both an Indemnified Party and the Indemnifying Party, and such Indemnified Party shall havereasonably concluded, based on the advice of legal counsel, that there is a conflict of interest between the Indemnifying Party and the
Indemnified
 Party with respect to such Action. In any event, the Indemnified Party shall cause its legal counsel to cooperate with theIndemnifying
 Party and its legal counsel. No Indemnified Party may settle any Third Party Claim without the written consent of theIndemnifying
 Party (not to be unreasonably withheld, conditioned or delayed) and, if the Indemnified Party is Purchaser, the writtenconsent
 of both Parents (not to be unreasonably withheld, conditioned or delayed). If the Indemnifying Party does not assume thedefense
 of a Third Party Claim, it shall nevertheless be entitled to participate in the defense of such Action at its own cost andexpense, and the Indemnified Party shall cooperate with the Indemnifying Party and its counsel in the defense against, and settlement
of, any such Third Party Claim.
(c) 
     In the event that any Indemnified Party has or may have an indemnification claim against any IndemnifyingParty
 under this Article  VII that  does not involve a Third Party Claim, the Indemnified Party shall promptly give written noticethereof to the Indemnifying Party indicating, with reasonable specificity, and based on the facts then known to the Indemnified Party,
the
 nature of such claim, the basis therefor, the amount and calculation of the Losses for which the Indemnified Party is entitled toindemnification
 under this Article  VII (and  a good-faith estimate of any such future Losses relating thereto), and the provisions ofthis
 Agreement or any Ancillary Implementing Agreement in respect of which such Losses shall have occurred, and the IndemnifiedParty
 shall promptly deliver to the Indemnifying Party any information or documentation related to the foregoing reasonablyrequested
 by the Indemnifying Party. A failure by the Indemnified Party to give notice in a timely manner pursuant to thisSection 7.3(c) 
shall not limit the obligations of 176

the Indemnifying Party under this Article VII  , except (i) to  the extent such Indemnifying Party is actually prejudiced thereby and (ii)as
 provided by Section  7.4 (unless,  with respect to indemnification pursuant to Section  7.1(b) or  Section 7.2 ,  in the case of theforegoing
 clauses  (i)  and  (ii),  Purchaser  Parent  has  Intentionally  Breached  (or  caused  Purchaser  to  Intentionally  Breach)  itsobligations
 pursuant to the immediately foregoing sentence). If the Indemnifying Party disputes its liability with respect to suchclaim,
 the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute and, ifnot
 resolved  through  negotiations  within  thirty  (30)  days  of  the  receipt  of  the  notice  of  such  indemnification  claim  by  theIndemnifying
 Party, such dispute shall be resolved by litigation in the appropriate court of competent jurisdiction set forth inSection
 10.10 ;  provided that  if the Indemnifying Party or the Indemnified Party is Purchaser, the Indemnifying Parties and theIndemnified
 Party shall not agree to settle or resolve any such claim with the written consent of both Parents (not to be unreasonablywithheld, conditioned or delayed).
Section 7.4 
      Expiration .  If the Closing has occurred, all covenants and agreements made herein or in any AncillaryImplementing
 Agreement which, in each case, by their terms contemplate actions or impose obligations following the Closing shallsurvive
 the Closing and remain in full force and effect in accordance with their terms; provided  that,  other than indemnificationobligations
 in respect of Taxes (the survival of which shall be governed exclusively by Section  6.5(l) ),  (a) the obligations ofPurchaser to assume, and to indemnify
 and hold harmless the Seller Parent Indemnified Parties and the Purchaser Parent IndemnifiedParties
 for, the Assumed Liabilities and the Purchaser Liabilities, (b) the obligations of Seller Parent to retain, and indemnify andhold
 harmless the Purchaser Indemnified Parties and the Purchaser Parent Indemnified Parties for, the Retained Liabilities and (c)the
 obligations of Purchaser Parent to retain, and indemnify and hold harmless the Purchaser Indemnified Parties and the SellerParent Indemnified Parties for, the Purchaser Parent Retained Liabilities, shall in each case survive the Closing indefinitely. All other
covenants
 and agreements contained herein or in any Ancillary Implementing Agreement shall survive the Closing and shallterminate
 and expire on the twelve (12) month anniversary of the Closing Date (other than the covenants and agreements set forththerein
 which by their terms contemplate actions or impose obligations following the Closing, which shall survive the Closing andremain
 in full force and effect in accordance with their terms). All representations and warranties made herein or in any AncillaryImplementing
 Agreement,  and  all  indemnification  obligations  under Section  7.1 with  respect  to  any  such  representations  orwarranties,
 shall terminate and expire on the fifteen (15) month anniversary of the Closing Date; provided  ,  however ,  that theFundamental
 Seller Parent Representations and the Fundamental Purchaser Parent Representations shall terminate and expire on thethree
 (3) year anniversary of the Closing Date. No Person shall be entitled to indemnification, and no Action seeking to recoverTaxes,
 Losses  or  other  relief  shall  be  commenced  or  maintained,  with  respect  to  any  breach  of  any  covenants,  agreements,representations
 or warranties contained in this Agreement or any Ancillary Implementing Agreement after the date on which suchcovenant,
 agreement, representation or warranty shall terminate pursuant to this Section  7.4 or  Section 6.5(l) ,  unless prior to suchtermination
 date a claim for indemnification with respect thereto has been made by written notice in accordance with Section 7.3  (in the case
 of Losses or other relief) or Section 6.5(d)  (in the  case of Taxes), in which case such claim for indemnification shall surviveuntil finally resolved in accordance with this Agreement.
177

Section 7.5       Certain Limitations . (a) 
     Notwithstanding the other provisions of this Agreement, neither Seller Parent nor Purchaser Parent, asapplicable,
 shall have any indemnification obligations (i) under Section  7.1(a)(iii) or  Section 7.1(b)(iii) ,  as applicable, for any Loss(together
 with any and all other Losses resulting from the same facts or circumstances) that is less than $20,000,000 (the “ De Minimis 
Claim  Threshold ”),  or (ii) under Section  7.1(a)(iii) or  Section 7.1(b)(iii) (except  with respect to any breach of anyFundamental
 Seller Parent Representation or Fundamental Purchaser Parent Representation) for any Loss that is equal to or greaterthan
 the De Minimis Claim Threshold, unless the aggregate amount of all Losses for which indemnification is available under theapplicable provision
 exceeds $200,000,000 (the “ Deductible  ”),  in which event the Indemnifying Party shall be required to pay onlythe
 amount of such Losses that exceeds the Deductible but only up to a maximum amount in respect of all such Losses (withoutgiving effect to the Deductible) in the aggregate of $2,000,000,000.
Section
 7.6       Losses Net of Insurance, Etc. The  amount of any Tax or Loss for which indemnification is providedunder
 Section 6.5(d), Section 7.1 or Section 7.2 shall be net of (i) any amounts recovered by the applicable Indemnified Partypursuant
 to any indemnification by or indemnification agreement with any third party, and (ii) any insurance proceeds or other cashreceipts
 or sources of reimbursement received with respect to such Tax or Loss, and (iii) in the case of Purchaser Parent as theIndemnifying Party, any amounts recovered by the
 Purchaser pursuant to the Contribution Agreement, dated as of April 22, 2014, byand among Purchaser Parent, Purchaser and Novartis
 AG, as amended (the source of any such amounts referred to in clause (i)  or  (ii),
 a “ Collateral Source ”),  in each case net of any Taxes imposed or reasonable out-of-pocket costs incurred in connection with thecollection
 of such insurance proceeds, cash receipts or sources of reimbursement. The applicable Indemnified Party shall use itscommercially reasonable efforts
 to seek recovery for such Taxes or Losses from all Collateral Sources. The Indemnifying Party mayrequire
 an Indemnified Party to assign to the Indemnifying Party the rights to seek recovery from any Collateral Sources (to theextent
 such rights are capable of assignment); provided  that  the Indemnifying Party will then be responsible for pursuing such claimat
 its own expense; provided  ,  further , that the Indemnified Party shall cooperate (at the Indemnifying Party’s expense) with theIndemnifying
 Party to seek such recovery. If the amount to be netted hereunder from any payment required under Section  6.5(d) or this 
Article VII is  determined  after  payment  by the Indemnifying  Party of any amount  otherwise  required  to be paid to anIndemnified
 Party pursuant to Section  6.5(d) or  this Article VII ,  the Indemnified Party shall repay to the Indemnifying Party,promptly
 after such determination, any amount that the Indemnifying Party would not have had to pay pursuant to Section  6.5(d) or this 
Article VII had such determination been made at the time of such payment. Section 7.7 
      No Right of Set-Off .  No Party shall have any right to set off any Taxes or Losses under Section 6.5(d) and
 this Article VII against  any payments to be made by such Party pursuant to this Agreement or any other agreement among theParties, including any Ancillary Agreement.
Section
 7.8       Materiality .  For purposes of Tax Claims subject to Section  6.5 and  of this Article  VII ,  no effect shallbe given to any qualification in the relevant representations and
178

warranties as to “material,” “materiality,” “Material Adverse Effect” or “Purchaser Material Adverse Effect” for purposes ofdetermining the amount of any Loss suffered or
 incurred by an Indemnified Party, but all such qualifications shall be given effect forpurposes of determining whether there has been a breach or inaccuracy of any representation or warranty.
Section 7.9 
      Mitigation; Other Limitations . (a) 
     Each of Seller Parent, Purchaser Parent, Purchaser and each Indemnified Party shall take, and cause itsAffiliates
 to take, all commercially reasonable steps to mitigate any Tax or Loss upon becoming aware of any event which wouldreasonably be expected to, or does, give rise thereto.
(b) 
     Notwithstanding anything to the contrary contained in this Agreement, the  obligations to  indemnify under thisAgreement,
 and the amount of any Loss for which indemnification is provided under Section  7.1 ,  shall be subject to the followinglimitations:
(i) 
     With respect to any Remedial Action, the applicable Indemnifying Party shall only be liable to the extentsuch
 Remedial Action is conducted in the Most Cost-Effective Manner. Regardless of whether any IndemnifyingParty
 or any Indemnified Party conducts any such Remedial Action, the applicable Indemnifying Party shall not beresponsible
 for  any  operation  and  maintenance  with  respect  to  any  such  institutional  or  engineering  controlssubsequent to completion of their initial installation at the applicable Real Property or Purchaser Real Property subject
to
 such Remedial Action, and such post-installation costs shall not be subject to claims for indemnification orreimbursement under this 
Article VII  . (ii) 
     With respect to any particular Environmental Liability, an Indemnifying Party’s obligations forindemnification
 or reimbursement in respect of such Environmental Liability, shall be deemed satisfied, completedand
 fully discharged upon the relevant Remediation Completion Date, and the Indemnifying Party shall no longer beresponsibl
e for ongoing obligations and Liabilities with respect to such Environmental Liabilities to the extent relatedto
 the Real Property (or Facilities thereon) or Purchaser Real Property (or Purchaser Facilities thereon), including theoperation and maintenance of any institutional and engineering controls.
(iii) 
     An Indemnifying Party shall not have any indemnification obligations for Losses relating to anyEnvironmental
 Liabilities to the extent such Losses relate to, result from, or arise out of any (1) exacerbation of anexisting
 condition due to a negligent or intentional act or omission by or on behalf of the Indemnified Party or itsAffiliates,
 (2) environmental investigation, drilling, sampling, testing or monitoring of any soil, surface water orgroundwater, by or on behalf of the applicable Indemnified Party or its Affiliates, after the Closing Date (except to the
extent
 required  by  Environmental  Laws  or  Environmental  Permits  or  a  Governmental  Authority;  conducted  inresponse
 to facts or conditions potentially indicating a material risk to health or the environment; conducted inconnection with defending
179

against or otherwise responding to a Third Party Claim; conducted to comply with the requirements of any RealProperty
 Lease or Purchaser Real Property Lease; reasonably and independently requested in writing by a third partyin
 connection with a sale, lease, sublease, financing, mortgage or other transaction involving any Real Property,Purchaser
 Real Property, Facility or Purchaser Facility as part of the third party’s normal business practices; orconducted
 consistent with industry practice in connection with the ordinary course of business and the IndemnifiedParty’s
 bona fide construction, renovation, demolition, removal, repair or expansion of improvements at any RealProperty,
 Purchaser Real Property, Facility or Purchaser Facility); or (3) decommissioning, closure or voluntaryshutdown
 of any Real Property, Purchaser Real Property, Facility or Purchaser Facility by or on behalf of theIndemnified Party or its Affiliates.
(c) 
     Notwithstanding anything to the contrary contained in this Agreement, in no event shall any Party be entitled toduplicative
 recovery directly or indirectly for the same Loss, including, in the case of either Parent (or any of their respectiveSubsidiaries),
 in their respective capacities as direct or indirect equity holders of Purchaser post-Closing; it being understood that tothe
 extent a Loss is suffered in the applicable Parent’s (or any of its respective Subsidiaries’) capacity as direct or indirect equityholders of
 Purchaser post-Closing, the Purchaser Parent Indemnified Parties and the Seller Parent Indemnified Parties, as applicable,shall
 only be entitled to directly seek indemnification or recover for such Loss under Section  7.1(a)(ii) or  Section 7.1(a)(iii) (in the case
 of the Purchaser Parent Indemnified Parties) or under Section  7.1(b)(ii) or  Section 7.1(b)(iii) (in  the case of the Seller ParentIndemnified Parties) to
 the extent such Loss cannot be remedied by means of an indemnification claim or recovery by Purchaser andits Subsidiaries under 
Section 7.1(a)  or  Section 7.1(b) , respectively. Section
 7.10       Sole Remedy/Waiver .  Except with respect to claims seeking specific performance or other equitablerelief
 with respect to covenants or agreements to be performed after the Closing pursuant to this Agreement, and except in the caseof
 fraud  with  respect  to  the  representations,  warranties,  covenants  and  agreements  contained  in  this  Agreement,  the  Partiesacknowledge
 and agree that the remedies provided for in Section  2.9 ,  Section 6.5 and  this Article VII shall  be the Parties’ sole andexclusive
 remedy, from and after the Closing, with respect to the subject matter of this Agreement or any of the AncillaryImplementing Agreements
 (but not with respect to any claims under the other Ancillary Agreements, which shall be governed by theterms
 thereof). In furtherance of the foregoing, and except as set forth in the exceptions set forth in the preceding sentence andexcept
 as provided in Section  2.9 ,  Section 6.5 and  this Article VII ,  from and after the Closing, the Parties hereby waive, on behalfof
 themselves and their Affiliates, to the fullest extent permitted by applicable Law, any and all other rights, claims and causes ofaction
 (including rights of contribution, if any) known or unknown, foreseen or unforeseen, which exist or may arise in the future,that
 they may have against the Sellers or any of their Affiliates, or Purchaser Parent or any of its Affiliates (including Purchaser andits
 Subsidiaries), as the case may be, in connection with the transactions contemplated by this Agreement or any of the AncillaryImplementing
 Agreements (but not with respect to any rights, claims or causes of action under the other Ancillary Agreementswhich,
 in each case, shall be governed by the terms thereof), whether arising under or based upon breach of warranty or contract(including for breach of any representation, warranty, covenant or
180

agreement), tortious conduct (including negligence), any Law (including any such Law relating to environmental matters (includingEnvironmental
 Laws) or arising under or based upon any securities Law, common law or otherwise) or otherwise. Each Party shallcause
 its respective Affiliates party to an Ancillary Implementing Agreement not to assert any claims or causes of action under suchAncillary
 Implementing Agreement, and all such claims shall be asserted only under this Agreement. Without limiting the generalityof
 the foregoing, in no event shall any Party, its Affiliates, successors or permitted assigns be entitled to claim or seek rescission ofthe transactions contemplated by this Agreement and the Ancillary Agreements.
Section
 7.11       Indemnification Payments .  A Party shall not be deemed to have suffered a Loss or Tax with respectto an
 item to the extent such Party was actually compensated therefor by reason of an increase in the amount otherwise paid to it or areduction in the amount otherwise paid by it pursuant to 
Section 2.9  . ARTICLE VIII
CONDITIONS TO CLOSING
Section
 8.1       Conditions to the Obligations of the Parties .  The respective obligations of each of the Parties toconsummate
 the Closing shall be subject to the satisfaction or written waiver (to the extent permitted by Law) by Purchaser Parentand Seller Parent, at or prior to the Closing, of each of the following conditions precedent:
(a) 
     There shall not be any Governmental Order in effect issued by a Governmental Authority of competentjurisdiction that enjoins or otherwise prohibits the Closing.
(b) 
     (i) The waiting period required under the HSR Act shall have expired or been terminated and any agreementbetween
 Purchaser Parent or Purchaser and a competent Governmental Antitrust Authority in a jurisdiction set forth on Annex  Centered
 into in accordance with this Agreement to delay consummation of the Closing has expired or been terminated; and (i) allother
 Approvals under Antitrust Laws of the jurisdictions set forth on Annex  C required  to be obtained for the consummation of theClosing shall have been obtained.
(c) 
     The Purchaser Parent Shareholder Approval shall have been obtained.Section
 8.2       Conditions to the Obligations of Purchaser and Purchaser Parent .  The obligation of Purchaser Parentand
 Purchaser to consummate the Closing shall be subject to the satisfaction, or the written waiver (to the extent permitted by Law)by Purchaser Parent, at or prior to the Closing, of each of the following further conditions precedent:
(a) 
     The representations and warranties of Seller Parent contained in Article  IV (other  than as set forth in thefollowing
 two sentences) shall be true and correct (without giving effect to any “material”, “materiality” or “Material AdverseEffect” qualifications
 set forth therein) as of the Closing Date as though made on the Closing Date (or, in the case of representationsand
 warranties that address matters only as of a particular date, as of such date), except to the extent that failures to be true andcorrect would not, individually or in the aggregate, have a Material
181

Adverse Effect. The Fundamental Seller Parent Representations shall be true and correct in all material respects as of the ClosingDate
 as though made on the Closing Date (or, in the case of representations and warranties that address matters only as of aparticular
 date, as of such date). The representation and warranty of Seller Parent set forth in Section 4.7(a)  shall  be true and correctin all respects as of the Closing Date as though made on the Closing Date.
(b) 
     Seller Parent shall have performed and complied in all material respects with the agreements and covenantsrequired by this Agreement to be performed or complied with by Seller Parent on or prior to the Closing Date.
(c) 
     Seller Parent shall have delivered to Purchaser Parent a certificate signed by a duly authorized officer of SellerParent to the effect that the conditions set forth in 
Sections 8.2(a)  and  8.2(b) have been satisfied.Section
 8.3       Conditions to the Obligations of Seller Parent .  The obligation of Seller Parent to consummate theClosing
 shall be subject to the satisfaction, or the written waiver (to the extent permitted by Law) by Seller Parent, at or prior to theClosing, of each of the following further conditions precedent:
(a) 
     The representations and warranties of Purchaser Parent contained in Article  V (other  than as set forth in thefollowing
 two sentences) shall be true and correct (without giving effect to any “material”, “materiality” or “Purchaser MaterialAdverse
 Effect” qualifications set forth therein) as of the Closing Date as though made on the Closing Date (or, in the case ofrepresentations
 and warranties that address matters only as of a particular date, as of such date), except to the extent that failures tobe
 true and correct would not, individually or in the aggregate, have a Purchaser Material Adverse Effect. The FundamentalPurchaser
 Parent Representations shall be true and correct in all material respects as of the Closing Date as though made on theClosing Date (or, in the case of represen
tations and warranties that address matters only as of a particular date, as of such date), otherthan
 the representations and warranties of Purchaser Parent contained in Section  5.3(a) ,  which shall be true and correct in allrespects, other than 
de
minimis
 inaccuracies (that do not impact the issued share capital of Purchaser following the Closing), as of the Closing
 Date as though made on the Closing Date (or, in the case of representations and warranties that address matters only as of aparticular
 date, as of such date). The representation and warranty of Purchaser Parent set forth in Section  5.7(a) shall  be true andcorrect in all respects as of the Closing Date as though made on the Closing Date.
(b) 
     Purchaser Parent and Purchaser shall have performed and complied in all material respects with the agreementsand
 covenants required by this Agreement to be performed or complied with by Purchaser Parent or Purchaser on or prior to theClosing Date.
(c) 
     Purchaser Parent shall have delivered to Seller Parent a certificate signed by a duly authorized officer ofPurchaser Parent to the effect that the conditions set forth in 
Sections 8.3(a)  and  8.3(b) have been satisfied.Section
 8.4       Frustration of Closing Conditions .  Without limiting Purchaser Parent’s rights under Section  6.24(f)and 
Section 6.24(g) , no Party may rely as a basis for terminating 182

this Agreement on the failure of any condition set forth in this Article  VIII to  be satisfied if such failure was caused by such Party’sor
 its Affiliates’ failure to act in good faith or to use the efforts required under this Agreement to cause the Closing to occur,including as required in 
Section 6.3  . ARTICLE IX
TERMINATION
Section 9.1 
      Termination . This Agreement may be terminated at any time prior to the Closing: (a) 
     by written agreement of Purchaser Parent and Seller Parent;(b) 
     by either Purchaser Parent or Seller Parent, by giving written notice of such termination to the other Party, if theClosing
 shall not have occurred on or prior to the close of business (New York time) on September 30, 2019 (as it may be extendedbelow,
 the “ Outside  Date ”);  provided that  if the conditions set forth in Sections  8.1(a) (where  the relevant Governmental Orderarises
 from or relates to Antitrust Laws) or 8.1(b)  shall not have been satisfied or waived by September 30, 2019, then eitherPurchaser
 Parent or Seller Parent may extend the Outside Date to the close of business (New York time) on December 31, 2019 byproviding
 written notice thereof to the other Party prior to the initial Outside Date; provided  ,  further , that following such extensionif
 the conditions set forth in Sections  8.1(a) (where  the relevant Governmental Order arises from or relates to Antitrust Laws) or8.1(b) 
shall not have been satisfied or waived by December 31, 2019, then either Purchaser Parent or Seller Parent may extend theOutside Date to the close of business (New York time) on March 31, 2020 by providing written notice thereof to the other Party prior
to the Outside Date as extended pursuant to the immediately preceding proviso; 
provided  ,  however , that (without limiting PurchaserParent’s
 rights under Section 6.24(f)  and  Section 6.24(g) )  the right to terminate this Agreement pursuant to this Section 9.1(b)  shall not
 be available to (i) any Party whose action or failure to fulfill any obligation under this Agreement, or, in the case of PurchaserParent,
 if the action of Purchaser or failure by Purchaser to fulfill any obligation under this Agreement, has been the cause of, orresulted in, the failure of the Closing to occur on or before such date or (ii) any Party during the pendency of any Action by any other
Party for specific performance of this Agreement;
(c) 
     by Purchaser Parent upon written notice to Seller Parent, if there shall have been a material breach of any of therepresentations,
 warranties, agreements or covenants set forth in this Agreement on the part of Seller Parent which has rendered thesatisfaction
 of the conditions set forth in Section  8.2(a) or  Section 8.2(b) incapable  of fulfillment and such breach is  incapable ofbeing
 cured prior to the Outside Date; provided  that  Purchaser Parent has given written notice to Seller Parent of such breach statingPurchaser
 Parent’s intention to terminate this Agreement pursuant to this Section  9.1(c) and  the basis for such termination at leastforty-five (45)
 days prior to such termination ;  provided ,  further , that the right to terminate this Agreement under this Section 9.1(c) shall
 not be available to Purchaser Parent if it or Purchaser has materially breached any representation, warranty, covenant or otheragreement
 contained  herein  in  a  manner  that  has  rendered  the  satisfaction  of  the  conditions  set  forth  in Section  8.3(a) or Section 8.3(b) 
incapable of fulfillment; 183

(d)      by Seller Parent upon written notice to Purchaser Parent, if there shall have been a material breach of any of therepresentations,
 warranties, agreements or covenants set forth in this Agreement on the part of Purchaser Parent or Purchaser whichhas rendered
 the satisfaction of the conditions set forth in Section 8.3(a)  or  Section 8.3(b) incapable of  fulfillment and such breach is incapable
 of being cured prior to the Outside Date; provided  that  Seller Parent has given written notice to Purchaser Parent of suchbreach
 stating Seller Parent’s intention to terminate this Agreement pursuant to this Section 9.1(d)  and the  basis for such terminationat
 least forty-five (45) days prior to such termination ;  provided ,  further , that the right to terminate this Agreement under thisSection
 9.1(d) shall  not be available to Seller Parent if it has materially breached any representation, warranty, covenant or otheragreement
 contained  herein  in  a  manner  that  has  rendered  the  satisfaction  of  the  conditions  set  forth  in Section  8.2(a) or Section 8.2(b) 
incapable of fulfillment; (e) 
     by either Seller Parent or Purchaser Parent, by giving written notice of such termination to the other Party, ifany
 Governmental Authority of competent jurisdiction shall have issued a Governmental Order permanently enjoining or otherwiseprohibiting
 the Closing and such Governmental Order shall have become final and nonappealable; provided  that  the right toterminate
 this Agreement pursuant to this Section  9.1(e) shall  not be available to any Party whose action or failure to fulfill anyobligation
 under this Agreement, or, in the case of Purchaser Parent, if the action of Purchaser or failure by Purchaser to fulfill anyobligation under this Agreement, has been the cause of, or resulted in, the issuance of such Governmental Order;
(f) 
     by either Seller Parent or Purchaser Parent, by giving written notice of such termination to the other Party, if thePurchaser Parent
 Shareholder Approval shall not have been obtained at the Purchaser Parent Shareholder Meeting at which a vote onthe Sale and the transactions contemplated by this Agreement is taken; or
(g) 
     by Seller Parent upon written notice to Purchaser Parent if there shall have been a Purchaser Parent AdverseRecommendation Change.
Section 9.2 
      Effect of Termination . (a) 
     In the event of termination of this Agreement pursuant to Section 9.1  ,  written notice thereof shall forthwith begiven
 to the other Parties, and, except as set forth in this Section 9.2  ,  this Agreement shall terminate and be void and have no effectand
 the transactions contemplated hereby shall be abandoned, without any liability or obligation on the part of any Party or itsrespective Affiliates, directors, officers or employees; 
provided  that if such termination shall res ult from (i) the Intentional Breach bya
 Party of any representation, warranty, covenant, or agreement in this Agreement, or (ii) fraud with respect to the representations,warranties, covenants
 and agreements contained in this Agreement, such Party shall be fully liable to the other Parties for any and alldamages,
 expenses (including reasonable attorneys’ fees and expenses), losses or liabilities of any nature and kind incurred orsuffered by the other Parties or their
 Affiliates as a result of such Intentional Breach or fraud. Notwithstanding the foregoing, nothingshall
 relieve any Party from reimbursement of the costs and expenses (and, as applicable, indemnification obligations) of any otherParty
 and  its  Affiliates  pursuant  to  any  provision  of  this  Agreement  that,  by  its  express  terms,  requires  reimbursement,indemnification
 or similar obligations by such Party. In the event of termination of this Agreement prior to the Closing pursuant toSection 9.1 
, the Parties shall, and 184

shall cause their applicable Affiliates to, take all action necessary to terminate any Ancillary Agreements, including any LocalImplementing Agreements, entered into as of or prior to such time.
(b) 
     Without limiting Section  9.2(a) ,  in the event of a termination of this Agreement pursuant to (i)  Section 9.1(b) (if and only if terminated at a time when the Purchaser Parent Shareholder Approval has not been obtained), (ii) 
Section 9.1(f)  or (iii) Section
 9.1(g) ,  Purchaser Parent shall pay to Seller Parent, by way of compensation, $900,000,000 (the “ Purchaser  Parent Termination Fee 
”) within one (1)  Business Day after the date of the termination of this Agreement by Seller Parent and, in the eventof
 a termination by Purchaser Parent, concurrently with, and as a condition precedent to, the termination of this Agreement, by wiretransfer of
 immediately available funds to an account designated in writing by Seller Parent; provided  that Purchaser Parent shall not be
 required to pay the Purchaser Parent Termination Fee on more than one occasion. Purchaser Parent acknowledges that theagreements
 contained in this Section 9.2(b)  are  an integral part of the transactions contemplated by this Agreement and that, withoutthese
 agreements, Seller Parent would not enter into this Agreement. Accordingly, if Purchaser Parent fails promptly to pay anyamount due pursuant to this 
Section 9.2(b)  , Purchaser  Parent shall also pay any reasonable and documented costs, fees and expensesincurred
 by Seller Parent (including reasonable attorneys’ fees) in connection with a legal action to enforce this Agreement thatresults
 in a judgment for such amount or any portion thereof against Purchaser Parent or its Affiliates. Any amount not paid whendue
 pursuant to this Section 9.2(b)  shall  bear interest from the date such amount is due until the date paid at a rate equal to the primerate
 as published in The 
Wall
Street
Journal
,  Eastern
Edition
,  in effect on the date such amount is due, plus three percent (3%).Notwithstanding
 anything to the contrary in this Agreement, except in the event of (i) an Intentional Breach by Purchaser Parent orPurchaser
 of any representation, warranty, covenant, or agreement in this Agreement or (ii) Purchaser Parent’s or Purchaser’s fraudwith
 respect  to  the  representations,  warranties,  covenants  and  agreements  contained  in  this  Agreement,  if  this  Agreement  isterminated
 in circumstances requiring the payment of the Purchaser Parent Termination Fee to Seller Parent, the payment in full ofthe
 Purchaser Parent Termination Fee by Purchaser Parent to Seller Parent, together with any interest, costs, fees or expensespayable,
 in each case in accordance with this ‎ Section  9.2(b) ,  shall be the sole and exclusive remedy of Seller Parent and all of itsAffiliates
 against Purchaser Parent and its Affiliates, and upon such payment, except in the event of such an Intentional Breach orfraud,
 none of Purchaser Parent or any of its Affiliates shall have any further liability or obligation (whether at law or equity, incontract,
 in tort or otherwise) to Seller Parent or any of its Affiliates, and their respective directors, officers and employees or otherRepresentatives,
 relating to or arising out of this Agreement, any Ancillary Agreement or any of the transactions contemplatedhereby or thereby.
(c) 
     Notwithstanding the termination of this Agreement, the following Sections of this Agreement shall remain infull
 force and effect: Section  6.1(b) (Information  and Documents), Section  9.1 (Termination),  Section  9.2 (Effect  of Termination)and 
Article X (Miscellaneous). (d) 
     If this Agreement is terminated in accordance with Section 9.1  , the Confidentiality Agreement and Clean Team Agreement
 shall each remain in full force and effect for the term provided for therein; except that Seller Parent and Purchaser Parentagree that the term
185

of the Confidentiality Agreement (including the employee non-solicitation prohibition therein) shall be extended (if a shorter termwould
 otherwise remain) to a period of two (2) years from the date of such termination and this Agreement shall be the requisitemutual written consent amending such Confidentiality Agreement.
ARTICLE X
MISCELLANEOUS
Section 10.1 
      Notices . All notices or other communications hereunder shall be deemed to have been duly given andmade
 if in writing and (a) when served by personal delivery upon the Party for whom it is intended, (b) one (1) Business Dayfollowing
 the day sent by overnight courier, return receipt requested, (c) when sent by facsimile, provided  that  the facsimile ispromptly
 confirmed, or (d) when sent by e-mail, provided  that  a copy of the same notice or other communication sent by e-mail isalso sent by overnight courier, return receipt
 requested, personal delivery, or facsimile as provided herein, on the same day as such e-mail
 is sent, in each case to the Person at the address, facsimile number or e-mail address set forth below, or such other address,facsimile number or e-mail address as may be designated in writing hereafter, in the same manner, by such Person:
To any Seller:
 
Pfizer Inc.235 East 42nd Street
New York, NY 10017 
   Attn: General Counsel
with a copy (which shall not constitute notice) to:
 
Wachtell, Lipton, Rosen & Katz51 West 52nd Street
New York, NY 10019 
   Attn: Edward D. Herlihy
   David K. Lam
   Jacob A. Kling 
E-mail: EDHerlihy@wlrk.com
   DKLam@wlrk.com
   JAKling@wlrk.com 
Fax: (212) 403-2000
186

To Purchaser Parent or Purchaser: 
GlaxoSmithKline Plc980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Attn: General Counsel Consumer Healthcare
with a copy (which shall not constitute notice) to:
 
Kirkland & Ellis LLP601 Lexington Avenue
New York, NY 10022 
   Attn: Daniel E. Wolf
   Eric L. Schiele, P.C.
   Claire E. James
   Patrick Jacobs
E-mail: daniel.wolf@kirkland.com
   eric.schiele@kirkland.com
   claire.james@kirkland.com
   patrick.jacobs@kirkland.com 
Fax: (212) 446-4900
Section
 10.2       Amendment; Waiver .  Any provision of this Agreement may be amended or waived if, and only if,such amendment
 or waiver is in writing and signed, in the case of an amendment, by the Parties hereto, or in the case of a waiver, bythe
 Party against whom the waiver is to be effective. No failure or delay by any Party in exercising any right, power or privilegehereunder
 shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercisethereof or the exercise of any other right, power or privilege.
Section 10.3 
      Assignment .  (a) No Party may assign any of its rights or obligations under this Agreement, includingby
 sale of stock, operation of Law in connection with a merger or sale of all or substantially all of the assets of such Party, withoutthe prior written consent of the other Parties.
(a) 
     Notwithstanding the foregoing and subject to Section  6.5(f) ,  Purchaser shall be entitled to designate one ormore
 of its Affiliates that are directly or indirectly wholly owned by Purchaser (each, a “ Purchaser  Designated Affiliate ”)  to be thepurchaser
 or transferee of some or all of the Shares or the other Purchased Assets and be the entity assuming some or all of theAssumed
 Liabilities (and to be a counterparty to one or more of the Ancillary Agreements), provided  that  no such designation(i)
 shall release Purchaser from its obligations under this Agreement or (ii) would reasonably be expected to restrict or delayconsummation
 of the transactions contemplated hereby or by the Ancillary Agreements in any material respect. Purchaser shall beresponsible
 for and shall pay or reimburse the Sellers for any Taxes and other reasonable out-of-pocket costs and expenses to theextent arising out of or resulting from the substitution of a Purchaser Designated Affiliate
187

(other than a Purchaser Designated Affiliate organized under the Laws of or Tax resident in the United States or the UnitedKingdom)
 for Purchaser as the purchaser or transferee of any of the Shares or the other Purchased Assets, or as the entity assumingsome
 or all of the Assumed Liabilities, or as a counterparty to one or more of the Ancillary Agreements, in accordance with thisSection
 10.3(b) ,  in each case other than (1) any such Taxes, costs or expenses arising out of or resulting from a substitutionrequested by
 a Seller or required by applicable Law or (2) to the extent the applicable Seller is entitled to a refund, credit or offset inrespect of such Taxes from any Taxing Authority.
Section
 10.4       Entire Agreement .  This Agreement (including the Seller Disclosure Letter, the Purchaser ParentDisclosure
 Letter and all Annexes and Exhibits) contains the entire agreement between the Parties with respect to the subject matterhereof
 and supersedes all prior agreements and understandings, oral or written, with respect to such matters, except for (i) theConfidentiality
 Agreement and the Clean Team Agreement which shall each remain in full force and effect and (ii) the AncillaryAgreements and
 any other written agreement of the Parties that expressly provides that it is not superseded by this Agreement. In theevent of
 a conflict between the terms of this Agreement and the terms of any Ancillary Agreement, the terms of this Agreement shallcontrol except to the extent expressly provided otherwise in any Ancillary Agreement.
Section
 10.5       Parties in Interest .  Except with respect to (i) the Purchaser Indemnified Parties, the Purchaser ParentIndemnified
 Parties and the Seller Parent Indemnified Parties solely with respect to Article  VII and  (ii) the Persons entitled toindemnification
 under Section  6.5(d) solely  with respect to Section  6.5(d) or,  in each case, as expressly set forth herein (includingSection
 6.21 ),  nothing in this Agreement, express or implied, is intended to confer upon any Person other than Purchaser Parent,Purchaser, the Sellers, or their permitted assigns, any rights or remedies under or by reason of this Agreement.
Section 10.6 
      Public Disclosure . Notwithstanding  anything herein to the contrary, each Party agrees that, except (x)subject
 to Section  6.24(f) and  Section 6.24(g) ,  in making a Purchaser Parent Adverse Recommendation Change or (y) as may berequired
 to comply with the requirements of any applicable Laws, and the rules and regulations of each stock exchange upon whichthe
 securities of either of the Parties are listed (in which case the disclosing Party will use its commercially reasonable efforts to(a)
 advise the other Party before making such disclosure and (b) provide such other Party a reasonable opportunity to review andcomment
 on such release or announcement and consider in good faith any comments with respect thereto), no press release orsimilar
 public announcement or communication shall, if prior to the Closing, be made or caused to be made by the Parties or theirAffiliates concerning
 the execution or performance of this Agreement unless the Parties shall have consulted in advance with respectthereto.
Section 10.7 
      Expenses .  Except as otherwise expressly provided in this Agreement, whether or not the transactionscontemplated
 by this Agreement are consummated, all costs and expenses incurred in connection with this Agreement and thetransactions contemplated hereby shall be borne by the Party incurring such costs and expenses.
Section 10.8 
      Disclosure Letters; Disclosures Modifying Other Sections of Agreement  . The Seller Disclosure Letter and the Purchaser Parent Disclosure Letter, and all
188

schedules attached thereto, and all Annexes and Exhibits attached to this Agreement, shall be construed with and as an integral partof
 this Agreement to the same extent as if the same had been set forth verbatim herein. Any capitalized terms used in any Annex,Exhibit or Schedule or in the
 Seller Disclosure Letter or Purchaser Parent Disclosure Letter but not otherwise defined therein shall bedefined
 as set forth in this Agreement. Any information, item or other disclosure set forth in any Section of the Seller DisclosureLetter
 or the Purchaser Parent Disclosure Letter, as the case may be, shall be deemed to be disclosed with respect to any otherSection
 of this Agreement (or to have been set forth in any other Section of the Seller Disclosure Letter or the Purchaser ParentDisclosure Letter,
 as the case may be), if the relevance of such disclosure to such other Section is reasonably apparent on the face ofsuch
 disclosure notwithstanding the omission of a reference or a cross-reference with respect thereto and notwithstanding anyreference
 to a Section of the Seller Disclosure Letter or Purchaser Parent Disclosure Letter, as applicable, in such Section of thisAgreement.
 The disclosure of any matter in any Section of the Seller Disclosure Letter or the Purchaser Parent Disclosure Lettershall
 expressly not be deemed to constitute an admission by any Party, or to otherwise imply, that any such matter is material forpurposes of this Agreement.
Section
 10.9       No Admission .  Nothing in this Agreement, any Ancillary Agreement or in any Section of the SellerDisclosure
 Letter or the Purchaser Parent Disclosure Letter shall be deemed an admission by any Party or any of their respectiveAffiliates
 (including the Conveyed Subsidiaries and their Subsidiaries), in any Action by or on behalf of or with a GovernmentalAuthority or
 other third party, that any such Party or any of their respective Affiliates, or that such third party or any of its respectiveAffiliates,
 is  or  is  not  violating  or  in  contravention  or  breach  of  or  default  under,  as  applicable,  any  Law,  GovernmentalAuthorization, Contract or Intellectual Property of any other Person.
Section 10.10 
      Governing Law; Jurisdiction . (a) 
     This Agreement (and any claim or controversy arising out of or relating to this Agreement) shall be exclusivelygoverned by
 and construed in accordance with the laws of the State of New York, without regard to the conflicts of law rules of suchstate.
(b) 
     Any Action relating to this Agreement, or the transactions contemplated hereby, shall be brought exclusively inthe U.S. District Court
 for the Southern District of New York or, if for any reason the U.S. District Court for the Southern District ofNew
 York lacks subject matter jurisdiction, any New York State court sitting in New York City, and each Party irrevocably(i)
 agrees and consents to be subject to the jurisdiction of the U.S. District Court for the Southern District of New York or, if for anyreason
 the U.S. District Court for the Southern District of New York lacks subject matter jurisdiction, any New York State courtsitting
 in New York City and (ii) waives any objection which it may have at any time to the laying of venue of such Action broughtin
 any such court, waives any claim that such Action has been brought in an inconvenient forum and further waives the right toobject,
 with respect to such Action, that such court does not have any jurisdiction over such Party. Each of Purchaser Parent andPurchaser
 hereby irrevocably designates, appoints and empowers GSK plc, with offices located at 980 Great West Road, BrentfordMiddlesex TW8
 9GS, England, as its designee, appointee and agent to receive, accept and acknowledge for and on its behalf serviceof any legal process, summons notices and documents
189

which may be served in any such Action. If for any reason GSK plc is unable or unwilling to continue to act as such designee,appointee
 and agent, each of Purchaser Parent and Purchaser agrees to immediately appoint a successor designee, appointee andagent
 in New York City acceptable to Seller Parent. THE PARTIES HEREBY AGREE THAT MAILING OF PROCESS OROTHER
 PAPERS IN CONNECTION WITH ANY SUCH ACTION IN THE MANNER PROVIDED IN SECTION  10.1 ,  OR INSUCH
 OTHER MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE THEREOFAND HEREBY WAIVE ANY OBJECTIONS TO SERVIC
E ACCOMPLISHED IN THE MANNER HEREIN PROVIDED.(c) 
     THE PARTIES AGREE THAT THEY HEREBY IRREVOCABLY WAIVE AND AGREE TO CAUSETHEIR
 RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY ACTION TO ENFORCE ORINTERPRET THE PROVISIONS OF THIS AGRE
EMENT.Section 10.11 
      Counterparts . This  Agreement may be executed in counterparts (including by facsimile or electronic.pdf
 submission), each of which shall be deemed an original, and all of which shall constitute one and the same agreement and shallbecome
 effective when one or more counterparts have been signed by each of the Parties and delivered (by telecopy or otherwise) tothe other Parties, it being understood that all Parties need not sign the same counterpart.
Section
 10.12       Headings .  The heading references herein and the table of contents hereto are for conveniencepurposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.
Section
 10.13       Severability .  The provisions of this Agreement shall be deemed severable and the invalidity,illegality
 or unenforceability of any provision shall not affect the validity, legality or enforceability of the other provisions hereof. Ifany
 term or other provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid, illegal orunenforceable,
 (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid, legaland
 enforceable, the intent and purpose of such invalid, illegal or unenforceable provision and (b) the remainder of this Agreementand
 the application of such provision to other Persons or circumstances shall not be affected by such invalidity, illegality orunenforceability,
 nor  shall  such  invalidity,  illegality  or  unenforceability  affect  the  validity,  legality  or  enforceability  of  suchprovision, or the application thereof, in any other jurisdiction.
Section
 10.14       Rules of Construction .  The Parties agree that they have been represented by counsel during thenegotiation
 and execution of this Agreement and have participated jointly in the negotiation and drafting of this Agreement and,therefore,
 in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly draftedby
 the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of anyprovision of this Agreement.
Section
 10.15       Specific Performance .  The Parties acknowledge and agree that irreparable harm would occur andthat
 the Parties would not have any adequate remedy at Law (i) for any actual or threatened breach of the provisions of thisAgreement
 or (ii) in the event that any of the provisions of this Agreement were not performed in accordance with their specificterms.
190

It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches ofthis
 Agreement and to specifically enforce the terms and provisions of this Agreement (including Section  6.3 )  and any otheragreement
 or instrument executed in connection herewith, without proof of actual damages, and each Party further agrees to waiveany
 requirement for the securing or posting of any bond in connection with such remedy. Each of the Parties agrees that it will notoppose the granting of an injunction, specific
 performance and other equitable relief on the basis that any other Party has an adequateremedy
 at Law or that any award of specific performance is not an appropriate remedy for any reason at Law or in equity. TheParties
 further agree that (x) by seeking the remedies provided for in this Section  10.15 ,  a Party shall not in any respect waive itsright
 to seek any other form of relief that may be available to a Party under this Agreement, including monetary damages (or theright
 to reimbursement of its costs and expenses relating to any enforcement actions hereunder) and (y) nothing contained in thisSection
 10.15 shall  require any Party to institute any proceeding for (or limit any Party’s right to institute any proceeding for)specific performance under this 
Section 10.15  before exercising  any termination right under Section 9.1  (and pursuing damages after such
 termination)  nor  shall  the  commencement  of  any  action  pursuant  to  this Section  10.15 or  anything  contained  in  thisSection 10.15 
restrict or limit any Party’s right to terminate this Agreement in accordance with the terms of  Section 9.1  or pursue any other
 remedies  under  this  Agreement  that  may  be  available  then  or  thereafter.  Notwithstanding  the  foregoing,  under  nocircumstances
 shall any Seller be permitted to receive both (1) a grant of specific performance to require Purchaser or PurchaserParent
 to consummate, and that results in the consummation of, the Closing and (2) payment of the Purchaser Parent TerminationFee.
Section 10.16 
      Affiliate Status . To the  extent that a Party is required hereunder to take certain action with respect toentities
 designated in this Agreement as such Party’s Affiliates, such obligation shall apply to such entities only during such periodof
 time that such entities are Affiliates of such Party. To the extent that this Agreement or any Ancillary Agreement requires anAffiliate of
 any Party to take or omit to take any action, such agreement and obligation includes the obligation of such Party to causesuch Affiliate to take or omit to take such action.
Section 10.17 
      Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege  . (a) 
     Each of Purchaser Parent and Purchaser waives and will not assert, and agrees to cause its Affiliates, including,following
 the Closing, the Conveyed Subsidiaries and their Subsidiaries, to waive and not assert, any conflict of interest arising outof
 or relating to the representation, after the Closing (the “ Seller  Post-Closing Representation ”),  of Seller Parent or any of itsAffiliates,
 or any shareholder, officer, employee or director of Seller Parent or any of its Affiliates (any such Person, a “ Seller Designated
 Person ”)  in any matter involving this Agreement, the Ancillary Agreements or any other agreements or transactionscontemplated
 hereby or thereby, by any legal counsel currently representing any Seller Designated Person in connection with thisAgreement,
 the Ancillary Agreements or any other agreements or transactions contemplated hereby or thereby, including Wachtell,Lipton, Rosen & Katz (any such representation, the “ 
Seller Current  Representation  ”). 191

(b)      Seller Parent waives and will not assert, and agrees to cause its Affiliates to waive and not assert, any conflict ofinterest
 arising out of or relating to the representation, after the Closing (the “ Purchaser  Post-Closing Representation ”),  ofPurchaser
 Parent or Purchaser or any of their Affiliates or any shareholder, officer, employee or director of Purchaser Parent,Purchaser or any of their Affiliates (any such Person, a “ 
Purchaser Designated Person  ”) in any matter involving this Agreement, the Ancillary
 Agreements or any other agreements or transactions contemplated hereby or thereby, by any legal counsel currentlyrepresenting any Purchaser Designated Person in connection with this Agreement, the Ancillary Agreements or any other agreements
or transactions contemplated hereby or thereby,
 including Kirkland & Ellis LLP and Slaughter and May (any such representation, the“ 
Purchaser Current Representation ”). (c) 
     Each of Purchaser Parent and Purchaser waives and will not assert, and agrees to cause its Affiliates, including,following
 the Closing, the Conveyed Subsidiaries and their Subsidiaries, to waive and not assert, any attorney-client or otherapplicable
 legal privilege or protection with respect to any communication between any legal counsel and any Seller DesignatedPerson
 occurring during the Seller Current Representation (the “ Seller  Privileged Communications  ”)  or in connection with anySeller
 Post-Closing Representation, including in connection with a dispute with Purchaser Parent or Purchaser or its Affiliates(including,
 following the Closing, any Conveyed Subsidiary or any of their Subsidiaries), including in respect of any claim forindemnification
 hereunder by a Purchaser Indemnified Party or a Purchaser Parent Indemnified Party, it being the intention of theParties that all
 such rights to such attorney-client and other applicable legal privilege or protection and to control such attorney-clientand
 other applicable legal privilege or protection shall be retained by the Sellers and their Affiliates and that the Sellers, and notPurchaser Parent, Purchaser or their Affiliates or the
 Conveyed Subsidiaries and their Subsidiaries, shall have the sole right to decidewhether
 or not to waive any attorney-client or other applicable legal privilege or protection. Accordingly, from and after Closing,none
 of Purchaser Parent, Purchaser or their Affiliates, including the Conveyed Subsidiaries and their Subsidiaries, shall have anyaccess to
 any such communications or to the files of the Seller Current Representation, all of which shall be and remain the propertyof
 the Sellers and not of Purchaser Parent, Purchaser or their Affiliates, including the Conveyed Subsidiaries and their Subsidiaries,or
 to internal counsel relating to such engagement, and none of Purchaser Parent, Purchaser or their Affiliates, including, followingthe
 Closing, the Conveyed Subsidiaries and their Subsidiaries, or any Person acting or purporting to act on their behalf shall seek toobtain
 the same by any process on the grounds that the privilege and protection attaching to such communications and files belongsto Purchaser Parent, Purchaser or their Affiliates, includ
ing, following the Closing, the Conveyed Subsidiaries and their Subsidiaries,or
 does not belong to the Sellers. Notwithstanding the foregoing, in the event that a dispute arises between Purchaser Parent,Purchaser
 or their Affiliates, including, following the Closing, the Conveyed Subsidiaries and their Subsidiaries, on the one hand,and
 a third party other than the Sellers or their Affiliates, on the other hand, Sellers shall not disclose any such Seller PrivilegedCommunications
 to such third party without the prior written consent of Purchaser unless required to do so by applicable Law orGovernmental Order.
(d) 
     Seller Parent waives and will not assert, and agrees to cause its Affiliates, to waive and not assert, any attorney-client
 or other applicable legal privilege or protection with respect to any communication between any legal counsel and anyPurchaser Designated Person occurring
192

during the Purchaser Current Representation (the “ Purchaser  Privileged Communications ”)  or in connection with any PurchaserPost-Closing
 Representation, including in connection with a dispute with Seller Parent or its Affiliates, including in respect of anyclaim
 for indemnification hereunder by a Seller Parent Indemnified Party, it being the intention of the Parties that all such rights tosuch
 attorney-client and other applicable legal privilege or protection and to control such attorney-client and other applicable legalprivilege
 or protection shall be retained by Purchaser Parent and its Affiliates (other than Purchaser) and that Purchaser Parent, andnot Seller Parent or Purchaser, shall have the
 sole right to decide whether or not to waive any attorney-client or other applicable legalprivilege
 or protection. Accordingly, from and after Closing, none of Seller Parent or Purchaser shall have any access to any suchcommunications
 or to the files of the Purchaser Current Representation, all of which shall be and remain the property of PurchaserParent
 and not of Seller Parent or its Affiliates or Purchaser or its Subsidiaries or to internal counsel relating to such engagement,and
 none of Seller Parent or its Affiliates or Purchaser or its Subsidiaries or any Person acting or purporting to act on their behalfshall
 seek to obtain the same by any process on the grounds that the privilege and protection attaching to such communications andfiles
 belongs  to  Seller  Parent  or  its  Affiliates  or  Purchaser  or  its  Subsidiaries  or  does  not  belong  to  the  Purchaser  Parent.Notwithstanding
 the foregoing, in the event that a dispute arises between Seller Parent or its Affiliates, on the one hand, and a thirdparty
 other than Purchaser Parent, Purchaser or their Affiliates, on the other hand, Purchaser Parent shall not disclose any suchPurchaser
 Privileged Communications to such third party without the prior written consent of Seller Parent unless required to do soby applicable Law or Governmental Order.
Section 10.18 
      Translation of Currencies . Unless otherwise agreed  in writing by Seller Parent and Purchaser Parent,all
 payments  to be  made  under  or pursuant  to this  Agreement  shall  be made  in Pound  sterling.  Except  with  respect  to thedeterminations
 set forth in the following sentence, and except to the extent otherwise provided in the Accounting Principles orPurchaser
 Accounting Principles with respect to the determinations of amounts included in the calculations of Business WorkingCapital,
 Business Net Cash, Purchaser Working Capital or Purchaser Net Cash, as applicable, in the event that the Parties need toconvert currencies under this Agreement, the relevant exchange rate shall
 be determined based on the Bloomberg BFIX rate in effectas
 of  5:00  p.m.  (New  York  time)  two  (2)  Business  Days  preceding  the  applicable  determination  date  as  published  onBloomberg.com.
 In the event that any Person needs to convert currencies for purposes of calculating the amount of any claim underSection 6.5(d) 
or  Article VII ,  the relevant exchange rate shall be determined based on the Bloomberg BFIX rate in effect as of 5:00pm
 (New York time) two (2) Business Days preceding the date of the written notice given for such claim under Section  6.5(d) or under 
Section 7.3 , as applicable, as published on Bloomberg.com. [ 
Signature
page
follows
] 193

IN WITNESS WHEREOF, the Parties have executed or caused this Agreement to be executed as of the date firstwritten above.
 
PFIZER INC.  
     
     
By: /s/ Albert Bourla 
  Name: Albert Bourla 
  Title: Chief Operating Officer 
     
     
     
GLAXOSMITHKLINE PLC  
     
     
By: /s/ Simon Dingemans 
  Name: Simon Dingemans 
  Title: Chief Finance Officer 
GLAXOSMITHKLINE CONSUMER HEALTHCAREHOLDINGS LIMITED
 
     
     
By: /s/ Simon Dingemans 
  Name: Simon Dingemans 
  Title: Director[ 
Signature
Page
to
Stock
and
Asset
Purchase
Agreement
] 
EXHIBIT 10.7Amendment No. 1
Pfizer Consolidated Supplemental Pension 
Plan for United States and Puerto Rico Employees(Amended and Restated De
cember 31, 2016)* * *
A new Appendix I is added to the end of “Part 
B: Provisions Applicable To The Pfizer Sub-Plan” of the Pfizer Consolidated Supplemental Pension Planfor United States an
d Puerto Rico Employees to read as follows:1

APPENDIX ISUPPLEMENTAL PRAP VOLUNTARY EARLY RETIREMENT PLAN
ARTICLE I
Purpose
SECTION 1.1    
This Appendix I contains
 the Supplemental PRAP Voluntary Early Retirement Plan (the "VERP/SSP SERP"), a Subplan to the Plan, which is beingadopted in order to provide a pension enhancement to 
certain members of the Retirement Plan who are U.S. employees of Pfizer Inc., and who elect to beincluded in the Voluntary
 Early Retirement Program (the “VERP”), or who are involuntarily terminated in connection with the new Organizing for Growth (“OFG”)operating model and receive the Spec
ial Separation Program (“SSP”) enhanced benefits under either the Pfizer Separation Plan, the Senior Leadership CouncilSeparation Plan or th
e Executive Severance Plan (the “OFG U.S. Program”).ARTICLE II
Definitions
SECTION 2.1.    
Whenever used herein, unless the conte
xt otherwise indicates, the following terms shall have the respective meanings as set forth below or as definedin Part A of the Plan:
        
Administrative Committee: the A
dministrative Committee of the Company.    
Calculation Date: the fi
rst day of the month coincident with or next following the later of (1) the date the Participant attains age 55 (orthe date the Participant would have atta
ined Rule of 90 if he or she had remained employed, if earlier) or (2) the date of the Participant’s Separationfrom Service.
Coordinating Office or Separat
ion Coordinating Office: the staff designated by the Plan Administrator to handle claims for benefitsunder the VERP and the OFG U.S. Program.
Election Period: the perio
d of time in which an eligible Employee may elect to participate in the VERP.Employee: any person who is a 
regular full-time or part-time employee of Pfizer Inc. or one of its affiliates in one of the 50 states orthe District of Colu
mbia, or an employee paid from the United States under the Pfizer International Assignment Policy, and in each case such employeeis on U.S. payroll and par
ticipating in U.S. benefits. Employees working for a Pfizer legal entity based in Puerto Rico are excluded from participating inthe VERP/SSP SERP.
OFG U.S. Program: the enhanced involunta
ry severance program established in connection the new OFG operating model whichconsists of enhanced benefits under thi
s VERP/SSP SERP, the Retirement Plan, the Pfizer Inc. Retiree Medical Plan, the Pfizer Inc. Health andInsurance Plan, the Pfizer Sav
ings Plan, the Pfizer Supplemental Savings Plan, and with respect to a Participant’s annual equity awards, andseverance benefits under either the Pf
izer Separation Plan, the Senior Leadership Council Separation Plan or the Executive Severance Plan.2

Participant: a person who is eligible for participation in the VERP/SSP SERP under the provisions of Appendix I; Article III.Payment Date: the date described in Append
ix I; Section 4.2 below.PRAP: the Pfizer Retirement An
nuity Plan which is contained in Part B of the Retirement Plan.        
Separation Date or Se
paration from Service or Separate(s) from Service: a Participant’s date of termination which shall constitute a"separation from service
" within the meaning of Code section 409A. With respect to an OFG Participant separated under the VERP, the SeparationDate shall be the OFG Partic
ipant’s date of termination, which shall be December 31, 2018 unless otherwise deferred by the Company. With respect toan OFG Participant separated under the SSP, the 
Separation Date shall be the OFG Participant’s date of termination.        
Supplemental VERP/SSP Plan Bene
fit: the amount of the benefit that a Participant is eligible to receive under this VERP/SSP SERPas described in Appendix 
I; Article IV.VERP: the Voluntary Ear
ly Retirement Program established in connection the new OFG operating model which consists of enhanced benefitsoffered under this VERP/SSP 
SERP, the Retirement Plan, the Pfizer Inc. Retiree Medical Plan, the Pfizer Inc. Health and Insurance Plan, the PfizerSavings Plan, the Pfizer Su
pplemental Savings Plan, and with respect to a Participant’s annual equity awards.VERP/SSP SERP: th
is Subplan contained in this Appendix I to the Plan established in order to implement the enhanced pensionbenefits offered under the VERP and OFG U.S. 
Program.VERP/SSP SERP Benefit Commencement Da
te or VERP BCD: the first day of the month coincident with or next following the date asof which the Participant 
would first be eligible to retire after reaching either (a) attainment of age 55 and completion of 10 years of retirement eligibilityservice or (b) Rule of 90, a
s described in Part B of the Retirement Plan. If the addition of 5 points enables the Participant to reach both (a) age 55 with10 years of service and (b) Ru
le of 90, the Participant’s VERP/SSP SERP Benefit Commencement Date shall be the date that corresponds to the morevaluable benefit.
ARTICLE III
Eligibility for Plan Benefit
SECTION 3.1.    An Employ
ee shall be a Participant and eligible to receive a Supplemental VERP/SSP Plan Benefit under this VERP/SSP SERP in anamount determined in accordance w
ith Appendix I; Article IV if he or she meets the following requirements:(a) he is an active Employe
e (including an Employee on short-term disability or a paid or unpaid leave of absence) who is a regular full-time or part-timeemployee of Pfizer Inc. or one of it
s affiliates in one of the 50 states or the District of Columbia, or an employee paid from the United States under the PfizerInternational Assignment
 Policy, and in each case such employee is on U.S. payroll and participating in U.S. benefits;(b) he elects to be voluntari
ly terminated under the VERP during the Election Period, and he is eligible for, signs a release and does not revoke it, andreceives benefits under the VE
RP or his employment is involuntarily terminated under the OFG U.S. Program and he signs a release and does not revoke it, andreceives benefits under
 the OFG U.S. Program;    (c) he has a Retirement Benefit unde
r Part B of the Retirement Plan and the addition of five (5) points as of December 31, 2018 for a VERPParticipant (including a VERP Participan
t who is re-classified as SSP subsequent to his termination of employment), or as of his Separation Date in the case of aParticipant who is ter
minated under the SSP, to his age, service, or any combination thereof would enable him to qualify for subsidized early retirement becausehe would reach either (i) 
age 55 and completion of 10 years of retirement eligibility service or (ii) Rule of 90, as described in Part B of the Retirement Plan.Employees who have already
3

reached either: (i) age 55 and completion of 10 years of retirement eligibility service; or (ii) Rule of 90, as described in Part B of the Retirement Plan as of theirSeparation Date, cannot benefit from the fi
ve (5) points ; (d) he has more than or equal to $235,000 in pensionab
le earnings under Part B of the Retirement Plan in 2017 or has an accrued benefitunder Part B of the Plan; and
(e) he is not an Excluded Emp
loyee. For this purpose, an Employee is an Excluded Employee if any of the following applies:•
The Employee’s terms and conditions of employment are subject to collective bargaining.•
The Employee is or has been a Named Executive Officer in the Company’s Annual Proxy Statement.•
The Employee is currently working for a Pfizer legal entity based in Puerto Rico.•
The Employee is receiving benefits from a Company-sponsored long-term disability plan.•
The Employee is on secondment in the United States.•
The Employee is not paid through the U.S. payroll and/or is not eligible for U.S. benefits.•
The Employee has been deemed ineligible through the Claims and Appeals Procedure.SECTION 3.2.    For the purposes of Appendi
x I; Section 3.1, with respect to a Participant who dies while in active service on or after his election toparticipate in VERP but befo
re executing the release agreement, t he spouse or the estate may sign the release agreement on his or her behalf, if applicable.ARTICLE IV
Supplemental VERP/SSP Plan Bene
fitsSECTION 4.1    If a Participant 
is eligible as determined in Appendix I; Article III, the Company shall make a lump sum cash payment to the Participantin an amount equ
al to the difference between (i) and (ii) below, discounted or increased if applicable from the Participant’s VERP/SSP SERP BenefitCommencement Date (“VE
RP BCD”) to the Participant’s Payment Date, using a discount rate equal to the first segment rate in Code Section 417(e)(3)(C),published in the third m
onth prior to the Calculation Date, where:(i) is the present value of the Pa
rticipant’s accrued benefit under the PRAP portion of the Retirement Plan and the Plan, determined as of the VERPBCD, reflecting (a) the ea
rly retirement reduction factor that would apply if five (5) points were added to the Participant’s age, service, or a combination thereofas of December 31, 2018 (or as of his Sepa
ration Date in the case of a Participant whose employment is terminated under the OFG U.S. Program), and (b)without reference to the lim
itations of Code Sections 415 and 401(a)(17);(ii) is the present va
lue of the Participant’s accrued benefit under the PRAP portion of the Retirement Plan and the Plan, determined as of the VERPBCD, without reflect
ing the 5-point enhancement described in (i) and without reference to the limitations in Code Sections 415 and 401(a)(17);For purposes of (ii) above, in the e
vent the Participant’s VERP BCD is prior to his attainment of age 55, the early retirement reduction applied to yearsbelow age 55 shall be the actuaria
l equivalent of the benefit at age 55, where actuarial equivalence is determined using an interest discount rate of 5% andmortality in accordance with Cod
e Section 417(e).4

The present values shall be calculated using the PRAP portion of the Retirement Plan’s actuarial assumptions for payment of lump sums as publishedin the third month prior to the Ca
lculation Date. The five (5) point enhancement applies solely for the purpose of determining the reduction for early retirement, ifany, with respect to the PRAP po
rtion of the benefit; it does not count for any purpose with respect to benefit formulas, the computation of the Normal RetirementBenefit, or the computation of the lump sum fa
ctors.In the event the Participant has chosen a s
ingle life annuity as his payment election, the amount determined in Section 4.1 shall be converted to a lifeannuity using an immediate annu
ity factor determined as of the Participant’s Payment Date, determined using the Code Section 417(e)(3)(C) interest ratepublished in the third month pr
ior to the Calculation Date and mortality table under Code Section 417(e) in effect as of the Participant’s Payment Date.SECTION 4.2.    Such lump sum pa
yment shall be made as soon as practicable in the January coincident with or following the later of (1) suchParticipant’s Separat
ion from Service, or (2) the Participant’s attainment of age 55 (or the date the Participant would have attained Rule of 90 if he or she hadremained employed, if e
arlier), unless the Participant has an Accrued Benefit under Part B of the Plan in which case the Supplemental VERP/SSP Plan Benefitwill be paid in ac
cordance with the payment elections under Part B of the Plan. Notwithstanding the foregoing, payments may not be made to a Key Employeeupon Separation from Service before the date 
which is six (6) months after the date of the Key Employee’s Separation from Service (within the meaning of Codesection 409A). In the event that payment is de
layed pursuant to the preceding sentence, payment shall be made (i) on the first day of the seventh monthfollowing the Key Employee’s Sep
aration from Service (within the meaning of Code section 409A), or, (ii) if earlier, the first day of the month after suchParticipant’s death during th
is period of delay. The above shall define the Participant’s Payment Date regardless of whether due to administrative delays, theactual payment is made after the Payment 
Date.SECTION 4.3    If a Participant d
ies after becoming eligible to receive a Supplemental VERP/SSP Plan Benefit and prior to the Participant’s PaymentDate, the following benefits a
re payable from the Plan in the form of a rollover to the Pfizer Supplemental Savings Plan in accordance with the provisions in PartB, Section 5.4 of the Plan, as if the Part
icipant had died during active employment:(i) If the Participant i
s married at the time of death, and the Participant’s spouse waives the QPSA, the lump sum death benefit equal to thebenefit determined in accordance 
with Appendix I; Section 4.1 of the VERP/SSP SERP shall be transferred to the PSSP account.(II) If the Participant is ma
rried at the time of death and the spouse does not waive the QPSA, no benefit is payable from the VERP/SSPSERP. However, pre-
retirement death benefits may be payable from the Retirement Plan and the Plan.(iii) If the Partic
ipant is not married at the time of death, the lump sum death benefit equal to the benefit determined in accordance withAppendix I; Section 4
.1 of the VERP/SSP SERP shall be transferred to the Participant’s Pfizer Supplemental Savings Plan account.(iv) The lump sum death benefit sha
ll be payable as of the January 1 coincident with or next following the Participant’s death.SECTION 4.4    If a
 Participant is rehired prior to the Participant’s Payment Date, the Participant shall be entitled to the VERP/SSP SERP Plan Benefitdetermined in accordance w
ith Appendix I; Section 4.1, payable as of the Participant’s Payment Date, as if the Participant had not been rehired. The five (5)point enhancement may not be used towards any other 
milestone.SECTION 4.5    The benefits payable under the 
VERP/SSP SERP are determined solely with respect to the PRAP formula and early retirementprovisions in Part B of the 
Retirement Plan and the corresponding section in the Plan. Nothing in the VERP/SSP SERP shall be construed as changingretirement benefits correspond
ing to any legacy retirement plan benefit, other than PRAP benefits.5

ARTICLE VAdministration and Claims and Ap
peals ProcedureSECTION 5.1.    The Committee has de
legated the ministerial authority to administer claims for benefits under the Plan to the Company’s SeparationCoordinating Office or its s
uccessor. The Separation Coordinating Office is responsible for determining who is eligible to become a Participant and fordetermining initial claims for bene
fits under the VERP/SSP SERP.SECTION 5.2.    The Committee has de
legated authority to administer the appeal of denied claims under the VERP/SSP SERP to the AdministrativeCommittee.
SECTION 5.3.    Any request by a Part
icipant or any other person for any benefit alleged to be due under the Plan shall be known as a “Claim” and theParticipant or other p
erson making a Claim, or the authorized representative of either, shall be known as a “Claimant.” To make a Claim, the Claimant mustsubmit the Claim in writing to th
e Separation Coordinating Office. The Claim must include a description of the benefit that the Claimant believes is due, thereason(s) the Claimant be
lieves such benefit is due and any information and documentation that the Claimant believes supports his Claim and that he wishes tohave the Separation Coordinating Off
ice consider.SECTION 5.4.    The
 Coordinating Office will process the Claim within 90 days of receipt of the Claim unless special circumstances require anextension of time for determin
ing the Claim. In such event, written notice of an extension of time to consider the Claim and the reasons for it, will be sent to theClaimant before the end of the init
ial 90-day period. The extension will not exceed a period of 90 days from the end of the initial 90-day period. If theCoordinating Office has 
not determined the Claimant’s eligibility for a Plan benefit within this 90-day period (180-day period if circumstances require an extensionof time) the Claimant may 
deem the Claim denied.SECTION 5.5.    In 
the event a Claim is denied, in whole or in part, the notice of denial will set forth: (i) the specific reason(s) for the denial; (ii) specificreference to the pertinent Plan provi
sions on which the denial is based; (iii) a description of any additional material or information necessary for the Claimant toperfect the Claim and an explanat
ion of why such material or information is necessary; and (iv) an explanation that, if an adverse determination is made onreview, the Claimant has a rig
ht to bring a civil action under Section 502(a) of ERISA.SECTION 5.6.    Within 60 day
s of receipt of notice of a Claim that has been denied in whole or in part, or from the date that a Claim is deemed denied,the Claimant may (i) submit an
 appeal, which is a written request for review by the Administrative Committee that includes all information and documents that theClaimant wishes to have the
 Administrative Committee consider; and (ii) review documents pertinent to the Claim. The Claimant shall be provided upon requestand free of charge, reasonable access to al
l documents and records and other information relevant to the Claim. If the Claimant does not request an appeal ofthe denied claim with
in the 60-day period, the Claimant shall be barred and estopped from challenging the denial.SECTION 5.7.    The Administ
rative Committee will review a denied Claim for which an appeal has been submitted and render a decision no later than60 days after receipt of the appeal, provided, ho
wever, that if special circumstances require an extension of time for determining the appeal, a decision shall berendered no later than 120 days after receipt of the appea
l. Written notice of any such extension and the reasons for it, shall be furnished to the Claimant beforethe end of the initial 60-day period. The e
xtension will not exceed a period of 60 days from the end of the initial 60-day period. If the Administrative Committeehas not rendered a decision with
in this 60-day period (120-day period if circumstances require an extension of time) the Claimant may deem the appeal denied.SECTION 5.8.    In 
the event an appeal is denied, in whole or in part, the Administrative Committee’s decision will set forth: (i) the specific reason(s) forthe denial; (ii) specific refere
nce to the pertinent VERP/SSP SERP provisions on which the denial is based; and (iii) an explanation that the Claimant has a rightto bring a civil action und
er Section 502(a) of ERISA.SECTION 5.9.    No legal act
ion may be brought for benefits under this VERP/SSP SERP until the Claimant has exhausted the administrativeprocedure described in this 
Article V. No legal action may be commenced at all unless commenced no later than one year following the issuance of a finaldecision on the Claim, o
r the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations6

on suits for all benefits shall apply in any forum where the Claimant may initiate such a suit. SECTION 5.10.    No member of the Board of 
Directors or of the Committee, the Administrative Committee, the Separation Coordinating Office, or itsdelegates shall be liab
le for any act or action, whether of commission or omission, taken by any other member, or by any officer, agent or employee or by anyinvestment advisor or finan
cial institution appointed by any such person; nor, except in circumstances involving his bad faith, for anything done or omitted to bedone by himself. Each m
ember of the Committee, Administrative Committee, and Separation Coordinating Office shall be fully indemnified and entitled to receivean advance of any related attorney fees in connect
ion with legal proceedings related to the Plan.    
ARTICLE VI
Miscellaneous
SECTION 6.1.    Each Partic
ipant shall, after his Separation Date, make himself available for such consultative and advisory services as the Companymay reasonably request, taking fa
irly into consideration the age, health, residence, and individual circumstances of the Participant, and provided such amount ofservices to be provided sha
ll not prevent the Participant’s termination from constituting a Separation from Service. If such Participant shall unreasonably refuseto render such services, the Co
mpany may require such Participant to reimburse any payments made hereunder.SECTION 6.2.    Any benefit hereunder 
which is unclaimed, including outstanding checks, may, as determined by the Retirement Committee, beforfeited.
SECTION 6.3.    The adoption of this Append
ix allows for the early vesting of certain benefits under the Plan and shall not be considered a modificationto the Plan.
SECTION 6.4.    The Company reser
ves the right to delay the Separation Date of any Participant who elected to be included in the VERP for a period ofup to six months (or until June 30, 2019
) without the consent of the Participant. Further, provided the Participant consents, the Company may delay theSeparation Date up to June 30, 2020.
7

EXHIBIT 10.12Amendment No. 4
Pfizer Supplemental Sav
ings Plan (the “PSSP”)* * *
(New material underlined; deletio
ns crossed out)1. Section 2.31 shall be clar
ified to read as follows:2.31 Regular Earnings.
However, for Pension Trans
fers, solely for purposes of the Retirement Savings Contribution, Regular Earnings shall not include any bonuses (including but not limited to, sales and GPP bonu
ses) earned paid or deferred in 2018 which reflects payment for services performed in 2017. 2. Section 3.5(c) is clarified 
to read as follows:3.5(c) For any Pension Transfer, the def
inition of “Regular Earnings” in connection solely with the calculation of the 2018 Retirement SavingsContributions under the Plan for 
such Pension Transfer shall not include any bonuses (including but not l imited to, sales and GPP bonuses) earned inpaid to or deferred by such Pension Tran
sfer during 2018 which reflects performance during 2017. 
EXHIBIT 10.13Amendment No. 5 to the
Pfizer Supplemental Sav
ings Plan (“PSSP”)* * *
(New material underlined)
1.
Section 2.32 of the PSSP is amended to read as follows:2.32         
Retirement . The term “Retirement” means a ter mination of employment with an Employer after the Eligible Employee has attained either (i) age65, or (ii) age 55 with at lea
st 10 Years of Service (as determined in accordance with the Qualified Plan) , or an Eligible Employee who was  eligible underthe Pfizer Voluntary Ear
ly Retirement Program or involuntarily terminated under the Special Separation Program under a Company-sponsored severanceplan, and who would attain either 
(i) age 65, or (ii) age 55 with at least 10 Years of Service, if credited with:(a)    An additional five
 years of age;(b)    An additional five
 Years of Service; or(c)    A combination (in 
months) of years of age and Years of Service, which combination does not exceed 60 months . 
EXHIBIT 10.26Amendment No. 1 to the
Pfizer Inc. Executive Severance Plan
* * *
(New material underlined)
1.
The Plan is clarified to provide that the Plan Administrator is the Executive Vice President, Worldwide Human Resources.2.
A new Appendix A is added to the end of the Pfizer Inc. Executive Severance Plan to read as follows:APPENDIX A
Special Separation Program
INTRODUCTION
The Company is adopting this Spe
cial Separation Program (“SSP”) in connection with the new Organizing for Growth operating model to provide enhancedseverance benefits to impacted el
igible employees under the Plan who meet the additional eligibility requirements set forth in this Appendix.This Appendix A sets forth certa
in special provisions applicable to eligible employees who may become eligible under the SSP. To the extent not superseded orspecifically addressed by the
 provisions of this Appendix A, the provisions of the Plan shall govern.ARTICLE I 
DEFINITIONS
Unless specifically defined below, all ot
her definitions are set forth in the Plan:1.1
“Active Health & Insurance Continuation” means the period of time, beginning on an SSP Participant’s Termination Date, for which an SSP Participant isoffered Continuing Group Health and L
ife Insurance Coverage in accordance with Appendix A; Section 3.1

1.2“Five Points Brochure” means the brochure prepared and describing certain enhancements available under the pension plans, savings plans, retireemedical plan and equity 
awards for certain eligible employees.1.3 “SSP” means the Special 
Separation Program set forth in this Appendix A.1.4 “SSP Participant” mean
s an eligible employee under the Plan who is eligible to participate in the SSP pursuant to Appendix A: Section 2.1 and becomes aParticipant pursuant to Appendix 
A; Section 2.2.ARTICLE 2
PARTICIPATION
2.1    Eligibility to Participate.
2.1.1
An eligible employee under the Plan shall become an SSP Participant if, on his Termination Date:(a)
He is an eligible e mployee under the Plan and is not, and has not been, a “named executive officer” in the Company’s Annual ProxyStatement;
(b)
He is involuntarily terminated du e to business restructuring or job elimination (which will be determined by the Plan Administrator, orits designee, in its so
le and absolute discretion), or due to exhaustion of short-term disability benefits; and(c)
His Official Notification Date is on or after December 21, 2018 and on or before August 2, 2019.2.1.2
An eligible employee shall also be eligible to participate in the SSP under the Plan if he elected to terminate employment under the terms ofthe Pfizer Voluntary Ear
ly Retirement Program and his position is eliminated by June 26, 2019. The Plan Administrator, or its designee, in itssole and absolute discretion, 
will determine whether the position was eliminated by June 26, 2019. In the event that this determination is madeafter the eligible employee
’s Termination Date, such SSP Participant shall be eligible for the cash severance determined under Plan only, andnot the additional benefits (inc
luding Active Health & Insurance Continuation) described in Appendix A; Section 3.2.2
Participation. An eligible employee  who is determined to be eligible to participate in the SSP under the provisions of this Appendix A; Article 2 becomesan SSP Participant after
 the Plan Administrator receives and accepts the eligible employee’s duly executed Release Agreement within the time periodspecified by such agreem
ent. The earliest date the Release Agreement may be signed is the eligible employee’s Termination Date. Participation willbegin on the eighth day after the eligib
le employee signs the Release Agreement, provided the eligible employee has not revoked the ReleaseAgreement during th
at time period. If an eligible employee dies while in active service on or after his or her Official Notification Date2

but before executing the Release Agreement, the estate may sign the Release Agreement on his or her behalf and receive the applicable cashseverance under the Plan and the Active 
Health & Insurance Continuation.ARTICLE 3
BENEFITS
3.1    Severance Pay.
3.1.1
If an eligible employee sa tisfies the eligibility requirements of Appendix A; Article 2. and becomes an SSP Participant, he will be entitled tocash severance in the amount determined unde
r the Plan.3.1.2
Continuing Group Health and Life In surance Coverage.(a)    Health Benefits.
(i)    An SSP Partic
ipant may continue coverage (“Active Health & Insurance Continuation”) at the active employee rates in effect with respectto his elections during the 2019 Annua
l Enrollment period, or on his Termination Date if his Termination Date is later than December 31, 2018, and asadjusted thereafter for active Emp
loyees, in accordance with the same terms as applicable to active employees. Such Active Health & InsuranceContinuation wil
l last for up to a maximum of three (3) years from the Termination Date. If an SSP Participant covers an eligible dependent who is nottheir tax dependent, the value of any subsid
ized company provided healthcare coverage results in imputed income to the SSP Participant. Any ActiveHealth & Insurance Coverage 
will end on the date as of which the SSP Participant becomes eligible for coverage under another employer’s grouphealth plans (regardless of 
whether he actually enrolls in such other plan). In addition, Active Health & Insurance Coverage will end if requiredcontributions for such coverage a
re not received on a timely basis. Continuation under the Pfizer Flexible Spending Account Plan Health Care Accountmay only be continued to the end of the calendar yea
r in which the Termination Date occurs.(ii)     After Active 
Health & Insurance Coverage ends and provided the SSP Participant was covered under the Company-sponsored medicalplan for the entire period and is not e
ligible for medical coverage under another employer’s plan, such SSP Participant may continue medical coveragefor an additional 18 months (except for the 
Health Care Account Plan that is beyond the calendar year following the year containing the Date ofTermination), at 102% of the full 
cost of coverage pursuant to his rights under the Consolidated Omnibus Budget Reconciliation Act (COBRA).(iii)    An SSP Participant who elects
 the continuing medical coverage provided under the SSP is also electing to continue any Company-sponsored dental, vision and bas
ic life insurance coverage in effect on his Termination Date provided he is participating in such coverage on his3

Termination Date. In all cases except for any COBRA elections, if an SSP Participant chooses to continue medical, dental, vision or basic life insurancecoverage pursuant to this package, he must choo
se to continue each of the medical, dental, vision and basic life insurance coverages (as capped in thecase of life insurance) 
in which he is participating on his Termination Date, or none of these coverages. There are no separate elections for thesecoverages. Dental and
 vision coverages continue in the same manner as provided with respect to medical coverage described in (a)(i) and (a)(ii) setforth above.
(iv)    If an SSP Participan
t who is eligible for Company-sponsored retiree medical coverage on his Termination Date, elects Active Health &Insurance Coverage and/or an additiona
l 18 months of COBRA coverage, he is also electing to defer enrollment in the Company-sponsored retireemedical plan (if available).
(v)    If an SSP Participa
nt does not elect Active Health & Insurance Coverage, the SSP Participant will be offered COBRA continuationcoverage, as applicable. The SS
P Participant will be offered to continue basic life insurance in accordance with the terms of the Pfizer Life InsurancePlan, as applicable.
(b)        Retiree Medical.
(i)    An SSP Participant who is 
eligible for Company-sponsored retiree medical coverage on his Termination Date may elect such coveragepursuant to the terms of such plan. An SSP 
Participant may not be enrolled for Company-sponsored retiree medical coverage while in Active Health &Insurance Continuation.
(ii)    An SSP Participant who is eligible 
for Company-sponsored retiree medical coverage may elect to terminate the Active Health & InsuranceCoverage or COBRA cont
inuation before the end of the continuation period, as applicable, and begin retiree medical coverage in accordance withqualified status changes and the prov
isions of the medical plan and retiree medical plan. To elect any applicable Company-sponsored retiree medicalcoverage, the SSP Participant 
will be required to certify that he has been continuously enrolled in medical coverage from his date continuing medicalcoverage ends to the date he enrolls for the Co
mpany-sponsored retiree medical coverage. For this purpose only, COBRA continuation coverage wouldqualify as continuous medi
cal coverage for the period such coverage is in effect. If an SSP Participant covers an eligible dependent who is not their taxdependent, the value of any subsidized compan
y provided retiree medical coverage results in imputed income to the SSP Participant.(c)
Life Management Resources. An SSP Participant who e
lects the Active Health & Insurance Coverage provided under the SSP is also electing to continue any coverageunder Life Management Resources, at no cost, fo
r the Active Health & Insurance Continuation period. After the end of the Active Health & InsuranceContinuation period, coverage can 
still be continued under COBRA at a cost of 102% of the full cost of coverage.4

(d)Life Insurance. (i)    An SSP Participant who is 
enrolled in a Company-sponsored life insurance plan on his Termination Date may continue his basic lifeinsurance coverage at active emp
loyee rates and in accordance with the same terms as applicable to active Employees, until the end of the three yearcontinuation period or the date as of wh
ich he becomes eligible for coverage under another employer’s group health plans (regardless of whether heactually enrolls in such other
 plan). After such Active Health & Insurance Coverage ends, the SSP Participant will be eligible for the conversion andportability rights offered unde
r the plan, as applicable. There is no additional 18 months of active life insurance coverage.(ii)    Company-sponso
red basic life insurance coverage is limited to the lowest of: (A) the SSP Participant’s coverage in effect on the daybefore his Termination Date; (
B) one times the SSP Participant’s annual pay (as defined in the applicable life insurance plan); or (C) $2,000,000. Thecost of insurance in excess of $50,000 
results in imputed income to the SSP Participant. Any employee supplemental and dependent life insurancecoverage ends as of the SSP Partic
ipant’s Termination Date, and the SSP Participant will be eligible for the conversion and portability rights offeredunder the plan, as applicable.
(e)    Educational Assistanc
e Program/Education/Retraining Benefit.(i)    An SSP Partic
ipant who has begun attending an approved course(s) under the Pfizer Educational Assistance Program before hisTermination Date, remains 
eligible for reimbursement for that pre-approved and already started course(s), as long as the SSP Participant satisfies all ofthe other requirements for reimbur
sement under the Educational Assistance Program. No additional courses will be approved.(ii)    An SSP Part
icipant shall be eligible for a $5,000 education/retraining allowance for approved courses and programs provided the coursesbegin (and are not just enrolled 
in) within 12 months of the Termination Date and the required documentation for reimbursement is submitted within 18months of the Termination Date.
(iii)    The Plan Administrator h
as final and absolute discretion to determine what constitutes “educational” or “retraining.”(f)    Miscellaneous Provisions.
(i)    Except as otherwi
se provided in this Appendix A: Section 3, all of the terms of the employee benefit plans described herein and asamended from time to time, shal
l apply. If there is a discrepancy, the terms of the official plan document for the applicable plan shall control.(ii)    Active Hea
lth & Insurance Coverage described in this Appendix A; Section 3, is subject to the terms and conditions of the particular plan,as in effect from time to time. A
ll of the benefit plans5

described herein, including this Plan, may be amended or terminated at any time and for any reason, with or without notice.(iii)    SSP Part
icipants may be eligible to participate in reasonable outplacement services as offered by the Company in its sole and absolutediscretion. In no case
 will the Company provide a payment to the Participant in lieu of these services.3.1.4    Except as otherwise prov
ided above or in the Five Points Brochure, no other severance benefits are payable to the SSP Participant under thePlan and the SSP, a
nd the following will apply:(a)
Active employee benefits end as of the Te rmination Date;(b)
Eligibility for any applicable retiree me dical, dental and/or life insurance benefits, if any, is determined as of the SSP Participant’sTermination Date and pursuant to the terms of the app
licable plans;(c)
The controlling condition s of any stock grants may be affected for an SSP Participant and are contained in the terms of the stockgrant letters, grant agreements, points of 
interest for each such grant, applicable stock plan, and Five Points Brochure.6

EXHIBIT 10.33TIME SHARING AGREEMENT
This Time Sharing Agreement 
(this "Agreement") is dated this 17th day of December 2018, by and between Pfizer Inc., a Delaware corporation (the"Company") and Ian C. Re
ad, an individual ("Lessee”).RECITALS
WHEREAS, Compan
y rightfully possesses and operates the aircraft identified on Schedule I hereto (the "Aircraft") under Part 91 of the Federal AviationRegulations (“FARs”) incidental to its
 primary business; andWHEREAS, Company desires to make t
he Aircraft available to Lessee, and Lessee desires to utilize the Aircraft, from time to time on a non-exclusivetime-sharing basis as autho
rized under Sections 91.501(b)(6), 91.501(c)(1) and 91.501(d) of the FARs; andWHEREAS, this 
Agreement is a time sharing agreement as defined in Section 91.501(c)(1) of the FAR, and use of the Aircraft pursuant to thisAgreement will comp
ly with the requirements of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d).NOW, THEREFORE, 
in consideration of the foregoing, and the other agreements contained herein, and for other good and valuable consideration, thereceipt and sufficiency of 
which is hereby conclusively acknowledged, the parties, intending to be legally bound hereby, agree as follows:1.     
Provision of Aircraft; Term. Company agrees to provide the Ai rcraft to and operate the Aircraft for Lessee on a non-exclusive basis from time totime as mutually agreed between the pa
rties pursuant to the provisions of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d) and to provide a fully qualified flightcrew for all operations 
conducted under this Agreement. This Agreement shall be effective on the date set forth above and shall remain in effect until terminatedby either party upon ten (10) business da
ys’ prior written notice to the other.2.     
Lease Fee. Lessee shall pay to Company for ea ch flight conducted under this Agreement a lease fee ("Lease Fee") not to exceed the actualexpenses of each specific fl
ight as authorized by FAR Part 91.501(d) (including related deadhead flights, if applicable). Such actual expenses shall include andare limited to:
(a)    Fuel, oil, lubricants
, and other additives;(b)    Travel expenses of the crew, 
including food, lodging and ground transportation;(c)    Hangar and tie-down cost
s away from the Aircraft's base of operations;(d)    Insurance obtained for the specif
ic flight;(e)
Landing fees, airpor t taxes and similar assessments;(f)    Customs, foreign
 permit, and similar fees directly related to the flight;(g)    In flight food and beverages;
(h)    Passenger ground transportation;
(i)    Flight planning and 
weather contract services; and
(j)An additional charge equal to 100 percent of the e xpenses listed in subparagraph 2(a) above.In no event shall the Lease Fee include any 
costs not listed above.3.     
Taxes . The parties acknowledge that, w ith the exception of Sections 2(g) and (h) hereof, the payments specified in Section 2 from Lessee toCompany are subject to federal ex
cise tax imposed under Article 4261 of the Internal Revenue Code of 1986, as amended (the “Federal Excise Tax”). Ifapplicable, Lessee shal
l pay to Company (for remittance to the appropriate governmental agency) all Federal Excise Tax applicable to flights of the Aircraftconducted hereunder.
4.     
Prepayment. From time to time, Lessee may de liver to Company a mutually agreed sum to fund an account for anticipated Lease Fees (the“Prepayment Fund”). No interest 
shall be paid on the Prepayment Fund. Immediately upon presentment of invoices for time sharing flights, Company shall applyfunds from the Prepayment Fund to pay for Lease Fees for su
ch flights. Monthly reconciliations shall be provided to Lessee which shall set forth the expensescomprising the Lease Fees of each spec
ific flight through the last day of the month in which any flight or flights for the account of Lessee occur. In the eventLease Fees exceed the Prepayment Fund in any gi
ven month, Lessee shall pay such Lease Fees upon receipt of the invoice for the amounts exceeding thePrepayment Fund, which invo
ice shall be presented within fifteen (15) days of the time such Lease Fees are incurred. Upon termination of this Agreement, anyfunds remaining in the Prepayment Fund 
shall be returned to Lessee within thirty (30) days. As a matter of clarification, the Prepayment Fund is in the nature ofa deposit and not payment for transportation unle
ss and until such time as an invoice for Lease Fees is presented and funds are withdrawn to pay such invoice.5.     
Operating Expenses. Company shall pay al l expenses related to the operation of the Aircraft for time-sharing flights when such expenses areincurred.
6.     
Flight Information. Lessee will provide Company with req uests for flight time and proposed flight schedules as far in advance of any given flightas possible. Requests for f
light time shall be in a form, whether written or oral, mutually convenient to, and agreed upon by the parties. In addition to theproposed schedules and flight ti
mes, Lessee shall provide at least the following information for each proposed flight prior to scheduled departure as required bythe Company or Company's
 flight crew:(a)    proposed departure point;
(b)    destination;
(c)    date and time of flight;
(d)
the number, name, and relationship to the Lessee of ant icipated passengers;(e)    the nature and extent of luggage and/or cargo to be carr
ied;(f)    the date and time of return flight, if an
y; and(g)    any other information concern
ing the proposed flight that may be pertinent or required by Company or Company's flight crew.7.     
Authority to Schedule. Company shall have fina l authority over the scheduling of the Aircraft. It is understood that Company shall not beobligated to retain or contract for add
itional flight crew or maintenance personnel or equipment in order to accommodate Lessee's schedule requests.2

8.     Operational Control. The Company shall be respons ible for all aspects of the physical and technical operation of the Aircraft and the safeperformance of all flights, and 
shall retain and exercise exclusive operational control of the Aircraft during all phases of flight, including pre-flight and post-flightduties, and including, with
out limitation, all flights during which Lessee and/or Lessee’s guests are on-board the Aircraft. Consistent with the Company’soperational control resp
onsibilities, Company shall be solely responsible to secure maintenance, preventive maintenance and required or otherwise necessaryinspections on the Aircraft, and 
shall take such requirements into account in scheduling the Aircraft. All costs and expenses related to the maintenance of theAircraft shall be the respon
sibility of the Company. No period of maintenance, preventative maintenance or inspection shall be delayed or postponed for thepurpose of scheduling
 the Aircraft, unless said maintenance or inspection can be safely conducted at a later time in compliance with all applicable laws andregulations, and within the sound d
iscretion of the pilot in command. All flight operations under this Agreement shall be conducted under Part 91 of the FAR.9.     
Authority of Pilot in Comman d and Flight Crew. For each flight conducted under this Ag reement, the Aircraft will be operated only by a qualifiedflight crew. The pilot 
in command shall have final and complete authority to cancel any flight for any reason or condition that in his or her judgment wouldcompromise the safety of the flight. Le
ssee specifically agrees that the flight crew, in its sole discretion, may terminate any flight, refuse to commence any flight,or take other action which in the 
considered judgment of the pilot in command is necessitated by considerations of safety. No such action of the pilot incommand shall create or support an
y liability for loss, injury, damage or delay to Lessee or any other person. The parties further agree that Company shall notbe liable for delay or fai
lure to furnish the Aircraft and crew pursuant to this Agreement for any reason whatsoever.10.     
Lessee’s Covenants, Representations and War ranties. Lessee covenants, represents and warrant s to the Company that during the term ofthis Agreement:
(a)    Lessee shall use the Ai
rcraft for and on account of Lessee’s own business or personal use only, and will not use the Aircraft for thepurpose of providing transportation of pa
ssengers or cargo for compensation or hire or in violation of applicable FARs or any agreementsentered into by the Company relating to the 
Aircraft;(b)    Lessee shall refrain f
rom incurring any mechanics or other lien in connection with inspection, preventative maintenance, maintenance orstorage of the Aircraft, whether perm
issible or impermissible under this Agreement, and Lessee shall not attempt to convey, mortgage, assign,lease or any way alienate the A
ircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action thatmight mature into such a lien; and
(c)    Lessee shall, and shal
l cause any passengers in Lessee’s party to, abide by and conform to all such laws, governmental and airportorders, rules and regulations, a
s shall from time to time be in effect relating in any way to the use of the Aircraft by a timesharing lessee.11.     
Risk of Loss. The Company assumes and shall bea r the entire risk of loss, theft, confiscation, damage to, or destruction of the Aircraft from anycause whatsoever, except to the extent attributab
le to the gross negligence or willful misconduct of Lessee or Lessee’s guests on the Aircraft.12.     
Insurance. During the term of t his Agreement, the Company shall maintain and have in force (i) all-risk hull insurance covering the fair marketvalue of the Aircraft which
 policy shall be deemed primary in the event of3

any incident or accident and (ii) aviation liability insurance of at least Three Hundred Million Dollars ($300,000,000) combined single limit. Company shall causeLessee to be added as an additional insured to 
its aviation liability insurance.13.     
Home Base. For purposes of this Agreement, the permanent base of ope ration of the Aircraft shall be as set forth on Schedule A hereto, or suchother location as shall b
e determined by the Company from time to time.14.     
Successors and Assigns. Neither this Agreement, nor any pa rty's interest herein shall be assignable to any other party whatsoever. ThisAgreement shall inure to the benefit of and be b
inding upon the parties hereto, and their respective heirs, representatives, successors and permitted assigns.15.     
Governing Law. This Agreement constitutes the enti re agreement of the parties with respect to the time share of the Aircraft as set forth herein.This Agreement shall be governed b
y, and construed in accordance with, the laws of the State of New York.    16.     
Subordination. All rights and interest s of Lessee hereunder and in and to the Aircraft are, and at all times shall be and remain, subject andsubordinate to the rights and interests of the o
wner of each Aircraft under the aircraft lease agreements between such owner and the Company. Notwithstandinganything to the contrary contained herein, th
is Agreement shall terminate, or be canceled, immediately at the option of the Aircraft owner upon the occurrence ofan event of default thereunder.
17.     
Counterparts . This Agreement may be executed in any nu mber of counterparts, each of which shall be deemed an original, and all of whichtogether shall constitute one and the same Ag
reement, binding on all the parties notwithstanding that all the parties are not signatories to the same counterpart.The parties may effectively de
liver an executed counterpart of a signature page of this Agreement by facsimile or in electronic (“pdf” or “tif”) format.18.     
Further Acts . Lessor and Lessee shall from t ime to time perform such other and further acts and execute such other and further instruments asmay be required by law or ma
y be reasonably necessary to: (i) carry out the intent and purpose of this Agreement; and (ii) establish, maintain and protect therespective rights and remed
ies of the other party.19.     
Entire Agreement . This Agreement constitutes the enti re understanding among the Parties with respect to its subject matter, and there are norepresentations, warranties, 
rights, obligations, liabilities, conditions, covenants, or agreements other than as expressly set forth herein.20.     
Severability . In the event that any one or more of the provisions of th is Agreement shall for any reason be held to be invalid, illegal, orunenforceable, those provisions 
shall be replaced by provisions acceptable to both Parties to this Agreement.21.     
Disclaimer; Consequenti al Damages . EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT,  NEITHER COMPANY NORAIRCRAFT OWNER HAVE MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE AIRCRAFT,
INCLUDING WITH RESPECT TO ITS DESIGN, CONDITION, QUAL
ITY OF MATERIALS AND WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANYPARTICULAR PURPOSE, AIRWORTHINESS OR SAFETY. IN NO EVENT SHALL COMPANY OR OWNER BE L
IABLE TO THE LESSEE, ITS MEMBERS,MANAGERS, OFFICERS, DIRECTORS, EMPLOYEES, AFFI
LIATES, GUESTS OR AGENTS (FOR THE PURPOSE OF THIS SECTION 21 HEREOF,COLLECTIVELY, “LESSEE”), FOR ANY INDIRECT, INCIDENTAL,
 CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES, HOWEVER ARISING,4

WHETHER COMPANY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGE, LOSS OR EXPENSE INCLUDING, WITHOUTLIMITATION, IN RESPECT OF ANY DELAY 
IN ARRIVAL OR DEPARTURE.22. 
    Notices. All communication s, declarations, demands, consents, directions, approvals, instructions, requests and notices required or permitted bythis Agreement shall be in
 writing and shall be deemed to have been duly given or made when delivered personally or transmitted electronically by e-mail orfacsimile, receipt a
cknowledged, or in the case of documented overnight delivery service or registered or certified mail, return receipt requested, delivery chargeor postage prepaid, on the date shown on the receipt therefo
r, in each case at the address set forth on Schedule A hereto:23.    TRUTH IN LEASING STATEMENT
 PURSUANT TO 14 CFR PART 91.23THE AIRCRAFT HAVE BEEN MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) DURING THE 12 M
ONTH PERIOD PRECEDING THEDATE OF THIS AGREEMENT.
THE COMPANY, A DELAWARE CORPORATION, CERTIFIES THAT THE AIRCRAFT ARE IN COMP
LIANCE WITH ALL APPLICABLEMAINTENANCE AND INSPECTION REQUIREMENTS FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT. THE AIRCRAFT WILL BE
MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) FOR OPERATIONS 
TO BE CONDUCTED UNDER THIS AGREEMENT.THE COMPANY CERTIFIES AND ACKNOWLEDGES THAT WHENEVER THE AIRCRAFT ARE OPERATED UNDER THIS AGREEMENT, THE
COMPANY SHALL BE KNOWN AS, CONSIDERED AND SHALL IN FACT BE RESPONSIBLE FOR OPERATI
ONAL CONTROL OF THE AIRCRAFTIDENTIFIED AND TO BE OPERATED UNDER THIS AGREEMENT. EACH PARTY CERTIFIES THAT 
IT UNDERSTANDS ITS RESPECTIVERESPONSIBILITIES, IF ANY, FOR COMP
LIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. I, THE UNDERSIGNED, JOHN D. WITZIG, ASVICE PRESIDENT OF THE COMPANY, CERTIFY THAT THE COMPANY IS RESPONSIB
LE FOR OPERATIONAL CONTROL OF THE AIRCRAFT FOROPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT AND THAT THE COMPANY UNDERSTANDS ITS RESPONSIBILITIES FOR COMP
LIANCEWITH APPLICABLE FEDERAL AVIATION REGULATIONS.
EACH PARTY UNDERSTANDS THAT AN EXPLANATION OF FACTORS BEARING ON OPERATIONAL CONTROL
 AND PERTINENT FEDERALAVIATION REGULATIONS CAN BE OBTAINED FROM THE NEAREST FAA
 FLIGHT STANDARDS DISTRICT OFFICE.THE ADDRESS OF THE COMPANY IS 235 EAST 42 
ND STREET, NEW YORK, NEW YORK 10017.IN WITNESS WH
EREOF, the parties have executed this Agreement as of the date first above written.PFIZER INC.
 
  By:/s/ JOHN D. WITZIG
Name: John D. Witzig
Title: Vice President
 
/s/ IAN C. READ
IAN C. READ
5

EXHIBIT 13Pfizer Inc. 2018 Financial Report
  
 

Financial ReviewPfizer Inc. and Subsidiary Companies
 
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 
2018 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 
2018 Financial Report, most of which are explained or defined below: 2018 Financial Report
This Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to  the Annual Report on Form 10-K for the fiscalyear ended December 31, 2018
2018 Form 10-K
Annual Report on Form 10-K for the fiscal year ended Decembe r 31, 2018ABO
Accumulated postretirement benefit obligation ACA (Also referred to as U.S. Healthcare
Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation ActACIP
Advisory Committee on Immunization Practices ALK
anaplastic lymphoma kinase Allergan
Allergan plc Alliance revenues
Revenues from alliance agreements under which we co-promote produc ts discovered or developed by other companies or usAllogene
Allogene Therapeutics, Inc. AMPA
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Anacor
Anacor Pharmaceuticals, Inc. AOCI
Accumulated Other Comprehensive Income Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. ASU
Accounting Standards Update ATM-AVI
aztreonam-avibactam Avillion
Avillion LLP Bain Capital
Bain Capital Private Equity and Bain Capital Life Sciences Bamboo
Bamboo Therapeutics, Inc. Biogen
Biogen Inc. Biopharma
Pfizer Biopharmaceuticals Group BMS
Bristol-Myers Squibb Company BRCA
BReast CAncer susceptibility gene CAR T
chimeric antigen receptor T cell CDC
U.S. Centers for Disease Control and Prevention Cellectis
Cellectis S.A. Cerevel
Cerevel Therapeutics, LLC CIAS
cognitive impairment associated with schizophrenia Citibank
Citibank, N.A. CML
chronic myelogenous leukemia Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Aust ralia, Scandinavian countries, Finland and New ZealandEEA
European Economic Area EGFR
epidermal growth factor receptor EH
Essential Health EMA
European Medicines Agency Emerging Markets
Includes, but is not limited to, the following markets:  Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the MiddleEast, Central Europe and Turkey
EPS
earnings per share EU
European Union Exchange Act
Securities Exchange Act of 1934, as amended FASB
Financial Accounting Standards Board FDA
U.S. Food and Drug Administration GAAP
Generally Accepted Accounting Principles GIST
gastrointestinal stromal tumors GPD
Global Product Development organization GSK
GlaxoSmithKline plc GS&Co.
Goldman, Sachs & Co. LLC HER
human epidermal growth factor receptor HER2-
human epidermal growth factor receptor 2 -negativehGH-CTP
human growth hormoneHIS
Hospira Infusion Systems Hisun
Zhejiang Hisun Pharmaceuticals Co., Ltd. Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited Hospira
Hospira, Inc. HR+
hormone receptor-positive ICU Medical
ICU Medical, Inc. IH
Innovative Health InnoPharma
InnoPharma, Inc. IPR&D
in-process research and development 
2018 Financial Report     
 i
Financial ReviewPfizer Inc. and Subsidiary Companies
 
IRC
Internal Revenue Code IRS
U.S. Internal Revenue Service IV
intravenous Janssen
Janssen Biotech, Inc. J&J
Johnson & Johnson King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.) LDL
low density lipoprotein LEP
Legacy Established Products LIBOR
London Interbank Offered Rate Lilly
Eli Lilly and Company LOE
loss of exclusivity MCC
Merkel Cell Carcinoma MCO
Managed Care Organization Medivation
Medivation, Inc. Merck
Merck & Co., Inc. Meridian
Meridian Medical Technologies, Inc. Moody’s
Moody’s Investors Service NAV
Net asset value NDA
new drug application NovaQuest
NovaQuest Co-Investment Fund II, L.P. o r NovaQuest Co-Investment Fund V, L.P., as applicableNSCLC
non-small cell lung cancer NYSE
New York Stock Exchange OPKO
OPKO Health, Inc. OTC
over-the-counter PARP
poly ADP ribose polymerase PBM
Pharmacy Benefit Manager PBO
Projected benefit obligation Pharmacia
Pharmacia Corporation PPS
Portfolio Performance Shares PP&E
Property, plant & equipment PSAs
Performance Share Awards PsA
psoriatic arthritis PTSRUs
Performance Total Shareholder Return Units PTUs
Profit Units RA
rheumatoid arthritis RCC
renal cell carcinoma R&D
research and development RPI
RPI Finance Trust RSUs
Restricted Stock Units Sandoz
Sandoz, Inc., a division of Novartis AG Sangamo
Sangamo Therapeutics, Inc. SEC
U.S. Securities and Exchange Commission Servier
Les Laboratoires Servier SAS SFJ
SFJ Pharmaceuticals Shire
Shire International GmbH SI&A
Selling, informational and administrative S&P
Standard and Poor’s SIP
Sterile Injectable Pharmaceuticals StratCO
Strategy and Commercial Operations Tax Cuts and Jobs Act or TCJA
Legislation commonly referred to as the U.S. Tax Cuts and  Jobs Act of 2017Teuto
Laboratório Teuto Brasileiro S.A. Teva
Teva Pharmaceuticals USA, Inc. TSR
Total Shareholder Return TSRUs
Total Shareholder Return Units U.K.
United Kingdom U.S.
United States ViiV
ViiV Healthcare Limited WRD
Worldwide Research and Development ii
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
INTRODUCTION
See the Glossary of Defined Terms at the beginning of this 
2018 Financial Report for terms used throughout this Financial Review . Our Financial Review is provided to assist readers in understanding the results of operations, financial condition and cash flows of Pfizer Inc. and its subsidiaries (the Company). It should be
 read in conjunction with theconsolidated financial statements and Notes to Consolidated Financial Statements. The discussion in this Financial Review contains forward-looking statements that involve
substantial risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, such as
those discussed in Part 1, Item 1A, “Risk Factors” of our 
2018 Form 10-K and in the “Forward-Looking Information and Factors That May Affect Future Results”, “Our Operating Environment” and “Our Strategy” sections of this Financial Review.
The Financial Review is organized as follows:
●
 Overview of Our Performance, Operating Environment, Strategy and OutlookBeginning on page 2  
 This section provides information about the following: Financial Highlights; Our Business; Our 2018 Performance; Our Operating Environment;The Global Economic Environment, Our Strategy; Our Business Development 
Initiatives, such as acquisitions, dispositions, licensing andcollaborations; and Our Financial Guidance for 2019.
  ●
 Significant Accounting Policies and Application of Critical Accounting Estimates and AssumptionsBeginning on page 16  
 This section discusses those accounting policies and estimates that we consider important in understanding our consolidated financialstatements. For additional discussion of our accounting policies, see Notes to Consolidated Financial Statements— 
Note 1. Basis of Presentation and Significant Accounting Policies 
.   ●
 Analysis of the Consolidated Statements of IncomeBeginning on page 20  
 This section includes the following sub-sections:   
○  Revenues—OverviewBeginning on page 20  
 This sub-section provides a high-level summary of our revenues, including revenue deductions.   
○  Revenues by Segment and GeographyBeginning on page 22  
 This sub-section provides an overview of revenues by segment and geography.   
○  Revenues––Selected Product DiscussionBeginning on page 24  
 This sub-section provides an overview of several of our biopharmaceutical products.   
○  Product Developments––BiopharmaceuticalBeginning on page 29  
 This sub-section provides an overview of important biopharmaceutical product developments.   
○  Costs and ExpensesBeginning on page 33  
 This sub-section provides a discussion about our costs and expenses.   
○  Provision/(Benefit) for Taxes on IncomeBeginning on page 36  
 This sub-section provides a discussion of items impacting our tax provisions.   
○  Non-GAAP Financial Measure (Adjusted Income)Beginning on page 37  
 This sub-section provides a discussion of an alternative view of performance used by management.  ●
 Analysis of Operating Segment InformationBeginning on page 42  
 This section provides a discussion of  the performance of each of our opera ting segments.  ●
 Analysis of the Consolidated Statements of Comprehensive IncomeBeginning on page 51  
 This section provides a discussion of changes in certain components of other comprehensive income.  ●
 Analysis of the Consolidated Balance SheetsBeginning on page 52  
 This section provides a discussion of changes in certain balance sheet accounts, including Accumulated other comprehensive loss .   ●
 Analysis of the Consolidated Statements of Cash FlowsBeginning on page 53  
 This section provides an analysis of our consolidated cash flows for the three years ended December 31, 2018.  ●
 Analysis of Financial Condition, Liquidity and Capital ResourcesBeginning on page 55  
 This section provides an analysis of selected measures of our liquidity and of our capital resources as of December 31, 2018 andDecember 31, 2017, as well as a discussion of our outstanding debt
 and other commitments that existed as of December 31, 2018 andDecember 31, 2017. Included in the discussion of outstanding debt
 is a discussion of the amount of financial capacity available to help fundPfizer’s future activities.
  ●
 New Accounting StandardsBeginning on page 59  
 This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yetadopted.
  ●
 Forward-Looking Information and Factors That May Effect Future ResultsBeginning on page 61  
 This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed inforward-looking statements presented in this Financial Review. Also included in this section are discussions of Financial Risk Management
and Contingencies, including legal and tax matters.
  Certain amounts in our Financial Review may not add due to rounding. All percentages have been calculated using unrounded amounts.
2018 Financial Report    
 
 1
Financial ReviewPfizer Inc. and Subsidiary Companies
 
OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK
Financial Highlights
The following charts provide a summary of certain financial performance (in billions, except per share data):
2018 Total Revenues––$53.6 billion
2018 Net Cash Flow from Operations––$15.8 billion An increase of 2% compared to 2017
A decrease of 6% compared to 2017 
 
2018 Reported Diluted EPS––$1.87
2018 Adjusted Diluted EPS (Non- GAAP )––$3.00* A decrease of 47% compared to 2017
An increase of 13% compared to 201 7 
 
*
For an understanding of Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP reported to non-GAAP adjusted information, see the “Non-GAAP FinancialMeasure (Adjusted Income)” sectio
n of this Financial Review.Our Business
We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of
healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across
developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our 
time. We collaborate with healthcareproviders, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our
products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us 
(Alliance revenues). From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through 
two distinct business segments: Pfizer InnovativeHealth (IH) and Pfizer Essential Health (EH). For additional information about this operating structure, see Notes to Consolidated Financial Statements–– 
Note 18A. Segment, Geographic and Other Revenue Information: Segment Information. 
At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global commercial structure consisting of three businesses. See the “Our Strategy––Organizing for Growth” and “––Commercial Operations” sections of this Financial Review
below for additional information.
On January 1, 2019, Dr. Albert Bourla succeeded Ian Read as Chief Executive 
Officer of the company and Ian Read transitioned from his role as Chairman and ChiefExecutive Officer to Executive Chairman of Pfizer’s Board of Directors.
The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The biopharmaceutical industry is highly competitive and highly regulated.
As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others:
 the loss or expirationof intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation,
pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For
additional information about these factors and challenges, see the “Our Operating Environment” and “The Global Economic Environment” sections of this Financial Review and
Part I, Item 1A, “Risk Factors” of our 
2018 Form 10-K. 2
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
The financial information included in our consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30 for each
year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented.
References to developed and emerging markets in this Financial Review include:
Developed markets
 U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinaviancountries, Finland and New Zealand
 
   Emerging markets (include, but are not limited to) Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, theMiddle East, Central Europe and Turkey
References to operational variances in this Financial Review pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances
are determined by multiplying or dividing, as appropriate, our current year U.S. dollar results by the current year average foreign exchange rates and then multiplying or
dividing, as appropriate, those amounts by the prior-year average foreign exchange rates. Although exchange rate changes are part of our business,
 they are not within ourcontrol. Exchange rate changes, however, can mask positive or negative trends in the business; therefore,
 we believe presenting operational variances provides usefulinformation to evaluate the results of our business.
On December 22, 2017, the U.S. enacted significant changes to
 U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changesthe U.S. corporate income tax system by, among other things, reducing the U.
S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from aworldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. 
For information on the TCJA, see Notes to Consolidated Financial Statements–– 
Note 5A . Tax Matters: Taxes on Income from Continuing Operations.Our significant recent business development activities include:
•
On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumerhealthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name. The joint venture is expected to
be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health and will be the largest global OTC
consumer healthcare business. In exchange for contributing our Consumer Healthcare business, we will receive a 32% equity stake in the company 
and GSK will own the remaining 68%. The transaction is expected to close in the second half of 2019, subject
 to customary closing conditions including GSK shareholder approval and requiredregulatory approvals. For additional information, see Notes to Consolidated Financial Statements–– 
Note 2C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
: Assets and Liabilities Held for Sale 
and the “Our Strategy” section of this Financial Review below. •
On February 3, 2017, we completed the sale of Pfizer’s global infusion systems net assets, HIS, to ICU Medical for up to approximately $900 million , composed of cash andcontingent cash consideration, ICU Medical common stock and seller financing 
. At closing, we received 3.2 million newly issued shares of ICU Medical common stock, which we initially valued at approximately 
$428 million (all of which we sold during 2018), a promissory note in the amount of $75 million and net cash of approximately $200 million 
before customary adjustments for net working capital. In addition, we are entitled to receive a contingent amount o f up to an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The operating results of HIS are included in
our consolidated statement of income and EH’s operating results through February 2, 2017 and, therefore, our financial results, and 
EH’s operating results, for the yearended December 31, 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial
results, and EH’s operating results, for the year ended December 31, 2016 reflect 12 months of HI
S global operations. Our financial results, and EH’s operating results, for2018 
do not reflect any contribution from HIS global operations. •
On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. 
for $1,040 million , composed of cash and contingent consideration. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and
, in accordance with our international reportingperiod, our financial results, EH’s operating results, and cash flows for the year ended December 31, 2017 reflect approximately 11 months of the small molecule anti-
infectives business acquired from AstraZeneca.
•
On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( 
$13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities . The remaining consideration was paid as of 
December 31, 2017 . Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended
December 31, 2016 reflect approximately three months of Medivation operations.
•
On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion , net of cash acquired), plus 
$698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016
reflect approximately six months of Anacor operations.
•
On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of thecompanies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016
, which the companies concluded qualified as an“Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal
quarter of 2016), Pfizer paid Allergan
2018 Financial Report    
 
 3
Financial ReviewPfizer Inc. and Subsidiary Companies
 
$150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see the Notes to Consolidated Financial Statements–– 
Note 4 . Other (Income)/Deductions 
–– Net ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement.For additional information, see Notes to Consolidated Financial Statements–– 
Note 2. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
and the “Our Strategy” and “Our Business Development Initiatives” sections of this Financial Review below.
Impact of Hurricanes in Puerto Rico
We have manufacturing and commercial operations in Puerto Rico, which were impacted by the hurricanes toward the end of the third quarter in 2017. While our three
manufacturing sites in Puerto Rico sustained some damage and became inoperable due to issues impacting Puerto Rico overall, all three sites have resumed operations and
remediation activities were completed in 2018. Our commercial sales offices in Puerto Rico have been operational since October 2017.
Product Manufacturing
We periodically encounter difficulties or delays in manufacturing, including due to suspension of manufacturing or voluntary recall of a product, or legal or regulatory actions
such as warning letters. For example, Hospira’s manufacturing facility in McPherson, Kansas is currently under the FDA inspection status of Official Action Indicated
 (OAI). Asa result of this status, the FDA may refuse to
 grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufacturedat our McPherson site until the site status is upgraded, which will require a successful re-inspection by the FDA. Future FDA inspections and regulatory activities will further
assess the adequacy and sustainability of corrections implemented at the site. Communication with the FDA on the sta
tus of the McPherson site is ongoing. For additionalinformation regarding the FDA inspection of the McPherson site, see Part I, I
tem 1A, “Risk Factors––Product Manufacturing, Sales and Marketing Risks” of our 2018 Form 10-K.
The product shortages we have been experiencing within our portfolio are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints,
technical issues and supplier quality concerns. We continue to remediate issues at legacy Hospira facilities manufacturing sterile injectables. Any continuing product shortage
interruption at these manufacturing facilities could negatively impact our financial results, specifically in our SIP portfolio. We continue to make progress on our comprehensive
remediation plan to upgrade and modernize these facilities, and we expect our supply issues to be substantially improved by the end of 2019.
Our 
2018 Performance Revenues–– 
2018 Revenues 
in 2018 increase d by $1.1 billion , or 2% , compared to 2017 , which reflects operational growth of $791 million , or 2% , and the favorable impact of foreign exchange of 
$310 million , or less than 1%. The following graph illustrates the components of the 
increase in revenues in 2018 : 
*
LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.4
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
The following provides an analysis of the changes in revenues in 
2018 : (MILLIONS OF DOLLARS)
    
   2017 
Revenues   $52,546  
   Operational growth/(decline):
   Continued growth from key brands 
(a)  and from recently launched products (b) , as well as growth from Biosimilars (c)  and our ConsumerHealthcare business, and the impact from CentreOne
  3,377 Declines from total Viagra 
(d)  (primarily in the U.S.), the Peri-LOE Products portfolio (excluding Viagra EH (d) , which was impacted by the shiftin the reporting of U.S. and Canada Viagra revenues to EH), the S
IP portfolio (primarily in developed markets), the LEP portfolio (primarily indeveloped markets), Enbrel (driven by declines in most developed Europe markets) and the hemophilia portfolio (primarily in developed
Europe)
  (2,520 ) Disposition-related impact of the February 2017 sale of HIS 
(e)  (97 )Other operational factors, net
  31 Operational growth, net
  791  
   Operational revenues
  53,337 Favorable impact of foreign exchange
  310 2018 
Revenues   $53,647 (a) 
 K ey brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 1 3, Xtandi, Lyrica-IH and Chantix/Champix.(b) 
 Growth from recently launched products include Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed Europe.(c) 
 Growth in Biosimilars, primarily from Inflectra in certain channels in the U.S., as well as in developed Europe.(d)
 
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenuesexcluding the U.S. and Cana
da through 2017). Therefore, in 2018, total Viagra revenues were reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH andViagra EH.
(e)
 
Impact on financial results for the sale of HIS in February 2017. The 2018 financial results do not reflect any contribution from HIS global operations, compared to approximately one month of HIS domesticoperations and approximately
 two months of HIS international operations in 2017.See the “Analysis of the Consolidated Statements of Income 
–– Revenues –– Overview” section below for more information, including a discussion of key drivers of ourrevenue performance.
Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income–– 
2018 The following provides an analysis of the 
decrease in Income from continuing operations before provision/benefit) for taxes on income for 2018 : (MILLIONS OF DOLLARS)
    
   Income from continuing operations before provision/(benefit) for taxes on income 
for the year ended December 31, 2017   $12,305  
   Favorable change in revenues
  1,101  
   Favorable/(Unfavorable) changes:
   Higher certain asset impairments 
(a)  (2,720 ) Higher 
Restructuring charges and certain acquisition-related costs (b)  (693 )Higher 
Research and development expenses (c)  (322 )Impact of net realized (gains)/losses on sales of investments in debt securities 
(a)  (186 )Lower net losses on early retirement of debt 
(a)  996 Impact of net periodic benefit costs/(credits) other than service costs 
(a)  389 Higher net gains recognized during the period on investments in equity securities 
(a)  362 Lower 
Selling, information and administrative expenses (d)  350 Higher income from collaborations, out-licensing arrangements and sales of compound/product rights 
(a)  271 All other items, net
  33 Income from continuing operations before provision/(benefit) for taxes on income 
for the year ended December 31, 2018   $11,885 (a) 
 See the Notes to Consolidated Financial Statements–– Note 4. Other (Income)/Deductions—Net . (b)
 
See the “Costs and Expenses–– Restructuring Charges and Oth er Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives ” and Notes to Consolidated Fin ancial Statements–– Note 3 . Restructuring Charges and Oth
er Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . (c) 
 See the “Costs and Expenses––Research and Development (R&D) Expenses” section of this Financial Review.(d) 
 See the “Costs and Expenses––Selling, Informational and Administrative (SI&A) Expenses” section of this Financial Review.For information on our tax provision and effective tax rate see the “Provision/(Benefit) for Taxes on Income” section o
f this Financial Review and Notes to ConsolidatedFinancial Statements–– 
Note 5A . Tax Matters: Taxes on Income from Continuing Operations.2018 Financial Report    
 
 5
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Our Operating Environment
Industry-Specific Challenges
Intellectual Property Rights 
and Collaboration/Licensing RightsThe loss, expiration or invalidation of intellectual property rights, patent litigation settlements with generic manufacturers and the expiration of co-promotion and licensing rights
can have a significant adverse effect on our revenues. Many of our branded products have multiple patents
 that expire at varying dates, thereby strengthening our overallpatent protection. However, once patent protection has expired or has been lost prior to the
 expiration date as a result of a legal challenge, we lose exclusivity on theseproducts, and generic pharmaceutical manufacturers generally produce similar products and sell them for a lower price. 
The date at which generic competition commences may be different from the date that the paten
t or regulatory exclusivity expires. However, when generic competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. Also,
 if one of our patents is found to be invalid by judicial, court oradministrative proceedings, such as inter partes 
review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, generic or competitive products could be introduced into
 the market resulting in the erosion of sales of our existingproducts. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In
June 2018, the Patent Trial and Appeal Board ruled on one patent
, holding that one claim was valid and that all other claims were invalid. The party challenging that patent hasappealed the decision. Challenges to other patents remain pending before the U.S. Patent
 and Trademark Office. The invalidation of these patents could potentially allow acompetitor pneumococcal vaccine into the marketplace.
A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. 
For example, as a result of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S
. in December 2017. In addition, the basic product patent for Lyrica in the U.S. will expirein June 2019, which includes the FDA’s grant of pediatric exclusivity that extended the period of market exclusivity in the U.
S. for Lyrica for an additional six months fromDecember 2018.
For additional information, see the “Recent Losses and Expected Losses of Product Exclusivity” section below.
Our biologic products, including BeneFIX, ReFacto, Xyntha, Bavencio, Prevnar 13/
Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada), may face in thefuture, or already face, competition from biosimilars (also referred to as follow-on biologics). 
If competitors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. For
example, Enbrel faces ongoing biosimilar competition in most developed Europe markets. The expiration or successful challenge of applicable patent rights could trigger this
competition, assuming any relevant regulatory exclusivity period has expired.
We have lost exclusivity for a number of our products in certain markets and we have lost collaboration rights with respect to a number of our alliance products in certain
markets, and we expect certain products to face significantly increased generic competition over the next few years.
Specifically:
Recent Losses and Expected Losses of Product Exclusivity
The following table provides information about certain of our products recently experiencing, or expected to experience in 
2019 , patent expirations or loss of regulatory exclusivity in the U.S., Europe or Japan, showing, by product, the key
 dates or expected key dates, the markets impacted and the revenues associated with those products inthose markets:
(MILLIONS OF DOLLARS)
        Product Revenues in Markets Impacted Products
  Key Dates (a)  Markets Impacted   Year Ended December 31,  
        2018  2017  2016 Viagra 
(b) 
June 2013 May 2014 
December 2017
  Major European markets Japan 
U.S.
  $274  
$850  
$1,217 Lyrica 
(c) 
July 2014June 2019
  Major European marketsU.S.
  3,852 3,901 3,831Zyvox 
(d) 
August 2014First half of 2015
January 2016
  JapanU.S.
Major European markets
  62 
103 
235Relpax
 December 2015December 2016
  Major European marketsU.S.
  90 176 263Vfend
 July 2016January 2016
  Major European marketsJapan
  106 150 299Tygacil
  April 2016  U.S.  25  45  80 Pristiq 
(e) March 2017  U.S.  71  133  578 (a) 
 Unless stated otherwise, “Key Dates” indicate patent-based expiration dates.(b) 
 As a result of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S. in December 2017.(c)
 
In November 2018, the FDA granted pediatric exclusivity for Lyrica in the U.S. for an additional six months to June 2019; pediatric exclusivity applies to both the basic product patent for Lyrica and a method oftreatment patent, both of
 which expired in the U.S. in December 2018.(d)
 
Pursuant to terms of a settlement agreement, certain formulations of Zyvox became subject to generic competition in the U.S. in January 2015. Other formulations of Zyvox became subject to generic competitionin the U.S. in the first half of 2015.
(e) 
 As a result of a patent litigation settlement with several generic manufacturers, generic versions of Pristiq launched in the U.S. in March 2017.6
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product
patent expires, see the “Patents and Other In
tellectual Property Rights” section in Part I, Item 1, “Business” of our 2018 Form 10-K. Our financial results in 
2018 reflect the impact of the loss of exclusivity of various products discussed above. We will continue to aggressively defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see
Notes to Consolidated Financial Statements–– 
Note 17A1. Contingencies and Certain Commitments : Legal Proceedings –– Patent Litigation . Regulatory Environment/Pricing a
nd Access––U.S. Healthcare LegislationIn March 2010, the ACA was enacted in the U.S.
 For additional information, see the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business”, of our2018 
Form 10-K. We recorded the following amounts as a result of the U.S. Healthcare Legislation:
Year Ended December 31,
(MILLIONS OF DOLLARS)
2018 2017 2016 Reduction to 
Revenues , related to the Medicare “coverage gap” discount provision $674 $ 450 $ 410 Selling, informational and administrative expenses 
, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of
branded prescription drug sales to specified government programs. 2018 also reflected a favorable true-up associated
with the updated 2017 invoice received from the federal government, which reflected a lower expense than what was
previously estimated for invoiced periods.
184 307 312 Regulatory Environment/P
ricing and Access––Government and Other Payer Group PressuresThe pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be
important to payers, governments, patients, and other stakeholders. We believe that medicines are amongst the
 most powerful tool for patients in curing, treating andpreventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when
determining a medicine’s price, including, for example, its impact on patients and their disease, other available treatments, the medicine’s potential to reduce other healthcare
costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with pa
tients, doctors and healthcare plans regarding their views. We alsonegotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the initial price. The price that patients pay
 in the U.S. for the medicinestheir physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers cover a much lower share of prescription drug costs than
medical services, which results in a greater proportion of out-of-pocket costs being passed on to patients for medicines, thereby making them less accessible and affordable.
We will continue to work with insurance providers, governments and others to improve access to today’s innovative treatments.
Governments, MCOs and other payer groups continue to seek increasing discounts on our products through a variety of means,
 such as leveraging their purchasing power,implementing price controls, and demanding price cuts (directly or by rebate actions). 
In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices
or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global economic pressures. 
In the U.S., government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or services provided using our
products. Any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented
could have an adverse impact on our results of operations. Significant Medicare reductions could also result if, for example, Congress proceeds with certain proposals to
convert the Medicare fee-for-service program into a premium support program, or Congress chooses to implement the recommendations made annually by the Medicare
Payment Advisory Commission, which are primarily intended to extend the fiscal solvency of the Medicare program.
Consolidation among MCOs has increased the negotiating power of MCOs and other third-party payers. Private third-party payers, as well as governments, increasingly
employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain
or maintain timely or adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely
impact revenue.
Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could
adversely affect our business if implemented. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the
perceived high cost of pharmaceuticals. At the federal level, for example, in May 2018, President Trump released his 
Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs 
(Blueprint). Pfizer communicated a formal response to the request for information that accompanied the Blueprint, and is participating in the subsequent rule-making process to advance the proposals that are most likely to bring meaningful out-of-pocket cost relief to patients.
 Certain proposals in the Blueprint, and related drug pricingmeasures proposed since the Blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry. As another example, in October 2018,
the Centers for Medicare and Medicaid Services solicited public comments on potential changes to payment for certain Medicare Part B drugs, including reducing the Medicare
payment amount for selected Medicare Part B drugs to more closely align with international drug prices. In addition, in January 2019, the White House O
ffice of Managementand Budget released the long awaited proposed rule submitted by the Office of 
Inspector General of the Department of Health and Human Services to remove safe harborprotections for drug rebates paid to insurance plans and PBMs for Medicare Part D and Managed Medicaid
2018 Financial Report    
 
 7
Financial ReviewPfizer Inc. and Subsidiary Companies
 
and to create new safe harbors. Among other changes, the proposed rule would explicitly exclude the reductions in price offered by drug manufacturers to
 PBMs in MedicarePart D and Managed Medicaid plans from protection under the “discount” safe harbor. It would also create a new safe harbor designed specifically for price reductions in
pharmaceutical products, but only those that are fully reflected in the price to the pa
tient at the pharmacy counter. Additionally, a new safe harbor was proposed to protectadministrative fees paid to PBMs, which must be at fair market value, a fixed fee and
 not based upon a percentage of volume or list price. Manufacturers could continue tonegotiate price reductions with PBMs and Medicare Part D and Managed Medicaid plans if their reductions meet that criterion. The proposed rule represents a large step
toward significantly altering the current rebate model in place with MCOs. We are in the process of evaluating the implications of the proposed rule on our operations and
processes, as well as the infrastructure that will be required in order to implement the rule once it is finalized. There have also been state legislative efforts to address drug
costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. Certain state legislation has been subject to legal challenges.
Adoption of new legislation regulating drug pricing at the federal or state level could further affect demand for, or pricing of, our products.
We believe medicines are the most efficient and effective use of healthcare dollars based on the value they
 deliver to the overall healthcare system. We will continue to workwith lawmakers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare sys
tem, and ensure access to medicines within anefficient and affordable healthcare system.
There have been significant efforts at the federal and state levels to
 reform the healthcare system by enhancing access to healthcare, improving the delivery of healthcare andfurther rationalizing payment for healthcare. For example, we face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate
some or all of the provisions of the ACA. For example, tax reform legislation enacted at the end
 of 2017 eliminates the tax penalty for individuals who do not maintain sufficienthealth insurance coverage beginning in 2019 (the so-called “individual mandate”). We anticipate continued Congressional interest in modifying provisions of the ACA,
particularly given the recent ruling in 
Texas v. Azar to invalidate the law as unconstitutional. At this time, the law remains in effect pending appeals o f the decision. Given theoutcomes of the 2018 U.S. midterm elections with Democrats taking over the U.S. House of
 Representatives and Republicans growing their majority in the U.S. Senate, webelieve it is unlikely Congress will find bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. The revenues generated for P
fizerby the health insurance exchanges and Medicaid expansion under the ACA are not material, so the impact of 
the change in law and similar recent administration actions isexpected to be limited. Any future replacement, modification or repeal of the ACA may adversely affec
t our business and financial results, particularly if the legislation reducesincentives for employer-sponsored insurance coverage. As another example, the Bipartisan Budget Act of 2018, which increased the discount we pay
 in the Medicare Part D“coverage gap” from 50% to 70%, will modestly increase our future Medicare Part D rebates. Any future healthcare reform efforts may adversely affect our business and
financial results.
Pfizer continues to monitor the ongoing dialogue around drug pricing and will take necessary action accordingly. After deferring previously announced price increases in July
2018, Pfizer increased the list price of certain products (comprising about 10% of its entire drug portfolio) effective January 15, 2019.
The potential for additional pricing and access pressures in the commercial sector continues to be significant. Some employers, seeking to avoid the tax on high-cost health
insurance in the ACA to be imposed in 2022, are already scaling back healthcare benefits and an increasing number are implementing high deductible benefit designs. This is
a trend that is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower
reimbursement rates and a reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare
provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review
processes.
Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health
outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward
providers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and restricted access 
to, new medicines. Atthe same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as a means of forestalling more
costly medical interventions.
Outside the U.S., governments, including the different EU Member States
, Japan, China, Canada and South Korea, may use a variety of cost-containment measures for ourpharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access and international
reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries). This international patchwork of price regulation and differing
economic conditions and incomplete value assessments across countries has led to varying health outcomes and some third-party trade in our products between countries.
In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price variations,
exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting from this dynamic can be
expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some European countries.
In addition, several important multilateral organizations, such as the United Nations (UN), including the World Health Organization (WHO), and the Organization for Economic
Cooperation and Development (OECD), are increasing scrutiny of international pharmaceutical pricing through issuing reports and policy recommendations (e.g., 
2016 UN High Level Panel Report on Access to Medicines 
). Late in 2018, two new reports critical of the pharmaceutical industry’s pricing practices were published: OECD’s Pharmaceutical Innovation and Access to Medicines 
and WHO’s Pricing of Cancer Medicines and its Impacts . These reports and upcoming public forums focused on their recommendations will continue to exert additional pricing pressures.
8
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
In response to the evolving U.S. and global healthcare spending landscape, we are continuing to work with health authorities, health 
technology assessment and qualitymeasurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products
. Further,we are seeking to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by
recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs.
Regulatory Environment––Pipeline
 ProductivityThe discovery and development of safe, effective new products, as well as the development o
f additional uses for existing products, are necessary for the continued strength ofour businesses. We have encountered increasing regulatory scrutiny of drug safety and efficacy, even as we continue 
to gather safety and other data on our products, beforeand after the products have been launched. Our product lines must be replenished over time in order to offse
t revenue losses when products lose their market exclusivity, aswell as to provide for earnings growth. We devote considerable resources to R&D activities. These activities involve a high degree of risk and cost and may take many years,
and with respect to any specific R&D project, there can be no assurance that 
the development of any particular product candidate or new indication for an in-line product willachieve the desired clinical endpoints and safety profile, will be approved by regulators or will be successful commercially.
During the development of a product, we conduct clinical trials to provide data on the drug’s safety and ef
ficacy to support the evaluation of its overall benefit-risk profile for aparticular patient population. In addition, after a product has been approved and launched, we continue 
to monitor its safety as long as it is available to patients, andpostmarketing trials may be conducted, including trials requested by regulators and trials that we do voluntarily to gain additional medical knowledge. For the entire life of the
product, we collect safety data and report safety information to the
 FDA and other regulatory authorities. The FDA and regulatory authorities in other jurisdictions may evaluatepotential safety concerns related to a product or a class of products and 
take regulatory actions in response, such as updating a product’s labeling, restricting the use of aproduct, communicating new safety information to the public, or, in rare cases, removing a product from the market.
Competition
Many of our prescription pharmaceutical products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. 
For additional information, see the “Competition” section in Part I, Item 1, “Business” of our 
2018 Form 10-K. The Global Economic Environment
In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed 
to the economic cycle, which impacts our biopharmaceuticaloperations globally.
•
Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on accessto medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments.
 Government financingpressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private
health technology assessments), or other means of cost control. Examples include the different EU Member Sta
tes, Japan, China, Canada, South Korea and a number ofother international markets. The U.S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growing
government influence as government programs continue to grow as a source of coverage.
•
Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. We seek tomanage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency
assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments
and foreign currency debt. As we operate in multiple foreign currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound
, the Canadian dollarand approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken
against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses
would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained
constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore,
significant changes in foreign exchange rates can impact our results and our financial guidance.
The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and Argentina, can
impact our results and financial guidance 
. For further information about our exposure to foreign currency risk, see the “Analysis of Financial Condition, Liquidity and Capital Resources” and the “Our Financial Guidance for 
2019 ” sections of this Financial Review. •
In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as “Brexit”. In March 2017, the U.K. government formally notifiedthe European Council of its intention to leave the EU after it 
triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of theexit and outlining the future relationship between the U.K. and the EU.
 Formal negotiations officially started in June 2017. This process continues to be highly complex andthe end result of these negotiations may pose certain implications to our research, commercial and general business operations in the U.K. and the EU,
 including theapproval and supply of our products. The EMA will be relocating from London, U.K. to Amsterdam, Netherlands by the
 scheduled date of Brexit at the end of March 2019.At present, it is still unclear whether and to what extent the U.
K. will remain within or aligned to the EU system of medicines regulation, and/or what separate requirementswill be imposed in the U.K. after it leaves the EU. However, both the U.K
. and the EU have issued detailed guidance for the industry on how medicines, medical devicesand clinical trials will be separately regulated in their respective territories in the event of a ‘hard Brexit’, meaning an outcome where no negotiated settlement is reached.
2018 Financial Report    
 
 9
Financial ReviewPfizer Inc. and Subsidiary Companies
 
We generated approximately 
2% of our worldwide revenues from the U.K. in 2018 including the foreign currency exchange impact from the weakening U.K. pound relative to the U.S. dollar to date. We recognize that 
there are still significant uncertainties surrounding the ultimate resolution of Brexit negotiations, and we will continue to monitorany changes that may arise and assess their potential impact on our business.
Pfizer’s preparations are well advanced to make the changes necessary to meet EU legal requirements after the U.K. is no longer a member state,
 especially in theregulatory, research, manufacturing and supply chain areas. The aim is to ensure the continuity of supply to patients in 
Europe (EU and the U.K.) and other global marketsimpacted by these changes. The one-time costs of making these adaptations are currently estimated at
 approximately $100 million and are expected to be incurredbetween 2018 and 2021.
•
On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantlychanges the U.S. corporate income tax system by, among other things, reducing the
 U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. internationaltaxation from a worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign
subsidiaries. 
For additional information, see the “Provision/(Benefit) for Taxes on Income” and “Analysis of Financial Condition, Liquidity and Capital Resources” sections of this Financial Review and Notes to Consolidated Financial Statements–– 
Note 5A . Tax Matters: Taxes on Income from Continuing Operations.Pfizer maintains a strong financial position while operating in a complex global environment. Due to our significant operating cash flows, financial assets, access to capital
markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the
foreseeable future. Our long-term debt is rated high quality by both S&P and Moody’s. 
As market conditions change, we continue to monitor our liquidity position. We havetaken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid,
well-diversified, available-for-sale debt securities. For further discussion of our financial condition and credit ratings, see the “Analysis of Financial Condition, Liquidity and
Capital Resources” section of this Financial Review.
These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors
That May Affect Future Results” section of this Financial Review and in Part I, 
Item 1A, “Risk Factors” of our 2018 Form 10-K. Our Strategy
We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also 
from a reductionin other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in
dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and 
treat disease and improve outcomes. We continueto work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access
and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company’s purpose: 
Breakthroughs that change patients’ lives . By doing so, we expect to create value for the patients we serve and for our shareholders.
Organizing for Growth
Today Pfizer has what we believe is the best pipeline in our history and several new industry-leading medicines that position us well for future growth. Following the impact of
the expected patent expiration of Lyrica in the U.S. in mid-2019, we expect 
to enter a period of significantly reduced revenue impact from patent expiries. This confluence ofevents has given us an opportunity to look at and refine how we organize our business to best
 achieve sustainable growth and to deliver our medicines and vaccines to themaximum number of people who need them.
At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each
 of which is led bya single manager—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Pfizer’s Consumer Healthcare business. We designed this new global structure to take
advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets.
Some additional information about each business follows:
•
Biopharma—a science-based innovative medicines business that includes our Innovative Health business units (except our Consumer Healthcare business), as well as anew Hospital business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We also incorporated our biosimilar portfolio into our
Oncology and Inflammation & Immunology therapeutic areas.
•
Upjohn—an off-patent branded and generic established medicines business, headquartered in China that includes 20 of our off-patent solid oral dose legacy brandsincluding Lyrica, Lipitor, Norvasc, Viagra and Celebrex, as well as certain generic medicines.
•
Pfizer’s Consumer Healthcare business—an over-the-counter medicines business, which we announced on December 19, 2018 will be contributed to, and combined with,GSK’s consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32%. See Notes to Consolidated Financial Statements–– 
Note 2C. 
Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-MethodInvestments and Privately Held Investment 
: Assets and Liabilities Held for Sale. We also reorganized our R&D operations as part of our Organizing for Growth reorganization:
•
WRD is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical & Safety organization in WRD that incorporatesthe former Chief Medical Office as well as the Worldwide Safety function;
•
The R&D organization within the EH business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars into WRDM and GPD andrealigning them with the relevant therapeutic areas (e.g., Oncology and Inflammation & Immunology);
•
The Regulatory function has been moved from the WRDM organization into the GPD organization; and•
Late-stage portfolio spend has been moved from IH to GPD and from EH to GPD and Upjohn.10
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
We re-aligned our commercial operations in 2019 for a number of reasons, including:
•
Bringing biosimilars into their therapeutic categories gives us the potential to leverage our R&D, regulatory and commercial infrastructure within the Biopharma business tomore efficiently bring those assets to market;
•
Making a business unit that is solely focused on medicines that are used in hospitals can potentially bring greater focus and attention to serving those customers anddeveloping those relationships;
•
Giving the Upjohn business more autonomy and a focus on maximizing the value of its products, particularly in emerging markets, gives it the opportunity to operate as astandalone business within Pfizer with the potential for sustainable modest growth; and
•
We believe this new structure better positions each business to achieve its growth potential as we transition to a period post-2020 where we expect higher and moresustained revenue growth due to declining LOEs and the potential of our late-stage pipeline.
Biopharma seeks to leverage a strong pipeline, organize around operational growth drivers, and capitalize on trends creating long-term growth opportunities, including:
•
An aging global population that is generating increased demand for innovative medicines that address patients’ unmet needs;•
Advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines; and•
The increasingly significant role of hospitals in healthcare systems.Urbanization and the rise of the middle class in emerging markets, particularly in Asia, provide growth opportunities for the Upjohn business. Our ability to work collaboratively
within local markets and to be fast, focused and flexible is intended to position this business to
 seize these opportunities. Upjohn will have distinct and dedicatedmanufacturing, marketing, regulatory and, subject to limited exceptions, enabling functions that report directly into the business providing autonomy and positioning Upjohn to
operate as a true stand-alone division. We created this new structure to, among other things, position Upjohn to
 optimize its distinct growth potential and provide us with theflexibility to access further opportunities to enhance value, which we continue to consider.
Results for 2018 and prior periods in our 2018 Form 10-K and in this 2018 Financial Report are reported on the basis under which we managed our business in 2018 and do
not reflect the 2019 reorganization. Beginning with our first-quarter 2019 financial results, our financial reporting will reflect the new organizational structure. We are evaluating
the impact to our operating segments and other costs and activities based on how the
 businesses are managed in 2019.As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, process and governance within each business
and the functions that support them. As our innovative pipeline matures with the an
ticipated progression of current trials and the initiation of new pivotal trials, we will need toincrease our R&D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-
creation activities. We are also initiating an enterprise-wide digital effort to help speed up drug development, enhance patient and physician experiences and access and
leverage technology and robotics to simplify and automate our processes.
In the fourth quarter of 2018, we took steps
 to simplify the organization, increase spans of control and reduce organizational layers, which impacted some managerial roles andresponsibilities. The impacts of these voluntary and involuntary plans were recorded as a special termination benefit, as well as severance in the fourth quarter of 2018, and
were reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. We
 also offered enhancements to certain employee benefits for ashort period of time. The expenses related to these enhancements for certain employee benefits did not
 have a material impact on our 2018 results of operations and anyexpected future impact of these enhancements are reflected in the to
tality of our annual guidance for 2019. To partially offset the incremental cost increases of increased R&Dinvestments and marketing activities in future periods, we expect to generate cost reduction opportunities, particularly in indirect SI&A.
Commercial Operations
From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through two distinct business segments: 
Pfizer InnovativeHealth (IH) and Pfizer Essential Health (EH). The IH and EH operating segments were each led by a single manager. Each operating segment had responsibility for its
commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-
concept. Each business had a geographic footprint across developed and emerging markets.
2018 Financial Report    
 
 11
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Some additional information about our business segments as of December 31, 2018 (prior to our new 2019 commercial organizational re-alignment) follows:
 
IH focused on developing and commercializing novel, value-creating medicines and
vaccines that significantly improve patients’ lives, as well as products for consumer
healthcare. 
Key therapeutic areas included internal medicine, vaccines, oncology, inflammation &
immunology, rare disease and consumer healthcare.
  EH included legacy brands that have lost or will soon lose market exclusivity in bothdeveloped and emerging markets, branded generics, generic sterile injectable
products, biosimilars and select branded products including anti-infectives. EH also
included an R&D organization, as well as our contract manufacturing business.
Through February 2, 2017, EH also included HIS.
Leading brands included: 
- 
Prevnar 13/Prevenar 13 - 
Xeljanz - 
Eliquis - 
Lyrica  (U.S., Japan and certain other markets) - 
Enbrel (outside the U.S. and Canada) - 
Ibrance - 
Xtandi - 
Chantix/Champix - Several OTC consumer healthcare products*
  Leading brands included: - 
Lipitor - Norvasc 
- Lyrica 
(Europe, Russia, Turkey, Israel and Central Asia countries) - 
Celebrex - 
Viagra** - Inflectra/Remsima 
- Sulperazon 
- 
Several other sterile injectable products *
According to Nicholas Hall’s retail sales data (based on moving annual total data through the third quarter of 2018), in 2018, our Consumer Healthcare business was thefifth-largest branded multi-national, OTC consumer healthcare business in the world and produced two of the ten largest selling consumer healthcare brands ( 
Centrum and Advil 
) in the world. **
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.
For additional information about the 
2018 performance of each of our operating segments, see the “Analysis of Operating Segment Information” section of this FinancialReview.
Description of Research and
 Development OperationsThe following description of R&D operations reflects operations as of 
December 31, 2018 . Innovation is critical to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. 
Our goal is to discover, develop and bring to market innovative products that address major unmet medical needs. 
Our R&D priorities include: •
delivering a pipeline of differentiated therapies and vaccines with the greatest medical and commercial potential;•
advancing our capabilities that can position Pfizer for long-term leadership; and•
creating new models for biomedical collaboration that will expedite the pace of innovation and productivity.To that end, our R&D primarily focuses on:
•
Inflammation and Immunology ; •
Internal Medicine ; •
Oncology ; •
Rare Diseases ; •
Vaccines ; and •
Biosimilars.In January 2018, we announced our decision to end internal neuroscience discovery and early development efforts and re-allocate funding to other areas where we have
stronger scientific leadership. The development of tanezumab and potential treatments for rare neuromuscular disorders is not impacted by this decision. In June 2018, we
announced our plan to invest up to $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, our venture investment vehicle. In Sep
tember2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a
 portfolio of clinical and preclinicalstage neuroscience assets primarily targeting disorders of the central nervous system, including Parkinson’s disease, epilepsy, Alzheimer’s disease, schizophrenia and
addiction. For additional information on the transaction with Bain Capital, see the Notes to Consolidated Financial Statements–– 
Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Divestitures 
. In 2018, we continued to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable
pipeline that is positioned to deliver value in the near term and over time. 
Our R&D spending was conducted through a number of matrix organizations: •
Research Units within our WRD organization were generally responsible for research and early-stage development assets for our IH business (assets that have not yetachieved proof-of-concept). 
Our Research Units were organized by therapeutic area to enhance flexibility, cohesiveness and focus. Because of our structure, we were able to rapidly redeploy resources within a Research Unit between various projects as necessary because in many instances the workforce shares similar skills, expertise and/or
focus.
12
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Our R&D organization within the EH business supported the large base of EH products and helped develop potential new sterile injectable drugs and therapeutic solutions,as well as biosimilars.
•
Our GPD organization, a unified center for late-stage development for our innovative products that was generally responsible for the operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in the Innovative portfolio. For WRD assets,
 GPD worked in close collaboration with the EarlyClinical Development group, which has expertise in various disciplines such as Biostatistics, Clinical Pharmacology and Digital Medicine. 
GPD helped enable more efficient and effective development and enhance our ability to accelerate and progress assets through our pipeline.
•
Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurred, provided technical expertise and other services tothe various R&D projects, and were organized into science-based functions (which were part of our WRD organization), such as Pharmaceutical Sciences, Medicine Design,
Regulatory and Drug Safety, and non-science-based functions, such as Facilities, Business Technology and Finance. 
As a result, within each of these functions, we were able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react
 quickly in response toevolving needs.
We manage R&D operations on a total-company basis through our matrix organizations described above. Specifically, a single committee with representation from the R&D
groups and the IH commercial organization was accountable for aligning resources among all of our WRD, GPD and IH R&D projects and for seeking to ensure optimal capital
allocation across the Innovative R&D portfolio. We believe that this approach also served to maximize accountability and flexibility. Our EH R&D organization managed its
resources separately from the WRD and GPD organizations.
Generally, we do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we do
 not manage a significant portion of ourR&D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, as
 conditions change, we believethat any prior-period information about R&D expense by development phase or by therapeutic area would not necessarily be representative of future spending.
While a significant portion of R&D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies developed by third
parties to incorporate into our discovery and development processes or projects, as well as our product lines, by entering into collaboration, alliance and license agreements
with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising
compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees to fund a portion of
 the development costs of one or more of ourpipeline products in exchange for rights to receive potential milestone payments, revenue sharing payments, profit sharing payments and/or royalties. Collaboration, alliance,
license and funding agreements and equity- or debt-based investments allow us to share risk and cost and to access external scientific and technological expertise, and
provide us the opportunity to advance our own products as well as the in-licensed or acquired products.
For additional information about R&D by operating segment, see the “Analysis of Operating Segment Information” section of 
this Financial Review. For additional informationabout our pending new drug applications and supplemental filings, see the “Analysis of the Consolidated Statements of Income––Product
 Developments––Biopharmaceutical”section of this Financial Review. For additional information about recent transactions and strategic investments that we believe have the potential to
 advance our pipeline, seethe “Our Business Development Initiatives” section of this Financial Review.
Intellectual Property Rights
We continue to aggressively defend our patent rights whenever appropriate against increasingly aggressive infringement, and we will continue to support efforts that strengthen
worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches
designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and
 we will continue toparticipate in the generics market for our products, whenever appropriate, once they lose exclusivity. Also, 
the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not
always be successful. 
For additional information about our current efforts to enforce our intellectual property rights and certain other patent proceedings, see Notes to Consolidated Financial Statements–– 
Note 17A1. Contingencies and Certain Commitments : Legal Proceedings –– Patent Litigation. For information on risks related to patent protection and intellectual property claims by third parties, see Part I, Item 1A, “Risk Factors––Risks Related to Intellectual Property” in our 
2018 Form 10-K. Capital Allocation and Expense
 ManagementWe seek to maintain a strong balance sheet and robust liquidity so that we continue to
 have the financial resources necessary to take advantage of prudent commercial,research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our
financial condition, liquidity, capital resources, share repurchases (including accelerated share repurchases) and dividends, see the “Analysis of Financial Condition, Liquidity
and Capital Resources” section of this Financial Review. For additional information about our recent business development activities, see the “Our Business Development
Initiatives” section of this Financial Review.
In December  
2018 , our Board of Directors declared a first-quarter 2019 dividend of $0.36 per share, an increase from the $0.34 per-share quarterly dividend paid during 2018 . For additional information, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this Financial Review and Notes to Consolidated Financial
Statements–– 
Note 12. Equity. We remain focused on achieving an appropriate cost structure for our company. For additional information about our cost-reduction and productivity initiatives, see the “Costs
and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-
2018 Financial Report    
 
 13
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Reduction/Productivity Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements–– 
Note 3 . Restructuring Charges and Other CostsAssociated with Acquisitions and Cost-Reduction/Productivity Initiatives.
Increasing Investment in the U.S. 
––After evaluating the expected positive net impact the TCJA will have on us, in early 2018,  we decided to take several actions:•
Over the five-year period from 2018 through 2022, we plan to invest approximately $5.0 billion in capital projects in the U.S., including the strengthening of our manufacturingpresence in the U.S. As part of this plan, in July 2018,
 we announced that we will increase our commitment to U.S. manufacturing with a $465 million investment to build oneof the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen our capability to
produce and supply critical, life-saving injectable medicines for patients around the world. Known as Modular Aseptic Processing, the new, multi-story, 400,000-square-foot
production facility will also support the area economy by creating an estimated 450 new jobs over the next several years.
•
We made a $500 million voluntary contribution to the U.S. Pfizer Consolidated Pension Plan in February 2018.•
In the fourth quarter of 2017, we made a $200 million charitable contribution to the Pfizer Foundation, an organization that provides grant and investment funding to supportorganizations and social entrepreneurs in an effort to improve healthcare delivery.
•
In the first quarter of 2018, we paid a special, one-time bonus to virtually all Pfizer colleagues, excluding executives, of $119 million in the aggregate. Our Business Development Initiatives
We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of
business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view
our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic
and financial approach to evaluating business development opportunities. 
We continue to evaluate business development transactions that have the poten tial to strengthen ourbusinesses and their capabilities, such as our acquisitions of Hospira, Medivation, Anacor and AstraZeneca’s small molecule anti-infectives business, as well as collaborations,
and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio
review process and also continue to consider business development activities that will advance our businesses.
For additional information on our business development activities, see Notes to Consolidated Financial Statements 
––Note 2. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
. The more significant recent transactions and events are described below:
•
Agreement to Form a New Consumer Healthcare Joint Venture (IH) ––On December 19, 2018, we announced that we entered into a definitive agreement with GS K underwhich we and GSK agreed to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK
Consumer Healthcare name. The joint venture is expected to be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health
and therapeutic oral health and will be the largest global OTC consumer healthcare business.
•
Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) ––On February 3, 2017, we completed the sale of our global infusion systems net assets,  HIS, to ICUMedical. In connection with this transaction, we recognized pre-tax income of 
$1 million in 2018 and pre-tax losses of $55 million in 2017 in Other (income)/deductions––net,representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs
 to sell.•
Acquisition of AstraZeneca’s Small Molecule Anti-Infectives Business (EH) ––On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. The total fair
value of the consideration transferred for this business was approximately 
$1,040 million , inclusive of cash paid and the fair value of contingent consideration. •
Acquisition of Medivation, Inc. (IH) ––On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately 
$14.3 billion in cash ( $13.9 billion , net of cash acquired). Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells, and talazoparib, which was approved by the FDA in October 2018, under the trade name
Talzenna, for the treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other
types of cancer. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the
U.S.
•
Acquisition of Bamboo Therapeutics, Inc. (IH) –– On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused ondeveloping gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting 
the central nervoussystem, for 
$150 million plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization.
•
Acquisition of Anacor Pharmaceuticals, Inc. (IH) –– On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately 
$4.9 billion in cash ( $4.5 billion net of cash acquired) plus $698 million debt assumed. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA in December 2016 under the trade name, Eucrisa 
, for the treatment of mild-to-moderate atopic dermatitis in patients two years of age and older, commonly referred to as a type of eczema. Anacor also holds the
 rights to Kerydin, a topical treatment for onychomycosis (toenail fungus) that isdistributed and commercialized by Sandoz 
in the U.S. 14
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. –– On November 1, 2016, we announced the discontinuation of the global clinicaldevelopment program for bococizumab. During December 2016, 
$31.3 million was refunded to NovaQuest representing amounts NovaQuest prepaid for development costs (under the May 2016 agreement described below) that were not used for program expenses due to the discontinuation of the development program. No additional payments
have been or are expected to be received from or paid to NovaQuest with respect to 
this agreement, which was terminated effective as of November 18, 2016.In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to 
fund up to $250 million in development costs related to certain Phase 3 clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound.
NovaQuest’s development funding was expected to cover up to 
40% of the development costs and was to be received over five quarters during 2016 and 2017. As therewas a substantive and genuine transfer of risk to NovaQuest, the development 
funding applicable to program expenses during 2016 was recognized as an obligation toperform contractual services and therefore has been recognized as a reduction of 
Research and development expenses as incurred. The reduction to Research and development expenses 
for 2016 totaled $180.3 million . •
Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. –– In April 2016, Pfizer entered into an agreement with NovaQuest under whichNovaQuest would fund up to 
$200 million in development costs related to certain Phase 3 clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding is expected to cover up
 to 100% of the development costs and will be received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer will be responsible for the remaining development
costs. As there is a substantive and genuine transfer of risk to
 NovaQuest, the development funding is recognized by us as an obligation to perform contractual services andtherefore is a reduction of 
Research and development expenses as incurred. The reduction to Research and development expenses totaled $57.6 million for 2018, $72.1 million 
for 2017 and $46.6 million for 2016. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately 
$267 million in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to 
Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as 
Cost of sales when incurred. •
Research and Development Arrangement with RPI Finance Trust –– In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, underwhich RPI would fund up to 
$300 million in development costs related to certain Phase 3 clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI’s development funding is expected to cover up to 
100% of the costs primarily for the applicable clinical trials until the second quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a subs
tantive and genuine transfer of risk to RPI,the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of 
Research and development expenses as incurred. The reduction to 
Research and development expenses totaled $99.3 million in 2018, $75.6 million for 2017 and $44.9 million for 2016. If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on
 the applicable clinical trials, RPI will be eligible to receive a combination ofapproval-based fixed milestone payments of up to 
$250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to 
Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as 
Cost of sales when incurred. Our Financial Guidance for 
2019 The following table provides our financial guidance for full-year 2019 
(a), (b) :Revenues
$52.0 to $54.0 billion Adjusted cost of sales as a percentage of revenues
20.8% to 21.8% Adjusted selling, informational and administrative expenses
$13.5 to $14.5 billion Adjusted research and development expenses
$7.8 to $8.3 billion Adjusted other (income)/deductions
Approximately $100 million of income Effective tax rate on adjusted income
Approximately 16.0% Adjusted diluted EPS
$2.82 to $2.92 (a) 
 The 2019 financial guidance reflec ts the following:•
A full year of revenue and expense contributions from Pfizer’s Consumer Healthcare business.•
Does not assume the completion of any business development transactions not completed as of December 31, 2018 , including any one-time upfr ont payments associated with such transactions.•
Financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS now excludes the impact of gains and losses on investments in equity securities. In 2018, Pfizer’s 2018 financial resultsincluded net gains on inv
estments in equity securities, which favorably impacted Adjusted other (income)/deductions by $586 million and Adjusted diluted EPS (2) by approximately $0.08 in 2018. Beginning In 2019, we will exclude the gai
ns and losses from equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control and cannot predict with any level of certaintyand because we do not 
believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. For example, we contributed assetsrelated to our allogeneic CAR T th
erapy to Allogene and received equity securities. We will restate our Adjusted income and Adjusted diluted EPS for prior periods for consistency with our 2019 presentation.•
Reflects an anticipated negative revenue impact of $2.6 billion due to recent and expect ed generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patentprotection.
•
Exchange rates assumed are as of mid-January 2019. Reflects the anticipated unfavorable impact of approximately $0.9 billion on revenues and approximately $0.06 on adjusted diluted EPS as a result of changes in foreign excha
nge rates relative to the U.S. dollar compared to foreign exchange rates from 2018.•
Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.7 billion shares, which reflects share  repurchases totaling $12.2 billion in 2018 and the weighted-average impact of an anti
cipated approximately $9 billion of share repurchases in 2019 , which 2018 Financial Report    
 
 15
Financial ReviewPfizer Inc. and Subsidiary Companies
 
have been completed through Feb
ruary 28, 2019. Dilution related to share-bas ed employee compensation programs is currently expected to offset the reduction in shares associated with these sharerepurchases by approximate
ly half.(b)
 
For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Non-GAAP Financial Measure (Adjusted Income)” section of thisFinancial Review.
Pfizer does not provide guid
ance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reportedfinancial measures on a forwar
d-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, net gainsor losses on equity securities an
d potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reportedresults for the guidance
 period.For information about our actual costs and anticipated costs and cost savings associated with our three-year cost-reduction initiative entered into in the
 fourth quarter of 2016,the Hospira acquisition, our recent business development activities, and global commercial structure, see the “Costs and Expenses––Restructuring Charges and Other Costs
Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements–– 
Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
Our 
2019 financial guidance is subject to a number of factors and uncertainties as described in the “Our Operating Environment”, “The Global Economic Environment”, “Our Strategy” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this Financial Review; and Part I
, Item 1A, “Risk Factors” of our 2018 Form 10-K.
SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND
ASSUMPTIONS
For a description of our significant accounting policies, see Notes to Consolidated Financial Statements–– 
Note 1. Basis of Presentation and Significant Accounting Policies . Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the
 most subjective andthe most complex judgments: (i) Acquisitions (Note 1D); (ii) Fair Value (Note 1E); (iii) Revenues (Notes 1B and 1G); (iv) Asset Impairments (Note 1L); (v) Tax Assets and
Liabilities and 
Income Tax Contingencies (Note 1P); (vi) Pension and Postretirement Benefit Plans (Note 1Q); and (vii) Legal and Environmental Contingencies (Note 1R). Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. See also Notes to Consolidated Financial
Statements–– 
Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and  Assumptions for a discussion about the risks associated with estimates and assumptions.
Acquisitions and Fair Value
For a discussion about the application of fair value to our recent acquisitions, see Notes to Consolidated Financial Statements— 
Note 2A. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Acquisitions 
. For a discussion about the application of fair value to our investments, see Notes to Consolidated Financial Statements— 
Note 7A. Financial Instruments : Fair Value Measurements 
. For a discussion about the application of fair value to our benefit plan assets, see Notes
 to Consolidated Financial Statements–– Note 11D. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Plan Assets 
. For a discussion about the application of fair value to our asset impairment reviews, see “Asset Impairment Reviews” below.
Revenues
Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the
 revenues are recognized. Suchvariable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such,
knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.
Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not
 been material to our overall business. On a quarterly basis, ouradjustments of estimates to reflect actual results generally have been less than 1% of revenues,
 and have resulted in either a net increase or a net decrease in revenues.Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. 
If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by
 program, typeof customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material
adjustment because of the extensive time delay between the recording of the accrual and its ultimate se
ttlement, an interval that can generally range up to one year. Becauseof this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.
Asset Impairment Reviews
We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least
annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the
amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in the Notes to Consolidated Financial
Statements–– 
Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of  Intangible Assets, Depreciation and Certain Long-Lived Assets.16
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Examples of events or circumstances that may be indicative of impairment include:
•
A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rightswould likely result in generic competition earlier than expected.
•
A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affectour ability to manufacture or sell a product.
•
A projection or forecast that indicates losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursementprogram that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that results in
a significant loss of market share or the inability to achieve the previously projected revenue growth, as well as the lack of acceptance of
 a product by patients, physiciansand payers. For IPR&D projects, this could result from, among other things, a change in outlook based
 on clinical trial data, a delay in the projected launch date oradditional expenditures to commercialize the product.
Identifiable Intangible Assets
As a result of our identifiable intangible asset impairment review work, we recognized a number of impairments of identifiable intangible assets for the years ended
December 31, 2018 
, 2017 and 2016 . See Notes to Consolidated Financial Statements–– Note 4. Other (Income)/Deductions — Net.When we are required to determine the fair value of intangible assets other than goodwill, we use an income approach, specifically the discounted cash flow method. We s
tartwith a forecast of all the expected net cash flows associated with the
 asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply anasset-specific discount rate to arrive at a net present value amount. Some of 
the more significant estimates and assumptions inherent in this approach include: the amount andtiming of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on 
the projections and the impact of technological riskassociated with IPR&D assets, as well as the selection of a long-term growth rate; the discount
 rate, which seeks to reflect the various risks inherent in the projected cashflows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash
 flows.While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, in general, intangible assets other than goodwill that are most at
risk of impairment include IPR&D assets (approximately 
$2.2 billion as of December 31, 2018 ) and newly acquired or recently impaired indefinite-lived brand assets. IPR&D assets are high-risk assets, as R&D is an inherently risky activity. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets
are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each
 reporting period. As such, immediately afteracquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment
charge.
Goodwill
As a result of our goodwill impairment review work, we concluded that none of our goodwill was impaired as of 
December 31, 2018 , and we do not believe the risk of impairment is significant at this time.
We first assess qualitative factors to determine whether it is more likely than not that the 
fair value of a reporting unit is less than its carrying amount. Qualitative factors that weconsider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more
likely than not that the fair value of a reporting unit is less than its carrying value, we then
 perform a quantitative fair value test.When we are required to determine the fair value of a reporting unit, as appropriate for the individual reporting unit, we mainly use the income approach but we may also use
the market approach, or a weighted-average combination of both approaches.
•
The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, the method that we use isthe discounted cash flow method. We start with a forecast of
 all the expected net cash flows associated with the reporting unit, which includes the application of a terminalvalue, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. 
Some of the more significant estimates and assumptions inherent inthis approach include: the amount and timing of the projected net cash flows, which includes the expected
 impact of technological risk and competitive, legal and/orregulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks 
to reflect the various risks inherent in the projectedcash flows; and the tax rate, which seeks to incorporate the geographic diversity of the
 projected cash flows.•
The market approach is a historical approach to estimating fair value and relies primarily on external information. Within the market approach are two methods that we mayuse:
◦
Guideline public company method—this method employs market multiples derived from market prices of stocks of companies that are engaged in the same or similar linesof business and that are actively traded on a free and open market and 
the application of the identified multiples to the corresponding measure of our reporting unit’sfinancial performance.
◦
Guideline transaction method—this method relies on pricing multiples derived from transactions of significant interests in companies engaged in the same or similar linesof business and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.
The market approach is only appropriate when the available external information is robust and deemed to be a reliable proxy for the specific reporting unit being valued;
however, these assessments may prove to be incomplete or inaccurate. Some of the more significant estimates and assumptions inherent in this approach include: 
theselection of appropriate guideline companies and transactions and the determination of applicable premiums and discounts based on any differences in ownership
percentages, ownership rights, business ownership forms or marketability between the reporting unit and the guideline companies and transactions.
2018 Financial Report    
 
 17
Financial ReviewPfizer Inc. and Subsidiary Companies
 
For all of our reporting units, there are a number of future events and factors tha
t may impact future results and that could potentially have an impact on the outcome ofsubsequent goodwill impairment testing. For a list of these factors, see the “Forward-Looking Information and Factors That May Affec
t Future Results” section of this FinancialReview and Part I, Item 1A, “Risk Factors” in our 
2018 Form 10-K. Benefit Plans
The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor bo
th IRC-qualified andsupplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for
retirees and their eligible dependents.
The accounting for benefit plans is highly dependent on actuarial estimates, assumptions and calculations, which can result from a complex series of judgments about fu
tureevents and uncertainties. The assumptions and actuarial estimates required to estimate the net employee benefit obligations for the
 defined benefit and postretirement plansinclude the discount rate; expected salary increases; certain employee-related factors, such as turnover, retirement age and mortality (life expectancy); expected return on plan
assets; and healthcare cost trend rates.
Effective January 1, 2018, accruals for future benefits under the
 Pfizer Consolidated Pension Plan (our largest U.S. defined benefit plan) and the defined benefit section of thePfizer Group Pension Scheme (our largest pension plan in the U.K.) were frozen and resulted in elimination of future service costs for the plans.
 The Pfizer defined contributionsavings plan provides additional annual contributions to those previously accruing benefits under the Pfizer Consolidated Pension Plan and active members of the Pfizer Group
Pension Scheme started accruing benefits under the defined contribution section of that
 plan.As of 
December 31, 2018 , the noncurrent portion of our pension benefit obligations, net, and our postretirement benefit  obligations, net decreased, in the aggregate, byapproximately 
$747 million compared to December 31, 2017 . The decrease reflects, among other things, the $500 million voluntary contribution we made to the U.S. Pfizer Consolidated Pension Plan in February 2018 and an increase in the discount rate used in the measurement of plan obligations, partially offset by 
the decrease in the actualreturns on plan assets.
Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made
in determining the costs of our benefit plans can materially impact our results of operations.
The following table provides (i) at the end of each year, the expected annual rate of return on
 plan assets for the following year, (ii) the actual annual rate of return on planassets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end o
f each year for our U.S. qualified pension plansand our international pension plans 
(a) : 
  2018  2017  2016 U.S. Qualified Pension Plans
         Expected annual rate of return on plan assets
  7.2  % 7.5 % 8.0 %Actual annual rate of return on plan assets
  (5.3 ) 16.2  8.1 Discount rate used to measure the plan obligations
  4.4  3.8  4.3 International Pension Plans
         Expected annual rate of return on plan assets
  3.9  4.4  4.7 Actual annual rate of return on plan assets
  (0.9 ) 10.3  9.3 Discount rate used to measure the plan obligations
  2.5  2.3  2.4 (a)
 
For detailed assumptions associated with our benefit plans, see Notes to Consolidated Financial Statements— Note 11B. Pension and Postretir ement Benefit Plans and Defined Contribution Plans: ActuarialAssumptions.
Expected Annual Rate of Return on Plan Assets
The assumptions for the expected annual rate of return on all of our plan assets reflect
 our actual historical return experience and our long-term assessment of forward-lookingreturn expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our 
targeted asset allocation in ourrespective plans.
The expected annual rate of return on plan assets for our U.S. plans and
 the majority of our international plans is applied to the fair value of plan assets at each year-end andthe resulting amount is reflected in our net periodic benefit costs in the following year.
The following table illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the
 expected annual rate of return on plan assets,holding all other assumptions constant (in millions, pre-tax):
 
  Change  Increase in 2019 Net PeriodicBenefit Costs
Assumption
      Expected annual rate of return on plan assets
  50 basis point decline  $104 The actual return on plan assets resulted in a net 
loss on our plan assets of approximately $895 million during 2018 . 18
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Discount Rate Used to Measure Plan Obligations
The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated
 and modified, asrequired, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or be
tter, that reflect the rates at which the pension benefitscould be effectively settled. The discount rate used to measure the plan obligations for our international plans is determined at least
 annually by reference to investment gradecorporate bonds, rated AA/Aa or better, including, when there is sufficient da
ta, a yield-curve approach. These discount rate determinations are made in consideration of localrequirements.
The measurement of the plan obligations at the end of the year will affect 
the amount of service cost, interest cost and amortization expense reflected in our net periodic benefitcosts in the following year.
The following table illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point
 decline in our assumption for the discount rate, holding allother assumptions constant (in millions, pre-tax):
 
  Change  Increase in 2019 NetPeriodic Benefit Costs
  2018 BenefitObligations
Assumption
     Increase  Increase Discount rate
  10 basis point decline  $13  $417 The change in the discount rates used in measuring our plan obligations as of 
December 31, 2018 resulted in a decrease in the measurement of our aggregate plan obligations by approximately 
$1.5 billion . Income Tax Assets and Liabilities
In the fourth quarter of 2017, we recorded an estimate of certain 
tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in theU.S. Federal corporate tax rate from 35% to 
21% , (ii) the impact on valuation allowances and other state income tax considerations, (iii) a repatriation tax liability on accumulated post-1986 foreign earnings for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight
 years through2026 that is reported in 
Other taxes payable in our consolidated balance sheet as of December 31, 2017, and (iv) deferred taxes on basis differences expected to  give rise tofuture taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a
result of the TCJA, in the fourth quarter of 2017,
 we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial taxsystem.
The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staf
f Q&A, Topic 740, No. 5,Accounting for Global Intangible Low-Taxed Income 
, states that we are permitted to make an accounting policy election to either recognize deferred taxes  for temporary basisdifferences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the
 tax is incurred. Weelected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. We were able to make a reasonable
estimate of the deferred taxes on the temporary differences expected to
 reverse in the future and provided a provisional deferred tax liability as of December 31, 2017.In 2018, we finalized our provisional accounting for the tax effects of the
 TCJA based on our best estimates of available information and data, and have reported and disclosedthe impacts within the applicable measurement period, in accordance with guidance issued by the SEC. The amounts recorded may change in the future due 
to uncertain taxpositions. With respect to the aforementioned repatriation tax liability, the first installment, due in April 2019, is reported in 
Income taxes payable, and the remaining liability is reported in 
Other taxes payable in our consolidated balance sheet as of December 31, 2018. We believe that there may be additional interpretations, clarifications and guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in
the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and
/or availability of attributes such as foreign tax and othercredit carryforwards.
Income tax assets and liabilities also include income tax valuation allowances and accruals for uncertain tax positions. For additional information, see Notes to Consolidated
Financial Statements— 
Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions ; Note 1P. Basis of Presentation and SignificantAccounting Policies: Tax Assets and Liabilities and Income Tax Contingencies 
and Note 5A. Tax Matters: Taxes on Income from Continuing Operations, as well as the “Analysis of Financial Condition, Liquidity and Capital Resources––Selected Measures of Liquidity and Capital Resources—Contractual Obligations” section of this Financial
Review 
. Contingencies
For a discussion about income tax contingencies, see Notes to Consolidated Financial Statements— 
Note 5D. Tax Matters: Tax Contingencies. For a discussion about legal and environmental contingencies, guarantees and indemnifications, see Notes to Consolidated Financial Statements— 
Note 17. Contingencies and Certain Commitments 
. 2018 Financial Report    
 
 19
Financial ReviewPfizer Inc. and Subsidiary Companies
 
ANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME
  
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018   2017   2016   18/17   17/16 Revenues
  $53,647   $52,546   $52,824   2  (1 )Cost of sales
  11,248   11,228   12,322   —  (9 )% of revenues
  21.0 % 21.4  % 23.3 %     Selling, informational and administrative expenses
  14,455   14,804   14,844   (2 ) — % of revenues
  26.9 % 28.2  % 28.1 %     Research and development expenses
  8,006  7,683  7,892  4  (3 )% of revenues
  14.9 % 14.6  % 14.9 %     Amortization of intangible assets
  4,893  4,758  4,056  3  17 % of revenues
  9.1 % 9.1  % 7.7 %     Restructuring charges and certain acquisition-related costs
  1,044  351  1,565  *  (78 )% of revenues
  1.9 % 0.7  % 3.0 %     Other (income)/deductions—net
  2,116  1,416  3,794  49  (63 )Income from continuing operations before provision/(benefit) for
taxes on income
  11,885   12,305   8,351  (3 ) 47 % of revenues
  22.2 % 23.4  % 15.8 %     Provision/(benefit) for taxes on income
  706  (9,049 )  1,123  *  * Effective tax rate
  5.9 % (73.5 )%  13.4 %     Income from continuing operations
  11,179   21,353   7,229  (48 ) * % of revenues
  20.8 % 40.6  % 13.7 %     Discontinued operations—net of tax
  10  2  17  *  (87 )Net income before allocation to noncontrolling interests
  11,188   21,355   7,246  (48 ) * % of revenues
  20.9 % 40.6  % 13.7 %     Less: Net income attributable to noncontrolling interests
  36  47  31  (24 ) 54 Net income attributable to Pfizer Inc.
  $11,153   $21,308   $7,215  (48 ) * % of revenues
  20.8 % 40.6  % 13.7 %     Certain amounts and percentages may reflect rounding adjustments.
*
Indicates calculation not meaningful or result is equal to or greater than 100%.Revenues 
— OverviewTotal revenues in 
2018 compared to 2017 reflects operational growth of $791 million , or 2% , and the favorable impact of foreign exchange of $310 million , or less than 1% ,in 
2018 , compared to 2017 . Compared to 2016, total revenues for 2017 were unfavorably impacted by approximately $200 million as a result of 2017 having one less selling day in both U.S. and
international markets.
Total revenues in 
2017 compared to 2016 reflect a slight operational decrease of $20 million, or less than 1%, and an unfavorable impact of foreign exchange of $259 million, or less than 1%, in 
2017 compared to 2016 . See the “Revenues by Segment and Geography” and “Revenues—Selected Product Discussion” sections of this Financial Review for additional analyses.
See the “Our Operating Environment—Industry-Specific Challenges—Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Review for
information about recent losses and expected losses of product exclusivity impacting product revenues.
A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For additional information,
see the “Patents and Other Intellectual Property Rights” section in Part 
I, Item 1, “Business” of our 2018 Form 10-K. We have significant operations outside the U.S., with revenues exceeding $500 million in the following number of countries:
20
  2018 Financial Report
 
Financial ReviewPfizer Inc. and Subsidiary Companies
 
By total revenues, the U.S., China and Japan are our three largest na
tional markets:
Inventory Stocking
Our policy relating to the supply of pharmaceutical inventory at domestic wholesalers, and in major international markets, is to generally maintain stocking levels under one
month on average and to keep monthly levels consistent from year to year based on patterns o
f utilization. We historically have been able to closely monitor these customerstocking levels by purchasing information from our customers directly or by obtaining other third-party information. We believe our data sources to be directionally reliable but
cannot verify their accuracy. Further, as we do not control this third-party data, we cannot be
 assured of continuing access. Unusual buying patterns and utilization are promptlyinvestigated.
Revenue Deductions
Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the
 revenues are recognized. Suchvariable consideration represents chargebacks, rebates, sales allowances and sales returns.These deductions represent estimates of related obligations and, as such,
knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. 
Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On
 a quarterly basis, our adjustments of estimates to reflect actual resultsgenerally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues.
 Product-specific rebates, however, can have asignificant impact on year-over-year individual product growth trends.
The following table provides information about revenue deductions:
  
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Medicare rebates 
(a)  $1,706  $1,316  $1,063 Medicaid and related state program rebates 
(a)  1,969  1,860  1,473 Performance-based contract rebates 
(a), (b)  3,377  3,245  2,560 Chargebacks 
(c)  6,461  6,047  5,736 Sales allowances 
(d)  5,592  5,165  4,623 Sales returns and cash discounts
  1,522  1,493  1,441 Total 
(e)  $20,627  $19,126  $16,895 (a) 
 Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.(b)
 
Performance-based contract rebates include contract rebates with managed care customers within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievementof contracted performance terms 
and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contractedperformance for specific products 
or sales milestones.(c) 
 Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.(d) 
 Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.(e)
 
For 2018 , associated with the following se gments: IH ( $8.9 billion ); and EH ( $11.7 billion ). For 2017 , associated with the following se gments: IH ( $9.0 billion ); and EH ( $10.1 billion ). For 2016 , associated with the following segments: IH ( 
$7.1 billion ); and EH ( $9.8 billion ). Total revenue deductions for 
2018 increase d 8% compared to 2017 , primarily as a result of: •
an increase in sales allowances as a result of sales growth, primarily in international markets;•
higher chargebacks to U.S. wholesalers of certain IH and EH products, partially offset by decreases in chargebacks as a result of decreases in sales of sterile injectableproducts;
•
an increase in Medicare rebates driven by increased sales of IH products through this channel; and•
an increase in Medicaid and related state program rebates, primarily as a result of increased sales of IH products through these programs.For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and
sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Consolidated Financial Statements–– 
Note 1G. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable 
. 2018 Financial Report    
 
 21
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Revenues by Segment and Geography
The following graphs show revenues by geography (dollars in billions):
The following table provides worldwide revenues by operating segment and geography:
 
  Year Ended December 31,   % Change  
  Worldwide   U.S.   International   Worldwide   U.S.  International(MILLIONS OF DOLLARS)
  2018 2017 2016 2018 2017 2016 2018 2017 2016 18/17 17/16 18/17 17/16 18/17 17/16Operating Segments 
(a) :                              IH
  $33,426 $31,422 $29,197 $18,959 $18,460 $16,773 $14,467 $12,962 $12,424 6 8 3 10 12 4EH
  20,221 21,124 23,627 6,370 7,567 9,596 13,851 13,557 14,031 (4) (11) (16) (21) 2 (3)Total revenues
  $53,647 $52,546 $52,824 $25,329 $26,026 $26,369 $28,318 $26,519 $26,455 2 (1) (3) (1) 7 —(a)
 
IH = the Innovative Health segment; and EH = the Essential Health segment. For additional information about each operating segment, see the “Our Strategy––Commercial Operations” section of this FinancialReview and Notes to Consolidat
ed Financial Statements–– Note 18A. Segment, Geograp hic and Other Revenue Information: Segment Information.We recorded direct product and/or alliance revenues of more than $1 billion for each of 10 products in 
2018 and for nine products in 2017 and 2016 . Direct Product And/Or Alliance Revenues of More Than $1 Billion
2018
  2017   2016 Prevnar 13/Prevenar 13
  Prevnar 13/Prevenar 13   Prevnar 13/Prevenar 13 Lyrica
  Lyrica   Lyrica Ibrance
  Ibrance   Enbrel Eliquis*
  Eliquis*   Ibrance Enbrel
  Enbrel   Lipitor Lipitor
  Lipitor   Eliquis* Xeljanz
  Xeljanz   Viagra Chantix/Champix
  Viagra   Sutent Sutent
  Sutent   Premarin family of products Norvasc
      * 
Eliquis  includes alliance revenues and direct sales in 2018, 2017 and 2016. These direct product sales and/or alliance product revenues represent 
51% of our revenues in 2018 , 46% of our revenues in 2017 and 43% of our revenues in 2016 . See the “Analysis of the Consolidated Statements of Income—Revenues—Selected Product Discussion” 
section of this Financial Review for additional information. 22
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
2018 
v. 2017The following provides an analysis of the change in revenues by geographic areas in 
2018 : (MILLIONS OF DOLLARS)
  Worldwide   U.S.   International Operational growth/(decline):
         Continued growth from certain key brands 
(a)  $2,815  $1,150  $1,664 Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe
markets
  217  147  69 Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio,
primarily in the U.S. and developed Europe
  195  158  37 Growth in our Consumer Healthcare business across all markets
  107  26  81 Impact from CentreOne primarily in emerging markets
  45  (127 ) 172 Lower revenues for total Viagra 
(b) , primarily in the U.S. due to generic competition that began in December2017
  (572 ) (572 ) — Decline from the Peri-LOE Products portfolio, driven by lower revenues in developed markets (excluding
Viagra EH), primarily due to expected declines in Lyrica in developed Europe and Celebrex and Pristiq in
the U.S. due to generic competition
  (558 ) (188 ) (371 )Impact from the SIP portfolio, driven by lower revenues in developed markets, primarily due to increased
competition across the portfolio and continued legacy Hospira product shortages in the U.S.
  (504 ) (589 ) 86 Impact from the LEP portfolio, driven by lower revenues in developed markets, primarily as a result of
industry-wide pricing challenges in the U.S. and generic competition
  (436 ) (592 ) 156 Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar
competition
  (350 ) —  (350 )Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed
Europe
  (100 ) (13 ) (88 )Impact on financial results from the sale of HIS in February 2017. 2018 does not reflect
 any contribution fromHIS global operations, compared to approximately one month of HIS domestic operations and
approximately two months of HIS international operations in the same period in 2017
  (97 ) (64 ) (33 )Other operational factors, net
  31  (34 ) 65 Operational growth/(decline), net
  791  (698 ) 1,489  
         Favorable impact of foreign exchange
  310  —  310 Revenues increase/(decrease)
  $1,101  $(698 ) $1,799 (a)
 
Certain key brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi, Lyrica––IH and Chantix/Champix. See the “Analysis of the Consolidated Statements of Income––Revenues––SelectedProduct Discussion" section of this Financi
al Review for product analysis information.(b)
 
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenuesexcluding the U.S. and Cana
da through 2017). Therefore, in 2018, total Viagra revenues were reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH andViagra EH.
Emerging markets revenues 
increase d $1.3 billion , or 11% , in 2018 to $12.7 billion , from $11.4 billion , reflecting an operational increase of $1.5 billion , or 13% . Foreign exchange had an 
unfavorable impact of approximately 2% on emerging markets revenues. The operational increase in emerging markets was driven by our EH segment, primarily by the Legacy Established Products portfolio and the Sterile Injectable Pharmaceuticals portfolio, as well as Prevenar 13, Ibrance and Eliquis in our IH segment.
2018 Financial Report    
 
 23
Financial ReviewPfizer Inc. and Subsidiary Companies
 
2017 
v. 2016The following provides an analysis of the change in revenues by geographic areas in 
2017 : (MILLIONS OF DOLLARS)
  Worldwide   U.S.   International Disposition-related operational impact:
          
         Approximately one month of HIS domestic operations and approximately two months of HIS internationaloperations in 2017, compared to twelve months of HIS global operations in 2016 (February 2017 sale)
  $(1,062 )  $(841 ) $(221 )Other operational growth/(decline):
         Continued growth from certain key brands 
(a)  1,608  1,104  503 Ibrance global growth: U.S. revenues increased primarily due to continued strong uptake in the metastatic
breast cancer setting. International revenues increased operationally, but were negatively impacted by a
one-time price adjustment to 2017 revenues related to finalizing reimbursement agreements in certain
developed Europe markets.
  993  757  236 Increase in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation)
  450  450  — Growth from Biosimilars, primarily from Inflectra in the U.S. and developed Europe markets
  209  115  94 Decline from Peri-LOE Products, primarily due to expected declines in Pristiq in the U.S. as well as Lyrica
(EH) and Vfend (both primarily in developed Europe markets)
  (957 ) (448 ) (509 )Lower revenues for Enbrel primarily in developed Europe markets due to continued biosimilar competition
  (448 ) —  (448 )Lower revenues for Viagra (IH) in the U.S. due to generic competition that began in December 2017
  (359 ) (359 ) — Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product
shortages in the U.S.
  (315 ) (460 ) 145 Decline in the Legacy Established Products portfolio primarily due to generic competition in developed
markets
  (188 ) (419 ) 231 Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the expected decline
in revenues for the adult indication in the U.S. due to a high initial capture rate of
 the eligible populationfollowing its successful fourth-quarter 2014 launch, which resulted in a smaller remaining “catch up”
opportunity compared to 2016, partially offset by growth from the pediatric indication. International revenues
increased primarily due to the favorable overall impact of timing and increased volume associated with
government purchases in certain emerging markets for the pediatric indication compared with prior year, as
well as from the inclusion of Prevenar 13 in additional national immunization programs in certain emerging
markets for the adult and pediatric indications in the fourth of quarter 2017.
  (108 ) (311 ) 203 Other operational factors, net
  157  68  89 Operational growth (decline), net
  (20 ) (343 ) 323  
         Unfavorable impact of foreign exchange
  (259 ) —  (259 )Revenues increase/(decrease)
  $(278 ) $(343 ) $64 (a) 
 Certain k ey brands represent Eliquis (globally), as well as Xeljanz and Lyrica - IH (both primarily i n the U.S.).Emerging markets revenues increased 
$979 million , or 9% , in 2017 to $11.4 billion , reflecting an operational increase of $1.1 billion , or 11% . Foreign exchange had an unfavorable impact of approximately 
2% on emerging markets revenues. The operational increase in emerging markets was primarily driven by our IH segment as well as ourLegacy Established Products and Sterile Injectable Pharmaceuticals portfolios.
For additional information about operating segment revenues, see the “Analysis of Operating Segment Information” section of this Financial Review.
Revenues—Selected Product Discussion
The tables below provide worldwide revenues, by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign
exchange. The difference between the total change and operational change represents the impact o
f foreign exchange. Amounts may not add due to rounding. All percentageshave been calculated using unrounded amounts. An asterisk (*) indicates the calculation is not meaningful or results are equal to or greater than 100%.
•
Prevnar 13/Prevenar 13 (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018  2017  Total  Oper. U.S.
  $3,360  $3,334  1   International
  2,443  2,268  8  8 Worldwide revenues
  $5,802  $5,601  4  4 The worldwide growth in 2018 was primarily driven by international operational 
growth due to higher volumes for the pediatric indication resulting from the second-quarter 2017 launch in China and increased orders associated with Gavi, the Vaccine Alliance, partially offset by
24
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
lower birth cohort and volumes in certain developed markets. The 
growth in 2018 in the U.S. was primarily due to the pediatric indication partially offset by the continued decline in revenues for the adult indication due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a
smaller remaining “catch up” opportunity (i.e., the opportunity to reach adults aged 65 years and older who have not been previously vaccinated with Prevnar 13),
compared to the prior-year period.
In 2014, the ACIP voted to recommend Prevnar 13 for routine use
 to help protect adults aged 65 years and older against pneumococcal disease, which for adults includespneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the
 CDCand U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. As with other
vaccines, the CDC regularly monitors the impact of vaccination and reviews the recommendations. During the October 2018 ACIP meeting, the CDC presented initial data
and indicated formal evaluation of evidence (grading) and a potential vote on the maintenance of the 65 years and older recommendation would likely happen in 2019. A
potential adverse change in the ACIP recommendation would negatively impact future Prevnar 13 revenues. We continue to generate and
 publish data and communicatewith the ACIP on the burden of pneumococcal disease and Prevnar 13 vaccine effec
tiveness and safety.•
Lyrica (EH (revenues from all of Europe, Russia, Turkey, Israel and Central Asia)/IH (revenues from all other geographies)):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $3,594  $3,463  4   International
  1,375  1,601  (14 ) (15 )Worldwide revenues
  $4,970  $5,065  (2 ) (2 )The operational 
decline in worldwide Lyrica revenues in 2018 was primarily driven by losses of exclusivity in developed Europe markets and Australia, partially offset by growth in the U.S. and growth in the orally dissolving tablet formulation in Japan.
The following table provides worldwide revenues for Lyrica in our IH segment, by geography:
 
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $3,594  $3,463  4   International
  1,028  1,048  (2 ) (3 )Worldwide revenues
  $4,622  $4,511  2  2 The operational 
growth in worldwide Lyrica revenues in our IH segment in 2018 was primarily due to growth in the U.S. and growth in the orally dissolving tablet formulation in Japan, partially offset by losses of exclusivity primarily in Australia.
The following table provides worldwide revenues for Lyrica in our EH segment, by geography:
 
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $—  $—  —   International
  347  553  (37 ) (39 )Worldwide revenues
  $347  $553  (37 ) (39 )The worldwide operational 
decline in our EH segment in 2018 was primarily due to losses of exclusivity in developed Europe markets. •
Ibrance (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $2,922  $2,825  3   International
  1,196  300  *  * Worldwide revenues
  $4,118  $3,126  32  32 The worldwide operational 
growth in 2018 reflects continued uptake in international markets, mostly driven by developed Europe, Japan and select emerging markets as we launched and secured access and reimbursement through 2017 and 2018, as well as the non-recurrence of a one-time price adjustment in 2017 related to finalizing
reimbursement agreements in certain developed Europe markets. The growth in 
2018 in the U.S. was primarily due to continued demand growth partially offset by uptake of competitors and increased rebates. Ibrance maintains class leadership among cyclin-dependent kinase inhibitors in major markets, supported by our scientific/clinical
data and continued positive patient experience.
2018 Financial Report    
 
 25
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Eliquis alliance revenues and direct sales (IH): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except
 in certain countries where Pfizer commercializes Eliquis andpays BMS compensation based on a percentage of net sales. We have
 full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plusa percentage of the net sales to end-customers in these markets. Eliquis is part of
 the Novel Oral Anticoagulant (NOAC) market; the agents in this class were developed asalternative treatment options to warfarin in appropriate patients.
 
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $1,849  $1,418  30   International
  1,585  1,105  43  40 Worldwide revenues
  $3,434  $2,523  36  35 The worldwide operational 
growth in 2018 was primarily driven by continued increased adoption in non-valvular atrial fibrillation, as well as oral anti-coagulant market share gain.
•
Enbrel (IH, outside the U.S. and Canada):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $—  $—  —   International
  2,112  2,452  (14 ) (14 )Worldwide revenues
  $2,112  $2,452  (14 ) (14 )The worldwide operational 
decline in 2018 was primarily due to ongoing biosimilar competition in most developed Europe markets, which is expected to continue. •
Lipitor (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018  2017  Total  Oper. U.S.
  $110  $161  (31 )  International
  1,952  1,754  11  9 Worldwide revenues
  $2,062  $1,915  8  5 The worldwide operational 
growth in 2018 was primarily driven by increased demand in China, partially offset by pricing pressures in China, the non-recurrence of favorable U.S. rebates that occurred in the third quarter of 2017 and generic competition in Japan.
•
Xeljanz (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $1,394  $1,133  23   International
  380  212  79  84 Worldwide revenues
  $1,774  $1,345  32  33 The 
growth in the U.S. in 2018 was primarily driven by increased adoption among rheumatologists, growing awareness among patients and improvements in payer access, and to a lesser extent, launches of the PsA
 indication in the first quarter of 2018 and ulcerative colitis indication in the third quarter of 2018.The operational 
growth internationally in 2018 was primarily driven by the 2017 approval of the RA indication in certain European markets, as well as continued uptake in Japan, Canada and emerging markets.
•
Chantix/Champix (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018  2017  Total  Oper. U.S.
  $838  $742  13   International
  247  255  (3 ) (5 )Worldwide revenues
  $1,085  $997  9  8 The 
growth in the U.S. in 2018 was primarily due to increased volume, improved patient access and positive price impact. The operational decline in 2018 internationally was primarily driven by lower demand in South Korea.
26
  2018 Financial Report
 
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Sutent (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018  2017  Total  Oper. U.S.
  $357  $374  (4 )  International
  692  707  (2 ) (3 )Worldwide revenues
  $1,049  $1,081  (3 ) (4 )The worldwide operational 
decline in 2018 was primarily due to lower volumes driven by competitive pressure in the U.S. and key European markets. •
Norvasc (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $36  $38  (5 )  International
  988  888  11  9 Worldwide revenues
  $1,024  $926  11  9 The worldwide operational 
growth in 2018 was primarily driven by increased demand in China, partially offset by generic competition in Japan and pricing pressures in China.
•
The Premarin family of products (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $783  $921  (15 )  International
  49  56  (12 ) (12 )Worldwide revenues
  $832  $977  (15 ) (15 )The worldwide operational 
decline in 2018 was primarily driven by generic competition in the U.S. •
Xtandi alliance revenues (IH): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to
 certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S.market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi
net sales (recorded in 
Other (income)/deductions—net ).  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018  2017  Total  Oper. U.S.
  $699  $590  18   International
  —  —  —  — Worldwide revenues
  $699  $590  18  18 The 
growth in the U.S. in 2018 was driven by continued growth of Xtandi in castration-resistant prostate cancer as well as reduction in patient assistance program (PAP) utilization in 2018 compared to 2017.
•
Celebrex (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018   2017   Total  Oper. U.S.
  $65  $164  (60 )  International
  621  611  2  — Worldwide revenues
  $686  $775  (11 ) (13 )The worldwide operational decline in 
2018 was primarily driven by the non-recurrence of the favorable U.S. rebates that occurred in 2017, lower volumes in the U.S., as well as pricing pressure in Mexico and China, partially offset by increased demand in China.
2018 Financial Report    
 
 27
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Inflectra/Remsima (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018   2017   Total  Oper. U.S.
  $259  $118  *   International
  383  301  27  23 Worldwide revenues
  $642  $419  53  50 The worldwide operational 
growth in 2018 was primarily due to continued uptake in certain channels in the U.S., as well as in developed markets in Europe, partially offset by pricing pressures in these markets.
Inflectra uptake in the U.S. is being driven by a number of factors,
 including purchases by closed systems, which value long-term savings over short-term rebating, andconsistent reimbursement in Medicare. To date, reimbursement coverage has been mixed. While we achieved 100% Medicare coverage, in the face of exclusionary
conduct by J&J, we have experienced access challenges among commercial payers where our lower priced product has not received access at parity to the innovator
product. We will continue to work with commercial payers to enable greater access for Inflectra. Additionally, in September 2017, Pfizer filed suit in the U.S
. District Courtfor the Eastern District of Pennsylvania against J&J alleging that J&J’s exclusionary contracts and other an
ticompetitive practices concerning Remicade® (infliximab) violatefederal antitrust laws.
•
Viagra (EH): Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S . and Canada, which were reported in IH through 2017, arereported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra revenues are reported in EH.
 
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $217  $789  (73 )  International
  419  416  1  — Worldwide revenues
  $636  $1,204  (47 ) (47 )The 
decline in the U.S. in 2018 was primarily due to the loss of exclusivity in December 2017. The relatively flat operational performance in 
2018 internationally was primarily driven by increased demand in China offset by lower volumes in Russia and developed Europe.
•
Sulperazon (EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017  Total  Oper. U.S.
  $—  $—  —   International
  613  471  30  27 Worldwide revenues
  $613  $471  30  27 The international operational 
growth in 2018 was primarily due to increased demand in China. •
Xalkori (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017   Total   Oper. U.S.
  $158  $223  (29 )  International
  366  371  (1 ) (4 )Worldwide revenues
  $524  $594  (12 ) (14 )The worldwide operational 
decline in 2018 was primarily due to volume declines in the ALK indication across certain developed markets, primarily in the U.S. and certain markets in developed Europe, due to competitive pressure. The decline was partially offset by a continued increase in diagnostic rates for the 
ALK gene mutation acrosskey markets and share in first-line ALK treatment outside the U.S., primarily in certain emerging markets, as well as uptake in treatment of patients
 with metastatic NSCLCwhose tumors are ROS1-positive.
•
Inlyta (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017   Total  Oper. U.S.
  $119  $126  (5 )  International
  178  213  (16 ) (16 )Worldwide revenues
  $298  $339  (12 ) (12 )
The worldwide operational decline in 2018 was primarily due to increased competition across developed markets.28
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
Eucrisa (IH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018 2017   Total  Oper. U.S.
  $147  $67  *   International
  —  —  —  — Worldwide revenues
  $147  $67  *  * The 
growth in the U.S. in 2018 was driven by increasing prescriber trial and adoption, enhanced patient awareness and availability of patient access programs. •
Alliance revenues (IH/EH):  
  Year Ended December 31,  
        % Change (MILLIONS OF DOLLARS)
  2018   2017   Total  Oper. U.S.
  $2,576  $2,037  26   International
  1,263  890  42  37 Worldwide revenues
  $3,838  $2,927  31  30 The worldwide operational 
growth in 2018 was mainly due to increases in Eliquis and Xtandi alliance revenues discussed above. ◦
Bavencio (IH) is being developed and commercialized in collaboration with Merck KGaA. Both companies jointly fund the majority of development and commercialization costs, and split equally any profits generated from selling any products containing avelumab from this collaboration. 
Bavencio is currently approved in metastatic MCC in the U.S., Europe and Japan and selected other markets, as
 well as in second line treatment of locally advanced or metastatic urothelial carcinoma in the U.S.See Notes to Consolidated Financial Statements–– 
Note 18C. Segment, Geographic and Other Revenue Information : Other Revenue Information for additional information regarding the primary indications or class of the selected products discussed above.
See the “Our Operating Environment—Industry-Specific Challenges—Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Review for
information regarding the expiration of various patent rights.
See Notes to Consolidated Financial Statements— 
Note 17. Contingencies and Certain Commitments for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.
PRODUCT DEVELOPMENTS—BIOPHARMACEUTICAL
We continue to invest in R&D to provide potential future sources of revenues through the
 development of new products, as well as through additional uses for in-line andalliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or
any of our other products in development.
We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline
that will deliver value in the near term and over time.
For additional information about our R&D organization, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our 
Strategy—Organizing forGrowth” and “—Description of Research and Development Operations” sections of this Financial Review.
A comprehensive update of Pfizer’s development pipeline was published as of 
January 29, 2019 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in
Phase 1 and all candidates from Phase 2 through registration.
The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as
well as additional indications and new drug candidates in late-stage development.
RECENT FDA APPROVALS
PRODUCT
INDICATION DATE APPROVED Daurismo (glasdegib)
Treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who havecomorbidities that pre
clude use of intensive induction chemotherapyNovember 2018Lorbrena (lorlatinib)
Treatment of patients with ALK-positive m etastatic NSCLC whose disease has progressed on crizotinib and at least oneother ALK inhibitor for metastatic dis
ease; or whose disease has progressed on alectinib or ceritinib as the first ALKinhibitor therapy for 
metastatic diseaseNovember 2018Talzenna (talazoparib)
Treatment of adult patients with d eleterious or suspected deleterious germline BRCA-mutated (gBRCAm) humanepidermal growth factor recept
or 2 (HER2)-negative locally advanced or metastatic breast cancerOctober 2018Vizimpro (dacomitinib)
First-line treatment of patients with metast atic non-small cell lung cancer with epidermal growth factor receptor exon 19deletion or exon 21 L8
58R substitution mutations as detected by an FDA-approved test, which is being developed incollaboration with SFJ
September 2018Nivestym (filgrastim-aafi) 
(a) A biosimilar to Neupogen ®  (filgrastim) for all eligible indications of the reference productJuly 2018 Xtandi (enzalutamide)
Treatment of men with non-metastatic c astration-resistant prostate cancer, which is being developed through acollaboration with Astellas
July 2018Xeljanz (tofacitinib)
Treatment of adult patients with mo derately to severely active ulcerative colitisMay 2018 Retacrit (epoetin alfa-epbx) 
(b) A biosimilar to Epogen® and Procrit® ( epoetin alfa) for all indications of the reference productMay 2018 (a) 
 Neupogen ® is a registered trademark of Amgen Inc.(b) 
 Epogen® is a registered U.S. trademark of Amgen Inc.; Procrit® is a registered U.S. trademark of J&J.2018 Financial Report    
 
 29
Financial ReviewPfizer Inc. and Subsidiary Companies
 
PENDING U.S. NDAs
 AND SUPPLEMENTAL FILINGSPRODUCT
PROPOSED INDICATI ONDATE FILED* Bavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-linetreatment of advanced ren
al cell carcinoma, which is being developed in collaboration with Merck KGaA, GermanyFebruary 2019PF-06410293 
(a) A potential biosimilar to Humira® (ad alimumab)January 2019 tafamidis meglumine
Treatment of transthyretin amyloid car diomyopathyJanuary 2019 tafamidis free acid
Treatment of transthyretin amyloid car diomyopathyJanuary 2019 PF-05280586 
(b) A potential biosimilar to Rituxan ®  (rituximab)September 2018 PF-06439535 
(c) A potential biosimilar to Avastin ®  (bevacizumab)August 2018 PF-05280014 
(d) A potential biosimilar to Herceptin ®  (trastuzumab)August 2017 tafamidis meglumine 
(e) Treatment of transthyretin familial amyloi d polyneuropathyFebruary 2012 *
The dates set forth in this column are the dates on which the FDA accepted our submissions.(a) 
 Humira ® is a registered trademark of AbbVie Biotechnology Ltd.(b) 
 Rituxan ® is a registered trademark of Biogen MA Inc.(c) 
 Avastin ® is a registered trademark of Genentech, Inc.(d)
 
Herceptin ® is a registered trademark of Genentech, Inc. In April 2018, we received a “complete response” letter from the FDA with respect to our biologics license application (BLA) for PF-05280014, our proposedbiosimilar to trastuzumab, which was su
bmitted for all indications of the reference product. The FDA highlighted the need for additional technical information, which does not relate to safety or clinical datasubmitted in the application. I
n October 2018, the FDA acknowledged for review our BLA resubmission.(e)
 
In May 2012, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that isreasonably likely to predict a clinic
al benefit. In June 2012, the FDA issued a “complete response” letter with respect to this tafamidis NDA. The FDA has requested the completion of a second efficacy study, andalso has asked for addition
al information on the data within the current tafamidis NDA. Pfizer has completed study B3461028, a global Phase 3 study to support a potential new indication in transthyretincardiomyopathy, which includes 
patients with wild type and variant transthyretin. This study has achieved its primary endpoint, and we are working with the FDA to identify next steps.REGULATORY APPROVALS AN
D FILINGS IN THE EU AND JAPANPRODUCT
DESCRIPTION OF EVENT DATE APPROVED DATE FILED* Zirabev 
(a) Application approved in th e EU for a biosimilar to Avastin ®  (bevacizumab) for the treatment of metastaticcarcinoma of the colon or rectum, m
etastatic breast cancer, unresectable advanced, metastatic or recurrentNSCLC, advanced and/or metast
atic renal cell cancer and persistent, recurrent, or metastatic carcinoma ofthe cervix
February 2019— Vyndaqel (tafamidis free acid)
Application filed in the EU for the tr eatment of adult symptomatic transthyretin cardiomyopathy— January 2019 Bavencio (avelumab)
Application filed in Japan for B avencio (avelumab) in combination with Inlyta (axitinib) for the first-linetreatment of advanced ren
al cell carcinoma, which is being developed in collaboration with Merck KGaA,Germany
—January 2019 Vizimpro (dacomitinib)
Application approved in Ja pan for the treatment of patients with locally advanced or metastatic non-smallcell lung cancer with EGFR mutations, which is 
being developed in collaboration with SFJJanuary 2019— PF-06410293 
(b) Application filed in the EU for a p otential biosimilar to Humira ®  (adalimumab)— November 2018 tafamidis meglumine
Application filed in Japan for tr eatment of transthyretin amyloid cardiomyopathy— November 2018 Xtandi (enzalutamide)
Application approved in th e EU for treatment of adult men with high-risk non-metastatic castration-resistantprostate cancer, which is being 
developed through a collaboration with AstellasOctober 2018— Trastuzumab BS for IV Infusion
60mg/150mg “Pfizer” 
(c) Application approved in Japan for a biosimilar to Herceptin ®  (trastuzumab)September 2018 — Lorbrena (lorlatinib)
Application approved in Ja pan for the treatment of patients with ALK-positive metastatic non-small cell lungcancer, previously treated with o
ne or more ALK inhibitorSeptember 2018— PF-05280586 
(d) Application filed in the EU for a p otential biosimilar to Rituxan ®  (rituximab)— August 2018 Xeljanz (tofacitinib)
Application approved in th e EU for the treatment of adult patients with moderately to severely activeulcerative colitis
 who have had an inadequate response, lost response, or were intolerant to eitherconventional therapy or a b
iologic agentJuly 2018— Trazimera 
(c) Application approved in th e EU for a biosimilar to Herceptin ®  (trastuzumab) for the treatment of humanepidermal growth factor (HER2) over
expressing breast cancer and HER2 overexpressing metastatic gastricor gastroesophageal junction adeno
carcinomaJuly 2018— Infliximab BS for IV Infusion 100mg “Pfizer”
(e)
Application approved in Japan for a biosimilar to Remicade ®  (infliximab)July 2018 — Xeljanz (tofacitinib)
Application approved in th e EU for Xeljanz in combination with methotrexate for the treatment of active PsAin adult patients who have
 had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic
 drug therapyJune 2018— talazoparib
Application filed in the EU for the tr eatment of patients with germline BRCA-mutated advanced breastcancer
—June 2018 Xeljanz (tofacitinib)
Application approved in Japan  for the treatment of ulcerative colitisMay 2018 — crisaborole
Application filed in the EU for the tr eatment of mild-to-moderate atopic dermatitis— May 2018 30
 
 2018 Financial Report
••
•
•
•
•
•
Financial ReviewPfizer Inc. and Subsidiary Companies
 
REGULATORY APPROVALS AN
D FILINGS IN THE EU AND JAPAN (cont’d.) PRODUCT
DESCRIPTION OF EVENT DATE APPROVED DATE FILED* Mylotarg (gemtuzumab ozoga
micin)Application approved in th e EU for treatment of patients age 15 years and above with previously untreated,de novo, CD33-positive acute my
eloid leukemia, except acute promyelocytic leukemiaApril 2018— Bosulif (bosutinib)
Application approved in th e EU for the treatment of adults with newly diagnosed chronic phase Philadelphiachromosome-positive chronic myelo
genous leukemia (Ph+ CML), which is being developed in collaborationwith Avillion
April 2018— dacomitinib 
(f) Application filed in the EU for the first-li ne treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mut
ations, which is being developed in collaboration with SFJ—March 2018 Steglatro (ertugliflozin)
Approval in the EU as an adju nct to diet and exercise to improve glycemic control in adults with type 2diabetes mellitus:
as monotherapy in patients
 for whom the use of metformin is considered inappropriate due to intoleranceor contraindications; and
in addition to other medi
cinal products for the treatment of diabetes, which is being developed incollaboration with Merck
March 2018— Segluromet (ertugliflo
zin and metformin)Approval in the EU as an adju nct to diet and exercise to improve glycemic control in adults with type 2diabetes mellitus:
in patients not adequat
ely controlled on their maximally tolerated dose of metformin alone;in patients on their maximally toler
ated doses of metformin in addition to other medicinal products for thetreatment of diabetes; and
in patients already being tr
eated with the combination of ertugliflozin and metformin as separate tablets,which is being developed i
n collaboration with MerckMarch 2018— Steglujan (ertuglifloz
in and sitagliptin)Approval in the EU as an adju nct to diet and exercise to improve glycemic control in adults with type 2diabetes mellitus:
when metformin and/or a 
sulphonylurea (SU) and one of the monocomponents of Steglujan do notprovide adequate glycaemic 
control; andin patients already being tr
eated with the combination of ertugliflozin and sitagliptin as separate tablets,which is being developed i
n collaboration with MerckMarch 2018— Xeljanz (tofacitinib)
Application filed in the EU for modifi ed release 11mg tablet for RA— March 2018 lorlatinib (PF-06463922)
Application filed in the EU for the tr eatment of patients with ALK-positive metastatic non-small cell lungcancer, previously treated with o
ne or more ALK inhibitors—February 2018 *
For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.(a) 
 Avastin ® is a registered trademark of Genentech, Inc.(b) 
 Humira ® is a registered trademark of AbbVie Biotechnology Ltd.(c) 
 Herceptin ® is a registered trademark of Genentech, Inc.(d) 
 Rituxan ® is a registered trademark of Biogen MA Inc.(e)
 
Remicade ® is a registered Japan trademark of Janssen. In February 2016, we divested the rights for development and commercialization of PF-06438179, a potential biosimilar to Remicade ® (infliximab) in the 28countries that form the EEA to Sand
oz, which was a condition to the European Commission’s approval of the Hospira transaction. We retain commercialization rights to PF-06438179 in all countries outside of theEEA.
(f) 
 In February 2019, the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for dacomitinib, as monotherapy, for the first-line treatment ofadult patients with locally adva
nced or metastatic NSCLC with EGFR-activating mutations.2018 Financial Report    
 
 31
Financial ReviewPfizer Inc. and Subsidiary Companies
 
LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS 
FOR IN-LINE AND IN-REGISTRATION PRODUCTS
PRODUCT
PROPOSED INDICATI ONBavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma,which is being developed i
n collaboration with Merck KGaA, Germany (ex-U.S./Japan)Bavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1, in combination with Talzenna (talazoparib), in patients with previously untreated advanced ovarian cancer, which is beingdeveloped in collaborati
on with Merck KGaA, GermanyBavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being develo
ped in collaboration with Merck KGaA, GermanyBavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1 for maintenance treatment, in the first-line setting, for patients with urothelial cancer, which is bei
ng developed in collaboration with Merck KGaA, GermanyBavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1 for maintenance treatment of advanced or metastatic gastric/ gastro-esophageal juncti
on cancers, which is being developed in collaboration with Merck KGaA, GermanyBavencio (avelumab)
A monoclonal antibody that i nhibits PD-L1 for treatment of locally advanced squamous cell carcinoma of the head and neck, which is bei
ng developed in collaboration with Merck KGaA, GermanyDaurismo (glasdegib)
A smoothened inhibitor, in com bination with azacitidine,    for the treatment of acute myeloid leukemiaIbrance (palbociclib)
Treatment of HER2+ advanced bre ast cancer, in collaboration with the Alliance Foundation Trials, LLCIbrance (palbociclib)
Treatment of high-risk early breast ca ncer, in collaboration with the German Breast GroupIbrance (palbociclib)
Treatment of HR+ early breast cancer, in c ollaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study GroupLorbrena (lorlatinib)
A next generation ALK/ROS1 tyrosin e kinase inhibitor for the first-line treatment of patients with ALK-positive advanced non-small cell lung cancerXeljanz (tofacitinib)
Treatment of ankylosing spondylitis Xtandi (enzalutamide)
Treatment of non-metastatic hormo ne-sensitive prostate cancer, which is being developed through a collaboration with AstellasXtandi (enzalutamide)
Treatment of metastatic hormone-se nsitive prostate cancer, which is being developed through a collaboration with AstellasTalzenna (talazoparib)
An oral PARP inhibitor, in combinatio n with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancerIn February 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that
 the Bavencio Phase 3 trial in patients with previously treated NSCLC did not meet itspre-specified primary endpoint. The alliance made the decision to discontinue further development in this indication.
In November 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that 
the Bavencio Phase 3 trial in platinum-resistant/refractory ovarian cancer did notmeet the pre-specified primary endpoints 
.  We continue to evaluate the detailed results of the trial.In December 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that da
ta from a planned interim analysis of the Bavencio Phase 3 trial in previously untreated advanced ovarian cancer did not support the study’s initial hypothesis, and therefore the alliance made the decision to 
terminate the trial in alignment with theindependent Data Monitoring Committee.
In February 2019, we announced that the company has taken steps
 to transition rheumatoid arthritis study patients who were on tofacitinib 10 mg twice daily to tofacitinib 5 mgtwice daily in the FDA post-marketing requirement study A3921133, a study performed in patients considered to be at high risk for certain side ef
fects. This action is beingtaken as the result of notification from the tofacitinib Rheumatology Data Safe
ty Monitoring Board of a safety signal regarding the tofacitinib 10 mg twice daily treatment arm instudy A3921133. The 5 mg twice daily dose is the FDA approved dose in the U.
S. for adult patients with moderate to severe rheumatoid arthritis. We continue to evaluate theinformation. 
NEW DRUG CANDIDATES IN
 LATE-STAGE DEVELOPMENTCANDIDATE
PROPOSED INDICATI ONaztreonam-avibactam
(PF-06947387)
A beta lactam/beta lactamase inhibitor for the treatment of complicated intra-abdominal infections, hospital acquired pneumonia/ventilator associated pneumoniafidanacogene elaparvovec (P
F-06838435)An investigational gene the rapy for the treatment of hemophilia BPF-06482077
A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae  serotypes covered by the vaccine 
in adults 18 years of age and olderPF-06651600
A Janus kinase 3 (JAK3) inhibitor for t he treatment of patients with moderate to severe alopecia areataPF-04965842
A Janus kinase 1 (JAK1) inhibitor for t he treatment of moderate-to-severe atopic dermatitisPF-06425090
A prophylactic vaccine for active immuniz ation to prevent clostridium difficile diseaserivipansel (GMI-1070)
A pan-selectin inhibitor for the tr eatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease, which was licensed from GlycoMimetics Inc.somatrogon (PF-06836922)
A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKOsomatrogon (PF-06836922)
A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKOtanezumab
An anti-nerve growth factor mon oclonal antibody for the treatment of pain, which is being developed in collaboration with LillyAdditional product-related programs are in various stages of discovery and development.
32
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
COSTS AND EXPENSES
The changes in expenses below reflect, among other things, the favorable impact of the February 2017 sale o
f HIS. The operating results of HIS are included in our operatingresults through February 2, 2017 and, therefore, operating results for 
2017 include approximately one month of HIS domestic operations and approximately two months of HIS international operations, while operating results for 
2016 reflect 12 months of HIS global operations. Our operating results for 2018 do not reflect any HIS global operations. Cost of Sales
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Cost of sales
  $11,248  $11,228  $12,322  —  (9 )As a percentage of 
Revenues   21.0 % 21.4 % 23.3 %   2018 
v. 2017Cost of sales 
increased $21 million , or were relatively flat in 2018 , compared to 2017 , primarily due to: •
increased sales volumes primary related to key products within our product portfolio;•
higher costs across the SIP portfolio, as a result of the complexity of high quality product manufacture across the legacy Hospira plants, which was partially offset bydecreases in other costs across various markets;
•
an increase in royalty expenses based on the mix of products sold; and•
the unfavorable impact of hedging activity on intercompany inventory of $65 million , partially offset by:
•
lower volumes from the SIP portfolio, in developed markets, primarily due to increased competition across the SIP portfolio and continued legacy Hospira product shortagesin the U.S.;
•
the non-recurrence of $195 million in inventory losses, overhead costs, and incremental costs related to the period in 2017 during which our Puerto Rico plants were notoperational due to hurricanes;
•
the favorable impact of foreign exchange of $153 million ; •
the non-recurrence of charges related to a product recall that occurred in 2017; and•
the favorable impact of the sale of HIS of $35 million.The 
decrease in Cost of sales as a percentage of revenues in 2018 , compared to 2017 , was primarily due to all of the factors discussed above, as well as an increase in alliance revenues, which have no associated cost of sales.
2017 
v. 2016Cost of sales 
decreased $1.1 billion , or 9% , in 2017 , compared to 2016 , primarily due to: •
the favorable impact of the sale of HIS global operations (which carried a higher cost of sales than other products) of $561 million;•
recognition of synergies related to our cost-reduction/productivity initiatives;•
the nonrecurring unfavorable impact of $248 million of acquired Hospira inventory, which is measured at fair value on the acquisition date and was amortized over the turn ofthe related inventory;
•
the favorable impact of foreign exchange of $140 million and the favorable offset of hedging gains of $52 million ; and •
a favorable change in product mix, including an operational decline in the SIP portfolio and the favorability attributed to products that have lost exclusivity,partially offset by:
•
$195 million in inventory losses, overhead costs related to the period in 2017 during which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from the hurricanes in Puerto Rico.
The 
decrease in Cost of sales as a percentage of revenues in 2017 , compared to 2016 , was primarily due to all of the factors discussed above, as well as an increase in alliance revenues, which have no associated cost of sales.
Selling, Informational and Administrative (SI&A) Expenses
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Selling, informational and administrative expenses
  $14,455  $14,804  $14,844  (2 ) — As a percentage of 
Revenues   26.9 % 28.2 % 28.1 %     2018 
v. 2017SI&A expenses 
decreased $350 million , or 2% , in 2018 , compared to 2017 , primarily due to: •
lower advertising, promotional and field force expenses, as well as general and administrative expenses, reflecting the benefits of cost-reduction and productivity initiatives;•
the non-recurrence of a $200 million charitable contribution to the Pfizer Foundation;•
decreased investment across several of our key products, primarily Viagra and Enbrel; and2018 Financial Report    
 
 33
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
lower healthcare reform expenses as a result of a true up of the prior year amount,partially offset by:
•
additional investment across several of our key products, primarily, Xeljanz, Ibrance, Eucrisa and Prevnar 13/Prevenar 13.•
additional investments in China; and•
a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, of $119 million , in the aggregate, in the first quarter of 2018. 2017 
v. 2016SI&A expenses 
decreased $40 million , or were relatively flat in 2017 , compared to 2016 , primarily due to: •
the non-recurrence of an allowance for doubtful trade accounts receivable of approximately $265 million, resulting from unfavorable developments with a distributor that wasrecorded in the first quarter of 
2016 ; •
lower advertising, promotional and field force expenses, reflecting the benefits of cost-reduction and productivity initiatives;•
lower spending for certain products, primarily Prevnar 13/Prevenar 13;•
the favorable impact of the sale of HIS global operations of $135 million; and•
lower spending for Viagra due to the loss of exclusivity in December 2017,offset by:
•
additional investment across several of our key products, primarily Eucrisa, Ibrance and Xeljanz, as well as biosimilars, primarily related to the U.S. launch of Inflectra; and•
an increase in charitable contributions, including a $200 million charitable contribution to the Pfizer Foundation, an organization that provides grant and investment funding tosupport organizations and social entrepreneurs in an effort to improve healthcare delivery.
Research and Development (R&D) Expenses
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Research and development expenses
  $8,006  $7,683  $7,892  4  (3 )As a percentage of 
Revenues   14.9 % 14.6 % 14.9 %     2018 
v. 2017R&D expenses 
increased $322 million , or 4% , in 2018 , compared to 2017 , primarily due to: •
increased costs associated with our Phase 3 clinical trials related to our JAK1 inhibitor (which was initiated in December 2017) and the C. difficile vaccine program (which was initiated in March 2017) as well as increased spending for our 20 valent pneumococcal conjugate vaccine candidate;
•
increased costs associated with the Bavencio program; and•
an increase in the value of the portfolio performance share grants reflecting changes in the price of Pfizer’s common stock, as well as management’s assessment of theprobability that the specified performance criteria will be achieved,
partially offset by:
•
decreased spending for biosimilars as several programs have reached completion; and•
the impact of our decision to end internal neuroscience discovery and early development efforts.2017 
v. 2016R&D expenses 
decreased $208 million , or 3% , in 2017 , compared to 2016 , primarily due to: •
lower expenses of approximately $743 million due to the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016 and thenon-recurrence of its associated close-out costs;
partially offset by:
•
increased costs associated with our oncology programs, primarily clinical trial spend on Medivation assets;•
lower development funding credits of approximately $124 million primarily related to the discontinuation of the global clinical development program for bococizumab in thefourth quarter of 2016;
•
increased costs associated with our C. difficile vaccine program, which initiated a Phase 3 clinical study in March 2017; •
an expense of $75 million resulting from our May 2017 agreement with Sangamo to develop and commercialize gene therapy programs for Hemophilia A; and•
increased costs associated with late stage development programs, including Xtandi, talazoparib and tanezumab.For additional information on Cost of sales, SI&A and R&D expenses by operating segment, see
 the “Analysis of Operating Segment Information” section of this FinancialReview.
34
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Amortization of Intangible Assets
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Amortization of intangible assets
  $4,893  $4,758  $4,056  3  17 As a percentage of 
Revenues   9.1 % 9.1 % 7.7 %     Amortization of intangible assets 
increased $135 million , or 3% in 2018 , compared to 2017 , primarily due to amortization expense of approximately $151 million (pre-tax) in 2018 
associated with the approval of Xtandi in the U.S. for the  treatment of non-metastatic castration-resistant prostate cancer. The U.S. approval resulted in the transfer of$2.7 billion 
from an indefinite-lived IPR&D intangible asset to a finite-lived Developed technology rights intangible asset. Amortization of intangible assets 
increased $703 million , or 17% , in 2017 , compared to 2016 , primarily due to amortization expense of approximately $797 million (pre-tax) in 2017 
associated with the identifiable intangible assets acquired from Medivation and Anacor, partially offset by assets that became fully amortized at the end of their estimateduseful lives and the favorable impact of the February 2017 sale of HIS.
See also Notes to Consolidated Financial Statements— 
Note 10A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Restructuring charges––acquisition-related costs 
(a)   $37  $105  $207  (64 ) (49 )Restructuring charges/(credits)––cost reduction initiatives 
(b)   745  (75 ) 849  *  * Restructuring charges
  782  30  1,055  *  (97 )Transaction costs 
(c)   1  4  127  (62 ) (97 )Integration costs 
(c)   260  317  383  (18 ) (17 )Restructuring charges and certain acquisition-related costs
  1,044  351  1,565  *  (78 )Net periodic benefit costs 
(d)  146  136  159  8  (15 )Total additional depreciation––asset restructuring
  50  91  207  (45 ) (56 )Total implementation costs
  194  227  340  (15 ) (33 )Costs associated with acquisitions and cost-reduction/productivity
initiatives 
(e)   $1,434  $805  $2,271  78  (65 )(a)
 
Restructuring charges––acquisition-related costs include employee termination costs, asset impairments and other exit costs associated with business combinations. Charges for 2018 were primarily due to asset write downs, partially offset by the rev
ersal of previously recorded accruals for employee termination costs related to our acquisition of Hospira. Restructuring charges for 2017 were primarily due to asset write-downs, partially offset by the revers
al of previously recorded accruals for employee termination costs. For 2017 and 2016, restructuring charges––acquisition-related costs were mainly related to our acquisitions ofHospira and Medivation.
(b)
 
Restructuring (credits)/charges––cost reduction initiatives relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions. For 2018, the charges were primarily relatedto employee termination costs a
nd asset write downs. The employee termination costs are associated with our improvements to operational effectiveness as part of the realignment of our organizational structureeffective at the beginning 
of 2019. For 2017, the credits are mostly related to the reversal of previously recorded accruals for employee termination costs, partially offset by asset write downs.(c) 
 For additional information, see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Oth er Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . (d)
 
For additional information, see Notes to Consolidated Financial Statements— Note 1B . Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 and Note 3.Restructuring Charges and Oth
er Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . (e)
 
Comprises Restructuring charges and cert ain acquisition-related costs as well as costs associated with our cost-r eduction/productivity initiatives included in Cost of sales , Research and development expenses,Selling, informational and a
dministrative expenses and/or Other (income)/deduction s––net as appropriate. For addition al information, see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Other Costs Associate
d with Acquisitions and Cost-Reduction/Productivity Initiatives . *
Indicates calculation not meaningful or result is equal to or greater than 100%.In connection with our acquisition of Hospira in September 2015, we focused our efforts on achieving an appropriate cost structure 
for the combined company. We achievedour expected 
$1 billion of annual cost savings in connection with the Hospira acquisition, 25% more than our initial cost savings target of $800 million . The one-time costs to generate the savings were approximately 
$1 billion (not including costs of $215 million for full-year 2015 associated with the return of acquired IPR&D rights), and the majority of these costs were incurred within the three-year period post-acquisition.
In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our 2014 global commercial structure reorganization,
manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise. 
Through December 31, 2016, we incurred 
$3.1 billion (pre-tax) in total costs for the 2014-2016 program. The cumulative ongoing annual cost savings associated with the 2014-2016 program (but not including expected cost savings associated with the
2018 Financial Report    
 
 35
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Hospira acquisition), are approximately $3.1 billion. These savings were recognized, for the most part, through the end of 2016. However, savings from costs incurred in the
last half of 2016 largely occurred in 2017.
2017-2019 Initiatives and Organizing for Growth
During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start o
f our2019 fiscal year, we would begin operating under our new commercial structure, which reorganizes our operations into three businesses 
–– Biopharma, a science-based Innovative medicines business; Upjohn, a global off-patent branded and generic established medicines business; and a Consumer Healthcare business. To operate effectively
in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the func
tionsthat support them. Beginning in the fourth quarter of 2018,
 we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our newstructure and have combined the 2017 to 2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. For the combined programs, to achieve
targeted savings of approximately 
$1.9 billion , we expect to incur approximately $2.2 billion in costs over the three-year period 2017-2019. Of this amount, we expect approximately 
40% to be related to manufacturing operations, and we expect approximately 20% of the charges to be non-cash. Anticipated savings through 2020 associated with the Organizing for Growth initiatives of approximately 
$500 million will be reinvested in our R&D pipeline and in selling and marketing to support our current and recently launched products and indications. For additional information about these programs and expected and actual total costs, see Notes
 to Consolidated Financial Statements—Note 3. 
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity
and the expiration of collaborative arrangements for various products.
Other (Income)/Deductions––Net
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Other (income)/deductions—net
  $2,116  $1,416  $3,794  49  (63 )For information about the components of 
Other (income)/deductions—net , see Notes to Consolidated Financial Statements— Note 4. Other (Income)/Deductions—Net. See also the “Analysis of Operating Segment Information” section of this Financial Review.
PROVISION/(BENEFIT) FOR TAXES ON INCOME
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Provision/(benefit) for taxes on income
  $706  $(9,049 )  $1,123  *  * Effective tax rate on continuing operations
  5.9 % (73.5 )%  13.4 %     *
Indicates calculation not meaningful or result is equal to or greater than 100%.2018 
v. 2017The 
higher effective tax rate in 2018 compared to 2017 was primarily the result of: •
the non-recurrence of a $10.7 billion tax benefit recorded in 2017 to reflect the enactment of the TCJA,partially offset by:
•
tax benefits related to the TCJA, including certain current year tax initiatives as well as favorable adjustments to the provisional estimate of the impact of the legislation,reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC;
•
the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as•
an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration ofcertain statutes of limitations.
2017 
v. 2016The 
lower effective tax rate in 2017 compared to 2016 was primarily the result of: •
the tax benefits associated with the remeasurement of deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings offoreign subsidiaries associated with the enactment of the TCJA; and
•
a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business,partially offset by:
•
the decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities and the expiration ofcertain statutes of limitations; and
36
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
the non-recurrence of tax benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claimsrelated to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax
position.
For details about discrete elements that impacted our tax provisions, see Notes to Consolidated Financial Statements— 
Note 5A. Tax Matters: Taxes on Income from Continuing Operations 
. Changes in Tax Laws
On December 22, 2017, the U.S. enacted significant changes to
 U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changesthe U.S. corporate income tax system by, among other things, reducing the U.
S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from aworldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. 
In accordance with guidance issued by the SEC we recorded provisional estimates of the legislation in the fourth-quarter 2017. In 2018, we finalized our provisional accounting for the tax
effects of the TCJA based on our best es
timates of available information and data, and have reported and disclosed the impacts within the applicable measurement period, inaccordance with guidance issued by the SEC. For additional information, see Notes to Consolidated Financial Statements— 
Note 5A. Tax Matters: Taxes on Income from Continuing Operations 
and the “Analysis of Financial Condition, Liquidity and Capital Resources––Selected Measures of Liquidity and Capital Resources—Contractual Obligations” section of this Financial Review.
On January 23, 2017, the Governor of Puerto Rico signed into law Act
 No. 3-2017, amending Section 2101 of the Puerto Rico Internal Revenue Code of 1994, which imposesan excise tax that was effective beginning in 2011 (Act 154). The excise 
tax is imposed on the purchase of products by multinational corporations and their affiliates from theirPuerto Rico affiliates. As originally adopted, the excise tax was to be in effec
t from 2011 through 2016 and the tax rate was to decline over time from 4% in 2011 to 1% in 2016.Act No. 2-2013 extended the excise tax through 2017 and,
 effective July 1, 2013, increased the tax rate to 4% for all years through 2017. Act No. 3-2017 further extended theexcise tax for all years through 2027 at a rate of 4%. The excise 
tax has been recorded in Cost of sales and Provision/(benefit) for taxes on income, as appropriate. All expected impacts in 2019 have been reflected in our financial guidance for 2019.
NON-GAAP FINANCIAL MEASURE (ADJUSTED INCOME)
General Description of Non-GA
AP Financial Measure (Adjusted Income)Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other
performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors’ understanding of our performance is enhanced by
disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the
results of our major operations––the discovery, development, manufacture, marketing and sale of prescription medicines, vaccines and consumer healthcare (OTC) products––
prior to considering certain income statement elements. We have defined Adjusted income as 
Net income attributable to Pfizer Inc. before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Similarly, we have defined the Adjusted income
components as 
Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets and Other(income)/deductions––net 
each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as 
Earnings per common share attributable to Pfizer Inc.––diluted before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the 
Adjusted diluted earnings pershare measure are not, and should not be viewed as,substitutes for U.S. 
GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share.The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:
•
senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;•
our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and•
senior management’s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures. The bonus plans for virtually allbonus-eligible, non-sales-force employees worldwide, including the Executive Leadership Team members and other members of senior management, are funded from a
pool based on the performance measured by three financial metrics, including Adjusted diluted earnings per share, which is derived from Adjusted income. This metric
accounts for 40% of the bonus pool funding. In addition,
 Adjusted operating income, which is derived from Adjusted income, is one of the measures utilized to determinepayout for performance share awards.
Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no s
tandardized meaning prescribed by U.S. GAAPand, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components
 (unlike U.S. GAAP net incomeand its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of
 similar measures ofother companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how
management assesses performance.
We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted
 diluted earnings per share measures have limitations,and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without
including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not
 provide a comparable view of our performance toother companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D
organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on
 an absolute basis2018 Financial Report    
 
 37
Financial ReviewPfizer Inc. and Subsidiary Companies
 
and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer’s long-term incentive compensation plans.
See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted
 information for 2018 , 2017 and 2016 below. Purchase Accounting Adjustments
Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These
impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in June 2016) and Medivation (acquired in September 2016), can
include the incremental charge to cost of sales from the sale of acquired inventory that was written up to
 fair value, amortization related to the increase in fair value of theacquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets
 (primarilymanufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, 
theAdjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those
 products.Certain of the purchase accounting adjustments can occur through 20 or more years, but this presentation provides an alternative view of our performance tha
t is used bymanagement to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and
investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which R&D costs previously have been
expensed.
However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This
component of Adjusted income is derived solely from the impacts of the items listed in the first paragraph of this sec
tion. We have not factored in the impacts of any otherdifferences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does no
t intend to berepresentative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and
 in the periods presented, may have been different; ourspeed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been
 different. In addition, our marketing efforts mayhave been received differently by our customers. As such, in total, there can be
 no assurance that our Adjusted income amounts would have been the same as presented hadwe discovered and developed the acquired intangible assets.
Acquisition-Related Costs
Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because
these costs are unique to each transaction and represent costs that
 were incurred to restructure and integrate two businesses as a result of the acquisition decision. Foradditional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset
acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.
We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in connection
with a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring a fully integrated set of activities.
For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the con
text of abusiness combination) can be viewed differently from those costs incurred in other, more normal, business contexts.
The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts typically ending within three
years of the transaction. Because of the need 
for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activitiescan be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the
 closure of excess facilities can take several years, as all manufacturingchanges are subject to extensive validation and testing and must be approved by the FDA
 and/or other global regulatory authorities.Discontinued Operations
Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such
operations. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines for strategic fit with our operations, we do
not build or run our businesses with the intent to sell them. Restatements due to discontinued operations do
 not impact compensation or change the Adjusted income measurefor the compensation in respect of the restated periods, but are presented 
for consistency across all periods.Certain Significant Items
Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an
individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature.
 Certain significant items may be highly variable and difficult topredict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs
stand on their own as they are specific to an event or goal with a defined 
term, but we may have subsequent programs based on reorganizations of the business, costproductivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances
specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the
 date of acquisition.Unusual items may represent items that are not part of our ongoing business; items that, either as a
 result of their nature or size, we would not expect to occur as part of ournormal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be
included as certain
38
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
significant items would be a major non-acquisition-related restructuring charge and associated implementation costs; amounts related to certain disposals of businesses,
products or facilities that do not qualify as discontinued operations under U.S. GAA
P; certain intangible asset impairments; adjustments related to the resolution of certain taxpositions; the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes 
to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from Continuing Operations 
or charges related to certain legal matters, such as certain of those discussed in Notes to Consolidated Financial Statements— 
Note 17A. Contingencies and Certain Commitments : Legal Proceedings and in Part II, Item 1, “Legal Proceedings” in our Quarterly Reports on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be
 considered certainsignificant items.
Beginning In 2019, we will exclude the gains and losses from equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control
and cannot predict with any level of certainty and because we do not believe that including these gains and
 losses assists investors in understanding our business or isreflective of our core operations and business. For example, we contributed assets related to our allogeneic CAR T therapy to Allogene and received equity securities. We will
restate our Adjusted income and Adjusted diluted EPS for prior periods for consistency with our 2019 presentation.
Reconciliation of GAAP Repor
ted to Non-GAAP Adjusted Information––Certain Line Items 
  2018 IN MILLIONS, EXCEPT PER COMMON SHARE DATA
  GAAPReported
  PurchaseAccounting
Adjustments 
(a) Acquisition-Related Costs 
(a) DiscontinuedOperations 
(a) CertainSignificant
Items 
(a) Non-GAAPAdjusted
Revenues
  $53,647  $—  $—  $—  $—  $53,647 Cost of sales
  11,248  3  (10 ) —  (110 ) 11,130 Selling, informational and administrative
expenses
  14,455  2  (2 ) —  (222 ) 14,232 Research and development expenses
  8,006  3  —  —  (47 ) 7,962 Amortization of intangible assets
  4,893  (4,612 )  —  —  —  281 Restructuring charges and certain acquisition-
related costs
  1,044  —  (299 ) —  (745 ) — Other (income)/deductions––net
  2,116  (182 ) (7 ) —  (3,181 )  (1,253 ) Income from continuing operations before
provision/(benefit) for taxes on income
  11,885  4,786  318  —  4,305  21,294 Provision/(benefit) for taxes on income 
(b) 706  915  54  —  1,625  3,301 Income from continuing operations
  11,179  3,871  264  —  2,680  17,994 Discontinued operations––net of tax
  10  —  —  (10 ) —  — Net income attributable to noncontrolling
interests
  36  —  —  —  —  36 Net income attributable to Pfizer Inc.
  11,153  3,871  264  (10 ) 2,680  17,958 Earnings per common share attributable to
Pfizer Inc.––diluted
  1.87  0.65  0.04  —  0.45  3.00 2018 Financial Report    
 
 39
Financial ReviewPfizer Inc. and Subsidiary Companies
 
 
  2017 IN MILLIONS, EXCEPT PER COMMON SHARE DATA
  GAAPReported
  PurchaseAccounting
Adjustments 
(a) Acquisition-Related Costs 
(a) DiscontinuedOperations 
(a) CertainSignificant
Items 
(a) Non-GAAPAdjusted
Revenues
  $52,546  $—  $—  $—  $—  $52,546 Cost of sales
  11,228  (47 ) (39 ) —  (363 ) 10,778 Selling, informational and administrative
expenses
  14,804  (16 ) —  —  (299 ) 14,489 Research and development expenses
  7,683  8  —  —  (38 ) 7,653 Amortization of intangible assets
  4,758  (4,565 )  —  —  —  193 Restructuring charges and certain acquisition-
related costs
  351  —  (426 ) —  75  — Other (income)/deductions––net
  1,416  (138 ) 9  —  (2,020 )  (733 )Income from continuing operations before
provision/(benefit) for taxes on income
  12,305  4,758  456  —  2,647  20,166 Provision/(benefit) for taxes on income 
(b) (9,049 )  1,331  173  —  11,577  4,033 Income from continuing operations
  21,353  3,426  283  —  (8,930 )  16,132 Discontinued operations––net of tax
  2  —  —  (2 ) —  — Net income attributable to noncontrolling
interests
  47  —  —  —  —  47 Net income attributable to Pfizer Inc.
  21,308  3,426  283  (2 ) (8,930 )  16,085 Earnings per common share attributable to
Pfizer Inc.––diluted
  3.52  0.57  0.05  —  (1.47 )  2.65  
  2016 IN MILLIONS, EXCEPT PER COMMON SHARE DATA
  GAAPReported
  PurchaseAccounting
Adjustments 
(a) Acquisition-Related Costs 
(a) DiscontinuedOperations 
(a) CertainSignificant
Items 
(a) Non-GAAPAdjusted
Revenues
  $52,824  $—  $—  $—  $—  $52,824 Cost of sales
  12,322  (295 ) (7 ) —  (397 ) 11,622 Selling, informational and administrative
expenses
  14,844  (3 ) —  —  (89 ) 14,751 Research and development expenses
  7,892  3  —  —  (34 ) 7,861 Amortization of intangible assets
  4,056  (3,928 )  —  —  —  128 Restructuring charges and certain acquisition-
related costs
  1,565  —  (716 ) —  (849 ) — Other (income)/deductions––net
  3,794  39  (62 ) —  (4,519 )  (748 )Income from continuing operations before
provision/(benefit) for taxes on income
  8,351  4,185  785  —  5,888  19,210 Provision/(benefit) for taxes on income 
(b) 1,123  1,248  104  —  1,943  4,418 Income from continuing operations
  7,229  2,937  682  —  3,944  14,792 Discontinued operations––net of tax
  17  —  —  (17 ) —  — Net income attributable to noncontrolling
interests
  31  —  —  —  —  31 Net income attributable to Pfizer Inc.
  7,215  2,937  682  (17 ) 3,944  14,761 Earnings per common share attributable to
Pfizer Inc.––diluted
  1.17  0.48  0.11  —  0.64  2.40 (a) 
 For details of adjustments, see “Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income” below.(b)
 
The effective tax rate on Non-GAAP Adjusted income was 15.5% in 2018 , 20.0% in 2017 and 23.0% in 2016 . The decrease in the effective tax r ate on Non-GAAP Adjusted income for 2018 compared with 2017 was primarily due to tax benefits ass
ociated with the December 2017 enactment of the TCJA, a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course ofbusiness, as well as an increase i
n benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes oflimitations. The decline in the effectiv
e tax rate on Non-GAAP Adjusted income in 2017 compared to 2016 was primarily due to tax benefits ass ociated with the enactment of the TCJA, primarily reflecting theremeasurement of U.S. deferred t
ax liabilities on deemed repatriated post-1986 earnings of foreign subsidiaries that were accrued during 2017, as well as a favorable change in the jurisdictional mix of earnings asa result of operating fluctuati
ons in the normal course of business, partially offset by a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with variousforeign tax authorities, and t
he expiration of certain statutes of limitations.40
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Details of Income Statement Items Included in GAAP
 Reported but Excluded from Non-GAAP Adjusted IncomeAdjusted income, as shown above, excludes the following items:
 
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Purchase accounting adjustments
         Amortization, depreciation and other 
(a)  $4,789  $4,711  $3,890 Cost of sales
  (3 ) 47  295 Total purchase accounting adjustments—pre-tax
  4,786  4,758  4,185 Income taxes 
(b)  (915 ) (1,331 )  (1,248 ) Total purchase accounting adjustments—net of tax
  3,871  3,426  2,937  
         Acquisition-related costs
         Restructuring charges 
(c)  37  105  207 Transaction costs 
(c)  1  4  127 Integration costs 
(c)  260  317  383 Net periodic benefit costs/(credits) other than service costs 
(d)  7  (9 ) 62 Additional depreciation—asset restructuring 
(e)  12  39  7 Total acquisition-related costs—pre-tax
  318  456  785 Income taxes 
(f)  (54 ) (173 ) (104 )Total acquisition-related costs—net of tax
  264  283  682  
         Discontinued operations
         Total discontinued operations—net of tax, attributable to Pfizer Inc. 
(g)  (10 ) (2 ) (17 ) 
         Certain significant items
         Restructuring charges/(credits) 
–– cost reduction initiatives (h)  745  (75 ) 849 Implementation costs and additional depreciation—asset restructuring 
(i)  232  279  540 Certain legal matters, net 
(j)  157  237  494 Loss on sale and impairment on remeasurement of HIS net assets 
(j)  (1 ) 55  1,712 Certain asset impairments 
(j)  3,101  379  1,426 Business and legal entity alignment costs 
(j)  4  71  261 Net losses on early retirement of debt 
(i)  3  999  312 Other 
(k)  65  700  294 Total certain significant items—pre-tax
  4,305  2,647  5,888 Income taxes 
(l)  (1,625 )  (11,577 )  (1,943 ) Total certain significant items—net of tax
  2,680  (8,930 )  3,944 Total purchase accounting adjustments, acquisition-related costs, discontinued operations and
certain significant items—net of tax, attributable to Pfizer Inc.
  $6,805  $(5,223 )  $7,546 (a) 
 Included primarily in Amortization of intangible assets . (b)
 
Included in Provision/(benefit) for taxes on income. Income taxes includes the tax eff ect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applyingthat jurisdiction’s applicable tax r
ate. Income taxes recorded in 2017 do not reflect any changes associated with the enactment of the TCJA. These changes resulting from the TCJA have been reflected in the lineitem, Certain significant items “Income tax
es”.(c)
 
Included in Restructuring charges and cert ain acquisition-related costs . Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations.Restructuring charges 
in 2018 were primarily due to asset write downs, p artially offset by the reversal of previously recorded accruals for employee termination costs related to our acquisition of Hospira.Restructuring charges for 201
7 were primarily due to asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs. For 2017 and 2016, restructuring charges––acquisition-related costs were mai
nly related to our acquisitions of Hospira and Medivation. Transaction costs represent external costs for banking, legal, accounting and other similar services. Integration costsrepresent external, increment
al costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. For additional information,see Notes to Consolidated Fina
ncial Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . (d)
 
Amounts for the 2017 and 2016 represent the net periodic benefit costs/(credits), excluding service costs, reclassified to Other (income)/deduction s––net as a result of the re trospective adoption of a newaccounting standard in th
e first quarter of 2018. For additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Signific ant Accounting Policies : Adoption of NewAccounting Standards in 2018 
. The credits for full-year 2017 included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of theremaining obligation assoc
iated with the Hospira U.S. qualified defined benefit pension plan.(e) 
 Primarily included in C ost of sales. Represents the impact of chan ges in estimated useful lives of assets involved in restructuring actions related to acquisitions . (f) 
 Included in Provision/(benefit) for taxes on income. Income taxes includes the tax eff ect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applyingthat jurisdiction’s
 applicable tax rate. Income taxes recorded in 2017 do not reflect any changes2018 Financial Report    
 
 41
Financial ReviewPfizer Inc. and Subsidiary Companies
 
associated with the December 2
017 enactment of the TCJA. These changes resulting from the TCJA have been reflected in Certain significant items “Income taxes”. 2016 also includes an unfavorable impact ofthe remeasurement of certain 
deferred tax liabilities resulting from our plant network restructuring activities.(g) 
 Included in Discontinued operations––net o f tax. For all years presented, represe nts post-close adjustments.(h)
 
Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in Restructuring charges and cert ain acquisition-related costs (see Notes to Consolidated Financia
l Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives ). For 2018, the charges were primar ily related toemployee termination costs an
d asset write downs. The employee termination costs are associated with our improvements to operational effectiveness as part of the realignment of our organizational structureeffective at the beginning
 of 2019. For 2017, the credits were mostly relat ed to the reversal of previously recorded accruals for employee termination costs, partially offset by asset write downs.(i) 
 Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges a nd Other Costs Associated withAcquisitions and Cost-Reduction/Pr
oductivity Initiatives ). For 2018 , included in Cost of sales ( $121 million ), Selling, informational and administrative expenses ( $72 million ) and Research and development expenses 
( $39 million ). For 2017 , included in Cost of sales ( $170 million ), Selling, informational and administrative expenses ( $71 million ) and Research and development expense s ( $38 million ). For 2016 , primarily included in 
Cost of sales ( $423 million ), Selling, informational and administrative expenses ( $81 million ) and Research and development expense s ( $32 million ). (j) 
 Included in Other (income)/deductions—net (see the Notes to Consolidate d Financial Statements— Note 4. Other (Income )/Deductions—Net ). (k)
 
For 2018 , included in Cost of sales ( $10 million income), Selling, informational and a dministrative expenses ( $151 million ), Research and development expenses ( $8 million ) and Other (income)/deductions–– net 
( $83 million income). For 2017 , included in Cost of sales ( $193 million ), Selling, informational and administrative expenses ( $229 million ) and Other (income)/deduction s––net ( $278 million ). For 2016 , primarily included in 
Cost of sales ( $27 million income), Selling, informational and a dministrative expenses ( $8 million ) and Other (income)/deduction s––net ( $311 million ). For 2018 , includes, among other things, (i) a non-cash 
$343 million pre-tax gain in Other (income)/deduction s––net associated with our transaction wit h Bain Capital to create a new biopharmaceutical company, Cerevel, to continue developmentof a portfolio of clinical and pr
eclinical stage neuroscience assets primarily targeting disorders of the central nervous system, (ii) a $119 million charge, in the aggregate, in Selling, informational  and administrativeexpenses 
for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December2017 enactment of the le
gislation commonly referred to as the TCJA, (iii) $59 million of incremental costs associated with the design, planning and implementation of the new organizational structure, effective inthe beginning of 201
9, and primarily include consulting, legal, tax, and advisory services and (iv) a non-cash $50 million pre-tax gain in Other (income)/deduction s––net as a result of the con tribution of ourallogeneic chimeric antigen r
eceptor T cell therapy development program assets in connection with our contribution agreement entered into with Allogene (see Notes to Consolidated Financial Statements— Note 2B. 
Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately HeldInvestment 
: Divestitures ). For 2017 includes, among ot her things, (i) a charitable contribution to the Pfizer Foundation of $200 million , which is included in Selling, i nformational and administ rative expenses ; (ii) $195 million 
in inventory losses, overhead c osts related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 andare included in 
Cost of sales ; (iii) an $81 million loss related to the sale of our 49% equity share in Hisun Pfizer, which is included in Other (income)/deduction s––net; and (iv) a net loss of $30 million related to the sale of our then 
40% ownership investment in Teuto, incl uding the extinguishment of a put option for the remaining 60% ownership interest, which is included in Other (income)/deduction s––net . For 2016, includes, among other thing
s, $150 million paid to Allergan for reimbursem ent of Allergan's expenses associated with the terminated transaction, which is included in Other (income)/deductions—net . (l) 
 Included in Provision/(benefit) for taxes on income. Income taxes includes the tax eff ect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applyingthat jurisdiction’s applicable tax r
ate. The amount in 2018 was favorably impacted primarily by tax benefits related to the TCJA, including certain current year tax initiatives as well as adjustments to the provisionalestimate of the legislation, rep
orted and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC. The amount in 2017 was favorably impacted by tax be nefits primarilyassociated with the remeasurem
ent of deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries associated with the TCJA. Theamount in 
2016 was favorably impacted by ben efits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix,which resulted in the receipt of i
nformation that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position. See Notes to Consolidated Financial Statements—Note 5A. 
Tax Matters : Taxes on Income f rom Continuing Operations . ANALYSIS OF OPERATING SEGMENT INFORMATION
The following tables and associated notes provide additional information about the performance of our two operating segments for the periods presented—the IH segment
 andthe EH segment. For additional information about each operating segment, see the “Our Strategy 
–– Commercial Operations” section of this Financial Review and Notes toConsolidated Financial Statements— 
Note 18. Segment, Geographic and Other Revenue Information . As described in Notes to Consolidated Financial Statements— 
Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation , acquisitions and divestitures have impacted our results of operations in 
2017 and 2016 . 42
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our consolidated statements of income:
 
  2018 (MILLIONS OF DOLLARS)
  Innovative Health(IH) 
(a) Essential Health(EH) 
(a) Other (b) Non-GAAP Adjusted 
(c) ReconcilingItems 
(d) GAAPReported
Revenues
  $33,426  $20,221  $—  $53,647  $—  $53,647 Cost of sales
  4,140  6,056  934  11,130  118  11,248 % of revenue
  12.4 % 29.9 % *  20.7 % *  21.0 %Selling, informational and administrative expenses
  6,961  2,612  4,659  14,232  223  14,455 Research and development expenses
  2,866  937  4,160  7,962  43  8,006 Amortization of intangible assets
  219  62  —  281  4,612  4,893 Restructuring charges and certain acquisition-
related costs
  —  —  —  —  1,044  1,044 Other (income)/deductions––net
  (1,017 )  (158 ) (78 ) (1,253 )  3,369  2,116 Income/(loss) from continuing operations before
provision/(benefit) for taxes on income
  $20,258  $10,712  $(9,676 )  $21,294  $(9,409 )  $11,885  
  2017 (MILLIONS OF DOLLARS)
  InnovativeHealth (IH) 
(a) Essential Health(EH) 
(a) Other (b) Non-GAAP Adjusted 
(c) ReconcilingItems 
(d) GAAPReported
Revenues
  $31,422  $21,124  $—  $52,546  $—  $52,546 Cost of sales
  4,091  5,937  750  10,778  449  11,228 % of revenue
  13.0 % 28.1 % *  20.5 % *  21.4 %Selling, informational and administrative expenses
  6,727  2,898  4,864  14,489  316  14,804 Research and development expenses
  2,544  1,052  4,057  7,653  31  7,683 Amortization of intangible assets
  129  65  —  193  4,565  4,758 Restructuring charges and certain acquisition-related
costs
  —  —  —  —  351  351 Other (income)/deductions––net
  (878 ) (287 ) 432  (733 ) 2,150  1,416 Income/(loss) from continuing operations before
provision/(benefit) for taxes on income
  $18,809  $11,460  $(10,104)  $20,166  $(7,861 )  $12,305  
  2016 (MILLIONS OF DOLLARS)
  InnovativeHealth (IH) 
(a) Essential Health(EH) 
(a) Other (b) Non-GAAP Adjusted 
(c) ReconcilingItems 
(d) GAAPReported
Revenues
  $29,197  $23,627  $—  $52,824  $—  $52,824 Cost of sales
  4,049  6,272  1,301  11,622  699  12,322 % of revenue
  13.9 % 26.5 % *  22.0 % *  23.3 %Selling, informational and administrative expenses
  6,957  3,296  4,499  14,751  92  14,844 Research and development expenses
  2,921  1,237  3,703  7,861  31  7,892 Amortization of intangible assets
  102  26  —  128  3,928  4,056 Restructuring charges and certain acquisition-related
costs
  —  —  —  —  1,565  1,565 Other (income)/deductions––net
  (998 ) (269 ) 519  (748 ) 4,543  3,794 Income/(loss) from continuing operations before
provision/(benefit) for taxes on income
  $16,166  $13,065  $(10,021)  $19,210  $(10,858 )  $8,351 *
Indicates calculation not meaningful or result is equal to or greater than 100%.(a) 
 Amounts represent the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment.The following organizat
ional change impacted our operating segments in 2018:Effective in the first quarter of 201
8, certain costs for Pfizer’s StratCO group, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated.StratCO costs primarily include headco
unt costs, vendor costs and data costs largely in support of Pfizer’s commercial operations. The majority of the StratCO costs reflect additional amounts that our operatingsegments would have incur
red had each segment operated as a standalone company during the periods presented. The reporting change was made to streamline accountability and speed decision making. In2017, we reclassified app
roximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other un allocated costs to conform to thecurrent period presentation
, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to con
form to the current period presentation.2018 Financial Report    
 
 43
Financial ReviewPfizer Inc. and Subsidiary Companies
 
(b) 
 Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below) that are managed outside of ou r two operating segments and includes the following: 
  2018  
  Other Business Activities         (MILLIONS OF DOLLARS)
  WRD (i) GPD (ii) Corporate (iii) OtherUnallocated 
(iv) Total Revenues
  $—  $—  $—  $—  $— Cost of sales
  —  —  168  767  934 Selling, informational and administrative expenses
  —  —  3,958  701  4,659 Research and development expenses
  2,341  788  957  73  4,160 Amortization of intangible assets
  —  —  —  —  — Restructuring charges and certain acquisition-related costs
  —  —  —  —  — Other (income)/deductions––net
  (148 ) (5 ) 13  62  (78 )Loss from continuing operations before provision/(benefit) for taxes on
income
  $(2,193 )  $(784 ) $(5,096 )  $(1,603 )  $(9,676 )  
  2017  
  Other Business Activities          (MILLIONS OF DOLLARS)
  WRD (i) GPD (ii) Corporate (iii) OtherUnallocated 
(iv) Total Revenues
  $—  $—  $—  $—  $— Cost of sales
  —  —  32  718  750 Selling, informational and administrative expenses
  —  (1 ) 4,159  706  4,864 Research and development expenses
  2,402  783  823  50  4,057 Amortization of intangible assets
  —  —  —  —  — Restructuring charges and certain acquisition-related costs
  —  —  —  —  — Other (income)/deductions––net
  (42 ) (5 ) 439  40  432 Loss from continuing operations before provision/(benefit) for taxes on
income
  $(2,361 )  $(777 ) $(5,452 )  $(1,514 )  $(10,104 )  
  2016  
  Other Business Activities          (MILLIONS OF DOLLARS)
  WRD (i) GPD (ii) Corporate (iii) OtherUnallocated 
(iv) Total Revenues
  $—  $—  $—  $—  $— Cost of sales
  —  —  198  1,103  1,301 Selling, informational and administrative expenses
  —  —  3,957  542  4,499 Research and development expenses
  2,359  690  612  41  3,703 Amortization of intangible assets
  —  —  —  —  — Restructuring charges and certain acquisition-related costs
  —  —  —  —  — Other (income)/deductions––net
  (28 ) (2 ) 681  (131 ) 519 Loss from continuing operations before provision/(benefit) for taxes on
income
  $(2,332 )  $(688 ) $(5,448 )  $(1,554 )  $(10,021 ) (i) 
 WRD—the R&D expenses managed by our WRD organization, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projectsto the IH segment via the GPD orga
nization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organizationalso has responsibility for certain sci
ence-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD isalso responsible for facilitating 
all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.(ii)
 
GPD––the costs associated with our GPD organization, which is generally responsible for the operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets inthe Innovative portfolio. GPD also 
provides technical support and other services to Pfizer R&D projects.(iii)
 
Corporate—the costs associated with Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs,compliance, and worldwide pr
ocurement), the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants forhealthcare quality improveme
nt and medical education, and partnerships with global public health and medical associations, as well as certain compensation and other corporate costs, such as interest incomeand expense, and gai
ns and losses on investments. Effective in the first quarter of 2018, certain costs for StratCO, which were previously reported in the operating results of our operating segments andCorporate, are reported in Ot
her Unallocated. For additional information, see note (iv) below.We recognized a net 
$13 million loss in 2018 in Cost of sales primarily related to euro-den ominated losses, partially offset by Japanese yen denominated gains on forward-exchange contracts designated ascash flow hedges of a por
tion of our foreign exchange-denominated intercompany forecasted inventory sales. We recognized a $52 million gain in 2017 as an offset to Cost of sales related to foreign currency forward-exchange contract
s designated as cash flow44
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
hedges of a portion of o
ur foreign exchange-denominated intercompany forecasted inventory sales. For additional information, see Notes to Consolidated Financial Statements–– Note 7F. Financial Instruments 
: Derivative Financial Instruments and Hedging Activities . (iv)
 
Other Unallocated—other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as businessunit (segment) management 
does not manage these costs (which include manufacturing variances associated with production). In connection with the StratCO reporting change, in 2017 we reclassifiedapproximately 
$468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other un allocated costs to conform to the current periodpresentation, and in 20
16, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corpo rate to Other unallocatedcosts to conform to the current peri
od presentation.For information purposes only, the following tables present reconciliations of our segment operating results to segment operating results including estimated Other costs
generally associated with each segment for 2018. While we do not manage our segments or have performance goals under such an allocated manner, we believe that some
investors may find this information useful in their analyses.
The estimated Other costs generally associated with our operating segments do not purport to reflect the
 additional amounts that each of our operating segments would haveincurred had each segment operated as a standalone company during the period presented.
For information purposes only, for 
2018 , we estimate that Other costs, as described above, for combined WRD and GPD costs of $3.0 billion , and combined Corporate and Other Unallocated costs of 
$5.8 billion after excluding (i) net interest-related expense not attributable to an operating segment included in Corporate (approximately $1.0 billion in 
Other (income)/deductions––net ); and (ii) net income from investments and other assets not attributable to an operating segment included in Corporate (approximately $72 million 
in Other (income)/deductions––net ), are generally associated with our operating segments, as follows:  
  2018  
     Estimated Other Costs Associated with IH (ii)    (MILLIONS OF DOLLARS)
  Innovative HealthNon-GAAP
Adjusted 
(i), (iii)  Estimated WRD/GPD (ii)  EstimatedCorporate/Other
Unallocated 
(ii)  Innovative Health withEstimated Other Costs
Associated with 
Innovative Health 
Non-GAAP Adjusted 
(ii),   (iii)Revenues
  $33,426      $33,426 Cost of sales
  4,140  —  142  4,282 Selling, informational and administrative expenses
  6,961  —  2,708  9,669 Research and development expenses
  2,866  3,097  938  6,901 Amortization of intangible assets
  219    (4 ) 215 Restructuring charges and certain acquisition-related costs
  —      — Other (income)/deductions––net
  (1,017 )  (152 ) (672 ) (1,841 ) Income/(loss) from continuing operations before
provision/(benefit) for taxes on income
  20,258  (2,945 )  (3,112 )  14,201  
  2018  
     Estimated Other Costs Associated with EH (ii)   (MILLIONS OF DOLLARS)
  Essential Health Non-GAAP
Adjusted 
(i), (iii)  Estimated WRD/GPD (ii)  EstimatedCorporate/Other
Unallocated 
(ii)  Essential Health with EstimatedOther Costs Associated with 
Essential Health 
Non-GAAP Adjusted 
(ii), (iii) Revenues
  $20,221      $20,221 Cost of sales
  6,056  —  792  6,849 Selling, informational and administrative expenses
  2,612  —  1,952  4,563 Research and development expenses
  937  32  92  1,061 Amortization of intangible assets
  62    4  66 Restructuring charges and certain acquisition-related costs
  —      — Other (income)/deductions––net
  (158 ) —  (192 ) (351 )Income/(loss) from continuing operations before
 provision/(benefit)for taxes on income
  10,712  (32 ) (2,648 )  8,032 (i) 
 Amount represents the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment. See note (a) above formore information.
(ii)
 
Represents costs not assessed to an operating segment, as business unit (segment) management does not manage these costs. For a description of these other costs and business activities, see note (b)above.
•
WRD/GPD –– The information provided for WRD and GPD was substantially all derived from our estimates of the costs incurred in connection with the R&D projects associated with each operating segment.•
Corporate/Other Unallocated –– The information provided for Corporate and Other Unallocated was derived mainly using proportional allocation methods based on global, regional or country revenues orglobal, regional or country 
headcount, as well as certain cost metrics, as appropriate, such as those derived from R&D and manufacturing costs, and, to a lesser extent, specific identification and estimates.Management believes that the
 allocations of Corporate and Other Unallocated costs are reasonable.The estimated Other costs generally 
associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segmentoperated as a standalone company
 during the period presented.(iii) 
 See note (c) below for an explanation of our Non-GAAP Adjusted financial measure.(c) 
 See the “Non-GAAP Financial Measure (Adjusted Income)” section of this Financial Review for a definition of these “Adjusted Income” components.2018 Financial Report    
 
 45
Financial ReviewPfizer Inc. and Subsidiary Companies
 
(d)
 
Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (suchas restructuring or legal charg
es), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, seethe “Non-GAAP Financial Measure (Adjust
ed Income)” section of this Financial Review.Innovative Health Operating Segment
2018 
vs. 2017IH 
Revenues increase d $2.0 billion , or 6% , to $33.4 billion , reflecting an operational increase of $1.9 billion , or 6% , and a de minimis impact of foreign exchange of $130 million 
. The following graph illustrates the components of the 
increase in IH Revenues : 
*
LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.The following provides an analysis of the 
increase in worldwide IH Revenues : (MILLIONS OF DOLLARS)
   IH 
Revenues , 2017   $31,422  
   Operational growth/(decline):   Continued growth from certain key brands 
(a)  2,815 Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed
Europe
  195 Growth in our Consumer Healthcare business across all markets
  107 Negative impact of the loss of exclusivity of Viagra in the U.S. in December 2017 and the
 resulting shift in the reporting of U.S. and Canada Viagrarevenues from IH to EH in 2018
  (823 )Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition
  (350 )Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed Europe
  (100 )Other operational factors, net
  31 Operational growth, net
  1,873  
   Favorable impact of foreign exchange
  130 IH 
Revenues  increase   2,004 IH 
Revenues , 2018   $33,426 (a)
 
Certain key brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi, Lyrica––IH and Chantix/Champix. See the “Analysis of the Consolidated Statements of Income––Revenues––SelectedProduct Discussion" section of this Financi
al Review for product analysis information.Total IH revenues from emerging markets increased 
$507 million , or 12% , to $4.9 billion in 2018 from $4.4 billion in 2017, reflecting a 16% operational increase . Foreign exchange had an 
unfavorable impact of 5% on total IH revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13,Ibrance and Eliquis.
Costs and Expenses
•
Cost of sales as a percentage of Revenues decrease d 0.6 percentage points, primarily driven by the favorable impact of foreign exchange.•
The increase in Cost of sales of 1% was primarily driven by an increase in royalty expenses based on the mix of products sold and an increase in sales volumes for variouskey products within our product portfolio, partially offset by the favorable impact of foreign exchange.
•
The increase in Selling, informational and administrative expenses of 3% was primarily driven by additional investment across several of our key products, primarily Xeljanz,Ibrance, Eucrisa and Prevnar 13/Prevenar 13 (pediatric indication), partially offset by a reduction related to Viagra as a result of the
 reclassification of Viagra IH to EH andlower healthcare reform expenses.
•
The increase in Research and development expenses of 13% primarily reflects: ◦
increased costs associated with the Bavencio program; and46
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
◦
increased costs associated with our Phase 3 clinical trials related to our JAK1 inhibitor (which was initiated in December 2017) and the C. difficile vaccine program (which was initiated in March 2017) as well as increased spending for our 20 valent pneumococcal conjugate vaccine candidate.
•
The favorable change in Other (income)/deductions––net primarily reflects a $116 million increase in income from collaborations, out-licensing arrangements and sales of compound/product rights, 
partially offset by a $13 million decrease in dividend income from our investment in ViiV. 2017 
vs. 2016IH 
Revenues increase d $2.2 billion , or 8% , to $31.4 billion , reflecting an operational increase of $2.3 billion , or 8% , partially offset by a de minimis impact of foreignexchange of 
$80 million . The following graph illustrates the components of the 
increase in IH Revenues : 
*
LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.The following provides an analysis of the 
increase in IH Revenues : (MILLIONS OF DOLLARS)
   IH 
Revenues,  2016   $29,197  
   Operational growth/(decline):
   Continued growth from key brands 
(a)  1,608 Ibrance global growth: U.S. revenues increased primarily due to continued strong uptake in the metastatic breast cancer setting. 
Internationalrevenues increased operationally, but were negatively impacted by a one-time price adjustment to 2017 revenues related to finalizing
reimbursement agreements in certain developed Europe markets.
  993 Increase in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation)
  450 Lower revenues for Enbrel primarily in developed Europe markets due to continued biosimilar competition
  (448 )Lower revenues for Viagra in the U.S. due to generic competition that began in December 2017
  (359 )Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the expected decline in revenues for the adult indication in
the U.S. due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a smaller
remaining “catch up” opportunity compared to 2016, partially offset by growth from the pediatric indication. International revenues increased
primarily due to the favorable overall impact of timing and increased volume associated with government purchases in certain emerging markets
for the pediatric indication compared with prior year, as well as from the inclusion of Prevenar 13 in additional national immunization programs in
certain emerging markets for the adult and pediatric indications in the fourth of quarter 2017.
  (108 )Other operational factors, net
  169 Operational growth, net
  2,305 Unfavorable impact of foreign exchange
  (80 )IH 
Revenues  increase   2,225 IH 
Revenues, 2017   $31,422 (a) 
 Key brands represent Eliquis (globally), as well as Xeljanz and Lyrica –– IH (both primarily in the U.S.).Total IH revenues from emerging markets increased $656 million, or 18%, to 
$4.4 billion in 2017 from $3.7 billion in 2016, reflecting an 18% operational increase. Foreign exchange had a de minimis impact on total IH revenues from emerging markets.
2018 Financial Report    
 
 47
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Costs and Expenses
•
Cost of sales as a percentage of Revenues decrease d 0.9 percentage points primarily driven by a favorable change in product mix, including an increase in alliance revenues, which have no associated cost of sales, partially offset by an increase in royalty expense, mostly related 
to Ibrance.•
The increase in Cost of sales of 1% was primarily driven by an increase in royalty expense, mostly related to Ibrance, partially offset by a favorable change in product mix.•
The decrease in Selling, informational and administrative expenses of 3% was primarily driven by the non-recurrence of an allowance for doubtful trade accounts receivable,resulting from unfavorable developments with a distributor that was recorded in the first quarter 2016, lower spending for certain products, primarily Prevnar 13/Prevenar 13
and Viagra (which lost exclusivity in the U.S. in December 2017), partially offset by additional investment across several of our key products, primarily Eucrisa, Ibrance and
Xeljanz.
•
The decrease in Research and development expenses of 13% primarily reflects: ◦
the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016 and the non-recurrence of its associated close-out costs,partially offset by increased costs associated with:
◦
our oncology programs, including clinical trial spend on Medivation assets;◦
our C. difficile vaccine program, which initiated a Phase 3 clinical study in March 2017; ◦
our tanezumab development program; and◦
an expense of $28 million, representing IH’s portion of the $75 million expense resulting from our May 2017 agreement with Sangamo to develop and commercialize genetherapy programs for Hemophilia A.
•
The unfavorable change in Other (income)/deductions––net primarily reflects: ◦
lower royalty income for Enbrel of $470 million, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement forEnbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013); and
◦
a $51 million decrease in Prezista royalties,partially offset by:
◦
a $256 million increase in dividend income from our investment in ViiV; and◦
a $176 million increase in Xtandi royalty income.Essential Health Operating Segment
2018 
vs. 2017EH 
Revenues decrease d $903 million, or 4% to $20.2 billion , reflecting an operational decrease of $1.1 billion, or 5% , partially offset by the favorable impact of foreignexchange of $180 million, or 1%.
The following graph illustrates the components of the 
decrease in EH Revenues : 
*
LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.48
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
The following provides an analysis of the 
decrease in worldwide EH Revenues : (MILLIONS OF DOLLARS)
  EH 
Revenues , 2017   $21,124  
   Operational growth/(decline):   Decline from the Peri-LOE Products portfolio, driven by lower revenues in developed markets (excluding Viagra EH), primarily due to expected
declines in Lyrica in developed Europe and Celebrex and Pristiq in the U.S. due to generic competition
  (558 )Impact from the SIP portfolio, driven by lower revenues in developed markets, primarily due to increased competition across the portfolio and
continued legacy Hospira product shortages in the U.S.
  (504 )Impact from the LEP portfolio, driven by lower revenues in developed markets, primarily as a result of industry-wide pricing challenges in the U.S.
and generic competition
  (436 )Impact on financial results for the sale of HIS in February 2017. 2018 does not
 reflect any contribution from HIS global operations, compared toapproximately one month of HIS domestic operations and approximately two months of HIS international operations in 2017
  (97 )Positive impact of Viagra, mostly driven by the shift in the reporting of U.S.
 and Canada Viagra revenues from IH to EH in 2018 (due to the loss ofexclusivity of Viagra in the U.S. in December 2017), partially offset by lower revenues in developed Europe markets (previously reported in EH)
  251 Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe markets
  217 Impact from CentreOne primarily in emerging markets
  45 Operational decline, net
  (1,082 ) Favorable impact of foreign exchange
  180 EH 
Revenues decrease   (903 )EH 
Revenues , 2018   $20,221 Total EH revenues from emerging markets increased $745 million, or 
11% , to $7.8 billion in 2018 from $7.0 billion in 2017, primarily driven by 11% operational growth from the LEP portfolio and 
13% operational growth from the SIP portfolio, partially offset by a 2% operational decline from the Peri-LOE Products portfolio. Foreign exchange had a de minimis 
impact on total EH revenues from emerging markets. Costs and Expenses
The changes in EH expenses below reflect, among other things, the favorable impact of the
 February 2017 sale of HIS. The operating results of HIS are included in EH’soperating results through February 2, 2017 and, therefore, operating results for EH for 
2017 include approximately one month of HIS domestic operations and approximately two months of HIS international operations. Operating results for EH for 
2018 do not reflect any contribution from HIS global operations. •
Cost of sales as a percentage of Revenues increase d 1.8 percentage points, primarily due to:◦
higher sales volume of Inflectra in the U.S. and developed Europe, and higher Pfizer CentreOne sales volumes, both of which carry higher product costs; and◦
lower sales volumes and margins as a result of product losses of exclusivity and generic competition in developed markets,partially offset by:
◦
lower sales volumes in the SIP portfolio, which carries a higher cost to produce, in developed markets, primarily due to increased competition across the SIP portfolio andcontinued legacy Hospira product shortages in the U.S.;
◦
the favorable impact of foreign exchange; and◦
the non-recurrence of charges related to a product recall that occurred in 2017.•
The increase in Cost of sales of 2% was primarily due to:◦
higher sales volumes of Inflectra in the U.S. and developed Europe, and higher Pfizer CentreOne sales volumes, both of which carry higher product costs; and◦
lower sales volumes in the SIP portfolio, which carries a higher cost to produce, in developed markets, primarily due to increased competition across the SIP portfolio andcontinued legacy Hospira product shortages in the U.S.,
partially offset by:
◦
lower sales volumes as a result of product losses of exclusivity and generic competition in developed markets; and◦
the non-recurrence of charges related to a product recall that occurred in 2017.•
Selling, informational and administrative expenses decrease d 10% mainly due to lower advertising, promotional and field force expenses, reflecting the benefits of cost- reduction and productivity initiatives, and lower general and administrative expenses 
, partially offset by additional investments in China . •
Research and development expenses decrease d 11% , primarily due to decreased spending for biosimilars as several programs have reached completion. •
The unfavorable change in Other (income)/deductions––net primarily reflects the non-recurrence of income from resolution of a contract disagreement, the non-recurrence of a gain on the redemption of an acquired bond in 2017 and the unfavorable impact of foreign exchange,
 partially offset by an increase in income from collaborations, out-licensing arrangements and sales of compound/product rights.
2018 Financial Report    
 
 49
Financial ReviewPfizer Inc. and Subsidiary Companies
 
2017 
vs. 2016EH 
Revenues decrease d $2.5 billion , or 11% , to $21.1 billion , reflecting an operational decrease of $2.3 billion , or 10%, and a 1% unfavorable impact from foreign exchange.
The following graph illustrates the components of the 
decrease in EH Revenues : 
*
LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.The following provides an analysis of the 
decrease in EH Revenues : (MILLIONS OF DOLLARS)
   EH 
Revenues , 2016   $23,627  
   Disposition:
   Approximately one month of HIS domestic operations and approximately two months of HIS international operations in 2017, compared to twelve
months of HIS global operations in 2016 (February 2017 sale)
  (1,062 ) Other Operational growth/(decline):
   Decline from Peri-LOE Products, primarily due to expected declines in Pristiq in the U.S. as well as Lyrica and Vfend (both primarily in developed
Europe markets)
  (957 )Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.
  (315 )Decline in the Legacy Established Products portfolio primarily due to generic competition in developed markets
  (188 )Growth from Biosimilars, primarily from Inflectra in the U.S. and developed Europe markets
  209 Other operational factors, net
  (13 )Operational decline, net
  (2,325 ) Unfavorable impact of foreign exchange
  (178 )EH 
Revenues  decrease   (2,503 ) EH 
Revenues,  2017   $21,124 Total EH revenues from emerging markets increased $323 million, or 5%, to 
$7.0 billion in 2017 from $6.7 billion in 2016, reflecting 7% operational growth, primarily driven by 6% operational growth from the Legacy Established Products portfolio and 17% operational growth from the Sterile Injectable Pharmaceuticals portfolio. Foreign exchange had
an unfavorable impact of 2%. Excluding HIS in both periods, EH revenues in emerging markets grew 8% operationally.
Costs and Expenses
The changes in EH expenses below reflect, among other things, the favorable impact of the
 February 2017 sale of HIS. The operating results of HIS are included in EH’soperating results through February 2, 2017 and, therefore, operating results for EH for 
2017 include approximately one month of HIS domestic operations and approximately two months of HIS international operations, while operating results for EH for 
2016 reflect 12 months of HIS global operations. •
Cost of sales as a percentage of Revenues increase d 1.6 percentage points primarily due to cost increases reflecting the shift to EH of certain legacy Hospira costs thatwere previously unallocated to EH as a result of harmonizing the Hospira cost policy, and the impact of product losses of exclusivity, partially offset by
 the favorable impactof the sale of HIS, which had a higher cost of sales 
than the other EH products, and the favorable impact of foreign exchange.•
The decrease in Cost of sales of 5% primarily reflects:◦ 
the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products;◦ 
the favorable impact of foreign exchange;◦ 
a net decrease in royalty expense and, to a lesser extent,◦ 
lower volumes driven by, among other things, the SIP portfolio, primarily due to legacy Hospira product shortages in the U.S.,50
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
partially offset by:
◦
cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy.•
Selling, informational and administrative expenses decrease d 12% , primarily due to the favorable impact of the sale of HIS, lower advertising, promotional, and field force expenses, reflecting the benefits of cost-reduction and productivity initiatives, as well as lower expenses associated with products that recently lost
 marketing exclusivity,partially offset by increased spending for biosimilars, primarily related to the U.S. launch of Inflectra.
•
Research and development expenses decrease d 15% primarily due to decreased spending for biosimilars, the close-out of certain postmarketing clinical trials and the favorable impact of the sale of HIS.
•
The favorable change in Other (income)/deductions––net primarily reflects the favorable impact of foreign exchange, a gain on the redemption of an acquired bond and an increase in Inflectra royalty income, partially offset by the non-recurrence of a resolution of a contract disagreement in the first quarter of
 2016.ANALYSIS OF THE CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Changes in the components of 
Accumulated other comprehensive loss reflect the following: 2018
•
For Foreign currency translation adjustments, net, primarily reflects the strengthening of the U.S. dollar against the euro, U.K. pound and Chinese renminbi. •
For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflects the impact of fair value re-measurements and the reclassification of amounts into income. For additional information, see Notes to Consolidated Financial Statements— 
Note 1B. Basis of Presentation and Significant Accounting Policies 
: Adoption of New Accounting Standards in 2018 and Notes to Consolidated Financial Statements— Note 7. Financial Instruments.
•
For Benefit plans: actuarial losses, net, primarily reflects (i) an increase due to the cumulative effect adjustment as of January 1, 2018 resulting from the adoption of a  newaccounting standard related to certain tax effects from AOCI;
 (ii) a decrease in actual returns on plan assets; (iii) an increase in our discount rate assumptions; (iv) theamortization of changes in the pension benefit obligation previously recognized in 
Other comprehensive income ; and (v) the favorable impact of foreign exchange. For additional information, see Notes to Consolidated Financial Statements— 
Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New AccountingStandards in 2018 
and Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans . •
For Tax provision/(benefit) on other comprehensive income/(loss), reflect the reclassification of the stranded tax amounts related to the TCJA  from AOCI to Retained earnings, 
which was recorded in the first quarter of 2018. For additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards 
and Notes to Consolidated Financial Statements— Note 5E. Tax Matters : Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
2017
•
For Foreign currency translation adjustments, net, primarily reflects the weakening of the U.S. dollar against the euro, U.K. pound and the Canadian dollar, as well as the reclassification of amounts related to (i) the agreement to sell our 40% ownership investment in Teuto and (ii) the sale of our 
49% equity share in Hisun Pfizer. For additional information, see Notes to Consolidated Financial Statements— 
Note 2F. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Equity-Method Investments 
. •
For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflect the impact of fair value re-measurements and the reclassification of amounts into net income. For additional information, see Notes to Consolidated Financial Statements— 
Note 7. Financial Instruments
•
For Benefit plans: actuarial losses, net, primarily reflects (i) an increase in the actuarial losses due to a decrease in our discount rate assumptions; (ii) an increase in actual returns on plan assets; (iii) the amortization of changes in the pension benefit obligation previously recognized in 
Other comprehensive income ; and (iv) the unfavorable impact of foreign exchange. For additional information, see Notes to Consolidated Financial Statements— 
Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
2016
•
Foreign currency translation adjustments, net, primarily reflects the strengthening of the U.S. dollar against the U.K. pound, Chinese renminbi, Mexican peso, and Argentine peso, partially offset by the weakening of the U.S. dollar against the
 Australian dollar and Japanese yen.•
For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflects the impact of fair value re-measurements and the reclassification of amounts into net income. For additional information, see Notes to Consolidated Financial Statements— 
Note 7. Financial Instruments 
. •
For Benefit plans: actuarial losses, net, reflects the actuarial losses related primarily to a decrease in the discount rate, partially offset by (i) the amortization of changes in the pension benefit obligation previously recognized in 
Other comprehensive income , and (ii) higher actual return on plan assets as compared to the expected return on plan assets. For additional information, see Notes to Consolidated Financial Statements— 
Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans 
and the “Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions––Benefit Plans” section o f this Financial Review.2018 Financial Report    
 
 51
Financial ReviewPfizer Inc. and Subsidiary Companies
 
ANALYSIS OF THE CONSOLIDATED BALANCE SHEETS
For information about certain of our financial assets and liabilities, including 
Cash and cash equivalents, Short-term investments, Long-term investments, Short-term borrowings, including current portion of long-term debt 
, and Long-term debt , see the “Analysis of the Consolidated Statements of Cash Flows” and the  “Analysis of FinancialCondition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources” sections of this Financial Review and Notes to Consolidated Financial
Statements— 
Note 7. Financial Instruments . For information about events and circumstances impacting our tax-related accounts, see Notes to Consolidated Financial Statements— 
Note 5. Tax Matters . For a description of changes in 
Total Equity , see the consolidated statements of equity. For information related to changes in 
Accumulated other comprehensive loss , see the “Analysis of the Consolidated Statements of Comprehensive Income” section of thisFinancial Review and Notes to Consolidated Financial Statements— 
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests . The changes in our asset and liability accounts as of 
December 31, 2018 , compared to December 31, 2017 , generally reflect, among other things, fluctuations in foreign currency exchange rates, the impact of the adoption of new accounting standards in 
the first quarter of 2018 and the reclassification to assets and liabilities held for sale inconnection with our pending consumer business joint venture with GSK 
. The following explanations exclude the impacts of foreign exchange, the adoption of new accountingstandards in the first quarter of 2018 and the pending consumer healthcare business joint venture with GSK
 (see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies 
: Adoption of New Accounting Standards in 2018 and Note 2C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
: Asset and Liabilities Held for Sale 
for additional information). •
For Trade accounts receivable, less allowance for doubtful accounts, the change reflects the timing of sales and collections in the normal course of business. •
For Inventories, the change reflects increases for certain products to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery, new product launches and the movement of products within our manufacturing network.
•
For Other current assets, the change reflects an increase in receivables associated with derivative financial instruments, partially offset by the receipt of a milestone payment related to the first marketing authorization for ertugliflozin (see Notes to Consolidated Financial Statements— 
Note 2E. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Research and
Development and Collaborative Arrangements 
). •
For PP&E, the change primarily reflects capital additions in the normal course of business, partially offset by depreciation during the period and reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see Notes to Consolidated Financial Statements— 
Note 3 . RestructuringCharges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives 
). •
For Identifiable intangible assets, less accumulated amortization , the change primarily reflects amortization for the period and intangible asset impairment charges (see Notes to Consolidated Financial Statements— 
Note 4. Other (Income)/Deductions-Net ), partially offset by an intangible asset recorded in connection with the EU approval of Mylotarg (see Notes to Consolidated Financial Statements— 
Note 10A. Identifiable Intangible Assets and Goodwill : Identifiable Intangible Assets ). •
For Trade accounts payable, the change reflects the timing of purchases and payments in the normal course of business. •
For Other current liabilities , the change reflects an increase in liabilities associated with: ◦
payments and accruals in the normal course of business;◦
reclassifications from noncurrent liabilities; and◦
accruals for restructuring activities associated with our Organizing for Growth initiative (see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost Reduction/Productivity Initiatives) 
; partially offset by decreases related to:
◦
payments for contingent consideration obligations;◦
payments to settle certain legal and product liability obligations;◦
payables related to derivative financial instruments; and◦
payments for the current portion of obligations recorded in connection with the U.S. approval of Bosulif, and the EU and U.S. approvals of Besponsa (see Notes toConsolidated Financial Statements— 
Note 7E. Financial Instruments : Other Noncurrent Liabilities ) .•
For Pension benefit obligations, net , the decrease primarily reflects the $500 million voluntary pension contribution we made to the U.S. Pfizer Consolidated Pension Plan in February 2018 and the impact of an increase in the discount rate used in the measurement of plan obligations, partially offse
t by a decrease in actual returns on plan assets.•
For Other noncurrent liabilities , the change reflects an increase in liabilities associated with: ◦
an increase in payables, associated with derivative financial instruments;◦
an increase in liabilities associated with the sale-leaseback of our New York headquarters (see the “Analysis of Financial Condition, Liquidity and Capital Resources—Selected Measures of Liquidity and Capital Resources 
—Contractual Obligations” section of this Financial Review for additional information); and ◦
a change in the fair value of contingent consideration (see Notes to Consolidated Financial Statements— Note 4 . Other (Income)/Deductions—Net ), 52
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
partially offset by:
◦
reclassifications to current liabilities.•
For Treasury stock, the change reflects open market share repurchases of $8.2 billion in 2018, as well as $4.0 billion paid to Citibank in March 2018 pursuant to the terms of an accelerated share repurchase agreement. See Notes to Consolidated Financial Statements— 
Note 12A. Equity: Common Stock for additional information. ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS
 
  Year Ended December 31,   % Change (MILLIONS OF DOLLARS)
  2018  2017  2016  18/17  17/16 Cash provided by/(used in):
               Operating activities
  $15,827  $16,802  $16,192  (6 ) 4 Investing activities
  4,525  (4,740 )  (7,791 )  *  (39 )Financing activities
  (20,441 )  (13,350 )  (9,228 )  53  45 Effect of exchange-rate changes on cash and cash equivalents and restricted
cash and cash equivalents
  (116 ) 53  (215 ) *  * Net decrease in 
Cash and cash equivalents and restricted cash and cash equivalents
  $(205 ) $(1,235 )  $(1,041 )  (83 ) 19 *
Indicates calculation not meaningful or result is equal to or greater than 100%.In the consolidated statements of cash flows, the line item, 
Other changes in assets and liabilities, net of acquisitions and divestitures , is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or out
flows, and excluding any other significant non-cash movements.Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our consolidated balance sheets.
Operating Activities
2018 
v. 2017Our net cash provided by operating activities was 
$15.8 billion in 2018 , compared to $16.8 billion in 2017 . The decrease in net cash provided by operating activities reflects a decrease in net cash generated from net income. The net cash generated reflects the
 timing of receipts from customers and payments to vendors in the ordinary course ofbusiness.
In 
2018 , the change in the line item Other adjustments, net primarily reflects, among other items: •
non-recurrence of a non-cash net loss on early retirement of debt under an exchange offer in 2017;•
unrealized net gains on equity securities resulting from the adoption of a new accounting standard on January 1, 2018 related to financial assets and liabilities (see Notes toConsolidated Financial Statements— 
Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 ); •
a decrease in debt extinguishment costs in 2018 related to early retirement of debt under an exchange offer in 2017, which have been reclassified from operating tofinancing activities in 2018 and 2017 in accordance with our implementation of a new accounting standard on January 1, 2018 related to the
 classification of debtprepayment and extinguishment costs (see Notes to Consolidated Financial Statements— 
Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption ofNew Accounting Standards in 2018 
); •
a non-cash gain associated with our transaction with Bain Capital to create a new biopharmaceutical company to continue development of a portfolio of clinical andpreclinical stage neuroscience assets (see Notes to Consolidated Financial Statements–– 
Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
: Divestitures ); and •
a non-cash gain on the contribution of Pfizer’s allogeneic CAR T developmental program assets, in connection with our contribution agreement with Allogene (see Notes toConsolidated Financial Statements— 
Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment 
: Divestitures ), partially offset by:
•
decreases in net realized gains on sales of investments in debt and equity securities;•
net losses on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales (that fixes the cost of inventory later sold to customers); and•
a decrease in gains on the sale of property, plant and equipment.In 
2018 and 2017 , the line item Other changes in assets and liabilities, net of acquisitions and divestitures, primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable,
 accrued compensation and other current and noncurrentliabilities.
For additional information about changes in other assets and liabilities account balances, see the “Analysis of the Consolidated Balance Sheets” in this Financial Review.
2018 Financial Report    
 
 53
Financial ReviewPfizer Inc. and Subsidiary Companies
 
2017 
v. 2016Our net cash provided by operating activities was 
$16.8 billion in 2017 , compared to $16.2 billion in 2016 . The increase in net cash provided by operating activities reflects the timing of receipts from customers and payments to vendors in the ordinary course of business, partially 
offset by an increase in benefit plan contributions. In 2017 , the change in the line item 
Other adjustments, net primarily reflects, among other items: •
a decrease in the provision for bad debt expense;•
an increase in dividends from our investment in ViiV reclassified from operating to investing activities;•
an increase in gains from sales of available-for-sale securities; and•
an increase in gains on the sale of property, plant and equipment,partially offset by:
•
a non-cash net loss on early retirement of debt under an exchange offer.In 
2017 and 2016 , the line item Other changes in assets and liabilities, net of acquisitions and divestitures, primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable,
 accrued compensation and other current and noncurrentliabilities. For 
2016 , this line item also includes the adjustments necessary to reflect the payments of certain legal claims accrued in prior periods, including for Protonix-related matters.
For additional information about changes in other assets and liabilities account balances, see the “Analysis of the Consolidated Balance Sheets” in this Financial Review.
Investing Activities
2018 
v. 2017Our net cash provided by investing activities was 
$4.5 billion in 2018 , compared to net cash used in investing activities of $4.7 billion in 2017 . The change in net cash used in investing activities was primarily attributable to:
•
an increase in net proceeds generated from the sale of investments of $8.6 billion in 2018 for cash needs; and •
a decrease in cash used for acquisitions, net of cash acquired of $1.0 billion due to the acquisition of the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business and substantially all of the remaining consideration for the Medivation acquisition in 
2017 (see Notes to Consolidated Financial Statements — 
Note 2A. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Acquisitions 
). 2017 
v. 2016Our net cash used in investing activities was 
$4.7 billion in 2017 , compared to net cash used in investing activities of $7.8 billion in 2016 . The change in net cash used in investing activities was primarily attributable to:
•
a decrease in cash used for acquisitions — cash paid of $1.0 billion, net of cash acquired, primarily for the acquisition of AstraZeneca’s small molecule anti-infectivesbusiness in 
2017 and substantially all of the remaining consideration for the Medivation acquisition, compared to cash paid of $18.4 billion , net of cash acquired, primarily for the acquisitions of Medivation, Bamboo and Anacor in 
2016 (see Notes to Consolidated Financial Statements— Note 2A. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Acquisitions 
); and •
an increase in Other investing activities, net, including dividends received from our investment in ViiV, partially offset by:
•
lower net proceeds generated from the sale of investments of $14.7 billion in 2017 for cash needs. Financing Activities
2018 
v. 2017Our net cash used in financing activities was 
$20.4 billion in 2018 , compared to $13.3 billion in 2017 . The increase in net cash used in financing activities was primarily attributable to:
•
$2.3 billion less proceeds raised from short-term borrowings in 2018 , compared to 2017 ; and •
higher purchases of common stock of $7.2 billion , partially offset by:
•
lower repayments on long-term debt of $2.6 billion . 2017 
v. 2016Our net cash used in financing activities was 
$13.3 billion in 2017 , compared to $9.2 billion in 2016 . The increase in net cash used in financing activities was primarily attributable to:
•
the issuance of long-term debt of $5.3 billion in 2017 , compared to $11.0 billion in 2016 (see Notes to Consolidated Financial Statements–– Note 7D. Financial Instruments: Long-Term Debt 
); and •
$7.7 billion cash dividends paid in 2017 , compared to $7.3 billion in the same period in 2016 , 54
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
partially offset by:
•
lower repayments on long-term debt of $1.5 billion , compared to 2016 ; and •
lower net repayments on short-term borrowings in 2017 of $619 million , compared to 2016 . ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We
continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable,
and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital
markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable
future, which include:
•
the working capital requirements of our operations, including our R&D activities;•
investments in our business;•
dividend payments and potential increases in the dividend rate;•
share repurchases;•
the cash requirements associated with our cost-reduction/productivity initiatives;•
paying down outstanding debt;•
contributions to our pension and postretirement plans; and•
business-development activities.Our long-term debt is rated high-quality by both S&P and Moody’s. See the “Credit Ratings” section below. As market conditions change,
 we continue to monitor our liquidityposition. We have taken and will continue to take a conservative approach to our financial investments. Bo
th short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.
Selected Measures of Liquidity and Capital Resou
rcesThe following table provides certain relevant measures of our liquidity and capital resources:
 
  As of December 31, (MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA)
  2018  2017 Selected financial assets 
(a) :      Cash and cash equivalents
  $1,139  $1,342 Short-term investments
  17,694  18,650 Long-term investments
  2,767  7,015  
  21,600  27,007 Debt:
     Short-term borrowings, including current portion of long-term debt
  8,831  9,953 Long-term debt
  32,909  33,538  
  41,740  43,491 Selected net financial liabilities 
(b)  $(20,140 )  $(16,484 )  
      Working capital 
(c)  $18,068  $10,714 Ratio of current assets to current liabilities
  1.57:1  1.35:1 Total Pfizer Inc. shareholders’ equity per common share 
(d)  $11.09  $11.93 (a) 
 See Notes to Consolidated Financial Statements–– Note 7. Financial Instruments for a description of certain assets held and for a description of credit risk related to our financial instruments held.(b)
 
The increase in selected net financial liabiliti es was primarily driven by the decrease in long-term investments used for cash needs, partially offset by the repayment of debt. We retain a strong financial liquidityposition as a result of our net c
ash provided by operating activities, our high-quality financial asset portfolio and access to capital markets. For additional information, see the “Credit Ratings” section of thisFinancial Review.
(c) 
 The increase in working capital wa s primarily due to:•
the reclassification to assets and liabilities held for sale in connection with our pending consumer business joint venture with GSK (see Notes to Consolidated Financial Statements–– Note 2 C. Acquisitions,Divestitures, Assets and Liabilities Held f
or Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Assets andLiabilities Held for Sale 
) ;•
a decrease in short-term borrowings as a result of repayments of commercial paper;•
an increase in inventory related to increases for certain products to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery, new product launches and themovement of products within our m
anufacturing network; and•
the timing of accruals, cash receipts and payments in the ordinary course of business,partially offset by:
•
a decrease in S hort-term investments mainly driven by the financing r equirements for share repurchase activities, dividend payments, capital expenditures and debt repayment, partially offset by operating cashflow generation, cash from empl
oyee stock option exercises and reclassification of long-term to short-term investments;•
an increase in income taxes payable primarily related to the reclassification of the first federal installment of the repatriation tax previously recorded in noncurrent liabilities and the timing of accruals in certainmajor markets in the ordinary cours
e of business; and•
the net impact of foreign currency exchange.(d) 
 Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury stock).2018 Financial Report    
 
 55
Financial ReviewPfizer Inc. and Subsidiary Companies
 
In September 2018, we completed a public offering of 
$5.0 billion aggregate principal amount of senior unsecured notes (see Notes to Consolidated Financial Statements–– Note 7D. 
Financial Instruments : Long-Term Debt ) .In December 2017, we exchanged approximately 
£833 million principal amount of senior unsecured notes due 2038 with an interest rate of 6.50% for £ 1.376 billion principal amount of senior unsecured notes due 2043 with an interest rate of 
2.735% (see Notes to Consolidated Financial Statements–– Note 7D. Financial Instruments: Long-Term Debt 
). In March 2017, we completed a public offering of 
$1.065 billion principal amount of senior unsecured notes due 2047 with an interest rate of 4.20% , and on March 6, 2017, we completed a public offering of € 
4.0 billion principal amount of senior unsecured notes with a weighted-average effective interest rate of 0.23% (see Notes to Consolidated Financial Statements–– 
Note 7D. Financial Instruments: Long-Term Debt ). In November 2016, we completed a public offering of 
$6.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 3.10% .
In June 2016, we completed a public offering of 
$5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% . For additional information about the sources and uses of our funds, see the “Analysis of 
the Consolidated Balance Sheets ” and “ Analysis of the Consolidated Statements ofCash Flows 
” sections of this Financial Review.Domestic and Internatio
nal Selected Financial AssetsMany of our operations are conducted outside the U.S., and significant portions of
 our selected financial assets are held internationally. The amount of funds held in U.S. taxjurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due 
to other reasons, such as business-development activities. Aspart of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the
TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, will also allow us to more easily access our selected
financial assets globally. As a result of the enactment of the TCJA
, in 2018 we repatriated the majority of our cash we held internationally as of year-end 2017.Credit Ratings
Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or
hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any o
ther rating.The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt:
NAME OF RATING AGENCY
 PfizerCommercial Paper
  PfizerLong-Term Debt
  Outlook
 Date of Last Rating Change
  Rating  Rating    Moody’s
  P-1  A1  Stable  October 2009 S&P
  A-1+  AA  Stable  October 2009 Debt Capacity––Lines of Cre
ditWe have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent
balances and short-term investments in excess of our commercial paper and other short-term borrowings. As of December 31, 2018, we had access to a 
$7.0 billion U.S. revolving credit facility expiring in 2023, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have
provided us an additional 
$553 million lines of credit, of which $502 million expire within one year. Of these total lines of credit, $7.5 billion were unused as of December 31, 2018.
LIBOR
From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps tha
t contain a variable element based on LIBOR. Banks currently reportinginformation used to set LIBOR will stop doing so after 2021. Various parties, including government agencies, are seeking to identify
 an alternative rate to replace LIBOR. Weare monitoring their efforts, and we will likely amend contracts to accommodate any replacement rate where it is not already provided.
Global Economic Conditions––Ge
neralThe global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash
flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and
 will maintain, the abilityto meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. 
For additional information see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating 
Environment––The Global Economic Environment” section in this FinancialReview.
56
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Global Economic Conditions––Ven
ezuela OperationsOur Venezuela operations continue to operate with the U.S. dollar as the func
tional currency due to the hyperinflationary status of the Venezuelan economy.We used the Venezuelan bolivar soberano rate of 85.87 as our best estimate to
 revalue our Venezuelan bolivar denominated net monetary assets. The current DICOM rate isabout 3,298.64. Future actions by the Venezuelan government in response to
 economic uncertainties could impact the recoverability of our investment in Venezuela, whichcould result in an impairment charge and, under extreme circumstances, could impact our ability to continue to operate in the country in the same manner as we have
historically. We have in Venezuela a few net monetary assets and 
$39 million of non-monetary assets, and $11 million of deferred foreign exchange losses reported in the balance sheet in 
Accumulated other comprehensive loss––Foreign currency translation adjustments at November 30, 2018 , our international quarter-end. Global Economic Conditions––Arge
ntina OperationsOur Argentina operations function in a hyperinflationary economy. The impact to Pfizer is not considered material.
Contractual Obligations
Payments due under contractual obligations as of December 31, 
2018 , mature as follows:  
     Years (MILLIONS OF DOLLARS)
  Total  2019  2020-2021   2022-2023   Thereafter Long-term debt, including current portion 
(a)  $37,684  $4,776  $5,935  $4,067  $22,907 Interest payments on long-term debt obligations 
(b)  20,680  1,443  2,518  2,330  14,389 Other long-term liabilities 
(c)  2,798  414  611  549  1,224 Operating leases 
(d)  3,317  300  462  515  2,040 Purchase obligations and other 
(e)  3,722  1,322  1,294  337  769 Other taxes payable 
—  deemed repatriated accumulated post-1986 earningsof foreign subsidiaries 
(f)  11,000  800  1,775  1,775  6,650 Uncertain tax positions 
(g)  19  19  —  —  — (a)
 
Long-term debt consists of senior unsecured notes (including fixed and floating rate, foreign currency denominated, and other notes), carried at historical proceeds, as adjusted, and capital lease obligations (seeNotes to Consolidated 
Financial Statements— Note 7. Financial Instruments ). Commitments under capital leases are not significant.(b)
 
Our calculations of expected interest payments incorporate only current period assumptions for interest rates, foreign currency translation rates and hedging strategies (see Notes to Consolidated FinancialStatements— 
Note 7. Financial Instruments ), and assume that interest is accru ed through the maturity date or expiration of the related instrument.(c)
 
Includes expected payments relating to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans. Excludes amounts relating to our U.S. qualifiedpension plans and international
 pension plans, all of which have a substantial amount of plan assets, because the required funding obligations are not expected to be material and/or because such liabilities do notnecessarily reflect future cash paym
ents, as the impact of changes in economic conditions on the fair value of the pension plan assets and/or liabilities can be significant. Also, excludes $4.6 billion of liabilities related to the fair value of d
erivative financial instruments, legal matters and employee terminations, among other liabilities, most of which do not represent contractual obligations. See also our liquidity discussionabove in this “Analysis of Financial Co
ndition, Liquidity and Capital Resources” section, as well as the Notes to Consolidated Financial Statements— Note 3. Restructuring Charges a nd Other Costs Associatedwith Acquisitions and Cost-Reductio
n/Productivity Initiatives, Note 7A. Financial Instruments: Fair Value Measurements, Note 11E. Pension and Postretirement Benefit Plans and Defined Contribution Plans: CashFlows, 
and Note 17. Contingencies and Certain Commitments . (d)
 
Includes future minimum rental commitments under non-cancelable operating leases. These amounts include an agreement we entered in April 2018 to lease space in an office building in New York City. We willrelocate our global hea
dquarters to this property with occupancy expected beginning in 2022. Our future minimum rental commitment under this 20-year lease is approximately $1.7 billion . In July 2018, we completed the sale of our curr
ent headquarters buildings. We also agreed to lease these properties from the buyer while we complete our relocation.(e)
 
Includes agreements to purchase goods and services that are enforceable and legally binding and includes amounts relating to advertising, information technology services, employee benefit administrationservices, and potential mileston
e payments deemed reasonably likely to occur. Also includes obligations to make guaranteed fixed annual payments over the next 8 years in connection with the U.S. and EUapprovals for Besponsa ( 
$422 million ) and an obligation to make  guaranteed fixed annual payments over the next 9 years for Bosulif ( $240 million ), both associated with R&D arrang ements. For additionalinformation, see Notes to Consoli
dated Financial Statements— Note 7E. Financial Instruments: Other No ncurrent Liabilities. Also includes consideration of $175 million paid in January 2019 related to ourpurchase of AstraZeneca’s small molec
ule anti-infective business. For additional information, see Notes to Consolidated Financial Statements— Note 2A. Acquisitions, Divestitures, Assets an d Liabilities Held forSale, Licensing Arrangements, R
esearch and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Acquisitions . (f) 
 Represents estimated cash payments related to the TCJA repatriation tax for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through2026 (with the first installment du
e in April 2019). Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.For additional information, see N
otes to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from Co ntinuing Operations and Note 5C. Tax Matters: Deferred Taxes.(g)
 
Includes only income tax amounts currently payable. We are unable to predict the timing of tax settlements related to our noncurrent obligations for uncertain tax positions as tax audits can involve complex issuesand the resolution of thos
e issues may span multiple years, particularly if subject to negotiation or litigation.The above table includes amounts for potential milestone payments under collaboration, licensing or other arrangements, if the payments are deemed reasonably likely to
occur. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization
milestones, which may span several years and which may never occur.
In 
2019 , we expect to spend approximately $2.3 billion on property, plant and equipment. We rely largely on operating cash flows to fund our capital investment needs. Due to our significant operating cash flows, we believe we have the ability to meet our capital investment needs and anticipate no delays to planned capital expenditures.
2018 Financial Report    
 
 57
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Off-Balance Sheet Arrangements
In the ordinary course of business and in connection with the sale of assets and businesses and
 other transactions, we often indemnify our counterparties against certainliabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If 
the indemnified party were to make asuccessful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various
restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of 
December 31, 2018 , the estimated fair value of our indemnification obligations was not significant.
Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-
promotion or other rights in specified countries with respect to certain of our products.
Share-Purchase Plans and Ac
celerated Share Repurchase AgreementsOur December 2015 $11 billion share repurchase program was exhausted in the third quarter of 2018.
In December 2017, the Board of Directors authorized an additional $10 billion share repurchase program, and share repurchases commenced thereunder in the third quarter of
2018 (the 2017 program).
On 
March 12, 2018 , we entered into an accelerated share repurchase agreement with Citibank to repurchase $4.0 billion of our common stock. In December 2018, the Board of Directors authorized a new 
$10.0 billion share repurchase program to be utilized over time. This new program is in addition to the $4.2 billion remaining under the company’s 2017 program authorization as of December, 31 2018. For additional information, see Notes to Consolidated Financial Statements–– 
Note 12. Equity.
The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including
our accelerated share repurchase agreements:
(SHARES IN MILLIONS, DOLLARS IN BILLIONS)
  2018 (a) 2017 (b) 2016 (c)Shares of common stock purchased
  307  150  154 Cost of purchase
  $12.2  $5.0  $5.0 (a)
 
Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank entered into on March 12, 2018, as well as other share repurchases. For additional information, see Notes toConsolidated Financial 
Statements–– Note 12 . Equity. (b)
 
Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank entered into on February 2, 2017. For additional information, see N otes to Consolidated FinancialStatements–– 
Note 12. Equity. (c)
 
Represents shares purchased pursuant to an accelerated share repurchase agreement entered into on March 8, 2016. For additional information, see N otes to Consolidated Financial Statements–– Note 12. Equity.
At December 31, 
2018 , our remaining share-purchase authorization was approximately $14.2 billion . In 2019, Pfizer anticipates approximately 
$9 billion of share repurchases, which have been completed through February 28, 2019. On 
February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. This agreement was entered into pursuant to our previously announced share repurchase authorization. For additional information, see Notes to Consolidated Financial Statements
— 
Note 19. Subsequent Event . Dividends on Common Stock
We paid dividends on our common stock of 
$8.0 billion in 2018 , $7.7 billion in 2017 and $7.3 billion in 2016 . In December 2018 , our Board of Directors declared a first-quarter 2019 dividend of 
$0.36 per share, payable on March 1, 2019 , to shareholders of record at the close of business on February 1, 2019 . The first-quarter 2019 cash dividend will be our 321 
st consecutive quarterly dividend.Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses and to seek to increase
shareholder value. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer’s Board of Directors and will continue to be
evaluated in the context of future business performance, we currently believe that we can support 
future annual dividend increases, barring significant unforeseen events.58
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
NEW ACCOUNTING STANDARDS
Recently Adopted Accounting Standards
See Notes to Consolidated Financial Statements— 
Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018.Recently Issued Accounting Standards, Not Adopted as of
 December 31, 2018Standard/Description
  Effective Date   Effect on the Financial Statements or Other Significant MattersIn February 2016, the FASB issued new guidance on accounting
for 
leases . The new ASU provides guidance for both lessee and lessor accounting models. Among other things, the new guidance
requires that a right of use asset and a lease liability be
recognized for leases with a duration of greater than one year.
Since its issuance, the FASB has issued several ASUs, including
amending the guidance to offer an additional transition method.
 
January 1, 2019. 
We have substantially completed our review of the impact of this newguidance. We will adopt this standard in the first quarter of fiscal 2019
utilizing the modified retrospective method, and therefore no
adjustments will be made to amounts in our prior period financial
statements. We expect to recognize approximately $1.5 billion of
additional assets and corresponding liabilities on our balance sheet as
of the beginning of fiscal 2019 and will record any cumulative effect of
adopting the new standard as an adjustment to the opening balance of
Retained Earnings. 
We do not expect that this adjustment to Retained Earnings 
 at adoption will have a material impact on our consolidated financial statements. We have also assessed the potential impact of
embedded leases on our consolidated financial statements, given our
manufacturing outsourcing, service arrangements and other
agreements. In connection with this guidance we have designed new
global processes, technological solutions and related controls to
provide the appropriate financial accounting and disclosure data. We
continue to monitor changes, modifications, clarifications or
interpretations undertaken by the FASB, which may impact our
conclusions.
In March 2017, the FASB issued new guidance that shortens 
theamortization period for certain callable debt securities held
at a premium 
. The new guidance requires the premium to be amortized to the earliest call date.
  January 1, 2019. 
We do not have any investments with features subject to this standardand do not expect this new guidance to have a material impact on our
consolidated financial statements.
In July 2017, the FASB issued new guidance on accounting for
certain financial instruments with characteristics of liabilities
and equity, 
 and accounting for certain financial instruments with down round features 
(a feature in a financial instrument that reduces the strike price of an issued financial instrument if the
issuer sells shares of its stock for an amount less than the
currently stated strike price of the issued financial instrument or
issues an equity-linked financial instrument with a strike price
below the currently stated strike price of the issued financial
instrument).
  January 1, 2019. 
We do not have any financial instruments with features subject to thisstandard and do not expect this new guidance to have a material
impact on our consolidated financial statements.
In June 2018, the FASB issued new guidance to simplify the
accounting for 
share-based payments to nonemployees  by aligning it with the accounting for share-based payments to
employees, with certain exceptions. Under the guidance, the
measurement of equity-classified nonemployee awards will be
fixed at the grant date.
  January 1, 2019. 
We do not have any share-based awards issued to nonemployees anddo not expect this new guidance to have a material impact on our
consolidated financial statements.
In June 2016, the FASB issued new guidance on accounting 
forcredit losses of financial instruments 
. The new guidance replaces the probable initial recognition threshold for incurred loss
estimates in current GAAP with a methodology that reflects
expected credit loss estimates.
 
January 1, 2020. Earlierapplication is permitted as of
fiscal years beginning after
December 15, 2018, including
interim periods within that fiscal
year.
 
We are assessing the impact of the provisions of this new guidance onour consolidated financial statements. This standard includes our
financial instruments, such as accounts receivable, and investments
that are generally of high credit quality.
Previously, when credit losses were measured under GAAP, an entity
generally only considered past events and current conditions in
measuring the incurred loss.
The new guidance requires us to identify, analyze, document and
support new methodologies for quantifying expected credit loss
estimates for our financial instruments, using information such as
historical experience and current economic conditions, plus the use of
reasonable supportable forecast information.
2018 Financial Report    
 
 59
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Standard/Description
  Effective Date   Effect on the Financial Statements or Other Significant MattersIn January 2017, the FASB issued new guidance for 
goodwill impairment testing 
. The new guidance eliminates the requirement to perform a hypothetical purchase price allocation to
measure goodwill impairment. Under the new guidance the
goodwill impairment test is performed by comparing the fair value
of a reporting unit with its carrying amount, and recognizing an
impairment charge for the amount by which the carrying amount
of the reporting unit exceeds its fair value, although it cannot
exceed the total amount of goodwill allocated to that reporting
unit.
  January 1, 2020. Earlierapplication is permitted.
 
We do not expect this new guidance to have a material impact on ourconsolidated financial statements.
In August 2018, the FASB issued new guidance related 
tocustomers’ accounting for implementation costs incurred in
a cloud computing arrangement that is considered a service
contract 
. The new guidance aligns the requirements for capitalizing implementation costs in such arrangements with the
requirements for capitalizing implementation costs incurred to
develop or obtain internal-use software. The new guidance can
be adopted either prospectively or retrospectively.
  January 1, 2020. Earlierapplication is permitted.
 
We are assessing the impact of the provisions of this new guidance onour consolidated financial statements. We do not expect this new
guidance to have a material impact on our consolidated financial
statements.
In November 2018, the FASB issued new guidance clarifying the
interaction between the accounting guidance for 
collaboration agreements and revenue from contracts with customers 
.  January 1, 2020. Earlierapplication is permitted
 We have assessed the impact of the provisions of this new guidanceand do not expect it will have a material impact on our consolidated
financial statements.
60
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks
and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,”
“expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning or by
using future dates in connection with any discussion of, among other things, our anticipated operating and 
financial performance, business plans and prospects, in-lineproducts and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, performance, timing of exclusivity and potential benefits
of Pfizer’s products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the
 reorganization of our commercialoperations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development ac
tivities, our ability to successfullycapitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include
statements relating to future actions, business plans and prospects, our acquisitions and other business development activities, our proposed 
transaction with GSK to combineour respective consumer healthcare businesses into a new consumer healthcare joint venture, prospective products or product approvals, our product pipeline, future
performance or results of current and anticipated products, sales efforts, expenses, interest rates,
 foreign exchange rates, the outcome of contingencies, such as legalproceedings, plans relating to share repurchases and dividends, government regulation and financial results, including, in particular, the anticipated progress in remediation
efforts at certain of our Hospira manufacturing facilities and the expectations related to our supply issues set 
forth in the “Overview of Our Performance, OperatingEnvironment, Strategy and Outlook––Our Business––Product Manufacturing” section of this Financial Review, the benefits expec
ted from the reorganization of our commercialoperations into three businesses effective at the beginning of our 2019 fiscal year and our expecta
tions regarding growth set forth in the “Overview of Our Performance,Operating Environment, Strategy and Outlook––Our Strategy––Organizing for Growth” section of 
this Financial Review, the expected timing of completion and benefits of ourproposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture set forth in the “Overview of 
OurPerformance, Operating Environment, Strategy and Outlook––Our Business,” “––Our Strategy” and “––Our 
Business Development Initiatives” sections of this FinancialReview, the anticipated costs related to our preparations for Brexit set forth in the “Overview of 
Our Performance, Operating Environment, Strategy and Outlook––OurOperating Environment––The Global Economic Environment” section of this Financial Review, our anticipated liquidity position set forth in the “Overview of Our Performance,
Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” and the “Analysis of Financial Condition, Liquidity and
Capital Resources” sections of this Financial Review, our plans for increasing investment in the U.S. set forth in the “Overview of Our Performance, Operating Environment,
Strategy and Outlook––Our Strategy––Capital Allocation and Expense Management––Increasing Investment in the
 U.S.” section of this Financial Review, the financialguidance set forth in the “Overview of Our Performance, Operating Environment, Strategy and
 Outlook––Our Financial Guidance for 2019 ” section of this Financial Review, the anticipated costs and savings, including from our cost-reduction/productivity initiatives, as well as from our Organizing for Growth initiative, set forth in the “Costs and
Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review and in Notes to
Consolidated Financial Statements–– 
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives , the benefits expected from our business development transactions, the planned capital spending set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources––
Selected Measures of Liquidity and Capital Resources––Contractual Obligations” section of this Financial Review and the contributions that we expect to make from our
general assets to the Company’s pension, postretirement and deferred compensation plans during 
2019 set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources––Selected Measures of Liquidity and Capital Resources––Contractual Obligations” section of this Financial Review and in Notes to Consolidated Financial
Statements–– 
Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans . Among the factors that could cause actual results to  differ materially frompast results and future plans and projected future results are the following:
•
the outcome of R&D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for ourpre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial
results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;
•
the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators,which will depend on myriad factors, including such regulator making a determination as to whether a product’s benefits outweigh its known risks and a determination of the
product’s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory
committees, such as the Advisory Committee on Immunization Practices, that may impact the use of
 our vaccines;•
the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;•
the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about theside effects or efficacy of, a product that
 could affect its availability or commercial potential;•
the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy theconditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the an
ticipated benefits of any such transactions, and the potentialneed to obtain additional equity or debt financing to pursue these opportunities which could result in increased leverage and impact our credit ratings;
•
competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products,biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;
•
the implementation by the FDA and regulatory authorities in many other countries of an abbreviated legal pathway to approve biosimilar products, which could subject ourbiologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;
2018 Financial Report    
 
 61
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
risks related to our ability to develop and launch biosimilars, including risks associated with “at risk” launches, defined as the marketing of a product by Pfizer before the finalresolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party,
and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the
innovator product;
•
the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;•
the ability to successfully market both new and existing products domestically and internationally;•
difficulties or delays in manufacturing, including delays caused by natural events, such as hurricanes; supply shortages at our facilities; and legal or regulatory actions, suchas warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, voluntary recall of a product or failure to secure product approvals;
•
trade buying patterns;•
the impact of existing and future legislation and regulatory provisions on product exclusivity;•
trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for ourproducts;
•
the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the taxtreatment of employer-sponsored health insurance that may be implemented;
•
the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. PatientProtection and Affordable Care Act, as amended by the Health Care and Educa
tion Reconciliation Act;•
U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, reimbursement or access, includingunder Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases
that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the
U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under government programs; restrictions on
U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be
implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to
innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;
•
legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;
•
the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions,changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;
•
contingencies related to actual or alleged environmental contamination;•
claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;•
any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;•
legal defense costs, insurance expenses and settlement costs;•
the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalidand/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged
infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion,
securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means
for resolving asbestos litigation, as well as tax issues;
•
the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seekmay not be granted on a timely basis, if at all;
•
our ability to protect our patents and other intellectual property, both domestically and internationally;•
interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;•
governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by theU.S. of income earned outside the U.S. that may result 
from pending and possible future proposals, including further clarifications and/or interpretations of the TCJA;•
any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;•
the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of ourmedicines;
•
the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.’s exit from the EU, which could have implications on ourresearch, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;
•
any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness andcompliance with applicable legal or regulatory requirements and industry standards;
62
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
•
any significant issues that may arise related to our joint ventures and other third-party business arrangements;•
changes in U.S. generally accepted accounting principles;•
further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries;•
uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact onus, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and
possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate;
 and the risks related to volatility of ourincome due to changes in the market value of equity investments;
•
any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. militaryaction overseas;
•
growth in costs and expenses;•
changes in our product, segment and geographic mix;•
the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;•
the impact of acquisitions, divestitures, restructurings, internal reorganizations, including the reorganization of our commercial operations into three businesses effective atthe beginning of the company’s 2019 fiscal year, any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of
 which requires upfront costsbut may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;
•
the impact of product recalls, withdrawals and other unusual items;•
the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;•
risks related to internal control over financial reporting;•
risks and uncertainties related to acquisitions, including, among other things, the ability to realize the anticipated benefits of those acquisitions, including the possibility thatthe expected cost savings and/or accretion from certain of those acquisitions will not be realized or will not be realized within the expected time frame; the risk that
 thebusinesses will not be integrated successfully; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our
ability to grow revenues for certain acquired products; significant transaction costs; and unknown liabilities; and
•
risks and uncertainties related to our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare jointventure, including, among other things, risks related to the satisfaction of the conditions 
to closing the transaction (including the failure to obtain necessary regulatory andGSK shareholder approvals) in the anticipated timeframe or at all and the possibility that the transaction does not close,
 risks related to the ability to realize the anticipatedbenefits of the transaction, including the possibility that the expected bene
fits and cost synergies from the proposed transaction will not be realized or will not be realizedwithin the expected time period, the risk that the businesses will not be integrated successfully, the possibility that
 a future separation of the joint venture may not occur,disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the announcement or the
 consummation of theproposed transaction on the market price of Pfizer’s common stock and on Pfizer’s operating results, significant transaction costs, unknown liabilities, the risk of litigation
and/or regulatory actions related to the proposed transaction, other business effects, including the e
ffects of industry, market, economic, political or regulatory conditions,future exchange and interest rates, changes in tax and other laws, regulations, rates and
 policies, future business combinations or disposals and competitive developments.We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate
assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past
results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned no
t to put unduereliance on forward-looking statements.
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except
 as required by law or bythe rules and regulations of the SEC. You are advised, however, to consult
 any further disclosures we make on related subjects.Certain risks, uncertainties and assumptions are discussed here and under the heading entitled “Risk Factors” in Part I, Item 1A. of
 our Form 10-K for the year endedDecember 31, 2018 
. We note these factors for investors as permitted by the  Private Securities Litigation Reform Act of 1995. You should understand that it is not possible topredict or identify all such factors. Consequently, you should not consider any such list to be a complete se
t of all potential risks or uncertainties.The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes
on income that each of our operating segments would have recorded had each segment operated as a standalone company during the
 periods presented.This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of
clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of 
the larger body of data. In addition, clinical trialdata are subject to differing interpretations, and, even when we view data as sufficient 
to support the safety and/or effectiveness of a product candidate or a new indication foran in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
2018 Financial Report    
 
 63
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Financial Risk Management
The objective of our financial risk management program is to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We
manage these financial exposures through operational means and through the use of third-party instruments. These practices may change as economic conditions change.
Foreign Exchange Risk
We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations, as well as in our financial assets (investments) and liabilities
(borrowings). Our net investments in foreign subsidiaries are also subject to currency risk.
On the commercial side, a significant portion of our revenues and earnings is exposed to changes in foreign exchange rates. See 
the “ Our Operating Environment — TheGlobal Economic Environment 
” section of this Financial Review for the key currencies in which we operate. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Where
foreign exchange risk cannot be mitigated via operational means, we may use foreign currency forward-exchange contracts and/or foreign currency swaps to manage that risk.
With respect to our financial assets and liabilities, our primary foreign exchange exposure arises predominantly from short-term and long-term intercompany receivables and
payables, and, to a lesser extent, from short-term and long-term investments and debt, where the asse
ts and/or liabilities are denominated in currencies other than thefunctional currency of the business entity.
We also hedge some forecasted intercompany sales denominated in euro, Japanese yen, Chinese renminbi, U.K. pound, Canadian dollar, and Australian dollar to protect
against longer-term movements.
In addition, under certain market conditions, we may seek to protect against possible declines in the reported net investments o
f our foreign business entities. In these cases,we may use foreign currency swaps, foreign currency forward-exchange contracts and/or foreign currency debt.
For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements— 
Note 7A. Financial Instruments 
: Fair Value Measurements . The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this sensitivity analysis, holding
all other assumptions constant and assuming that a change in one currency’s rate relative to the U.S.
 dollar would not have any effect on another currency’s rates relative tothe U.S. dollar, if the dollar were to appreciate against all other currencies by 10%, as of 
December 31, 2018 , the expected adverse impact on our net income would not be significant.
Interest Rate Risk
We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on 
Pfizer’s immediate andintermediate liquidity needs.
With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on
 prevailing market conditions. Ourfloating-rate assets are subject to the risk that short-term interest rates may fall and, as a
 result, the investments would generate less interest income. Fixed-rate investmentsprovide a known amount of interest income regardless of a change in interest rates. We sometimes use interest rate swaps in our financial investment portfolio.
We borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into
derivative financial instruments like interest rate swaps.
For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements— 
Note 7A. Financial Instruments 
: Fair Value Measurements . The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this sensitivity analysis, holding all other
assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point decrease in
interest rates as of 
December 31, 2018 , the expected adverse impact on our net income would not be significant. Equity Price Risk
We hold equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such
securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the 
fair value of equity investments. Fromtime to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk.
Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the
expected adverse impact on our net income would not be significant.
64
 
 2018 Financial Report
Financial ReviewPfizer Inc. and Subsidiary Companies
 
Contingencies
Legal Matters
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other
product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications (see Notes to
Consolidated Financial Statements— 
Note 17. Contingencies and Certain Commitments ) .Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We
do not believe that any of these matters will have a material adverse effect on our 
financial position. However, we could incur judgments, enter into settlements or revise ourexpectations regarding the outcome of certain matters, and such developments could have a material adverse effect on
 our results of operations in the period in which theamounts are accrued and/or our cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and,
 therefore,determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range o
f reasonably possible loss inexcess of amounts accrued. Our assessments are based on estimates and assumptions that
 have been deemed reasonable by management, but the assessment processrelies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause
 us tochange those estimates and assumptions.
Tax Matters
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business for tax matters (see Notes to Consolidated Financial
Statements— 
Note 5D. Tax Matters : Tax Contingencies ). We account for income tax contingencies using a benefit recognition model. If our initial assessment fails to result in the recognition of
 a tax benefit, we regularly monitor ourposition and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that
 sufficiently raise the likelihood ofprevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable
settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on 
the results of audits of federal, state and local and foreign incometax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a
 position relative tothe “more-likely-than-not” standard.
Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but
 our estimates of unrecognized tax benefits and potentialtax benefits may not be representative of actual outcomes, and variation from such es
timates could materially affect our financial statements in the period of settlement or whenthe statutes of limitations expire, as we treat these events as
 discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formaladministrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to
 our uncertain tax positions, and suchchanges could be significant.
2018 Financial Report    
 
 65
Management’s Report on Internal Control Over Financial Reporting 
Management’s Report
We prepared and are responsible for the financial statements that appear in our 
2018 Financial Report. These financial statements are in conformity with accounting principles generally accepted in the United States of America and, therefore, include amounts based on informed judgments and es
timates. We also accept responsibility for thepreparation of other financial information that is included in this document.
Report on Internal Control Ove
r Financial ReportingThe management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f)
under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of
America. The Company’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of 
the Company; (ii) provide reasonable assurance that transactions are recorded asnecessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are
being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effec
t on the financial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation o
f effectiveness tofuture periods are subject to the risk that controls may become inadequate because of changes in conditions or 
that the degree of compliance with the policies or proceduresmay deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 
2018 . In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in 
Internal Control—Integrated Framework (2013) . Based on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December 31, 
2018 . The Company’s independent auditors have issued their auditors’ report on the Company’s internal control over financial reporting. That report appears in our 
2018 Financial Report under the heading, 
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting . 
 
 Albert Bourla
  Chief Executive Officer
  
 
Frank D’Amelio
 Loretta Cangialosi Principal Financial Officer
 Principal Accounting Officer  
   February 28, 2019
   66
 
 2018 Financial Report
Audit Committee Report 
The Audit Committee reviews Pfizer’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements
and the reporting process, including the system of internal controls.
The Committee met and held discussions with management and the independent registered public accounting firm regarding the fair and complete presentation of Pfizer’s
results and the assessment of Pfizer’s internal control over financial reporting. We discussed significant accounting policies applied in Pfizer’s financial statements, as well as,
when applicable, alternative accounting treatments. Management represented to the Committee that the consolidated financial statements were prepared in accordance with
accounting principles generally accepted in the United States of America, and the Committee reviewed and discussed the consolidated financial statements with management
and the independent registered public accounting firm. The Committee discussed with the independent registered public accounting firm matters required to be discussed
under applicable Public Company Accounting Oversight Board (PCAOB) standards.
In addition, the Committee reviewed and discussed with the independent registered public accounting firm the auditor’s independence from Pfizer and its management. As part
of that review, we received the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent registered public accounting
firm’s communications with the Audit Committee concerning independence, and the Committee discussed the independent registered public accounting firm’s independence
from Pfizer.
We also considered whether the independent registered public accounting firm’s provision of non-audit services to Pfizer is compatible with the auditor’s independence. The
Committee concluded that the independent registered public accounting firm is independent from Pfizer and its management.
As part of our responsibilities for oversight of Pfizer’s Enterprise Risk Management process, we reviewed and discussed company policies with respect to risk assessment and
risk management, including discussions of individual risk areas, as well as an annual summary of the overall process.
The Committee discussed with Pfizer’s Internal Audit Department and independent registered public accounting firm the overall scope of and plans for their respective audits.
The Committee meets with the Chief Internal Auditor, Chief Compliance, Quality and Risk Officer and representatives of the independent registered public accounting firm, in
regular and executive sessions, to discuss the results of their examinations, the evaluations of Pfizer’s internal controls, and the
 overall quality of Pfizer’s financial reporting andcompliance programs.
In reliance on the reviews and discussions referred to above, the Committee has recommended to the Board of Directors, and the 
Board has approved, that the auditedfinancial statements be included in Pfizer’s Annual Report on Form 10-K for the year ended December 31, 
2018 , for filing with the U.S. Securities and Exchange Commission. The Committee has selected, and the Board of Directors has ratified, the selection of 
Pfizer’s independent registered public accounting firm for 2019 . The Audit Committee
 
Suzanne Nora Johnson, Chair
Dennis A. Ausiello
Joseph J. Echevarria
James C. Smith
 
February 28, 2019
The Audit Committee Report does not constitute soliciting material, and shall not be deemed to be filed or incorporated by reference into any Company filing under the
Securities Act of 1933, as amended, or the Securities Exchange 
Act of 1934, as amended, except to the extent that the Company specifically incorporates the Audit CommitteeReport by reference therein.
2018 Financial Report    
 
 67
Report of Independent Registered Public Accounting Firm on theConsolidated Financial Statements
 
The Board of Directors and Sha
reholders of Pfizer Inc.:Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Pfizer Inc. and 
Subsidiary Companies (the Company) as of December 31, 2018 and 2017 , and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in 
the three-year period ended December 31, 2018 , and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements referred to above present 
fairly, in all material respects, thefinancial position of Pfizer Inc. and Subsidiary Companies as of December 31, 
2018 and 2017 , and the results of their operations and their cash flows for each of the years inthe three-year period ended December 31, 
2018 , in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight 
Board (United States) (PCAOB), the Company’s internal control overfinancial reporting as of December 31, 
2018 , based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated 
February 28, 2019 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and
 are required to be independent with respect to the Company in accordancewith the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAO
B. Those standards require that we plan and perform the audit to obtain reasonable assurance aboutwhether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of
material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
 risks. Such procedures includedexamining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accoun
tingprinciples used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
  
KPMG LLP
 
We have not been able to determine the specific year that KPMG and our predecessor firms began serving as the Company’s auditor, however, we are aware that KPMG andour predecessor firms have served as the Company’s auditor since at least 1942.
 
New York, New York 
February 28, 2019
68
 
 2018 Financial Report
Report of Independent Registered Public Accounting Firm onInternal Control Over Financial Reporting
 
The Board of Directors and Sha
reholders of Pfizer Inc.:Opinion on Internal Control Over Financial Reporting
We have audited Pfizer Inc. and Subsidiary Companies’ (the Company) internal control over financial reporting as of December 31, 
2018 , based on criteria established in Internal Control 
— Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 
2018 , based on criteria established in Internal Control-Integrated Framework (2013) issued by COSO.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight 
Board (United States) (PCAOB), the consolidated balance sheets ofPfizer Inc. and Subsidiary Companies as of December 31, 
2018 and 2017 , and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 
2018 , and the related notes (collectively, the consolidated financial statements), and our report dated February 28, 2019 
expressed an unqualified opinion on those consolidated financial statements. Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
financial reporting, included in the accompanying 
Management’s Report on Internal Control Over Financial Reporting . Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
 Commission and thePCAOB.
We conducted our audit in accordance with the standards of the PCAO
B. Those standards require that we plan and perform the audit to obtain reasonable assurance aboutwhether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating ef
fectiveness of internal control based on the assessed risk.Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those
policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
 the assets ofthe company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of
 thecompany; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could
have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation o
f effectiveness tofuture periods are subject to the risk that controls may become inadequate because of changes in conditions,
 or that the degree of compliance with the policies or proceduresmay deteriorate.
  
KPMG LLP
New York, New York
 
February 28, 2019
2018 Financial Report    
 
 69
Consolidated Statements of IncomePfizer Inc. and Subsidiary Companies
 
 
  Year Ended December 31, (MILLIONS, EXCEPT PER COMMON SHARE DATA)
  2018  2017  2016 Revenues
  $53,647  $52,546  $52,824 Costs and expenses:
       Cost of sales 
(a)  11,248  11,228  12,322 Selling, informational and administrative expenses 
(a)  14,455  14,804  14,844 Research and development expenses 
(a)  8,006  7,683  7,892 Amortization of intangible assets
  4,893  4,758  4,056 Restructuring charges and certain acquisition-related costs
  1,044  351  1,565 Other (income)/deductions––net
  2,116  1,416  3,794 Income from continuing operations before provision/(benefit) for taxes on income
  11,885  12,305  8,351 Provision/(benefit) for taxes on income
  706  (9,049 )  1,123 Income from continuing operations
  11,179  21,353  7,229 Discontinued operations:
         Income from discontinued operations––net of tax
  10  (1 ) 16 Gain on disposal of discontinued operations––net of tax
  —  3  — Discontinued operations––net of tax
  10  2  17 Net income before allocation to noncontrolling interests
  11,188  21,355  7,246 Less: Net income attributable to noncontrolling interests
  36  47  31 Net income attributable to Pfizer Inc.
  $11,153  $21,308  $7,215  
         Earnings per common share––basic 
:        Income from continuing operations attributable to Pfizer Inc. common shareholders
  $1.90  $3.57  $1.18 Discontinued operations––net of tax
  —  —  — Net income attributable to Pfizer Inc. common shareholders
  $1.90  $3.57  $1.18 Earnings per common share––diluted 
:       Income from continuing operations attributable to Pfizer Inc. common shareholders
  $1.86  $3.52  $1.17 Discontinued operations––net of tax
  —  —  — Net income attributable to Pfizer Inc. common shareholders
  $1.87  $3.52  $1.17  
         Weighted-average shares––basic
  5,872  5,970  6,089 Weighted-average shares––diluted
  5,977  6,058  6,159 (a)
 
Exclusive of amortization of intangible assets, except as disclosed in Note 1L. Basis of Presentation a nd Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-LivedAssets.
Amounts may not add due to
 rounding.See Notes to Consolidated Financial Statements, which are an integral part of these statements.
70
 
 2018 Financial Report
Consolidated Statements of Comprehensive IncomePfizer Inc. and Subsidiary Companies
 
 
  Year Ended December 31, (MILLIONS)
  2018  2017  2016 Net income before allocation to noncontrolling interests
  $11,188  $21,355  $7,246  
       Foreign currency translation adjustments, net
  $(799 ) $1,116  $(815 )Reclassification adjustments 
(a)  (22 ) 162  —  
  (821 ) 1,278  (815 )Unrealized holding gains/(losses) on derivative financial instruments, net
  220  (10 ) (442 )Reclassification adjustments for (gains)/losses included in net income 
(b)  27  (520 ) 452  
  247  (530 ) 10 Unrealized holding gains/(losses) on available-for-sale securities, net
  (185 ) 818  248 Reclassification adjustments for (gains)/losses included in net income 
(b)  124  (244 ) (118 )Reclassification adjustments for unrealized gains included in 
Retained earnings (c)  (462 ) —  —  
  (522 ) 574  130 Benefit plans: actuarial losses, net
  (649 ) (212 ) (1,888 ) Reclassification adjustments related to amortization
  242  588  558 Reclassification adjustments related to settlements, net
  142  117  127 Other
  112  (145 ) 195  
  (153 ) 348  (1,009 ) Benefit plans: prior service (costs)/credits and other, net
  (9 ) (2 ) 184 Reclassification adjustments related to amortization
  (181 ) (184 ) (173 )Reclassification adjustments related to curtailments, net
  (19 ) (18 ) (26 )Other
  2  —  6  
  (207 ) (203 ) (8 )Other comprehensive income/(loss), before tax
  (1,457 )  1,468  (1,692 ) Tax provision/(benefit) on other comprehensive income/(loss) 
(d)  518  (262 ) (174 )Other comprehensive income/(loss) before allocation to noncontrolling interests
  $(1,975 )  $1,730  $(1,518 )  
       Comprehensive income before allocation to noncontrolling interests
  $9,214  $23,085  $5,728 Less: Comprehensive income attributable to noncontrolling interests
  16  62  28 Comprehensive income attributable to Pfizer Inc.
  $9,198  $23,023  $5,701 (a)
 
For the year ended December 31, 2017, the foreign currency translation adjustments reclassified into Other (income)/deductions—net in the consolidated stateme nt of income primarily result from the sale of our40% 
ownership investment in  Teuto and the sale of our 49% equity share in Hisun Pfizer. See Note 2F. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research andDevelopment and Collabor
ative Arrangements, Equity-Method Investments and Privately Held Investment: Equity-Method Investments . (b)
 
Reclassified into Other (income)/deductions—net and Cost of sales in the consolidated stateme nts of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. FinancialInstruments: Derivative Financial Instrume
nts and Hedging Activities.(c) 
 For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 . (d) 
 See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).Amounts may not add due to
 rounding.See Notes to Consolidated Financial Statements, which are an integral part of these statements.
2018 Financial Report    
 
 71
Consolidated Balance SheetsPfizer Inc. and Subsidiary Companies
 
 
  As of December 31, (MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA)
  2018  2017  
      Assets
      Cash and cash equivalents
  $1,139  $1,342 Short-term investments
  17,694  18,650 Trade accounts receivable, less allowance for doubtful accounts: 2018—$541; 2017—$584
  8,025  8,221 Inventories
  7,508  7,578 Current tax assets
  3,374  3,050 Other current assets
  2,461  2,289 Assets held for sale
  9,725  12 Total current assets
  49,926  41,141 Long-term investments
  2,767  7,015 Property, plant and equipment, less accumulated depreciation
  13,385  13,865 Identifiable intangible assets, less accumulated amortization
  35,211  48,741 Goodwill
  53,411  55,952 Noncurrent deferred tax assets and other noncurrent tax assets
  1,924  1,855 Other noncurrent assets
  2,799  3,227 Total assets
  $159,422   $171,797  
      Liabilities and Equity
     Short-term borrowings, including current portion of long-term debt: 2018—$4,776; 2017—$3,546
  $8,831  $9,953 Trade accounts payable
  4,674  4,656 Dividends payable
  2,047  2,029 Income taxes payable
  1,265  477 Accrued compensation and related items
  2,397  2,196 Other current liabilities
  10,753  11,115 Liabilities held for sale
  1,890  — Total current liabilities
  31,858  30,427  
      Long-term debt
  32,909  33,538 Pension benefit obligations, net
  5,272  5,926 Postretirement benefit obligations, net
  1,338  1,504 Noncurrent deferred tax liabilities
  3,700  3,900 Other taxes payable
  14,737  18,697 Other noncurrent liabilities
  5,850  6,149 Total liabilities
  95,664  100,141  
      Commitments and Contingencies
     
      Preferred stock, no par value, at stated value; 27 shares authorized; issued:
 2018—-478; 2017—-524  19  21 Common stock, $0.05 par value; 12,000 shares authorized; issued: 2018—-9,332; 2017—-9,275
  467  464 Additional paid-in capital
  86,253  84,278 Treasury stock, shares at cost: 2018—3,615; 2017—-3,296
  (101,610 )  (89,425 ) Retained earnings
  89,554  85,291 Accumulated other comprehensive loss
  (11,275 )  (9,321 ) Total Pfizer Inc. shareholders’ equity
  63,407  71,308 Equity attributable to noncontrolling interests
  351  348 Total equity
  63,758  71,656 Total liabilities and equity
  $159,422   $171,797 Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.72
 
 2018 Financial Report
Consolidated Statements of EquityPfizer Inc. and Subsidiary Companies
 
 
  PFIZER INC. SHAREHOLDERS   
Preferred Stock   Common Stock     Treasury Stock           (MILLIONS, EXCEPT PREFERRED SHARES)
  Shares StatedValue
 Shares ParValue
 Add’lPaid-In
Capital
 Shares Cost  RetainedEarnings
 Accum.Other
Comp.
Loss
 Share -holders’
Equity
 Non-controlling
Interests
 TotalEquity
Balance, January 1, 2016
  649  $26  9,178  $459 $81,016 (3,003)  $(79,252)  $71,993 $(9,522)  $64,720 $278  $64,998Net income
                 7,215     7,215  31  7,246 Other comprehensive income/(loss), net of tax
                    (1,514 )  (1,514)  (3 ) (1,518) Cash dividends declared:
                             Common stock
                 (7,446 )     (7,446)     (7,446) Preferred stock
                 (2 )    (2 )    (2 )Noncontrolling interests
                       —  (10 ) (10 )Share-based payment transactions
      52  3  1,672  (3 ) (111 )       1,563     1,563 Purchases of common stock
            (154 ) (5,000 )        (5,000)     (5,000) Preferred stock conversions and redemptions
  (52 ) (2 )     (2 ) —  —        (5 )    (5 )Other 
(a)    —  —  —  —  —  —  13  —  13  —  13 Balance, December 31, 2016
  597  24  9,230  461  82,685  (3,160)  (84,364 )  71,774  (11,036 )  59,544 296  59,840Net income
                 21,308     21,308 47  21,355Other comprehensive income/(loss), net of tax
                    1,715  1,715  14  1,730 Cash dividends declared:
                             Common stock
                 (7,789 )     (7,789)    (7,789) Preferred stock
                 (1 )    (1 )   (1 )Noncontrolling interests
                       —  (9 ) (9 )Share-based payment transactions 
(b)      45  2  1,597  15  (63 )       1,536     1,536 Purchases of common stock
            (150 ) (5,000 )        (5,000)     (5,000) Preferred stock conversions and redemptions
  (73 ) (3 )     (3 ) —  1        (5 )    (5 )Other
          —  —     —    —  —  — Balance, December 31, 2017
  524  21  9,275  464  84,278  (3,296)  (89,425 )  85,291  (9,321 )  71,308 348  71,656Net income
                 11,153     11,153 36  11,188Other comprehensive income/(loss), net of tax
                    (1,955 )  (1,955)  (20 ) (1,975) Cash dividends declared:
                             Common stock
                 (8,060 )     (8,060)     (8,060) Preferred stock
                 (1 )    (1 )    (1 )Noncontrolling interests
                       —  (12 ) (12 )Share-based payment transactions
      57  3  1,977  (12 ) 13        1,993     1,993 Purchases of common stock
            (307 ) (12,198 )        (12,198)     (12,198) Preferred stock conversions and redemptions
  (46 ) (2 )     (3 ) —  —        (4 )    (4 )Other 
(c)          —  —     1,172     1,172  —  1,172 Balance, December 31, 2018
  478  $19  9,332  $467 $86,253 (3,615)  $(101,610)  $89,554 $(11,275)  $63,407 $351  $63,758(a)
 
Represents the $13 million cumulative effect of the adopti on of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, for certain elements of the accounting for share-based payments. Foradditional information, 
see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation an d Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial Report 
. (b 
) 
2017 treasury shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents th at were scheduled for near-term settlement. These common share equivalents werepaid in the first quar
ter of 2018.(c
)
 
Primarily represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification ofcertain tax effects from 
Accumulated other comprehen sive income . For additional information, see N otes to Consolidated Financial Statements–– Note 1B. Basis of Presentation an d Significant AccountingPolicies: Adoption of
 New Accounting Standards in Pfizer’s 2018 Financial Report. Amounts may not add due to
 rounding.
See Notes to Consolidated Financial Statements, which are an integral part of these statements.2018 Financial Report    
 
 73
Consolidated Statements of Cash FlowsPfizer Inc. and Subsidiary Companies
 
   
  Year Ended December 31, (MILLIONS)
  2018  2017  2016  
         Operating Activities
         Net income before allocation to noncontrolling interests
  $11,188  $21,355  $7,246 Adjustments to reconcile net income before allocation to noncontrolling interests
 to net cash provided by operating activities:       Depreciation and amortization
  6,384  6,269  5,757 Asset write-offs and impairments
  3,398  634  1,613 Loss on sale of HIS net assets
  (1 ) 55  1,712 TCJA impact 
(a)   (596 ) (10,660 )  — Deferred taxes from continuing operations
  (2,205 )  (2,410 )  (700 )Share-based compensation expense
  949  840  691 Benefit plan contributions in excess of expense
  (1,095 )  (961 ) (712 )Other adjustments, net
  (1,268 )  344  487 Other changes in assets and liabilities, net of acquisitions and divestitures:
         Trade accounts receivable
  (644 ) 259  (134 )Inventories
  (717 ) (357 ) 365 Other assets
  (16 ) 7  (47 )Trade accounts payable
  431  46  871 Other liabilities
  98  (67 ) (223 )Other tax accounts, net
  (78 ) 1,446  (734 )Net cash provided by operating activities
  15,827  16,802  16,192  
         Investing Activities
       Purchases of property, plant and equipment
  (2,042 )  (1,956 )  (1,823 ) Purchases of short-term investments
  (11,677 )  (14,596 )  (15,957 ) Proceeds from redemptions/sales of short-
term investments  17,581  10,302  29,414 Net (purchases of)/proceeds from 
redemptions/sales of short-term investments with original maturities of three months or less  (3,917 )  2,058  (4,218 ) Purchases of long-term investments
  (1,797 )  (3,537 )  (8,011 ) Proceeds from redemptions/sales of long-term
 investments  6,244  3,579  11,268 Acquisitions of businesses, net of cash acquired
  —  (1,000 )  (18,368 ) Acquisitions of intangible assets
  (154 ) (261 ) (176 )Other investing activities, net 
(b)   288  671  80 Net cash provided by/(used in) investing activities
  4,525  (4,740 )  (7,791 )  
         Financing Activities
       Proceeds from short-term bor
rowings  3,711  8,464  7,472 Principal payments on short-term borrowings
  (4,437 )  (9,947 )  (5,093 ) Net (payments on)/proceeds from sho
rt-term borrowings with original maturities of three months or less  (1,617 )  1,422  (3,060 ) Proceeds from issuance of long-term debt
  4,974  5,274  10,976 Principal payments on long-term debt
  (3,566 )  (6,154 )  (7,689 ) Purchases of common stock
  (12,198 )  (5,000 )  (5,000 ) Cash dividends paid
  (7,978 ) (7,659 ) (7,317 ) Proceeds from exercise of stock options
  1,259  862  1,019 Other financing activities, net
  (588 ) (611 ) (536 )Net cash used in financing activities
  (20,441 )  (13,350 )  (9,228 ) Effect of exchange-rate changes on cash and cash
 equivalents and restricted cash and cash equivalents  (116 ) 53  (215 )Net decrease in cash and cash equivalents and restricted cash and cash
 equivalents  (205 ) (1,235 )  (1,041 ) Cash and cash equivalents and restricted cash and cash equivalents, beginning
  1,431  2,666  3,707 Cash and cash equivalents and restricted cash and cash equivalents, end
  $1,225  $1,431  $2,666  
- Continued -

 74
 
 2018 Financial Report
Consolidated Statements of Cash FlowsPfizer Inc. and Subsidiary Companies
 
   
  Year Ended December 31,  
  2018  2017  2016 Supplemental Cash Flow Information
       Non-cash transactions:
         Exchange of $1.1 billion net book value 6.50% U.K. pound-denominated bonds ma
turing in 2038 for $1.8 billion of new 2.735% U.K.pound-denominated bonds maturing in 2043, resulting in a debt ex
tinguishment loss of $747 million (c)   $—  $1,848  $— Receipt of ICU Medical common stock 
(b)   —  428  — Promissory note from ICU Medical 
(b)   —  75  — Equity investment in Cerevel Therapeutics, Inc. in exchange for Pfizer’s por
tfolio of clinical and preclinical neuroscience assets (b)   343  —  — Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets 
(b)   92  —  — Cash paid (received) during the period for:
       Income taxes
  $3,655  $2,489  $2,521 Interest
  1,311  1,518  1,451 Interest rate hedges
  (38 ) (199 ) (338 )(a)
 
As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income (i) for the year ended Decemb er 31, 2017 was favorably impacted by approximately $10.7 billion , primarily reflecting the remeasurem
ent of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and (ii) for the year endedDecember 31, 2018 was favor
ably impacted by approximately $600 million , primarily related to certain tax initiativ es associated with the TCJA, as well as favorable adjustments to the provisional estimates of thelegislation. See 
Note 5A. Tax Matters: Taxes on Income from Co ntinuing Operations for additional information. (b)
 
For additional information, see Note 2B. Acquisitions, Divestitures, Assets an d Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-MethodInvestments and Privately Held Investm
ent: Divestitures . (c)
 
The $747 million is included in the net loss of $846 million upon the exchange and early ret irement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Lon g-Term Debt for additional information.
Amounts may not add due to
 rounding.See Notes to Consolidated Financial Statements, which are an integral part of these statements.
2018 Financial Report    
 
 75
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 1 
. Basis of Presentation and Significant Accounting PoliciesA. 
Basis of PresentationSee the Glossary of Defined Terms at the beginning of this 
2018 Financial Report for terms used throughout the consolidated financial statements and related notes in this 2018 
Financial Report. The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the
United States of America (U.S. GAAP). The decision of
 whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economicor other control over the entity. Typically, we do not seek control by means other than vo
ting interests. For subsidiaries operating outside the U.S., the financial information isincluded as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S.
 subsidiaries is as of and for the year ended December 31 for eachyear presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses
have been eliminated. Beginning on January 1, 2018, only taxes paid on intercompany inventory sales transactions are deferred until recognized upon the sale of 
the inventoryto a third party, reflecting the adoption of a new accounting standard in 
the first quarter of 2018. Prior to the adoption of this new accounting standard in the first quarter of2018, taxes paid on intercompany sales transactions were deferred until recognized upon sale of the asset to a 
third party. See Note 1B for further information. From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through 
two distinct business segments: Pfizer InnovativeHealth (IH) and Pfizer Essential Health (EH). For additional information, see 
Note 18 . Certain amounts in the consolidated financial statements and associated notes may not add due to
 rounding. All percentages have been calculated using unrounded amounts.In the first quarter of 2018, as of January 1,
 2018, we adopted eleven new accounting standards. See Note 1B for further information. Our recent significant business development activities include:
•
On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumerhealthcare businesses into a new consumer healthcare joint venture, which will operate globally under the GSK Consumer Healthcare name. Assets and liabilities
associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. We expect to complete
the transaction during the second half of 2019, subject to cus
tomary closing conditions, including GSK shareholder approval and required regulatory approvals.•
On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical, a global device manufacturer, for up to approximately $900 million 
, composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing. HIS includes IV pumps, solutions and devices. The operating results of HIS are included in the consolidated statement of income and 
EH’s operating results through February 2, 2017 and,therefore, our financial results, and EH’s operating results, for the year ended December 31, 2017 reflect approximately one month of HIS
 domestic operations andapproximately two months of HIS international operations, while our financial results, and EH’s operating results, for the year ended December 31, 2016 reflect 12 months of
HIS global operations. Our financial results, and EH’s operating results, for 
2018 do not reflect any contribution from HIS global operations. •
On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights toAstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. for 
$1,040 million , composed of cash and contingent consideration. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and
, in accordance with our international reportingperiod, our financial results, EH’s operating results, and cash flows for the year ended December 31, 2017 reflect approximately 11 months of the small molecule anti-
infectives business acquired from AstraZeneca.
•
On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( 
$13.9 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets , liabilities, operating results and cash flows ofMedivation. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect
approximately three months of Medivation operations.
•
On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion , net of cash acquired), plus 
$698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016
reflect approximately six months of Anacor operations.
•
On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of thecompanies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016
, which the companies concluded qualified as an“Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal
quarter of 2016), Pfizer paid Allergan 
$150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 4 ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement.
For additional information, see 
Note 2 . 76
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
B. 
Adoption of New Accounting Standards in 2018On January 1, 2018, we adopted 
eleven new accounting standards. The quantitative impacts on our prior period consolidated financial statements of adopting the following new standards are summarized in the tables within the section titled 
Impacts to our Consolidated Financial Statements , further below. Revenues 
––We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or
determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount
 that reflects the consideration we expect toreceive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no
 adjustments were made to amounts in our priorperiod financial statements. We recorded the cumulative effect of adopting the standard as
 an adjustment to increase the opening balance of Retained earnings by $584 millionon a pre-tax basis ( 
$450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions –– net primarily forupfront and milestone payments on our collaboration arrangements ( 
$394 million , pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84 million 
(pre-tax) related to the timing of recognizing Revenues and Cost of sales on certain product shipments. The impact of adoption did not have a material impact to our consolidated statement of income for the year ended 
December 31, 2018 nor on our consolidated balance sheet as of December 31, 2018 . For additional information, see Note 1G 
and Note 1H . Financial Assets and Liabilities 
––The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to prior guidance and requires:
•
certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readilydeterminable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the
identical or similar investment of the same issuer;
•
a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and•
separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes tothe financial statements.
We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments
 were made to amounts in our prior period financialstatements. We recorded the cumulative effect of adopting the
 standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax basis ( 
$419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity securities. In 2018, we recorded net unrealized 
gains on equity securities of $477 million , in Other (income)/deductions––net . For additional information, see Note 4 and Note7 
.Presentation of Net Periodic Pension and Postretirement Benefit Cost 
––We adopted a new accounting standard that requires the net periodic pension and postretirement benefit costs other than the service costs be presented in 
Other (income)/deductions––net, and that the presentation be applied retrospectively. We adopted the presentation of the net periodic benefit costs other than service costs by reclassifying these cos
ts from Cost of sales , Selling, informational and administrative expenses , Research anddevelopment expenses 
and Restructuring charges and certain acquisition-related costs to Other (income)/deductions––net . We elected to apply the practical expedient as it is impracticable to determine the disaggregation of the cost components for amounts capitalized within 
Inventories and property, plant and equipment and amortized in each of those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in 
Note 11 to apply the retrospective presentation for comparative periods.
As of January 1, 2018, only service costs will be included in amounts capitalized in 
Inventories or property, plant and equipment, while the other components of net periodic benefit costs will be included in 
Other (income)/deductions –– net . For additional information, see Note 4 and Note 11 . Income Tax Accounting 
––The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, unless the asset transferred is inventory. We adopted
 the standard utilizing the modified retrospective method, and, therefore, no adjustments weremade to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the s
tandard as an adjustment to decrease the opening balance ofRetained earnings 
by $189 million . Accounting for Hedging Activities 
––The standard includes the following changes: •
Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk;•
Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest raterisk;
•
No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedginginstrument with the earnings effect of the hedged item;
•
Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedgeeffectiveness; and
•
Simplifies hedge effectiveness testing.We early adopted the new accounting standard on January 1, 2018 on a prospective basis. 
In 2018, we recorded income of $107 million in Other (income)/deductions –– net ,whereas this item would have been classified in interest income in prior periods. For additional information, see 
Note 7F . 2018 Financial Report    
 
 77
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Reclassification of Certain Tax Effects from AOCI 
––We early adopted a new accounting standard that provides guidance on the reclassification of certain tax ef fects fromAOCI. Under the new guidance, we elected to reclassify the stranded tax amounts
 related to the TCJA from AOCI to Retained earnings . We adopted the new accounting standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as
 an adjustment to increase the opening balance of Retained earnings 
by $495 million , primarily due to the effect of the change in the U. S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application ofthe TCJA was not material to our consolidated financial statements.
Classification of Certain Transactions in the Statement of Cash Flows 
––We retrospectively adopted an accounting standard that changed the presentation of  certaininformation in the consolidated statements of cash flows, including the classification of:
•
debt prepayment and extinguishment costs, resulting in an increase in Operating activities –– Other adjustments, net and a decrease in Financing activities –– Otherfinancing activities, net 
of $7 million for the year ended December 31, 2018 ; and •
accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities –– Other adjustments, net , and an increase in Financing activities 
–– Other financing activities, net of $83 million for the year ended December 31, 2018 . The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon
after a business acquisition date will be classified as 
Investing activities , while payments made thereafter will be classified as Financing activities . Payments made in excess of the amount of the original contingent consideration liability will be classified as 
Operating activities . The adoption of this guidance did not have a material impact to our consolidated financial statements.
Presentation of Restricted Cash in the Statement of Cash Flows 
––We adopted, on a retrospective basis, the new accounting standard, which requires that restricted cash and restricted cash equivalents be included with 
Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the consolidated statements of cash flows. As a result, for the
 year ended December 31, 2018 , $2 million is presented as a decrease in Cash, cash equivalents, restricted cash and restrictedcash equivalents.
Definition of a Business 
––We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If substantially all of the fair value of the gross asse
ts acquired is concentrated in a single identifiable asset, the transaction will not qualifyfor treatment as a business. To be considered a business, a set of
 integrated activities and assets must include, at a minimum, an input and a substantive process that togethersignificantly contribute to the ability to create outputs, without regard as to whether a
 purchaser could replace missing elements. In addition, the definition of the term “output”has been narrowed to make it consistent with the updated revenue recognition guidance. In 2018, 
there was no impact to our consolidated financial statements from theadoption of this new standard.
Derecognition of Nonfinancial Assets 
––We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory. The standard provides that the gain or loss is de
termined by the difference between the consideration received and the carrying value of theasset. In 2018, there was no impact to our consolidated financial statements 
from the adoption of this new standard.Accounting for Modifications of Share-Based Payment Awards 
––We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a share-based payment award be accounted for as a modification. There was no impact to our consolidated financial statements from the adoption o
f this new standard.Impacts to our Consolidated Financial Statements 
––The impacts on our prior period consolidated financial statements of adopting the new standards described above are summarized in the following tables:
Adoption of the standard related to pension and postretirement benefit costs
 impacted our prior period consolidated statements of income as follows: 
  2017 (MILLIONS OF DOLLARS)
  As PreviouslyReported
  Effect of ChangeHigher/(Lower)
  As Restated Cost of sales
  $11,240  $(12 ) $11,228 Selling, informational and administrative expenses
  14,784  20  14,804 Research and development expenses
  7,657  27  7,683 Restructuring charges and certain acquisition-related costs
  487  (136 ) 351 Other (income)/deductions––net
  1,315  101  1,416 Income from continuing operations before provision for 
  taxes on income  12,305  —  12,305  
            2016 (MILLIONS OF DOLLARS)
  As PreviouslyReported
  Effect of ChangeHigher/(Lower)
  As Restated Cost of sales
$ 12,329 $ (7 )$12,322 Selling, informational and administrative expenses
14,837 7 14,844 Research and development expenses
7,872 20 7,892 Restructuring charges and certain acquisition-related costs
1,724 (159 )1,565 Other (income)/deductions––net
3,655 139 3,794 Income from continuing operations before provision for taxes on income
8,351 — 8,351 78
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Adoption of the standards impacted our consolidated balance sheet as follows:
 
     Effect of New Accounting Standards Higher/(Lower)    (MILLIONS OF DOLLARS)
  As PreviouslyReported Balance at
December 31, 2017
  Revenues   Financial Assetsand Liabilities
  Income TaxAccounting
  Reclassification ofCertain Tax Effects
from AOCI
  Balance atJanuary 1,
2018
Trade accounts receivable
  $8,221  $13  $—  $—  $—  $8,234 Inventories
  7,578  (11 ) —  —  —  7,567 Current tax assets
  3,050  (11 ) —  (3 ) —  3,036 Noncurrent deferred tax assets and
other noncurrent tax assets
  1,855  (17 ) —  —  —  1,838 Other noncurrent assets
  3,227  —  —  (204 ) —  3,023 Other current liabilities
  11,115  (123 ) —  —  —  10,992 Noncurrent deferred tax liabilities
  3,900  106  —  (18 ) —  3,988 Other noncurrent liabilities
  6,149  (459 ) —  —  —  5,690 Retained earnings
  85,291  450  419  (189 ) 495  86,466 Accumulated other comprehensive loss
  (9,321 )  —  (419 ) —  (495 ) (10,235 ) 2018 Financial Report    
 
 79
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Adoption of the standards related to the classification of certain transactions in 
the statements of cash flows and the presentation of restricted cash in the statement of cashflows impacted our consolidated statement of cash flows as follows:
 
  2017  
     Effect of New Accounting Standards Inflow/(Outflow)    (MILLIONS OF DOLLARS)
  As PreviouslyReported
  Cash Flow Classification  Restricted Cash   As Restated Operating Activities
            Other adjustments, net
  $50  $294  $—  $344 Other changes in assets and liabilities, net of acquisitions and
divestitures––Other assets
  (31 ) —  38  7 Investing Activities
            Proceeds from redemptions/sales of short-term investments
  10,307  —  (5 ) 10,302 Proceeds from redemptions/sales of long-term investments
  3,594  —  (14 ) 3,579 Other investing activities, net
  650  21  —  671 Financing Activities
            Principal payments on short-term borrowings
  (9,990 )  43  —  (9,947 ) Net proceeds from short-term borrowings with original maturities
of three months or less
  1,401  20  —  1,422 Other financing activities, net
  (233 ) (378 ) —  (611 )Net decrease in cash and cash equivalents and restricted cash
and cash equivalents
  (1,254 )  —  19  (1,235 ) Cash and cash equivalents and restricted cash and cash
equivalents, beginning
  2,595  —  70  2,666 Cash and cash equivalents and restricted cash and cash
equivalents, ending
  1,342  —  89  1,431  
               2016  
     Effect of New Accounting Standards Inflow/(Outflow)    (MILLIONS OF DOLLARS)
  As PreviouslyReported
  Cash Flow Classification  Restricted Cash   As Restated Operating Activities
            Other adjustments, net
  $208  $278  $—  $487 Other changes in assets and liabilities, net of acquisitions and
divestitures––Other assets
  (60 ) —  13  (47 )Investing Activities
            Proceeds from redemptions/sales of short-term investments
  29,436  —  (22 ) 29,414 Proceeds from redemptions/sales of long-term investments
  11,254  —  14  11,268 Other investing activities, net
  51  28  —  80 Financing Activities
            Principal payments on short-term borrowings
  (5,102 )  9  —  (5,093 ) Net (payments on)/proceeds from short-term borrowings with
original maturities of three months or less
  (3,084 )  24  —  (3,060 ) Other financing activities, net
  (196 ) (340 ) —  (536 )Net decrease in cash and cash equivalents and restricted cash
and cash equivalents
  (1,046 )  —  5  (1,041 ) Cash and cash equivalents and restricted cash and cash
equivalents, beginning
  3,641  —  65  3,707 Cash and cash equivalents and restricted cash and cash
equivalents, ending
  2,595  —  70  2,666 80
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet that sum to the
 total of the sameamounts shown in the consolidated statements of cash flows:
(MILLIONS OF DOLLARS)
  December 31,2018
 December 31, 2017
Cash and cash equivalents
  $1,139  $1,342 Restricted cash and cash equivalents in 
Short-term investments   32  — Restricted cash and cash equivalents in 
Long-term investments   55  — Restricted cash and cash equivalents in 
Other current assets   —  14 Restricted cash and cash equivalents in 
Other noncurrent assets   —  75 Total cash and cash equivalents and restricted cash and cash equivalents shown in the consolidated balance sheets
  $1,225  $1,431 Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of P
fizermedicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines.
C. Estimates and Assumptions
In preparing the consolidated financial statements, we use certain estimates and assumptions that affec
t reported amounts and disclosures, including amounts recorded anddisclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated
statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks,
 sales allowances and sales returns), determining thecost of inventory that is sold, allocating cost in the form of depreciation and amortization, and
 estimating restructuring charges and the impact of contingencies, as well asdetermining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as
accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and
 estimates are used indetermining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales
returns, and restructuring reserves, all of which also impact the consolidated statements of income.
Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but
 that can be inherently uncertain and unpredictable. If ourestimates and assumptions are not representative of actual outcomes, our results could be materially impacted.
As future events and their effects cannot be
 determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events andcircumstances may occur that might cause us to change those estimates and assumptions. We are subject
 to risks and uncertainties that may cause actual results to differfrom estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and
assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts
 and circumstances indicate the need forchange.
For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements–– 
Note 5A . Tax Matters: Taxes on Income fromContinuing Operations.
D. Acquisitions
Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We accoun
t for acquired businesses using theacquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of 
theacquisition date and that the fair value of acquired IPR&D be recorded on the balance shee
t. Transaction costs are expensed as incurred. Any excess of the considerationtransferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that
 do not constitute a business, as defined in U.S.GAAP, no goodwill is recognized and acquired IPR&D is expensed.
Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date
. Fair value is generallyestimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date
until the contingency is resolved. These changes in fair value are recognized in earnings in 
Other (income)/deductions––net . Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. E. Fair Value
We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair
value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting
of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to
sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the
2018 Financial Report    
 
 81
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and af
ter the transfer.When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of 
the following techniques:•
Income approach, which is based on the present value of a future stream of net cash flows.•
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.•
Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.Our fair value methodologies depend on the following types of inputs:
•
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).•
Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other thanquoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means
(Level 2 inputs).
•
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and
 can rely heavily on estimates and assumptions. Forinformation about the risks associated with estimates and assumptions, see 
Note 1C. F. Foreign Currency Translation
For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their
U.S. dollar equivalents at exchange rates in effect as of the
 balance sheet date and we translate functional currency income and expense amounts to their U.S. dollarequivalents at average exchange rates for the period. The U.S. dollar effects 
that arise from changing translation rates are recorded in Other comprehensive income/(loss) . The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in 
Other (income)/deductions––net . For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet da
te, with translation adjustments recorded in Other (income)/deductions–– net 
, and we translate non-monetary items at historical rates.G 
. Revenues and Trade Accounts ReceivableOn January 1, 2018, we adopted a new accounting standard for revenue recognition. For further information, see 
Note 1B . We recorded direct product sales and/or alliance revenues of more than 
$1 billion for each of ten products in 2018 and for each of nine products in 2017 and 2016 . In the aggregate, these direct products sales and/or alliance product revenues represent 
51% of our revenues in 2018 , 46% of our revenues in 2017 and 43% of our revenues in 2016 
. See Note 18C for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets
begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business includes OTC brands with a focus on dietary supplements, pain
management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a
 much lesser extent,consumer healthcare products worldwide to developed and emerging market countries.
Revenue Recognition 
––We record revenues from product sales when there is a transfer of control of the product from us to  the customer. We determine transfer of controlbased on when the product is shipped or delivered and title passes to the customer.
•
Customers ––Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and
integrated delivery networks. Our consumer healthcare customers include retailers and, to a lesser extent, wholesalers and distributors.
Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs,
including those managed through pharmacy benefit managers, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales
allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented
 or unpatented).•
Our Sales Contracts ––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales 
are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of  exclusivity,product recalls or a changing competitive environment.
•
Deductions from Revenues –– Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that therevenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the
related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.
Specifically:
•
In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managersand legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We
record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions
written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is
82
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D
participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the
utilization that is expected to result from the discount in the coverage gap. We
 evaluate this estimate regularly to ensure that the historical trends and future expectations areas current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.
•
Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales withineach period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s to
tal unbudgetedpharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of
reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.
•
Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amountsincurred, as we settle these deductions generally within two to five weeks of incurring the liability.
•
Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices;historical returns as a percentage of sales; an understanding of the reasons for past returns; es
timated shelf life by product; an estimate of the amount of time betweenshipment and return or lag time; and any other factors that could impact the estimate o
f future returns, such as loss of exclusivity, product recalls or a changing competitiveenvironment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.
•
We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate thecost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.
Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and
cash discounts totaled 
$5.4 billion as of December 31, 2018 and $4.9 billion as of December 31, 2017 . The following table provides information about the balance sheet classification of these accruals:
  
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017 Reserve against 
Trade accounts receivable, less allowance for doubtful accounts   $1,288  $1,352  
      Other current liabilities :       Accrued rebates
  3,208  2,674 Other accruals
  531  512  
      Other noncurrent liabilities  399  385 Total accrued rebates and other accruals
  $5,426  $4,923 The accrued rebates increased from the prior year-end due to an increase in Medicare rebates driven by increased sales of IH products through this channel.
Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can
 rely heavily on estimates andassumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from 
Revenues . Trade Accounts Receivable 
—Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other
current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been
exhausted.
H. Collaborative Arrangements
Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature o
f the arrangement (including its contractualterms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as
alliance revenues, a component of 
Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable
period. The related expenses for selling and marketing these products are included in 
Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration
arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty
payments to collaboration partners as 
Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net. Reimbursements to or from our collaboration partners for development costs are recorded net in 
Research and development expenses . Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as 
Research and development expenses . Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in 
Identifiable intangible assets—Developed technology rights . Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in 
Other (income)/deductions—net over the development period for the collaboration products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval
milestone payments earned by us may be recognized in 
Other (income)/deductions—net immediately when 2018 Financial Report    
 
 83
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a
medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may
recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be
probable of a significant reversal.
On January 1, 2018, we adopted a new accounting standard on revenue recognition (see 
Note 1B ). As a result of the adoption, we recognized the following cumulative effect adjustments related to collaboration arrangements to 
Retained earnings : •
$394 million (pre-tax) for collaborative arrangements where upfront, pre-approval and regulatory approval milestone payments received from our collaboration partners are recognized in 
Other (income)/deductions—net over a reduced period. Under the new standard, the income from upfront and pre-approval milestone payments due to us is typically recognized over the development period for the collaboration when our performance obligation, in addition to granting a license, is to provide R&D services to our
collaboration partners, and major regulatory approval milestones are typically recognized immediately when earned as the related development period has ended. The
income from upfront and milestone payments is typically recognized immediately as earned if our performance obligation, in addition to granting a license, is only for
commercialization activities. Under the old standard, this income was recognized over the combined development and estimated commercialization (including co-promotion)
period for the collaboration products.
•
$82 million (pre-tax) for collaborative arrangements where we manufacture products for our collaboration partners and recognize Revenues and Cost of sales for product shipments at an earlier point in time. Under the new standard, revenue is recognized when we transfer control of the products to our collaboration partners. Under the old
standard, revenue was recognized when our collaboration partners sell the products and transfer title to their third party customers.
I. Cost of Sales and Inventories
We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We
regularly review our inventories for impairment and reserves are established when necessary.
J. Selling, Informational and Administ
rative ExpensesSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising,
shipping and handling, information technology and legal defense. Advertising expenses totaled approximately 
$3.1 billion in 2018 , $3.1 billion in 2017 and $3.2 billion in 2016 . Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs.
K. Research and Development Expenses
R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs
 incurred in connection with certain licensingarrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as
expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives
regulatory approval, we record any milestone payments in 
Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
R&D expenses related to upfront and milestone payments for intellectual property rights totaled 
$197 million in 2018 , $169 million in 2017 and $82 million in 2016 . For additional information, see 
Note 2E . L. Amortization of Intangible Asse
ts, Depreciation and Certain Long-Lived AssetsLong-lived assets include:
•
Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any  significant improvements afterpurchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on
 a straight-line basis over the estimated useful life of theindividual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.
•
Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at fair value. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can
be determined.
•
Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets . Goodwill is not amortized.Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds
and intellectual property is included in 
Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in 
Cost of sales, Selling, informational and administrative expenses 
and/or Research and development expenses, as appropriate. We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least
annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the
amount by which the fair value is less than the carrying value of these assets.
84
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Specifically:
•
For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairmentindicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset
, or asset group, and compare this estimated amount to thecarrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book
 value over fair value. In addition, in all cases of animpairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.
•
For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, forthe excess of book value over fair value. In addition, in all cases of an impairment review other than for I
PR&D assets, we re-evaluate whether continuing to characterize theasset as indefinite-lived is appropriate.
•
For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, wethen determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of 
the reporting unit andrecord an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.
Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about
the risks associated with estimates and assumptions, see 
Note 1C. M. Restructuring Charges and 
Certain Acquisition-Related CostsWe may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our
cost-reduction and productivity initiatives. Included in 
Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of
 an asset, that incremental impact isclassified in 
Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business
acquisition are expensed as incurred 
. Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events
 and uncertainties and can relyheavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. N. Cash Equivalents and Statement of 
Cash FlowsOn January 1, 2018, we adopted standards related to the classification of
 certain transactions in the statements of cash flows and the presentation of restricted cash in thestatement of cash flow. For further information, see 
Note 1B . Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. 
Ifitems meeting this definition are part of a larger investment pool, we classify them as 
Short-term investments . Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the
classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the na
ture of thehedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to 
their purpose and accountingnature.
O. Investments and Derivative Financial Instru
mentsOn January 1, 2018, we adopted new accounting standards for financial assets and liabilities as well as accounting for hedging activities. For further information, see 
Note 1B . Our investments are comprised of the following: trading funds and securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and
ability to hold the investment to maturity) and private equity securities. The classification of an investment can depend on
 the nature of the investment, our intent and ability tohold the investment, and the degree to which we may exercise influence.
•
Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net. •
Available-for-sale debt securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized. •
Held-to-maturity debt securities are carried at amortized cost.•
Private equity securities are carried at equity-method or at cost. For additional information, see Note 1B. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of
 the investee’s income andexpenses in 
Other (income)/deductions—net . The excess of the cost of the  investment over our share of the equity of the investee as of the acquisition date is allocated tothe identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not
include amounts of contingent consideration.
Realized gains or losses on sales of investments are determined by using the specific identification cost method.
We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-
than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
2018 Financial Report    
 
 85
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Derivative financial instruments are carried at fair value in various balance sheet categories (see 
Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in 
Other comprehensive income/(loss) (see Note 7F ). A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. P. Tax Assets and Liabilities and Income Tax Contingencies
On January 1, 2018, we adopted new accounting standards for income tax accounting as
 well as reclassification of certain tax effects from AOCI. For further information, seeNote 1B 
. Current tax assets primarily includes income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax
obligations.
Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between 
the financial reporting and tax bases of assets and liabilitiesusing enacted tax rates and laws, including the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets
 are notrecoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, 
that would be implemented, ifnecessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net
 amount in the noncurrent section ofour consolidated balance sheet.
Other taxes payable in our consolidated balance sheet as of December 31, 2018 includes liabilities for uncertain tax positions and the noncurrent portion of 
the repatriation taxliability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we plan to elect, with the filing of our 2018 U.S.
Federal Consolidated Income Tax Return, payment over eight years through 2026. See 
Note 5A for additional information. We account for income tax contingencies using a benefit recognition model. If we consider that a 
tax position is more likely than not to be sustained upon audit, based solely onthe technical merits of the position, we recognize the benefit. We measure the benefit
 by determining the amount that is greater than 50% likely of being realized uponsettlement, presuming that the tax position is examined by the appropriate taxing authority that
 has full knowledge of all relevant information.Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the
tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of 
theposition to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of tha
t tax year with theappropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and
 local and foreign income tax filings, statute of limitationsexpirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-
than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12
 months. Interest andpenalties, if any, are recorded in 
Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability. Amounts recorded for valuation allowances and income tax contingencies can result from a complex series of judgments about future events and uncertainties and can rely
heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. Q. Pension and
 Postretirement Benefit PlansOn January 1, 2018, we adopted a new accounting standard for the
 presentation of net periodic pension and postretirement benefit cost. For further information, see Note 1B . The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have
 both IRC-qualified andsupplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for
retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined bene
fit plans as an asset or liability on our consolidatedbalance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable
benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension
plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to
the expected cost of providing medical insurance benefits, as well as the extent to which those
 costs are shared with the employee or others (such as governmental programs).Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the
 service costs are recognized in Other (income)/deductions—net . Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and
 uncertainties and can rely heavily onestimates and assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C. 86
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
R. Legal and Environmental Contingencies
We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other
product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for
these contingencies to the extent that we conclude tha
t a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimatethan any other amount within the range, we accrue that amount. Alternatively, when no
 amount within a range of loss appears to be a better estimate than any other amount,we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
 assumptions.For information about the risks associated with estimates and assumptions, see 
Note 1C. S. Share-Based Payments
Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values
are generally amortized on a straight-line basis over the vesting terms into 
Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses 
, as appropriate. Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see 
Note 1C . Note 2 
. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research andDevelopment and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment
A. Acquisitions
AstraZeneca’s Small Molecule Anti-Infectives Business (EH)
On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s
small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the marketed products Zavicefta™ (ceftazidime-
avibactam), Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). In 2017,
under the terms of the agreement, we made payments of approximately 
$605 million to AstraZeneca related to the transaction. We made an additional milestone payment of $125 million 
in our first fiscal quarter of 2018 and we made a deferred payment of $175 million to AstraZeneca in January 2019. In addition, we may be required to pay an additional milestone payment of 
$75 million if the related milestone is achieved prior to December 31, 2021, and up to $600 million if sales of Zavicefta™ exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta™ and ATM-AVI in certain markets for a
 period ending on the later of 10 years from firstcommercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted
payments are expected to be in the range of approximately 
$327 million to $553 million . The total fair value of consideration transferred for AstraZeneca’s small molecule anti- infectives business was approximately 
$1,040 million inclusive of cash paid of $555 million and the fair value of contingent consideration of $485 million (which is composed of the deferred payment, the 
$50 million milestone payment made in the second quarter of 2017, the $125 million milestone payment made in our first fiscal quarter of 2018 and the future expected milestone and royalty payments). In connection with this acquisition, we recorded 
$894 million in Identifiable intangible assets , consisting of $728 million in Developed technology rights 
and $166 million in IPR&D . We also recorded $92 million in Other current assets related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, 
$73 million in Goodwill and $19 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
Medivation, Inc. (IH)
On September 28, 2016, we acquired Medivation for 
$81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion 
, net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities. The remaining consideration was paid as of 
December 31, 2017 . Medivation is a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps
in the androgen receptor signaling pathway within tumor cells. Xtandi is approved for the treatment of castration-resistant prostate cancer. In
 the third quarter of 2018, upon theapproval of Xtandi in the U.S. for the treatment o
f men with non-metastatic castration-resistant prostate cancer, we transferred the remaining IPR&D value of Xtandi to Developed technology rights 
(see Note 10A ). Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. The Medivation portfolio also includes talazoparib, which was approved by the FDA in October 2018
, under the trade name Talzenna, for thetreatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other types of cancer. In
connection with this acquisition, we recorded 
$12.2 billion in Identifiable intangible assets , primarily consisting of $8.1 billion of Developed technology rights with an average useful life of approximately 
12 years and $4.1 billion of IPR&D, and recorded $6.1 billion of Goodwill, $4.0 billion of net income tax liabilities, and $259 million of assumed contingent consideration of which 
$35 million has been paid through December 31, 2018. In 2017 and 2016, we recorded measurement period adjustments to the es timatedfair values initially recorded in 2016, which resulted in a reduction in 
Identifiable intangible assets of approximately $1.0 billion with a corresponding change to Goodwill and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the
acquisition date. The 2017 results included a decrease of approximately 
$38 million to Amortization of intangible assets which reflected the cumulative pre-tax impact of the measurement period adjustments to 
Identifiable intangible assets that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result
2018 Financial Report    
 
 87
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to
 the assets acquired and the liabilities assumed has beencompleted.
Bamboo Therapeutics, Inc. (IH)
On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the po
tential treatmentof patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for 
$150 million , plus potential milestone paymentsof up to 
$495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately 
$343 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $167 million , consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of 
$45 million . We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately 
$43 million . Upon acquiring the remaining interest in Bamboo in the third quarter of 2016, we recognized a gain of $2 million 
on our existing investment in Other (income)/deductions––net over the one-year allocation period . This acquisition provides us with several clinical and pre-clinicalassets that complement our rare disease portfolio, an advanced recombinant Adeno-associated virus vector design and production technology, and a fully functional Phase
 I/IIgene therapy manufacturing facility. Bamboo is a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded 
$330 million of Identifiable intangibleassets, 
consisting entirely of IPR&D. We also recorded $142 million of Goodwill and $94 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
Anacor Pharmaceuticals, Inc. (IH)
On June 24, 2016, we acquired Anacor for 
$99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus 
$698 million debt assumed. Anacor is a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. 
Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA in December 2016 under the trade name, Eucrisa 
. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and recorded $4.9 billion 
in Identifiable intangible assets , primarily consisting of $4.8 billion of IPR&D , and recorded $646 million of Goodwill and $346 million of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.
B. Divestitures
Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)
On October 6, 2016, we announced that we entered into
 a definitive agreement under which ICU Medical agreed to acquire all of our global infusion systems net assets, HIS,for approximately 
$1 billion in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result o f the performance of HIS relative to ICUMedical’s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately 
$900 million 
, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. The revised transaction closed on February 3, 2017. At closing, we received 
3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately 
$428 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which were reported as equity securities at fair value in 
Long-term investments on the consolidated balance sheet as of December 31, 2017. Upon the sale of  these shares in 2018,we realized a full gain of 
$302 million on these securities, although our income statement only reflects a gain of $47 million as the balance of the previously unrealized gain was recorded as a cumulative effect adjustment upon the adoption of a new accounting s
tandard (see Note 1B ). We also received a promissory note in the amount of $75 million , which was repaid in full as of December 31, 2017, and net cash of approximately 
$200 million before customary adjustments for net working capital, which is reported in Other investing activities, net 
on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up toan additional 
$225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. We recognized a pre-tax gain of approximately 
$1 million in 2018 and pre-tax losses of $55 million in 2017 in Other (income)/deductions––net, representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to
 sell. For additional information, see Note 4 . The sale of the HIS net assets was fully completed in all jurisdictions as of year-end 2018.
In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of 
the HIS net assets to ICU Medical. Theseagreements primarily related to administrative services, and were provided for a period of 24 months after the closing date. We will also manufacture and supply certain HIS
products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These
agreements are not material to Pfizer and none confers upon us the ability to influence the operating and
/or financial policies of ICU Medical subsequent to the sale.At 
December 31, 2016 , we determined that the carrying value of the HIS net assets  held for sale exceeded their fair value less estimated costs to sell, resulting in a pre-taximpairment charge of 
$1.7 billion , which is included in Other (income)/deductions––net for the year ended December 31, 2016 (see Note 4 ). The decline in value resulted from lower expectations as to future cash flows to be generated by HIS,
 primarily as a result of an increase in competition for customer contracts and pricing factors that were notinitially anticipated.
Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc. (WRD)
In April 2018, Pfizer and Allogene announced that the two companies entered into a
 contribution agreement for Pfizer’s portfolio of assets related to allogeneic CAR T therapy,an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene received from Pfizer rights to pre-clinical and clinical CAR T assets, all of
which were previously licensed to Pfizer from French cell therapy company, Cellectis, beginning in 2014 and French pharmaceutical company, Servier, beginning in 2015.
Allogene assumed responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer will continue to participate financially in the development of the CAR T
portfolio through an ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate 
7% ownership stake in Cellectis that88
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T
therapies in exchange for an upfront payment of 
$80 million , as well as potential future development, regulatory and commercial milestone payments and royalties. In connection with the Allogene transaction, Pfizer recognized a non-cash 
$50 million pre-tax gain in Other (income)/deductions––net in the second quarter of 2018 , representingthe difference between the 
$127 million fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see Note 4 ). In October 2018, Allogene consummated an initial public offering of new shares of its common stock, which resulted in Pfizer’s preferred stock converting into common stock
and a decrease in our ownership percentage from approximately 
25% to approximately 18% as of December 31, 2018. The closing price on the day of the initial public offering was 
$25 per share. Beginning as of the date of the initial public offering, our investment in Allogene is being measured at fair value with changes in fair value recognized in netincome (see 
Note 4 ). Sale of Phase 2b Ready AMPA Receptor Potentiator for CI
AS to Biogen Inc. (WRD)In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIA
S to Biogen. We received $75 million upfront and have the opportunity to receive up to $515 million 
in future development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized the $75 million upfront payment in 
Other (income)/deductions––net in the second quarter of 2018 (see Note 4 ). In the fourth quarter of 2018, we recognized an additional $10 million milestone in Other (income)/deductions––net 
(see Note 4). We will record the other milestones and royalties to Other (income)/deductions––net when due, or earlier if we have sufficient experience to determine such amounts are not probable of significant reversal.
Divestiture of Neuroscience Assets (WRD)
In September 2018, we and Bain Capital entered into a transaction to create a
 new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical andpreclinical stage neuroscience assets primarily targeting disorders of the central nervous system including Parkinson’s disease, epilepsy, Alzheimer’s disease, schizophrenia
and addiction. These assets were part of the neuroscience discovery and early development efforts, which we announced we were ending in January 2018. In
 connection withthis transaction, we out-licensed the portfolio to Cerevel in exchange for a 
25% ownership stake in Cerevel’s parent company, Cerevel Therapeutics, Inc., and potential future regulatory and commercial milestone payments and royalties. Bain Capital has committed to invest 
$350 million to develop the portfolio, with the potential for additional funding as the assets advance. In connection with the transaction,
 we recognized a non-cash $343 million pre-tax gain in Other (income)/deductions––net in the third quarter of 2018, representing the fair value of the equity investment received as the assets transferred 
had a book value of $0 (see Note 4 ). Our investment in Cerevel Therapeutics, Inc. is reported in 
Long-term investments on the consolidated balance sheet as of December 31, 2018. C. 
Assets and Liabilities Held for SaleOn December 19, 2018, we announced that we entered into a definitive agreement with GS
K under which we and GSK have agreed to combine our respective consumerhealthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name. In exchange for contributing our
Consumer Healthcare business, we will receive a 
32% equity stake in the company and GSK will own the remaining 68% . The transaction is expected to close in the second half of 2019, subject to customary closing conditions including GSK shareholder approval and required regulatory approvals. Upon the closing of the transaction, we will
deconsolidate our Consumer Healthcare business and recognize a gain for the difference in the fair value of our 
32% equity stake in the company and the carrying value of our Consumer Healthcare business. We will account for our 
32% equity stake in the company after closing of the transaction as an equity-method investment . Assets and liabilitiesassociated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. The Consumer Healthcare
business assets held for sale are reported in 
Assets held for sale and Consumer Healthcare business liabilities held for sale are reported in Liabilities held for sale . This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries. The amounts associated with the Consumer
Healthcare business, as well as other assets classified as held for sale consisted of the following:
2018 Financial Report    
 
 89
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
 
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017 Assets Held for Sale
      Cash and cash equivalents
  $32  $— Trade accounts receivable, less allowance for doubtful accounts
  532  — Inventories
  538  — Other current assets
  56  — PP&E
  675  — Identifiable intangible assets, less accumulated amortization
  5,763  — Goodwill
  1,972  — Noncurrent deferred tax assets and other noncurrent tax assets
  54  — Other noncurrent assets
  57  — Total Consumer assets held for sale
  9,678  — Other assets held for sale 
(a)  46  12 Assets held for sale
  $9,725  $12  
      Liabilities Held for Sale
       
      Trade accounts payable
  $406  $— Income taxes payable
  39  — Accrued compensation and related items
  93  — Other current liabilities
  353  — Pension benefit obligations, net
  39  — Postretirement benefit obligations, net
  33  — Noncurrent deferred tax liabilities
  870  — Other noncurrent liabilities
  56  — Total Consumer liabilities held for sale
  $1,890  $— (a) 
 Other assets held for sale consist of PP&E.As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was 
$977 million in 2018, $863 million in 2017 and $780 million 
in 2016. D. Licensing Arrangements
Shire International GmbH (IH)
In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative
colitis and Crohn’s disease, to Shire for an upfront payment of 
$90 million , up to $460 million in development and sales-based milestone payments and potential future royalty payments on commercialized products. The 
$90 million upfront payment was initially deferred and recognized in Other (income)/deductions––net ratably through December 2017. In the first quarter of 2018, we recognized 
$75 million in Other (income)/deductions––net for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis, and in 
the third quarter of 2018, we recognized $35 million in Other(income)/deductions––net 
for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment ofCrohn’s disease (see 
Note 4 ). BionTech AG (WRD)
In August 2018, a multi-year R&D arrangement went into effect between BionTech A
G (BionTech), a privately held company, and Pfizer to develop mRNA-based vaccines forprevention of influenza (flu). In September 2018, we made an upfront payment of 
$50 million to BionTech, which was recorded in Research and development expenses, and BionTech is eligible to receive up to an additional 
$325 million in future development and sales based milestones and future royalty payments associated with worldwide sales. As part of the transaction, we also purchased 
169,670 newly-issued ordinary shares of BionTech for $50 million in the third quarter of 2018, which are reported in Long-term investments 
in the consolidated balance sheet as of December 31, 2018. E. Research and Development and Collabo
rative ArrangementsWe adopted a new accounting standard for revenue recognition and changed our accounting policies with respect to collaborative arrangements accordingly. For additional
information, see 
Note 1B . Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P.
On November 1, 2016, we announced the discontinuation of the global clinical development program for bococizumab. During December 2016, 
$31.3 million was refunded to NovaQuest representing amounts NovaQuest prepaid for development costs (under the May 2016 agreement described below) that were not used for program expenses due
to the discontinuation of the development program. No additional payments have been or are expected to be
 received from or paid to NovaQuest with respect to thisagreement, which was terminated effective as of November 18, 2016.
90
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to 
fund up to $250 million in development costs related to certain Phase 3 clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound.
NovaQuest’s development funding was expected to cover up to 
40% of the development costs and was to be received over five quarters during 2016 and 2017. As there was asubstantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses during 2016 was recognized as an obligation to
 performcontractual services and therefore has been recognized as a reduction of 
Research and development expenses as incurred. The reduction to Research and development expenses 
for 2016 totaled $180.3 million . Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.
In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to 
$200 million in development costs related to certain Phase 3 clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s
development funding is expected to cover up to 
100% of the development costs and will be received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer will be responsible for the remaining development costs. As there is a substantive and genuine transfer of risk to NovaQues
t, the development fundingis recognized by us as an obligation to perform contractual services and therefore is a reduction of 
Research and development expenses as incurred. The reduction to Research and development expenses 
totaled $57.6 million for 2018, $72.1 million for 2017 and $46.6 million for 2016. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately 
$267 million in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets
and amortized to 
Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when incurred.
Research and Development Arrangement with RPI Finance Trust
In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI
 would fund up to $300 million in development costs related to certain Phase 3 clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI’s
development funding is expected to cover up to 
100% of the costs primarily for the applicable clinical trials until the second quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a substantive and genuine 
transfer of risk to RPI, the development funding is recognized by us as an obligation to performcontractual services and therefore is a reduction of 
Research and development expenses as incurred. The reduction to Research and development expenses totaled $99.3 million 
for 2018, $75.6 million for 2017 and $44.9 million for 2016. If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indicationbased on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to 
$250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and
amortized to 
Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred.
Collaborative Arrangements
In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of
research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or
commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the ac
tivity. Our rights andobligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and
we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.
The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
 
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Revenues 
—Revenues (a)  $571  $606  $659 Revenue 
s—Alliance revenues (b)  3,838  2,927  1,746 Total revenues from collaborative arrangements
  4,409  3,533  2,405 Cost of sales 
(c)  (296 ) (329 ) (315 )Selling, informational and administrative expenses 
(d)  (90 ) (54 ) (5 )Research and development expenses 
(e)  162  222  64 Other income/(deductions)—net 
(f)  281  249  542 (a) 
 Represents sales to our partners of products manufactured by us.(b) 
 Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.(c)
 
Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated withinventory purchased from
 our partners.(d) 
 Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.(e)
 
Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $50 million in 2018 , $15million 
in 2017 and $15 million in 2016 . Our collaboration with Lilly (see b elow) also includes reimbursements of $98 million in 2018, $147 million in 2017 and $120 million in 2016. (f) 
 Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada,partially offset by a full year of royalti
es earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.2018 Financial Report    
 
 91
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated
 with the products underthe collaborative arrangements.
In addition, in connection with our collaborative arrangements, we paid post-approval milestones of 
$140 million in 2017 related to our collaboration with Merck KGaA (see below). These payments were recorded in 
Identifiable intangible assets –– Developed technology rights. We did not pay post-approval milestones to collaboration partners in 2018 or 2016. We also recorded milestones earned related to our collaboration with Merck (see below) of 
$40 million in 2018 to Other (income)/deductions––net and $150million 
in 2017, substantially all of which was included in the adjustment to increase the opening balance of Retained earnings upon the adoption of a new accounting standard for revenue recognition, effective January 1, 2018 (see 
Note 1B ). Collaboration with Merck & Co., Inc. (IH)
Under a worldwide collaboration agreement, except for Japan, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose
combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the European Commission in March 2018 as Steglatro,
Segluromet and Steglujan. Merck exclusively promotes Steglatro and the two fixed-dose combination products and we share revenues and certain costs with Merck on a 
60% / 40% 
basis, with Pfizer having the 40% share. In the first quarter of 
2017 , we received a $90 million milestone payment from Merck upon the FDA’s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in 
Other noncurrent liabilities, 
and through December 31, 2017, was being recognized in Other (income)/deductions––net over a multi-year period. As of December 31, 2017, we were due a $60 million 
milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As o f December 31, 2017, the$60 million 
due from Merck was deferred and primarily reported in Other noncurrent liabilities . In the first quarter of 2018, in connection with the  approval of ertugliflozin in theEU, we recognized a 
$40 million milestone payment from Merck in Other (income)/deductions––net (see Note 4 ). We are eligible for additional payments associated with the achievement of future commercial milestones. In the first quarter of 2018, in connection with the adoption o
f a new accounting standard, as of January 1, 2018, the $60 million of deferred income and approximately 
$85 million of the $90 million of deferred income associated with the above-mentioned milestone payments were recorded to and included in the 
$584 million cumulative effect adjustment to Retained earnings . See Note 1B for additional information. Collaboration with Eli Lilly & Company (IH)
In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will equally
share product-development expenses as well as potential revenues and certain product-related costs. We received a 
$200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in 
Other noncurrent liabilities, and through December 31, 2017, was being recognized in 
Other (income)/deductions––net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015. The FDA granted Fast Track designation for tanezumab for the treatment
 of chronic pain in patients with osteoarthritis A and chronic lowback pain in June 2017. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory
and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accoun
ting standard, as of January 1, 2018, approximately $107 million of deferred income associated with the above-mentioned upfront payment was recorded to and included in the 
$584 million cumulative effect adjustment to Retained earnings . See 
Note 1B for additional information. Approximately $37 million of the upfront payment continues to be deferred, of  which approximately $30 million is reported in Other current liabilities 
and approximately $8 million is reported in Other noncurrent liabilities as of December 31, 2018. This amount is expected to be recognized in Other (income)/deductions––net 
over the remaining development period for the product between 2019 and 2020. Collaboration with Merck KGaA (IH)
In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, currently approved as Bavencio for
metastatic MCC and for patients with locally advanced or metastatic UC in certain countries and in development as a potential treatment for multiple other types of
 cancer. Weand Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA’s
broad portfolio of approved and investigational oncology therapies. Also, as part of the agreement, we gave Merck K
GaA certain co-promotion rights for Xalkori in the U.S. andseveral other key markets. Under the terms of the agreement, in the fourth quarter of
 2014, we made an upfront payment of $850 million to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately 
$2.0 billion . During 2017, we made $140 million in milestone payments to Merck KGaA, which were recorded in 
Identifiable intangible assets –– Developed technology rights, for approvals of avelumab received in 2017 for the MCC indication in the U.S., the EU and Japan, and for the metastatic UC indication in the U.S. 
Both companies jointly fund the majority of development and commercialization costs, and split equally any profits generated from selling any products containing avelumab from this collaboration. 
In September 2018, the companies announced positive top-line results from the pivotal Phase 3 JAVELIN Renal 101 study evaluating Bavencio (avelumab) in combination with Inlyta (axitinib), compared with Sutent (sunitinib) as initial therapy for patients with
advanced RCC. In December 2018, both companies amended the collaborative agreement such that Pfizer will be solely responsible for the development and
commercialization of its anti PD-1 antibody. Under the terms of the amended agreement, Pfizer paid Merck KGaA an up-front payment
 and we will make a potential milestoneand tiered royalty payments should the Pfizer anti PD-1 antibody achieve regulatory and commercial success.
92
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
F. Equity-Method Investments
Investment in Hisun Pfizer Pharmaceuticals Company Limited (EH)
In September 2012, we and Hisun, a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell
pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of 
$250 million , of which our portion was 
$122.5 million . As a result of the contributions from both parties, Hisun Pfizer holds a broad port folio of branded generics covering cardiovascular disease, infectiousdisease, oncology, mental health and other therapeutic areas.
We accounted for our interest in Hisun Pfizer as an equity-method investment, due to the
 significant influence we had over the operations of Hisun Pfizer through our boardrepresentation, minority veto rights and 
49% voting interest. Our investment in Hisun Pfizer was reported in Long-term investments , and our share of Hisun Pfizer’s net income was recorded in 
Other (income)/deductions––net. On November 10, 2017, we sold our 
49% equity share in Hisun Pfizer to Sapphire I (HK) Holdings Limited, an investment fund managed by Hillhouse Capital, for a total of $286 million 
in cash which included our carrying value of $270 million in cash plus $16 million to cover certain taxes incurred on the transaction. As a result of the  saletransaction, we recognized a loss of 
$81 million in the fourth quarter of 2017 for the recognition in earnings of the currency translation adjustment associated with our investment. After the sale transaction, Hisun Pfizer changed its name but retained its
 current rights to manufacture, sell and distribute all of Hisun Pfizer’s currently marketedand pipeline products in China. We are providing technical, manufacturing and regulatory services in connection with a technology transfer process being run by Hisun Pfizer to
support Hisun Pfizer’s objective that the products that we had previously licensed to Hisun Pfizer, will in the future, be manufac
tured locally in China. We continue to supplycertain products to Hisun Pfizer for a period of time, after the sale transaction, 
to facilitate a smooth transition.In 2016, we determined that we had other-than-temporary declines in the value of Hisun Pfizer, and, therefore, we recognized a loss o
f $452 million in Other(income)/deductions––net 
(see Note 4 ), consisting of losses recognized in the first, second and fourth quarters of 2016.  In the first and second quarters of 2016, wedetermined that we had other-than-temporary declines in the value of Hisun Pfizer and, therefore, we recognized a loss of 
$81 million and $130 million , respectively. The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to
 the continuedslowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. In the 
fourth quarter of 2016, we recognized a loss of 
$241 million to reduce the carrying value of our investment in Hisun Pfizer to approximately $270 million at December 31, 2016. In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of 
the various risks inherent in the projected cash flows, and anominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net
cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the
 long-term growth rate, which seeks to project thesustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash
 flows, including country risk.Investment in Laboratório Teuto Brasileiro S.A. (EH)
We entered into an agreement on June 30, 2017 to exit our investment in Teu
to, a 40% -owned generics company in Brazil, and sell our 40% interest in Teuto to the majority shareholders. As part of the agreement, we waived our option to acquire the remaining 
60% of Teuto, and Teuto’s other shareholders have waived their option to sell their 60% stake in the company to us. As a result, in the
 second quarter of 2017, we recognized a net loss of approximately $30 million in Other (income)/deductions––net (see Note 4 ), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders’ option to sell their 
60% stake in the company to us, and the recognition in earnings of the currency translation adjustment associated
 with the Teuto investment. The transaction closed on August 16,2017.
In 2016, we determined that we had an other-than-temporary decline in the value of Teuto, and,
 therefore, in 2016, we recognized a loss of $50 million in Other(income)/deductions––net 
(see Note 4 ) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to  begenerated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the
Brazilian Real.
In valuing our investment in Teuto, we used discounted cash flow techniques, reflecting our best estimate o
f the various risks inherent in the projected cash flows, and anominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net
cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the
 long-term growth rate, which seeks to project thesustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash
 flows, including country risk.G. Privately Held Investment
AM-Pharma B.V. (WRD)
In April 2015, we acquired a minority equity interest in AM-Pharma, a privately-held Dutch biopharmaceutical company focused on the development of human recombinant
Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option became exercisable
after completion of a Phase 2 trial of recAP for the 
treatment of Acute Kidney Injury related to sepsis in the first quarter of 2018. We declined to exercise the option and theoption expired unexercised during the second quarter of 2018. Under the terms of the agreement, we originally paid 
$87.5 million for both the exclusive option and the minority equity interest, which was recorded as a cost-method investment in 
Long-term investments . During the fourth quarter of 2017, we recognized a loss of $43 million in Other(income)/deductions––net 
(see Note 4 ) for an impairment of our long-term investment. 2018 Financial Report    
 
 93
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 3 
. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/ProductivityInitiatives
We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For
example:
•
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may includeexpenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees,
assets and activities that will not continue in the combined company); and
•
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions,workforce reductions and the expansion of shared services, including the development of global systems.
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as
 informationtechnology, shared services and corporate operations.
In connection with our acquisition of Hospira in September 2015, we focused our efforts on achieving an appropriate cost structure 
for the combined company. We incurredcosts of approximately 
$1 billion (not including costs of $215 million in 2015 associated with the return of acquired IPR&D rights as described in the Current-Period Key Activities 
section below) associated with the integration of Hospira. The majority of these costs were incurred within the three -year period post-acquisition. In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our 2014 global commercial structure reorganization,
manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise.
2017-2019 Initiatives and Organizing for Growth
During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start o
f our2019 fiscal year, we would begin operating under our new commercial structure, which reorganizes our operations into three businesses 
–– Biopharma, a science-based Innovative medicines business; Upjohn, a global off-patent branded and generic established medicines business; and a Consumer Healthcare business. To operate effectively
in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the func
tionsthat support them. Beginning in the fourth quarter of 2018,
 we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our newstructure and have combined the 2017 to 2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. Initiatives for 
the combined programinclude activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and
 the simplification andoptimization of our operating business structure and functions that support them. Through December 31, 2018, we incurred approximately 
$713 million associated with manufacturing optimization, and approximately 
$752 million associated with other activities. In 2019, we expect restructuring, implementation and additional depreciation charges of about 
$800 million and, of that amount, we expect approximately 20% of the total charges will be non-cash.
Current-Period Key Activities
In 
2018 , we incurred costs of $1.4 billion composed of $1.1 billion associated with the 2017-2019 and Organizing for Growth initiatives, $274 million associated with the integration of Hospira and 
$45 million associated with all other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
 
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Restructuring charges/(credits):
         Employee terminations
  $459  $(181 ) $839 Asset impairments 
(a)  290  190  142 Exit costs
  33  21  74 Total restructuring charges 
(b)  782  30  1,055 Transaction costs 
(c)  1  4  127 Integration costs 
(d)  260  317  383 Restructuring charges and certain acquisition-related costs
  1,044  351  1,565 Net periodic benefit costs recorded in 
Other (income)/deductions––net (e)  146  136  159 Additional depreciation––asset restructuring, virtually all of which is recorded in 
Cost of sales (f)  50  91  207 Implementation costs recorded in our consolidated statements of income as follows 
(g) :         Cost of sales
  83  118  230 Selling, informational and administrative expenses
  72  71  81 Research and development expenses
  39  38  25 Other (income)/deductions––net
  —  —  3 Total implementation costs
  194  227  340 Total costs associated with acquisitions and cost-reduction/productivity initiatives
  $1,434  $805  $2,271 94
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
(a)
 
The asset impairment charges for 2018 are largely associated with cost re duction initiatives not associated with acquisitions. The asset impairment charges for 2017 are largely associated with our acquisitions ofHospira and Medivation. The ass
et impairment charges included in restructuring charges for 2017 and 2016 are primarily associated with abandoned assets. See (b) below for additional information.(b)
 
In 2018 , restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs are associated with our improvements to operational effectiveness aspart of the realignment o
f our organizational structure effective at the beginning of 2019 . In 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, partially offset bycredits associated with cost-reductio
n and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting fromrevisions of our severance be
nefit estimates. In 2016 , restructuring charges are larg ely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions ofHospira and Medivation. Employ
ee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many ofwhich may be paid out durin
g periods after termination.The restructuring activities in 
2018 are associated with the  following:•
IH ( $176 million charge ); EH ( $31 million charge ); WRD/GPD ( $135 million charge ); manufacturing operations ( $403 million charge ); and Corporate ( $38 million charge ). The restructuring activities in 
2017 are associated with the  following:•
IH ( $83 million credit ); EH ( $6 million credit ); WRD/GPD ( $19 million charge ); manufacturing operations ( $89 million charge ); and Corporate ( $12 million charge ), The restructuring activities in 
2016 are associated with the  following:•
IH ( $255 million charge ); EH ( $155 million charge ); WRD/GPD ( $145 million charge ); manufacturing operations ( $328 million charge ); and Corporate ( $172 million charge ). (c)
 
Transaction costs represent external costs for banking, legal, accounting and other similar services, which in 2017 were directly related to our acquisitions of Hospira, Anacor and Medivation.Transaction costs in2016 were mostly related to o
ur acquisitions of Medivation and Anacor, and the terminated transaction with Allergan.(d)
 
Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2018 , integration costs were primarily relat
ed to our acquisition of Hospira. In 2017 , integration costs primarily related t o our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the settlement of the Hosp
ira U.S. qualified defined benefit pension plan (see Note 11 ). In 2016, integration costs prim arily related to our acquisition of Hospira and the terminated transaction with Allergan.(e)
 
In 2018 , primarily represents the net pe nsion curtailments and settlements included in Other (income)/deduction s––net upon the adoption of a new accoun ting standard in the first quarter of 2018. In 2017,primarily represents the net pe
nsion curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified toOther (income)/deduction
s––net as a result of the retrospective a doption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by acceleratedamortization of actuarial losses a
nd prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. In 2016, primarily represents the netpension curtailments and settl
ements as well as the accelerated amortization of unrecognized loss and prior service costs related to our acquisition of Hospira, which were reclassified to Other (income)/deductions––net 
as a result of the retrospective a doption of a new accounting standard in the first quarter of 2018. For additional information, see Note 1B and Note 11 . (f) 
 Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.(g) 
 Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.The following table provides the components of and changes in our restructuring accruals:
(MILLIONS OF DOLLARS)
  EmployeeTermination
Costs
 AssetImpairment
Charges
  Exit Costs   Accrual Balance, January 1, 2017
  $1,547  $—  $36  $1,583 Provision/(Credit)
  (181 ) 190  21  30 Utilization and other 
(a)  (326 ) (190 ) 9  (508 )Balance, December 31, 2017 
(b)  1,039  —  66  1,105 Provision
  459  290  33  782 Utilization and other 
(a)  (295 ) (290 ) (51 ) (636 )Balance, December 31, 2018 
(c)  $1,203  $—  $49  $1,252 (a) 
 Includes adjustments for foreign currency translation.(b) 
 Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ). (c) 
 Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ). 2018 Financial Report    
 
 95
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 4. 
Other (Income)/Deductions—Net The following table provides components of 
Other (income)/deductions––net :  
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Interest income 
(a)  $(333 ) $(391 ) $(470 )Interest expense 
(a)  1,316  1,270  1,186 Net interest expense
  983  879  716 Royalty-related income 
(b)  (495 ) (499 ) (905 )Net (gains)/losses on asset disposals 
(c)  (71 ) 45  (51 )Net gains recognized during the period on investments in equity securities 
(d)  (586 ) (224 ) (18 )Net realized (gains)/losses on sales of investments in debt securities 
(e)  141  (45 ) (35 )Income from collaborations, out-licensing arrangements and sales of compound/product rights 
(f)  (488 ) (217 ) (108 )Net periodic benefit costs/(credits) other than service costs 
(g)  (288 ) 101  139 Certain legal matters, net 
(h)  157  240  510 Certain asset impairments 
(i)  3,115  395  1,447 Loss on sale and impairment on remeasurement of HIS net assets 
(j)  (1 ) 55  1,712 Business and legal entity alignment costs 
(k)  4  71  261 Net losses on early retirement of debt 
(l)  3  999  312 Other, net 
(m)  (357 ) (383 ) (186 )Other (income)/deductions––net
  $2,116  $1,416  $3,794 (a)
 
2018 v. 2017 ––Interest income decrease d primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activitythat occurred in the fou
rth quarter of 2017. 2017 v. 2016 ––Interest income decrease d primarily driven by a lower investment balance. Interest expense increased, primarily as a result of higher short-term interestrates, offset, in part, by the retireme
nt of high-coupon debt and the issuance of new low-coupon debt. Capitalized interest expense totaled $73 million in 2018 , $ 72 million in 2017 and $ 61 million in 2016 . (b)
 
Royalty-related income decreased in 2017 , primarily due to lower royalty income f or Enbrel of $470 million in 2017 , compared to 2016, resul ting from the expiration on October 31, 2016 of the 36 -month royaltyperiod under the collab
oration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-relatedincome of 
$176 million in 2017 , compared to 2016 . (c)
 
In 2018, primarily includes a realized gain on sale of property of $60 million . In 2017 , primarily includes an $81 million realized loss related to the sale of our then 49% -owned equity-method inves tment in HisunPfizer and a realized net loss of 
$30 million related to the sale of our 40% ownership investment in  Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest, partially offset by a realized gain on sale
 of property of $52 million . In 2016, primarily includes realiz ed gains on sales of property and other assets.(d)
 
The net gains on investments in equity securities in 2018 , include unrealized net g ains on equity securities of $477 million , reflecting the adoption of a new accounting standard in the first quarter of 2018. Netgains in 
2018 were primarily dri ven by unrealized gains of $466 million related to our investment in Allo gene. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains andlosses on virtually all equity securities wit
h readily determinable fair values were reported in Accumulated other comprehen sive income . For additional information, see Note 1B, Note 2B and Note 7B . (e)
 
In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of $402 million and a net loss of $18 million from derivative finan cial instruments used to hedge the foreign exchangecomponent of the matured 
available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of $280 million . Proceeds from the sale of availa ble-for-sale debtsecurities were 
$5.7 billion in 2018. In 2017, primarily includes gross r
ealized gains on sales of available-for-sale debt securities of $451 million , partially offset by gross realized loss es on sales of available-for-sale debt securities of $281 million and a net 
loss of $120 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debtsecurities were 
$5.1 billion in 2017. In 2016, primarily includes gross r
ealized gains on sales of available-for-sale debt securities of $666 million , partially offset by gross realized loss es on sales of available-for-sale debt securities of $548 million and a net 
loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debtsecurities were 
$10.2 billion in 2016. (f) 
 Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In 2018 , primarily includes, among other things, (i) approximately 
$118 million in milestone income from multiple lice nsees, (ii) $110 million in milestone payments received fr om Shire, of which $75 million was received in the first quarter of 2018 relatedto their first dosing of a patient i
n a Phase 3 clinical trial for the treatment of ulcerative colitis and $35 million was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3clinical trial for the treatment of Croh
n’s disease, (iii) an upfront payment to us and a recognized milestone totaling $85 million for the sale of an AMPA receptor p otentiator for CIAS to Biogen, (iv) $62 million in gains related to sales of comp
ound/product rights and (v) a $40 million milestone payment from Merck in conj unction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C, Note 2D 
and Note 2E . In 2017, primarily includes, amo ng other things, $101 million in milestone payments received fr om multiple licensees and an $85 million gain related to sales of comp ound/product rights. In2016, primarily include
s, among other things, a $50 million gain related to sales of  compound/product rights and $33 million in milestone payments received fr om multiple licensees.(g)
 
Represents the net periodic benefit costs/(credits), excluding service costs, as a result of the adoption of a new accounting standard in the first quarter of 2018. Effective January 1, 2018, the U.S. PfizerConsolidated Pension Plan 
was frozen to future benefit accruals and for 2018 , resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses.There was also a greater than 
expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see Note 1B and Note 11 . (h)
 
In 2018 , primarily includes legal reserves for c ertain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a $94 million charge to resolve a class action l
awsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a $79 million charge to reflect damages aw arded by a jury in a patentmatter. In 2016, primarily includes 
amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual wher
e a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter.(i) 
 In 2018 , primarily includes intangible ass et impairment charges of $3.1 billion , mainly composed of (i) $2.6 billion related to EH developed te chnology rights, $242 million related to EH licens ing agreements and$80 million 
related to EH IPR&D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) $117 million related to a multi-ant igen vaccine IPR&Dprogram for adults undergoing
 elective spinal fusion surgery; (iii) $31 million related to an IH develope d technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungusmarket marketed in the U.S. market only; 
and (iv) $17 million of other IPR&D assets acquired in co nnection with our acquisition of Innopharma. In 2018, 96
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
the intangible asset impairme
nt charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as wellas higher manufacturing costs, l
argely stemming from ongoing manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&D program was the result of the Phase2b trial reaching futility at a pre-
planned interim analysis. The intangible asset impairment c harge related to the IH developed technology righ t reflects , among other things, upd ated commercial forecasts. Inaddition, 
2018 includes other asset i mpairments of  $13 million . In 2017, primarily in
cludes intangible asset impairment charges of $337 million , reflecting (i) $127 million related to developed technology  rights, acquired in connection with our acquisition of Hospira, for ageneric sterile injectable pro
duct for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology  rights, acquired in connection with our acquisition of Hospira, for asterile injectable pain reliever; (iii) 
$39 million related to developed tec hnology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26 million 
related to developed tec hnology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to other developed techn
ology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitiveenvironment. In addition,
 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. l ong-term investment (see Note 2G ). In 2016, primarily in
cludes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology  rights for a generic injectable antibiotic product for the treatment ofbacterial infections; and (ii) 
$265 million related to an IPR&D compound f or the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D compounds acquired in connect
ion with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in con
nection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition, 2016 includes an impairment
 loss of $452 million related to Pfizer’s then 49% -owned equity-method investm ent with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% - owned equity-method investm
ent in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2F . The intangible asset impairment c
harge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatorydelays, including delays resulti
ng from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016for the sterile injectable IPR&D compo
unds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profilesof certain compounds. The inta
ngible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things,the impact of regulatory delays, t
he impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for2016 for other IPR&D assets acquir
ed in connection with our acquisition of King reflect changes in the competitive environment.(j) 
 In 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February3, 2017. In 2016, repres
ents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. (k)
 
Represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities,as well as to streamline our intercom
pany supply operations to better support each business.(l) 
 In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in2016.
(m)
 
In 2018 , includes (i) a non-cash $343 million pre-tax gain associated with o ur transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinicaland preclinical stage neur
oscience assets primarily targeting disorders of the central nervous system (see Note 2B ), (ii) dividend income of $253 million from our investment in ViiV, (iii) a non-cas h $50 million pre- tax gain on the contributio
n of Pfizer’s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in whichPfizer obtained a 
25% ownership stake in Al logene (see Note 2B ), and (iv) a non-cash $17 million pre-tax gain on the cash settl ement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg(see 
Note 7E ), partially offset by charges of $207 million , reflecting the change in the fair value of contingent consideration and $59 million of incremental costs associated with t he design, planning andimplementation of the new or
ganizational structure, effective in the beginning of 2019, and primarily include consulting, legal, tax, and advisory services. In 2017, includes, among other things, dividend income of$266 million 
from our investment in ViiV, and income of $62 million from resolution of a contract disa greement. In 2016, includes among other things, $150 million paid to Allergan for re imbursement of Allergan’sexpenses associated with the t
erminated transaction (see Note 1A ); and income of $116 million from resolution of a contract disagreement.The asset impairment charges included in 
Other (income)/deductions––net are based on estimates of fair value. The following table provides additional information about the intangible assets that were impaired during 2018 in 
Other (income)/deductions––net :  
     Year Ended December31,
 
  Fair Value (a)  2018 (MILLIONS OF DOLLARS)
  Amount  Level 1  Level 2  Level 3  Impairment Intangible assets––Developed technology rights 
(b)  $665  $—  $—  $665  $2,647 Intangible assets––Licensing agreements and other 
(b)  150  —  —  150  242 Intangible assets 
–– IPR&D (b)  95 — — 95 214 Total
  $910  $—  $—  $910  $3,103 (a) 
 The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E. (b)
 
Reflects intangible assets written down to fair value in 2018 . Fair value was determined using t he income approach, specifically the multi-period excess earnings method, also known as the discounted cash flowmethod. We started with a forecast of 
all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significantestimates and assumptions inh
erent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on theproduct; the discount rate, whic
h seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.2018 Financial Report    
 
 97
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 5 
. Tax MattersA. Taxes on Income from Continuing Ope
rationsThe following table provides the components of 
Income from continuing operations before provision/(benefit) for taxes on income :  
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 United States
  $(4,403 )  $(6,879 )  $(8,534 ) International
  16,288  19,184  16,886 Income from continuing operations before provision/(benefit) for taxes on income 
( a), (b)  $11,885  $12,305  $8,351 (a)
 
2018 v. 2017 –– The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on investments inequity securities and increase
d revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the SIP portfolio. The decrease in international income was primarilyrelated to lower interest income r
eceived primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related toIbrance and Eliquis.
(b)
 
2017 v. 2016 –– The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HISnet assets, lower certain asset impairm
ents and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in internationalincome was primarily due to the n
on-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain assetimpairments.
The following table provides the components of 
Provision/(benefit) for taxes on income  based on the location of the taxing authorities:  
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 United States
         Current income taxes:
         Federal
  $668  $1,267  $342 State and local
  9  45  (52 )Deferred income taxes:
         Federal
  (1,663 )  (2,064 )  (419 )State and local
  16  (304 ) (106 )Total U.S. tax provision
  (970 ) (1,055 )  (235 )TCJA 
(a)         Current income taxes
  (3,035 )  13,135  — Deferred Income taxes
  2,439  (23,795 )  — Total TCJA tax provision
  (596 ) (10,660 )  — International
         Current income taxes
  2,831  2,709  1,532 Deferred income taxes
  (558 ) (42 ) (175 )Total international tax provision
  2,273  2,667  1,358 Provision/(benefit) for taxes on income
  $706  $(9,049 )  $1,123 (a)
 
The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussionbelow and 
Note 5C . In
 the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in theU.S. Federal corporate tax rate from 35% to 
21% , (ii) the impact on valuation allowances and other state income tax considerations, (iii) the $15.2 billion repatriation tax liability on
 accumulated post-1986 foreign earnings for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight yearsthrough 2026
 that is reported in Other taxes payable in  our consolidated balance sheet as of December 31, 2017 and (iv) deferred taxes on basis differences expected to giverise
 to  future  taxes  on  global  intangible  low-taxed  income.  In  addition,  we  had  provided  deferred  tax  liabilities  in  the  past  on  foreign  earnings  that  were  not  indefinitelyreinvested. As a result of
 the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change tothe territorial tax system.
In 2018, we finalized our provis
ional accounting for the tax effects of the TCJA, based on our best estimates of available information and data, and have reported and disclosedthe
 impacts within the applicable measurement period, in accordance with guidance issued by the SEC, and recorded a favorable adjustment of approximately $100 million to Provision/(benefit)
 for taxes on income .  The amounts recorded may change in the future due to uncertain tax positions. With respect to the aforementioned repatriation taxliability, our
 revised estimate is approximately $15 billion .  The first installment, due in April 2019, is reported in Income taxes payable ,  and the remaining liability is reported inOther
 taxes payable in  our consolidated balance sheet as of December 31, 2018. We believe that there may be additional interpretations, clarifications and guidance from theU.S.
 Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in the period ofissuance.
 In  addition,  our  obligations  may  vary  as  a  result  of  changes  in  our  uncertain  tax  positions  and/or  availability  of  attributes  such  as  foreign  tax  and  other  creditcarryforwards.
The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staf
f Q&A, Topic 740, No. 5,Accounting for Global Intangible Low-Taxed Income 
, states that we are permitted to make an accounting policy election to either recognize deferred taxes  for temporary basisdifferences expected to reverse as global intangible low-taxed income in future
98
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
years or provide for the tax expense related to such income in the year the tax is incurred. We have
 elected to recognize deferred taxes for temporary differences expected toreverse as global intangible low-taxed income in future years. In 2017, we provided a provisional deferred tax liability of approximately 
$1.0 billion based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. In 2018, this estimate was finalized
and we have provided for an additional deferred tax liability of approximately 
$200 million , resulting in a deferred tax liability of approximately $1.2 billion . In 
2018 , the Provision/(benefit) for taxes on income was impacted by the following: •
estimated U.S. net tax benefits of approximately $600 million associated with the enactment of the TCJA (see discussion above), primarily reflecting: ◦
approximately $500 million of tax benefits associated primarily with certain current year tax initiatives; ◦
approximately $100 million of tax benefits associated with adjustments to our provisional accounting for the tax e ffects of the TCJA, reported and disclosed within theapplicable measurement period, in accordance with guidance issued by the SEC, primarily consisting of:
◦
$160 million of tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries; and◦
$140 million of tax benefits associated with the remeasurement of other U.S. de ferred tax liabilities,partially offset by:
◦
$200 million of tax expense related to future taxes on global intangible low-taxed income; •
tax benefits of approximately $700 million representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and
•
tax benefits of approximately $740 million related to certain asset impairments. In 
2017 , the Provision/(benefit) for taxes on income was impacted by the following: •
estimated U.S. net tax benefits of $10.7 billion associated with the enactment of the TCJA (see discussion above), primarily reflecting: ◦
$22.8 billion tax benefit associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see Note 5C ); ◦
$1.6 billion tax benefit associated with the remeasurement of other U.S. deferred tax liabilities, primarily associated with intangibles (see Note 5C ); ◦
$12.9 billion tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries; ◦
$1.0 billion tax expense related to future taxes on global intangible low-taxed income (see Note 5C ); and ◦
approximately $100 million tax benefit primarily associated with certain tax initiatives; •
U.S. tax expense of approximately $1.3 billion related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries; •
tax benefit of approximately $370 million related to net losses on early retirement of debt; •
tax benefits of approximately $150 million representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and
•
the non-deductibility of a $307 million fee payable to the federal government as a result of the U.S . Healthcare Legislation.In 
2016 , the Provision/(benefit) for taxes on income was impacted by the following: •
U.S. tax expense of approximately $1.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S . that will not be indefinitelyreinvested overseas, virtually all of which were earned in 2016;
•
tax benefits of approximately $460 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations;
•
benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, whichresulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position;
•
net tax benefits of $89 million , related to the adoption of a new accounting standard in the  fourth quarter of 2016, as of January 1, 2016, requiring excess tax benefits ordeficiencies of share-based compensation to be recognized as a component of the 
Provision/(benefit) for taxes on income (see Notes to Consolidated Financial Statements–– 
Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial Report); •
the non-deductibility of a $312 million fee payable to the federal government as a result of the U.S . Healthcare Legislation; and•
the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015.In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in 
Provision/(benefit) for taxes on income 
(see Note 2A ). 2018 Financial Report    
 
 99
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
B. Tax Rate Reconciliation
The reconciliation of the U.S. statutory income tax rate to our ef
fective tax rate for Income from continuing operations  follows:  
  Year Ended December 31,  
  2018  2017  2016 U.S. statutory income tax rate
  21.0  % 35.0  % 35.0  %TCJA impact 
(a)  (5.0 ) (86.6 )  — Taxation of non-U.S. operations 
 (b), (c), (d)  (6.1 ) (17.0 )  (13.8 ) Tax settlements and resolution of certain tax positions 
(e)  (5.8 ) (1.2 ) (5.5 )U.S. Healthcare Legislation 
(e), (f)  (0.4 ) 0.9  1.3 U.S. R&D tax credit and manufacturing deduction 
(e)  (0.7 ) (0.7 ) (1.0 )Certain legal settlements and charges 
(e)  (0.1 ) 0.1  (2.9 )All other, net 
(g)  3.1  (3.9 ) 0.3 Effective tax rate for income from continuing operations
  5.9  % (73.5 )%  13.4  %(a) 
 For a discussion about the enactment of the TCJA, see Note 5A. (b)
 
For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions,which, for 2017, include
s the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in Note 5A , changes in uncertain tax p ositions not included in the reconciling item called “Taxsettlements and resolution of c
ertain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year,and the rate impact of this comp
onent is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and otherU.S. tax implications of our foreign o
perations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from thejurisdictional location of earni
ngs; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of oureffective tax rate each year that c
an result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriationcosts, can vary as a result of the rep
atriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such asrestructuring charges, asset impairm
ents and gains and losses on strategic business decisions. See also Note 5A for the components of pre -tax income and Provision/(benefit) for taxes on income, which is based on the location of the taxin
g authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income . (c)
 
In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and otherincentives associated with our su
bsidiaries in Puerto Rico and Singapore. 2016 also includes incentives in Costa Rica and the Dominican Republic related to the Hospira infusion systems business, which was soldto ICU Medical in February 2017. We b
enefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefitfrom incentive tax 
rates effective through 2031 on income from manufacturing and other operations.(d)
 
The favorable rate impacts in 2018 and 2017 also reflect lower repatriation costs associated with the estimated income of our foreign subsidiaries. The favorable rate impact in 2016 also includes the non- recurrence of the non-de
ductibility of a foreign currency loss related to Venezuela.(e)
 
For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and manufacturing deduction and the impact of certain legalsettlements and charges, see 
Note 5A. (f) 
 The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as wellas certain tax initiatives.
(g)
 
All other, net in 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain taxinitiatives in the no
rmal course of business.C. Deferred Taxes
Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.
The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:
 
  2018 Deferred Tax*   2017 Deferred Tax* (MILLIONS OF DOLLARS)
  Assets   (Liabilities)   Assets   (Liabilities) Prepaid/deferred items
  $1,655  $(325 ) $1,837  $(132 )Inventories
  280  (10 ) 405  (3 )Intangible assets 
(a)  532  (7,620 )  685  (10,808 ) Property, plant and equipment
  160  (1,011 )  124  (755 )Employee benefits
  2,292  (134 ) 2,346  (109 )Restructurings and other charges
  266  —  240  (8 )Legal and product liability reserves
  415  —  480  — Net operating loss/tax credit carryforwards 
(b), (c)  2,512  —  4,502  — Unremitted earnings
  —  (83 ) —  (85 )State and local tax adjustments
  264  —  178  — All other
  200  (274 ) 492  (424 ) 
  8,576  (9,456 )  11,289  (12,325 ) Valuation allowances
  (2,068 )  —  (2,203 )  — Total deferred taxes
  $6,508  $(9,456 )  $9,086  $(12,325 ) Net deferred tax liability 
(d)     $(2,948 )     $(3,238 ) *
For 2018 and 2017, the deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See Note 5A . 2018 excludes deferred ta x assets andliabilities associated with fully dedic
ated consumer healthcare subsidiaries. For additional information, see Note 2C . 
100 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
(a) 
 The decrease in 2018 is primarily the result of amortization of i ntangible assets and certain impairment charges.(b) 
 The decrease in 2018 is primarily a result of the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See Note 5A . (c)
 
The amounts in 2018 and 2017 are reduced for unrecognized tax benefits of $3.3 billion and $3.4 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax creditcarryforwards that are available, 
under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.(d)
 
In 2018 , Noncurrent deferred tax assets and other noncurrent tax assets ( $0.8 billion ), and Noncurrent deferred tax liabilities ( $3.7 billion ). In 2017 , Noncurrent deferred tax assets and other noncurrent taxassets 
( $0.7 billion ), and Noncurrent deferred tax liabilities ( $3.9 billion ). We have carryforwards, primarily related to net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and/or state, as well
as international, income taxes payable with either an indefinite life or expiring at various times from 2018 to 2038. Certain of our U.S. net operating losses are subject
 tolimitations under IRC Section 382.
Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future 
taxable income thatincorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax asse
ts.As of December 31, 2018, we have not made a U.S. 
tax provision on approximately $31.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2018 is not practicable.
D. 
Tax ContingenciesWe are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax
positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and
 theresolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have
 beendeemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax bene
fits may not be representative of actual outcomes, and variationfrom such estimates could materially affect our financial statements in the period of settlement or when the sta
tutes of limitations expire, as we treat these events as discreteitems in the period of resolution.
For a description of our accounting policies associated with accounting for income tax contingencies, see 
Note 1P. For a description of the risks associated with estimates and assumptions, see 
Note 1C. Uncertain Tax Positions
As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax
 positions will be sustained upon audit. As of December 31, 2018 we had approximately 
$5.1 billion in net unrecognized tax benefits, excluding associated interest and as of December 31, 2017 we had approximately $5.4 billion in net unrecognized tax benefits, excluding associated interest.
•
Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment ofincome taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to
 minimizedouble taxation, commonly referred to as the competent authority process. The recoverability of these assets,
 which we believe to be more likely than not, is dependent uponthe actual payment of taxes in one tax jurisdiction and, in some cases, the
 successful petition for recovery in another tax jurisdiction. As of December 31, 2018 we had approximately 
$1.1 billion in assets associated with uncertain tax positions. These amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( 
$1.0 billion ) and Noncurrent deferred tax liabilities ( $128 million ). As of December 31, 2017 , we had approximately $1.2 billion in assets associated with uncertain tax positions. These amounts were included in 
Noncurrent deferred tax assets and other noncurrent tax assets ( $1.0 billion ) and Noncurrent deferred tax liabilities ( $118 million 
). •
Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differsfrom the amounts taken or expected to be taken in a 
tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issuescommon among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.
The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:
(MILLIONS OF DOLLARS)
  2018  2017  2016 Balance, beginning
  $(6,558 )  $(5,826 )  $(5,919 ) Acquisitions 
(a)  —  10  (83 )Increases based on tax positions taken during a prior period 
(b)  (192 ) (49 ) (11 )Decreases based on tax positions taken during a prior period 
(b), (c)  561  28  409 Decreases based on settlements for a prior period 
(d)  123  35  126 Increases based on tax positions taken during the current period 
(b)  (370 ) (753 ) (489 )Impact of foreign exchange
  56  (121 ) (5 )Other, net 
(b), (e)  121  118  146 Balance, ending 
(f)  $(6,259 )  $(6,558 )  $(5,826 ) (a) 
 For 2017 and 2016, primarily related to the acquisitions of Medivation and Anacor. See also Note 2A . (b) 
 Primarily included in Provision/(benefit) for taxes on income.(c) 
 Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A. (d) 
 Primarily related to cash payments and reductions of tax attributes.2018 Financial Report    
 
 101
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
(e) 
 Primarily related to decreases as a result of a lapse of applicable statutes of limitations.(f) 
 In 2018 , included in Income taxes payable ( $11 million ), Current tax assets ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $47 million ), Noncurrent deferred tax liabilities ( $3.2 billion 
) and Other taxes payable ( $3.0 billion ). In 2017 , included in Income taxes payable ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $123 million ), Noncurrentdeferred tax liabilities 
( $3.3 billion ) and Other taxes payable ( $3.2 billion ). •
Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on income 
in our consolidated statements of income. In 2018 , we recorded a net increase in interest of $103 million . In 2017 , we recorded a net increase in interest of $208 million 
; and in 2016 , we recorded a net increase in interest of $72 million . Gross accrued interest totaled $1.1 billion as of December 31, 2018 (reflecting a decrease of approximately 
$16 million as a result of cash payments) and gross accrued interest totaled $975 million as of December 31, 2017 (reflecting a decrease of approximately $4 million 
as a result of cash payments). In 2018 , this amount was included in Income taxes payable ( $6 million ) and Other taxes payable ( $1.1 billion ). In 2017 , this amount was included in 
Other taxes payable ( $975 million ). Accrued penalties are not significant. See also Note 5A. Status of Tax Audits and Potential Impact
 on Accruals for Uncertain Tax PositionsThe U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:
•
With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealingcertain disputed issues. Tax years 2011-2015 are currently under audit. Tax years 2016-2018 are open, but not under audit. 
All other tax years are closed.•
With respect to Hospira, the federal income tax audit of tax year 2014 through short-year 2015 was effectively settled in the second quarter of 2018. All other tax years areclosed.
•
With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer.In addition to the open audit years in the U.S.,
 we have open audit years in other major tax jurisdictions, such as Canada (2013-2018), Japan (2017-2018), Europe (2011-2018,primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2018, primarily reflecting Brazil) and Puerto Rico (2011-2018).
Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate 
that it is reasonably possible that withinthe next 12 months, our gross unrecognized tax benefits, exclusive of interest,
 could decrease by as much as $75 million , as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on
 estimates and assumptions that have been deemed reasonable by management, but our estimatesof unrecognized tax benefits and potential tax benefits may not be
 representative of actual outcomes, and variation from such estimates could materially affect our financialstatements in the period of settlement or when the statutes
 of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with therelevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to
our uncertain tax positions, and such changes could be significant.
E. Tax Provision/(Benefit) on Other 
Comprehensive Income/(Loss)The following table provides the components of the 
Tax provision/(benefit) on other comprehensive income/(loss) :  
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Foreign currency translation adjustments, net 
(a)  $94  $(215 ) $(15 )Unrealized holding gains/(losses) on derivative financial instruments, net
  21  72  (75 )Reclassification adjustments for (gains)/losses included in net income
  27  (224 ) 158 Reclassification adjustments of certain tax effects from AOCI to 
Retained earnings (b)  1  —  —  
  50  (152 ) 83 Unrealized holding gains/(losses) on available-for-sale securities, net
  (23 ) 102  49 Reclassification adjustments for (gains)/losses included in net income
  16  (60 ) (15 )Reclassification adjustments for tax on unrealized gains from AOCI to 
Retained earnings (c)  (45 ) —  —  
  (53 ) 42  34 Benefit plans: actuarial losses, net
  (141 ) (59 ) (535 )Reclassification adjustments related to amortization
  55  192  186 Reclassification adjustments related to settlements, net
  33  42  45 Reclassification adjustments of certain tax effects from AOCI to 
Retained earnings (b)  637  —  — Other
  29  (39 ) 36  
  612  137  (269 )Benefit plans: prior service (costs)/credits and other, net
  2  —  67 Reclassification adjustments related to amortization
  (39 ) (67 ) (64 )Reclassification adjustments related to curtailments, net
  (4 ) (7 ) (10 )Reclassification adjustments of certain tax effects from AOCI to 
Retained earnings (b)  (144 ) —  — Other
  —  —  (1 ) 
  (185 ) (74 ) (7 )Tax provision/(benefit) on other comprehensive income/(loss)
  $518  $(262 ) $(174 )(a) 
 Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.(b) 
 For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. (c) 
 For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B . 102
  2018 Financial Report
 
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following table provides the changes, net of tax, in 
Accumulated other comprehensive loss :  
  Net Unrealized Gain/(Losses)   Benefit Plans    (MILLIONS OF DOLLARS)
  ForeignCurrency
Translation
Adjustments
  Derivative FinancialInstruments
  Available-For-Sale Securities
  ActuarialGains/(Losses)
  Prior Service(Costs)/ Credits
and Other
  Accumulated OtherComprehensive
Income/(Loss)
Balance, January 1, 2016
  $(5,863 )  $421  $(227 ) $(4,733 )  $880  $(9,522 ) Other comprehensive income/(loss) 
(a)   (797 ) (73 ) 96  (740 ) (1 ) (1,514 ) Balance, December 31, 2016
  (6,659 )  348  (131 ) (5,473 )  879  (11,036 ) Other comprehensive income/(loss) 
(a)   1,479  (378 ) 532  211  (129 ) 1,715 Balance, December 31, 2017
  (5,180 )  (30 ) 401  (5,262 )  750  (9,321 ) Other comprehensive income/(loss) due to the
adoption of new accounting standards 
(b)   (2 ) (1 ) (416 ) (637 ) 144  (913 )Other comprehensive income/(loss) 
(a)   (893 ) 198  (53 ) (128 ) (166 ) (1,041 ) Balance, December 31, 2018
  $(6,075 )  $167  $(68 ) $(6,027 )  $728  $(11,275 ) (a) 
 Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $20 million loss in 2018 , $14 million income in 2017 and $3 million loss in 2016 . (b)
 
Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain taxeffects from AOCI. For additional informatio
n, see Note 1B. As of 
December 31, 2018 , we estimate that we will reclassify into 2019 income the following pre-tax amounts currently held in Accumulated other comprehensive loss : $258million 
of unrealized pre-tax net gains on derivative financial instruments (which is expected to be offset primarily by net losses resulting from reclassification adjustments related to net 
losses related to foreign currency exchange-denominated forecasted intercompany inventory sales and available-for-sale debt securities); $242 million of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and 
$186 million of prior service credits, primarily related to benefit plan amendments.
2018 Financial Report    
 
 103
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 7 
. Financial InstrumentsA. 
Fair Value MeasurementsFinancial Assets and Liabilities Measured at Fair Value on a Recurring Basis
On January 1, 2018, we adopted a new accounting and disclosure standard related to accounting 
for the recognition of financial assets and liabilities. For additional informationsee 
Note 1B . The following table presents the financial assets and liabilities measured at fair value using a market
 approach on a recurring basis by balance sheet categories and fair value hierarchy levelas defined in 
Note 1E :  
  December 31, 2018   December 31, 2017 (MILLIONS OF DOLLARS)
  Total  Level 1  Level 2  Total  Level 1  Level 2 Financial assets measured at fair v
alue on a recurring basis:                  Short-term investments
                  Classified as equity securities:
                  Money market funds
  $1,571  $—  $1,571  $2,115  $—  $2,115 Equity 
(a)   29  17  11  35  16  19  
  1,600  17  1,583  2,150  16  2,134 Classified as available-for-sale d
ebt securities:                  Government and agency—non-U.
S.  9,609  —  9,609  12,242  —  12,242 Corporate and other
  5,482  —  5,482  3,120  —  3,120  
  15,091  —  15,091  15,362  —  15,362 Total short-term investments
  16,691  17  16,674  17,512  16  17,496 Other current assets
                  Derivative assets:
                  Interest rate contracts
  97  —  97  104  —  104 Foreign exchange contracts
  477  —  477  234  —  234 Total other current assets
  574  —  574  337  —  337 Long-term investments
                  Classified as equity securities:
                  Equity 
(a)   1,223  1,193  30  1,440  1,398  42 Classified as trading securities:
                  Equity
  50  50  —  73  73  —  
  1,273  1,243  30  1,514  1,472  42 Classified as available-for-sale d
ebt securities:                  Government and agency—non-U.
S.  94  —  94  387  —  387 Corporate and other
  397  —  397  4,702  36  4,667  
  491  —  491  5,090  36  5,054 Total long-term investments
  1,764  1,243  521  6,603  1,507  5,096 Other noncurrent assets
                  Derivative assets:
                  Interest rate contracts
  335  — 335  477  —  477 Foreign exchange contracts
  232  — 232  7  —  7 Total other noncurrent assets
  566  — 566  484  —  484 Total assets
  $19,595  $1,260 $ 18,335  $24,937  $1,523  $23,414  
                  Financial liabilities measured at fair value on a recur
ring basis:                  Other current liabilities
                  Derivative liabilities:
                  Interest rate contracts
  $5  $—  $5  $1  $—  $1 Foreign exchange contracts
  78  —  78  201  —  201 Total other current liabilities
  82  —  82  201  —  201 Other noncurrent liabilities
                  Derivative liabilities:
                  
Interest rate contracts  378  —  378  177  —  177 Foreign exchange contracts
  564  —  564  313  —  313 Total other noncurrent liabilities
  942  —  942  490  —  490 Total liabilities
  $1,024  $—  $1,024  $691  $—  $691 (a)
 
As of December 31, 2018 , short-term equity securities of $11 million and long-term equity secu rities of $29 million are held in trust for benefits attri butable to the former Pharmacia Savings Plus Plan. As of December 31, 2017 
, short-term equity securities of $19 million and long-term equity secu rities of $42 million are held in trust for benefits attri butable to the former Pharmacia Savings Plus Plan.104
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis
The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market
approach:
 
  December 31, 2018   December 31, 2017  
  Carrying Value   Estimated Fair Value   Carrying Value   Estimated Fair Value (MILLIONS OF DOLLARS)
     Total  Level 2     Total  Level 2 Financial Liabilities
                  Long-term debt, excluding 
the current portion  $32,909  $35,260  $35,260  $33,538  $37,253  $37,253 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term
borrowings not measured at fair value on a recurring basis were not significant as of 
December 31, 2018 or December 31, 2017 . The fair value measurements of our held-to- maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments
in the life sciences sector, are based on Level 3 inputs using a market approach.
In addition, as of 
December 31, 2018 and 2017 , we had long-term receivables whose fair value is based on Level 3 inputs. As of December 31, 2018 and 2017 , the differences between the estimated fair values and carrying values of these receivables were not significant.
Total Short-Term and Long-Term Investments
The following table represents our investments by classification type:
 
  As of December 31, (MILLIONS OF DOLLARS)
  2018   2017 Short-term investments
      Equity securities
  $1,600  $2,150 Available-for-sale debt securities
  15,091  15,362 Held-to-maturity debt securities
  1,003  1,138 Total Short-term investments
  $17,694  $18,650  
      Long-term investments
      Equity securities
  $1,223  $1,440 Trading equity securities
  50  73 Available-for-sale debt securities
  491  5,090 Held-to-maturity debt securities
  59  4 Private equity investments carried at equity-method or cost
  944  408 Total Long-term investments
  $2,767  $7,015 Held-to-maturity cash equivalents
  $199  $719 Fair Value Methodology
The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities:
•
Trading debt securities—quoted market prices.•
Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjustedinterest rate yield curves.
•
Equity securities—quoted market prices and observable net asset value prices.•
Derivative assets and liabilities (financial instruments)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data.Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices
for currencies. The credit risk impact to our derivative financial instruments was not significant.
•
Money market funds—observable net asset value prices.We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other
third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial
instruments.
2018 Financial Report    
 
 105
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
B. Investments
At December 31, 2018 and 2017, the investment securities portfolio consisted of debt
 securities that were virtually all investment-grade. Information on investments in debt and equity securities at December 31, 2018 and December 31, 2017 is as follows, including, as of
 December 31, 2018, the contractualmaturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:
 
  December 31, 2018   December 31, 2017  
     Gross Unrealized      Maturities (in Years)        Gross Unrealized     (MILLIONS OF DOLLARS)
  AmortizedCost
 Gains  Losses  Fair Value Within 1  Over 1 to 5
 Over 5  Total  AmortizedCost
 Gains  Losses Fair ValueAvailable-for-sale debt securities
                                 Government and agency 
–– non-U.S. $9,754  $7  $(58 ) $9,703  $9,609  $94  $—  $9,703  $12,616  $61  $(48 ) $12,629Corporate and other 
(a)  5,905  —  (27 ) 5,878  5,482  394  3  5,878  7,859  15  (52 ) 7,823 Held-to-maturity debt securities
                                 Time deposits and other
  668  —  —  668  610  24  35  668  1,091  —  —  1,091 Government and agency 
–– non-U.S. 592  —  —  592  592  —  —  592  770  —  —  770 Total debt securities
  $16,920  $8  $(85 ) $16,842  $16,293 $512  $38  $16,842 $22,337  $77  $(100) $22,313Available-for-sale equity securities 
(b)                                Money market funds
                         $2,115  $—  $—  $2,115 Equity
                         728  586  (124 ) 1,190 Total available-for-sale equity securities
                         $2,843  $586  $(124) $3,304 (a) 
 Primarily issued by a diverse group of corporations.(b) 
 Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B . The following table presents the net unrealized gains and losses for the period that relate to equity securities still held at the
 reporting date, calculated as follows:(MILLIONS OF DOLLARS)
  December 31, 2018 Net gains recognized during the period on investments in equity securities 
(a) $586 Less: Net gains recognized during the period on equity securities sold during the period
  (109 )Net unrealized gains during the reporting period on equity securities still held at the reporting date
  $477 (a)
 
The net gains on investments in equity securities are reported in Other (income)/deductions –– net and, for 2018 , include unrealized net ga ins on equity securities reflecting the adoption of a new accountingstandard in the first
 quarter of 2018. For additional information, see Note 4 . C. Short-Term Borrowings
Short-term borrowings include:
 
  As of December 31, (MILLIONS OF DOLLARS)
  2018   2017 Commercial paper
  $3,100  $6,100 Current portion of long-term debt, principal amount 
(a)    4,781  3,532 Other short-term borrowings, principal amount 
(b)  966  320 Total short-term borrowings, principal amount
  8,847  9,951 Net fair value adjustments related to hedging and purchase accounting
  (5 ) 14 Net unamortized discounts, premiums and debt issuance costs
  (11 ) (12 )Total 
Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted   $8,831  $9,953 (a) 
 For additional information, see Note 7D . (b) 
 Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F . The weighted-average effective interest rate on commercial paper outstanding was approximately 
2.42% as of December 31, 2018 and 1.36% as of December 31, 2017 . On June 24, 2016, we acquired Anacor and assumed its short-term debt with an acquisition date fair value of 
$698 million , which was redeemed in the second and third quarters of 2016.
As of December 31, 
2018 , we had access to a $7.0 billion U.S. revolving credit facility expiring in 2023, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional 
$553 million lines of credit, of which $502 million expire within one year. Of these total lines of credit, 
$7.5 billion were unused as of December 31, 2018. 106
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
D. Long-Term Debt
New Issuances
In 2018, we issued the following senior unsecured notes:
(MILLIONS OF DOLLARS)
      Maturity Date
  Interest Rate   Principal September 2021
  3.000% notes (a) $1,000 September 2023
  Floating rate notes (LIBOR plus 0.33%) (b) 300 September 2023
  3.200% notes (a) 1,000 September 2028
  3.600% notes (a) 1,000 September 2038
  4.100% notes (a) 700 September 2048
  4.200% notes (a) 1,000 Total long-term debt issued 
(c)  $5,000 (a) 
 Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.(b) 
 Floating rate notes may not be redeemed by their terms prior to maturity.(c) 
 The weighted-average effective interest rate for the notes at issuance was 3.56% . In March 2017, we completed a public offering of 
$1.065 billion principal amount of senior unsecured notes due 2047 with an interest rate of 4.20% , and also in March 2017, we completed a public offering of € 
4.0 billion principal amount of senior unsecured notes with a weighted-average effective interest rate of 0.23% . On November 21, 2016, we completed a public offering of 
$6.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 3.10% 
. On June 3, 2016, we completed a public offering of 
$5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% . Retirements
In January 2019, we repurchased all 
€1.1 billion principal amount outstanding of the 5.75% euro-denominated debt that was due June 2021 before the maturity date at a redemption value of 
€1.3 billion . As a result, we recorded a net loss of approximately $138 million , which included the related termination of cross-currency swaps, and that was recorded in 
Other (income)/deductions––net in the consolidated statement of income in the first quarter of 2019. In December 2017, we exchanged approximately 
£833 million and repurchased £197 million principal amount of the outstanding 6.50% debt before the maturity date at a redemption value of 
£1.7 billion , leaving £470 million principal amount of the 6.50% debt due 2038 outstanding. Also, in December 2017, we repurchased approximately €834 million 
principal amount of the outstanding 5.75% debt before the maturity date at a redemption value of €1.0 billion , leaving approximately €1.2 billion of the 5.75% euro- denominated debt due 2021 outstanding as of December 31, 2017. As a
 result, we recorded a net loss of approximately $846 million and $153 million upon the exchange and early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a
 net loss on early retirement of debt of $999 million 
. which included the related termination of cross-currency swaps, and that were recorded in Other (income)/deductions––net in the consolidated statement of income (see 
Note 4 ). In November 2016, we repurchased 
$3.4 billion carrying value of outstanding debt before the maturity date at a redemption value of $3.7 billion . The debt repurchased included 
$3.27 billion carrying value of 6.20% senior notes due March 2019. As a result, we recorded a total net loss of approximately $312 million upon the early redemption of debt, which included the related termination of interest rate swaps, and which was recorded in 
Other (income)/deductions––net in the consolidated statement of income (see Note 4 
). 2018 Financial Report    
 
 107
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2018 and 2017 by maturity:
 
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017 Notes due 2019 (1.3%) 
(a)  $—  $4,848 Notes due 2020 (1.2% and 1.1%)
  1,474  1,528 Notes due 2021 (3.4% and 3.5%)
  4,459  3,550 Notes due 2022 (0.3%)
  1,145  1,199 Notes due 2023 (3.6% and 4.3%)
  2,892  1,592 Notes due 2024 (4.4%)
  1,500  1,500 Notes due 2026-2028 (3.3% and 3.2%)
  5,718  4,759 Notes due 2034 (6.5%)
  750  750 Notes due 2036-2039 (6.0% and 6.2%)
  7,301  6,636 Notes due 2040-2044 (3.8%)
  4,004  4,106 Notes due 2046-2048 (4.2%)
  3,315  2,315 Total long-term debt, principal amount
  32,558  32,783 Net fair value adjustments related to hedging and purchase accounting
  479  872 Net unamortized discounts, premiums and debt issuance costs
  (136 ) (125 )Other long-term debt
  7  8 Total long-term debt, carried at historical proceeds, as adjusted
  $32,909  $33,538 Current portion of long-term debt, carried at historical proceeds (not included above (1.3% and 2.4%))
  $4,776  $3,546 (a) 
 At December 31, 2018, the debt issuances have been reclassified to the current portion of long-term debt.Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.
E. Other Noncurrent Liabilities
Mylotarg (gemtuzumab ozogamicin)
In April 2018, the EU approved Mylotarg for the treatment of acute
 myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixedannual payments over a 
ten -year period aggregating $301 million related to an R&D arrangement. We recorded the estimated net present value of $240 million as a liability and an intangible asset in 
Developed technology rights as of the approval date. In June 2018, we entered into  a transaction with the obligee to buyout the remaining liability forthe fixed annual payments for a lump sum payment of 
$224 million . As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash$17 million 
pre-tax gain in Other (income)/deductions––net in the second quarter of 2018 (see Note 4 ). Bosulif (bosutinib)
In December 2017, the U.S. FDA approved Bosulif for the treatment
 of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, weincurred an obligation to make guaranteed fixed annual payments over a 
ten -year period aggregating $416 million related to an R&D arrangement. We recorded the estimated net present value of 
$364 million as of the approval date as an intangible asset in Developed technology rights . In August 2018, we entered into a transaction with the obligeeto buyout a portion of the remaining liability for the fixed annual payments for a lump sum payment of 
$71 million . As a result of the buyout transaction, the liability was reducedand we recognized a non-cash 
$9 million pre-tax gain in Other (income)/deductions––net in the third quarter of 2018 . The present value of the remaining future payments as ofDecember 31, 2018 
is $209 million , of which $23 million is recorded in Other current liabilities and $186 million is recorded in Other noncurrent liabilities . Besponsa (inotuzumab ozogamicin)
In August 2017, the U.S. FDA approved 
Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a 
nine - year period aggregating 
$296 million related to an R&D arrangement. We recorded the estimated net present value of $248 million as of the approval date as an intangible asset in 
Developed technology rights . The present value of the remaining future payments as of December 31, 2018 is $243 million , of which $7 million is recorded in Other current liabilities 
and $235 million is recorded in Other noncurrent liabilities . In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a 
nine -year period aggregating $148 million related to an R&D arrangement. We recorded the estimated net present value of $123 million as of the approval date as an intangible asset in 
Developed technology rights . The present value of the remaining future payments as of December 31, 2018 is $122 million , of which $3 million is recorded in 
Other current liabilities and $119 million is recorded in Other noncurrent liabilities . The differences between the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of these obligations were not significant as
of 
December 31, 2018 . 108
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
F 
. Derivative Financial Instruments and Hedging ActivitiesWe adopted a new accounting standard in the first quarter of 2018, as
 of January 2018. For additional information, see Note 1B. Foreign Exchange Risk
A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in 
foreign exchange rates. We manage our foreign exchange risk,in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency
liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of
derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency,
or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.
All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet.
The derivative financial instruments primarily hedge or offset exposures in the 
euro, U.K. pound, Japanese yen, Swedish krona and Chinese Renminbi . Changes in fair value are reported in earnings or in 
Other comprehensive income/(loss) , depending on the nature and purpose of the financial instrument (hedge or offset  relationship) and theeffectiveness of the hedge relationships, as follows:
•
Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fairvalue of the hedged risk. Upon the adoption of the new standard in 2018
, for certain foreign exchange contracts, we exclude an amount from the assessment of hedgeeffectiveness and recognize that excluded amount through an amortization approach. We also recognize the offse
tting foreign exchange impact attributable to the hedgeditem in earnings.
•
Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. Upon the adoption of
 the new standard in 2018,for certain foreign exchange contracts, we exclude an amount from the assessment of hedge e
ffectiveness and recognize that excluded amount through an amortizationapproach.
•
Upon the adoption of the new standard in 2018, for foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize thatexcluded amount through an amortization approach. We record in 
Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange- denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the
 sale or substantial liquidation ofour net investments. Historically, as part of our net investment hedging program, we recognized the gain and loss impact on foreign exchange contracts designated
 ashedges of our net investments in earnings in three ways: over time 
–– for the periodic net swap payments; immediately –– to the extent of any change in the differencebetween the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net
 investments –– to the extent of change in the foreign exchangespot rates.
•
For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used tooffset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essen
tiallytake the opposite currency position of that reflected in the month-end balance sheet
 to counterbalance the effect of any currency movement.As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a
 portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar 
-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. For 2017, any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for 2017.
Interest Rate Risk
Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis
position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. Historically, we strove to borrow
primarily on a floating-rate basis; but in recent years we borrowed on a long-term fixed-rate basis. From time to time, depending on market conditions, we will change the profile
of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or of
fset the fixedinterest rates on the hedged item, matching the amount and timing of the
 hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair
value are reported in earnings, as follows:
•
We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of thehedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to 
the hedged risk in earnings.For 2017, any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for 2017.
2018 Financial Report    
 
 109
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated
 ashedging instruments and those that are not designated as hedging instruments:
(MILLIONS OF DOLLARS)
  December 31, 2018   December 31, 2017  
     Fair Value      Fair Value  
  Notional   Asset   Liability   Notional   Asset   Liability Derivatives designated as hedging instruments:
                  Foreign exchange contracts 
(a)  $22,984  $654  $586  $18,723  $179  $459 Interest rate contracts
  11,145  432  383  12,430  581  178  
     1,085  968     760  637  
                  Derivatives not designated as hedging instruments:
                  Foreign exchange contracts
  $15,154  55  55  $14,300  62  54  
                  Total
     $1,140  $1,024     $822  $691 (a) 
 As of December 31, 2018 , the notional amount of o utstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.8 billion . The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:
 
  Amount of Gains/(Losses) 
Recognized in OID 
(a), (b)  Amount of Gains/(Losses) Recognized in OCI 
(a), (c)  Amount of Gains/(Losses) Reclassified from 
OCI into OID and COS 
(a), (c) 
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017  2018  2017  2018  2017 Derivative Financial Instruments in Cash Flow Hedge
Relationships:
             Foreign exchange contracts 
(d)  $—  $(6 ) $80  $(12 ) $(182 ) $520 Amount excluded from effectiveness testing recognized
in earnings based on an amortization approach
  —    140    153    
                  Derivative Financial Instruments in Fair Value HedgeRelationships:
                  Interest rate contracts
  (348 ) (60 ) —  —  —  — Hedged item gain
  348  60  —  —  —  — Foreign exchange contracts
  5  (19 ) —  —  —  — Hedged item gain/(loss)
  (5 ) 19  —  —  —  —  
                  Derivative Financial Instruments in Net Investment HedgeRelationships:
                  Foreign exchange contracts
  —  —  175  —  —  — The portion of gains/(losses) on foreign exchange
contracts excluded from the assessment of hedge
effectiveness
  —    77    68    
                  Non-Derivative Financial Instruments in Net InvestmentHedge Relationships:
                  Foreign currency short-term borrowings
  —  —  68  —  —  — Foreign currency long-term debt 
(e)  —  —  149  (580 ) —  —  
                  Derivative Financial Instruments Not Designated asHedges:
                  Foreign exchange contracts
  136  (87 ) —  —  —  — All other net
  —  —  (1 ) 2  2  1  
  $136  $(93 ) $688  $(591 ) $41  $520 (a)
 
OID = Other (income)/deductions—net,   included in Other (income)/deductions—net in the consolidated state ments of income . COS = Cost of Sales, included in Cost of sales in the consolidated state ments ofincome. OCI = Other comprehensive inc
ome/(loss), included in the consolidated statements of comprehensive income . (b) 
 For 2017, there is no significant ineffectiveness.(c)
 
For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss) ––Unrealized holding gains/(losses) on derivative financial instruments,net 
. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency tra
nslation adjustments, net.(d)
 
Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $156 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign ex
change cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.(e)
 
Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.4 billion as of December 31, 2018 , which are used as hedging  instruments in net investment hedges. Long-termdebt includes foreign curre
ncy long-term borrowings with carrying values of $3.2 billion as of December 31, 2018 , which are used as hedging  instruments in net investment hedges.110
  2018 Financial Report
 
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded:
(MILLIONS OF DOLLARS)
 December 31, 2018 Cost of sales
  $11,248 Other (income)/deductions—net
  2,116 The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:
 
  Carrying Amount of HedgedAssets/Liabilities
  Cumulative Amount of Fair ValueHedging Adjustment Gains/(Losses)
Included in the Carrying Amount of the
Hedged Assets/Liabilities
(MILLIONS OF DOLLARS)
  December 31, 2018   December 31, 2018 Long-term investments
  $45  $(1 )Short-term borrowings, including current portion of long-term debt
  1,499  5 Long-term debt
  9,952  45 Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both
counterparties’ exposure to risk of defaulting on amounts owed by the other party. As o
f December 31, 2018 , the aggregate fair value of these derivative instruments that are in a net liability position was 
$472 million , for which we have posted collateral of $544 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any
 additional collateral to our counterparties.As of 
December 31, 2018 , we received cash collateral of $881 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in 
Short-term borrowings, including current portion of long-term debt. G. Credit Risk
On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not
 expect to incur a significant loss fromfailure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual
counterparty, except for certain significant customers. For additional information, see 
Note 18C . As of December 31, 2018 , we had amounts due from a well-diversified, high quality group of banks ( 
$4.4 billion ) from around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the
ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the coun
terparty, see Note 7F above. Note 8. Inventories
The following table provides the components of 
Inventories :  
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017 Finished goods
  $2,262  $2,883 Work in process
  4,701  3,908 Raw materials and supplies
  546  788 Inventories 
(a)  $7,508  $7,578 Noncurrent inventories not included above 
(b)  $618  $683 (a)
 
The change from December 31, 2017 primarily reflects the reclassification of $538 million to Assets held for sale during the fourth quarter o f 2018 (see Note 2C) and a decrease due to foreign e xchange, partiallyoffset by increases for certain pro
ducts to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery, new product launches and the movement of products within ourmanufacturing network.
(b) 
 Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.2018 Financial Report    
 
 111
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 9 
. Property, Plant and EquipmentThe following table provides the components of 
Property, plant and equipment :  
  Useful Lives   As of December 31, (MILLIONS OF DOLLARS)
  (Years)   2018  2017 Land
  -  $500  $540 Buildings
  33-50  9,920  10,254 Machinery and equipment
  8-20  11,871  11,902 Furniture, fixtures and other
  3-12 1/2  4,693  4,661 Construction in progress
  -  2,992  2,680  
     29,977  30,037 Less: Accumulated depreciation
     16,591  16,172 Property, plant and equipment 
(a)     $13,385  $13,865 (a)
 
The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $675 million to Assets held for sale during the fourth quarter o f 2018 (see Note 2C ), reductions due to asset impairments largely associate
d with cost reduction initiatives not associated with acquisitions (see Note 3 ), and the impact of foreign exc hange, partially offset by capital additions.Note 10. 
Identifiable Intangible Assets and Goodwill A. 
Identifiable Intangible AssetsBalance Sheet Information
The following table provides the components of 
Identifiable intangible assets :  
  December 31, 2018   December 31, 2017 (MILLIONS OF DOLLARS)
  GrossCarrying
Amount
  AccumulatedAmortization
  IdentifiableIntangible
Assets, less
Accumulated
Amortization
  GrossCarrying
Amount
 AccumulatedAmortization
  IdentifiableIntangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
                  Developed technology rights 
(a)  $89,430  $(58,895 )  $30,535  $89,550  $(54,785 )  $34,765 Brands 
(a)  923  (708 ) 215  2,134  (1,152 )  982 Licensing agreements and other
  1,436  (1,140 )  296  1,911  (1,096 )  815  
  91,788  (60,743 )  31,045  93,595  (57,033 )  36,562 Indefinite-lived intangible assets
                  Brands and other 
(a)  1,994    1,994  6,929    6,929 IPR&D 
(a)  2,171    2,171  5,249    5,249  
  4,165    4,165  12,179    12,179 Identifiable intangible assets 
(b)  $95,954  $(60,743 )  $35,211  $105,774   $(57,033 )  $48,741 (a)
 
The changes in the gross carrying amount of Developed technology rights , Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets heldfor sale 
during the fourth quarter o f 2018 (see Note 2C ), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtan di in the U.S. for the treatment of men with non-metastatic castration-resistant prostat
e cancer, which is being developed through a collaboration with Astellas (see Note 2A ), (iii) $240 million of Developed technology rights recorded in connection wi th the EUapproval of Mylotarg (see 
Note 7E ), as well as impairments of $ 2.9 billion of Developed technology rights ( see Note 4) . (b)
 
The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to the reclassification of $5.8 billion of intangible assets, net, ( $6.3 billion total gross carrying amount) to Assets held for sale 
during the fourth quarter o f 2018 (see Note 2C ) and amortization and impairm ents, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see 
Note 7E ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
 
  December 31, 2018  
  IH   EH   WRD Developed technology rights
  76 % 24 % — Brands, finite-lived
  —  100 % — Brands, indefinite-lived
  —  100 % — IPR&D
  65 % 18 % 17 %112
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Developed Technology Rights
Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to
develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that
 we have acquired with respect to products, compounds and/or processesthat have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized
products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi,
Prevnar 13/Prevenar 13 Infant, Eucrisa, Premarin, Prevnar 13/Prevenar 13 Adult, Enbrel and,
 to a lesser extent Tygacil, Pristiq, Refacto AF and Bosulif. Also included in thiscategory are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.
Brands
Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protec
tion. The moresignificant components of indefinite-lived brands are the following (in order of significance): Xanax, Medrol and Depo-Medrol. The more significant components of finite-lived
brands are the following (in order of significance): Depo-Provera and Zavedos.
IPR&D
IPR&D assets represent R&D assets that have not yet
 received regulatory approval in a major market. A significant component of IPR&D at December 31, 2018 is the program for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part o
f the Medivation acquisition. IPR&D assets arerequired to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort.
 Accordingly, during the development periodafter the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S
. or the EU, or in a series of other countries,subject to certain specified conditions and management judgment. At that time, we will determine the useful life of 
the asset, reclassify the asset out of IPR&D and beginamortization. If the associated R&D effort is abandoned, the related 
IPR&D assets will likely be written-off, and we will record an impairment charge.For IPR&D assets, the risk of failure is significant and there can be no certainty 
that these assets ultimately will yield successful products. The nature of the biopharmaceuticalbusiness is high-risk and, as such, we expect that many of these IPR&D asse
ts will become impaired and be written off at some time in the future.Amortization
The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately 
9 years. Totalamortization expense for finite-lived intangible assets was 
$5.0 billion in 2018 , $4.8 billion in 2017 and $4.1 billion in 2016 . The following table provides the annual amortization expense expected for the years 2019 through 2023:
(MILLIONS OF DOLLARS)
  2019  2020  2021  2022  2023 Amortization expense
  $4,581  $3,552  $3,467  $3,217  $2,920 B. Goodwill
The following table provides the components of and changes in the carrying amount of 
Goodwill : (MILLIONS OF DOLLARS)
  IH  EH  Total Balance, January 1, 2017
  $30,134  $24,315  $54,449 Additions 
(a)  572  92  664 Other 
(b)  435  404  840 Balance, December 31, 2017
  31,141  24,811  55,952 Other 
(c)  (2,264 )  (277 ) (2,541 ) Balance, December 31, 2018
  $28,877  $24,534  $53,411 (a)
 
IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (seeNote 2A 
). (b) 
 Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.(c)
 
Primarily reflects the impact of the reclassification of $ 2.0 billion to Assets held for sale during the fourth quarter o f 2018 (see Note 2C), foreign exchange and the contr ibution of the allogeneic CAR Tdevelopmental program ass
ets and operations to Allogene that constituted a business for accounting purposes (see Note 2B ). 2018 Financial Report    
 
 113
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 11 
. Pension and Postretirement Benefit Plans and Defined Contribution PlansThe majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we
sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of
the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of
 employees with restrictions ondiscriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to
certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.
A. Components of Net Pe
riodic Benefit Costs and Changes in Other Comprehensive LossThe following table provides the annual (income)/cost and changes in 
Other comprehensive income/(loss)  for our benefit plans:  
  Year Ended December 31,  
  Pension Plans        
  U.S.Qualified 
(a)  U.S.Supplemental
(Non-Qualified)
  International   PostretirementPlans
(MILLIONS OF DOLLARS)
  2018  2017  2016  2018 2017 2016  2018  2017  2016  2018 2017 2016 Service cost 
(b)  $—  $269  $257 $— $24 $18  $136 $171 $165 $39 $42 $41 Interest cost
  598  634  646  55  54  53  212  204  233  72  90  101 Expected return on plan assets
  (1,040)  (1,005)  (958 ) —  —  —  (360 ) (345 ) (381 ) (37 ) (36 ) (34 )Amortization of:
                            Actuarial losses 
(b)  120  393  395  13  50  37  101  116  93  7  31  32 Prior service cost/(credits)
  2  3  5  (1 ) (1 ) (1 ) (4 ) (4 ) (3 ) (178) (182) (174 )Curtailments
  12  13  10  1  1  1  (4 ) —  (2 ) (17 ) (19 ) (26 )Settlements
  113  75  90  26  39  28  4  4  9  —  —  — Special termination benefits
  6  —  —  10  —  —  —  1  1  2  —  — Net periodic benefit
costs/(income) reported in
Income 
(c)  (189 ) 382  444  103 166 137  84  147  115  (111) (75 ) (59 )(Income)/cost reported in 
Other comprehensive income/(loss) 
(d) 361  141  253  (189) 23  121  84  (301 ) 640  105 (8 ) 3 (Income)/cost recognized in
Comprehensive income
  $171  $523  $697 $(86) $189 $258 $168 $(154) $755 $(6 ) $(83) $(56 )(a)
 
In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining planparticipants with a third-party insur
ance provider. As a result, we were relieved of the $156 million net pension benefit obligation  and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses 
and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions — net (see Note 3 ). (b)
 
Effective January 1, 2018, we froze two significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to theplan freeze, the average 
amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the averageamortization period in prior ye
ars utilized the expected future service period of plan participants.(c)
 
We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deduction s––net on the consolidated statements o
f income. For additional information, see Note 1B and Note 4 . (d)
 
In 2017 and 2016, the changes to Other comprehensive (income)/loss for the international plans w as impacted by foreign currency movements. For details of the changes in Other comprehensive (income)/loss, see the benefit plan activity in t
he consolidated statements of comprehensive income.The following table provides the amounts in 
Accumulated other comprehensive loss  expected to be amortized into 2019 net periodic benefit costs:   
  Pension Plans     (MILLIONS OF DOLLARS)
  U.S. Qualified
  U.S. Supplemental (Non-Qualified)
  International   Postretirement Plans Actuarial losses 
(a)  $(148 ) $(9 ) $(81 ) $(4 )Prior service credits and other
  3  1  3  178 Total
  $(145 ) $(9 ) $(78 ) $175 (a)
 
Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expectedlife expectancy of the plan p
articipants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for 2019 are 24.2 years for our U.S. qualified plans, 
25.3 years for our U.S. supplemental (n on-qualified) plans, 20 years for our international plans, and 9.3 years for our postretirement plans.114
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
B. Actuarial Assumptions
The following table provides the weighted-average actuarial assumptions of our benefit plans:
(PERCENTAGES)
  2018  2017  2016 Weighted-average assumptions used to determine benefit obligations
         Discount rate:
         U.S. qualified pension plans
  4.4%  3.8%  4.3% U.S. non-qualified pension plans
  4.3%  3.7%  4.2% International pension plans
  2.5%  2.3%  2.4% Postretirement plans
  4.3%  3.7%  4.2% Rate of compensation increase:
         U.S. qualified pension plans 
(a)  —  2.8%  2.8% U.S. non-qualified pension plans 
(a)  —  2.8%  2.8% International pension plans
  1.4%  2.5%  2.6% Weighted-average assumptions used to determine net periodic benefit cost
         Discount rate:
         U.S. qualified pension plans
  3.8%  4.3%  4.5% U.S. non-qualified pension plans
  3.7%  4.2%  4.5% International pension plans interest cost 
(b)  2.0%  2.1%  2.7% International pension plans service cost 
(b)  2.3%  2.3%  3.0% Postretirement plans
  3.7%  4.2%  4.5% Expected return on plan assets:
         U.S. qualified pension plans
  7.5%  8.0%  8.0% International pension plans
  4.4%  4.7%  5.2% Postretirement plans
  7.5%  8.0%  8.0% Rate of compensation increase:
         U.S. qualified pension plans
  2.8%  2.8%  2.8% U.S. non-qualified pension plans
  2.8%  2.8%  2.8% International pension plans
  2.5%  2.6%  2.6% (a)
 
Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members’ accrued benefits to that date no longer increase in line with future compensation increases. Therate of compensation inc
rease is therefore no longer an assumption used to determine the benefit obligation.(b)
 
Effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with thischange, the effective rate for i
nterest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the
 net periodic benefit cost for the subsequent fiscal year. Therefore, theassumptions used to determine net periodic benefit cost for each year are established at the end o
f each previous fiscal year, while the assumptions used to determine benefitobligations are established at each fiscal year-end.
The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at
 least an annual basis. We revise these assumptions basedon an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost
 of providing retirement benefits.The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the
 prevailing market rate of aportfolio of high-quality fixed income investments, rated AA/Aa or better that reflect
 the rates at which the pension benefits could be effectively settled. For our internationalplans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/
Aa or better, including, when there is sufficient data, a yield curveapproach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 
2018 resulted in higher discount rates as compared to the prior year.
The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:
 
  2018  2017 Healthcare cost trend rate assumed for next year (up to age 65)
  5.8 % 6.1 %Healthcare cost trend rate assumed for next year (age 65 and older)
  6.5 % 7.0 %Rate to which the cost trend rate is assumed to decline
  4.5 % 4.5 %Year that the rate reaches the ultimate trend rate
  2037  2037 The following table provides the effects as of December 31, 2018 of a one-percentage-point increase or decrease in the healthcare cost
 trend rate assumed for postretirementbenefits:
(MILLIONS OF DOLLARS)
  Increase   Decrease Effect on total service and interest cost components
  $3  $(2 )Effect on postretirement benefit obligation
  35  (27 )
2018 Financial Report     
 115
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and
 can rely heavilyon estimates and assumptions. For a description of the risks associated with estimates and assumptions, see 
Note 1C . C. Obligations and Funded Status
The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status
 of our benefit plans:  
  Year Ended December 31,  
  Pension Plans        
  U.S. Qualified (a) U.S. Supplemental(Non-Qualified)
  International (b) PostretirementPlans 
(c)(MILLIONS OF DOLLARS)
  2018  2017  2018  2017  2018  2017  2018  2017 Change in benefit obligation 
(d)                         
                        Benefit obligation, beginning
  $16,702  $15,547  $1,495  $1,450  $10,607  $9,691  $2,028  $2,254 Service cost
  —  269  —  24  136  171  39  42 Interest cost
  598  634  55  54  212  204  72  90 Employee contributions
  —  —  —  —  7  6  102  94 Plan amendments
  (22 ) —  —  —  29  2  2  — Changes in actuarial assumptions and other
  (1,219 )  1,614  (152 ) 110  (169 ) 135  (122 ) (177 )Foreign exchange impact
  —  —  —  —  (457 ) 760  (4 ) 5 Acquisitions/divestitures/other, net
  —  —  —  —  (2 ) 26  —  1 Curtailments
  11  11  1  —  (3 ) —  (1 ) 1 Settlements
  (391 ) (842 ) (72 ) (98 ) (34 ) (31 ) —  — Special termination benefits
  6  —  10  —  —  1  2  — Benefits paid
  (546 ) (530 ) (58 ) (45 ) (373 ) (357 ) (249 ) (280 )Benefit obligation, ending 
(d)  15,141  16,702  1,280  1,495  9,952  10,607  1,870  2,028  
                        Change in plan assets
                        Fair value of plan assets, beginning
  14,284  12,556  —  —  8,863  7,683  494  458 Actual gain/(loss) on plan assets
  (796 ) 2,005  —  —  (77 ) 811  (22 ) 39 Company contributions
  500  1,095  129  143  209  160  145  183 Employee contributions
  —  —  —  —  7  6  102  94 Foreign exchange impact
  —  —  —  —  (380 ) 561  —  — Acquisitions/divestitures, net
  —  —  —  —  —  30  —  — Settlements
  (391 ) (842 ) (72 ) (98 ) (34 ) (31 ) —  — Benefits paid
  (546 ) (530 ) (58 ) (45 ) (373 ) (357 ) (249 ) (280 )Fair value of plan assets, ending
  13,051  14,284  —  —  8,215  8,863  469  494 Funded status—Plan assets less than benefit
obligation
  $(2,089 )  $(2,418 )  $(1,280 )  $(1,495 )  $(1,738 )  $(1,745 )  $(1,401 )  $(1,534 ) (a)
The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the discount rate at the end of 2018, partially offset by a decrease in actual return on plan assets.(b) 
 The favorable change in the international plans’ funded status was primarily due to favorable currency movements, partially offset by a decrease in the actual return on plan assets.(c) 
 The favorable change in the funded status of our postretirement plans was primarily due to an increase in the discount rate at the end of 2018, partially offset by a decrease in actual return on plan assets.(d)
 
For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.1 billion in 2018 
and $16.7 billion in 2017 . The ABO for our  U.S. supplemental (non-qualified) pension plans was $1.3 billion in 2018 and $1.5 billion in 2017 . The ABO for our international pe nsion plans was $9.5 billion in 2018 
and $10.1 billion in 2017 . 116
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides information as to how the funded status is recognized in our consolidated balance sheets:
  
  As of December 31,  
  Pension Plans        
  U.S. Qualified   U.S. Supplemental (Non-Qualified)
  International   Postretirement Plans
(MILLIONS OF DOLLARS)
  2018  2017  2018  2017  2018  2017  2018  2017 Noncurrent assets 
(a)  $—  $—  $—  $—  $401  $454  $—  $— Current liabilities 
(b)  (1 ) —  (167 ) (160 ) (28 ) (26 ) (29 ) (31 )Noncurrent liabilities 
(c)  (2,088 )  (2,418 )  (1,113 )  (1,336 )  (2,111 )  (2,172 )  (1,371 )  (1,504 ) Funded status
  $(2,089 )  $(2,418 )  $(1,280 )  $(1,495 )  $(1,738 )  $(1,745 )  $(1,401 )  $(1,534 ) (a) 
 Included primarily in Other noncurrent assets . (b) 
 Included in Accrued compensation and re lated items . (c) 
 Included in Pension benefit obligations , net and Postretirement benefit obligations , net, as appropriate.The following table provides the pre-tax components of cumulative amounts recognized in 
Accumulated other comprehensive loss :  
  As of December 31,  
  Pension Plans        
  U.S. Qualified   U.S. Supplemental (Non-Qualified)
  International   Postretirement Plans
(MILLIONS OF DOLLARS)
  2018  2017  2018  2017  2018  2017  2018  2017 Actuarial losses 
(a)  $(5,061 )  $(4,677 )  $(370 ) $(561 ) $(2,372 )  $(2,322 )  $(202 ) $(293 )Prior service (costs)/credits
  1  (23 ) 1  1  —  34  994  1,190 Total
  $(5,060 )  $(4,699 )  $(370 ) $(559 ) $(2,372 )  $(2,288 )  $792  $897 (a)
 
The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between theexpected return and actual 
return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehen sive loss and are amortized into net periodic benefit costs primarily over theaverage remaining service p
eriod for active participants for plans that are not frozen or the expected life expectancy of plan participants for frozen plans, using the corridor approach.The following table provides information related to the funded status of selected benefit plans:
 
  As of December 31,  
  Pension Plans  
  U.S. Qualified   U.S. Supplemental (Non-Qualified)
  International (MILLIONS OF DOLLARS)
  2018  2017  2018  2017  2018  2017 Pension plans with an ABO in excess of plan assets:
                  Fair value of plan assets
  $13,051  $14,284  $—  $—  $4,514  $882 ABO
  15,141  16,702  1,280  1,495  6,286  2,724 Pension plans with a PBO in excess of plan assets:
                  Fair value of plan assets
  13,051  14,284  —  —  5,432  1,626 PBO
  15,141  16,702  1,280  1,495  7,571  3,825 All of our U.S. plans and many of our international plans were underfunded as of 
December 31, 2018 . 2018 Financial Report    
 
 117
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
D. Plan Assets
The following table provides the components of plan assets:
  
      Fair Value (a)          Fair Value (a)    (MILLIONS OF DOLLARS)
  As of December 31, 
2018
 Level 1 Level 2 Level 3 AssetsMeasured at
NAV 
(b)  As of December 31, 
2017
 Level 1 Level 2 Level 3 AssetsMeasured at
NAV 
(b) U.S. qualified pension plans
                            Cash and cash equivalents
  $443  $53  $390  $—  $—  $655  $115 $540  $—  $— Equity securities:
                          Global equity securities
  3,156  3,119  37  —  —  4,157  4,118 38  1  — Equity commingled funds
  933  —  634  —  299  1,194  —  802  —  392 Fixed income securities:
                          Corporate debt securities
  4,654  1  4,650  3  —  4,250  5  4,242  3  — Government and agency
obligations
  1,391  —  1,391  —  —  1,316  —  1,316  —  — Fixed income commingled funds
  96  —  —  —  96  94  —  —  —  94 Other investments:
                          Partnership investments 
(c)  1,165  —  —  —  1,165  1,197  —  —  —  1,197 Insurance contracts
  192  —  192  —  —  215  —  215  —  — Other commingled funds 
(d)  1,021  —  —  —  1,021  1,206  —  —  —  1,206 Total
  $13,051  $3,173  $7,294 $3  $2,581  $14,284  $4,238 $7,153 $4  $2,889 International pension plans
                            Cash and cash equivalents
  $246  $39  $208  $—  $—  $385  $48  $337  $—  $— Equity securities:
                          Global equity securities
  2  2  —  —  —  154  146  8  —  — Equity commingled funds
  1,876  —  1,413  —  463  2,897  —  1,594  —  1,303 Fixed income securities:
                          Corporate debt securities
  727  —  727  —  —  588  —  588  —  — Government and agency
obligations 
(e)   1,305  —  1,305  —  —  716  —  716  —  — Fixed income commingled funds
  1,770  —  1,007  —  762  2,181  —  1,340  —  841 Other investments:
                          Partnership investments 
(c)  57  —  4  —  53  42  —  7  —  35 Insurance contracts 
(f)   759  —  74  684  1  496  —  75  420  1 Other 
(d), (f)   1,473  —  71  382  1,020  1,404  —  408  468  528 Total
  $8,215  $40  $4,809 $1,065 $2,300  $8,863  $194 $5,073 $887  $2,709 U.S. postretirement plans 
(g)                             Cash and cash equivalents
  $—  $—  $—  $—  $—  $—  $—  $—  $—  $— Equity securities:
                          Global equity securities
  —  —  —  —  —  —  —  —  —  — Equity commingled funds
  —  —  —  —  —  —  —  —  —  — Fixed income securities:
                          Corporate debt securities
  —  —  —  —  —  —  —  —  —  — Government and agency
obligations
  —  —  —  —  —  —  —  —  —  — Fixed income commingled funds
  —  —  —  —  —  —  —  —  —  — Other investments:
                          Partnership investments 
(c)  —  —  —  —  —  —  —  —  —  — Insurance contracts
  469  —  469  —  —  494  —  494  —  — Other commingled funds 
(d)  —  —  —  —  —  —  —  —  —  — Total
  $469  $—  $469  $—  $—  $494  $—  $494  $—  $— (a)
Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1 E). (b)
Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of thefair value hierarchy to the amo
unts presented for the total pension benefits plan assets.(c 
)  Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.(d) 
 Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.(e) 
 Government and agency obligations are inclusive of repurchase agreements.
(f)  See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.(g) 
 Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.118
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:
 
  Year Ended December 31,  
  International Pension Plans  
  Insurance contracts   Other (MILLIONS OF DOLLARS)
  2018  2017  2018  2017 Fair value, beginning
  $420  $254  $468  $324 Actual return on plan assets:
         Assets held, ending
  1  1  15  18 Assets sold during the period
  —  —  —  1 Purchases, sales, and settlements, net
  188  138  (31 ) 94 Transfer into/(out of) Level 3
  107  —  (51 ) — Exchange rate changes
  (31 ) 27  (20 ) 30 Fair value, ending
  $684  $420  $382  $468 A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and
 can rely heavily on estimates and assumptions. For adescription of our general accounting policies associated with developing fair value estimates, see 
Note 1E. For a description of the risks associated with estimates and assumptions, see 
Note 1C. Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in
the fund based on the reported year-end NAV. Partnership and Other investments
 are valued based on year-end reported NAV (or its equivalent), with adjustments asappropriate for lagged reporting of up to three months.
The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:
•
Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may includeshort-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.
•
Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they aretraded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published
NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted,
suspended, or illiquid and are typically valued using their last available price.
•
Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which theyare traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2
investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or
quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment
managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.
•
Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they aretraded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments.
Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.
2018 Financial Report    
 
 119
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets
 for benefit plans:  
  As of December 31,   
  TargetAllocation Percentage
  Percentage of Plan Assets (PERCENTAGES)
  2018  2018  2017 U.S. qualified pension plans
         Cash and cash equivalents
  0-10%  3.4 % 4.6 %Equity securities
  35-55%   31.3 % 37.5 %Fixed income securities
  28-53%   47.1 % 39.6 %Other investments 
(a)  5-20%  18.2 % 18.3 %Total
  100 % 100 % 100 %International pension plans
         Cash and cash equivalents
  0-10%  3.0 % 4.3 %Equity securities
  20-40%   22.9 % 34.4 %Fixed income securities
  35-60%   46.3 % 39.3 %Other investments
  10-35%   27.9 % 21.9 %Total
  100 % 100 % 100 %U.S. postretirement plans
         Cash and cash equivalents
  0-5%  —  — Equity securities
  —  —  — Fixed income securities
  —  —  — Other investments
  95-100%   100 % 100 %Total
  100 % 100 % 100 %(a)
 
Actual percentage of plan assets in Other investments for 2018 includes $192 million , as compared to $215 million in 2017 , related to a group fixed a nnuity insurance contract that was executed by legacy Wyethfor certain members of its defined 
benefit plans prior to Pfizer acquiring the company in 2009, and $177 million in 2018 , as compared to $253 million in 2017 , related to an invest ment in a partnership whoseprimary holdings are public e
quity securities. Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage ne
t periodic benefitcosts and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return
expectations are developed based on a diversified, global investment strategy that takes into account
 historical experience, as well as the impact of portfolio diversification,active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change
, we may adjust ourtargets accordingly and our asset allocations may vary from the target allocations.
Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of 
the respective plans’ long-term benefitobligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset
classes and our liability profile.
Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. 
In determining investment policies andassociated target allocations, each committee or board considers a wide variety of factors. As such, the
 target asset allocation for each of our international pension plans is seton a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the
 international pension plans seek to reflect the combined targetallocations across all such plans, while also showing the range within which the target allocations for each plan typically falls.
The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative
securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing
agreement.
E. Cash Flows
It is our practice to fund amounts for our qualified pension plans that are at least
 sufficient to meet the minimum requirements set forth in applicable employee benefit laws andlocal tax laws.
120
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table provides the expected future cash flow information related to our benefit plans:
  
  Pension Plans    (MILLIONS OF DOLLARS)
  U.S. Qualified   U.S. Supplemental(Non-Qualified)
  International   Postretirement Plans Expected employer contributions:
            2019
 $11  $167  $177  $160 Expected benefit payments:
            2019
  $1,387  $167  $354  $166 2020
  1,089  121  372  171 2021
  1,058  114  380  171 2022
  1,020  113  385  168 2023
  1,018  103  387  165 2024–2028
  4,837  445  2,068  777 The above table reflects the total U.S. and international plan benefits projected 
to be paid from the plans or from our general assets under the current actuarial assumptionsused for the calculation of the benefit obligation and, therefore, actual bene
fit payments may differ from projected benefit payments.F. Defined Contribution Plans
We have defined contribution plans in the U.S. and several other countries. For the majority of the
 U.S. defined contribution plans, employees may contribute a portion of theirsalaries and bonuses to the plans, and we match, in cash, a portion of 
the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehiresand transfers to the U.S. or Puerto Rico, we no longer offer a
 defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the definedcontribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each
employee’s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans
transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of 
$622 million in 2018, 
$380 million in 2017 and $317 million in 2016 . Note 12 
. EquityA. Common Stock
We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of
the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On October 23, 2014, we announced that
 the Board ofDirectors had authorized an 
$11 billion share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a new 
$11 billion share repurchase program (the December 2015 Stock Purchase Plan), which was exhausted in the third quarter of 2018. In December 2017, the Board ofDirectors authorized an additional 
$10 billion share repurchase program, to be utilized over time, and share repurchases commenced thereunder in the third quarter of 2018 (the 2017 program). In December 2018, the Board of Directors authorized a new 
$10.0 billion share repurchase program to be utilized over time. This new program is in addition to the 
$4.2 billion remaining under the company’s 2017 program authorization as of December, 31 2018. On March 8, 2016, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase 
$5 billion of our common stock. Pursuant to the terms of the agreement, on March 10, 2016, we paid 
$5 billion to GS&Co. and received an initial delivery of approximately 136 million shares of our common stock from GS&Co. based on a price of 
$29.36 per share, which represented, based on the closing share price of our common stock on the NYSE on March 8,  2016, approximately 80% of the notional amount of the accelerated share repurchase agreement. On June 20, 2016, the
 accelerated share repurchase agreement with GS&Co. was completed, which, per the terms ofthe agreement, resulted in GS&Co. owing us a certain number of shares of Pfizer common stock.
 Pursuant to the agreement’s settlement terms, we received an additional 18 million 
shares of our common stock from GS&Co. on June 20, 2016. The  average price paid for all of the shares delivered under the accelerated share repurchase agreementwas 
$32.38 per share. The common stock received is included in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization.
On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase 
$5 billion of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid 
$5 billion to Citibank and received an initial delivery of approximately 126 million shares of our common stock from Citibank at a price of 
$31.73 per share, which represented, based on the closing price of our common stock on the NYSE on February 2,  2017, approximately 80% of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the
agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s set
tlement terms, we received an additional 24 million 
shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was 
$33.31 per share. The common stock received is included in Treasury Stock . This agreement was entered into pursuant to our previously announced share repurchase authorization.
On 
March 12, 2018 , we entered into an accelerated share repurchase agreement with Citibank to repurchase $4.0 billion of our common stock. Pursuant to the terms of the agreement, on 
March 14, 2018 , we paid $4.0 billion to Citibank and received an initial delivery of approximately 87 million shares of our common stock from Citibank at a price of 
$36.61 per share, which represented, based on the closing 2018 Financial Report    
 
 121
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
price of our common stock on the NYSE on 
March 12, 2018 , approximately 80% of the notional amount of the accelerated share repurchase agreement. On September 5, 2018, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of
shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 
21 million shares of our common stock from Citibank on September 7, 2018. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was 
$36.86 per share. The common stock received is included in 
Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. Open market purchases totaled 
$8.2 billion in 2018 under our publicly announced share-purchase plans. The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including
our accelerated share repurchase agreements:
(SHARES IN MILLIONS, DOLLARS IN BILLIONS)
  2018 (a) 2017 (b) 2016 (c)Shares of common stock purchased
  307  150  154 Cost of purchase
  $12.2  $5.0  $5.0 ( 
a)  Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on March 12, 2018, as well as other share repurchases. See above for additional information.(b) 
 Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information.(c) 
 Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through 
December 31, 2018 , our remaining share-purchase authorization was approximately  
$14.2 billion at December 31, 2018 . On 
February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. This agreement was entered into pursuant to our previously announced share repurchase authorization. For additional information, see 
Note 19 . B. Preferred Stock
The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 
6.25% , which are accumulated and paid quarterly. The per-share stated value is 
$40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder’s option, into 
2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the da
te of issuance. We may redeem the preferred stock at any time or upon termination of thePreferred ESOP, at our option, in cash, in shares of
 common stock, or a combination of both at a price of $40,300 per share. C. Employee Stock Ownership Plans
We have 
two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the
 eventual conversion of allocatedpreferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. 
As of December 31, 2018 , the Preferred ESOP held preferred shares convertible into approximately 
1 million shares of our common stock, and the Common ESOP held approximately 49 million shares of our common stock. As of December 31, 2018 , all shares of preferred and common stock held by the ESOPs have been allocated 
to the Pfizer U.S. defined contribution plan participants. The compensation cost related to theCommon ESOP was 
$19 million in 2018 , $11 million in 2017 and $9 million in 2016 . Note 13. Share-Based Payments
Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in
competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of RSUs, P
PSs,TSRUs, stock options, PSAs, PTSRUs and PTUs,
 as determined by the Compensation Committee.The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Plan, as amended and resta
ted. The 2014 Plan provides for 520 million shares to be authorized for grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 
Plan provides that the number ofstock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted 
to any one individual during any 36-month period is limited to 
20 million shares, and that RSUs, PPSs and PS As count as three shares, while TSRUs, PTSRUs and stock options count as one share, toward themaximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one
individual during any 36-month period was limited to 
8 million shares. As of December 31, 2018 , 195 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to
 a lesser extent, treasury stock to satisfy our obligations under these programs.122
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
A. Impact on Net Income
The following table provides the components of share-based compensation expense and the associated tax benefit:
 
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 TSRUs 
(a)  $302  $221  $134 RSUs
  286  301  299 PPSs
  276  209  135 PSAs
  62  47  13 Stock options
  12  55  106 Directors’ compensation
  10  7  4 Share-based payment expense
  949  840  691 Tax benefit for share-based compensation expense 
(b)  (180 ) (163 ) (205 )Share-based payment expense, net of tax
  $769  $677  $486 (a) 
 Includes $7.0 million of expense for PTSRUs. (b) 
 2018 and 2017 include the impact of the TCJA on income taxes.Amounts capitalized as part of inventory cost were not significant for any period presented.
B. Total Shareholder Ret
urn UnitsTSRUs are awarded to senior and other key management, and, beginning in 2016, to certain other employees. TSRUs entitle the holders to
 receive a number of shares of ourcommon stock with a value equal to the difference between the defined settlement price and 
the grant price, plus the dividends accumulated during the five -year or seven - year term, if and to the extent the to
tal value is positive. The settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth orseventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the
 date of the grant. The TSRUs are automatically settled on thefifth or seventh anniversary of the grant but vest on 
the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture.On October 26, 2016, the Compensation Committee approved the modification of current outstanding grants
 of TSRU awards, effective November 1, 2016, to permit a holderwho is "retiree eligible" (at least age 
55 with at least 10 years of service), to elect to exercise and convert his/her TSRUs when vested, into PTUs. The value received upon theelection and conversion is calculated by taking the change in stock price ( 
20 trading day average ending on the exercise date (Election Price) less the grant price) plusaccumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to de
termine the number of PTUs. The PTUs willbe entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs original settlement date (i.e.,
 the fifth orseventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. This modification applied to
approximately 
2,900 employees, including members of senior management. There was no incremental compensation cost resulting from the modification. Beginning in 2017,TSRUs were granted with the right for retirement-eligible employees to elect to exercise and convert their TSRUs, when vested, into PTUs. We measure the value of T
SRUgrants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis
over the vesting term into 
Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate. The following table provides the weighted-average assumptions used in the valuation of TSRUs:  
 
  Year Ended December 31,2018
 2017  2016 Expected dividend yield 
(a)  3.73 % 3.69 % 3.85 %Risk-free interest rate 
(b)  2.60 % 1.98 % 1.31 %Expected stock price volatility 
(c)  20.00 %  18.39 %  21.64 % Contractual term (years)
  5.12  5.11  5.12 (a) 
 Determined using a constant dividend yield during the expected term of the TSRU.(b) 
 Determined using the interpolated yield on U.S. Treasury zero-coupon issues.(c) 
 Determined using implied volatility, after consideration of historical volatility.2018 Financial Report    
 
 123
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table summarizes all TSRU activity during 2018:
 
  TSRUs(Thousands)
  Weighted-AverageGrant-Date
Fair Value
Per TSRU
  Weighted-AverageGrant Price
Per TSRU
Nonvested, December 31, 2017
  103,906   $6.07  $32.47 Granted
  47,755  7.42  35.75 Vested 
(a)  (7,203 )  6.67  34.49 Forfeited
  (5,512 )  6.55  33.88 Nonvested, December 31, 2018
  138,945   $6.48  $33.44 (a)
 
Includes the modification of approximately 1.7 million TSRUs to approximately 260 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modifiedto permit the vesting upon termi
nation. The impact to compensation expense was immaterial.The following table summarizes TSRU and PTU information as of December 31, 2018 
(a), (b) : 
  TSRUs(Thousands)
  PTUs(Thousands)
  Weighted-Average
Grant Price
Per TSRU
  Weighted-AverageRemaining
Contractual Term
(Years)
 AggregateIntrinsic
Value
(Millions)
TSRUs Outstanding
  156,534   —  $33.09  3.1  $2,073 TSRUs Vested 
(c)  17,588  —  30.30  1.5  332 TSRUs Expected to vest 
(d)  133,878   —  33.38  3.2  1,688 TSRUs exercised and converted to PTUs
  —  1,385  $—  0.5  $60 (a) 
 In 2018 , we settled 7,643,846 TSRUs with a we ighted-average grant price of $23.13 per unit. (b) 
 In 2018 , 2,809,652 TSRUs with a we ighted-average grant price of $27.86 per unit were converted into 1,408,622 PTUs. (c)
 
Includes the modification of approximately 1.7 million TSRUs to approximately 260 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modifiedto permit the vesting upon termi
nation. The impact to compensation expense was immaterial.(d) 
 The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.The following table provides data related to all TSRU activity:
 
  Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)
  2018  2017  2016 Weighted-average grant-date fair value per TSRU
  $7.42  $6.23  $5.83 Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax
  $246  $232  $164 Weighted-average period over which TSRU cost is expected to be recognized (years)
  1.6  1.7  1.9 C. Performance Total Shareh
older Return UnitsIn December 2017, PTSRUs were awarded to the then Chairman and Chief Executive Officer and the then
 Group President, Pfizer Essential Health. These awards weregranted in connection with our Board’s succession planning for the Chairman and Chief Executive Officer and our announcement on November 13, 2017 that our 
then GroupPresident, Pfizer Innovative Health had been appointed Chief Operating Officer of 
Pfizer effective January 1, 2018. We also announced that effective January 1, 2018, the thenGroup President, Pfizer Essential Health, had been appointed Group President, P
fizer Innovative Health. In addition to having the same characteristics of TSRUs, PTSRUsrequire special service and performance conditions. On December 29, 2017, 
1,372,213 PTSRUs were granted to the Chairman and Chief Executive Officer and 343,053 PTSRUs were granted to the new head of Innovative Health at a grant
 price of $36.22 and a grant-date fair value of $5.83 . We measure the value of PTSRU grants as of the grant date
 using a Monte Carlo simulation model. The values determined through this fair value methodology generally areamortized on a straight-line basis over the vesting term into 
Selling, informational and administrative expenses as appropriate. D. Restricted Stock Units
RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock
, including shares resulting fromdividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after 
three years of continuous service from the grant date.
We measure the value of RSU grants as of the grant date using 
the closing price of our common stock. The values determined through this fair value methodology generallyare amortized on a straight-line basis over the vesting term into 
Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate.
124
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table summarizes all RSU activity during 2018:
 
  Shares (Thousands)
  Weighted-AverageGrant-Date Fair Value
Per Share
Nonvested, December 31, 2017
  22,241  $32.64 Granted
  9,083  35.90 Vested 
(a)  (3,701 )  34.02 Reinvested dividend equivalents
  974  38.96 Forfeited
  (1,321 )  33.85 Nonvested, December 31, 2018
  27,276  $33.70 (a)
 
Includes the modification of approximately 150 thousand RSUs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms weremodified to permit vesting upo
n termination. The impact to the compensation expense was immaterial.The following table provides data related to all RSU activity:
(MILLIONS OF DOLLARS)
  Year Ended December 31,2018
 2017  2016 Total fair value of shares vested 
(a)  $146  $584  $293 Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax
  $256  $254  $262 Weighted-average period over which RSU cost is expected to be recognized (years)
  1.7  1.7  1.7 (a)
 
2018 includes modification of approximately 150 thousand RSUs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms weremodified to permit vesting upo
n termination. The impact to the compensation expense was immaterial. 2017 includes the modification for a commitment to pay approximately 6.4 million RSUs to approximately 9,900 
employees, including senio r and key management employees, for 6.6 million RSUs. These shares were paid in the first quarter of 2018.E. Portfolio Performance Shares
PPSs are awards granted to select employees which, when vested, entitle the holder to receive, a
t the end of the performance period, a number of shares within a possiblerange of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the
 awardsvest after 
three years of continuous service from the grant date and the number of shares paid, if any , depends on the achievement of predetermined goals related to Pfizer’slong-term product portfolio during a 
five -year performance period from the year of the grant date. The number of shares that may be earned over the performance periodranges from 
0% to 200% of the initial award. We measure the value of PPS grants as of the
 grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortizedon a straight-line basis over the probable vesting term into 
Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes
 in the number of shares that are probable ofbeing earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved and/or changes in management’s
assessment of the probable vesting term.
The following table summarizes all PPS activity during 2018, with the shares representing the maximum award that could be achieved:
 
  Shares (Thousands)
  Weighted-AverageIntrinsic Value
Per Share
Nonvested, December 31, 2017
  20,973  $36.22 Granted
  6,769  35.74 Vested 
(a)  (7,483 )  37.31 Forfeited
  (998 ) 38.23 Nonvested, December 31, 2018 
(b)  19,261  $43.65 (a)
Includes the modification of approximately 200 thousand PPSs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms weremodified to permit the vesting u
pon termination. The impact to compensation expense was immaterial.(b) 
 Vested and non-vested shares outstanding, but not paid as of December 31, 2018 were 33.9 million . The following table provides data related to all PPS activity:
(MILLIONS OF DOLLARS)
  Year Ended December 31,2018
 2017  2016 Total fair value of shares vested 
(a)  $169  $131  $118 Total compensation cost related to nonvested PPS awards not yet
 recognized, pre-tax  $102  $94  $93 Weighted-average period over which PPS cost is expected to be recognized (years)
  1.8  1.7  1.8 (a)
 
Includes the modification of approximately 200 thousand PPSs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modifiedto permit the vesting upon termi
nation. The impact to compensation expense was immaterial.2018 Financial Report    
 
 125
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
F. Performance Share Awards
PSAs are awarded to senior and other key management. PSAs vest
 after three years of continuous service from the grant date. The number of shares paid, if any,  includingshares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to 
two measures: (i) operatingincome (for performance years through 2018) or net income (for 2019 and later years) over 
three one -year periods; and (ii) TSR as compared to the NYSE ARCAPharmaceutical Index (DRG Index) over the 
three -year performance period. The number of shares paid from awards granted in 2014 depends upon the achievement of predetermined goals related to Pfizer's TSR as compared to an industry peer group, for the three-year performance period from the year of the grant da
te. The number ofshares that are earned over the performance period ranges from 
0% to 200% of the initial award. We measure the value of PSA grants as of the
 grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortizedon a straight-line basis over the probable vesting term into 
Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes
 in the number of shares that are probable ofbeing earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved.
The following table summarizes all PSA activity during 2018, with the shares granted representing the maximum award that could be achieved:
 
  Shares (Thousands)
  Weighted-AverageIntrinsic Value
Per Share
Nonvested, December 31, 2017
  4,024  $36.22 Granted
  1,833  35.74 Vested 
(a)  (112 ) 39.58 Forfeited
  (463 ) 37.12 Nonvested, December 31, 2018
  5,282  $43.65 (a)
 
Includes the modification of a few PSAs to a few employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified to permit the vesting upontermination. The impact to compens
ation expense was immaterial.The following table provides data related to all PSA activity:
 
  Year Ended December 31, (MILLIONS OF DOLLARS)
  2018   2017   2016 Total fair value of shares vested 
(a)  $4  $58  $9 Total compensation cost related to nonvested PSA grants not
 yet recognized, pre-tax  $41  $34  $30 Weighted-average period over which PSA cost is expected to be recognized (years)
  1.8  1.8  1.8 (a)
 
Includes the 2018 modification of a few PSAs to a few employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified to permit the vesting upontermination. The impact to compens
ation expense was immaterial. Includes the 2017 modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and keymanagement employees, for 
1.1 million PSAs. These shares were paid in the first quarter of 2018. G. Stock Options
Stock options are awarded to select employees and, when vested, entitle the holder to
 purchase a specified number of shares of our common stock at a price per share equalto the closing market price of our common stock on the date of grant.
Beginning in 2016, only a limited set of overseas employees received stock option grants. 
No stock options were awarded to senior and other key management in any periodpresented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted vest a
fter three years of continuous service from the grant date and have a contractual term of 
10 years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In theevent of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period of 
three months following the date employment is terminated or through their remaining term, depending on various conditions.
We measure the value of stock option grants as of the grant
 date using the Black-Scholes-Merton option-pricing model. The values determined through this fair valuemethodology generally are amortized on a straight-line basis over the vesting term into 
Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses 
, as appropriate. The following table provides the weighted-average assumptions used in the valuation of stock options:
 
  Year Ended December 31,   
  2018  2017  2016 Expected dividend yield 
(a)  3.73 % 3.69 % 3.85 %Risk-free interest rate 
(b)  2.85 % 2.23 % 1.55 %Expected stock price volatility 
(c)  20.02 %  18.39 %  21.64 % Expected term (years) 
(d)  6.75  6.75  6.75 (a) 
 Determined using a constant dividend yield during the expected term of the option.(b) 
 Determined using the interpolated yield on U.S. Treasury zero-coupon issues.(c) 
 Determined using implied volatility, after consideration of historical volatility.(d) 
 Determined using historical exercise and post-vesting termination patterns.126
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
The following table summarizes all stock option activity during 2018:
 
  Shares(Thousands)
  Weighted-AverageExercise Price
Per Share
  Weighted-AverageRemaining Contractual
Term
(Years)
 AggregateIntrinsic Value 
(a)(Millions)
Outstanding, December 31, 2017
  150,757   $27.27      Granted
  1,372  35.74      Exercised
  (47,740 )  26.59      Forfeited
  (219 ) 33.96      Expired
  (379 ) 24.69      Outstanding, December 31, 2018 
(b)  103,791   27.69  4.4  $1,657 Vested and expected to vest, December 31, 2018 
(c )  103,621   27.68  4.4  1,655 Exercisable, December 31, 2018
  100,078   $27.47  4.2  $1,619 (a) 
 Market price of our underlying common stock less exercise price.(b)
 
Includes the modification of approximately 190 thousand stock options to a few employees, i ncluding management employees, in connection with our Organizing for Growth initiative. The terms were modified topermit a longer exercise term after t
ermination.(c) 
 The number of options expected to vest takes into account an estimate of expected forfeitures.The following table summarizes data related to all stock option activity:
 
  Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)
  2018  2017  2016 Weighted-average grant-date fair value per stock option
  $5.06  $4.01  $3.89 Aggregate intrinsic value on exercise
  $625  $331  $389 Cash received upon exercise
  $1,259  $862  $1,019 Tax benefits realized related to exercise
  $115  $95  $112 Total compensation cost related to nonvested stock options not yet
 recognized, pre-tax  $5  $10  $58 Weighted-average period over which stock option compensation cost is expected to be recognized (years)
  1.7  0.8  1.1 Note 14. Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following table provides the detailed calculation of 
Earnings per common share  (EPS) :  
  Year Ended December 31, (IN MILLIONS)
  2018  2017  2016 EPS Numerator––Basic
        Income from continuing operations
  $11,179  $21,353  $7,229 Less: Net income attributable to noncontrolling interests
  36  47  31 Income from continuing operations attributable to Pfizer Inc.
  11,143  21,306  7,198 Less: Preferred stock dividends––net of tax
  1  1  1 Income from continuing operations attributable to Pfizer Inc. common shareholders
  11,142  21,305  7,197 Discontinued operations––net of tax
  10  2  17 Less: Discontinued operations––net of tax, attributable to noncontrolling interests
  —  —  — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders
  10  2  17 Net income attributable to Pfizer Inc. common shareholders
  $11,152  $21,307  $7,214 EPS Numerator––Diluted
       Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
  $11,143  $21,306  $7,197 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions
  10  2  17 Net income attributable to Pfizer Inc. common shareholders and assumed conversions
  $11,153  $21,308  $7,214 EPS Denominator
       Weighted-average number of common shares outstanding––Basic 
(a)  5,872  5,970  6,089 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible
preferred stock and accelerated share repurchase agreements 
(a)  105  89  70 Weighted-average number of common shares outstanding––Diluted
  5,977  6,058  6,159 Stock options that had exercise prices greater than the average market price of our common stock issuable
under employee compensation plans 
(b)  2  36  63 Cash dividends declared per share
  $1.38  $1.30  $1.22 
(a) 
2017 includes the effect of the modification for a commitment to pay 15.2 million common-share equivalents th at were scheduled for near-term settlement. These common share equivalents were paid in the firstquarter of 2018.
(b)
 
These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutiveeffect.
2018 Financial Report    
 
 127
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 15 
. Lease CommitmentsWe lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay
 directly for taxes, insurance, maintenance and otheroperating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was 
$301 million in 2018 , $314 million in 2017 and $292 million 
in 2016 . The future minimum rental commitments under non-cancelable operating leases follow:
(MILLIONS OF DOLLARS)
  2019  2020  2021  2022  2023  After 2023 Lease commitments
  $300  $252  $210  $267  $248  $2,040 Note 16. Insurance
Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-
insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost
and availability of coverage have resulted in self-insuring certain exposures, including product liability. 
If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash
 flows or results of operations in theperiod in which the amounts are paid and/or accrued (see 
Note 17 ). Note 17 
. Contingencies and Certain CommitmentsWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of
our tax contingencies, see 
Note 5D. For a discussion of our legal contingencies, see below. A 
. Legal ProceedingsOur legal contingencies include, but are not limited to, the following:
•
Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in themajority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of paten
t protection for a drug, a significant loss of revenues fromthat drug or impairment of the value of associated assets.
•
Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims,among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual,
provable injury and other matters.
•
Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that willvary from matter to matter.
•
Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S.and in other jurisdictions. 
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We
do not believe that any of these matters will have a material adverse effect on our 
financial position. However, we could incur judgments, enter into settlements or revise ourexpectations regarding the outcome of certain matters, and such developments could have a material adverse effect on
 our results of operations in the period in which theamounts are accrued and/or our cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and,
 therefore,determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range o
f reasonably possible loss inexcess of amounts accrued. Our assessments are based on estimates and assumptions that
 have been deemed reasonable by management, but the assessment processrelies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause
 us tochange those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on
estimates and assumptions.
The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and
qualitative factors in order to assess materiality, such as, among other things, the amount of
 damages and the nature of any other relief sought in the proceeding, if suchdamages and other relief are specified; our view of the merits of the claims and of the strength o
f our defenses; whether the action purports to be, or is, a class action and, ifnot certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been
transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be
important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information
that is available to the reader; the potential impact of the proceeding on our reputation;
 and the extent of public interest in the matter. In addition, with respect to patent mattersin which we are the plaintiff, we consider, among other things, the financial significance of the product protected by
 the patent(s) at issue. As a result of considering qualitativefactors in our determination of
128
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is
remote.
A1 
. Legal Proceedings––Patent LitigationLike other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits
 involveclaims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of 
the generic drugmanufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts 
to enforce, patent rights with respect tocertain products constitute unfair competition and/or violations of antitrust laws. In addition to the
 challenges to the U.S. patents on a number of our products that are discussedbelow, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to
which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing
and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. 
We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the
European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of
 others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several
of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the United States. In June 2018,
 the PatentTrial and Appeal Board ruled on one patent, holding that 
one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision.Challenges to other patents remain pending before the U.S. Patent and Trademark Of
fice. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate
 foralleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their
attempts to bring generic pharmaceutical and biosimilar products to market. 
If one of our marketed products is found to infringe valid patent rights of  a third party, such thirdparty may be awarded significant damages, or we may be prevented from further sales of that product. Such
 damages may be enhanced as much as three-fold in the eventthat we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.
Actions In Which We Are 
The PlaintiffBosulif (bosutinib)
In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF 
Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals,Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.
S.District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to
market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic
myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a paten
t-infringement actionagainst MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an
abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering
polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wye
th brought an additional patent-infringement actionagainst Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of 
two other patents challenged by Sun, which expire in 2025 and 2026,respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia.
EpiPen
In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for 
the District ofNew Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is
challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.
Precedex Premix
In June 2014, 
Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit
 setting, whichexpires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject
 of the lawsuit) filed suit againstBen Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and
infringement of the patent. In October 2014, 
Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not materialto Pfizer.
In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic
version of Hospira’s premix version of Precedex and containing allegations that 
four patents relating to the Precedex premix formulations and their use, all of which expire in2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for 
the District of Delaware asserting the validity and infringementof the patents that are the subject o
f the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals 
for the Federal Circuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a
generic version of Hospira’s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which
expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the
validity and infringement of those patents. In
2018 Financial Report    
 
 129
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
December 2018, the District Court ruled that the asserted patents were invalid. Hospira has appealed the District Court’s decision to the U.S. Court of
 Appeals for the FederalCircuit.
In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had
 filed an abbreviated new drug application with the FDA seeking approval to market a genericversion of Hospira’s premix version of Precedex and containing allegations that 
four patents relating to the Precedex premix formulations and their use, all of which expire in2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the
 District of Delaware asserting the validity and infringementof the patents that are the subject o
f the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals).In December 2017, Gland Pharma Limited (Gland) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic
version of Hospira’s premix version of Precedex and containing allegations that 
six patents relating to the Precedex premix formulations and their use, all of which expire in2032, were invalid or not infringed. In February 2018, Hospira filed suit against Gland in the U.S. District Court for the District of Delaware asserting the validity and
infringement of 
four patents that are the subject of the lawsuit.In December 2017, Jiangsu Hengrui Medicine Co., Ltd. (Hengrui) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market
a generic version of Hospira’s premix version of Precedex and containing allegations that 
six patents relating to the Precedex premix formulations and their use, all of whichexpire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Hengrui in the U.S. District Court for the District of Delaware asserting the validity and
infringement of 
four patents that are the subject of the lawsuit.In February 2018, Baxter Healthcare Corporation (Baxter) filed a declaratory judgment action against Hospira in the U.S. District Court for the District of Delaware seeking a
declaration of non-infringement of 
four patents relating to the Precedex premix formulations and their use. One of the patents included in the action expires in 2019 and the other 
three patents expire in 2032. In March 2018, Hospira filed a counterclaim for infringement of the patent expiring in 2019. In November 2018, the case was dismissed bymutual agreement of the parties.
Xeljanz (tofacitinib)
In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the
 District ofDelaware asserting the infringement and validity of 
three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2018, we settled all of our claims against MicroLabs on terms not material to P
fizer.Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the
 U.S. District Court for the District of Delawareasserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd
. inits abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional
patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the
 District of Delaware asserting the infringement and validity of anotherpatent challenged by Sun Pharmaceutical Industries Ltd, which covers the active ingredient and expires in December 2025. In October 2018
, we brought a third patentinfringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of
 Delaware asserting the infringement and validity of our patentcovering the extended release formulation of tofacitinib, which expires in 2034.
In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S.
 District Court forthe District of Delaware asserting the infringement and validity of 
three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an entiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug
application seeking approval to market a generic version of tofacitinib 5 mg tablets.
Also, in March 2017, we brought separate actions in the U.S. District Court for the District of
 Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai PharmaceuticalCo., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, Prinston) and against Breckenridge Pharmaceutical Inc.,
 Pensa Pharma S.A. and Laboratorios Del Dr.Esteve, S.A. (collectively, Breckenridge) on the 
two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respectiveabbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional paten
t-infringement actionagainst Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of 
four additional patents challenged by Breckenridge, three of which expire in December 2020 and 
one of which expires in December 2025. In March 2018, we brought another patent infringement action against Prinston in the U.S. DistrictCourt for the District of Delaware asserting the infringement and validity of an additional patent, which had been subsequently challenged by Prinston and which expires in
December 2025. In May 2018, we settled all of our claims against Breckenridge on terms not material to Pfizer. In January 2019,
 we settled all of our claims against Prinstonon terms not material to Pfizer.
In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc
. (Teva) in the U.S. District Court for the District of Delawareasserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application
seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. 
Inlyta (axitinib)
In April 2018, Apotex Inc. notified us that
 it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc.asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In
 May 2018, we filed suit against Apotex Inc. in the U.S. District Courtfor the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.
Kerydin (tavaborole)
In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of
Kerydin. The generic companies 
  assert the invalidity and non-infringement of methods of use and130
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor,
 our wholly-owned subsidiary , filed infringementlawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S.
 District Court for the District of West Virginia.Matters Involving Our Collaboration/Licensing Pa
rtnersToviaz (fesoterodine)––Inter-Partes Reviews
In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews
of 
five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB Pharma GmbH, and
 we have an exclusive, worldwide license to market Toviaz from UCBPharma GmbH. In July 2016, the Patent Trial and Appeal Board agreed to
 institute inter partes reviews of all five patents. Amerigen Pharmaceuticals Limited (Amerigen),Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions
upholding all 
five patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the FederalCircuit 
. In January 2018, Mylan withdrew its appeal. Amerigen’s appeal of the decision upholding the patent covering salts of fesoterodine that expires in 2022 was the onlypending appeal. In January 2019, the U.S. Court of Appeals 
for the Federal Circuit affirmed the U.S. Patent and Trademark Office’s decision upholding the validity of the patentcovering salts of fesoterodine that expires in 2022.
Xtandi (enzalutamide)
In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., 
Astellas US LLC and Astellas PharmaUS, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S.
 District Court for the District of Delaware againstActavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apo
tex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents,
which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a pa
tent-infringement suit against RoxaneLaboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of
enzalutamide. In June and July 2018, we settled all of our claims against Actavis and Apotex
, respectively, on terms not material to Pfizer.Eliquis
In February, March, and April 2017, 
twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the 
three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. 
Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS andPfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of
 West Virginia,asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each
 generic filer challenged. Some generic filers challenged only the2031 patent, some challenged both the 2031 and 2026 patent
, and one generic company challenged all three patents. We and BMS have settled with certain of the genericcompanies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future.
Actions In Which We Are 
The DefendantInflectra (infliximab-dyyb)
In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S
. District Court for the District of Massachusetts against Hospira,Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe 
six patentsrelating to infliximab, its manufacture and use. Claims with respect to 
four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibodypatent and a patent relating to cell culture media. In January 2018, the
 antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, theU.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that 
the patent relating to cell culture media was not infringed.Janssen has appealed the District Court’s decision to the U.S. Court of Appeals for the
 Federal Circuit.Bavencio (avelumab)
In July 2017, BMS, E.R. Squibb & 
Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District ofDelaware against Pfizer, Merck KGaA, and EMD Serono, Inc., alleging that Bavencio (avelumab) infringes 
one patent relating to methods for treating tumors with anti-PD-L1antibodies, which expires in 2023. In February 2019, we settled this matter on terms not material to Pfizer.
A2. Legal Proceedings––Product Litigation
Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other
products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
Asbestos
Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos
safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-
related and other claims. As of 
December 31, 2018 , approximately 46,400 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in
2000
2018 Financial Report    
 
 131
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.
Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing
asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.
There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned
by Pfizer or its subsidiaries.
Effexor
Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions,
 affiliates of Wyeth andcertain other defendants relating to Effexor XR, which is the extended-release formulation of Ef
fexor. The plaintiffs in each of the class actions seek to represent a classconsisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Ef
fexor XRfrom any of the defendants from June 14, 2008 until the
 time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch ofgeneric Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain o
f the actions, the antitrust, consumer protection and various other laws ofcertain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Ef
fexor XR in the Orange Book, enforcing certain patents for Effexor XRand entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each
 of the plaintiffs seeks treble damages (for itself in theindividual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor 
XR in the U.S. and itsterritories since June 14, 2008. All of these actions have been consolidated in the U.S
. District Court for the District of New Jersey.In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the o
ther directpurchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct
purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the
 Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuitreversed the District Court’s decisions and remanded the claims to the District Court.
Lipitor
•
Antitrust ActionsBeginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in
most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy.
 The plaintiffs in these various actions seek to represent nationwide, multi-state or statewideclasses consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic
Lipitor) from any of the defendants from March 2010 until the cessation of the de
fendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in thelaunch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant
to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets
beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents
 for Lipitor. Each of the actions seeks, among other things,treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition,
individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert
 claims and seek relief for the plaintiffs that are substantiallysimilar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a
Multi-District Litigation ( 
In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with
prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of
Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and 
for leave to amend theircomplaint to the U.S. Court of Appeals for the Third Circuit. In Augus
t 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remandedthe claims to the District Court.
Also, in January 2013, the State of West
 Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief onbehalf of the State of West 
Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions describedabove.
•
Personal Injury ActionsA number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes
 purportedlyas a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages.
In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( 
In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 
) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigationwere remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases
pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of
 Appeals for the Fourth Circuit. In June 2018, theU.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision.
Viagra
A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the
exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Plaintiffs seek compensatory and punitive damages.
132
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( 
In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 
) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly, were transferred for coordinated pre-trial proceedings to the Multi-District Litigation ( 
In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL- 2691 
). Intravenous Solutions
Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and
certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent a class consisting of all persons and en
tities in the U.S. who directly purchasedintravenous saline solution sold by any of the defendants from January 1, 2013 until the 
time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that thedefendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S
. in violation offederal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the puta
tive classes) and an injunction against defendants for alleged price overchargesfor intravenous saline solution in the U.S. since January 1, 2013. All of these ac
tions have been consolidated in the U.S. District Court for the Northern District of Illinois. In July2018, the District Court granted defendants’ motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in
September 2018. On February 3, 2017, we completed the sale of our global infusion systems net
 assets, HIS, which includes intravenous saline solution, to ICU Medical. Thelitigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.
Hormone Therapy Consumer Class Action
A certified consumer class action is pending against Wyeth in the U.S. District Court for the Sou
thern District of California based on the alleged off-label marketing of itshormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth’s hormone-replacement
products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a
full refund of the purchase price.
Eliquis
A number of individual and multi-plaintiff lawsuits have been filed against us and BMS in various federal and state courts pursuant to which plaintiffs seek 
to recover forpersonal injuries, including wrongful death, due to bleeding allegedly as a result of the ingestion of Eliquis. Plaintiffs seek compensatory and punitive damages.
In February 2017, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( 
In Re: Eliquis (Apixaban) Products Liability Litigation MDL-2754 
) in the U.S. District Court for the Southern District of New York. In July 2017 , the District Court dismissed substantially all of the actions that were pending in theMulti-District Litigation. In August 2017, certain plaintiffs appealed the District Court’s dismissal to the U.S. Court of Appeals for 
the Second Circuit.EpiPen
Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian,
and/or various entities affiliated with Mylan N.V., and Mylan N.V. Chief Executive Officer, Heather 
Bresch. The plaintiffs in these actions seek to represent U.S. nationwideclasses comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of
 the defendants’ allegedlyunlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of
 New Jersey on behalf of a purported class of direct purchaser plaintiffsagainst Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. Against Pfizer and/or its affiliates, plaintiffs generally allege that Pfizer’s and/or its
affiliates’ settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various sta
te antitrust or consumerprotection laws. At least one lawsuit also alleges that Pfizer and/or Mylan N.V. violated the 
federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filedvarious consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan Pharmaceuticals regarding EpiPen. Plaintiffs seek treble
damages for alleged overcharges for EpiPen since 2009. In August 2017, the ac
tions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation ( In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation 
, MDL-2785) in the U.S. District Court for the District of Kansas with other EpiPen- related actions against Mylan N.V. and/or its affiliates to which Pfizer, King and Meridian are not parties.
Nexium 24HR and Protonix
A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and
state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against us
 involveNexium 24HR and/or Protonix and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017
, the federalactions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( 
In re: Proton-Pump Inhibitor Products Liability Litigation (No. II)) in the U.S. District Court for the District of New Jersey.
Docetaxel 
•
Personal Injury ActionsA number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed
permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product
, Taxotere. Plaintiffs seekcompensatory and punitive damages.
In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( 
In re Taxotere (Docetaxel) Products Liability Litigation , MDL-2740) in the U.S. District Court for the Eastern District of Louisiana.
•
Mississippi Attorney General Government InvestigationIn October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of
 the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer
Protection Act. The action seeks civil penalties and injunctive relief. 
2018 Financial Report    
 
 133
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
A3 
. Legal Proceedings––Commercial and Other MattersAverage Wholesale Price Litigation
Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the
 defendants providedaverage wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AW
P is used todetermine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but 
one of those actions have beenresolved through settlement, dismissal or final judgment. The plaintiff state, Illinois, 
in the one remaining action, claims that the alleged spread between the AWPs at whichpurchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The ac
tion alleges, among other things, fraud 
and violation of the state’s unfair trade practices and consumer protection statutes and seeks monetary and other relief, including civil penalties and treble damages.
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and
spun off the shares of Solutia. In 2000,
 Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operationsto a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by
Pfizer in 2003 and is a wholly-owned subsidiary of Pfizer.
In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to
 indemnify Pharmacia for, any liabilities related to Pharmacia’s formeragricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural
business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.
In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of
its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited
to sites that Solutia has owned or operated. In addition, in connec
tion with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmaciafor, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New
Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to
 Former Monsanto’s chemicalbusinesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated
biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical
businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.
Environmental Matters
In 2009, we submitted to the U.S. Environmental Protection 
Agency (EPA) a corrective measures study report with regard to Pharmacia’s discontinued industrial chemicalfacility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EP
A, and we commenced construction of the site remedyin late 2011 under an Updated Administrative Order on Consent with the EPA.
Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation’s (formerly, American Cyanamid Company) discontinued industrial
chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement with the EPA and
 Order on Consentfor Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the
 Bound Brook facility. In May 2012, we completed construction of an interimremedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, 
the EPA issued a final remediation plan for the BoundBrook facility’s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings
Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to
 undertake detailed engineeringdesign of the remedy for the main plant area and to perform a focused feasibility study for 
two adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed acomplaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to
 implement the remedyfor the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement 
Agreement) was entered by the District Court. We haveaccrued for the estimated costs of the site remedies for the North Haven and 
Bound Brook facilities. In September 2018, the EPA issued a final remediation plan for the twoadjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study.
We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as
 amended, and otherstate, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.
Contracts with Iraqi Ministry of Health
In October 2017, a number of United States service members, civilians, and their families brought a complaint in the Federal District Court for the District of Columbia against a
number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-
Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical
device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.
S. Department of Justice requested documents related to this matter, which arebeing provided.
Allergan Complaint for Indemnity
In August 2018, Pfizer was named as a defendant in a
 third-party complaint for indemnity, along with King, a Pfizer subsidiary, filed by Allergan Finance LLC (Allergan) in aMulti-District Litigation ( 
In re National Prescription Opiate Litigation MDL 2804 ) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserts claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. 
In December 2018, the District Court dismissedthe lawsuit.
134
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
A4. Legal Proceedings––Government Investigations
Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in
which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, substantial fines and/or civil penalties, limitations on our
ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the
matter could result from government investigations. 
In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the mat
ters discussed below.Phenytoin Sodium Capsules
In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a
 third party, but retained the right to supply the finished product to that third party. InMay 2013, the U.K. Competition & Markets Authority (CMA) informed us that it had launched an
 investigation into the supply of phenytoin sodium capsules in the U.K. market.In August 2015, the CMA issued a Statement
 of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrustlaws. In December 2016, the CMA imposed a 
£84.2 million fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA decision to The Competition Appeal Tribunal in February 2017 
. On June 7, 2018, the Competition Appeal Tribunal overturned the CMA decision as well as the associated fine. The CMA has appealed the judgment to the Court ofAppeal.
Greenstone Investigations
Since July 2017, the U.S. Department of Justice’s Antitrust Division has been investigating our Greenstone
 generics business. We believe this is related to an ongoing antitrustinvestigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone. In April 2018, Greenstone received requests for
information from the Antitrust Department of the Connecticut Office of
 the Attorney General. We have been providing information pursuant to these requests.Subpoena relating to Manufacturing of Quillivant XR
In October 2018, we received a subpoena from the U.S. A
ttorney’s Office for the Southern District of New York seeking records relating to our relationship with another drugmanufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We are producing records pursuant to the
 subpoena.Civil Investigative Demand relating to Meridian Medical Technologies
In February 2019, we received a civil investigative demand from the U.S. Attorney’s Office for the
 Southern District of New York (SDNY).  The civil investigative demand seeksrecords and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site.  We will be producing records in response to this civil
investigative demand.
Intravenous Solutions
See 
Note 17A5. Contingencies and Certain Commitments Legal Proceedings –– Matters Resolved During 2018 –– Intravenous Solutions Government Investigation below for information regarding government investigations related to sales of intravenous solution products.
Contracts with Iraqi Ministry of Health
See 
Note 17A3. Contingencies and Certain Commitments : Legal Proceedings––Commercial and Other Matters––Contracts with Iraqi Ministry of Health above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.
Docetaxel 
–– Mississippi Attorney General Government InvestigationSee 
Note 17A2. Contingencies and Certain Commitments : Legal Proceedings –– Product Litigation –– Docetaxel –– Mississippi Attorney General Government Investigationabove for information regarding a government investigation related to Docetaxel marketing practices.
A5. Legal Proceedings––Matters Resolved 
During 2018During 2018, certain matters, including the matters discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-
principle.
Celebrex
Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of P
fizer relating toCelebrex. The plaintiffs sought to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants
, or indirectlypurchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants’ allegedly
unlawful conduct. The plaintiffs alleged delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various
other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation and prolonging the impact of sham litigation
through settlement activity that further delayed generic entry. Each of 
the actions sought treble damages on behalf of the putative class for alleged price overcharges forCelebrex since May 31, 2014. In December 2014, the District Court granted the parties’ joint motions to consolidate the direct purchaser and end-payer cases, and all such
cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers’ and end-payers’ amended complaints,
respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers’ amended complaint. In February 2016, the
District Court denied in part and granted in part our motion to dismiss the end-payers’ amended complaint, and in August 2016, the District Court dismissed substantially all of
the end-payers’ remaining claims. In February 2017, the District Court dismissed with prejudice all of the end-payers’ claims. In March 2017, the end-payers appealed the
District Court’s order dismissing their claims with prejudice to the U.S. Court of Appeals for the Fourth Circuit. In August 2017, the District Court granted the
 direct purchasers’motion for class certification. In November 2017, Pfizer and the direct purchasers entered into an agreement to resolve the direct purchasers’ class action for 
$94 million . In April 2018, the court approved the agreement. In November 2017, Pfizer and the end-payers entered into
 an agreement to resolve the claims of the end-payer plaintiffs onterms not material to Pfizer.
2018 Financial Report    
 
 135
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Subpoenas relating to Copayment Assistance Organizations
In December 2015 and July 2016, Pfizer received subpoenas from the U.S. Attorney’s O
ffice for the District of Massachusetts requesting documents related to the PatientAccess Network Foundation and other IRC 501(c)(3) organizations that provide financial assistance to Medicare patients. In May 2018, Pfizer entered into a civil settlement 
toresolve the matter. Pfizer paid 
$23.85 million to the United States, and entered into a five -year Corporate Integrity Agreement with the Office of the Inspector General of theDepartment of Health and Human Services.
Civil Investigative Demand relating to Pharmacy Benefit Managers
In March 2016, Pfizer received a civil investigative demand from the U.S. Attorney’s Office for 
the SDNY related to Pfizer’s contractual relationships with pharmacy benefitmanagers with respect to certain pharmaceutical products over the period from January 1, 2006 to the present. We have provided information to 
the government in response tothis civil investigative demand. In July 2018, Pfizer was served with a qui tam complaint that appears to be related to
 the SDNY investigation. The complaint was unsealedfollowing the government’s decision not to intervene in the case.
Intravenous Solutions Government Investigation
In April 2017, Pfizer, Hospira and two employees of Pfizer received grand jury subpoenas issued by the United States District Court for 
the Eastern District of Pennsylvania, inconnection with an investigation by the U.S. Department of Justice, An
titrust Division. The subpoenas seek documents related to the sale, manufacture, pricing and shortagesof intravenous solutions, including saline, as well as communications among industry participants regarding these issues. The Department of Justice investigation is also the
subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. In addition, in August 2015, the
 New York Attorney General issued asubpoena to Hospira for similar information. Hospira has produced records to the New York Attorney General and coordinated with ICU Medical to produce records to the U.S.
Department of Justice. 
In December 2018, the U.S. Department of Justice informed Pfizer that it  had closed its investigation.B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses and
 other transactions, we often indemnify our counterparties against certainliabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If
 the indemnified party were to make asuccessful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions
and limitations. Historically, we have not paid significant amounts under these provisions and, as of 
December 31, 2018 , the estimated fair value of these indemnification obligations was not significant.
In addition, in connection with our entry into certain agreements, our counterparties agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. 
toco-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by
 Biogen Idec MA Inc. against EMD Serono Inc.and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United S
tates Court of Appeals for the Federal Circuit. EMD Serono Inc. hasacknowledged that it is obligated to satisfy any award of damages.
Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and 
that now are subsidiaries of Pfizer.C. Certain Commitments
•
As of December 31, 2018 , we had agreements totaling $3.7 billion to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.
•
As of December 31, 2018 , we have obligations to make guaranteed fixed annual payments over an eight -year period in connection with the U.S. and EU approvals for Besponsa ( 
$422 million ) and an obligation to make guaranteed fixed annual payments over a nine -year period for Bosulif ( $240 million ), both associated with R&D arrangements.
•
As of December 31, 2018 , in connection with the TCJA, we have an estimated $15 billion repatriation tax liability on accumulated post-1986 earnings of foreign subsidiaries for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight
 years through 2026. The first installment, due in April2019, is reported in 
Income taxes payable and the remaining installments are reported in Other taxes payable in our consolidated balance sheet as of December 31, 2018. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and
 other credit carryforwards. See Note 5A for additional information.
Note 18. 
Segment, Geographic and Other Revenue Information A. Segment Information
We regularly review our segments and the approach used by management to evaluate performance and allocate resources. At the
beginning of our fiscal year 2019, we reorganized our commercial operations. Prior to the reorganization effective January 1, 2019, we managed our commercial operations
through 
two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments were each led by a single manager.Each operating segment had responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line
products that generally have achieved proof-of-concept. Each business had a geographic footprint across developed and emerging markets. Our chief operating decision
maker used the revenues and earnings of the 
two operating segments, among other factors, for performance evaluation and resource allocation. As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 
2018 , 2017 and 2016 . 136
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Some additional information about our business segments and other costs and business activities as of December 31, 2018 (prior to our new 2019 commercial organizational
re-alignment) follows:
Operating Segments
 
IH focused on developing and commercializing novel, value-creating medicines and
vaccines that significantly improve patients’ lives, as well as products for consumer
healthcare.
Key therapeutic areas included internal medicine, vaccines, oncology, inflammation &
immunology, rare disease and consumer healthcare.
  EH included legacy brands that have lost or will soon lose market exclusivity in bothdeveloped and emerging markets, branded generics, generic sterile injectable
products, biosimilars and select branded products including anti-infectives. EH also
included an R&D organization, as well as our contract manufacturing business.
Through February 2, 2017, EH also included HIS.
Leading brands included:
- 
Prevnar 13/Prevenar 13- 
Xeljanz- 
Eliquis- 
Lyrica  (U.S., Japan and certain other markets) - 
Enbrel (outside the U.S. and Canada) - 
Ibrance- 
Xtandi- 
Chantix/Champix- Several OTC consumer healthcare products (e.g., 
Centrum  and Advil )   Leading brands included:- 
Lipitor- Norvasc
- Lyrica 
(Europe, Russia, Turkey, Israel and Central Asia countries) - 
Celebrex- 
Viagra*- Inflectra/Remsima
- Sulperazon
- 
Several other sterile injectable products*
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.
The following organizational change impacted our operating segments in 2018:
•
Effective in the first quarter of 2018, certain costs for Pfizer’s StratCO group, which were previously reported in the operating results of our operating segments andCorporate, are reported in Other Unallocated. StratCO costs primarily include headcount costs, vendor costs and data costs largely in support of
 Pfizer’s commercialoperations. The majority of the StratCO costs reflect additional amounts that our operating segments
 would have incurred had each segment operated as a standalonecompany during the periods presented. The reporting change was made to streamline accountability and speed decision making. In 2017, we reclassified approximately
$468 million 
of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs to conform to the current period presentation, and in 2016, we reclassified approximately 
$312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million 
of costs from Corporate to Other unallocated costs to conform to the current period presentation.Other Costs and Business Activities
Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the
 following:•
WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segmentvia the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The
WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the
various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all
safety-event activities.
•
GPD, which is generally responsible for the operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in theInnovative portfolio. GPD also provides technical support and other services to Pfizer R&D projects.
•
Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs,compliance and worldwide procurement), the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities,
clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations, as well
as certain compensation and other corporate costs, such as interest income and expense, and gains and losses on
 investments. Effective in the first quarter of 2018, certaincosts for StratCO, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated. For additional
information, see note below on Other unallocated costs.
•
Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operatingsegment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). In connection with the
StratCO reporting change, in 2017, we reclassified approximately 
$468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs to conform to the current period presentation,
 and in 2016, we reclassified approximately $312 million of costs from IH, approximately 
$167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.•
Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments toinventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the
2018 Financial Report    
 
 137
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in
some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or
size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, bu
t are not limited to, non-acquisition-related restructuringcosts, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
Segment Assets
We manage our assets on a total company basis, not by operating segment, as
 many of our operating assets are shared (such as our plant network assets) or commingled(such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any
asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets
 were approximately $159 billion as of December 31, 2018 
and approximately $172 billion as of December 31, 2017 . Selected Income Statement Information
As described in 
Note 1A , acquisitions and divestitures have impacted our results of operations in 2018 , 2017 and 2016 . The following table provides selected income statement information by reportable segment:
 
  Revenues   Earnings (a)   Depreciation and Amortization (b)  
  Year Ended December 31,   Year Ended December 31,   Year Ended December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016  2018  2017  2016  2018  2017  2016 Reportable Segments:
                           IH 
(c)  $33,426 $31,422 $29,197 $20,258 $18,809 $16,166 $629  $534  $583 EH 
(c)  20,221  21,124  23,627  10,712  11,460  13,065  547  579  600 Total reportable segments
  53,647  52,546  52,824  30,970  30,269  29,231  1,175  1,113  1,183 Other business activities 
(d), (e)   —  —  —  (2,977 )  (3,137 )  (3,020 )  93  90  85 Reconciling Items:
                  Corporate 
(c), (e)   —  —  —  (5,096 )  (5,452 )  (5,448 )  363  337  356 Purchase accounting adjustments 
(e)   —  —  —  (4,786 )  (4,758 )  (4,185 )  4,620  4,565  3,890 Acquisition-related costs 
(e)   —  —  —  (318 ) (456 ) (785 ) 12  39  7 Certain significant items 
(f)   —  —  —  (4,305 )  (2,647 )  (5,888 )  38  52  200 Other unallocated 
(c) , (e)  —  —  —  (1,603 )  (1,514 )  (1,554 )  82  72  35  
  $53,647 $52,546 $52,824 $11,885 $12,305 $8,351  $6,384  $6,269  $5,757 (a)
 
Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings include d ividend income from our investme nt in ViiV of $253 million in 2018 and $266 million in 2017 . For additional information, see 
Note 4. (b) 
 Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.(c)
 
In connection with the StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocat
ed costs, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated cos
ts to conform to the current period presentation.(d) 
 Other business activities includes the costs managed by our WRD and GPD organizations.(e) 
 For a description, see the “Other Costs and Business Activities” section above.(f) 
 Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur aspart of our normal busine
ss on a regular basis.For Earnings in 
2018 , certain significant items includes: (i) restr ucturing charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million , (ii) net charges for certain legal m
atters of $157 million , (iii) income of $1 million , representing an adjustme nt to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv)certain asset impair
ment charges of $3.1 billion , (v) charges for business and le gal entity alignment of $4 million , (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $65 million , which includes, among othe
r things, a non-cash $343 million pre-tax gain in Other (income)/deduction s––net associated with our transaction wit h Bain Capital to create a new biopharmaceutical company,Cerevel, to continue develo
pment of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and adminis
trative expenses , for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expectedpositive net impact of the Decemb
er 2017 enactment of the legislation commonly referred to as the TCJA, $59 million of incremental costs associated with t he design, planning and implementation of the neworganizational structure, effectiv
e in the beginning of 2019, and primarily including consulting, legal, tax, and advisory services and a non-cash $50 million pre-tax gain in Other (income)/deduction s––net as a result of the contribution of o
ur allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B , Note3 
and Note 4 . For Earnings in 
2017 , certain significant items includes: (i) restr ucturing charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million , (ii) charges for ce
rtain legal matters of $237 million , (iii) charges of $55 million , representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv)certain asset impair
ment charges of $379 million , (v) charges for business and le gal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $700 million . For additional information, see 
Note 2B , Note 3 and Note 4.For Earnings in 
2016 , certain significant items includes: (i) restr ucturing charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.4 billion , (ii) charges for ce
rtain legal matters of $494 million , (iii) an impairment charge relate d to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment charges of 
$1.4 billion , (v) charges for business and le gal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $294 million . For additional information, see 
Note 3 and Note 4 . 138
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Equity in the net income of investees accounted for by the
 equity-method is not significant for any of our operating segments.The operating segment information does not purport to represent the revenues, costs and 
Income from continuing operations before provision/(benefit) for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.
B. 
Geographic InformationAs described in 
Note 1A , the February 3, 2017 sale of HIS impacted our results of operations in 2018 , 2017 and 2016 . The following table provides revenues by geographic area:
 
Year Ended December 31, (MILLIONS OF DOLLARS)
2018  2017  2016 United States
$ 25,329  $26,026  $26,369 Developed Europe 
(a)9,116 8,508  9,306 Developed Rest of World 
(b)6,551 6,612  6,729 Emerging Markets 
(c)12,651 11,399  10,420 Revenues
$ 53,647  $52,546  $52,824 (a)
 
Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.3 billion in 2018 , $6.8 billion in 2017 and $7.2 billion in 2016 
. (b) 
 Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.(c) 
 Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.Revenues exceeded 
$500 million in each of 11 countries outside the U.S. in 2018 , 2017 and 2016 . The U.S. is the only country to contribute more than 10% of total revenue in 
2018 , 2017 and 2016 . As a percentage of revenues, our two largest national markets outside the U. S. were Japan, which contributed 8% of total revenue in each of 2018,2017 and 2016, and China, which contributed 
8% of total revenue in 2018, 7% of total revenue in 2017 and 6% of total revenues in 2016.The following table provides long-lived assets by geographic area:
 
  As of December 31, (MILLIONS OF DOLLARS)
  2018  2017  2016 Property, plant and equipment, net
         United States
  $7,089  $6,971  $6,649 Developed Europe 
(a)  4,204  4,345  4,228 Developed Rest of World 
(b)  490  632  643 Emerging Markets 
(c)  1,602  1,917  1,797 Property, plant and equipment, net
  $13,385  $13,865  $13,318 (a) 
 Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.(b) 
 Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.(c) 
 Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.C. Other Revenue Information
Significant Customers
We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 
2018 , sales to our three largest U.S. wholesaler customers represented approximately 
15% , 11% and 10% of total revenues, respectively, and, collectively, represented approximately 34% of total trade accounts receivable as of December 31, 2018 
. In 2017 , sales to our three largest U.S. wholesaler customers represented approximately 16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 
36% of total trade accounts receivable as of December 31, 2017 . In 2016 , sales to our three largest U.S. wholesaler customers represented approximately 
16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 29% of total trade accounts receivable as of December 31, 2016 
. For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses. 2018 Financial Report    
 
 139
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Significant Product Revenues
As described in 
Note 1A , acquisitions and divestitures have impacted our results of operations in 2018 , 2017 and 2016 . The following table provides d
etailed revenue information for several of our major products:(MILLIONS OF DOLLARS)
     Year Ended December 31, PRODUCT
  PRIMARY INDICATION OR CLASS  2018  2017  2016 TOTAL REVENUES
     $53,647  $52,546  $52,824 PFIZER INNOVATIVE HEALTH (IH) 
(a)   $33,426  $31,422  $29,197 Internal Medicine
  $9,996  $9,684  $8,858 Lyrica IH 
(b)  Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathicpain due to spinal cord in
jury  4,622  4,511  4,165 Eliquis alliance revenue
s and directsales
  Atrial fibrillation, deep vein thrombosis, pulmonary embolism 3,434  2,523  1,713 Chantix/Champix
  An aid to smoking cessation treatment in adults 18 years of age or older  1,085  997  842 BMP2
  Development of bone and cartilage  279  261  251 Toviaz
  Overactive bladder  271  257  258 Viagra IH 
(c)   Erectile dysfunction  —  823  1,181 All other Internal Medicine
  Various  306  312  447 Vaccines
  $6,332  $6,001  $6,071 Prevnar 13/Prevenar 13
  Vaccines for prevention of pneumococcal disease  5,802  5,601  5,718 FSME/IMMUN-TicoVac
  Tick-borne encephalitis vaccine  184  134  114 Trumenba
  Meningococcal Group B vaccine  116  88  84 All other Vaccines
  Various  230  177  155 Oncology
  $7,202  $6,056  $4,563 Ibrance
  Advanced breast cancer  4,118  3,126  2,135 Sutent
 Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progressionon, or intolerance to, 
imatinib mesylate) and advanced pancreatic neuroendocrine tumor  1,049  1,081  1,095 Xtandi alliance revenues
  Castration-resistant prostate cancer  699  590  140 Xalkori
  ALK-positive and ROS1-positive advanced NSCLC  524  594  561 Inlyta
  Advanced RCC  298  339  401 Bosulif
  Philadelphia chromosome–positive chronic myelogenous leukemia  296 233 167 All other Oncology
  Various  219  93  63 Inflammation & Immunology (I&I)
  $4,080  $3,968  $3,928 Enbrel (Outside the U
.S. and Canada) 
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosingspondylitis and nonradio
graphic axial spondyloarthritis 
2,112  2,452  2,909 Xeljanz
 RA, PsA, ulcerative colitis 1,774  1,345  927 Eucrisa
  Mild-to-moderate atopic dermatitis (eczema)  147 67 — All other I&I
  Various  46  103  93 Rare Disease
  $2,211  $2,240  $2,369 Genotropin
  Replacement of human growth hormone  558  532  579 BeneFIX
  Hemophilia  554  604  712 Refacto AF/Xyntha
  Hemophilia  514  551  554 Somavert
  Acromegaly  267  254  232 All other Rare Disease
  Various  318  300  292 Consumer Healthcare
     $3,605  $3,472  $3,407 PFIZER ESSENTIAL HEALTH (EH) 
(d)   $20,221  $21,124  $23,627 Legacy Established Products (LEP) 
(e)   $10,540  $10,894  $11,197 Lipitor
  Reduction of LDL cholesterol  2,062  1,915  1,758 Norvasc
  Hypertension  1,024  926  962 Premarin family
  Symptoms of menopause  832  977  1,017 Xalatan/Xalacom
  Glaucoma and ocular hypertension  318  335  363 Effexor
  Depression and certain anxiety disorders  311  297  278 EpiPen
  Epinephrine injection used in treatment of life-threatening allergic reactions  303  290  386 Zoloft
  Depression and certain anxiety disorders  298  291  304 
Zithromax  Bacterial infections  290  270  272 Xanax
  Anxiety disorders  223  225  222 Sildenafil Citrate
  Erectile dysfunction  56  56  — All other LEP
  Various  4,822  5,313  5,636 140
 
 2018 Financial Report
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
(MILLIONS OF DOLLARS)
     Year Ended December 31, PRODUCT
  PRIMARY INDICATION OR CLASS   2018  2017  2016 Sterile Injectable Pharmaceuticals (SIP) 
(f)   $5,214  $5,673  $6,014 Sulperazon
  Treatment of infections  613  471  396 Medrol
  Steroid anti-inflammatory  427  483  450 Fragmin
  Slows blood clotting  293  306  318 Tygacil
  Tetracycline class antibiotic  249  260  274 Zosyn/Tazocin
  Antibiotic  229  194  146 Precedex
  Sedation agent in surgery or intensive care  213  243  264 All other SIP
  Various  3,191  3,715  4,166 Peri-LOE Products 
(g)   $2,944  $3,223  $4,220 Celebrex
  Arthritis pain and inflammation, acute pain  686  775  733 Viagra EH 
(c)   Erectile dysfunction  636  382  383 Vfend
  Fungal infections  392  421  590 Lyrica EH 
(b)   Epilepsy, neuropathic pain and generalized anxiety disorder  347  553  801 Zyvox
  Bacterial infections  236  281  421 Revatio
  Pulmonary arterial hypertension  227  252  285 Pristiq
  Depression  206  303  732 All other Peri-LOE Products
  Various  213  257  276 Biosimilars 
(h)   Various  $769  $531  $319 Inflectra/Remsima
  Inflammatory diseases  642  419  192 All other Biosimilars
  Various  127  112  127 Pfizer CentreOne 
(i)      $755  $706  $718 Hospira Infusion Systems (HIS) 
(j)  Various  $—  $97  $1,158 Total Lyrica 
(b)  Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathicpain due to spinal cord in
jury  $4,970  $5,065  $4,966 Total Viagra 
(c)   Erectile dysfunction  $636  $1,204  $1,564 Total Alliance revenues
  Various  $3,838  $2,927  $1,746 (a)
 
The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant(recorded in All other Internal M
edicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order toalign these products with our m
anagement of the women’s health portfolio within EH.(b)
 
Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate ofworldwide revenues from Lyrica IH a
nd Lyrica EH.(c)
 
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenuesexcluding the U.S. and 
Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH. Total Viagra revenues in 2017 and 2016 represented the aggregate of worldwide revenuesfrom Viagra IH and Viagra EH.
(d) 
 The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).(e)
 
Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity sharein Hisun Pfizer. As a result, effective in the first 
quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging marketswithin Pfizer CentreOne.
Effective January 1, 2017, All oth
er LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these productswith our management of the w
omen’s health portfolio within EH. See note (a) above.(f) 
 Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the firstquarter of 2018, Hisun Pfizer-rel
ated revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.(g)
 
Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; andworldwide revenues for Celebr
ex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017 and 2016),see note (c) above.
(h)
 
Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in theU.S. and Retacrit (biosimilar epoetin z
eta) in the U.S. and certain European and Africa/Middle Eastern markets.(i) 
 Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to ourmanufacturing and supply 
agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-relatedrevenues, previously reporte
d in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.(j) 
 HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IVsolutions and their associate
d administration sets.2018 Financial Report    
 
 141
Notes to Consolidated Financial StatementsPfizer Inc. and Subsidiary Companies
 
Note 19. 
Subsequent Event A. Accelerated Share Repurc
hase AgreementOn 
February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. Pursuant to the terms of the agreement, on 
February 12, 2019 , we paid approximately $6.8 billion to GS&Co. and received an initial delivery of approximately 130 million shares of our common stock from 
GS&Co. , which represented, based on the closing price of our common stock on the NYSE on February 7, 2019 , approximately 80% of the notional amount of the accelerated share repurchase agreement. As of February 28, 2019, the
 common stock received is included in Treasury Stock . At settlement of the agreement, which is expected to occur during or prior to the third quarter of 2019, 
GS&Co. may be required to deliver additional shares of common stock to us, or, under certain circumstances, we may be required to deliver shares of our common stock or may elect to make a cash payment to 
GS&Co. , with the number of shares to be delivered or the amount of such payment, as well as the final price per share, based on the volume-weighted average price, less a discount, of
 Pfizer’s common stock during the term of thetransaction. This agreement was entered into pursuant to our previously announced share repurchase authorization. After giving effect to
 the accelerated share repurchaseagreement and other share repurchases through February 28, 2019, our remaining share-purchase authorization was approximately  
$5.3 billion on February 28, 2019. 142
 
 2018 Financial Report
Selected Quarterly Financial Data (Unaudited)Pfizer Inc. and Subsidiary Companies
 
 
  Quarter (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)
  First   Second   Third   Fourth 2018
            Revenues
  $12,906  $13,466  $13,298  $13,976 Costs and expenses 
(a)  8,736  8,895  9,035  14,051 Restructuring charges and certain acquisition-related costs 
(b)  43  44  85  872 Income/(loss) from continuing operations before provision for taxes on income/(loss)
  4,127  4,527  4,177  (946 )Provision/(benefit) for taxes on income/(loss) 
(c)  556  648  66  (563 )Income/(loss) from continuing operations
  3,571  3,879  4,111  (383 )Discontinued operations—net of tax
  (1 ) —  11  — Net income/(loss) before allocation to noncontrolling interests
  3,570  3,879  4,122  (383 )Less: Net income attributable to noncontrolling interests
  9  7  8  11 Net income/(loss) attributable to Pfizer Inc.
  $3,561  $3,872  $4,114  $(394 )Earnings/(loss) per common share—basic:
            Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
  $0.60  $0.66  $0.70  $(0.07 ) Discontinued operations—net of tax
  —  —  —  — Net income/(loss) attributable to Pfizer Inc. common shareholders
  $0.60  $0.66  $0.70  $(0.07 ) Earnings/(loss) per common share—diluted:
            Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders
  $0.59  $0.65  $0.69  $(0.07 ) Discontinued operations—net of tax
  —  —  —  — Net income/(loss) attributable to Pfizer Inc. common shareholders
  $0.59  $0.65  $0.69  $(0.07 ) (a)
 
The fourth quarter of 2018 historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The fourth quarter of 2018 includes $3.1 billion 
in certain asset impairments recorded in Other (income)/deduction s––net . For additional information, see N otes to Consolidated Financial Statements— Note 4 . Other (Income)/Deductions—Net . (b)
 
In the fourth quarter of 2018, includes restructuring charges that were primarily related to employee termination costs and asset write downs. The employee termination costs are associated with our improvementsto operational effectiveness 
as part of the realignment of our organizational structure effective at the beginning of 2019. For additional information, see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Oth
er Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives . (c)
 
The third and fourth quarters of 2018 reflect the impact of t he TCJA on the Provision/(benefit) for taxes on income . For additional information, see N otes to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from Continui
ng Operations . Basic and diluted EPS are computed independently for each of the periods presented.
 Accordingly, the sum of the quarterly EPS amounts may not agree to the total for theyear.
2018 Financial Report    
 
 143
Selected Quarterly Financial Data (Unaudited)Pfizer Inc. and Subsidiary Companies
 
 
  Quarter (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)
  First (a) Second   Third   Fourth 2017
            Revenues
  $12,779  $12,896  $13,168  $13,703 Costs and expenses 
(b)  8,744  9,011  9,469  12,665 Restructuring charges and certain acquisition-related costs
  84  70  114  84 Income from continuing operations before provision/(benefit) for taxes on income
  3,951  3,815  3,585  953 Provision/(benefit) for taxes on income 
(c)  821  739  727  (11,335 ) Income from continuing operations
  3,130  3,077  2,858  12,289 Discontinued operations—net of tax
  —  2  —  1 Net income before allocation to noncontrolling interests
  3,130  3,078  2,858  12,290 Less: Net income attributable to noncontrolling interests
  9  5  18  15 Net income attributable to Pfizer Inc.
  $3,121  $3,073  $2,840  $12,274 Earnings per common share—basic:
            Income from continuing operations attributable to Pfizer Inc. common shareholders
  $0.52  $0.52  $0.48  $2.06 Discontinued operations—net of tax
  —  —  —  — Net income attributable to Pfizer Inc. common shareholders
  $0.52  $0.52  $0.48  $2.06 Earnings per common share—diluted:
            Income from continuing operations attributable to Pfizer Inc. common shareholders
  $0.51  $0.51  $0.47  $2.02 Discontinued operations—net of tax
  —  —  —  — Net income attributable to Pfizer Inc. common shareholders
  $0.51  $0.51  $0.47  $2.02 (a)
 
In accordance with our international reporting period, our consolidated statement of income for the first quarter of 2017 reflects approximately two months of the small molecule anti-infectives business acquiredfrom Astra Zeneca.
(b)
 
The fourth quarter of 2017 historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The fourth quarter of 2017  includes a netloss on early retire
ment of debt of $999 million , inclusive of the related terminati on of cross currency swaps.(c) 
 The fourth quarter of 2017 reflects the impact of the TCJA. For additional information, see Notes to Consolidated Financial Statements — Note 5A. Tax Matters: Taxes on Income from Continuing Operations . Basic and diluted EPS are computed independently for each of the periods presented.
 Accordingly, the sum of the quarterly EPS amounts may not agree to the total for theyear.
144
 
 2018 Financial Report
Financial SummaryPfizer Inc. and Subsidiary Companies
 
 
  Year Ended/As of December 31, (a)(MILLIONS, EXCEPT PER COMMON SHARE DATA)
  2018  2017  2016  2015  2014 Revenues
  $53,647  $52,546  $52,824  $48,851  $49,605 Income from continuing operations
  11,179  21,353  7,229  6,975  9,119 Total assets
  159,422   171,797   171,615   167,381   167,473 Long-term obligations 
(b)  63,807  69,714  80,660  72,985  74,265 Earnings per common share—basic
               Income from continuing operations attributable to Pfizer Inc. common shareholders
  $1.90  $3.57  $1.18  $1.13  $1.43 Discontinued operations—net of tax
  —  —  —  —  0.01 Net income attributable to Pfizer Inc. common shareholders 
(c)  $1.90  $3.57  $1.18  $1.13  $1.44 Earnings per common share—diluted
               Income from continuing operations attributable to Pfizer Inc. common shareholders
  $1.86  $3.52  $1.17  $1.11  $1.41 Discontinued operations—net of tax
  —  —  —  —  0.01 Net income attributable to Pfizer Inc. common shareholders
  $1.87  $3.52  $1.17  $1.11  $1.42 Cash dividends declared per common share
  $1.38  $1.30  $1.22  $1.14  $1.06 (a)
 
2017 reflects the February 3, 2017 sale of HIS to ICU Medical. 2017 and 2018 reflect the acquisition of the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business,primarily outside of
 the U.S. on December 22, 2016. 2016, 2017 and 2018 reflect the acquisition of Medivation on September 28, 2016 and the acquisition of Anacor on June 24, 2016, and 2015, 2016, 2017 and2018 reflect the acquisi
tion of Hospira on September 3, 2015.(b) 
 Defined as Long-term debt, Pension b enefit obligations, net, Postretirement benefit obligations, net, Noncurrent deferred tax liabilities, Other taxes payable and Other noncurrent liabilities.(c)
 
2018 and 2017 reflect the impact of the TCJA on the Provision/(benefit) for taxes on income . For additional information, see N otes to Consolidated Financial Statements — Note 5A. Tax Matters: Taxes onIncome from Continuing 
Operations.2018 Financial Report    
 
 145
Peer Group Performance GraphPfizer Inc. and Subsidiary Companies
 
The following graph assumes a $100 investment on December 31, 2013, and reinvestment of all dividends, in each of the Company’s Common Stock, the
 S&P 500 Index, anda composite peer group of the major U.S. and European-based pharmaceutical companies, which are: Abbott Laboratories (for 2012 only), AbbVie Inc.
 (beginning in 2013),Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly & Co., GlaxoSmithKline plc, Johnson & Johnson
, Merck and Co., Inc., Novartis AG, Roche Holding AGand Sanofi SA.
Five Year Performance
 
 
  2013   2014   2015   2016   2017   2018 PFIZER        
  $100.0   $105.3   $112.8   $117.8   $136.4   $170.3 PEER GROUP
  $100.0   $112.4   $114.1   $114.7   $134.3   $145.4 S&P 500      
  $100.0   $113.7   $115.2   $129.0   $157.2   $150.3  
146
 
 2018 Financial Report
EXHIBIT 21 
The following is a list of subsidiaries of the Comp
any as of December 31, 2018, omitting some subsidiaries which, considered in the aggregate,would not constitute a significant subsid
iary. Company Name
Where Incorporated or Organized Agouron Pharmaceuticals, LLC
California AH Robins LLC
Delaware AHP Holdings B.V.
Netherlands AHP Manufacturing B.V.
Netherlands Alacer Corp.
California Alpharma Pharmaceuticals LLC
Delaware American Food Industries LLC
Delaware Anacor Pharmaceuticals, Inc.
Delaware Ayerst-Wyeth Pharmaceuticals LLC
Delaware Bamboo Therapeutics, Inc.
Delaware Bioren, LLC
Delaware Blue Whale Re Ltd.
Vermont C.P. Pharmaceuticals International C.V.
Netherlands CICL Corporation
Delaware COC I Corpora
tionDelaware Coley Pharmaceutical GmbH
Germany Coley Pharmaceutical Group, Inc.
Delaware Continental Pharma, Inc.
Belgium Covx Technologies Ireland Limited
Ireland Cyanamid de Argentina S.A.
Delaware Cyanamid de Colombia, S.A.
Delaware Distribuidora Mercantil Centro Americana, S.A.
Delaware Encysive Pharmaceuticals Inc.
Delaware Excaliard Pharmaceuticals, Inc.
Delaware Farminova Produtos Farmaceuticos de Inovacao, Lda.
Portugal Ferrosan A/S
Denmark Ferrosan International A/S
Denmark Ferrosan S.R.L.
Romania FoldRx Pharmaceuticals, Inc.
Delaware Fort Dodge Manufatura Ltda.
Brazil G. D. Searle
 & Co. LimitedUnited Kingdom G. D. Searle
 International Capital LLCDelaware G. D. Searle
 LLCDelaware Genetics Institute, LLC
Delaware GenTrac, Inc.
Wisconsin GI Europe, Inc.
Delaware GI Japan, Inc.
Delaware Greenstone LLC
Delaware HBAF Ltd.
Bahamas 1

Hospira (China) Enterprise Management Co. Ltd.People’s Republic of China Hospira Adelaide Pty Ltd
Australia Hospira Australia Pty Ltd
Australia Hospira Benelux BVBA
Belgium Hospira Enterprises B.V.
Netherlands Hospira France SAS
France Hospira Holdings (S.A.) Pty Ltd
Australia Hospira Ireland Holdings
 Unlimited CompanyIreland Hospira Ireland Sales Limited
Ireland Hospira Limited
Hong Kong Hospira NZ Limited
New Zealand Hospira Philippines, Inc.
Philippines Hospira Pte. Ltd.
Singapore Hospira Pty Limited
Australia Hospira Puerto Rico, LLC
Delaware Hospira Singapore Pte Ltd
Singapore Hospira UK Limited
United Kingdom Hospira Worldwide, LLC
Delaware Hospira Zagreb d.o.o.
Croatia Hospira, Inc.
Delaware InnoPharma, Inc.
Delaware International Af
filiated Corporation LLCDelaware JMI-Daniels Pharmaceuticals, Inc.
Florida John Wyeth & Brother Limited
United Kingdom Kiinteistö oy Espoon Pella
vaniementie 14Finland King Pharmaceuticals Holding
s LLCDelaware King Pharmaceuticals LLC
Delaware King Pharmaceuticals Research an
d Development, LLCDelaware Korea Pharma Holding Co
mpany LimitedHong Kong Laboratoires Pfizer, S.A.
Morocco Laboratorios Parke Davis, S.L.
Spain Laboratorios Pfizer Ltda.
Brazil Laboratórios Pfizer, Lda.
Portugal Laboratorios Wyeth LLC
Pennsylvania Laboratorios Wyeth S.A.
Venezuela Mayne Pharma IP Holdings (Euro) Pty Ltd
Australia Medivation Field Solutions
 LLCDelaware Medivation LLC
Delaware Medivation Neurology LLC
Delaware Medivation Prostate Therapeutics LLC
Delaware Medivation Services LLC
Delaware Medivation Technologies LLC
Delaware Meridian Medical Technologie
s, Inc.Delaware Monarch Pharmaceuticals, LLC
Tennessee MTG Divestitures LLC
Delaware Neusentis Limited
United Kingdom 2

PAH USA IN8 LLCDelaware Parke Davis Limited
Hong Kong Parke, Davis & Company LLC
Michigan Parkedale Pharmaceuticals, Inc.
Michigan P-D Co., LLC
Delaware Peak Enterprises LLC
Delaware PF Asia Manufacturing B.V.
Netherlands PF Consumer Healthcare 1 LLC
Delaware PF Consumer Healthcare B.V.
Netherlands PF Consumer Healthcare Canada ULC
Canada PF Consumer Healthca
re New Zealand LimitedNew Zealand PF Healthcare Australia Pty Ltd
Australia PF OFG (Thailand) Limited
Thailand PF OFG Australia Pty Ltd
Australia PF OFG HELLAS L.T.D.
Greece PF OFG Hong Kong Limited
Hong Kong PF OFG New Zealand ULC
New Zealand PF OFG South Korea 1 B.V.
Netherlands PF PR Holdings C.V.
Netherlands PF PRISM C.V.
Netherlands PF PRISM Holdings S.a.r.l.
Luxembourg PF Prism S.á.r.l.
Luxembourg PFE Holdings G.K.
Japan PFE Pfizer Holdings 1 LLC
Delaware PFE PHAC Holdings 1 LLC
Delaware PFE Wyeth Holdings LLC
Delaware PFE Wyeth-Ayerst (Asia) LLC
Delaware Pfizer
France Pfizer (China) Research and Developme
nt Co. Ltd.People’s Republic of China Pfizer (Malaysia) Sdn Bhd
Malaysia Pfizer (Perth) Pty Ltd
Australia Pfizer (Thailand) Limited
Thailand Pfizer (Wuhan) Research and Development Co. Ltd.
People’s Republic of China Pfizer AB
Sweden Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products & Ch
emicalsS.A.E.
EgyptPfizer Afrique de L'Ouest
Senegal Pfizer AG
Switzerland Pfizer Anti-Infectives AB
Sweden Pfizer ApS
Denmark Pfizer AS
Norway Pfizer Asia Manufacturing Pte. Ltd.
Singapore Pfizer Asia Pacific Pte Ltd.
Singapore Pfizer Atlantic Holdings S.a.r.l.
Luxembourg Pfizer Australia Holdings B.V.
Netherlands Pfizer Australia Holdings Pty Limited
Australia 3

Pfizer Australia Investments Pty LtdAustralia Pfizer Australia Pty Ltd
Australia Pfizer B.V.
Netherlands Pfizer Baltic Holdings B.V.
Netherlands Pfizer Biofarmacêutica, Sociedade Uni
pessoal LdaPortugal Pfizer Biologics (Hangzhou) Co. Ltd
People’s Republic of China Pfizer Biologics I
reland Holdings LimitedIreland Pfizer Biotech Corporation
Taiwan Pfizer Bolivia S.A.
Bolivia Pfizer Brazil Holding SARL
Luxembourg Pfizer Canada ULC
Canada Pfizer CentreSource Asia Pacific Pte. Ltd.
Singapore Pfizer Chile S.A.
Chile Pfizer Cia. Ltda.
Ecuador Pfizer Colombia Spinco I LLC
Pennsylvania Pfizer Commercial Holdings Coöperati
ef U.A.Netherlands Pfizer Commercial Holdings TRAE Kft.
Hungary Pfizer Commercial TRAE Trading Kft.
Hungary Pfizer Consumer Healthcare AB
Sweden Pfizer Consumer Healthcare GmbH
Germany Pfizer Consumer Healthcare Limited
United Kingdom Pfizer Consumer Manufacturing Italy S.r.l.
Italy Pfizer Corporation Austria Gesellschaft m.b.H.
Austria Pfizer Corporation Hong Kong Limited
Hong Kong Pfizer Corporation S. de R.L.
Panama Pfizer Croatia d.o.o.
Croatia Pfizer Deutschland GmbH
Germany Pfizer Development LP
United Kingdom Pfizer Development Services (UK) Limited
United Kingdom Pfizer Domestic Ventures Limited
Jersey Pfizer Dominicana, S.R.L
Dominican Republic Pfizer East India B.V.
Netherlands Pfizer Eastern Investments B.V.
Netherlands Pfizer Egypt S.A.E.
Egypt Pfizer Enterprise Holdings B.V.
Netherlands Pfizer Enterprises LLC
Delaware Pfizer Enterprises SARL
Luxembourg Pfizer ESP Pty. Ltd.
Australia Pfizer Europe Finance B.V.
Netherlands Pfizer Export B.V.
Netherlands Pfizer Export Company
Ireland Pfizer Export Holding Company B.V
Netherlands Pfizer Finance Share Service (Dalian) Co., Ltd.
People’s Republic of China Pfizer Financial Services
Belgium Pfizer France International Investments
France Pfizer Free Zone Panama, S. de R.L.
Panama 4

Pfizer GEP, S.L.Spain Pfizer Global Holdings B.V.
Netherlands Pfizer Global Supply Japan Inc.
Japan Pfizer Global Trading
Ireland Pfizer Group Luxembourg SARL
Luxembourg Pfizer Gulf FZ-LLC
United Arab Emira tesPfizer H.C.P. Corporation
New York Pfizer Health AB
Sweden Pfizer Health Solutions Inc.
Delaware Pfizer Healthcare India Private Limited
India Pfizer Healthcare Ireland
Ireland Pfizer Hellas, A.E.
Greece Pfizer Himalaya Holdings
 Coöperatief U.A.Netherlands Pfizer Holding France
France Pfizer Holding Ventures
Ireland Pfizer Holdings Corporation
Delaware Pfizer Holdings Europe
 Unlimited CompanyIreland Pfizer Holdings G.K.
Japan Pfizer Holdings In
ternational CorporationDelaware Pfizer Holdings International Luxemb
ourg (PHIL) SARLLuxembourg Pfizer Hungary Holdings TRAE Kft.
Hungary Pfizer Ilaclari Limited Sirketi
Turkey Pfizer Innovations AB
Sweden Pfizer Innovations LLC
Russia Pfizer Innovative Supply Point Internationa
l BVBABelgium Pfizer International LLC
New York Pfizer International Markets B.V.
Netherlands Pfizer International Operations
France Pfizer International S. de R.L.
Panama Pfizer International Trading (Shangha
i) LimitedPeople’s Republic of China Pfizer Investment Capital Unlimited Company
Ireland Pfizer Investment Co. Ltd.
People’s Republic of China Pfizer Investment Holdings S.a.r.l.
Luxembourg Pfizer Ireland Investments Limited
Ireland Pfizer Ireland PFE Holding 1 LLC
Delaware Pfizer Ireland Pharmaceuticals
Ireland Pfizer Ireland Ventures Unlimited Company
Ireland Pfizer Italia S.r.l.
Italy Pfizer Italy Group Holding S.r.l.
Italy Pfizer Japan Inc.
Japan Pfizer Laboratories (Pty) Limited
South Africa Pfizer Laboratories Limited
Kenya Pfizer Laboratories PFE (Pty) Ltd
South Africa Pfizer Leasing Ireland Limited
Ireland Pfizer Leasing UK Limited
United Kingdom 5

Pfizer LimitedIndia Pfizer Limited
Taiwan Pfizer Limited
United Kingdom Pfizer LLC
Russia Pfizer Luxco Holdings SARL
Luxembourg Pfizer Luxembourg Global Holdin
gs S.à r.l.Luxembourg Pfizer Luxembourg SARL
Luxembourg Pfizer Manufacturing Austria G.m.b.H.
Austria Pfizer Manufacturing Belgium N.V.
Belgium Pfizer Manufacturing Deutschland GmbH
Germany Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG
Germany Pfizer Manufacturing Holdings LLC
Delaware Pfizer Manufacturing Ireland Unlimited Company
Ireland Pfizer Manufacturing LLC
Delaware Pfizer Manufacturing Services
Ireland Pfizer MAP Holding, Inc.
Delaware Pfizer Medical Technology Group (Belgi
um) N.V.Belgium Pfizer Medicamentos Genericos e Participacoes Ltda.
Brazil Pfizer Mexico Luxco SARL
Luxembourg Pfizer Mexico, S.A. de C.V.
Mexico Pfizer Middle East for Pharmaceuticals, Animal Health an
d Chemicals S.A.E.Egypt Pfizer New Zealand Limited
New Zealand Pfizer Norge AS
Norway Pfizer North American Holdings Inc.
Delaware Pfizer OFG Germany GmbH
Germany Pfizer OTC B.V.
Netherlands Pfizer Overseas LLC
Delaware Pfizer Oy
Finland Pfizer Pakistan Limited
Pakistan Pfizer Parke Davis (Thailand) Ltd.
Thailand Pfizer Parke Davis Sdn. Bhd.
Malaysia Pfizer PFE ApS
Denmark Pfizer PFE AsiaPac Holding B.V.
Netherlands Pfizer PFE Australia Holding B.V.
Netherlands Pfizer PFE Australia Pty Ltd
Australia Pfizer PFE B.V.
Netherlands Pfizer PFE Baltic Holdings B.V.
Netherlands Pfizer PFE Belgium SPRL
Belgium Pfizer PFE Brazil Holding S.à r.l.
Luxembourg Pfizer PFE CIA. Ltda.
Ecuador Pfizer PFE Colombia
 Holding LLCDelaware Pfizer PFE Colombia S.A.S
Colombia Pfizer PFE Croatia Holding B.V.
Netherlands Pfizer PFE Eastern Investments B.V.
Netherlands 6

Pfizer PFE Finland OyFinland Pfizer PFE France
France Pfizer PFE Global Holdings B.V.
Netherlands Pfizer PFE İlaçları Anonim Şirketi
Turkey Pfizer PFE Ireland Pharmaceuticals Holdi
ng 1 B.V.Netherlands Pfizer PFE Limited
Taiwan Pfizer PFE Luxembourg S.à r.l.
Luxembourg Pfizer PFE Mexico Holding 3 LLC
Delaware Pfizer PFE New Zealand
 Holding B.V.Netherlands Pfizer PFE Norway Holding S.à r.l.
Luxembourg Pfizer PFE Peru Holding LLC
Delaware Pfizer PFE Peru S.R.L.
Peru Pfizer PFE Pharmaceuticals Israel Holding L
LCDelaware Pfizer PFE Pharmaceuticals Israel Ltd.
Israel Pfizer PFE PILSA Holdco S.à r.l.
Luxembourg Pfizer PFE Private Limited
Singapore Pfizer PFE Service Company Holding B.V.
Netherlands Pfizer PFE Singapore
 Holding B.V.Netherlands Pfizer PFE Singapore Pte. Ltd.
Singapore Pfizer PFE Spain B.V.
Netherlands Pfizer PFE Spain Holding, S.L.
Spain Pfizer PFE Switzerland GmbH
Switzerland Pfizer PFE Turkey Holding 1 B.V.
Netherlands Pfizer PFE Turkey Holding 2 B.V.
Netherlands Pfizer PFE UK Holding 4 LP
United Kingdom Pfizer PFE US Holdings 4 LLC
Delaware Pfizer PFE US Holdings 5 LLC
Delaware Pfizer PFE, spol. s r.o.
Czech Republic Pfizer Pharm Algerie
Algeria Pfizer Pharma GmbH
Germany Pfizer Pharma PFE GmbH
Germany Pfizer Pharmaceutical (Wuxi) Co., Ltd.
People’s Republic of China Pfizer Pharmaceutical Enterprises Global Manag
ement Co.,Ltd.People’s Republic of China Pfizer Pharmaceutical Trading Limited Lia
bility Company (a/k/a Pfizer Kft. or PfizerLLC)
HungaryPfizer Pharmaceuticals Global B.V.
Netherlands Pfizer Pharmaceuticals Israel Ltd.
Israel Pfizer Pharmaceuticals Korea Limited
Republic of Korea Pfizer Pharmaceuticals LLC
Delaware Pfizer Pharmaceuticals Ltd.
People’s Republic of China Pfizer Pharmaceuticals Tunisie Sarl
Tunisia Pfizer Pigments Inc.
Delaware Pfizer Polska Sp. z.o.o.
Poland Pfizer Private Limited
Singapore Pfizer Production LLC
Delaware 7

Pfizer Products Inc.Connecticut Pfizer Products India Private Limited
India Pfizer R&D Holding B.V.
Netherlands Pfizer R&D Japan G.K.
Japan Pfizer R&D UK Limited
United Kingdom Pfizer Research (NC), Inc.
Delaware Pfizer Romania SRL
Romania Pfizer S.A.
Peru Pfizer S.A. (Belgium)
Belgium Pfizer S.A.S.
Colombia Pfizer S.G.P.S. Lda.
Portugal Pfizer S.R.L.
Argentina Pfizer S.r.l.
Italy Pfizer Saidal Manufacturing
Algeria Pfizer Santé Familiale
France Pfizer Saudi Limited
Saudi Arabia Pfizer Seiyaku K.K.
Japan Pfizer Service Company BVBA
Belgium Pfizer Service Company Ireland Unlimited Comp
anyIreland Pfizer Services 1
France Pfizer Services LLC
Delaware Pfizer Shared Services Unlimited Company
Ireland Pfizer Shareholdings Intermediate SARL
Luxembourg Pfizer Spain Holdings B.V.
Netherlands Pfizer Specialties Limited
Nigeria Pfizer SRB d.o.o.
Serbia Pfizer Strategic Investment Holdings LLC
Delaware Pfizer Trading Polska sp.z.o.o.
Poland Pfizer TRAE Holdings Kft.
Hungary Pfizer Transactions LLC
Delaware Pfizer Tunisie SA
Tunisia Pfizer Vaccines LLC
Delaware Pfizer Venezuela, S.A.
Venezuela Pfizer Venture Investments LLC
Delaware Pfizer Ventures (US) LLC
Delaware Pfizer Ventures LLC
Delaware Pfizer Worldwide Se
rvices Unlimited CompanyIreland Pfizer Zona Franca, S.A.
Costa Rica Pfizer, Inc.
Philippines Pfizer, S.A.
Costa Rica Pfizer, S.A. de C.V.
Mexico Pfizer, S.L.
Spain Pfizer, spol. s r.o.
Czech Republic Pharmacia & Upjohn Company LLC
Delaware Pharmacia & Upjohn LLC
Delaware Pharmacia & Upjohn, S.A. de C.V.
Mexico 8

Pharmacia Brasil Ltda.Brazil Pharmacia Hepar LLC
Delaware Pharmacia Holding AB
Sweden Pharmacia Inter-American LLC
Pennsylvania Pharmacia International B.V.
Netherlands Pharmacia Limited
United Kingdom Pharmacia LLC
Delaware PHILCO Holdings S.à r.l.
Luxembourg PHIVCO Corp.
Delaware PHIVCO Holdco S.à r.l.
Luxembourg PHIVCO Luxembourg S.à r.l.
Luxembourg PIMB OFG Spain Holding, S.L.
Spain PT. Pfizer Indonesia
Indonesia Renrall LLC
Wyoming Rinat Neuroscience Corp.
Delaware Roerig S.A.
Chile Searle Laboratorios, Lda.
Portugal Servicios P&U, S. de R.L. de C.V.
Mexico Shiley LLC
California Sinergis Farma-Produtos Farmaceuticos, Lda.
Portugal Solinor LLC
Delaware Sugen LLC
Delaware Tabor LLC
Delaware Treerly Health Co., Ltd
People’s Republic of China Upjohn Global Holdings B.V.
Netherlands Upjohn Laboratorios Lda.
Portugal Upjohn South Africa (Pty) Ltd.
South Africa Upjohn US 1 LLC
Delaware Upjohn US 2 LLC
Delaware Vesterålens Naturprodukter A/S
Denmark Vesterålens Naturprodukter AB
Sweden Vesterålens Naturprodukter AS
Norway Vesterålens Naturprodukter OY
Finland Vicuron Holdings LLC
Delaware Warner Lambert del Uruguay S.A.
Uruguay Warner-Lambert Company AG
Switzerland Warner-Lambert Company LLC
Delaware Whitehall International Inc.
New York W-L LLC
Delaware Wyeth (Asia) Limited
Delaware Wyeth (Thailand) Ltd.
Thailand Wyeth AB
Sweden Wyeth Australia Pty Limited
Australia Wyeth Ayerst Inc.
Delaware Wyeth Ayerst S.à r.l.
Luxembourg 9

Wyeth Consumer Healthcare LLCPennsylvania Wyeth Europa Limited
United Kingdom Wyeth Farma, S.A.
Spain Wyeth Holdings LLC
Maine Wyeth Industria Farmaceutica Ltda.
Brazil Wyeth KFT.
Hungary Wyeth Lederle S.r.l.
Italy Wyeth LLC
Delaware Wyeth Pakistan Limited
Pakistan Wyeth Pharmaceutical Co., Ltd.
People’s Republic of China Wyeth Pharmaceuticals Company
Puerto Rico Wyeth Pharmaceuticals FZ-LLC
United Arab Emira tesWyeth Pharmaceuticals India Private Limited
India Wyeth Pharmaceuticals LLC
Delaware Wyeth Puerto Rico, Inc.
Puerto Rico Wyeth Subsidiary Illinois Corporation
Illinois Wyeth Whitehall Export GmbH
Austria Wyeth-Ayerst (Asia) Limited
Delaware Wyeth-Ayerst International LLC
Delaware Wyeth-Ayerst Promotions Limited
Delaware 10

EXHIBIT 23Consent of Independent Registered Public Accoun
ting FirmTo the Board of Directors and the Shareholders of Pfizer Inc.:
We consent to the incorporation by reference in this 
2018 Annual Report on Form 10-K of Pfizer Inc. of our reports dated February 28, 2019 , with respect to the consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of 
December 31, 2018 and 2017 , and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the years in the three-year period ended 
December 31, 2018 , and the effectiveness of internal control over financial reporting as of December 31, 2018 
, which reports appear in the 2018 Annual Report on Form 10-K of Pfizer Inc. We also consent to the incorporation by reference of our reports in the following Registration Statements:
-Form S-8 dated October 27, 1983 (File No. 2-87473),
-Form S-8 dated March 22, 1990 (File No. 33-34139),
-Form S-8 dated January 24, 1991 (File No. 33-38708),
-Form S-8 dated November 18, 1991 (File No. 33-44053),
-Form S-8 dated May 27, 1993 (File No. 33-49631),
-Form S-8 dated May 19, 1994 (File No. 33-53713),
-Form S-8 dated October 5, 1994 (File No. 33-55771),
-Form S-8 dated December 20, 1994 (File No. 33-56979),
-Form S-8 dated March 29, 1996 (File No. 333-02061),
-Form S-8 dated September 25, 1997 (File No. 333-36371),
-Form S-8 dated June 19, 2000 (File No. 333-39606),
-Form S-8 dated April 27, 2001 (File No. 333-59660),
-Form S-8 dated April 16, 2003 (File No. 333-104582),
-Form S-8 dated November 18, 2003 (File No. 333-110571),
-Form S-8 dated December 18, 2003 (File No. 333-111333),
-Form S-8 dated April 26, 2004 (File No. 333-114852),
-Form S-8 dated March 1, 2007 (File No. 333-140987),
-Form S-4 dated March 27, 2009 (File No. 333-158237),
-Form S-8 dated October 16, 2009 (File No. 333-162519),
-Form S-8 dated October 16, 2009 (File No. 333-162520),
-Form S-8 dated October 16, 2009 (File No. 333-162521),
-Form S-8 dated March 1, 2010 (File No. 333-165121),
-Form S-8 dated March 2, 2015 (File No. 333-202437),
-Form S-4 dated September 3, 2015 (File No. 333-206758), and
-Form S-3 ASR dated February 26, 2018 (File No. 333-223221).
/s/ KPMG LLP
New York, New York 
February 28, 2019 
EXHIBIT 31.1Certification by the Chief Executive O
fficer Pursuant toSection 302 of the Sarbanes-Oxley Act of 2002
I, Albert Bourla, certify that:
1. 
I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;2. 
Based on my knowledge, this repo rt does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the ci
rcumstances under which such statements were made, not misleading with respect to the period covered by this report;3. 
Based on my knowledge, the financ ial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, re
sults of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. 
The registrant's other certify ing officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d
-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for theregistrant and have:
(a) Designed such disc
losure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material in
formation relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,particularly during the perio
d in which this report is being prepared;(b) Designed such interna
l control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide rea
sonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposesin accordance with gener
ally accepted accounting principles;(c) Evaluated the effectiveness of the 
registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosu
re controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in th
is report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the regist
rant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, theregistrant's internal contr
ol over financial reporting; and5.    The registrant's other certify
ing officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit 
committee of the registrant's board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and m
aterial weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect t
he registrant's ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not materia
l, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.
Date:  
February 28, 2019 /s/ ALBERT BOURLA
    Albert Bourla
    Chief Executive Officer
  
EXHIBIT 31.2Certification by the Chief Financial Office
r Pursuant toSection 302 of the Sarbanes-Oxley Act of 2002
I, Frank A. D'Amelio, certify 
that:1. 
I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;2. 
Based on my knowledge, this repo rt does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the ci
rcumstances under which such statements were made, not misleading with respect to the period covered by this report;3. 
Based on my knowledge, the financ ial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, re
sults of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. 
The registrant's other certify ing officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d
-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for theregistrant and have:
(a) Designed such disc
losure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material in
formation relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,particularly during the perio
d in which this report is being prepared;(b) Designed such interna
l control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide rea
sonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposesin accordance with gener
ally accepted accounting principles;(c) Evaluated the effectiveness of the 
registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosu
re controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in th
is report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the regist
rant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, theregistrant's internal contr
ol over financial reporting; and5. 
The registrant's other certify ing officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit 
committee of the registrant's board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and m
aterial weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect t
he registrant's ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not materia
l, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.
Date:  
February 28, 2019 /s/ FRANK A. D'AMELIO
    Frank A. D'Amelio
    Chief Financial Officer, Executive Vice Presiden
t,Business Operations and Global Supply
  
EXHIBIT 32.1Certification by the Chief Executive O
fficer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant toSection 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, A
lbert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. forthe year ended 
December 31, 2018 (the “Report”) fully co mplies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934,and that the information contained in that Repo
rt fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc./s/ ALBERT BOURLA
    Albert Bourla
    Chief Executive Officer
   
    February 28, 2019    This certification ac
companies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to theextent required by such Act, be deemed fi
led by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”). Such certificat
ion will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,except to the extent that the Company specifi
cally incorporates it by reference.
EXHIBIT 32.2Certification by the Chief Financial Office
r Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant toSection 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Fran
k A. D'Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of PfizerInc. for the year ended 
December 31, 2018 (the “Report”) fully co mplies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Actof 1934, and that the information contained in that Repo
rt fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc./s/ FRANK A. D'AMELIO
    Frank A. D'Amelio
    Chief Financial Officer, Executive Vice Presiden
t,Business Operations and Global Supply
 
    February 28, 2019    This certification ac
companies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to theextent required by such Act, be deemed fi
led by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”). Such certificat
ion will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,except to the extent that the Company specifi
cally incorporates it by reference.